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This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary. 
 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is 
also presented, but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced. 
 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a public health statement that describes, in nontechnical language, a substance's relevant 
toxicological properties.  Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance's health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR. 
 
 Each profile includes the following: 
 
 (A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects; 
 
 (B) A determination of whether adequate information on the health effects of each substance 
is available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and 
 
 (C) Where appropriate, identification of toxicologic testing needed to identify the types or 
levels of exposure that may present significant risk of adverse health effects in humans. 
 
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.   
 
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed.  Staffs of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel 
and was made available for public review.  Final responsibility for the contents and views expressed in 
this toxicological profile resides with ATSDR. 
 
 
Patrick N. Breysse, Ph.D., CIH
  
Director, National Center for Environmental Health and 
 
Agency for Toxic Substances and Disease Registry 
 















The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the 
most significant potential threat to human health, as determined by ATSDR and the EPA.  Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile 
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for 
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA 
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise 



















   
   
 






      
   
     
  
 
    
  
 
    
  
  
   
     





    
      
   
   
 
 
   




       
  
 
   
 
  














QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets,
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Chapter 1 How Can (Chemical X) Affect Children?
Chapter 1 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)
Internet: http://www.atsdr.cdc.gov
The following additional material is available online at www.atsdr.cdc.gov:
Case Studies in Environmental Medicine—Case Studies are self-instructional publications designed to 
increase primary care provider’s knowledge of a hazardous substance in the environment and to
aid in the evaluation of potentially exposed patients.  
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 











    
    
   
  
 










    
   
  










   
 
  




   
    
 
   
 
    
   
         
 
 
   
 
     
   
 
PBDEs viii
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 395 E Street, S.W., Suite 9200, 
Patriots Plaza Building, Washington, DC 20201 • Phone: (202) 245-0625 or 1-800-CDC-INFO 
(800-232-4636).
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Publically Available Information
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266.
The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with
recognized expertise in medical toxicology.  Contact: ACMT, 10645 North Tatum Boulevard, 
Suite 200-111, Phoenix AZ 85028 • Phone:  844-226-8333 • FAX:  844-226-8333 • Web Page:
http://www.acmt.net.
The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists 
who respond to questions from public health professionals, clinicians, policy makers, and the
public about the impact of environmental factors on the health of children and reproductive-aged
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The American Association of Poison Control Centers (AAPCC) provide support on the prevention and 
treatment of poison exposures.  Contact:  AAPCC, 515 King Street, Suite 510, Alexandria VA
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SRC, Inc., North Syracuse, NY
THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2. Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each
profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to
assure consistency across profiles and adherence to instructions in the Guidance.





























    
  
 
    
 
 











   
    
     
   
 
   










A peer review panel was assembled for polybrominated diphenyl ethers. The panel consisted of the 
following members:
Dr. Stuart Harrad, Division of Environmental Health and Risk Management, School of
Geography, Earth, and Environmental Sciences, University of Birmingham, Edgbaston, 
Birmingham, United Kingdom;
2. Dr. James R. Olson, Jr., Department of Chemistry, University at Buffalo, State University of New
York, Buffalo, New York; and
3. 	 Dr. Christopher Metcalfe, Metcalfe C. Environmental and Resource Studies, Trent University, 
1600 West Bank Drive, Peterborough, Ontario, Canada.
These experts collectively have knowledge of polybrominated diphenyl ether’s physical and chemical
properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final 

























DISCLAIMER .............................................................................................................................................. ii 
 




QUICK REFERENCE FOR HEALTH CARE PROVIDERS .................................................................... vii
  
CONTRIBUTORS ....................................................................................................................................... xi 
 




LIST OF FIGURES ................................................................................................................................... xix 
 
LIST OF TABLES ..................................................................................................................................... xxi 
 
 
1.  PUBLIC HEALTH STATEMENT FOR POLYBROMINATED DIPHENYL ETHERS (PBDEs) ....... 1 
 
 
2.  RELEVANCE TO PUBLIC HEALTH ................................................................................................... 9 
 




2.2 	 SUMMARY OF HEALTH EFFECTS ......................................................................................... 11 
 
2.3 	 MINIMAL RISK LEVELS (MRLs) ............................................................................................ 26
  
 
3.  HEALTH EFFECTS .............................................................................................................................. 43 
 
3.1  INTRODUCTION ........................................................................................................................ 43 
 
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE ..................................... 44 
 
3.2.1  Inhalation Exposure .............................................................................................................. 45
  
3.2.1.1  Death .............................................................................................................................. 45 
 
3.2.1.2  Systemic Effects ............................................................................................................. 46
  
3.2.1.3  Immunological and Lymphoreticular Effects ................................................................ 55 
 
3.2.1.4  Neurological Effects ...................................................................................................... 56 
 
3.2.1.5  Reproductive Effects ...................................................................................................... 56 
 
3.2.1.6  Developmental Effects ................................................................................................... 56 
 
3.2.1.7  Cancer ............................................................................................................................ 57
  
3.2.2  Oral Exposure ........................................................................................................................ 57
  
3.2.2.1  Death .............................................................................................................................. 57
  
3.2.2.2  Systemic Effects........................................................................................................... 135
  
3.2.2.3  Immunological and Lymphoreticular Effects .............................................................. 175
  
3.2.2.4  Neurological Effects .................................................................................................... 181
  
3.2.2.5  Reproductive Effects .................................................................................................... 185
  
3.2.2.6  Developmental Effects ................................................................................................. 197 
 
3.2.2.7  Cancer .......................................................................................................................... 236 
 
3.2.3  Dermal Exposure ................................................................................................................. 240 
 
3.2.3.1  Death ............................................................................................................................ 240 
 
3.2.3.2  Systemic Effects........................................................................................................... 240
  
3.2.3.3  Immunological and Lymphoreticular Effects .............................................................. 243
  
3.2.3.4  Neurological Effects .................................................................................................... 243
  
3.2.3.5  Reproductive Effects .................................................................................................... 243
  
3.2.3.6  Developmental Effects ................................................................................................. 243
  
3.2.3.7  Cancer .......................................................................................................................... 243
  
3.3  GENOTOXICITY ...................................................................................................................... 243
  
3.4  TOXICOKINETICS ................................................................................................................... 246
  
3.4.1  Absorption ........................................................................................................................... 246
  













3.4.1.2  Oral Exposure .............................................................................................................. 246
  
3.4.1.3  Dermal Exposure ......................................................................................................... 252
  
3.4.2  Distribution ......................................................................................................................... 253
  
3.4.2.1  Inhalation Exposure ..................................................................................................... 253
  
3.4.2.2  Oral Exposure .............................................................................................................. 253
  
3.4.2.3  Dermal Exposure ......................................................................................................... 260
  
3.4.3  Metabolism .......................................................................................................................... 260
  
3.4.4  Elimination and Excretion ................................................................................................... 267
  
3.4.4.1  Inhalation Exposure ..................................................................................................... 267
  
3.4.4.2  Oral Exposure .............................................................................................................. 268
  
3.4.4.3  Dermal Exposure ......................................................................................................... 270
  
3.4.5  Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models ........... 270
  
3.5  MECHANISMS OF ACTION ................................................................................................... 273
  
3.5.1  Pharmacokinetic Mechanisms ............................................................................................. 273
  
3.5.2  Mechanisms of Toxicity ...................................................................................................... 276
  
3.5.3  Animal-to-Human Extrapolations ....................................................................................... 296
  
3.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS ........................... 297
  
3.7  CHILDREN’S SUSCEPTIBILITY ............................................................................................ 299
  
3.8  BIOMARKERS OF EXPOSURE AND EFFECT ..................................................................... 308
  
3.8.1  Biomarkers Used to Identify or Quantify Exposure to PBDEs ........................................... 309
  
3.8.2  Biomarkers Used to Characterize Effects Caused by PBDEs ............................................. 310
  
3.9  INTERACTIONS WITH OTHER CHEMICALS ..................................................................... 311
  
3.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ................................................ 314
  
3.11  METHODS FOR REDUCING TOXIC EFFECTS .................................................................... 316
  
3.11.1  Reducing Peak Absorption Following Exposure ............................................................. 316
  
3.11.2  Reducing Body Burden ................................................................................................... 317
  
3.11.3  Interfering with the Mechanism of Action for Toxic Effects .......................................... 318
  
3.12  ADEQUACY OF THE DATABASE ........................................................................................ 320
  
3.12.1  Existing Information on Health Effects of PBDEs .......................................................... 320
  
3.12.2  Identification of Data Needs ............................................................................................ 322
  
3.12.3  Ongoing Studies .............................................................................................................. 336
  
 
4.  CHEMICAL AND PHYSICAL INFORMATION .............................................................................. 343
  
4.1  CHEMICAL IDENTITY ............................................................................................................ 343
  
4.2  PHYSICAL AND CHEMICAL PROPERTIES ......................................................................... 352
  
 
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .......................................................... 359
  
5.1  PRODUCTION .......................................................................................................................... 359 
 
5.2  IMPORT/EXPORT .................................................................................................................... 361 
 
5.3  USE ............................................................................................................................................ 361 
 
5.4  DISPOSAL ................................................................................................................................. 362 
 
 
6.  POTENTIAL FOR HUMAN EXPOSURE ......................................................................................... 365
  
6.1  OVERVIEW ............................................................................................................................... 365 
 
6.2  RELEASES TO THE ENVIRONMENT ................................................................................... 366
  
6.2.1  Air ....................................................................................................................................... 366
  
6.2.2  Water ................................................................................................................................... 370
  
6.2.3  Soil ...................................................................................................................................... 372
  
6.3  ENVIRONMENTAL FATE ...................................................................................................... 373 
 
6.3.1  Transport and Partitioning ................................................................................................... 373
  













6.3.2.1  Air ................................................................................................................................ 376
  
6.3.2.2  Water ............................................................................................................................ 377
  
6.3.2.3  Sediment and Soil ........................................................................................................ 381
  
6.3.2.4  Other Media ................................................................................................................. 381
  
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .................................. 381
  
6.4.1  Air ....................................................................................................................................... 382
  
6.4.2  Water ................................................................................................................................... 385
  
6.4.3  Sediment and Soil ............................................................................................................... 386
  
6.4.4  Other Environmental Media ................................................................................................ 390
  
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE ........................................ 433
  
6.6  EXPOSURES OF CHILDREN .................................................................................................. 437
  
6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .............................................. 439
  
6.8  ADEQUACY OF THE DATABASE ........................................................................................ 439
  
6.8.1  Identification of Data Needs ............................................................................................... 440
  
6.8.2  Ongoing Studies .................................................................................................................. 443
  
 
7.  ANALYTICAL METHODS................................................................................................................ 445
  
7.1  BIOLOGICAL MATERIALS .................................................................................................... 447
  
7.2  ENVIRONMENTAL SAMPLES .............................................................................................. 450
  
7.3  ADEQUACY OF THE DATABASE ........................................................................................ 455
  
7.3.1  Identification of Data Needs ............................................................................................... 455
  
7.3.2  Ongoing Studies .................................................................................................................. 456
  
 
8.  REGULATIONS, ADVISORIES, AND GUIDELINES ..................................................................... 457
  
 
9.  REFERENCES .................................................................................................................................... 463
  
 




A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS ............................................................. A-1
  
B.  USER’S GUIDE .................................................................................................................................. B-1
  


































3-1.  Levels of Significant Exposure to Lower Brominated Diphenyl Ethers – Inhalation ........................ 49
  
 
3-2.  Levels of Significant Exposure to Lower Brominated Diphenyl Ethers – Oral ............................... 103
  
 
3-3.  Levels of Significant Exposure to Decabromodiphenyl Ether – Oral .............................................. 130
  
 
3-4.  Structures and General Metabolic Scheme for Hydroxylated Metabolites of BDE 47 Produced 

by Human Liver Microsomes ........................................................................................................... 263
  
 
3-5.  Structures and General Metabolic Scheme for Hydroxylated Metabolites of BDE 99 Produced 

by Human Liver Microsomes ........................................................................................................... 264
  
 
3-6.  Structures and General Metabolic Scheme for Hydroxylated Metabolites of BDE 100 Produced 
 
by Human Liver Microsomes and Human CYP2B6 ........................................................................ 265
  
 
3-7.  Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a 
 
Hypothetical Chemical Substance .................................................................................................... 272
  
 
3-8.  Existing Information on Health Effects of Polybrominated Diphenyl Ethers (PBDEs) ................... 321
  
 
6-1.  Total On- and Off-Site Releases of Decabromodiphenyl Ether, 1998–2012 ................................... 369
  
 
6-2.  Temporal Trends in the Concentrations (ng/g Lipid Weight) of PBDE Congeners in Lake Trout
  

































3-1.  Levels of Significant Exposure to Lower Brominated Diphenyl Ethers – Inhalation ........................ 46
  
 
3-2.  Levels of Significant Exposure to Lower Brominated Diphenyl Ethers – Oral ................................. 58
  
 
3-3.  Levels of Significant Exposure to Decabromodiphenyl Ether – Oral .............................................. 110
  
 
3-4.  Levels of Significant Exposure to Lower Brominated Diphenyl Ethers – Dermal .......................... 241
  
 
3-5.  Genotoxicity of Polybrominated Diphenyl Ethers (PBDEs) In Vivo................................................ 245
  
 
3-6.  Genotoxicity of Polybrominated Diphenyl Ethers (PBDEs) In Vitro ............................................... 247
  
 
3-7.  Ongoing Research for PBDEs in Humans ........................................................................................ 337
  
 
4-1.  Chemical Identity of Polybrominated Diphenyl Ether (PBDE) Congeners ..................................... 345
  
 
4-2.  Chemical Identity of Technical Polybrominated Diphenyl Ethers (PBDEs) .................................... 351
  
 










4-5.  Typical Congener Composition of Penta-, Octa-, and Deca- Brominated Diphenyl
  
Ether (BDE) ...................................................................................................................................... 357
  
 
5-1.  Facilities that Produce, Process, or Use Decabromodiphenyl Ether ................................................. 360
  
 





6-2.  Concentrations (pg/m3) of Several Polybrominated Diphenyl Ethers (PBDEs) in Air Samples ...... 383
  
 
6-3.  Concentrations (ng/g) of Several Polybrominated Diphenyl Ethers (PBDEs) in Sediment and 

Suspended Particulate Samples ........................................................................................................ 388
  
 
6-4.  PBDE Concentrations (pg/g Wet Weight) in 18 U.S. Meat and Fish Samples ................................ 392
  
 
6-5.  Concentrations (ng/g Dry Weight) of Several Polybrominated Diphenyl Ethers (PBDEs) in
  
Biosolids (Sewage Sludge) and Effluents ........................................................................................ 396
  
 
6-6.  Concentrations (ng/g Lipid Weight, Except as Noted) of Several Polybrominated Diphenyl
  
Ethers (PBDEs) in Freshwater Fish Samples from the United States .............................................. 398
  
 
6-7.  Concentrations (ng/g Lipid Weight Except as Noted) of Several Polybrominated Diphenyl
  














6-8.  C	 oncentrations (ng/g Lipid Weight) of Several Polybrominated Diphenyl Ethers (PBDEs) in 

Marine Aquatic Species.................................................................................................................... 408 
 
 
6-9.  	Concentrations (ng/g Lipid Weight) of Several Polybrominated Diphenyl Ethers (PBDEs) in 

Marine Animals ................................................................................................................................ 413 
 
 
6-10.  Concentrations (ng/g Lipid Weight) of Several Polybrominated Diphenyl Ethers (PBDEs) in 

Human Blood Samples ..................................................................................................................... 422 
 
 
6-11.  Concentrations (ng/g Lipid Weight) of Several Polybrominated Diphenyl Ethers (PBDEs) in 

Human Adipose Tissue Samples ...................................................................................................... 424 
 
 
6-12.  Concentrations (ng/g Lipid Weight) of Several Polybrominated Diphenyl Ethers (PBDEs) in 

Human Breast Milk Samples ............................................................................................................ 425 
 
 
6-13.  Concentrations of PBDE Congeners in Human Milk from Nursing Mothers in the United 

States (2001–2004) (ng/g Lipid) ...................................................................................................... 430 
 
 
7-1.  A	 nalytical Methods for Determining Polybrominated Diphenyl Ethers (PBDEs) in Biological
  
Materials ........................................................................................................................................... 448 
 
 
7-2.  A	 nalytical Methods for Determining Polybrominated Diphenyl Ethers (PBDEs) in 
 
Environmental Samples .................................................................................................................... 451 
 
 



























    
          
     
  
   
 
   
   
   




   
      
   
  
 
   
    
     
 
    
  
    
    
	
1PBDEs
1. PUBLIC HEALTH STATEMENT FOR POLYBROMINATED 
DIPHENYL ETHERS (PBDEs)
This Public Health Statement summarizes the Division of Toxicology and Human Health Science’s
findings on PBDEs, tells you about them, the effects of exposure, and describes what you can do to limit
that exposure.
The U.S. Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the
nation. These sites make up the National Priorities List (NPL) and are sites targeted for long-term federal
clean-up activities.  U.S. EPA has not found PBDEs in any of the 1,832 current or former NPL sites. The 
total number of NPL sites evaluated for PBDEs is not known.  But the possibility remains that as more
sites are evaluated, sites with PBDEs may be identified.  This information is important because these 
future sites may be sources of exposure, and exposure to PBDEs may be harmful.
If you are exposed to PBDEs, many factors determine whether you’ll be harmed.  These include how
much you are exposed to (dose), how long you are exposed (duration), and how you are exposed (route of
exposure).  You must also consider the other chemicals you are exposed to and your age, sex, diet, family
traits, lifestyle, and state of health.
WHAT ARE PBDEs?
PBDEs are flame-retardant chemicals that were added to a variety of consumer products to make them
difficult to burn. These substances are not single chemical compounds, but rather mixtures of several
brominated substances. The entire family of PBDEs consists of 209 possible substances that are referred
to as congeners.  
There were three important commercial PBDE mixtures (i.e., penta-, octa-, and deca- bromodiphenyl
ethers [BDEs]).  DecaBDE’s main use was for electronic enclosures, such as television cabinets.
OctaBDE was largely used in plastics for business equipment. PentaBDE was principally used in foam
for cushioning in upholstery.  PentaBDE and octaBDE mixtures were voluntarily withdrawn from the
U.S. marketplace by their manufacturers at the end of 2004 and decaBDE was not to be manufactured or
imported into the United States after December 31, 2013.  In 2003, the European Union (EU) passed a
Directive to ban the marketing and use of penta- and octaBDE that took effect in 2004. In 2008, the use
of decaBDE was restricted by a EU’s Restriction of Hazardous Substances (RoHS) Directive.
   
 









    
 
      
    
       
  
 
    
      
    
     
 
   
   
 
   
 
         
   
   
 
     
    
     
       
      




       
     
    
2PBDEs
1.  PUBLIC HEALTH STATEMENT
WHAT HAPPENS TO PBDEs WHEN THEY ENTER THE ENVIRONMENT?
PBDEs can be released into the air, water, and soil at places where they are produced or used.  Despite the
phase out of penta-, octa-, and decaBDE, vast amounts of consumer products still contain PBDEs, and 
these products are intended to be used for several more years. Some of these products include older
televisions, computers, and furniture containing polyurethane foam.  
PBDEs have very low water solubility, and when these substances are released to water, they typically
bind to sediment.  PBDEs in consumer items put in landfills may leach through the soil into groundwater.
This is not likely to be a problem, however, because these substances generally bind strongly to soil
particles, and therefore, do not move easily through soil layers.
Soils and sediments are major sinks for PBDEs.  Various food items, including fish, meat, and dairy
products, have been shown to contain low concentrations of PBDEs.
HOW MIGHT I BE EXPOSED TO PBDEs?
Humans can be exposed to PBDEs in a wide variety of ways, including eating contaminated foods or
contaminated dusts/soils, breathing in contaminated air, or having skin contact with contaminated soil/ 
dust/commercial products.
The primary route of exposure to PBDEs for the general population of the United States is from ingestion 
of contaminated dust in indoor environments, including both personal residences and work-place 
environments. PBDEs have been detected in residential house dust, which you can breathe in or swallow
in low concentrations. This can occur because PBDEs are physically mixed into consumer products from 
which they have the potential to escape into the environment when conditions are ideal. Ingestion of
house dust (and to a lesser degree skin exposure to house dust) accounts for between 80 and 90% of total
PBDE exposures of the general population.  The remaining exposure to PBDEs in the United States is
from food ingestion.  You may be exposed to PBDEs through ingestion of contaminated foods, 
particularly those with high fat content, such as fatty fish.  In breastfeeding infants, breast milk may be a 
major source of PBDE exposure because PBDEs can accumulate in breast milk.  Due to the chemical
nature of PBDEs, they have not been detected in water to any significant extent; therefore, drinking water
is not expected to be a major route of exposure to PBDEs.  While exposure to dust appears to be the major
   
 











      
   
   
 
   
    
  
  
   
 
   
 
    
   
  









   


































1.  PUBLIC HEALTH STATEMENT
exposure pathway for the general population of North American residents, PBDE exposure through 
dietary routes appears to be more important for European communities.
PBDEs have been detected in air samples, indicating that people can also be exposed by inhalation.
Consumer products such as computer and electronic equipment (e.g., televisions) treated with PBDEs can 
continue to release these substances to air over time.
PBDEs can enter soil from discarded products (e.g., in landfills).  Biosolids may also contain PBDEs;
therefore, they may be inadvertently released to soils from the use of biosolids that are applied to add
nutrients to farmlands.  If you touch soil containing PBDEs, a small amount of PBDEs may pass through
your skin into the bloodstream; ingestion of soil can lead to higher PBDE exposure.  This route may be
especially important for children who display a lot of hand to mouth activity.
HOW CAN PBDEs ENTER AND LEAVE MY BODY?
PBDEs can enter your body from food, air, water, or soil. The ways that PBDEs might enter and leave 
your body depend on the chemical structures of the congener components.  The higher-brominated 
PBDEs, particularly decaBDE, act somewhat differently in the body than do lower-brominated PBDEs.  
If you breathe air that contains PBDEs, or swallow food, water, soil, or dust contaminated with PBDEs, 
the lower-brominated congeners are more likely than decaBDE to enter your body through your lungs and 
stomach and pass into the bloodstream.
Once PBDEs are in your body, the congeners might partially change into breakdown products called 
metabolites.
PBDEs and their metabolites can leave your body, mainly in the feces and a very small amount in urine.  
DecaBDE, with an apparent half-time of 15 days, tends to be eliminated from your body faster than 
lower-brominated PBDEs, with apparent half-times as high as 94 days.  Lower brominated PBDEs can 
stay in your body for many years, stored mainly in body fat.  DecaBDE also accumulates in body fat, but
to a lesser degree.  Both lower-brominated PBDEs and decaBDE can concentrate in breast milk fat and
can enter the bodies of children through breastfeeding.  Lower-brominated PBDEs and decaBDE also can
enter the bodies of unborn babies through the placenta.
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1. PUBLIC HEALTH STATEMENT
HOW CAN PBDEs AFFECT MY HEALTH? 
Nothing definite is known about the health effects of PBDEs in people.  The majority of information 
regarding toxicity of PBDEs and their breakdown products (metabolites) is from animal studies; however,
several recent studies have evaluated associations between PBDE concentrations in human tissues (e.g., 
blood, breast milk) and various health effects.  Due to differences in how decaBDE is absorbed and stored 
in your body, decaBDE is expected to be less toxic than lower-brominated PBDEs.  
Rats and mice that ingested small amounts of lower-brominated PBDEs during early development had
neurobehavioral changes and damage to their reproductive systems as adults.  Altered neurobehavior was 
also observed in rats and mice that ingested decaBDE during early development, but at doses higher than 
observed for lower-brominated PBDEs.  Adult rats and mice that ingested moderate amounts of lower­
brominated PBDEs for short periods of time had mainly thyroid and liver effects.  Additional findings
from short-term animal studies suggest that some PBDEs might impair the immune system.  Animals
exposed to PBDEs by skin contact showed signs of skin irritation only if they had been scratched.
As with short-term exposure, rats and mice that ingested PBDEs for longer periods during early
development also showed neurobehavioral changes; again, effects occurred at higher doses with
decaBDE.  Evidence from human studies is also suggestive of an association between PBDE exposure 
and altered neurodevelopment.  Adult rats and mice that ingested small amounts of lower-brominated 
PBDEs over several weeks or months developed effects in the male reproductive system, thyroid, and 
liver.  Adult animals that ingested small amounts of decaBDE over several weeks or months developed
effects in the pancreas (diabetes), nervous system, immune system, and reproductive system.  Evidence
for PBDE-mediated effects from human studies in systems other than the developing nervous system is 
inconclusive or non-existent.
We don’t know if PBDEs can cause cancer in people, although liver tumors developed in rats and mice
that ate extremely large amounts of decaBDE throughout their lifetime.  Lower-brominated PBDEs have
not yet been tested for cancer in animals.  
The International Agency for Research on Cancer (IARC) has classified PBDE as a Group 3 carcinogen 
(not classifiable as to its carcinogenicity to humans) based on inadequate evidence of carcinogenicity in
humans and inadequate or limited evidence in experimental animals. The EPA assigns the cancer
category Group D (not classifiable as to human carcinogenicity) to mono-, di-, tri-, tetra-, penta-, hexa-, 
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octa-, and nonaBDEs and reports “inadequate information” to classify the specific congeners
2,2’,4,4’-tetraBDE, 2,2’,4,4’,5-pentaBDE, and 2,2’,4,4’,5,5’-hexaBDE.  However, EPA assigns a 
classification of “suggestive evidence of carcinogenic potential” for decaBDE.  The Department of Health 
and Human Services has not classified PBDEs as carcinogens.  The American Conference of
Governmental Industrial Hygienists (ACGIH) has no data regarding cancer classifications for PBDEs.
See Chapters 2 and 3 for more information on health effects of PBDEs.
HOW CAN PBDEs AFFECT CHILDREN?
This section discusses potential health effects of PBDE exposure in humans from when they’re first
conceived to 18 years of age.
Studies indicate that infants and toddlers have higher exposures to PBDEs compared to older children or
adults. The most likely way that infants might be exposed to PBDEs is from breast milk containing
PBDEs, although fetuses in the womb could also be exposed.  Toddlers and older children are exposed to 
PBDEs in generally the same way as are adults, mainly by ingesting contaminated household dust and 
food.  However, soil/dust ingestion in small children (age 1−5 years) is much higher than in older children 
and adults.  Because of their smaller weight, children’s intake of PBDEs per kilogram (or pound) of body
weight may be greater than that of adults.  Children who live near hazardous waste sites might
accidentally eat some PBDEs by putting dirty hands or other soil/dirt covered objects in their mouths, or
through eating without washing their hands.  Some children also eat dirt on purpose.  It is also possible
that children could be exposed to PBDEs following transport of the chemical on clothing from the
parent’s workplace to the home. 
As indicated above, young children can be exposed to PBDEs both before birth and from breast milk.  
Both lower-brominated PBDEs and decaBDE have been found in breast milk, and they can be transferred
to babies and young children.  In general, however, any risks from exposures in mother’s milk are
outweighed by the benefits of breastfeeding.  You should consult your health care provider if you have 
any concerns about PBDEs and breastfeeding.  Since the fetus and child are still developing, effects of
PBDEs might be more significant if exposure occurs during the periods before and soon after birth.
Evidence suggests that fetuses and young children are more susceptible to PBDEs than adults.  Subtle 
behavioral changes have been observed in animals exposed to PBDEs within the first 2 weeks of life, and 
results from human studies are suggestive of an effect of PBDEs on neurodevelopment in children, 
   
 













     
     



























1.  PUBLIC HEALTH STATEMENT
including impaired cognitive development (comprehension, memory), impaired motor skills, increased 
impulsivity, and decreased attention.  One study reported that early PBDE exposure was a risk factor for
the development of Attention Deficit Hyperactivity Disorder (ADHD); however, another study did not
find a link between PBDE exposure and ADHD.  One study investigating potential associations between
early PBDE exposure and autism did not find a link between maternal PBDE serum levels and autistic 
behaviors in 4–5-year old children.  One possible explanation for the observed behavioral effects might be
related to changes in the thyroid, because development of the nervous system is dependent on thyroid 
hormones.  Damage to developing reproductive organs and immune suppression have also been observed 
in animals exposed to PBDEs during development.  It is unknown if these effects occur in human 
children.
PBDEs have not caused birth defects in animals or impaired the ability for rats or mice to become 
pregnant or stay pregnant.
HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PBDEs?
If your doctor finds that you have been exposed to significant amounts of PBDEs, ask whether your
children might also be exposed.  Your doctor might need to ask your state health department to 
investigate.
Ingestion and dermal contact with indoor dust containing PBDEs is the major exposure pathway to 
residents of the United States.  Dust containing PBDEs can collect on your hands and be ingested through
hand-to-mouth activities; regular hand washing may decrease PBDE exposure from this route.
Additionally, PBDE exposure may be decreased by regular vacuuming and cleaning of air ducts and 
filters to reduce indoor dust levels.
Since many older consumer products such as televisions, computers, and furniture containing
polyurethane foam contain PBDEs, replacing older products with newer ones that do not contain these
substances may decrease residential PBDE exposure.
ARE THERE MEDICAL TESTS TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
PBDEs? 
PBDEs and their breakdown products (metabolites) can be measured in human blood, hair, and breast
milk.  However, the detection of PBDEs or their metabolites cannot predict the kind of health effects that
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might develop from that exposure.  Because PBDEs and their metabolites either leave the body or are
distributed to body fat fairly rapidly, the tests need to be conducted within days if an acute, high-level
exposure is suspected.  
For more information on the different substances formed by PBDE breakdown and on tests to detect these 
substances in the body, see Chapters 3 and 7.
WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT
HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  Regulations
can be enforced by law.  Federal agencies that develop regulations for toxic substances include the
Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA),
and the Food and Drug Administration (FDA).  Recommendations provide valuable guidelines to protect
public health but cannot be enforced by law.  Federal organizations that develop recommendations for
toxic substances include the Agency for Toxic Substances and Disease Registry (ATSDR) and the 
National Institute for Occupational Safety and Health (NIOSH).
Regulations and recommendations can be expressed as “not-to-exceed” levels; that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value usually based on levels that affect
animals; levels are then adjusted to help protect humans.  Sometimes these not-to-exceed levels differ
among federal organizations.  Different organizations use different exposure times (an 8-hour workday or
a 24-hour day), different animal studies, or emphasize some factors over others, depending on their
mission.
Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that issued the regulation
or recommendation.
EPA requires that companies that transport, store, or dispose of monobrominated diphenyl ether
(monoBDE) (or diphenyl ether with one bromine attached to the structure, represented by Chemical
Abstracts Service [CAS] Registry Number 101-55-3; Resource Conservation and Recovery Act [RCRA]
waste number U030) follow the rules and regulations of the federal hazardous waste management
program because it has been listed (U-list) as a hazardous waste due to toxicity concerns.  EPA also limits
the amount of monoBDE put into publicly owned waste water treatment plants.  To minimize exposure of
   
 


















































1.  PUBLIC HEALTH STATEMENT
people to monoBDE, EPA requires that industry tell the National Response Center each time 100 pounds
or more of monoBDE have been released to the environment.
OSHA has not set permissible exposure limits (PELs) to protect workers against adverse health effects 
resulting from exposure to PBDEs.  NIOSH has not recommended guidelines for worker exposure limits.
WHERE CAN I GET MORE INFORMATION?
If you have any questions or concerns, please contact your community or state health or environmental
quality department, or contact ATSDR at the address and phone number below.  ATSDR can also provide
publically available information regarding medical specialists with expertise and experience recognizing,
evaluating, treating, and managing patients exposed to hazardous substances.
• Call the toll-free information and technical assistance number at
1-800-CDCINFO (1-800-232-4636) or
• Write to:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
1600 Clifton Road NE
Mailstop F-57
Atlanta, GA 30329-4027
Toxicological profiles and other information are available on ATSDR’s web site:
http://www.atsdr.cdc.gov.
















   
  
  
   
 
    
    





    
  
   
   
 
   
 
  
   
  








2. RELEVANCE TO PUBLIC HEALTH
2.1  BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PBDEs IN THE UNITED 
STATES 
PBDEs are classes of structurally similar brominated hydrocarbons in which 2–10 bromine atoms are 
attached to the molecular structure (i.e., diphenyl ether).  Monobrominated structures (i.e., one bromine
atom attached to the molecule) are often included when describing PBDEs.  There are 209 different
molecular combinations, or congeners, that are possible for PBDEs, although only a limited number exist 
in commercial mixtures.  Based on the number of bromine substituents, there are 10 homologous groups
of PBDE congeners (monobrominated through decabrominated), with each homologous group containing
one or more isomers.  The mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, and decabromo­
congeners can exist in 3, 12, 24, 42, 46, 42, 24, 12, 3, and 1 isomers, respectively.  The general chemical











where m + n = 1 to 10
Due to the ether linkage and the position and number of bromine atoms, there are important three-
dimensional differences in the structures of PBDEs that can influence the molecules’ receptor interactions 
and toxicological properties as discussed in Section 3.5, Mechanisms of Action.  In general, PBDEs are
not expected to have the same array of three-dimensional conformations as either polybrominated 
biphenyls (PBBs) or polychlorinated biphenyls (PCBs).
PBDEs are brominated organic compounds that were used as flame retardant additives in plastics, textiles,
and other materials.  As additives, they are physically mixed into product applications, rather than 
chemically bound.  Therefore, they have the potential to migrate from the plastic matrix into the
environment when conditions are ideal.  Production of PBDEs began in the 1970s and has continued until
recently.  PentaBDE and octaBDE mixtures were voluntarily withdrawn from the U.S. marketplace by
their manufacturers at the end of 2004; however, the manufacture and use of decaBDE continued past that
date.  In December of 2009, the two remaining U.S. producers of decaBDE and the largest U.S. importer
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of this product announced commitments to phase out manufacture and importation of decaBDE for most
uses in the United States by December 31, 2012, and to end manufacture and import for all uses by the
end of 2013.
PBDEs are persistent in the environment and most congeners can be considered bioaccumulative.  The
fully brominated congener, BDE 209, has a lower tendency to bioconcentrate due to its molecular
dimensions; however, numerous studies have detected this substance in tissues of birds, mammals, and
fish (see Section 6.4.4). 
Monitoring and body-burden data indicate that PBDEs are ubiquitous in the environment and that the
general population is exposed to these substances through their past use as flame retardants.  A study that
examined stored blood samples from 1973 (prior to the use of PBDEs as flame retardants) showed 
virtually no detections of these substances in human blood; however, varying concentrations of many
PBDE congeners were detected in all blood samples collected in 2003 from 39 residents in Mississippi
and 10 residents in New York City, illustrating the widespread exposure to PBDEs since their inception.  
Body burden data have consistently shown the residents of North America have higher concentrations of
PBDEs in blood than people residing in Europe, likely due to differences in past production and use of
commercial formulas.
House dust was identified as a major source of exposure to PBDEs by a systematic study of American
exposure routes.  In the United States, concentration levels found in soil, house dust, and air tended to be
greater in indoor samples compared to outdoor samples.  The EPA calculated the adult intake dose of total
PBDEs to be 7.1 ng/kg body weight/day.  It estimated children’s intakes as 47.2 ng/kg body weight/day
for 1–5 year olds, 13.0 ng/kg body weight/day for 6–11 year olds, and 8.3 ng/kg body weight/day for 12– 
19 year olds.  The much higher dose for children aged 1−5 years was largely due to higher soil/dust
ingestion in this age group. Exposure to indoor dust was the predominant exposure pathway for PBDEs
in these calculations. It was estimated that 90% of the intake resulted from house dust inhalation or
dermal exposure.  This does not include special populations such as infants that are primarily exposed 
through breastfeeding.  PBDE concentrations were generally lower in house dust samples collected
outside of the United States compared with dust samples collected within the United States.  The specific 
PBDE congeners detected in house dust and food vary; BDE 209 is more commonly detected within 
indoor environments where exposure is more likely to occur through intake of contaminated dust and air.  
PBDE contamination of food is more likely a result of past emissions or ongoing emissions from
dumpsites and older products that still contain pentaBDE, which is mainly composed of the congeners 
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BDE 47 and BDE 99. Ingestion of PBDEs through the diet appears to be the predominant pathway for
European communities. In China, the decaBDE congener, BDE 209, was the most abundant congener
detected in both maternal and cord blood samples where industrial production of BDE 209 may result in 
exposure.
2.2  SUMMARY OF HEALTH EFFECTS 
Information is available on the potential health effects of formerly used commercial PBDE mixtures 
(pentaBDE, octaBDE, and decaBDE) as well as several individual PBDE congeners.  As subsequently
discussed, the toxicity of decaBDE is generally less pronounced than for lower-brominated PBDEs
following acute and repeated-dose exposures.  This difference in toxicity may be related to differences in
pharmacokinetics, resulting in lower bioavailability of decaBDE (see Sections 2.3 and 3.4 for more
details).  
The preponderance of health effects information on PBDEs is from studies of orally exposed laboratory
animals and human studies in which the main exposure route is unknown, but expected to be oral.  As 
summarized below and detailed in Chapter 3 (Health Effects), the main targets of concern following
PBDE exposure in humans are the developing nervous and reproductive systems, the developing and 
mature endocrine system, the liver, and the male reproductive system.  Other potential targets are the 
female reproductive system, the adult nervous system, and the developing and adult immune system;
however, evidence for these end points is limited.  In other systems/organs, available data provide no
consistent evidence for exposure-related effects (respiratory, cardiovascular, gastrointestinal,
hematological, renal, dermal, or ocular effects); therefore, effects in these systems are considered unlikely 
to occur following PBDE exposure.  
Developmental Effects.
Neurodevelopment. Numerous epidemiological studies have reported results suggestive of an effect of
PBDE on neurodevelopment in children.  PBDE concentrations in cord blood, maternal or infant serum, 
and/or breast milk have been correlated with cognitive score and adaptive behavior deficits in infants; 
mental and physical development deficits in infants/toddlers at ages 12, 24, and 36 months; language and 
social developmental score deficits in toddlers at 24 months; increased impulsivity in toddlers at 24– 
36 months; poor social competence and attention deficit hyperactivity disorder (ADHD) or increased
attention problems in 4-year-old children; impaired fine motor coordination, verbal memory and 
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comprehension, and sustained attention in 5–7-year-old children; and poor attention and executive
function deficits in 9–12-year-old children.  In one birth cohort, no associations were observed between 
maternal serum PBDEs and neonatal behavior in 5-week-old infants or autistic behaviors at 4–5-year-old 
children; however, children from the same cohort showed associations between maternal serum PBDEs 
and decreased IQ and increased hyperactivity at 5 years of age and executive function deficits at 5– 
8 years of age.  Pre- and perinatal studies in animals also consistently reported neurodevelopmental
effects following exposure to lower-brominated PBDEs and decaBDE at doses ≥0.06 and 
≥2.22 mg/kg/day, respectively, including neurobehavioral alterations, delayed ontogeny of reflexes, 
ultrastructural changes in the hippocampus, altered nicotinic receptor density, altered electrophysiology, 
and altered gene and protein expression levels.  
Based on human and animal data, the developing nervous system is a target of concern for both lower­
brominated PBDEs and decaBDE.
Endocrine System Development. In infants, developmental exposure to PBDEs and infant serum or cord 
blood thyroxine (T4) levels were either negatively associated or not associated.  Associations between 
developmental PBDE exposure and infant serum or cord blood triiodothyronine (T3) and thyroid 
stimulating hormone (TSH) were similarly inconsistent.  In animals, numerous studies have reported 
decreased serum T4 and/or T3 levels in pups after gestational and lactational exposure to penta- or
tetraBDE at doses as low as 0.3 mg/kg/day in rats and 452 mg/kg/day in mice. Significant reductions in 
serum T3 levels were also observed in offspring following gestational and lactational exposure to 
decaBDE at 146 mg/kg/day in rats and 1,500 mg/kg/day in mice, although no changes were observed in 
serum T4 or TSH.  A dose-related decrease in serum T4 was observed in neonatal male mice exposed to
decaBDE doses of 6–20 mg/kg/day from postnatal day (PND) 2 to 15, but no change was observed in 
neonatal females.  
While human data are inconsistent, they suggest that PBDEs can interact with thyroid hormone
homeostasis in infants and children. These data, along with available animal studies, indicate that the 
developing thyroid is a target of concern for PBDE exposure, especially lower-brominated PBDEs.  
Reproductive System Development. Male reproductive effects significantly associated with PBDE
exposure in infants included congenital cryptorchidism (undescended testes), decreased cord serum total 
testosterone (but not free testosterone, estradiol [E2], aromatase index, sex hormone binding globulin, or
Anti-Müllerian hormone), increased serum levels of the sex hormones, E2, free E2, and inhibin B (but not
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testosterone, luteinizing hormone [LH], follicle-stimulating hormone [FSH], or sex hormone binding
globulin) at 3 months of age, and increased testes volume in boys at 18 months of age.  In contrast, no 
relationships were observed between maternal PBDE exposure and hypospadias (abnormal location of the
urinary tract opening) in male offspring, PBDE concentrations in children’s adipose tissue and 
cryptorchidism, or various measures of sexual maturation in female offspring.  However, serum PBDE
levels in 6–8-year-old females were significantly associated with delayed onset of puberty in a
longitudinal cohort of U.S. girls.
In animal studies, reproductive effects were observed in adult F1 offspring of dams exposed to a single 
dose of pentaBDE at 0.06 mg/kg on gestation day (GD) 6, including reductions in testicular weight, 
sperm/spermatid number, and daily sperm production in males and a decreased number of secondary
follicles and ultrastructural changes in the ovaries in females (although F1 fertility when mated to an
unexposed animal was not impaired).  In animals exposed pre- or perinatally to decaBDE, reproductive
effects were observed in adult male offspring of dams exposed to decaBDE doses of 10–1,500 mg/kg/day 
from GD 0 to 17, including testicular lesions, decreased anogenital distance (AGD), and altered sperm
parameters.  In contrast, no exposure-related changes in AGD, onset of puberty, or reproductive organ 
weight and histology were reported in offspring of dams exposed to decaBDE at doses up to 
1,000 mg/kg/day during gestation and lactation or doses up to 20 mg/kg/day from PND 2 to 15.  No 
exposure-related changes in reproductive development were reported in female offspring of dams exposed
to decaBDE at doses up to 1,000 mg/kg/day during gestation and lactation or doses up to 20 mg/kg/day
from PND 2 to 15.
Based on limited human and adequate animal data, it is possible that oral PBDE exposure during
development may adversely affect the developing reproductive system, particularly the male reproductive 
system.  However, data are too limited to adequately determine whether or not PBDE exposure in infants
and children will lead to altered reproductive performance as adults.
Immune System Development. In offspring of rat dams exposed to pentaBDE at doses up to 
25 mg/kg/day via gavage for 70 days prior to mating through PND 21, a significant dose-related trend
was observed in the incidence of apoptotic lymphocytes and tingible macrophages in the thymus of
PND 43 males, but not females. In PND 28 offspring of mouse dams exposed to decaBDE at doses
≥260 mg/kg/day from GD 10 to PND 21, pulmonary viral titers of respiratory syncytial virus (RSV)
(measured 5 days post-infection) were significantly increased. These animal data suggest that oral PBDE
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exposure during development may lead to immunosuppression; however, data are too limited to 
adequately assess the immunotoxic potential of PBDE exposure in infants and children.
Embryotoxicity, Fetotoxicity, and Physical Growth and Development. No human studies have evaluated
associations between embryotoxicity or fetotoxicity and PBDE exposure.  One study reported a
significant increased risk for preterm birth in women with high serum PBDE concentrations, compared 
with low PBDE concentrations; however, other studies did not observe a significant association between
gestational length and PBDE concentrations. Evidence for altered physical growth and development from
human studies is inconsistent, with some studies reporting associations between PBDE concentrations in 
maternal/cord serum, breast milk, or placental tissue and decreased birth weight, length, chest
circumference, head circumference, and/or body mass index (BMI), some reporting no associations, and a
limited number reporting increased birth weight, length, and/or head circumference. Available data from
animal studies indicate that PBDEs are not embryotoxic or fetotoxic at PBDE doses below doses that
elicited maternal toxicity, although occasional observations of reduced pup weight were reported.
Based on animal studies, it is unlikely that oral PBDE exposure will cause embryotoxicity or fetotoxicity
in humans; however, human and animal data indicate that PBDE exposure could potentially lead to low
birth weight or other impacts on physical development.
Endocrine Effects.
Thyroid. Numerous studies have been performed to evaluate the relationship between concentrations of
PBDE in body tissues and circulating thyroid hormone levels in human populations.  While these studies
have demonstrated that PBDE can perturb the human endocrine system and affect hormone levels, the
specific findings are not consistent across studies.  For example, even limiting the discussion to studies
that evaluated both PBDE concentrations and thyroid hormone levels in serum samples collected only
from adult men, studies have reported positive associations with T4, negative associations with T4, and no 
association with T4. Similar inconsistencies were found in studies in pregnant women, with studies
reporting a positive associations with T4, no association with T4, or negative associations with T4.  Results
were similarly inconsistent regarding the association between PBDE concentrations and serum T3 and 
TSH.
In contrast to inconsistencies observed in human studies, altered serum thyroid hormone levels have been 
consistently reported in laboratory animals exposed to lower-brominated PBDEs.  Reduced serum T4 has 
   
 









      
  
  
      
 
    
   
      




     
   
      
   
  
    
    
   
 
    
       
  
    
   
       
  
 





2. RELEVANCE TO PUBLIC HEALTH
been reported in animals following acute or intermediate exposure to lower-brominated PBDEs at doses 
as low as 0.8 mg/kg/day.  At higher doses (≥30 mg/kg/day), some studies also report reduced serum T3 
and/or increased serum TSH; however, other studies reported no significant changes in serum T3 and/or
TSH levels in rats exposed to doses up to 300 mg/kg/day.  In rat dams, reduced serum T4 has been
observed following exposure to lower-brominated PBDEs at doses as low as 0.06 mg/kg/day during
gestation or gestation plus lactation.  In mouse dams, no exposure-related changes were observed
following exposure to pentaBDE at 452 mg/kg/day from GD 4 to PND 17.  Exposure to pentaBDE at
doses up to 120 mg/kg/day during gestation or gestation plus lactation did not significantly alter maternal 
serum T3 and/or TSH in most studies; however, a study reported reduced maternal serum T3 after
exposure to pentaBDE at 30 mg/kg/day via dosed cookies from GD 1 to PND 21.
Histopathological changes in the thyroid (e.g., follicular cell hyperplasia, increased epithelial
thickness/height, altered morphology of epithelium, cellular debris, degeneration) have been observed in 
intermediate-duration studies of lower-brominated BDEs at doses as low as 20 mg/kg/day in rats,
0.45 mg/kg/day in mice, and 0.06 mg/kg/day in mink.  Increased thyroid weights were reported in rats
exposed to doses of penta- or octaBDE as low as 50 mg/kg/day for 90 days; however, no exposure-related
changes in thyroid weights were observed in rats exposed to doses of penta- or octaBDE up to 
200 mg/kg/day for 15–28 days or in F0 or F1 mink exposed to dietary pentaBDE at doses up to 
0.31 mg/kg/day in one-generation studies (4 weeks pre-mating through postnatal week [PNW] 6 or 33).  
In acute studies, no exposure-related changes in thyroid weight or histology were observed in rats 
exposed to penta- or tetraBDE doses up to 36 mg/kg/day for 14 days
Unlike the lower-brominated PBDEs, serum T4 levels were not altered in rats exposed to decaBDE at
doses up to 600 mg/kg/day for 4–90 days.  Some studies reported reduced serum T3 levels in rats exposed
to decaBDE at doses as low as 50 mg/kg/day for 28–90 days, but another 90-day study reported no 
change in serum T3 levels in rats exposed to decaBDE at doses up to 100 mg/kg/day. Serum TSH was 
reduced in male rats exposed to decaBDE at doses ≥300 mg/kg/day for 33 days. At higher doses
(≥950 mg/kg/day), significant reductions in serum T4 and T3 were observed in male mice exposed for
35 days and pregnant mice exposed from GD 7 to 9.  
In chronic studies of decaBDE, thyroid follicular cell hyperplasia was observed in male mice exposed to
≥3,200 mg/kg/day for 103 weeks; no histopathological changes in the thyroid were observed at doses up 
to 7,780 mg/kg/day in female mice, 2,240 mg/kg/day in male rats, or 2,550 mg/kg/day in female rats.  In
intermediate-duration studies, dose-related increases in thyroid hyperplasia were reported for male rats 
   
 








     
    
   
     
   
   
     
    
 
   
    
 
 
     
      
      
     
 
    
    




   
  
      
   
  
  




2. RELEVANCE TO PUBLIC HEALTH
exposed to a low-purity decaBDE compound at ≥80 mg/kg/day for 30 days, but hyperplasia was not
observed in rats or mice exposed to high-purity decaBDE at doses up 8,000 or 9,500 mg/kg/day,
respectively, for 13 weeks or in rat dams exposed to doses up to 146 mg/kg/day from GD 10 to PND 21.  
However, multiple areas of degenerated follicular epithelium and slight attenuation of the follicular
epithelium were observed in the thyroid glands of young male rats exposed to decaBDE at doses
≥300 mg/kg/day for 33 days.  No changes in thyroid weight were observed in rats exposed to decaBDE at
doses up to 90 mg/kg/day for 28 days, but increased thyroid weights were reported in rat dams exposed to 
≥2 mg/kg/day from GD 10 to PND 21 and young male rats exposed to 600 mg/kg/day for 33 days.
While human data are inconsistent, they suggest that PBDEs can interact with thyroid hormone
homeostasis. These data, along with available animal studies, indicate that the thyroid is a target of
concern for PBDE exposure, especially lower-brominated PBDEs.
Pancreas. An analysis of cross-sectional National Health and Nutrition Examination Survey (NHANES)
data showed a significant increase in the risk of diabetes associated with serum concentrations of BDE
153 (but not BDE 28, BDE 47, BDE 99, or BDE 100), although the risk was higher with exposure to 50– 
75th percentile BDE 153 concentrations than >75th percentile BDE 153 concentrations. Serum BDE 153 
concentrations (but not BDE 28, BDE 47, BDE 85, BDE 99, BDE 100, or BDE 154) were also shown to 
be significantly associated with increased odds of developing gestational diabetes in a cohort of
258 pregnant women.  However, other cross-sectional and prospective studies found no relationship 
between serum PBDE concentrations and diabetes in an adult cohort from Wisconsin, an elderly cohort in 
Finland, or an elderly cohort in Sweden.
An intermediate-duration study evaluated insulin-regulation and pancreatic morphology in rats following 
exposure to decaBDE at 0, 0.05, 1, or 20 mg/kg/day daily via gavage in corn oil for 8 weeks.  Serum
insulin was significantly decreased by 50–60% at 1 and 20 mg/kg/day, and glucose levels were
concomitantly increased by 12, 18, and 21% at 0.05, 1, and 20 mg/kg/day.  Consistent with the insulin 
findings, morphological changes were seen in the pancreas at 1 and 20 mg/kg/day (blurred boundaries
among pancreatic islet cells; quantitative data not reported).  Additionally, microarray analysis indicated
that type I diabetes mellitus (T1DM) canonical pathways were significantly enriched following decaBDE
exposure. Subsequently, gene act network and gene coexpression network found that some major
histocompatibility complex molecules and TNF-α were involved in the T1DM pathway.  Only one other
animal study evaluated the pancreas following decaBDE exposure.  In rats exposed to decaBDE via
gavage for 28 days at doses of 0, 0.27, 0.82, 2.47, 7.4, 22.2, 66.7, or 200 mg/kg/day, slight or moderate
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insulitis was observed in the Langerhan’s islets of the “majority of samples,” but findings were not
exposure-related.  Similarly, no exposure-related effects were observed for serum glucose levels.  The
only other study evaluating serum glucose levels after decaBDE exposure instead reported reduced serum
glucose levels in male rats exposed to 20 mg/kg/day of a dietary PBDE mixture containing 52.1%
pentaBDE (DE-71), 44.2% decaBDE (BDE 209), and 0.4% octaBDE (DE-79) for 70 days.  The observed 
decreased glucose levels could be due to the pentaBDE component, as male rats exposed to pentaBDE at
doses of 0.27–200 mg/kg/day for 28 days also showed decreased glucose levels; the study authors did not
report the lowest dose at which glucose levels were significantly lower in male rats, but they reported a 
BMD10RD of 179.55 mg/kg/day and a BMDL10RD of 66.7 mg/kg/day.  
Limited human evidence is inconclusive regarding potential associations between diabetes and PBDE
exposure; however, considering the animal data, the pancreas may be a target of concern for oral PBDE
exposure.  
Hepatic Effects. Liver effects have been reported in adult, pregnant, and developing animals exposed 
to lower-brominated PBDEs.  Histopathological effects in the liver (hepatocellular hypertrophy, necrosis, 
and vacuolation) were consistently observed in animals exposed to lower-brominated PBDEs for 15– 
90 days at doses ≥0.45 mg/kg/day, regardless of life-stage.  In acute exposure studies, fatty degeneration
of the liver was observed following a single pentaBDE dose of 2,000 mg/kg or repeated pentaBDE doses 
of 200 mg/kg/day for 7 or 14 days.  Increased liver weight was also observed in animals exposed to
lower-brominated PBDEs for 1–14 days at doses ≥8 mg/kg/day and 15–90 days at doses ≥1.2 mg/kg/day.  
In studies that evaluated hepatic enzyme induction (e.g., elevated ethoxyresorufin o-deethylase [EROD],
methoxyresorufin o-deethylase [MROD], pentoxy-resorufin o-deethylase [PROD], and uridine
diphosphoglucuronyl transferase [UDPGT] activity), significantly increased enzyme activities were 
observed in animals following acute or intermediate-duration exposure to doses ≥3 or ≥0.06 mg/kg/day,
respectively, and were always observed at doses at or below the dose causing elevated liver weights in the 
same study.  No studies evaluating liver effects following chronic exposure to lower-brominated PBDEs
were located.
Evidence for hepatic toxicity following exposure to decaBDE is less consistent than evidence for lower­
brominated PBDEs.  There is no evidence of hepatic toxicity following acute exposure to decaBDE at
doses up to 1,000 mg/kg/day for 4–14 days.  In intermediate-duration studies, slight to moderate
hepatocellular hypertrophy was observed in rats exposed to decaBDE at 60 mg/kg/day for 28 days, in 
pregnant rats exposed to 300 mg/kg/day for 21 days, and in mice exposed to 9,400 mg/kg/day for
   
 








     
    
   
    
      
   
  
   
    
     
   
 
   
      
   
  
  
     
 




   
 
      
  
       
     
      
  




2. RELEVANCE TO PUBLIC HEALTH
28 days; however, other studies did not report exposure-related changes in liver histology following
exposure to decaBDE at doses up to 9,500 mg/kg/day for 3–13 weeks.  In an older study using an impure
decaBDE compound containing lower-brominated congeners (77% decaBDE, 22% nonaBDE, 0.8%
octaBDE), centrilobular cytoplasmic enlargement and vacuolation, as well as increased liver weight, were
observed in male rats exposed to dietary doses of ≥80 and 800 mg/kg/day, respectively, for 30 days.  
Increased liver weights were also reported in rats exposed to doses ≥1 mg/kg/day for 8 weeks and mice
exposed to 9,400 mg/kg/day for 28 days, but other intermediate-duration studies reported no exposure-
related changes in liver weights at doses of 1,000 mg/kg/day for 21–90 days.  In chronic studies, exposure
to decaBDE for 103 weeks caused liver lesions that included neoplastic nodules in rats at
≥1,120 mg/kg/day, thrombosis and degeneration in rats at 2,240 mg/kg/day, and centrilobular hypertrophy
and granulomas in mice at ≥3,200 mg/kg/day.
Developing animals appear to be more susceptible to liver damage following exposure to decaBDE than 
adult animals. Transient histopathological changes (diffuse liver cell hypertrophy with increased
cytoplasmic eosinophilia) and elevated liver weights were observed in male and female rat offspring
exposed to decaBDE from GD 10 to PND 21 at ≥2 and 146 mg/kg/day, respectively.  Fatty degeneration, 
elevated liver weights, and elevated liver enzymes were observed in young male rats exposed to decaBDE
at ≥300 mg/kg/day from PND 10 to 42.  In mice, decaBDE exposure from GD 0 to 17 caused acute cell
swelling of hepatocytes associated with pressure occlusion of hepatic sinusoids and elevated liver
enzymes in PND 71 male offspring at ≥10 mg/kg/day; however, liver weight was unaltered at doses up to
600 mg/kg/day.  
No studies are available on hepatic effects of PBDEs in humans.  Based on the evidence in animals,
PBDEs are potentially hepatotoxic in humans, especially lower-brominated PBDEs.
Male Reproductive Effects. Several studies have found results suggestive of reproductive effects in 
men associated with exposure to PBDE, including significant inverse correlations between serum
concentrations of BDE 153 (hexaBDE) and sperm concentration and testis size in young adult Japanese
males, significantly reduced sperm mobility in association with increased serum PBDE concentrations
(BDE 47, BDE 100, and total) in Canadian men recruited at a fertility clinic, and altered parameters of
semen quality associated with selected BDEs in men participating in a prospective cohort study in 
Michigan and Texas.  Although a number of studies have evaluated the potential effects of PBDE
exposure on male reproductive hormone levels, these studies collectively do not show consistent effects 
associated with PBDE exposure.  
   
 









    
  
    
   
  
   
   
     
   
  
  
   
     
   
 
   




   
  
   
  
    
 
  
   
  





2. RELEVANCE TO PUBLIC HEALTH
Reproductive effects have been reported in male rodents following intermediate-duration exposure to the
lower-brominated PBDE congener tetraBDE, including decreased serum testosterone at
≥0.001 mg/kg/day, histopathological changes in rat or mouse testes (increased epithelial thickness,
multinucleated giant cells, vacuolar spaces, apoptosis, germ cell loss) at doses ≥0.03 or
≥0.045 mg/kg/day, and decreased sperm production in rats at 1 mg/kg/day.  No dose-related changes were 
observed in testicular weight or sperm morphology, motility, or capacitation at doses up to 30 mg/kg/day.  
For other lower-brominated PBDEs (pentaBDE, octaBDE), no exposure-related effects were observed in
serum testosterone levels at doses up to 60 mg/kg/day for 15–70 days, sperm parameters at doses up to 
20 mg/kg/day for 20 days, or male reproductive histology or organ weight at doses up to 750 mg/kg/day 
for 38–90 days.  However, in acute studies, serum testosterone levels were significantly decreased by
~40–45% in male rats 45 days after a single gavage exposure to pentaBDE at doses ≥0.6 mg/kg and dose-
related decreases in androgen-dependent tissue weights (prostate, seminal vesicle, Cowper’s gland, gland
penis, levator ani bulbo cavernosus) were observed in castrated rats exposed to pentaBDE at doses 
≥30 mg/kg/day for 9 days (Herschberger assay).
Studies of decaBDE have been more limited. Decreased relative testes and epididymides weights,
degenerative changes in the seminiferous tubules, reduced sperm count and viability, and reduced serum
testosterone were reported in male mice exposed to decaBDE at 950 mg/kg/day via gavage for 35 days,
compared with controls; no exposure-related effects were observed at 750 mg/kg/day.  In contrast, no 
changes in sperm count, motility, or morphology were observed in rats or mice exposed to decaBDE at
doses up to 60 or 1,500 mg/kg/day for 28–50 days; however, exposure-related decreases were observed in
one sperm velocity measure (lateral head amplitude) in mice exposed to ≥500 mg/kg/day.  A dose-related
decrease in epididymis weight and a dose-related increase in seminal vesicle/coagulation gland weight 
were observed in rats exposed to 1.7–60 mg/kg/day for 28 days; however, the lowest doses at which the 
effects were observed were not reported.  No testicular weight changes were observed at doses up to 
60 mg/kg/day.  In other intermediate-duration studies, no exposure-related changes in organ weight were 
reported for male reproductive organs in rats or mice exposed to decaBDE doses up to 800 or
1,500 mg/kg/day.  Histopathological changes in male reproductive tissues have not been reported in rats 
or mice exposed to decaBDE at doses up to 2,550 or 7,780 mg/kg/day, respectively, for 103 weeks.  
Findings were negative in a one-generation study that exposed male and female rats to an impure
decaBDE compound containing lower-brominated congeners (77% decaBDE, 22% nonaBDE, 0.8%
octaBDE) for 60 days prior to mating through PND 21.  
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Based on the evidence in humans and animals, lower-brominated PBDEs are potentially toxic to the male 
reproductive system in humans.  Available data for decaBDE provide very limited evidence of male 
reproductive damage.
Female Reproductive Effects. Evidence for reproductive effects in women associated with
exposure to PBDEs is inconsistent.  Increased length of menstrual periods (prior to pregnancy) was 
associated with increased breast milk concentrations of PBDEs in a study of 46 Taiwanese women, and 
with plasma levels of BDE 47 and BDE 153 in a study of 42 Cree women of James Bay, Canada, but not
in a smaller study with 20 Taiwanese women or in 223 Californian women.  Age at menarche was not
associated with PBDE concentrations in breast milk; however, an analysis of cross-sectional data from a 
sample of 271 adolescent girls (NHANES) found that higher serum PBDE concentrations were associated
with younger age of menarche.  Decreased fecundability (i.e., increases in time to pregnancy between
stopping contraception and becoming pregnant) was significantly associated with increased serum
concentrations of BDE 47, BDE 99, BDE 100, and BDE 153 (and their sum) in 223 Californian women; 
however, fecundability was not significantly related to serum PBDE concentrations in a cohort of
501 Michigan and Texas couples followed prospectively for 1 year after discontinuing contraception for
the purpose of becoming pregnant.  A study of 65 women from Boston undergoing in vitro fertilization
found no association between serum PBDE concentrations and risk of implantation failure, but did find a
significantly increased risk of failure associated with increased (i.e., above median) concentrations of
BDE 153 (but not other congeners or total PBDE) in follicular fluid.  PBDEs were not associated with
Polycystic Ovary Syndrome or with diagnosis of uterine fibroids. 
In one-generation animal studies, no exposure-related changes were observed in reproductive end points
(number of pregnancies, gestation length, number, size, or sex ratio of litters) in rats or mice exposed to 
lower-brominated PBDEs at doses up to 25 or 1 mg/kg/day, respectively.  Similarly, in gestation plus
lactation studies, no exposure-related effects on litter parameters (successful delivery of litters, gestation
length, litter size, sex ratio, number of live pups) were observed in rats or mice exposed to lower­
brominated PBDEs at doses up to 32 or 10 mg/kg/day, respectively, during gestation and lactation only.  
The number of litters surviving until PND 8 was significantly decreased following exposure to tetraBDE
at 0.1 mg/kg/day from pre-mating day 28 through PND 21 in one study; however, reduced pup survival
was not reported in other studies.  In a one-generation study in mink, females exposed to pentaBDE at
doses ≥0.25 mg/kg/day from pre-mating day 28 through PNW 6 did not whelp.  It is not clear in one study
whether mink exposed to 0.25 mg/kg/day never became pregnant or had complete litter loss.  However, 
another study reported that female mink exposed to 0.31 mg/kg/day had no exposure-related changes in
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mating success; rather, sows showed complete litter loss with 70% showing clear postimplantation loss.
In one-generation and intermediate-duration studies, no changes in reproductive organ weight or
histology were observed in female rats, mice, or mink exposed to lower-brominated PBDEs at doses up to 
750, 0.45, or 0.31 mg/kg/day, respectively.  One acute study reported increased paired ovary weight after
exposure to tetraBDE at 0.14 mg/kg on GD 6; however, no changes in reproductive organ weight or
histology were observed in female rats acutely exposed to pentaBDE at doses up to 300 mg/kg/day.
In female mice exposed to dietary tetraBDE for 28 days, serum testosterone and E2 were significantly
increased at 0.45 mg/kg/day; no other study reported altered reproductive hormones in females.
Information on reproductive effects of decaBDE is limited. Findings were negative in a one-generation 
study that exposed male and female rats to an impure decaBDE compound contaminated with lower­
brominated congeners (77% decaBDE, 22% nonaBDE, 0.8% octaBDE) for 60 days prior to mating 
through PND 21. In a gestational exposure study in mice (GDs 7–9), significant increases were observed
in the percentage of postimplantation loss per litter and resorptions per litter in dams exposed to ≥750 and
≥1,500 mg/kg/day, respectively.  Additionally, the percentage of live fetuses per litter was significantly 
decreased by 10% in dams exposed to 2,000 mg/kg/day. Histological changes in the ovaries (atrophic 
changes, decreased number of follicles, and increased fibrotic tissue) were observe in female rats exposed
to decaBDE at 300 mg/kg/day from 3 weeks of age, through mating to untreated males, gestation, and
lactation (~11 weeks); F0 reproductive success was not reported.  In other studies, no histopathological
changes in female reproductive organs were observed in rats or mice following intermediate- or chronic-
duration exposure to decaBDE at doses up to 8,000 or 9,500 mg/kg/day, respectively.
Based on inconsistent data in humans and animals, it is unclear whether PBDEs affect the female 
reproductive system in adults.
Adult Neurological Effects. While neurobehavioral development is a potential effect of concern for
PBDE exposure in humans, available human data are too limited to determine if PBDE exposure is 
neurotoxic in adults or adolescents.  No association was found between serum PBDE concentrations and 
neuropsychological function assessed by 34 tests of cognitive and motor function, affective state, and 
olfactory function in a study population of 144 volunteers (67 males and 77 females) between the ages of
55 and 74 years who lived for at least 25 years in the upper Hudson valley of New York State.  In 
515 secondary students from Belgium (mean age 14.9 years), serum PBDE concentrations were not
associated with most aspects of neurological performance measured in a battery of neurological tests;
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however, there was a significant deterioration in performance in the finger tapping test with increasing
PBDE level, suggesting an effect of PBDE on motor activity.
Evidence for neurological effects of lower-brominated PBDEs in adult animals is limited.  In repeat-
exposure neurobehavioral studies, impaired learning and memory were observed in male rats exposed to
tetraBDE at ≥0.1 mg/kg/day for 30 days and impaired attention and inhibitory control were observed in 
male mice exposed to pentaBDE at 26.2 mg/kg/day for 125 days. No exposure-related neurobehavioral
changes were observed in rats exposed to pentaBDE at doses ≤17.5 mg/kg/day for 90–125 days or male 
rats exposed once to pentaBDE doses up to 1.2 mg/kg/day.  No exposure-related changes in brain weight
and/or histology were observed in animals exposed to lower-brominated PBDEs at doses up to 
750 mg/kg/day.
Evidence for neurological effects of decaBDE in adult animals is extremely limited. Decreased anxiety
behavior in the elevated-plus maze was observed in male mice exposed to decaBDE for 15 days;
however, no exposure-related changes were observed in anxiety behaviors in the light/dark test, in 
learning or memory in the Morris water maze, or in general neurological behaviors assessed using a 
functional observation battery.  In another study, no changes were observed in open-field behavior of
male rats exposed to decaBDE at doses up to 50 mg/kg/day via gavage for 90 days.  No changes in brain 
weight were observed in rats or mice exposed to decaBDE at doses up to 90 or 160 mg/kg/day, 
respectively, for 15–60 days. No overt signs of neurotoxicity were observed in rats and mice exposed to
decaBDE in estimated dietary doses as high as 16,000–19,000 mg/kg/day for 14 days, 8,000– 
9,000 mg/kg/day for 13 weeks, or 2,550–7,780 mg/kg/day for 103 weeks.  Although the high doses and 
extended exposure durations provided opportunities for the induction and/or development of clinical
signs, the study is limited by lack of testing for subtle behavioral changes and neurodevelopmental
effects.
Based on available data in humans and animals, it is unclear whether PBDEs affect the adult nervous 
system.
Immunological and Lymphoreticular Effects. Limited human data regarding potential
immunotoxic effects of PBDEs are available. A significant negative association was found between
serum concentrations of lower-brominated PBDE and number of circulating lymphocytes in a subset of a 
cohort of 33 adolescent children from the Netherlands.  No effects on pokeweed mitogen-stimulated DNA
proliferation or IgG immunoglobulin synthesis were found in human lymphocytes exposed to lower­
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brominated PBDEs in vitro. Studies of Swedish subjects reported a significantly negative association
between serum levels of BDE 47 and levels of protein complement 3, but not with levels of multiple
inflammatory markers.  In a study of Chinese children, serum levels of BDE 28 and 209 were associated
with an increased risk of asthma. 
There is limited evidence for impaired immune function in animals following exposure to lower­
brominated PBDEs; however, comprehensive immunological evaluations have not been performed on any
congener or previously used commercial mixture.  The plaque-forming splenic cell antibody response to
injected sheep red blood cells was significantly reduced in mice exposed to 72 mg/kg/day pentaBDE for
14 days; single doses as high as 500 mg/kg had no effect.  In the same study, exposure to up to 
72 mg/kg/day had no effect on natural killer cell (NKC) activity. In vitro production of IgG
immunoglobulin from pokeweed mitogen-stimulated splenocytes was reduced in mice exposed to
36 mg/kg/day pentaBDE for 14 days.  Other 14-day studies in mice found no changes in NKC activity to
murine YAC-1 target cells at pentaBDE doses up to 72 mg/kg/day or numbers of splenic and thymic
lymphocyte subsets at pentaBDE doses up to 36 mg/kg/day, although 18 mg/kg/day of tetraBDE caused 
significantly reduced numbers of total lymphocytes and CD4+, CD8+, and CD45R+ subtypes in spleen.  
In the only intermediate-duration study evaluating immune function, no dose-related changes were 
observed in antibody-mediated immunity to keyhole limpet hemocyanin (KLH) or phytohemagglutinin 
(PHA) skin response in mink exposed to pentaBDE at doses up to 0.78 mg/kg/day for 9 weeks.
Histopathological changes in the spleen (hyperplasia, germinal center development) were reported in
some studies following intermediate-duration exposure to lower-brominated PBDEs at doses as low as 
0.63 mg/kg/day in mink and at 0.45 mg/kg/day in mice. In other studies, no exposure-related changes 
were observed in spleen, thymus, lymph node, and/or bone marrow tissue histology in rats exposed to 
lower-brominated PBDEs at doses up to 750 mg/kg/day for 28–90 days.  Additionally, no exposure-
related changes were observed in the histology of the spleen, thymus, Peyer’s patches, or mesenteric 
lymph nodes in rat dams exposed to pentaBDE at doses up to 25 mg/kg/day via gavage for 70 days prior
to mating through PND 21 (~21 weeks).
Exposure to decaBDE at 1,800 mg/kg/day for 28 days did not cause increased pulmonary viral titers of
RSV (measured 5 days post-infection) in mice.  In rat dams exposed to 300 mg/kg/day from 21 days prior
to mating through PND 21, altered T-lymphocyte cell population distribution in the thymus and a
significantly reduced response to in vitro PHA exposure in cultured lymphocytes were observed.  In 
another study, no dose-related changes were reported for T-cell, B-cell, or macrophage population 
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distribution in the spleen of rats exposed to decaBDE at doses up to 60 mg/kg/day via gavage for 28 days.  
In a high-dose study, female mice exposed to decaBDE at 800 mg/kg every other day showed impaired 
CD4 T-cell function from 4 to 10 months of exposure, compared with controls.  
Chronic ingestion of decaBDE caused splenic lesions (hematopoiesis, fibrosis, lymphoid hyperplasia) in 
rats exposed to ≥1,200 mg/kg/day for 103 weeks.  After exposure for 13 weeks, histopathological
examinations of spleen, thymus, lymph node, and/or bone marrow tissues showed no effects in rats or
mice exposed to decaBDE at doses up 8,000 or 9,500 mg/kg/day.  In rat dams exposed to decaBDE at 
300 mg/kg/day for 21 days prior to mating through PND 21, lesions of the thymus (thickened thymus
capsule, decreased lymphoid tissue in the cortex with adipose tissue replacement, increased medulla size,
and obscured corticomedullary junction) and spleen (decreased size and number of lymphoid nodules, 
thinner lymphatic sheath around arteries, and fibrotic tissue with macrophages in the medulla) were
observed.
Evidence from animals suggests that PBDE exposure may cause immune suppression, but data are limited 
and inconsistent.  Additionally, comprehensive immunological evaluations have not been performed and 
human data are extremely limited.  Therefore, currently available information is insufficient to adequately
characterize the human immunotoxic potential of PBDEs.
Cancer. In human case-control epidemiological studies, no clear associations have been found between
non-Hodgkin’s lymphoma risk and exposure to BDE 47 in a group of Swedish men and women including
19 cases and 27 controls, testicular cancer risk and serum PBDE (sum of BDE 47, BDE 99, and 
BDE 153) in a small group of Swedish men and women including 58 cases and 58 controls, breast cancer
risk and adipose concentrations of PBDE (BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, and their
sum) in a group of women from the San Francisco Bay area of California including 78 cases and 
56 controls, breast cancer and BDE 47 in serum in native Alaskan women, thyroid cancer and serum
PBDE (BDE 47, BDE 99, BDE 100, BDE 153, and their sum) in participants in a large multicenter
clinical trial in the United States that included 104 cases and 208 controls, or prostate cancer and serum
levels of BDE 47 in a study involving 208 prostate cancer incident cases and 268 controls in Singaporean 
males.  In a study examining the association between exocrine pancreatic cancer risk and PBDE 
concentrations in adipose tissue (sum of BDE 28, BDE 47, BDE 66, BDE 100, BDE 99, BDE 85, 
BDE 154, BDE 153, BDE 138, and BDE 183) in a group of Swedish men and women, PBDE
concentrations were significantly higher in the 21 cases compared with the 59 controls.  Case-control
analysis found that the risk of pancreatic cancer was not significantly increased with lipid PBDE using
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median concentration in controls as a cut-off after adjustment for age, sex, and BMI at tissue sampling;
however, the increase in risk was significant when the BMI adjustment was performed for the year before 
tissue sampling (body weight 1 year before tissue sampling obtained by questionnaire).
For most PBDEs, including pentaBDE and octaBDE, animal studies of carcinogenic effects are not
available; cancer data on PBDEs in animals are limited to results of studies on commercial decaBDE
products.  In a bioassay conducted by the National Toxicology Program (NTP), male and female rats were
exposed to high purity commercial decaBDE (lots that were 96 or 94–97% pure) in the diet in low doses
of 1,120 and 1,200 mg/kg/day, respectively, and high doses of 2,240 and 2,550 mg/kg/day, respectively,
for 103 weeks.  Male and female mice were similarly exposed to low doses of 3,200 and 
3,760 mg/kg/day, respectively, and high doses of 6,650 and 7,780 mg/kg/day, respectively.  Incidences of
neoplastic nodules in the liver were significantly increased in the male and female rats, although the term
neoplastic nodule is poorly defined and understood, and is no longer used by NTP to characterize
hepatoproliferative lesions in rats.  Incidences of hepatocellular adenoma or carcinoma (combined) were
significantly increased in the male mice.  Slightly elevated incidences of thyroid gland follicular cell
adenoma or carcinoma (combined) were additionally observed in exposed male mice, although the
increases were not statistically significant.  Carcinogenicity was also evaluated in rats that were exposed
to 0.01, 0.1, or 1.0 mg/kg/day dietary doses of a 77.4% decaBDE mixture (containing 21.8% nonaBDE
and 0.8% octaBDE) for approximately 2 years.  No exposure-related neoplastic changes were found, but
the power of this study to detect carcinogenic effects is limited by the very low dose levels in comparison
to those tested in the NTP bioassay.
The EPA hazard descriptor for decaBDE is “suggestive evidence of carcinogenic potential” based on:
(1) no studies of cancer in humans exposed to decaBDE; (2) a statistically significant increase in
incidence of neoplastic nodules and a slight increase in incidence of carcinomas (not statistically
significant) in the liver of low- and high-dose male rats and high-dose female rats; (3) a significantly
increased incidence of hepatocellular adenoma or carcinoma (combined) in male mice at the low dose and 
marginally increased incidence at the high dose; (4) a nonsignificantly increased incidence of
hepatocellular adenoma or carcinoma (combined) in female mice; (5) a slightly greater (but statistically
not significant) incidence of thyroid gland adenomas or carcinomas (combined) in dosed male and female 
mice; (6) a significantly increased incidence in male mice, at both doses, of follicular cell hyperplasia, 
considered by many as a precursor to thyroid tumors; and (7) an apparent absence of genotoxic potential.  
DecaBDE has been classified as a Group 3 carcinogen (not classifiable as to its carcinogenicity to
humans) by the International Agency for Research on Cancer (IARC) based on inadequate evidence of
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carcinogenicity in humans and inadequate or limited evidence in experimental animals.  The EPA assigns 
the cancer category Group D (not classifiable as to human carcinogenicity) to mono-, di-, tri-, tetra-, 
penta-, hexa-, octa-, and nonaBDEs and reports “inadequate information” to classify the specific 
congeners 2,2’,4,4’-tetraBDE, 2,2’,4,4’,5-pentaBDE, and 2,2’,4,4’,5,5’-hexaBDE. The Department of
Health and Human Services has not evaluated PBDEs for carcinogenicity. ACGIH has no data regarding
cancer classifications for PBDEs.
2.3  MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for PBDEs. An
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
People are environmentally exposed to PBDE mixtures of different congeneric composition than 
previously used commercial PBDE products.  Although the toxicity or potency of environmental mixtures
of congeners consequently may be greater or less than that of the commercial PBDE mixtures or
individual congeners, there are insufficient mixture toxicity data on which to directly base MRLs for
environmental PBDEs.  Due to the likelihoods that (1) multiple mechanisms (aryl hydrocarbon receptor
[AhR]-receptor-dependent mechanisms, AhR-independent mechanisms, or both) may be involved in 
health effects induced by PBDEs, (2) different PBDE congeners may produce effects by different
mechanisms, and (3) humans are exposed to complex mixtures of interacting PBDEs with differing
   
 








    
  
   
     
   
 
   
     
  
    
 
      
  
    
    
  






        
  
     
   
  
    
     
   
 
  
   
PBDEs 27
2. RELEVANCE TO PUBLIC HEALTH
biological activities, as well as to the lack of a suitable approach for quantitatively evaluating joint toxic 
action from concurrent exposures to PBDEs, PBBs, PCBs, chlorinated dibenzo-p-dioxins (CDDs), and/or
chlorinated dibenzofurans (CDFs) in the environment, data from previously used commercial PBDE
mixtures and individual congeners were reviewed to develop MRLs for assessing health risks from
environmental exposures to PBDEs.
Separate MRLs were derived for lower-brominated PBDEs and decaBDE based on important differences 
in pharmacokinetics and toxicity of decaBDE compared to lower-brominated PBDEs. The most recent
and best available estimates of oral absorption efficiencies for PBDE congeners indicate a range of 10– 
26% for decaBDE (BDE 209) and 70–85% for tetraBDE (BDE 47), pentaBDE (BDE 99, BDE 100), and 
hexaBDE (BDE 153, BDE 154) (Chen et al. 2006; Hakk et al. 2002a, 2002b, 2009; Morck and Klasson 
Wehler 2001; Morck et al. 2003; Örn and Klasson-Wehler 1998; Riu et al. 2008; Sandholm et al. 2003;
Sanders et al. 2006a, 2006b; Staskal et al. 2005).  Consistent with the higher absorption efficiencies of the
lower-brominated congers, the animal toxicity database indicates that toxic effects occur at lower doses 
following exposure to lower-brominated PBDEs than following exposure to decaBDE.  For example, the
acute exposure levels required to cause neurobehavioral effects in mice are higher for decaBDE
(≥2.22 mg/kg) than penta-, tetra-, and hexaBDE (≥0.8, ≥1, and ≥0.45 mg/kg, respectively) (Eriksson et al. 
2001; Gee and Moser 2008; Johansson et al. 2008; Sand et al. 2004; Viberg et al. 2003a, 2003b, 2004a, 
2004b).  
Inhalation MRLs
Lower-brominated BDEs. Derivation of an acute-duration MRL for lower-brominated BDEs is not
recommended at this time due to insufficient information.  The inhalation database for acute-duration 
exposure to PBDEs is essentially limited to a single 14-day unpublished industry-sponsored study of
octaBDE in rats (Great Lakes Chemical Corporation 1978).  In this study, groups of five male and five
female Charles River CD rats were whole-body exposed to dust of an unspecified commercial octaBDE
mixture in mean analytical concentrations of 0, 0.6, 3.7, 23.9, or 165.2 mg/m3 for 8 hours/day for
14 consecutive days. The average mass median aerodynamic diameter (MMAD) and geometric standard
deviation (GSD) of the particles were 3.5 µm and 2, respectively.  Study end points included clinical
signs (including observations for respiratory distress and nasal and ocular irritation), body weight and 
food consumption, hematology (5 indices), blood chemistry (5 indices, thyroid hormones not assessed), 
urinalysis (10 indices), organ weights (5 organs including thyroid/parathyroid), gross pathology, and 
histology (21 tissues including nasal turbinates, trachea, lungs, and thyroid).  The clinical laboratory tests
   
 













       
      
   




    
  
  
    
     
   
     
 
     
  
   
  
 
      
   
 
 
      
    
 
    





2. RELEVANCE TO PUBLIC HEALTH
were limited to rats in the control and two highest dose groups.  The histological exams were limited to
the control and highest dose groups, except for the liver, which was examined in all groups.  Signs of
increased respiration rate (rapid breathing) were observed by the end of each exposure period in rats 
exposed to ≥24 mg/m3; this effect always disappeared by the following morning.  Liver weight was
significantly increased and hepatic lesions occurred in rats exposed to ≥3.7 mg/m3. At 3.7 mg/m3, the
liver lesions consisted of very slight to slight, focal to multifocal cytoplasmic enlargement of the
hepatocytes, accompanied by focal acidophilic degeneration of individual to small groups of cells. The 
liver lesions were similar in the higher dose groups except that the hepatocyte enlargement was multifocal
to diffuse in distribution, and there were focal, small to large areas of hepatocellular necrosis present to a
very slight to marked degree.  There were no exposure-related histological changes in other tissues.
As detailed above, hepatocellular hypertrophy accompanied by some degenerative hepatocellular changes 
was found following exposure to octaBDE at concentrations ≥3.7 mg/m3 for 14 days (Great Lakes 
Chemical Corporation 1978).  However, this study is limited by small animal numbers and incomplete
evaluation of other end points at lower doses.  Additionally, a well-designed 13-week study (Great Lakes 
Chemical Corporation 2000) found hepatocellular hypertrophy at a higher minimum effect level
(16 mg/m3) than the 14-day study, but no degenerative liver changes. The available information indicates 
that there is insufficient evidence for considering the hepatic changes as adverse acute effects. More 
importantly, exposure to ≥16 mg/m3 caused changes in serum levels of thyroid hormones (decreased T3, 
increased TSH) in the 13-week study.  Thyroid hormone levels were not determined in the 14-day study.  
Therefore, due to the lack thyroid hormone data in the 14-day study, as well as the lack of any clear
lowest-observed-adverse-effect levels (LOAELs) for the other end points in the 14-day study, particularly
at exposures levels below the LOAEL for thyroid effects in the 13-week study, the data are inadequate to 
derive an MRL for acute-duration exposure.
• An MRL of 0.006 mg/m3 has been derived for intermediate-duration inhalation exposure (15– 
364 days) to lower-brominated BDEs.
The intermediate-duration inhalation MRL is based on a no-observed-adverse-effect level (NOAEL) of 
1.1 mg/m3 for changes in thyroid hormones in rats that were intermittently exposed to octaBDE for
13 weeks (Great Lakes Chemical Corporation 2000).  Calculation of the MRL is detailed below.
The inhalation database for intermediate-duration exposure to PBDEs consists of one well-conducted
13-week study (Great Lakes Chemical Corporation 2000).  This is an unpublished industry-sponsored 
study in which a commercial octaBDE product (bromine content 78.7%) was administered to groups of
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10 male and 10 female Crl:CD(SD)IGS BR rats, via nose-only inhalation as a dust aerosol, in measured 
concentrations of 0 (air only), 1.1, 16, or 202 mg/m3 for 6 hours/day, 5 days/week, for 13 weeks.  The 
mean MMADs in the low to high exposure groups were 2.0, 2.7, and 2.8 μm, and the corresponding mean 
GSDs were 3.37, 3.72, and 3.01.  Clinical and physical signs, body weight, food consumption, and 
survival were evaluated throughout the study.  Ophthalmic, hematology (11 indices), serum chemistry
(18 indices), and serum thyroid hormone (TSH, total T3, and total T4) evaluations were performed near
the end of the exposure period.  Urine analyses were not conducted.  Comprehensive necropsies, organ 
weight measurements, and histological examinations (including respiratory tract and thyroid) were
performed following exposure termination.  
Hepatic, nasal, lung, thyroid, and ovarian effects were observed (Great Lakes Chemical Corporation
2000). The liver was affected in both sexes as shown by dose-related increases in centrilobular
hepatocellular hypertrophy at ≥16 mg/m3 and liver weight (absolute and relative) at 202 mg/m3. Total
incidences of centrilobular hepatocellular hypertrophy in the 0, 1.1, 16, and 202 mg/m3 groups were 1/10, 
0/10, 3/10, and 10/10, respectively, in males and 0/10, 0/10, 3/10, and 6/10, respectively, in females;
severity was predominantly minimal in affected animals from all groups.  The incidence of nasal goblet 
cell lesions was increased at 202 mg/m3, but showed no clear dose-related trends for increasing incidence 
or severity.  Total incidences of nasal goblet cell hypertrophy were slightly increased in nasal level II of
both sexes at ≥1.1 mg/m3; respective incidences in the 0, 1.1, 16, and 202 mg/m3 exposure groups were
4/10 (all minimal), 9/10 (7 minimal, 2 mild), 6/10 (all minimal), and 10/10 (9 minimal, 1 mild) in males, 
and 2/10 (all minimal), 6/10 (all minimal), 4/10 (all minimal), and 8/10 (all minimal) in females.  Nasal 
goblet cell hypertrophy was also slightly increased in nasal level IV in males at 202 mg/m3 (4/10, 0/10, 
1/10, and 8/10, all minimal severity, not increased in females).  Histological changes in the lungs included 
alveolar histiocytosis and chronic active inflammation that were only clearly increased in incidence at
202 mg/m3. Total incidences of alveolar histiocytosis at 0, 1.1, 16, and 202 mg/m3 were 3/10, 5/10, 5/10, 
and 10/10, respectively, in males, and 0/10, 5/10, 2/10, and 10/10, respectively, in females.
Corresponding total incidences of chronic active lung inflammation were 0/10, 0/10, 2/10, and 10/10 in 
males, and 0/10, 1/10, 1/10, and 10/10 in females. The severity of both lesion types tended to increase 
from minimal at lower doses to mild/moderate at 202 mg/m3. Gross lung changes also occurred in both 
sexes at 202 mg/m3; these included lung firmness and white discoloration and/or enlargement in the
bronchial and/or mediastinal lymph nodes.  The lymph node effects correlated with the histological
finding of granulomatous inflammation.  There were no exposure-related gross or histopathological 
changes in the spleen, bone marrow, thymus, or other tissues, including thyroid. Thyroid hormone
assessments, however, showed exposure-related decreases in mean thyroxine (total T4) at ≥16 mg/m3 in 
   
 








     
    
 
    
   
   
     
 
     
  
    
     
   
       
    
     
 
 
          
        
 
  
       
     
     
      
 






2. RELEVANCE TO PUBLIC HEALTH
both sexes, and increases in TSH at ≥16 mg/m3 in males and 202 mg/m3 in females.  The changes were 
usually statistically significant (p<0.05 or p<0.01) compared to controls and were considered to be
consistent with chemical-induced hypothyroidism.  There were no serum T3 changes.  Qualitative 
histological evaluations of step sections of ovaries showed an absence of corpora lutea in 3/10 females 
exposed to 202 mg/m3, compared to 0/10 in the control and lower exposure groups.  This 30% incidence
was interpreted to be a treatment-related effect because an absence of corpora lutea was considered
unusual in rats at 20 weeks of age.
Considering the minimal severity of the nasal goblet cell hypertrophy, lack of clear dose-related
increasing trends for incidences and severity of this nasal effect, clear identification of both a NOAEL
(1.1 mg/m3) and LOAEL (16 mg/m3) for changes in serum levels of thyroid hormones, and abundant
evidence for thyroid effects of PBDEs in oral studies, the effects on thyroid hormones are the most
appropriate basis for estimation of an intermediate-duration inhalation MRL.  The MRL of 0.006 mg/m3 
was derived by dividing the NOAELHEC of 0.53 mg/m3 by an uncertainty factor of 30 (3 for species to 
species extrapolation with dosimetric adjustments and 10 for human variability) and a modifying factor of
3 (for an incomplete database reflecting a single study in one species).  The NOAELHEC was calculated
using the following equations:
NOAELADJ = 1.1 mg/m3 x 6 hours/24 hours x 5 days/7 days = 0.196 mg/m3 
NOAELHEC = NOAELADJ x RDDR = 0.196 mg/m3 x 2.7 = 0.53 mg/m3
The regional deposited dose ratio (RDDR) for the extrathoracic region was used to extrapolate deposited 
doses in rats to deposited doses in humans. The following parameters were used to calculate the RDDR:
MMAD of 2.0 μm with a mean GSD (sigma g) of 3.37, default human body weight of 70 kg, and a
default female F344 rat body weight of 0.18 kg.  Additional information on the derivation of the
intermediate-duration inhalation MRL for lower-brominated BDEs is provided in Appendix A.
No MRL was derived for chronic-duration inhalation exposure to lower-brominated BDEs due to a lack
of chronic studies.
Decabromodiphenyl Ether.  No MRLs were derived for acute-, intermediate-, or chronic-duration 
inhalation exposure to decaBDE due to a lack of inhalation studies on this PBDE congener.
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Oral MRLs
Lower-brominated Diphenyl Ethers
• An MRL of 0.00006 mg/kg/day has been derived for acute-duration oral exposure (14 days or
less) to lower-brominated diphenyl ethers.
The acute oral MRL is based on a LOAEL of 0.06 mg/kg/day for endocrine effects in rat dams and
reproductive and neurobehavioral effects in F1 offspring exposed to 2,2’,4,4’,5-pentaBDE (BDE 99) on 
GD 6 via gavage (Kuriyama et al. 2005, 2007; Talsness et al. 2005).  The MRL was estimated by dividing
the 0.06 mg/kg LOAEL by an uncertainty factor of 1,000 (10 for use of a LOAEL, 10 for animal to 
human extrapolation, and 10 for human variability).  
In a series of reports, pregnant rats were exposed to BDE 99 at 0, 0.06, or 0.3 mg/kg via gavage on GD 6 
(Kuriyama et al. 2005, 2007; Talsness et al. 2005).  Serum thyroid hormones levels (T3, free-T3, T4, free­
T4) were analyzed in dams and pups on PNDs 1, 14, and 22 (Kuriyama et al. 2007).  Male and female
offspring were evaluated for emergence of physical landmarks and reflexes and for open-field behavior
on PNDs 36 and 71 (Kuriyama et al. 2005).  Twelve male offspring per dose group were sacrificed at
PND 140, and the thymus, spleen, liver, testis, epididymis, seminal vesicle, and ventral prostate were 
weighed.  The right testis and caudal epididymis were retained for spermatid and sperm counts and
morphology, respectively.  Additionally, blood was collected for analysis of testosterone and LH levels
(Kuriyama et al. 2005).  Similarly, 10 F1 females per group were sacrificed ~PND 90 for histological
evaluation of the ovary, uterus, and vagina.  Ovarian follicles were counted in 10 ovaries from each 
group, and 1 ovary from 1 female offspring in each group was analyzed by transmission electron
microscopy (Talsness et al. 2005).  Fertility was assessed in F1 males and females (20/group) mated to
unexposed partners.  The uterine and F2 fetal weights and the number of implantations, resorptions, and 
fetuses were determined. The F2 fetuses were examined for external anomalies and when present, the
fetuses were stained and examined for skeletal anomalies (Kuriyama et al. 2005; Talsness et al. 2005).  In
a separate group of F1 males, male sexual behavior was assessed in 20 males/group at ~PND 160 
(Kuriyama et al. 2005).  
Serum T4 levels were significantly decreased by 23–33% in the 0.06 and 0.3 mg/kg dams, sacrificed on 
PND 1.  No changes were observed in T3, free-T3, or free-T4 at PND 1 or any thyroid hormone levels at
PND 22 in dams.  In pups, no dose-related changes were observed at PND 1 or 14.  At PND 22, serum T4 
was significantly decreased by 19–22% in F1 males and females and serum free-T4 was significantly
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decreased by 24% in F1 females exposed to 0.3 mg/kg (Kuriyama et al. 2007).  For F1 development of
physical landmarks and reflexes, no exposure-related effects were observed for the age at fur
development or eye opening, testes descent, or the ability to master the rotating rod test.  However, 
significant delays in the eruption of incisors in F1 pups and the development of the cliff-drop aversion 
reflex were observed in F1 males in the 0.3 mg/kg group, compared with controls.  During a 24-hour
observation of open-field activity, total activity, time spent active, duration of activity per active phase,
and total activity per active phase were all significantly increased in F1 offspring on PND 36 in the
0.3 mg/kg group, compared with controls.  On PND 71, the increased total activity and time spent active
persisted in the 0.3 mg/kg group, and was also significantly increased in the 0.06 mg/kg group.  
In F1 males sacrificed on ~PND 140, no exposure-related changes were observed in body weight, liver
weight, or thymus weight; however, absolute spleen weight was significantly increased by 9% in the 
0.06 and 0.3 mg/kg groups, and relative spleen weight was significantly increased by 12% in the
0.06 mg/kg group.  Compared with controls, significantly altered male reproductive organ weights at
PND 140 included a 10 and 11% decrease in relative testes and epididymis weight, respectively, in the
0.3 mg/kg group and a 5% decrease in relative epididymis weight in the 0.06 mg/kg group; no significant
changes were observed in absolute organ weights.  In both dose groups, the number of spermatids and 
sperm and daily sperm production were significantly decreased, compared with controls.  No exposure-
related effects were observed for sperm morphology.  No changes were observed in serum testosterone or
LH levels.  Despite sperm alterations, no significant exposure-related effects were observed in male 
reproductive function or the majority of male sexual behaviors. The only significantly altered male 
sexual behavior was a 32% decrease in the percent of males with two or more ejaculations.  
In F1 females sacrificed on ~PND 90, no statistically significant, exposure-related histological changes 
were observed at the light microscopic level in the ovary, uterus, or vagina of female offspring, and no 
exposure-related effects were observed in the number of ovarian follicles.  However, multiple
ultrastructural changes were noted in the ovaries of PND 90 female offspring from dams exposed to 
0.06 or 0.3 mg/kg, including destruction of the surface of the serosal epithelial cells, necrosis, and
numerous vesicular structures with dense granular material within the cytoplasm.  Additional changes 
observed in the 0.3 mg/kg group included degenerative changes and aggregates of small and large 
vesicles filled with homogeneously dense granular material in the cytoplasm and clumped chromatin
within the condensed nucleus.  No exposure-related changes were found for F1 female pregnancy rate,
total implantation sites, implantation sites/dam, F2 fetuses/gravid dam, or total number of live F2 fetuses.  
However, the resorption rates were 12 and 15% in the 0.06 and 0.03 mg/kg groups, respectively, 
   
 









     
  
   
   
     
 
  
   
 
    
 
       




   
 
     
  




   
 
    
     
  
  
   
  
    
 
 
   
  
 
      






2. RELEVANCE TO PUBLIC HEALTH
compared with the control rate of 9%.  Statistics were not reported; however, the resorption rates in the 
exposed rats were also reportedly increased compared with historical controls (average control resorption
rate=5.4%, with rates up to 10% considered to be within normal limits).  In addition, the percentage of
litters with resorptions was higher in the exposed females, being 47% in the control group and 69% and 
72% in the 0.06 and 0.3 mg/kg groups, respectively.  In F2 pups, mean fetal weight was significantly
increased (by 5%) in the 0.06 mg/kg group, but not in the 0.3 mg/kg group, compared with controls.  
Three fetuses from different litters in the 0.3 mg/kg/day group showed skeletal anomalies (tail, skull, 
vertebrae); however, this incidence of anomalies in 3/18 litters is not significantly elevated compared with
the control incidence of 0/19 (Fisher’s exact test, performed for this review). 
Collectively, these studies indicate a LOAEL of 0.06 mg/kg, the lowest dose tested, for endocrine effects
in F0 dams (decreased serum T4), reproductive effects in F1 adult offspring (impaired spermatogenesis, 
ultrastructural changes in ovaries, increased resorptions in F1 females mated to unexposed males) and
neurobehavioral effects in F1 adult offspring (increased activity in open field). No NOAEL was
identified.  
Data from other several acute-duration studies of PBDEs support the selection of the co-critical effects 
observed at the LOAEL of 0.06 mg/kg:
• Numerous studies reported reduced serum T4 levels in adult, nonpregnant mice and rats following
acute exposure to commercial pentaBDE mixtures (Bromkal 70, Bromkal 70-5 DE, DE-71), the
commercial octaBDE mixture DE-79, or 2,2’,4,4’-tetraBDE (BDE 47).  Significant reductions of
19–92% have been reported following gavage exposure at doses ≥10 and ≥0.8 mg/kg/day in rats
and mice, respectively, for 1–14 days (Darnerud and Sinjari 1996; Fowles et al. 1994; Hallgren 
and Darnerud 1998, 2002; Hallgren et al. 2001; Hoppe and Carey 2007; Richardson et al. 2008;
Stoker et al. 2004, 2005; Zhou et al. 2001).
• In a companion study to the critical studies described above, pregnant rats (8/group) were
administered BDE 47 (98% purity) at 0, 0.14, or 0.7 mg/kg via gavage in peanut oil vehicle on 
GD 6 (Talsness et al. 2008).  As observed in pentaBDE-exposed F1 females, ultrastructural
changes (accumulation of vesicular structures with homogeneously dense granular material in the 
cytoplasm of the stromal cells, large vacuoles) were observed in the ovaries of F1 females from
both dose groups on PND 100.  No exposure-related changes were observed in F1 female fertility
or F2 litter parameters.  F1 males were not evaluated for developmental reproductive effects 
following tetraBDE exposure.
• Alterations in open-field activity have been consistently reported in mice exposed to pentaBDE
(BDE 99) at doses ≥0.8 mg/kg on PND 3 or 10 and evaluated at 2–8 months of age, characterized 
by decreased activity during the first 20-minute period of a 1-hour session, followed by increased 
activity during the third 20-minute period (Eriksson et al. 2002b, 2006; Fischer et al. 2008; Sand 
et al. 2004; Viberg et al. 2002, 2004a, 2004b).  Several other 1-day exposure studies reported
   
 








    
   
  
    
 
   
      
       
 
 




   
 
      
     
      
   
   
 
      
   
      
  




    
      
 
   
      
  
    




2. RELEVANCE TO PUBLIC HEALTH
similar findings in rats and mice following exposure to various lower-brominated PBDEs. 
Decreased spontaneous activity and/or impaired habituation were observed in rats exposed to 
BDE 99 at 8 mg/kg on PND 10, mice exposed to 2’,4,4’,5,5’-hexaBDE (BDE 153) at
≥0.45 mg/kg on PND 10, mice exposed to BDE 47 at 10.5 mg/kg on PND 10, mice exposed to 
2,2’,3,4,4’,5’,6-heptaBDE (BDE 183) at 15.2 mg/kg on PND 3, and mice exposed 
2,2’,3,4,4’,5,5’,6-octaBDE (BDE 203) at 16.8 mg/kg on PND 3 or 10 (Eriksson et al. 2001; 
Viberg et al. 2003a, 2005, 2006).  Increased vertical activity was significantly increased at
4 months, but not at 2 months, in mice exposed to BDE 47 at ≥1 mg/kg on PND 10; no changes
were observed in horizontal activity or habituation (Gee and Moser 2008).  
Additional information on the derivation of the acute-duration oral MRL for lower-brominated BDEs is 
provided in Appendix A.
• An MRL of 0.000003 mg/kg/day has been derived for intermediate-duration oral exposure (15– 
364 days) to lower-brominated BDEs.
The intermediate oral MRL is based on a minimal LOAEL of 0.001 mg/kg/day for a 34% reduction in
serum testosterone in male rats exposed to 2,2’,4,4’-tetraBDE (BDE 47) for 8 weeks via gavage (Zhang et
al. 2013b). The MRL was estimated by dividing the 0.001 mg/kg/day minimal LOAEL by an uncertainty
factor of 300 (3 for use of a minimal LOAEL, 10 for animal to human extrapolation, and 10 for human 
variability).
Groups of 20 male rats were exposed to BDE 47 (≥98.7%) at 0, 0.001, 0.03, or 1 mg/kg/day via gavage in 
corn oil 6 days/week for 8 weeks (Zhang et al. 2013b).  Twenty-four hours after the final treatment, rats 
were sacrificed. Testes were fixed for histological analysis and labeling of apoptotic cells or prepared for
analysis of sperm production.  Daily sperm production was estimated by dividing the total number of
mature spermatids per testis by 6.1 (i.e., the days of the seminiferous cycle that the spermatids are present
in the seminiferous epithelium).  Testicular samples were examined for reactive oxygen species (ROS)
and mRNA expression of apoptosis related proteins (ser15, ser473, p53, PTEN, AKT, BAD, caspase 3, 
FAS, FASL).  Serum levels of E2, FSH, LH, and testosterone were measured.  Histological examination 
of the testes showed a significant increase in the number of multinucleated giant cells (arising from
spermatocytes that aborted meiosis) at ≥0.03 mg/kg/day and abundant vacuolar spaces in the seminiferous 
epithelium at 1 mg/kg/day (quantitative data not reported).  Additionally, the number of apoptotic cells
was significantly increased by 1.9- and 3-fold in the testes of rats from the 0.03 and 1 mg/kg/day groups, 
respectively, and the mRNA levels of several apoptosis genes were elevated in a dose-related manner.
Daily sperm production was significantly decreased by 23% in the 1 mg/kg/day group, compared with 
controls.  Serum testosterone was significantly decreased by ~34, 53, and 62% in the 0.001, 0.03, and
1 mg/kg/day groups, respectively, compared with controls.  No exposure-related changes were observed
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in serum E2, FSH, or LH levels. Testicular ROS levels were significantly elevated at 1 mg/kg/day,
compared with controls.  A minimal LOAEL of 0.001 mg/kg/day was determined for this study based on 
the 34% decrease in serum testosterone.  The change in testosterone is considered a minimal LOAEL
because it is unclear if the magnitude of change represents a biologically adverse effect; however, this 
statistically significant reduction in serum testosterone is considered an early indication of damage to the 
male reproductive system, considering the additional effects observed at ≥0.03 mg/kg/day (histological
lesions in testes, sperm effects).
One additional rat study and a mouse study report histopathological changes in the testes following
intermediate-duration exposure to tetraBDE at ≥0.03 mg/kg/day; neither study evaluated serum
testosterone levels (Huang et al. 2015; Wang et al. 2013).  In the rat study, a NOAEL of 0.001 mg/kg/day
and a LOAEL of 0.03 mg/kg/day were identified for increased epithelial thickness and spermatocyte 
apoptosis in the testes of males exposed to BDE 47 for 8 weeks via gavage (Huang et al. 2015).  In the 
mouse study, a NOAEL of 0.0015 mg/kg/day and a LOAEL of 0.045 mg/kg/day were identified for germ
cell loss and increased apoptosis in the testes of males exposed to BDE 47 for 30 days via gavage (Wang 
et al. 2013).  
No other study evaluated testicular histopathology following exposure to BDE 47.  Following
intermediate exposure to other congeners, no changes in testicular histology were observed in rats 
exposed to commercial pentaBDE mixtures (Bromkal 70-5 DE, DE-71) at gavage doses up to 
250 mg/kg/day for 15–28 days (Becker et al. 2012; Oberg et al. 2010), commercial penta- or octaBDE
mixtures (DE-71, unspecified octa mixture) at dietary doses up to 750 mg/kg/day for 28–90 days (IRDC
1976, 1977; WIL Research Laboratories 1984), or a pentaBDE mixture (52.1% pentBDE, 44.2%
decaBDE, 0.4% octaBDE) at dietary doses up to 20 mg/kg/day for 70 days (Ernest et al. 2012).  However,
testicular apoptosis was not evaluated in any of these studies.  
No other study evaluated serum testosterone levels following exposure to BDE 47.  However, as observed 
with exposure to BDE 47, acute exposure to 0.06 or 1.2 mg/kg of 2,2’,4,4’,5-pentaBDE (BDE 99) also
led to a significant 40–45% decrease in serum testosterone levels in rats (Alonso et al. 2010).  No other
studies evaluated this end point following exposure to single congeners. Other studies evaluating serum
testosterone levels after intermediate-duration exposure to lower-brominated PBDEs mixtures (DE-71, 
dietary PBDE mixture described above) did not report exposure-related decreases (Becker et al. 2012;
Ernest et al. 2012; Stoker et al. 2005).  These data suggest that the individual congeners, BDE 47 and
BDE 99, which have been identified as two of the most abundant congeners for human exposure (Harrad 
   
 













    
 
 










   
   
  
   
   
   
     
   
   
      















2. RELEVANCE TO PUBLIC HEALTH
et al. 2004; Lorber 2008; Wong et al. 2013), may have a greater capacity to alter serum testosterone levels 
than PBDE mixtures.
One-generation studies of BDE 47 reported developmental effects at ≥0.03 mg/kg/day, including:
• Impaired spatial learning in the Barnes maze in PNW 8 offspring of mouse dams fed tetraBDE­
dosed cornflakes from pre-mating day 28 through PND 21 (Koenig et al. 2012).
• Decreased center-field activity in an open field (indicating increased anxiety) in PND 60 female
offspring from mouse dams fed tetraBDE-dosed cornflakes from pre-mating day 28 through 
PND 21 (Ta et al. 2011).
• Decreased pre-weaning weight, decreased pup vocalizations on PNDs 8–10, and decreased 
sociability on PND 72 in female offspring of mouse dams exposed to tetraBDE via gavage from
pre-mating day 28 through PND 21 (Woods et al. 2012).
Additional information on the derivation of the intermediate-duration oral MRL for PBDEs is provided in
Appendix A.
A chronic-duration oral MRL was not derived for lower-brominated PBDEs due to insufficient data.  
Only one chronic study of PBDEs other than high-purity decaBDE has been conducted (Kociba et al. 
1975; Norris et al. 1975a).  In this study, Sprague-Dawley rats (25/sex/dose level) were fed a 77.4% pure 
commercial decaBDE mixture (containing 21.8% nonaBDE and 0.8% octaBDE) for approximately
2 years.  Evaluations that included clinical signs, body weight, food consumption, hematology, clinical
chemistry, urine indices, and comprehensive histological examinations showed no exposure-related
effects. The highest NOAEL is 1 mg/kg/day (highest tested dose), but this NOAEL is not appropriate for
MRL estimation due to insufficient sensitivity of the study.  In particular, using the NOAEL of
1 mg/kg/day and an uncertainty factor of 100, a chronic oral MRL based on this study would be 5 times 
higher than the 0.002 mg/kg/day intermediate MRL.  A similar pattern was observed for thyroid effects in 
the study used to derive the acute-duration oral MRL (Zhou et al. 2001) as summarized above.  Due to the
insufficiencies of the chronic data for MRL derivation, the intermediate oral MRL could be used as a 
value for chronic exposure.
Decabromodiphenyl Ether
• An MRL of 0.01 mg/kg/day has been derived for acute-duration oral exposure (14 days or less) to 
decabromodiphenyl ether
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The MRL was derived based on a NOAEL of 1.34 mg/kg for neurobehavioral effects in 2–4-month-old 
mice following a single exposure to 2,2’,3,3’,4,4’,5,5’,6,6’-decaBDE (BDE 209) on PND 3 (Buratovic et 
al. 2014; Johansson et al. 2008).  The MRL was estimated by dividing the 1.34 mg/kg NOAEL by an 
uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability).  
In the first study (Johansson et al. 2008), neonatal male mice (3–4 litters/group) were exposed to a single
dose of BDE 209 (98% purity) at 0, 1.34, 2.22, 13.4, or 20.1 mg/kg via gavage in a 20% fat emulsion 
vehicle (1:10 mixture egg lecithin and peanut oil) on PND 3 (Johansson et al. 2008).  Mice were observed 
for clinical signs of toxicity and body weight was measured at PND 3 and PNW 4.  Spontaneous motor
behavior (locomotion, rearing, total activity) was evaluated in an open field test at 2 months
(10 mice/group) and at 4 months (16 mice/group).  Motor activity was measured during a 60-minute
period, divided into three 20-minute intervals.  Nicotine-induced behavior was evaluated at 4 months
following single subcutaneous injections of 80 µg nicotine/kg (8/group) or 10 mL 0.9% NaCl/kg
(8/group).  Anxiety was assessed at 4 months using the elevated plus maze.  No clinical signs of toxicity
or body weight effects were observed.  At 2 months, significantly decreased locomotion, rearing, and total
activity were observed during the first 20-minute interval of the open field assessment in mice exposed to
≥2.22 mg/kg, compared with controls.  However, during the third 20-minute interval, when activity
should decrease due to habituation, locomotion, rearing, and total activity were significantly increased in
mice exposed to ≥13.4 mg/kg.  None of the end points measured were significantly altered in mice 
exposed to 1.34 mg/kg.  At 4 months, significantly decreased locomotion, rearing, and total activity were
observed during the first interval of the open field assessment in mice exposed to ≥2.22 mg/kg, compared 
with controls.  During the third interval, significantly increased locomotion, rearing, and total activity
were observed in mice exposed to ≥2.22 mg/kg.  Additionally, total activity, but not rearing or
locomotion, was significantly decreased during the first 20-minute interval in the 1.34 mg/kg group; no 
significant changes were observed during the third interval in the 1.34 mg/kg group. Statistical analysis
shows that habituation ability declined in mice exposed to ≥2.22 mg/kg/day when tested at 4 months of
age, compared with 2 months of age.  At 4 months, nicotine exposure caused significantly decreased
activity during the first interval in mice exposed to ≥13.4 mg/kg, compared with saline-injected mice 
from the same decaBDE exposure group.  This finding is the opposite of the expected increase in activity
due to nicotine exposure, which was observed in controls and lower dose decaBDE groups.  During the
third interval, mice exposed to ≥13.4 mg/kg and nicotine showed impaired habituation.  No exposure-
related effects were observed in the elevated plus maze assessment. A NOAEL of 1.34 mg/kg and a
LOAEL of 2.22 mg/kg were determined for the nonhabituating profile (i.e., decreased activity early in the
test period and increased activity late in the test period). The singular finding of decreased total activity
   
 








   
  
     




   






     
 
 
    
  
   
    
  
   
      
   
     
 
  
      





2. RELEVANCE TO PUBLIC HEALTH
during the first 20-minute interval at 4 months in the 1.34 mg/kg group was not considered sufficient to 
establish a LOAEL of 1.34 mg/kg.  The nonhabituating profile, which is a common effect observed with 
developmental PBDE exposure (Eriksson et al. 2002b, 2006; Fischer et al. 2008; Sand et al. 2004; Viberg
et al. 2002, 2003a, 2004a, 2004b), was considered to be a stronger basis for a NOAEL/LOAEL
determination.
In the second study (Buratovic et al. 2014), neonatal male mice (6 litters/group; 31–40 males and 23– 
34 females per group) were administered 2,2’,3,3’,4,4’,5,5’,6,6’-decaBDE (BDE 209, >95% purity) at
doses of 0, 1.34, 5.76, or 13.4 mg/kg via gavage in a 20% fat emulsion vehicle (1:10 mixture egg lecithin
and peanut oil) on PND 3.  Mice were observed for clinical signs of toxicity and body weight changes 
throughout the study (no further details were provided).  Spontaneous motor behavior (locomotion, 
rearing, total activity) was evaluated in an open field at 2 months (18/sex/group).  Motor activity was
measured during a 60-minute period, divided into three 20-minute intervals.  Directly after spontaneous 
motor evaluation, 9/sex/group were injected with a cholinergic agent (0.25 mg/kg paraoxon in males, 
80 µg/kg nicotine in females), while the other 9/sex/group were injected with 0.9% saline, for evaluation 
of cholinergic-induced locomotion.  At 4 months, spontaneous behavior was assessed again in the saline-
injected animals only (9 males/group at all doses and 9 females/group in the control and high-dose group 
only).  Learning and memory was assessed using the Morris water maze at 5 and 7 months in 13– 
15 males from the 0, 5.76, and 13.4 mg/kg groups only (the same mice were evaluated at each time point).  
In the spontaneous activity assessment, a dose-related decrease in locomotion, rearing, and total activity
was observed during the first 20 minutes of open field testing in a novel environment at 2 months. 
Decreases were significant at all doses tested in both sexes; however, findings were only dose-related for 
total activity.  However, during the third 20-minute interval, when activity should decrease due to 
habituation, locomotion, rearing, and total activity were significantly increased in males and females at 
≥5.76 mg/kg. At 2 months, cholinergic agents caused decreased activity during the first interval in mice
exposed to ≥5.76 mg/kg, compared with saline-injected mice from the same decaBDE exposure group.
This finding is the opposite of the expected increase in activity due to paraoxon or nicotine exposure, 
which was observed in controls and low-dose decaBDE groups.  During the third interval, mice exposed 
to ≥5.76 mg/kg and cholinergic agent showed impaired habituation.  At 4 months, total activity during the
first 20 minutes was still significantly decreased at all doses in males, and locomotion and rearing were
significantly decreased in males in the mid- and high-dose groups only; all three parameters were 
significantly decreased in high-dose females (other doses not evaluated).  All three parameters were 
significantly increased in high-dose males and females during the third 20-minute period, indicating
decreased habituation; locomotion and rearing were also slightly, but significantly, increased in mid-dose
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males.  In the Morris water maze, initial learning was comparable between exposed and control mice at
5 and 7 months.  However, latencies to find the escape platform during the reversal learning phase
(learning to find the escape platform in a new location after initial training) were significantly longer in
mid- and high-dose males at 5 and 7 months (other exposure groups not assessed). A NOAEL of
1.34 mg/kg and a LOAEL of 5.76 mg/kg were determined for the nonhabituating profile (i.e., decreased 
activity early in the test period and increased activity late in the test period).  Similar to the Johansson et
al. (2008) study, the finding of decreased total activity during the first 20-minute interval at 2 and 
4 months in the 1.34 mg/kg group was not considered sufficient to establish a LOAEL of 1.34 mg/kg.
The nonhabituating profile was considered to be a stronger basis for a NOAEL/LOAEL determination, 
and additional neurological effects (impaired learning, altered response to cholinergic agents) support a 
LOAEL of 5.76 mg/kg.
A similar study supports the LOAEL of 2.22 mg/kg for altered neurobehavior in developmentally
exposed mice.  Decreased spontaneous activity and impaired habituation were observed in 2- and 
6-month-old mice exposed to BDE 209 at doses ≥2.22 mg/kg on PND 3, which was the lowest dose tested
(Viberg et al. 2003b).  These effects were not observed if exposure was on PND 10 or 19 at doses up to 
20.1 mg/kg (Viberg et al. 2003b).  Additionally, decreased spontaneous activity was observed in 
2-month-old rats following exposure to BDE 209 doses ≥6.7 mg/kg on PND 3 (lowest dose tested)
(Viberg et al. 2007).  At 20.1 mg/kg, impaired habituation and decreased nicotine-induced behavior were
also observed.  This nonhabituating behavior profile (i.e., decreased activity early in the test period and 
increased activity late in the test period) is consistent with neurobehavioral alterations observed following
early postnatal exposure to lower-brominated PBDEs and has been reported in adult mice neonatally
exposed to certain PCB congeners (see the Acute MRL Worksheet for lower-brominated PBDEs for more
details).
Additional neurodevelopmental effects observed in mice following acute exposure to BDE 209 from 
PND 2 to 15 at 20 mg/kg/day via micropipette include delayed ontogeny of reflexes, increased
locomotion in males at PND 70, and learning impairment and impulsivity at 16 months, but not at
3 months (Rice et al. 2007, 2009). In rats, impaired learning was observed in Morris water maze in
PND 25 rat offspring of dams exposed to BDE 209 from GD 1 to 14 at doses ≥30 mg/kg/day via gavage
(Chen et al. 2014).
Additional information on the derivation of the acute-duration oral MRL for BDE 209 is provided in 
Appendix A.
   
 









    
   
 
    
    
  




    
   






   
  
   





   
     
   
     
 




2. RELEVANCE TO PUBLIC HEALTH
• An MRL of 0.0002 mg/kg/day has been derived for intermediate-duration oral exposure (15– 
364 days) to decabromodiphenyl ether.
The MRL was derived based on a minimal LOAEL of 0.05 mg/kg/day for a 12% increase in serum 
glucose in adult rats exposed to 2,2′,3,3′,4,4′,5,5′,6,6′-decabromodiphenyl ether (BDE 209) for 8 weeks
via gavage (Zhang et al. 2013a).  The MRL was estimated by dividing the 0.05 mg/kg/day LOAEL by an
uncertainty factor of 300 (3 for use of a minimal LOAEL, 10 for animal to human extrapolation, and 10
for human variability).
Groups of 10 male rats were exposed to BDE 209 at 0, 0.05, 1, or 20 mg/kg/day daily via gavage in corn 
oil for 8 weeks (Zhang et al. 2013a).  Rats were observed for clinical signs of toxicity and body weights
were measured every 3 days.  Rats were fasted for 24 hours after the final gavage treatment, and then 
sacrificed.  Body weights and heart, spleen, lung, kidney, and liver weights were recorded.  Blood was
collected for clinical chemistry analysis (serum total cholesterol, triglycerides, glucose, insulin, and 
TNF-α) and determination of plasma markers of oxidative stress (malondialdehyde [MDE], reduced
glutathione [GSH], and superoxidase dismutatase [SOD]).  Liver samples from three rats in the control
and low-dose (0.05 mg/kg/day) groups were collected for microarray analysis (Affymetrix GeneChip), 
and gene ontogeny category, pathway, gene-act-network, and gene co-expression analyses were 
conducted.  Quantitative real-time-polymerase chain reaction (qPCR) was performed to quantitate gene
expression to validate the gene expression data obtained from microarray analysis.  No clinical signs of
toxicity or body weight effects were observed. The relative liver weight was significantly decreased at
1 and 20 mg/kg/day by 9% (absolute liver weights were not reported).  No changes were observed in 
relative weights of heart, spleen, lung, or kidney.  No exposure-related changes were reported in serum
cholesterol or triglyceride levels.  Serum glucose levels were significantly increased by 12, 18, and 21%
in the 0.05, 1, and 20 mg/kg/day groups, compared with controls.  Serum insulin was significantly
decreased by 50–60% at 1 and 20 mg/kg/day.  Subsequent to this finding, the pancreas was evaluated 
histologically.  Consistent with the insulin findings, morphological changes were seen at 1 and 
20 mg/kg/day, including blurred boundaries among pancreatic islet cells (quantitative data not reported).  
Plasma SOD activity was significantly decreased in all exposed groups and plasma GSH was significantly
decreased at 1 and 20 mg/kg/day.  Serum TNF-α was significantly increased at 1 and 20 mg/kg/day.
Additionally, decaBDE induced 1,257 liver gene transcript changes, and 18 canonical pathways were
significantly enriched.  Four of them were involved in immune diseases, including autoimmune thyroid 
disease, graft-versus-host disease, allograft rejection, and T1DM.  Subsequently, gene act network and 
gene coexpression network found that some major histocompatibility complex molecules and TNF-α 
   
 








    
   
 
   
   
      
 
    
    
       
      
   
   
    
 
   
 
 
   
   
     
  
  
   
    
    
   
    
    
 
        
   




2. RELEVANCE TO PUBLIC HEALTH
were involved in the T1DM pathway. A minimal LOAEL of 0.05 mg/kg/day was determined for this
study based on the 12% increase in serum glucose levels.  The change in glucose is considered a minimal
LOAEL because it is unclear if the magnitude of change represents a biologically adverse effect;
however, the increase in serum glucose is considered to be part of a spectrum of effects indicative of
altered insulin homeostasis and toxicity to the pancreas, including decreased serum insulin and 
morphological changes in pancreatic islet cells observed at ≥1 mg/kg/day following decaBDE exposure.  
The relevance of these findings to human health is uncertain.  An analysis of cross-sectional NHANES
data showed a significant increase in risk of diabetes associated with serum concentrations of BDE 153 
(but not other congeners), although the risk was higher with exposure to 50–75th percentile BDE 153
concentrations than >75th percentile BDE 153 concentrations (Lim et al. 2008). Serum BDE 153 
concentrations (but not BDE 28, BDE 47, BDE 85, BDE 99, BDE 100, or BDE 154) were also shown to 
be significantly associated with increased odds of developing gestational diabetes in a cohort of
258 pregnant women (Smarr et al. 2016).  However, other cross-sectional and prospective studies found
no relationship between serum PBDE concentrations and diabetes in an adult cohort from Wisconsin 
(Turyk et al. 2015), an elderly cohort in Finland (Airaksinen et al. 2011), or an elderly cohort in Sweden 
(Lee et al. 2011).
Only one other animal study evaluated the pancreas following decaBDE exposure.  In rats exposed to 
BDE 209 via gavage for 28 days at doses of 0, 0.27, 0.82, 2.47, 7.4, 22.2, 66.7, or 200 mg/kg/day, slight
or moderate insulitis was observed in the Langerhan’s islets of the “majority of samples,” but findings 
were not exposure-related (Van der ven et al. 2008a).  Similarly, no exposure-related effects were 
observed for serum glucose levels (Van der ven et al. 2008a).  The only other study evaluating serum
glucose levels after decaBDE exposure instead reported reduced serum glucose levels in male rats 
exposed to 20 mg/kg/day of a dietary PBDE mixture containing 52.1% pentaBDE (DE-71), 44.2%
decaBDE (BDE 209), and 0.4% octaBDE (DE-79) for 70 days (Ernest et al. 2012). The observed 
decreased glucose levels could be due to the pentaBDE component, as male rats exposed to pentaBDE at
doses of 0.27–200 mg/kg/day for 28 days also showed decreased glucose levels; the study authors did not
report the lowest dose at which glucose levels were significantly lower in male rats, but they reported a 
BMD10RD of 179.55 mg/kg/day and a BMDL10RD of 66.7 mg/kg/day (Van der ven et al. 2008b).  Other
effects occurred at doses 4–40-fold higher than the observed pancreatic and related effects:
• A LOAEL of 2 mg/kg/day was identified for transient histopathological effects in the liver of
male offspring and kidney of female offspring of rat dams exposed to BDE 209 from GD 10 to
PND 21 (no NOAEL identified) (Fujimoto et al. 2011).
   
 











   
 












    
   
   
  
  
   
     
      
   
  
     
      
    
 
  
    
     








2. RELEVANCE TO PUBLIC HEALTH
• A LOAEL of 10 mg/kg/day was identified for hepatocytic swelling in the liver, vacuolization in 
the interstitial cells of testes, and sperm damage in PND 71 male offspring of mouse dams 
exposed to BDE 209 from GD 0 to 17 (no NOAEL identified) (Tseng et al. 2008, 2013).
• A LOAEL of 20 mg/kg-day was identified for decreased anxiety in mice treated with BDE 209
by daily gavage for 15 days (no NOAEL identified) (Heredia et al. 2012).
• A LOAEL of 20.1 mg/kg/day was identified for altered hippocampal electrophysiology in rats
exposed to BDE 209 on GD 1 to PND 41, PNDs 1–21, or PNDs 22–41 (no NOAEL identified)
(Xing et al. 2009).
Additional information on the derivation of the intermediate-duration oral MRL for decaBDE is provided
in Appendix A.
No MRL was derived for chronic-duration oral exposure to decaBDE.  Only one chronic study of high-
purity decaBDE has been conducted.  In this study, F344 rats and B6C3F1 mice (50/sex/group per
species) were administered a commercial decaBDE product (94–97% pure) in the diet for 103 weeks
(NTP 1986).  Calculated dietary doses based on body weight and food intake were 0, 1,120, or
2,240 mg/kg/day for male rats; 0, 1,200, or 2,550 mg/kg/day for female rats; 0, 3,200, or 6,650 mg/kg/day
for male mice; and 0, 3,760, or 7,780 mg/kg/day for female mice. Animals were examined daily for
clinical signs.  Body weights and food consumption were measured throughout the study, and 
comprehensive gross and histological examinations were performed on all animals in all dose groups, 
including those that were moribund or died during the study.  No hematology, clinical chemistry, or urine
indices or thyroid hormone levels were evaluated. Liver degeneration and thrombosis were significantly
(p<0.05) increased in male rats at 2,240 mg/kg/day; respective incidences in the control, low, and high 
dose groups were 13/50, 19/50, and 22/50 for degeneration and 1/50, 0/50, and 9/50 for thrombosis.  The
thrombosis was characterized by a near total occlusion of a major hepatic blood vessel by a dense fibrin 
coagulum.  Neoplastic nodules in the liver were significantly increased in a dose-related manner in males 
exposed to doses ≥1,120 mg/kg/day and in females exposed to 2,550 mg/kg/day. However, no treatment-
related increases were observed in the incidence of hepatocellular carcinomas.  Other effects in exposed
rats included fibrosis of the spleen, lymphoid hyperplasia of the mandibular lymph nodes, and acanthosis
of the forestomach at 2,240 mg/kg/day.  In mice, histopathological changes occurred in males exposed to
3,200 mg/kg/day, including centrilobular hypertrophy and granulomas in the liver and follicular cell 
hyperplasia in the thyroid. An MRL was not derived because the lowest tested dose, 1,120 mg/kg/day in
male rats, is a LOAEL for a liver lesion (neoplastic nodules) that is precancerous and associated with
thrombosis in the same tissue.
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3. HEALTH EFFECTS
3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of PBDEs.  It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
PBDEs are classes of brominated hydrocarbons that were previously used as flame retardant additives in
plastics, textiles, and other materials.  Production of PBDEs began in the 1970s and has continued until
recently.  PentaBDE and octaBDE mixtures were voluntarily withdrawn from the U.S. marketplace by
their manufacturers at the end of 2004; however, the manufacture and use of decaBDE continued past that
date (EPA 2010).  In December of 2009, the two remaining U.S. producers of decaBDE and the largest 
U.S. importer of this product announced commitments to phase out manufacture and importation of
decaBDE for most uses in the United States by December 31, 2012, and to end manufacture and import
for all uses by the end of 2013 (EPA 2013j).  Although PBDEs are no longer produced or used, concern 
continues to exist for health effects of PBDEs due to evidence that PBDE congeners have become 
ubiquitously distributed in the environment and are present in tissues and breast milk of the general
population (EPA 2010; Meijer et al. 2008; Park et al. 2011; Rawn et al. 2014; Schecter et al. 2010).  
PBDEs comprise compounds in which 1–10 bromine atoms are attached to the biphenyl structure in up to 
209 different combinations.  Based on the number of bromine substituents, there are 10 homologous
groups of PBDEs (monobrominated through decabrominated), each containing one or more isomers.  
PBDEs are structurally similar when viewed in one dimension, differing only in the ether linkage between 
the two phenyl rings in PBDEs, but the oxygen bridge confers three-dimensional conformational
differences that can influence toxicological properties.  Consequently, on the basis of chemical structure, 
it cannot be assumed that the health effects of PBDE congeners are necessarily similar.  Reviews on the
health effects and other aspects of PBDEs include those by Bellinger (2013), Darnerud et al. (2001), de
Boer et al. (2000a), de Wit (2002), Dingemans et al. (2011), EPA (2008a, 2008b, 2008c, 2008d), Gill et
al. (2004), Hardy (1999, 2002a, 2002b), Hardy et al. (2009), Markowski (2007), McDonald (2002), 
Rahman et al. (2001), Silberhorn et al. (1990), and WHO (2006).  Discussions of health effects are
divided into lower-brominated congeners and decaBDE due to important differences in pharmacokinetics 
and toxicity of decaBDE compared to lower-brominated PBDEs. Toxicity data for previously used 
   
 








     




    




   
 
  
   
  
      
     
 
 
   
     
     
 
     
  
   
 
   
     
     




PBDE mixtures as well as individual PBDE congeners are included in this profile, with mixtures being
categorized by their most prominent congener (see Table 4-3, Physical and Chemical Properties of
Technical PBDE Mixtures).  Using current health effects evaluation procedures, toxicity data for
individual congeners may over- or underestimate the actual health risk of PBDE mixtures because 
congeners vary in toxic potency and may be influenced by other congeners in an additive, less-than­
additive, or more-than-additive way.  It is also important to recognize that the PBDEs to which people
may be exposed may be different from the original PBDE source because of possible changes in congener
composition resulting from differential partitioning and transformation in the environment and/or
differential biological metabolism and retention.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death,
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
   
 















   
 
    
     
 
    
 
 
     
 
     
  
      






   
  
   
  
     
      




the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure 
A few studies have examined groups of chemical workers involved in the manufacture and distribution of
PBDEs (Bahn et al. 1980; Brown et al. 1981; Chanda et al. 1982; Landrigan et al. 1979; Rosenman et al. 
1979; Stross et al. 1981).  These people are believed to have been exposed predominantly by dermal
contact and inhalation, although the oral route cannot be ruled out.  Results from these studies, therefore, 
are discussed in this section as well as in Section 3.2.3.  The highest NOAEL and all LOAEL values from
each reliable inhalation study of health effects end points in each species and duration category for
PBDEs are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.1.1  Death 
No studies were located regarding death in humans after inhalation exposure to PBDEs.
No deaths occurred in groups of five male and five female rats that were chamber-exposed to pentaBDE
aerosol (compound dissolved in corn oil), octaBDE dust, or decaBDE dust in concentrations as high as
200,000, 60,000, or 48,200 mg/m3, respectively, for 1 hour and observed for the following 14 days (IRDC 
1974, 1975a, 1975b).  Confidence in these studies is limited by a lack of control data.  There was no 
mortality in rats that were exposed to dusts of commercial octaBDE products at concentrations of
174 mg/m3 for 8 hours/day for 14 consecutive days (Great Lakes Chemical Corporation 1978) or
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4 Rat 13 wk 16 F 202 F (absence of corpora lutea Great Lakes Chemical5 d/wk(CD) in ovaries) Corporation 20006 hr/d 
OctaBDE (technical) 
a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate-duration (15-364 days) inhalation minimal risk level (MRL) of 0.006 mg/m3 for lower brominated diphenyl ethers.  The MRL was derived by 
converting the animal NOAEL of 1.1 mg/m3 to a duration-adjusted human equivalent concentration (NOAELHEC) of 0.53 mg/m3, and dividing by an uncertainty factor of 30 (3 for 
species to species extrapolation with dosimetric adjustments and 10 for human variability) and a modifying factor of 3 (for an incomplete data base). 
Note on chemical form: The chemical form in all studies was a technical octaBDE mixture (exact composition was not reported). 
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = female; Gastro = gastrointestinal; Hemato = hematological; hr = hour(s); Immuno/Lymphoret = 
immunological/lymphoreticular; LOAEL = lowest observed adverse effect level; Musc/skel = muscular/skeletal; NOAEL = no observed adverse effect level; Resp = respiratory; T4 = 
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	Figure 3-1. Levels of Significant Exposure to Lower Brominated Diphenyl Ethers - Inhalation 
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3. HEALTH EFFECTS
3.2.1.2  Systemic Effects
Systemic effects that have been observed in humans and animals following inhalation exposure to PBDEs
are described below.
Respiratory Effects. No studies were located regarding respiratory effects in humans after inhalation
exposure to PBDEs.
Transient signs of respiratory distress that included tachypnea or dyspnea developed in rats that were 
chamber-exposed to pentaBDE aerosol (compound dissolved in corn oil), octaBDE dust, or decaBDE
dust in very high concentrations of 200,000, 60,000, and 48,200 mg/m3, respectively, for 1 hour (IRDC 
1974, 1975a, 1975b).  Confidence in these effect levels is low due to a small number of tested animals 
and lack of control data.  
One 14-day inhalation study of commercial octaBDE has been conducted.  In this study, rats were
chamber-exposed to concentrations of 0, 0.6, 3.7, 23.9, or 165.2 mg/m3 as powdered dust for 8 hours/day
for 14 consecutive days (Great Lakes Chemical Corporation 1978).  Increased respiration rate occurred at
≥23.9 mg/m3. The rapid breathing pattern developed by the end of each exposure period, always
disappeared by the following morning, and was not observed at lower exposure concentrations.  
Histological examinations of the control and 165.2 mg/m3 rats (other groups not examined) showed no 
changes in tissues that included nasal turbinates, trachea, lungs, and mediastinal lymph nodes).  
Histological changes in the lungs, but no clearly observed changes in the nasal cavity, were found in a
study of rats that were nose-only exposed to 0, 1.1, 16, or 202 mg/m3 as dust aerosol for 6 hours/day, 
5 days/week for 13 weeks (Great Lakes Chemical Corporation 2000).  The pulmonary effects included 
alveolar histiocytosis and chronic active inflammation, which occurred in both sexes, and were only
clearly induced at 202 mg/m3.  Total incidences of alveolar histiocytosis in the 0, 1.1, 16, and 202 mg/m3 
exposure groups were 3/10, 5/10, 5/10, and 10/10 in males, respectively, and 0/10, 5/10, 2/10, and 
10/10 in females, respectively.  Respective total incidences of chronic active lung inflammation were 
0/10, 0/10, 2/10, and 10/10 in males, and 0/10, 1/10, 1/10, and 10/10 in females.  Both lesions were
predominantly minimal or mild in severity, with moderate severity occurring in a few high-dose animals.
Additional effects included gross pulmonary changes in both sexes at 202 mg/m3; these included lung
firmness and white discoloration and/or enlargement in the bronchial and/or mediastinal lymph nodes.  
The gross lymph node changes correlated with the histological granulomatous inflammation.  Effects in 
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3. HEALTH EFFECTS
nasal tissues were equivocal. Incidences of nasal goblet cell hypertrophy were slightly increased in nasal
level II of both sexes at ≥1.1 mg/m3, but changes in incidence were not clearly dose-related and there was 
essentially no increase in severity from minimal levels with increasing dose.  Total incidences of goblet
cell hypertrophy in nasal level II in the 0, 1.1, 16, and 202 mg/m3 exposure groups were 4/10, 9/10, 6/10, 
and 10/10 respectively, in males, and 2/10, 6/10, 4/10, and 8/10, respectively, in females.  Minimal
severity goblet cell hypertrophy was also slightly increased in nasal level IV in males at 202 mg/m3 (4/10, 
0/10, 1/10, and 8/10), but not in females.
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans after
inhalation exposure to PBDEs.
No histopathological changes were observed in the heart of rats that were exposed to dusts of commercial
octaBDE products at concentrations of 174 mg/m3 for 8 hours/day for 14 consecutive days (Great Lakes 
Chemical Corporation 1978), or ≤202 mg/m3 for 6 hours/day, 5 days/week for 13 weeks (Great Lakes 
Chemical Corporation 2000).
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans after
inhalation exposure to PBDEs.
No histopathological changes were observed in the stomach and lower gastrointestinal tract of rats that
were exposed to dusts of commercial octaBDE products at concentrations of 174 mg/m3 for 8 hours/day
for 14 consecutive days (Great Lakes Chemical Corporation 1978), or ≤202 mg/m3 for 6 hours/day, 
5 days/week for 13 weeks (Great Lakes Chemical Corporation 2000). 
Hematological Effects. No studies were located regarding hematological effects in humans after
inhalation exposure to PBDEs.
No adverse hematological changes occurred in rats that were exposed to 24.4 or 174 mg/m3 of
commercial octaBDE dust aerosol for 8 hours/day for 14 consecutive days (Great Lakes Chemical
Corporation 1978).  Evaluation of a limited number of indices (hemoglobin, hematocrit, total erythrocyte
count, and total and differential leukocyte counts) showed no unusual responses except for an elevation in
leukocyte numbers. The observed increase in leukocyte counts was considered to be an unusual response
by the investigators, although it was within the normal range for control rats in their laboratory.  
Comprehensive hematological assessments showed no unusual changes in rats exposed to commercial
   
 








     
  
 
       
 
 
     
  
     
     
      
   
      
  
     
 
   
     
   
     
  
  
    
   
  
    
     
 




        
PBDEs 53
3. HEALTH EFFECTS
octaBDE as dust aerosol at concentrations of ≤202 mg/m3 for 6 hours/day, 5 days/week for 13 weeks
(Great Lakes Chemical Corporation 2000).
Hepatic Effects. No studies were located regarding hepatic effects in humans after inhalation
exposure to PBDEs.
Hepatic effects were observed in a 14-day inhalation study of dusts of commercial octaBDE mixtures.  In
this study, rats were chamber-exposed to concentrations of 0, 0.6, 3.7, 23.9, or 165.2 mg/m3 as powdered 
dust for 8 hours/day for 14 consecutive days (Great Lakes Chemical Corporation 1978). Increased liver
weight and hepatic histological changes occurred in rats exposed to concentrations ≥3.7 mg/m3.  At
3.7 mg/m3, the liver lesions consisted of very slight to slight severity focal to multifocal cytoplasmic 
enlargement of the hepatocytes, accompanied by focal acidophilic degeneration of individual to small
groups of cells.  The liver lesions were similar in rats exposed to concentrations ≥24.4 mg/m3, except that
the hepatocyte enlargement was multifocal to diffuse in distribution and accompanied by focal, small to 
large areas of hepatocellular necrosis of very slight to marked degree.
Similar hepatic changes were found in a study of rats that were nose-only exposed to 0, 1.1, 16, or
202 mg/m3 commercial octaBDE as dust aerosol for 6 hours/day, 5 days/week for 13 weeks (Great Lakes
Chemical Corporation 2000).  The liver was affected in both sexes as shown by dose-related increases in
centrilobular hepatocellular hypertrophy at ≥16 mg/m3 and increased liver weight (absolute and relative)
at 202 mg/m3.  Respective total incidences of centrilobular hepatocellular hypertrophy (predominantly
minimal to mild) in the 0, 1.1, 16, and 202 mg/m3 groups were 1/10, 0/10, 3/10, and 10/10 in males, and 
0/10, 0/10, 3/10, and 6/10 in females.  Serum chemistry evaluations showed no clear effects of exposure.  
Serum cholesterol was significantly increased (66.2% more than controls, p<0.01) in 202 mg/m3 females,
but the magnitude of the elevation was not considered toxicologically significant.  Some other statistically
significant serum chemistry alterations (increased mean globulin and total protein, decreased
albumin/globulin ratio) also occurred in females exposed to 202 mg/m3, but these changes were not
considered exposure-related due to small magnitudes of changes and lack of similar changes in the males.
Renal Effects. No studies were located regarding renal effects in humans after inhalation exposure to 
PBDEs.
No histopathological changes were observed in the kidneys or urinary bladder of rats that were exposed to
dusts of commercial octaBDE products at concentrations of 174 mg/m3 for 8 hours/day for 14 consecutive 
   
 









   
 
 
     
 
    
       




   
  
   
   
     
   
    
     
 
  
   
   
   
 









days (Great Lakes Chemical Corporation 1978) or ≤202 mg/m3 for 6 hours/day, 5 days/week for
13 weeks (Great Lakes Chemical Corporation 2000).  Urinalyses were not performed in any of these
studies.
Endocrine Effects. There is evidence suggestive of hypothyroidism in a small group of workers who 
were occupationally exposed to decaBDE (Bahn et al. 1980).  In another study, plasma levels of thyroid 
hormones (T3 and free T4) and eight PBDE congeners (tetra- to heptaBDEs) were monitored for 198– 
221 days in three electronic dismantling workers (Pettersson et al. 2002).  The hormones remained within
normal ranges and there were no correlations between levels of hormones and the plasma concentrations 
of congeners. 
An acute inhalation study of commercial octaBDE dust in rats showed no histopathological changes in the
thyroids, parathyroids, adrenals, or pituitary following chamber exposure to 174 mg/m3 as powdered dust
for 8 hours/day for 14 consecutive days (Great Lakes Chemical Corporation 1978).  Rats that were nose-
only exposed to commercial octaBDE at concentrations of 1.1, 16, or 202 mg/m3 for 6 hours/day, 
5 days/week for 13 weeks similarly showed no histological changes in the adrenals, pancreas,
parathyroids, pituitary, or thyroids (Great Lakes Chemical Corporation 2000). Measurements of serum
levels of thyroid hormones in the 13-week rat study, however, showed exposure-related decreases in
mean thyroxine (total T4) in both sexes exposed at ≥16 mg/m3, and increases in TSH in males exposed at 
≥16 mg/m3 and in females exposed at 202 mg/m3.  The changes were usually statistically significant
(p<0.05 or p<0.01) compared to controls and were considered by the investigators to be consistent with 
chemical-induced hypothyroidism.  There were no serum T3 changes, thyroid-attributable clinical signs or
body weight effects, or gross or histopathological changes in the thyroid.  The 1.1 mg/m3 LOAEL for
thyroid effects was used as the basis for the intermediate-duration MRL for inhalation exposure to 
octaBDE, as indicated in the footnote to Table 3-1 and discussed in Chapter 2 and Appendix A.
Dermal Effects. No studies were located regarding dermal effects in humans after inhalation exposure 
to PBDEs.
No gross or histological changes in the skin were observed in rats that were nose-only exposed to
commercial octaBDE as dust aerosol at concentrations of ≤202 mg/m3 for 6 hours/day, 5 days/week for
13 weeks (Great Lakes Chemical Corporation 2000).
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3. HEALTH EFFECTS
Ocular Effects. No studies were located regarding ocular effects in humans after inhalation exposure 
to PBDEs.
Transient signs of ocular irritation that included eye squint, erythema, and/or ocular discharge were 
observed in rats that were chamber-exposed to pentaBDE aerosol (compound dissolved in corn oil), 
octaBDE dust, or decaBDE dust in concentrations of 2,000, 2,000, and 48,200 mg/m3, respectively, for
1 hour (IRDC 1974, 1975a, 1975b).  Confidence in these effect levels is low due to a small number of
tested animals and lack of control data.
No histopathological changes were observed in eyes of rats that were chamber-exposed to ≤174 mg/m3 of
commercial octaBDE as powdered dust for 8 hours/day for 14 consecutive days (Great Lakes Chemical
Corporation 1978).  Opthalmoscopic and histological examinations showed no ocular effects in rats
following nose-only exposure to ≤202 mg/m3 of commercial octaBDE dust aerosol for 6 hours/day, 
5 days/week for 13 weeks (Great Lakes Chemical Corporation 2000).
3.2.1.3  Immunological and Lymphoreticular Effects 
A study conducted in China examined the association between serum levels of four BDEs (28, 47, 66, and 
209), as well as PCBs and organochlorine pesticides, and the prevalence of asthma in children (3–6 years 
old) living in a heavily populated area (Meng et al. 2016).  The study involved 620 cases and 
218 controls. Serum analyses showed significantly higher levels of BDEs in cases than in controls.
BDE 209 had the highest mean concentration in cases, 4.02 ng/g lipid, compared to 1.73 ng/g lipid in 
controls.  In multivariable-adjusted analyses, the odds ratio (OR) for risk of asthma associated with 1 ng/g
increase was statistically significant only for BDE 28 (OR 3.63; 95% confidence interval [CI] 1.23– 
10.70).  Strafication of children based on asthma severity showed that BDE 209 was positively correlated 
with the severity of the condition (OR 1.40; 95% CI 1.14–1.72).  PCBs and organochlorine pesticide also
were associated with increased risk of asthma.
No histopathological changes were observed in the spleen, mesenteric or mediastinal lymph nodes, or
bone marrow from rats that were exposed to 174 mg/m3 of octaBDE dust for 8 hours/day for
14 consecutive days (Great Lakes Chemical Corporation 1978). Rats that were nose-only exposed to 
commercial octaBDE at concentrations of 1.1, 16, or 202 mg/m3 as dust aerosol for 6 hours/day, 
5 days/week for 13 weeks similarly showed no effects in bone marrow, spleen, or thymus, although gross
changes in pulmonary lymph nodes were observed at 202 mg/m3 (Great Lakes Chemical Corporation
   
 













   
 
    
       





   
 
   
 
         
   
    
   
  
    











2000). The effects included discolored and/or enlarged bronchial and mediastinal lymph nodes, and 
appeared to be associated with concurrent granulomatous inflammation of the lungs.  
3.2.1.4  Neurological Effects 
No studies were located regarding neurological effects in humans after inhalation exposure to PBDEs.
No clinical signs of neurotoxicity were observed in rats that were exposed to dusts of commercial
octaBDE products at concentrations of 174 mg/m3 for 8 hours/day for 14 consecutive days (Great Lakes 
Chemical Corporation 1978) or ≤202 mg/m3 for 6 hours/day, 5 days/week for 13 weeks (Great Lakes 
Chemical Corporation 2000).  Histological examinations of nervous system tissues, performed only in the 
13-week study, showed no effects in the brain (forebrain, midbrain, hindbrain), optic nerve, or a 
peripheral nerve (sciatic).
3.2.1.5  Reproductive Effects
No studies were located regarding reproductive effects in humans after inhalation exposure to PBDEs.
No histopathological changes were observed in testes or ovaries from rats that were exposed to 
commercial octaBDE at concentrations ≤174 mg/m3 as powdered dust for 8 hours/day for 14 consecutive 
days (Great Lakes Chemical Corporation 1978).  A histological effect in the ovaries was found in a study
of rats that were nose-only exposed to 0, 1.1, 16, or 202 mg/m3 as dust aerosol for 6 hours/day, 
5 days/week for 13 weeks (Great Lakes Chemical Corporation 2000).  Absence of corpora lutea, based on 
qualitative evaluation of step sections of the ovary, was found in 3/10 females at 202 mg/m3, compared to 
0/10 incidences in the control and both lower exposure groups.  The investigators interpreted this 30%
increase in incidence be treatment-related because an absence of corpora lutea was considered unusual in 
rats at 20 weeks of age.  No gross or histopathological changes were observed in the oviduct, uterus, or
vagina, or in male reproductive tissues (testes with epididymides and vas deferens).
3.2.1.6  Developmental Effects 
No studies were located regarding developmental effects in humans or animals after inhalation exposure
to PBDEs.
   
 








   
 
   
 
     
 
   
     
    
  
 
    
      




     
     
   
      
      
       
  
 
   
  
      
   
 
     
  
      





No studies were located regarding cancer in humans or animals after inhalation exposure to PBDEs.
3.2.2 Oral Exposure
Human data presented below are primarily from studies that attempted to identify relationships between
concentrations of PBDE in serum or other tissues and various health outcomes.  Details of PBDE
exposure in these study populations are typically unknown.  However, exposure is presumed to have been
primarily by the oral route for those studies presented below.
The highest NOAEL and all LOAEL values from each reliable study of health effects end points in each
species and duration category for PBDEs are recorded in Tables 3-2 (lower PBDEs) or 3-3 (decaBDE)
and plotted in Figures 3-2 (lower PBDEs) or 3-3 (decaBDE).
3.2.2.1  Death 
Single-dose gavage LD50 values of 5,000 and 6,200 mg/kg were determined for pentaBDE (Saytex 115 
and DE-71, respectively) in rats that were observed for 14 days (British Industrial Biological Research
Association 1977; Pharmakon Research International Inc. 1984).  Another study found that a single
5,000 mg/kg dose of pentaBDE caused deaths in four of five rats in the 14 days following treatment,
whereas doses ≤500 mg/kg caused no mortality (IRDC 1975b). No deaths occurred in rats exposed to 
pentaBDE in estimated dietary doses of ≤90 mg/kg/day for 28 days (IRDC 1976) or ≤100 mg/kg/day for
90 days (WIL Research Laboratories 1984).
No deaths occurred in rats that were administered octaBDE by gavage in single doses ≤5,000 mg/kg and 
observed for the following 14 days (IRDC 1975a).  Intermediate-duration dietary studies with octaBDE, 
resulted in no mortality in rats exposed to estimated dietary doses of ≤90 mg/kg/day for 28 days or
≤750 mg/kg/day for 13 weeks (IRDC 1976, 1977).
No deaths occurred in rats that were treated with a single gavage dose of ≤5,000 mg/kg of decaBDE or
≤2,000 mg/kg of 77.4% decaBDE (containing 21.8% nonaBDE and 0.8% octaBDE) and observed for the
following 14 days (IRDC 1974; Norris et al. 1975a).  No mortality was observed in rats and mice that
were exposed to decaBDE via diet in estimated doses of ≤16,000 and ≤19,000 mg/kg/day, respectively,
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5000 (14-day LD50) Pharmakon Research 
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Albina et al. 2010 
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Chemical Form Comments 







40 F (porphyria) 
8 F (porphyria) 
200 F (fatty degeneration) 










200 F (fatty degeneration) 
200 F (10% decrease in body 
weight gain) 
Bruchajzer et al. 2010 
PentaBDE (technical) 
2156
Table 3-2  Levels of Significant Exposure to Lower Brominated Diphenyl Ethers  - Oral	 (continued) 
Exposure/ LOAEL 
Reference 
Chemical Form Comments 
Duration/ 
Frequency NOAEL Less Serious Serious 
(Route) 
System (mg/kg) (mg/kg) (mg/kg) 
once Hepatic 200 F 2000 F (fatty degeneration) 5 d observation 200 2000
Bruchajzer et al. 2011 
(GO) PentaBDE (technical) 
Bd Wt 200 F 2000 F (11% decrease in body 
200 weight gain) 
2000
200 F 2000 F (11% decrease in body 
200 weight gain) 
2000
7 d Hepatic 2 F 8 F (porphyria) 1 x/d 2 8
(GO) 
Bruchajzer et al. 2012 
OctaBDE (technical) 
Bd Wt 8 F 40 F (9% decrease in body 
8 weight gain) 
40
14 d Hepatic 8 F 40 F (porphyria) 1 x/d 8 40
(GO) 
Bruchajzer et al. 2012 
OctaBDE (technical) 
Bd Wt 8 F 40 F (5% decrease in body 
8 weight gain) 
40


















































































































































Less Serious	 Serious 
(mg/kg/day)	 (mg/kg/day) 
18		 (reduced serum T4) 
18 F		 (reduced serum T4, 
reduced T4 protein 
binding) 
18 F		 (reduced liver vitamin A) 
18 F		 (reduced serum T4) 
14 M (reduced serum T4) 
Reference 
Chemical Form 
Darnerud and Sinjari 1996 
PentaBDE (Bromkal 70) 
Ellis-Hutchings et al. 2009 
PentaBDE (DE-71) 
Hallgren and Darnerud 2002 
TetraBDE (BDE47) 
Hallgren et al. 2001 
PentaBDE (Bromkal 70-5DE) 




changes in serum 
thyroid hormone levels. 
No exposure-related 
changes in fat pad 
weight, adipocyte 
number, size, viability, 
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response to sheep red 




Richardson et al. 2008 
TetraBDE (BDE47) 
Darnerud and Thuvander 1998 
PentaBDE (Bromkal 70-5DE) 
Darnerud and Thuvander 1998 
PentaBDE (DE-71) 
Fowles et al. 1994 
PentaBDE (DE-71) 




changes in spleen or 
thymus weight, number 
or distribution of 
lymphocyte 
subpopulations, or in 
vitro IgG production. 
No exposure-related 
change in spleen or 
thymus weights or 
antibody respose to 























































































0.6 F (decreased serum 
testosterone) 













30 M 60 M (increased serum LH) 
30 M (20% decrease in ventral 
prostate weight) 
Stoker et al. 2005 
PentaBDE (DE-71) 




changes in spleen or 
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No changes in brain 




avoidance test, or 
Morris water maze. 
No treatment-related 
changes in gravid 
uterine weight or 












































































200 Argus Research Laboratories 
1985a 




10 25 (increased resorptions 
and reduced fetal body 
weight) 
Argus Research Laboratories 
1985b 




1 2 (delayed ossification, 
liver and heart 
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changes in ovary 
weight or histology. 
Mice were 
ovariectomized 3 
weeks prior to 
exposure; no change in 
uterus weight or 
uterus/vaginal 
histology. 
No changes in number, 
sex, and weight of 
fetuses, fetal death, 
early and late 
resorptions, gross 
malformations, or 
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120 Ellis-Hutchings et al. 2009 
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No exposure-related 
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habituation) 

































































25 50 (reduced fetal weight and 
increased skeletal 
variations associated 
with maternal tox) 






1 10 (reduced serum T4 in 
fetuses) 





10 M Costa et al. 2015 
TetraBDE (BDE47) 
No exposure-related 





6.8 M (decreased post-tetanic 
and long term potential in 
hippocampal slices at 
Pnd 17-19) 





0.8 M (altered spontaneous 
activity and habituation at 
2-4 months) 





0.7 M 10.5 M (altered spontaneous 
activity and habituation at 
2-4 months) 




























































8 M (altered spontaneous 










8 M (altered spontaneous 
activity and habituation at 
4 months) 














0.8 M 12 M (altered spontaneous 
activity and habituation at 
4-6 months) 





0.8 M (decreased activity and 
impaired learning and 
memory during at 2-6 
months) 





1 M (increased motor activity 
at 4 months) 


























































30 M Gee et al. 2008 
TetraBDE (BDE47) 
No exposure-related 
changes in offspring 
body weight or serum 




12 M (decreased spontaneous 
activity and impaired 
habituation at 2 months) 





0.4 0.8 (decreased total activity 
at 2 months) 





8 M (decreased spontaneous 
activity, altered 
habituation, and altered 
response to cholinergic 
agent at 2 months) 





0.45 M (decreased spontaneous 
activity at 6 months) 











Chemical Form Comments 
Less Serious Serious 
(mg/kg) (mg/kg) 
once 
Pnd 10  
(G) 
0.4
0.4 0.8 (decreased spontaneous 
activity and impaired 
habituation at 2-8 
months) 







0.4 M 12 M (decreased spontaneous 
activity, impaired 
habituation, and 
decreased density of 
cholinergic nicotinic 
receptors in 
hippocampus at 4 
months) 






16.8 M (decreased spontaneous 
activity and impaired 
habituation at 2 months) 






16.8 M (decreased spontaneous 
activity, impaired 
habituation, and impaired 
learning and memory at 
2-3 months) 






15.2 M (decreased spontaneous 
activity at 2 months) 































































a FrequencyKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (mg/kg) (mg/kg) (mg/kg) 
88 Mouse once 15.2 MPnd 10(NMRI) 
(G) 
89 Mouse once 18.5 MPnd 3(NMRI) 
(G) 
90 Mouse once 18.5 M (decreased spontaneousPnd 10(NMRI) activity and impaired
(G) habituation at 2 months) 
91 Rabbit 13 d 5 F 15 F (delayed ossification ofGd 7-19(New sternebrae with








Viberg et al. 2006 
HeptaBDE (BDE183) 
Viberg et al. 2006 
NonaBDE (BDE206) 
Viberg et al. 2006 
NonaBDE (BDE206) 
Breslin et al. 1989 
OctaBDE (technical) 
Bansal et al. 2014 
PentaBDE (DE-71) 
Comments 
No change in 
spontaneous activity or 
habituation at 2 
months. 
No changes in 
spontaneous motor 
behavior or habituation 
at 2 months. 












































































































Less Serious	 Serious 
(mg/kg/day)	 (mg/kg/day) 
30 M (follicular cell hypertrophy 
and hyperplasia in 
thyroid, reduced serum 
T3 and T4, increased 
serum TSH) 




30 M (decreased serum T3 






5 M (reduced serum T4) 




Becker et al. 2012 
PentaBDE (DE-71) 
Becker et al. 2012 
PentaBDE (DE-71) 
Bondy et al. 2011, 2013 
PentaBDE (DE-71) 
Bowers et al. 2015 
PentaBDE (DE-71) 
Comments 
Study 1 (conducted at 
ILS) 
Study 2 (conducted at 
RTI) 






















































8 F (porphyria) 













8 F (porphyria) 







1 x/d Bd Wt 40 F 200 F (12% decrease in body weight gain) 





1 x/d Bd Wt 40 F 200 F (14% decrease in body weight gain) 











8 F (porphyria) 
40 F (9% decrease in body 
weight gain) 


























































Bd Wt 8 F 40 F (8% decrease in body 
weight gain) 








































Daubie et al. 2011 
PentaBDE (BDE99) 
No exposure-related 








Bd Wt 26.2 M 








































































Chemical Form Comments 
Hepatic 50 (hepatocellular 
hypertrophy and 
vacuolization) 
Dunnick et al. 2012 
PentaBDE (DE-71) 
Endocr 50 (thyroid gland follicular 
hypertrophy) 
Bd Wt 50 M 50 F (14% decrease in body 
weight) 
Hepatic 18 F (reduced liver vitamin A) Ellis-Hutchings et al. 2006 
PentaBDE (DE-71) 
Endocr 
Bd Wt 18 F 




2 M 20 M (reduced serum T4; 
increased epithelial 
thickness of inner 
follicles and vacuolation 
of the luminal apices of 
epithelial cells in thyroid) 
Ernest et al. 2012 
52.1% penta-, 44.2% deca-, 
0.4% octa-BDE 
No exposure-related 
changes in hepatic 
clinical chemistry. 
Bd Wt 20 M 



























































































Chemical Form Comments 
2.5 25 (decreased hepatic 
vitamin A content) 
Fattore et al. 2001 
PentaBDE (Bromkal 70-5DE) 
14 M (reduced serum T4) Hoppe and Carey 2007 
PentaBDE (technical) 
14 M 


















































Key to Species Frequency 







116	 Rat 13 wk 
(CD) (F) 
117 Rat		 36 d 





























70 F 750 F (reduced erythrocytes, 
hematocrit and 
hemoglobin) 
5 M (cytomegaly with 
vacuolation and necrosis 
at higher doses) 
50 M 600 M (minimal increase in 
tubular degenerative 
changes) 
7 F 50 M (increased thyroid weight 
with follicular epithelial 
changes at higher doses) 
750 F 
750 F 
70 F 600 M (12% reduced body 
weight gain) 






























Key to Species Frequency 












119 Rat		 ~11 wk 
Pmd 28 -(Long- Evans) 
Pnd 21 
(IN) 

























Chemical Form Comments 
250 Oberg et al. 2010 
PentaBDE (Bromkal 70-5DE) 
250 
250 
2.5 25 (centrilobular 
hypertrophy, reduced 
vitamin A content in liver) 
250 
250 
25 250 (hypercalcemia, 
magnesemia, and 
phosphatemia in males; 
hyperatremia and 
hypokalemia in females) 
11.4 F Poon et al. 2011 
PentaBDE (DE-71) 
Rats were given 
pentaBDE-dosed 
vanilla wafers. 










































Bd Wt 60 M 








Bd Wt 120 M 



































Key to Species Frequency 




































Chemical Form Comments 
200 Van der Ven et al. 2008b 
PentaBDE (DE-71) 
NOAEL values for Bd 
Wt, Hepatic, Endocr, 
and Metab effects are 
BMDL(RD10%) values 
for decreased Bd Wt, 
vitamin A in liver, 










3.2 F (reduced serum T4) Wang et al. 2011a 
TetraBDE (BDE47) 
125 Rat 
Table 3-2  Levels of Significant Exposure to Lower Brominated Diphenyl Ethers  - Oral (continued) 
xposure/ LOAEL 
uration/ 
requency NOAEL Less Serious Serious 
(Route) 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) 
Reference 
Chemical Form Comments 
90 d Resp 100 
(F) 100











Hepatic 2 (hypertrophy, mild 











Bd Wt 10 100 (reduced weight gain) 
10 100
30 d Bd Wt 1 M 1 x/d 1
(GO) 
Yan et al. 2012 
TetraBDE (BDE47) 
6 wk Bd Wt 0.2 F Gd 1 - Pnd 21 0.2
Zhao et al. 2014 


















































































Gd 6 - Pnd 21 
(GO) 
36 d 

























Less Serious	 Serious 
(mg/kg/day)	 (mg/kg/day) 




0.45 F (hepatocyte vacuolation, 
pyknotic nuclei in the 
hepatocytes, periportal 
lymphocytic infiltration) 
0.45 F (cellular debris in the 
follicular lumen of thyroid; 
increased serum 
testosterone and E2) 
Reference 
Chemical Form 
Zhou et al. 2002 
PentaBDE (DE-71) 
Branchi et al. 2005 
PentaBDE (BDE99) 
Koenig et al. 2012 
TetraBDE (BDE47) 





from a modified syringe 
or gavage. 











































Gd 4 - Pnd 17 





Gd 4 - Pnd 17 














































452 F Skarman et al. 2005 
PentaBDE (BDE99) 
452 F 
452 F Skarman et al. 2005 
PentaBDE (Bromkal 70-5DE) 
452 F 
1 F Ta et al. 2011 
TetraBDE (BDE47) 




changes in glucose 
tolerance, insulin 
resistance, lipogenesis, 
or liver weight or 
histology. 
BDE-99; No change in 
maternal serum T4 
levels. 
Bromkal 70-5DE; no 
change in maternal 
serum T4 levels. 
Dams were fed 
tetraBDE-dosed 
cornflakes. 





































































1.2 M (swollen hepatic cells) 
1.2 M (10% decrease in relative 
kidney weight) 
150 M (increased relative liver 






150 M (increased relative liver 






0.63 M (21% decrease in body 
weight) 
Zhang et al. 2014 
DiBDE (BDE15) 
Zhang et al. 2015b 
TetraBDE (BDE47) 
Zhang et al. 2015a 
TetraBDE (BDE47) 




























































System (mg/kg/day) (mg/kg/day)	 (mg/kg/day) 
16-17 wk Bd Wt 0.31 FPmw 4 -
Pnw 6 
(F) 
43-44 wk Bd Wt 0.06Pmw 4 -
Pnw 33 
(F) 











Zhang et al. 2009 
PentaBDE (DE-71) 
Zhang et al. 2009 
PentaBDE (DE-71) 










changes in spleen or 
thymus weight or 
histology. 
No exposure-related 
changes in spleen 
weight or spleen or 
thymus histology. 
No exposure-related 
changes in spleen 
weight or spleen or 
thymus histology. 
No exposure-related 
changes in spleen 
weight or spleen or 
thymus histology. 
2078







Frequency NOAEL Less Serious Serious 
(Route) 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) 






28 d 250 1 x/d 250
(GO) 
Oberg et al. 2010 
PentaBDE (Bromkal 70-5DE)
ue-
90 d 100 
(F) 100
WIL Research Laboratories 
1984 
) PentaBDE (DE-71) 
 
/c) 
28 d 0.45 F (follicular hyperplasia and 
(F) lymphocytic infiltration in 
spleen; lymphocytic 
Maranghi et al. 2013 
TetraBDE (BDE47) 
apoptosis and Hassal's 
bodies in thymus) 
0.45
9 wk 0.08 M 0.63 M (spleen hyperplasia) 
(F) 0.08 0.63






































changes in spleen 
weight or spleen or 
thymus histology. 
No exposure-related 
changes in spleen or 
thymus weight or 
histology. 
No exposure-related 
changes in thymus 
weight or spleen or 
thymus histology. 
Immune function was 
not altered (KLH 
antibody induction, 































a FrequencyKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) 
Neurological 




153 Rat 125 d 17.5 M 26.2 M (impaired attention andPnd 1-125(Long- Evans) inhibitory control)
(F) 




155 Rat 28 d 200
(Wistar) (G) 
156 Rat 30 d 0.1 M (impaired learning and1 x/d(Sprague- memory; decreased
Dawley) (GO) glutamate and receptor 
density in hippocampus) 

































changes in elevated 
plus-maze, open-field, 
or Morris water maze 
test. 
No exposure-related 
changes in brain weight 
or histology. 
No exposure-related 
changes in brain weight 
or histology. 
No maternal 



























































30 M 60 M (67% increase in serum 
prolactin; dose-related 
increase in serum 
testosterone and FSH) 











25 Bondy et al. 2011, 2013 
PentaBDE (DE-71) 
6 wk 
Gd 1 - Pnd 21 
(IN) 
30 F Bowers et al. 2015 
PentaBDE (DE-71) 
Comments 
Study 1 (conducted at 
ILS) 
Study 2 (conducted at 




or serum reproductive 
hormone levels. 
No treatment-related 
changes in the number 
of pregnant females, 
litters, or litter size. 
Dams were given 
DE-71-dosed cookies. 
No treatment-related 
changes in no. of 
implants, no. of litters, 
litter size, or sex ratio. 
2166





Frequency NOAEL Less Serious Serious 
(Route) 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) 
36 d 2 F Gd 6 - Pnd 21 2
Cheng et al. 2009 
(GO) PentaBDE (BDE99) 
70 d 20 M 
(F) 20
Ernest et al. 2012 
52.1% penta-, 44.2% dec
0.4% octa-BDE 
8 wk 0.001 M 0.03 M (increased epithelial 
(GO) 0.001 thickness in testes, 
spermatocyte apoptosis) 
Huang et al. 2015 
TetraBDE (BDE47) 
0.03













































changes in number of 














































a FrequencyKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) 














170 Rat 20 d 30 F 60 F (delayed vaginalPnd 22-41(Wistar) opening)
(GO) 
































weight or histology. 
Rats were given 
pentaBDE-dosed 
vanilla wafers; no 
change in number of 
pregnancies, 
implantation sites, or 






























































60 M (delayed PPS, 22-28% 
decrease in prostate and 
seminal vesicle weights) 
















0.001 M (34% reduction in serum 
testosterone) 
Zhang et al. 2013b 
TetraBDE (BDE47) 
6 wk 
Gd 1 - Pnd 21 
(GO) 
0.2 M Zhao et al. 2014 
PentaBDE (BDE99) 
Comments 
Male NOAEL is a 
BMDL(RD10%) for 




changes in female 
reproductive organ 




weight or histology. 
No exposure-related 
changes in gestational 
lengths, litter sizes, sex 























































Gd 6 - Pnd 21 
(GO) 
30 F Zhou et al. 2002 
PentaBDE (DE-71) 
36 d 










0.45 F (increased serum 
testosterone and E2) 









No change in the 
gestation length, litter 
size, or sex ratio 
Administered via 
"self-administration" 
from a modified syringe 
or gavage; No change 
in gestation length, 
litter size, # live pups, 
or sex ratio. 
Mice were fed 1-2 
tetraBDE dosed 
cornflakes; no change 
in the number of 
pregnancies, size of 




weeks prior to 
exposure; no change in 


























































Gd 4 - Pnd 17 
~every 3 d 
(GO) 
452 F Skarman et al. 2005 
PentaBDE (BDE99) 
29 d 
Gd 4 - Pnd 17 
~every 3 d 
(GO) 
452 F Skarman et al. 2005 









0.0015 M 0.045 M (germ cell loss and 
apoptosis in testes) 






0.03 F 0.1 F (58% decrease in litters 
surviving until Pnd 8) 
Woods et al. 2012 
TetraBDE (BDE47) 
Comments 
BDE-99; no change in 
maternal serum T4 
levels. 
Bromkal 70-5DE; no 
changes in pregnancy 
rate, gestation length, 
or litter size. 
Dams were fed 
tetraBDE-dosed 
cornflakes; no change 
in gestation length, 
litter size, or sex ratio. 
Females carrying on 
copy of a truncated 
Mecp2 gene were 
mated to unexposed 
wild-type males; LSE 
values are based on 







































































0.06 F 0.31 F (complete litter loss) Zhang et al. 2009 
PentaBDE (DE-71) 
5 wk 
Gd 6 - Pnd 21 
(IN) 
1 M 10 M (reduced serum T4 in 
Pnd 21 offspring) 
Bansal et al. 2014 
PentaBDE (DE-71) 




Gd 6 - Pnd 21 
(GO) 
1 2 (altered neurobehavior, 
decreased hippocampal 
BDNF, and decreased 
serum T3, T4, and free 
T4 in offspring at Pnd 
21-23) 






0.5 M 5 M (decreased serum T4 in 
male offspring on Pnd 
43) 














































Gd 1 - Pnd 21 
(IN) 
0.3 3 (reduced serum T3 and 
T4 in Pnd 21 offspring) 
Bowers et al. 2015 
PentaBDE (DE-71) 






Gd 6 - Pnd 21 
(GO) 
2 M (delayed appearance of 
reflexes, impaired 
learning/memory at Pnd 
36-37, and oxidative 
stress in the 
hippocampus at Pnd 37) 







15 M Driscoll et al. 2012 
PentaBDE (DE-71) 
No learning or attention 





Gd 6 - Pnd 18 
(GO) 
18 (decreased serum T4 in 
offspring) 
Ellis-Hutchings et al. 2006 
PentaBDE (DE-71) 
Half of the dams in 
each group were 
maintained on a 




Gd 6 - Pnd 21 
(GO) 
1.7 10.2 (reduced serum T4 in 
offspring at Pnd 7 and 
14, reduced mammary 
gland development at 
Pnd 21, reduced female 
body weight from Pnd 
29-58) 





















































Gd 6 - Pnd 21 
(GO) 
0.96 M 2.85 M (reduced serum T4 in 
male offspring at Pnd 
7-21) 





Gd 6 - Pnd 21 
(GO) 
11.2 (reduced serum T4 in 
offspring at Pnd 7-21) 













Gd 6 - Pnd 21 
(GO) 
5.7 (reduced serum T4) 
1.7 M (hypertensive reaction to 
hyperosmotic stress in 
adult male offspring ) 
Poon et al. 2011 
PentaBDE (DE-71) 
Shah et al. 2011 
PentaBDE (DE-71) 






Gd 6 - Pnd 21 
(GO) 
1.7 10.2 (transient reduction in 
serum T4 in offspring at 
Pnd 4 and 21) 





Gd 1 - Pnd 14 
(F) 
3.2 (reduced serum T4 in 
offspring at Pnd 7 and 
14) 
































































Gd 1 - Pnd 21 
(GO) 
0.2 M Zhao et al. 2014 
PentaBDE (BDE99) 
36 d 
Gd 6 - Pnd 21 
(GO) 
1 10 (reduced serum T4 in 
offspring on Pnd 4 and 
14) 
Zhou et al. 2002 
PentaBDE (DE-71) 
36 d 
Gd 6 - Pnd 21 18 M (transient alterations in open-field behavior of 
offspring at Pnd 34) 
Branchi et al. 2005 
PentaBDE (BDE99) 
5 wk 
Gd 8 - Pnd 21 
(GO) 






0.03 (impaired learning in 
offspring at Pnw 8) 




changes in reflex 
maturation, motor 
coordination, or spatial 
learning of Pnd 3-36 
offspring; no offspring 
body weight effects. 
Administered via 
"self-administration" 
from a modified syringe 
or gavage; data from 





changes in offspring 
body weight, motor 
activity at Pnd 21, or 
social interaction at 
Pnd 70. 
























































Gd 4 - Pnd 17 
~every 3 d 
(GO) 
452 Skarman et al. 2005 
PentaBDE (BDE99) 
29 d 
Gd 4 - Pnd 17 
~every 3 d 
(GO) 
452 (reduced serum T4 in 
offspring at Pnd 11) 
Skarman et al. 2005 





0.03 F (decreased center-field 
activity in open field in 
female offspring at Pnd 
60) 






0.03 F (decreased pre-weaning 
weight; decreased pup 
vocalizations on Pnd 
8-10, decreased 
sociability on Pnd 72) 






0.05 Bull et al. 2007 
PentaBDE (DE-71) 
Comments 
BDE-99; no changes in 
offspring body weight 
or serum T4 levels 
Bromkal 70-5DE 
Dams were fed 
tetraBDE-dosed 
cornflakes. 
Females carrying on 
copy of a truncated 
Mecp2 gene were 
mated to unexposed 
wild-type males; LSE 
values are based on 
the wild-type offspring 
only. 
No cholinergic effects 
in 6-week-old offspring. 


























0.05 Bull et al. 2007 
PentaBDE (DE-71) 










0.06 Zhang et al. 2009 
PentaBDE (DE-71) 
No change in body 
weight, organ weights, 
plasma T3/T4, hepatic 
(F) enzyme activity, or 
thyroid histology in 

















a The number corresponds to entries in Figure 3-2. 
b Three studies were used to derive an acute oral minimal risk level (MRL); concentration divided by an uncertainty factor of 1000 (10 for use of a LOAEL, 10 for animal to human, 
and 10 for human variability), resulting in an MRL of 0.00006 mg/kg/day. 
c Used to derive an intermediate oral minimal risk level (MRL); concentration divided by an uncertainty factor of 300 (3 for use of a minimal LOAEL, 10 for animal to human, 10 for 
human variability), resulting in an MRL of 0.000003 mg/kg/day. 
Note on chemical form: Mixtures are identified by composition or trade name (if reported); otherwise, they are reported as "technical".  Trade names include Bromkal 70, Bromakal 
70-5 DE, DE-71, and Saytex 115 for pentaBDE mixtures and DE-79, FR-1208, and Saytex 111 for octaBDE mixtures. For the studies by Bruchajzer (2011) and Bruchajzer et al. 
(2010, 2011, 2012), the mixtures were made to resemble formerly used commercial mixtures. The pentaBDE mixture was composed of 63.2% pentaBDE, 21.4% tetraBDE, 15.4% 
hexaBDE, and 0.04% heptaBDE; the octaBDE mixture was composed of 65.7% octaBDE, 14.8% heptaBDE, 1.7% hexaBDE, and 17.8% nona- and deca-BDE.  Individual congeners 
are identified by IUPAC number: BDE 15 = 4,4'-diBDE; BDE 47 = 2,2',4,4'-tetraBDE; BDE 99 = 2,2',4,4',5-pentaBDE; BDE 153 = 2,2',4,4',5,5'-hexaBDE; BDE 183 = 
2,2',3,4,4',5',6-heptaBDE; BDE 203 = 2,2',3,4,4',5,5',6-octaBDE; BDE 206 = 2,2',3,3',4,4',5,5',6-nonaBDE 
BDNF = brain derived neurotrophic factor; Bd Wt = body weight; BMDL = benchmark dose lower confidence limit; Cardio = cardiovascular; d = day(s); E2 = estradiol; Endocr = 
endocrine; (F) = feed; F = Female; FSH = follicle stimulating hormone; (G) = gavage; Gastro = gastrointestinal; Gd = gestational day; (GO) = gavage in oil; Hemato = hematological; 
IgG = immunoglobulin G; Immuno/Lymphoret = immunological/lymphoreticular; IN = ingestion; LH = luteinizing hormone; KLH = keyhole limpet hemocyanin; LD50 = lethal dose, 50% 
kill; LOAEL = lowest-observed-adverse-effect level; M = male; Metab = metabolism; Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; 
PHA = phytohemagglutinin; Pmd = pre-mating day; Pmw = pre-mating week; Pnd = post-natal day; Pnw = post-natal week; PPS = preputial separation; Resp = respiratory; T3 = 
triiodothyronine; T4 = thyroxine; TSH = thyroid stimulating hormone; x = time(s); wk = week(s) 
D H R Emg/kg/day 
10000 






10r 11r 12r 
18r100 35m 39m15r36m 28r16r 
8r 10r 11r 14r37m 26r 27r 28r 32r 
37m 20r 34m 36m 37m 38m 17r 19r 20r 21r 
10 39m 32r 33r8r 9r 13r 14r 
19r 
26r 27r 33r 
13r 
4r 5r 5r1 






















 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans

























Figure 3-2. Levels of Significant Exposure to Lower Brominated Diphenyl Ethers - Oral 





















35m 23r 42m 
32r 33r 51m29r8r 9r 10r 11r 12r 
18r100 39m 6r
36m 43m26r 27r 28r 48r31r10r 11r 13r 14r37m 20r 41m 43m 40r 48r 49r25r 31r 
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89m 90m85m 86m 87m 88m 91h75m 79m 84m71m10 68m 53r 62r 67r72m 73m 74m 81m 65r69m 
91h 
62r54r 
1 77m 54r 58r 59r 67r70m 75m 76m 80m 83m 65r71m 
























 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans












































1000 116r 116r 116r 116r 116r 
118r 118r 118r 118r123r 123r 123r 123r 138m 139m 
100 125r 125r 125r 125r 125r 114r 115r116r 
109r 116r 
112r 118r 95r111r106r 110r104r
10 114r 115r97r 98r 101r 
95r 116r 
94r 112r 118r105r98r 101r 125r103r 
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Figure 3-2. Levels of Significant Exposure to Lower Brominated Diphenyl Ethers - Oral (Continued) 
























1000 116r 116r 
133m 134m 133m 134m 
123r 123r 138m 139m 
100 125r 125r 125r114r 115r 
122r 93r 94r109r 116r 
93r 94r 96r 120r 128r 136m 96r95r111r110r 129m108r 113r 117r10 92r 125r 128r 97r116r
95r 
124r93r 94r 96r 120r 121r 
111r 125r117r 
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Figure 3-2. Levels of Significant Exposure to Lower Brominated Diphenyl Ethers - Oral (Continued) 
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Bd Wt 16000 NTP 1986 








Endocr 100 F Zhou et al. 2001 
DecaBDE (DE-83R) 
No exposure-related 
changes in serum 
thyroid hormone levels. 






Endocr 750 F 1500 F (reduced maternal serum 
T4) 







Bd Wt 19000 NTP 1986 





































Key to Species Frequency 


















Less Serious	 Serious 
(mg/kg/day)	 (mg/kg/day) 




6.7 M (decreased spontaneous
	
activity at 2 months)
	
5.76		 (decreased activity and 
impaired habituation at 
2-4 months; impaired 
learning at 5-7 months) 
750		 (10% decrease in fetal
	




2.22 M (decreased activity and 
impaired habituation at 2 
and 4 months) 
Reference 
Chemical Form 
Sakamoto et al. 2013 
DecaBDE (BDE209) 
Chen et al. 2014 
DecaBDE (BDE209) 
Viberg et al. 2007 
DecaBDE (BDE209) 
Buratovic et al. 2014 
DecaBDE 
Chi et al. 2011 
DecaBDE (BDE209) 
Johansson et al. 2008 
DecaBDE (BDE209) 
Comments 
No change in liver 
































































Key to Species Frequency 







15 Mouse 14 d 
(C57BL/6J) Pnd 2-15 
(IN) 
16 Mouse		 14 d 
Pnd 2-15(C57BL/6J) 
(IN) 
17 Mouse		 once 
Pnd 3(NMRI) 
(G) 
18 Mouse		 once 
Pnd 10(NMRI) 
(G) 





20 Rat 36 d 





NOAEL Less Serious Serious 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) 
6 20 (delayed ontogeny of 
reflexes in males and 
females, increased 
locomotion in Pnd 70 
males, reduced serum T4 
in Pnd 21 males) 
6 20 (learning impairment and 
impulsivity at 16 months 
of age) 
2.22 M (decreased spontaneous 




Bd Wt 1000 F 
Reference 
Chemical Form 
Rice et al. 2007 
DecaBDE (BDE209) 
Rice et al. 2009 
DecaBDE (BDE209) 
Viberg et al. 2003b 
DecaBDE (BDE209) 
Viberg et al. 2003b 
DecaBDE (BDE209) 
Viberg et al. 2003b 
DecaBDE (BDE209) 









No change in 
spontaneous activity or 
habituation at 2, 4, or 6 
months. 
No change in 
spontaneous activity or 



























































































Chemical Form Comments 
1000 F 
1000 F 




Bruchajzer et al. 2010 
DecaBDE (BDE209) 








100 M 300 M (fatty degeneration, 
inflammatory foci) 
Lee et al. 2010 
DecaBDE (BDE209) 
600 M 


























Key to Species Frequency 











27	 Rat 13 wk 





















Chemical Form Comments 
300 F (hepatocyte 
degeneration, 
eosinophilic changes) 
Liu et al. 2012 
DecaBDE (BDE209) 
300 F (12% decrease in 








































































60 F (increased serum T3) 








Hepatic 100 M Wang et al. 2010 
DecaBDE (BDE209) 
No change in kidney 
weight, clinical 
chemistry parameters, 














Endocr 50 M Wang et al. 2011b 
DecaBDE (BDE209) 
No exposure-related 
changes in serum 
thyroid hormone levels. 









0.05 M (12% increase in serum 
glucose) 
Zhang et al. 2013a 
DecaBDE (BDE209) 



























































































Chemical Form Comments 
20 M Heredia et al. 2012 
DecaBDE (BDE209) 
160 Liang et al. 2010 
DecaBDE (BDE209) 
160 Liang et al. 2010 
DecaBDE (BDE209) 





























































Hepatic 9400 M (moderate hepatocellular 
hypertrophy) 
Sakamoto et al. 2013 
DecaBDE (BDE209) 





Endocr 750 M 950 M (reduced serum T3 and 
T4) 
Sarkar et al. 2015 
DecaBDE (BDE209) 


















Gd 10 - Pnd 21 
(F) 


































































300 F (increased spleen weight, 
lesions in spleen and 
thymus, altered T-cell 
distribution, decreased 
serum IgM, IgG, 
decreased lymphocyte 
proliferation) 















DecaBDE (technical, 94-97% 
pure) 





every other day 
(GO) 
800 F (impaired CD4 T cell 
immune function) 










changes in spleen 
weight or spleen or 
thymus histology. 
No exposure-related 
changes in spleen or 
thymus weight or 




































































DecaBDE (technical, 94-97% 
pure) 










20.1 (decreased synaptic 
potency, short-term 
plasticity, and long-term 
potentiation on Pnd 60) 





20 M (decreased anxiety 
behaviors) 





160 Liang et al. 2010 
DecaBDE (BDE209) 
Comments 
No change in 
pulmonary viral load 
after RSV infection 1 
week after exposure 
period. 
No changes in 
open-field behavior. 
No exposure-related 
changes in brain weight 






































































80 160 (transient reduction in 
brain AchE activity) 
Liang et al. 2010 
DecaBDE (BDE209) 
36 d 
Gd 6 - Pnd 21 
(GO) 
1000 F Biesemeier et al. 2011 
DecaBDE (BDE209) 
32 d 

















changes in brain weight 
or AchE activity. 
No treatment-related 
changes in maternal 
toxicity, gestation 
length, or number of 
implantations. 
No change in number 
of implantations, live 

























































300 F (atrophic and fibrotic 
changes in ovary, 
decreased number of 
ovarian follicles) 






8000 NTP 1986 










9500 NTP 1986 










750 M 950 M (13-18% decrease in 
relative testis and 
epididymides weight, 












100 M 500 M (reduced amplitude of 
lateral head velocity of 
sperm; reduced sperm 
mitochondrial membrane 
potential) 


































































1500 F Tseng et al. 2008 
DecaBDE (BDE209) 
31 d 
Gd 10 - Pnd 21 
(F) 
260 F Watanabe et al. 2008 
DecaBDE (BDE209) 
31 d 
Gd 10 - Pnd 21 
(F) 
2900 F Watanabe et al. 2010b 
DecaBDE (BDE209) 
36 d 
Gd 6 - Pnd 21 
(GO) 
1000 Biesemeier et al. 2011 
DecaBDE (BDE209) 
32 d 
Gd 10 - Pnd 21 
(F) 
2 (diffuse liver cell 
hypertrophy with 
cytoplasmic eosinophilia 
in male offspring and 
cytoplasmic eosinophilia 
in the cortical proximal 
tubules of the kidney of 
female offspring at Pnd 
20; recovered by Pnw 
11) 
Fujimoto et al. 2011 
DecaBDE (BDE209) 
Comments 
No change in 
gestational length or 
litter size, no change in 
ovary weight. 
No change in the 
number of litters. 
No change in the 
number of litters. 
No treatment-related 
changes in litter size, 
sex ratio, pup survival 




























































1000 F Hardy et al. 2002 





20.1 Xing et al. 2009 
DecaBDE (BDE209) 
61 d 
Gd 1 - Pnd 41 
(G) 
20.1 (decreased synaptic 
potency, short-term 
plasticity, and long-term 
potentiation in 
hippocampus in Pnd 60 
offspring) 





20.1 (altered long-term 
potentiation in 
hippocampus of Pnd 60 
offspring) 





20.1 (decreased synaptic 
potency, short-term 
plasticity, and long-term 
potentiation in 
hippocampus on Pnd 60) 
Xing et al. 2009 
DecaBDE (BDE209) 
Comments 
No change in 
hippocampal 
eletrophysiological 
readings in Pnd 60 
offspring. 
DecaBDE administered 
to dams Gd 1- Pnd 21 





















































10 M (hepatocytic swelling in 
male offspring at Pnd 71) 







10 M (vacuolization in 
interstitial cells of testes 
and sperm damage in 
male offspring at Pnd 71) 





Gd 10 - Pnd 21 
(F) 
34 260 (15% decrease in pup 
weight on Pnd 21; 
increased viral load in 
lung and IFN-gamma in 
BALF in offspring on Pnd 
33) 
Watanabe et al. 2008 
DecaBDE (BDE209) 
Pups were infected 




Gd 10 - Pnd 21 
(F) 
290 2900 (increased viral load in 
lung and altered cytokine 
expression BALF in 
offspring on Pnd 29-33) 
Watanabe et al. 2010b 
DecaBDE (BDE209) 
Pups were infected 






9100 M (CEL: liver neoplastic 
nodules; altered foci) 







every other day 
(GO) 
800 F (5/10 died vs. 1/10 
controls) 

























































Kociba et al. 1975; Norris et al. 
1975a 








































































1120 M (precancerous neoplastic 
nodules) 
Renal 2550 F 
Endocr 2550 F 




























































DecaBDE (technical, 94-97% 
pure) 
Gastro 3760 F 7780 F (ulcers) 
Hemato 7780 F 
Musc/skel 7780 F 
Hepatic 3200 M (centrilobular hypertrophy 
and granulomas) 
Renal 7780 F 








Bd Wt 7780 F 
1 Kociba et al. 1975; Norris et al. 
1975a 
77% decaBDE, 22% nonaBDE 
No exposure-related 






1200 F (splenic hematopoiesis) NTP 1986 






7780 F NTP 1986 
DecaBDE (technical, 94-97% 
pure) 
No exposure-related 























































Kociba et al. 1975; Norris et al. 
1975a 
































1120 M (CEL: liver neoplastic 
nodules) 
NTP 1986 




















































a The number corresponds to entries in Figure 3-3. 
b Used to derive an acute oral minimal risk level (MRL); concentration divided by an uncertainty factor of 100 (10 for animal to human, and 10 for human variability), resulting in an 
MRL of 0.01 mg/kg/day. 
c Used to derive an intermediate oral minimal risk level (MRL); concentration divided by an uncertainty factor of 300 (3 for use of a minimal LOAEL,10 for animal to human, 10 for 
human variability), resulting in an MRL of 0.0002 mg/kg/day. 
Note on chemical form: Mixtures are identified by composition or trade name (if reported); otherwise, they are reported as "technical".  Trade names for decaBDE include DE-83R 
(98% decaBDE). The individual congener is identified by by IUPAC number: BDE 209 = 2,2',3,3',4,4',5,5',6,6'-decaBDE. Where study authors report use of decaBDE, without further 
compositional information, it is assumed the pure congener (BDE 209) was used. 
AchE = acetylcholinesterase; BALF = brochoalveolar lavage fluid; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = 
feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd = gestational day; (GO) = gavage in oil; Hemato = hematological; IFN = interferon;  IgG = immunoglobulin G; IgM = 
immunoglobulin M; Immuno/Lymphoret = immunological/lymphoreticular; IN = ingestion ; LOAEL = lowest-observed-adverse-effect level; M = male; Musc/skel = musculoskeletal; 
NOAEL = no-observed-adverse-effect level; NS = not specified; Pmd = pre-mating day; Pnd = post-natal day; Pnw = post-natal week; Resp = respiratory; RSV = respiratory 
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10000 36m 36m 36m 36m 36m 36m 36m37m27r 27r 27r 27r 27r 27r 27r 
1000 21r 22r 
25r 26r 
100 25r 29r 29r24r 24r 
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NOAEL - Animals
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10000 36m 36m 48m 62m37m27r 27r 45r 61r 
67m 
42m 49m39m 40m 65m 
1000 20r 21r 22r 56r38m 38m 63m47m38m 63m25r 59r64m 
26r 44r 60r41m 66m 
33m 34m 35m 53m 54m 55m23r 57r 
100 25r 29r 29r 64m24r 24r 43r 58r55m
28r 28r 46r30r 30r 50r 
28r 
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71r 72r 73r 74r 
69r 
*Doses represent the lowest dose tested per study that produced a tumorigenic
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10000 
mg/kg/day 
83m 83m 83m 83m 83m 83m 83m 86m 89m89m 
83m 83m 83m 91m 
82r 82r 82r 82r 82r 82r 82r 88r82r 88r 




1 81r 81r 81r 81r 81r 81r 81r 81r 81r 81r 84r 87r 87r 
*Doses represent the lowest dose tested per study that produced a tumorigenic
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3. HEALTH EFFECTS
In intermediate-duration dietary studies with decaBDE, there was no exposure-related mortality in rats 
that were exposed to estimated dietary doses of ≤90 mg/kg/day for 28 days (IRDC 1976) or rats and mice
fed estimated doses of ≤8,000 and ≤9,500 mg/kg/day, respectively, for 13 weeks (NTP 1986).  In chronic
studies, there were no effects on survival in rats that were fed 0.01–1.0 mg/kg/day of a 77.4% decaBDE
mixture (containing 21.8% nonaBDE and 0.8% octaBDE) for 2 years (Kociba et al. 1975; Norris et al.
1975a), or in rats and mice fed decaBDE in estimated doses of ≤2,550 and ≤7,780 mg/kg/day,
respectively, for 103 weeks (NTP 1986). However, Feng et al. (2015) reported that 5/10 female mice
died following exposure to decaBDE (98% purity) every other day via gavage for up to 2 years at a dose
of 800 mg/kg/dose, compared with 1/10 vehicle control mice.  No cause of death or gross or microscopic
pathology was reported for animals that died.  In surviving mice, various histopathological lesions were 
qualitatively described in the brain, heart, lung, liver, spleen, kidney, and ovaries of exposed animals, but
incidence data were not provided.  Due to the high mortality and lack of quantitative data, this chronic
study is not discussed in the Systemic Effects section below.
The LD50 and LOAEL values for death are recorded in Tables 3-2 (lower BDEs) and 3-3 (decaBDE) and 
plotted in Figures 3-2 (lower BDEs) and 3-3 (decaBDE).
3.2.2.2  Systemic Effects
The systemic effects in humans and animals following oral exposure to PBDEs are described below.  The
highest NOAEL and all LOAEL values from each reliable study for systemic end points in each species 
and duration category are recorded in Tables 3-2 (lower-brominated PBDEs) or 3-3 (decaBDE) and 
plotted in Figures 3-2 (lower-brominated PBDEs) or 3-3 (decaBDE).
Respiratory Effects. No studies were located regarding respiratory effects in humans after oral
exposure to PBDEs. Effects of PBDEs on respiratory function have not been studied in orally exposed 
animals.
No histopathological changes in the respiratory tract or exposure-related changes in lung weight were 
observed in rats exposed to pentaBDE at doses up to 250 mg/kg/day for 28 days via gavage (Oberg et al. 
2010; Van der ven et al. 2008a) or in rats exposed to dietary pentaBDE at doses up to 100 mg/kg/day for
90 days (WIL Research Laboratories 1984).  Similarly, no changes in respiratory tract histology were 
observed in rats exposed to dietary octaBDE at doses up to 750 mg/kg/day for 13 weeks (IRDC 1977).  
   
 













    
    
      
 
 
    
      
     
   
    
  
 
     
 
       
     
  
    
      




   
  
 




No exposure-related changes in lung weight were observed in rats exposed to a dietary penta-decaBDE
mixture (52.1% pentaBDE, 44.2% decaBDE, 0.4% octaBDE) at 20 mg/kg/day for 70 days (Ernest et al. 
2012) or in F0 or F1 rats exposed pentaBDE at 18 mg/kg/day from GD 6 to PND 18 via gavage (Ellis-
Hutchings et al. 2006).
To determine if PBDE exposure alters vitamin A homeostasis in rats in a manner similar to the related
PBB compounds (ATSDR 2004), vitamin A levels were measured in lung tissue following exposure to 
pentaBDE at 0, 2.5, 25, or 250 mg/kg/day via gavage (Oberg et al. 2010). No significant changes in lung 
vitamin A levels were observed at any dose.
No histopathological changes in respiratory tract tissues were found in rats and mice exposed to dietary
decaBDE at estimated doses of ≤8,000 and ≤9,500 mg/kg/day, respectively, for 13 weeks or estimated
doses of ≤2,550 and ≤7,780 mg/kg/day, respectively, for 103 weeks (NTP 1986).  Additionally, no 
histopathological changes in respiratory tract tissues were observed in rats that were fed ≤1.0 mg/kg/day 
of a 77.4% decaBDE mixture (containing 21.8% nonaBDE and 0.8% octaBDE) for 2 years (Kociba et al.
1975; Norris et al. 1975a).
Based on animal studies, respiratory effects are not likely to occur following oral exposure to PBDEs.
Cardiovascular Effects. No relationship was found between serum concentrations of tetraBDE
(BDE 47) and carotid atherosclerosis (carotid artery plaques determined by ultrasound) or stroke in a
population of 1,016 70-year-old volunteers (50.2% female) from Uppsala, Sweden (Lee et al. 2012; Lind 
et al. 2012).  BDE 47 was detected in the serum of 77.2% of subjects with a median concentration of
12.6 pg/mL. No associations were observed between serum PBDE levels and gestational hypertension in
258 pregnant women from the Longitudinal Investigation of Fertility and the Environment (LIFE) cohort
in Michigan and Texas (Smarr et al. 2016).
A case control study of 43 children (9–11 years old) from Upstate New York reported an association
between higher levels of serum PBDEs and greater sympathetic activation during acute psychological
stress and greater anger (Gump et al. 2014).  Specifically, BDE 28 was associated with greater heart rate,
lower pre-ejection period, and lower total peripheral resistance.  BDE 47 and BDE 100 were associated 
with significantly lower diastolic blood pressure, and BDE 100 was also associated with a shorter pre­
ejection period during acute stress.  Lipid-adjusted mean blood levels of BDEs 28, 47, and 100 were 1.07, 
8.53, and 0.86 ng/g, respectively.  The investigators speculated that PBDE-induced increased levels of
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3. HEALTH EFFECTS
calcium/calmodulin-dependent protein kinase II in the hippocampus may mediate the heart’s response to
β-adrenergic stimulation.
Effects of PBDE on cardiovascular function have not been studied in orally exposed animals.  
No exposure-related changes in heart histology or weight were observed in rats exposed to pentaBDE at
doses up to 250 mg/kg/day for 28 days via gavage (Oberg et al. 2010; Van der ven et al. 2008a), dietary
pentaBDE at doses up to 100 mg/kg/day for 90 days (WIL Research Laboratories 1984), or dietary
octaBDE at doses up to 750 mg/kg/day for 13 weeks (IRDC 1977).  Additionally, no exposure-related
changes in heart weight were observed in rats exposed to dietary penta- or octaBDE at doses up to
90 mg/kg/day for 28 days (IRDC 1976), in rats exposed to a dietary penta-decaBDE mixture (52.1%
pentaBDE, 44.2% decaBDE, 0.4% octaBDE) at 20 mg/kg/day for 70 days (Ernest et al. 2012), in F0 or
F1 rats exposed to dietary pentaBDE at doses up to 0.31 mg/kg/day for 4 weeks prior to mating through
PNW 6 or 33 (Zhang et al. 2009), in F0 or F1 rats exposed pentaBDE at 18 mg/kg/day from GD 6 to
PND 18 via gavage (Ellis-Hutchings et al. 2006), or in rats exposed to diBDE at 1.2 mg/kg/day for
28 days via gavage (Zhang et al. 2014).
No histopathological changes in the heart were found in rats and mice exposed to dietary decaBDE at
estimated doses of ≤8,000 and ≤9,500 mg/kg/day, respectively, for 13 weeks or estimated doses of
≤2,550 and ≤7,780 mg/kg/day, respectively, for 103 weeks (NTP 1986).  No exposure-related changes in
heart histology or weight were observed in rats that were fed ≤1.0 mg/kg/day of a 77.4% decaBDE
mixture (containing 21.8% nonaBDE and 0.8% octaBDE) for 2 years (Kociba et al. 1975; Norris et al. 
1975a). In addition, no exposure-related changes in heart weight were observed in rats exposed decaBDE
at doses up to 20 mg/kg/day for 8 weeks via gavage (Zhang et al. 2013a) or to dietary decaBDE at doses 
up to 90 mg/kg/day for 28 days (IRDC 1976).
Based on human and animal studies, cardiovascular effects are not likely to occur following oral exposure
to PBDEs.
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans after
oral exposure to PBDEs.
No histopathological changes in the gastrointestinal tract were found in rats exposed to pentaBDE at
doses up to 200 mg/kg/day for 28 days via gavage (Van der ven et al. 2008b), dietary pentaBDE at doses
   
 








   
   
 
    
     
      
     
   
    
    
 
   
 
 
      
 
     
      
        
   
  
    
    
        











up to 100 mg/kg/day for 90 days (WIL Research Laboratories 1984), or dietary octaBDE at doses up to
750 mg/kg/day for 13 weeks (IRDC 1977).  
No histopathological changes in gastrointestinal tract tissues were found in rats and mice fed decaBDE in
estimated doses of ≤8,000 and ≤9,500 mg/kg/day, respectively, for 13 weeks (NTP 1986).  In chronic
dietary studies, there was no gastrointestinal tract histopathology in rats that were fed ≤1.0 mg/kg/day of a
77.4% decaBDE mixture (containing 21.8% nonaBDE and 0.8% octaBDE) for 2 years (Kociba et al.
1975; Norris et al. 1975a).  Higher dietary doses of decaBDE for 103 weeks caused acanthosis of the 
forestomach in rats exposed to 2,240 mg/kg/day (no effects at ≤1,200 mg/kg/day) and stomach ulcers in 
mice exposed to 7,780 mg/kg/day (no effects at ≤3,760 mg/kg/day) (NTP 1986).
Based on animal studies, gastrointestinal effects are not likely to occur following oral exposure to PBDEs 
at environmentally-relevant exposure concentrations.
Hematological Effects.
Human Studies.  Hematological end points were evaluated in a subset of 18 of a cohort of 33 children 
(18 girls and 15 boys) born in the Amsterdam/Zaandam area of the Netherlands and aged 14–19 years at
the time of the study (Leijs et al. 2009).  Serum PBDE concentrations (determined as the sum of
congeners 28, 47, 85, 99, 100, 153, 154, and 183) ranged from 5 to 74 ng/g lipid with a mean of 13.9 ng/g
lipid.  Serum samples were used to assess hemoglobin, thrombocytes, and white blood cell count and 
differential. The researchers found a negative statistical association (not further described) between 
number of lymphocytes and PBDE concentrations in serum.  Congener-specific analysis showed the main
contributors to be BDE 183, BDE 154, and BDE 85. Although dioxins and PCBs were also assessed, no 
association with lymphocytes was found for these chemicals. The only other finding for PBDE was a 
positive association between serum hemoglobin and PBDE, primarily due to congeners 85 and 153. A 
Chinese study of 40 subjects exposed to PBDEs in an electronic waste dismantling area reported a 
significantly elevated neutrophil percentage among the workers compared to a group of 15 unexposed
controls (Xu et al. 2015a).  In addition, exposed subjects had significantly lower percentages of
monocytes, lymphocytes, hemoglobin, and platelets than controls, while total white cell counts were not
significantly different between the two groups.  PBDEs assessed included congeners 15, 27, 85, 99, 100, 
153, 154, and 184.  Exposure was likely by multiple routes.  PCBs also were found associated with
lowered percentages of monocytes and lymphocytes.
   
 











   
  
     
 
     




      
    
  
       
   
 
   
   
   
   
    
   
    
       
 
 
     
     
      





Lower-brominated PBDEs:  Following exposure to dietary octaBDE at 750 mg/kg/day for 13 weeks, 
female rats showed 26, 22, and 22% decreases in erythrocytes, hematocrit, and hemoglobin, respectively;
male rats showed a 10% decrease in erythrocytes at 600 mg/kg/day (IRDC 1977).  No changes were
observed in total or differential white blood cell counts (IRDC 1977).  No changes in hematological
parameters, including erythrocyte count, hemoglobin, hematocrit, full and differential leukocyte count, 
and platelet count, were observed in rats following pentaBDE exposure to dietary doses up to
100 mg/kg/day for 90 days (WIL Research Laboratories 1984) or gavage up to 250 mg/kg/day for 28 days
(Oberg et al. 2010). 
In another 28-day study, rats were exposed to pentaBDE at 0, 0.27, 0.82, 2.47, 7.4, 22.2, 66.7, or
200 mg/kg/day via gavage (Van der ven et al. 2008b). The study authors reported minor dose-related
changes in white blood cell differentials from femoral shaft bone marrow in male rats (blood hematology
not evaluated); however, the doses at which these effects were observed were not reported.  Instead,
results were reported in terms of benchmark dose (BMD) analysis (Van der ven et al. 2008b).
Statistically significant changes included increased number and percentage of monocytes (maximum 
increase of 69.5 and 66.7%, respectively; BMD/BMDLRD20%=11.2/0.7 and 31.8/3 mg/kg/day, 
respectively) and decreased percentage of eosinophilic granulocytes (maximum decrease of 20%; 
(BMDRD20%=28.6, BMDL not determined).  The study authors also reported a significant, dose-related
increase in the number and percentage of large unstained cells (maximum increase of 79.7 and 85.1%, 
respectively; BMD/BMDLRD20%=76.3/42.8 and 64.3/9.8 mg/kg/day, respectively), which they indicated
may represent large or reactive lymphocytes, monocytes, or leukemic blasts (abnormal myeloblasts), 
typically associated with viral disease, leukemia, or endocrine active compounds.  Since results were 
reported in terms of BMD analysis only, data and statistics for individual dose groups were not available 
for independent analysis. No data regarding other standard hematological end points were reported (Van
der ven et al. 2008b). 
Male mink exposed to dietary pentaBDE at doses of 0.63 or 0.78 mg/kg/day for 9 weeks showed 
significant 13 and 12% decreases in hematocrit, respectively; neither the number of red blood cells nor
hemoglobin levels were evaluated (Martin et al. 2007).  According to study authors, most of the ranges in 
the differential white blood cell counts fell within that expected for male mink of this age; however, the
percentage of neutrophils was increased significantly by ~22% at 0.63 mg/kg/day and 37% at
0.78 mg/kg/day, the percentage of lymphocytes decreased significantly by ~33% at 0.78 mg/kg/day, and 
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the neutrophil:lymphocyte ratio increased significantly by ~90% at 0.78 mg/kg/day (data reported 
graphically) (Martin et al. 2007).  Total white blood cell counts were not reported.  No hematological
effects were observed at 0.08 mg/kg/day (Martin et al. 2007). The minor hematological changes are of
uncertain toxicological significance.
In a poorly-reported study, mouse dams exposed to pentaBDE from GD 6 to PND 21 via gavage did not
show any hematological effects at doses up to 200 mg/kg/day (Hong et al. 2010).  
DecaBDE:  No hematological changes were observed in rats exposed to ≤60 mg/kg/day of decaBDE via
gavage for 28 days (Van der ven et al. 2008a).  In dietary studies with decaBDE, no hematological
changes were found in rats exposed to ≤800 mg/kg/day for 30 days (Norris et al. 1973, 1975a), 
≤8,000 mg/kg/day for 13 weeks (NTP 1986), or ≤2,550 mg/kg/day for 103 weeks (NTP 1986), or in mice
exposed to ≤9,500 mg/kg/day for 13 weeks or ≤7,780 mg/kg/day for 103 weeks (NTP 1986). There also
were no hematological effects in rats exposed by diet to ≤1.0 mg/kg/day of a 77.4% decaBDE mixture
(containing 21.8% nonaBDE and 0.8% octaBDE) for 2 years (Kociba et al. 1975; Norris et al. 1975a).
In a poorly-reported study, mouse dams exposed to decaBDE from GD 6 to PND 21 via gavage showed 
significant increases in the number of white blood cells and neutrophils at 500 mg/kg/day, compared with 
controls, but not at 2,500 or 12,500 mg/kg/day (Hong et al. 2010).  
Summary.  Minor hematological changes observed in humans and animal are of uncertain toxicological
significance.  Based on the available information, it is unlikely that adverse effects would occur in the 
human hematological system following oral PBDE exposure.
Musculoskeletal Effects. No association was found between serum PBDE concentrations (BDE 47, 
BDE 99, BDE 100, BDE 153, BDE 154, BDE 209, and their sum) and bone mineral density (measured by
x-ray in the forearm) or serum concentrations of biochemical markers of bone metabolism (osteocalcin
and crosslaps [a peptide of type I collagen]) in a population of 50 post-menopausal Swedish women 
married or previously married to professional fisherman on the east coast of the country and born before 
1954 (Weiss et al. 2006). Median serum ∑PBDE concentration in this population was 3.6 ng/g fat.
No musculoskeletal changes were seen in rats following exposure to pentaBDE at doses up to
200 mg/kg/day for 28 days via gavage (Van der ven et al. 2008b) or dietary pentaBDE at doses up to 
100 mg/kg/day for 90 days (WIL Research Laboratories 1984).
   
 










    
   
    
      
      
 
   
 
 
      





   
    
    
 




   
    
 
   
    
      
  




No changes in bone parameters were observed in rats exposed to decaBDE at doses up to 60 mg/kg/day
for 28 days via gavage (Van der ven et al. 2008a). Dietary studies with decaBDE found no 
histopathological changes in musculoskeletal tissues in rats exposed to ≤8,000 mg/kg/day for 13 weeks 
(NTP 1986), ≤1.0 mg/kg/day (77.4% containing 21.8% nonaBDE and 0.8% octaBDE) for 2 years 
(Kociba et al. 1975; Norris et al. 1975a), or ≤2,550 mg/kg/day for 103 weeks (NTP 1986), or in mice
exposed to ≤9,500 mg/kg/day for 13 weeks or ≤7,780 mg/kg/day for 103 weeks (NTP 1986).  
Based on human and animal studies, musculoskeletal effects are not likely to occur following oral
exposure to PBDEs.
Hepatic Effects. No studies were located regarding hepatic effects in humans after oral exposure to
PBDEs.
Acute-Duration Animal Studies
Lower-brominated PBDEs:  A series of gavage studies evaluated liver histology following a single
exposure to pentaBDE doses of 0, 25, 200, or 2,000 mg/kg or repeat exposures to pentaBDE doses of 0, 8, 
40, or 200 mg/kg/day for 7 or 14 days (Bruchajzer et al. 2010, 2011).  Fatty degeneration of the liver was
observed in female rats following pentaBDE exposure via gavage at 2,000 mg/kg for 1 day (Bruchajzer et
al. 2011) or 200 mg/kg/day for 7 or 14 days (Bruchajzer et al. 2010).  In the single-exposure study, rats
from the 2,000 mg/kg group showed steatosis of the microvesicular type, which was most frequently
observed in the central and intermediate zones of lobules; however, animal incidence numbers were not
reported (Bruchajzer et al. 2011).  At 4 and 12 hours after pentaBDE administration, these changes were
noted in no more than 25% of hepatocytes; after 24–120 hours, fatty degeneration embraced 26–75% of
hepatocytes; and after 120 hours, a mixed type of change (micro- and macrovesicular) was observed
(Bruchajzer et al. 2011). In the repeated-exposure studies, rats from the 200 mg/kg/day group showed 
steatosis of the microvesicular type in 3–25% of hepatocytes after 7 days and steatosis of the 
microvesicular and mascrovesicular type in 26–75% of hepatocytes in the central and intermediate zones 
of lobules (Bruchazjer et al. 2010).  Again, animal incidence data were not reported.  No exposure-related
histological changes in the liver were reported for single doses ≤200 mg/kg or repeated doses
≤40 mg/kg/day (Bruchazjer et al. 2010, 2011).  In the only other study that included histopathological
examination, histological changes were not observed in male rats 45 days after a single administration of
pentaBDE at doses up to 1.2 mg/kg (Albina et al. 2010).  
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In the Bruchazjer et al. (2010, 2011) studies, no biologically relevant changes were observed in serum
clinical chemistry values.  Serum alanine transaminase (ALT) and aspartate transaminase (AST) activity
levels were slightly increased to 130 and 170–190% of control values following a single gavage exposure
to 2,000 mg/kg, respectively, after 72–120 hours; no changes were reported for doses ≤200 mg/kg
(Bruchazjer et al. 2011). The study authors did not report statistics; however, these serum chemistry
changes are not considered biologically relevant since the magnitude of change, compared with control, is
<2-fold.  Similarly, no exposure-related changes were observed in serum ALT or AST at doses up to 
200 mg/kg/day for 7 or 14 days (Bruchajzer et al. 2010).  Another 14-day gavage study found no 
exposure-related changes in serum sorbital dehydrogenase (SDH) levels in rats exposed to pentaBDE at
56.4 mg/kg/day or octaBDE at 76.6 mg/kg/day (equimolar doses) (Carlson 1980b).  In male rats exposed 
once to pentaBDE at doses of 0, 0.6, or 1.2 mg/kg, serum ALT activity was significantly increased by
~72% in the 1.2 mg/kg group, compared with control, when evaluated 45 days after exposure (Alonso et
al. 2010).  However, this change is not considered biologically relevant because the magnitude of change,
compared with control, is <2-fold, the measured ALT activity of 31 U/l was well within reference value
ranges for adult male rats (20–81 U/l) (Charles River Laboratories 1998), and no changes were observed 
in serum AST, alkaline phosphatase (ALP), or lactate dehydrogenase (LDH) (Alonso et al. 2010).
Bruchajzer et al. (2010, 2011) also reported altered markers of oxidative stress in the liver following
exposure to pentaBDE.  Liver malondialdehyde (MDA) levels were significantly elevated after exposure 
to ≥200 mg/kg/day for 1–14 days (Bruchajzer et al. 2010, 2011).  Levels of reduced glutathione (GSH) in 
the liver were not increased following a single exposure; however, GSH concentration was elevated at
≥40 mg/kg/day after 7 days and ≥8 mg/kg/day after 14 days (Bruchajzer et al. 2010, 2011).  Oxidized 
glutathione (GSSG) was significantly elevated after single exposures to ≥25 mg/kg, but no changes in 
glutathione S-transferase (GST) activity were observed (Bruchajzer et al. 2010). Liver GSSG levels and
GST activity were not evaluated following 7- or 14-day exposures.  In another study, liver GSH levels
were significantly decreased and liver SOD activity, GSSG levels, and GSSG/GSH ratio were
significantly increased in male rats 45 days after a single gavage administration of pentaBDE at 0.6 or
1.2 mg/kg (Albina et al. 2010).
In two other studies by Bruchazjer and colleagues (Bruchazjer 2011; Bruchazjer et al. 2012), female rats 
were examined for hepatic porphyria following exposure to pentaBDE at doses of 0, 8, 40, or
200 mg/kg/day or octaBDE at doses of 0, 2, 8, 40, or 200 mg/kg/day via gavage for 7 or 14 days.  
PentaBDE caused significant dose-related elevations in total porphyrin levels in the liver following
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exposure to ≥40 mg/kg/day for 7 days (~2–6-fold) or ≥8 mg/kg/day for 14 days (~3–11-fold). Following 
gavage exposure to octaBDE for 7 days, liver concentrations of high carboxylated porphyrins (octa- and 
hepta-) were significantly elevated at 8, 40, and 200 mg/kg/day by ~4-, 4-, and 7-fold, respectively,
compared with vehicle controls (Bruchajzer et al. 2012).  Lower carboxylated porphyrins were <1% of
total liver porphyrins measured, and were not further analyzed.  Following exposure to octaBDE for
14-days, total liver concentrations of high carboxylated porphyrins were increased by ~3-fold in the 
200 mg/kg/day group only, compared with vehicle controls (Bruchajzer et al. 2012).  However, the
vehicle controls at this duration had an unusually high hepatic porphyrin levels (4-fold increase compared 
with untreated control).  When compared with the untreated controls, porphyrin levels were significantly
increased by ~2-, 4-, 6-, and 7-fold in the 2, 8, 40, and 200 mg/kg/day groups, respectively, supporting
that exposure to octaBDE for 14 days causes porphyria as observed in the 7-day study.  These studies also
measured hepatic delta-aminolevulinate synthase (ALA-S) activity and delta-aminolevilinate dehydratase
(ALA-D) activity, two enzymes involved in heme biosynthesis.  The results were mixed.  PentaBDE
exposure caused a significant elevation in ALA-S activity at ≥40 mg/kg/day after 7 or 14 days (ALA-D 
was not measured), while octaBDE exposure caused a significant increase in ALA-S activity at
≥8 mg/kg/day after 7 days and significant decreases in ALA-S activity at 200 mg/kg/day after 14 days
and ALA-D activity at ≥40 mg/kg/day after 7 or 14 days (Bruchajzer 2011; Bruchajzer et al. 2012).  
The gavage studies by Bruchajzer and colleagues (Bruchajzer 2011; Bruchajzer et al. 2012) also reported 
elevated liver weights accompanied by hepatic microsomal enzyme induction.  Significant relative liver
weight increases (data reported graphically) were about ≥30% after a single exposure to pentaBDE at
≥200 mg/kg (Bruchajzer et al. 2011), ≥13% after exposure to pentaBDE at 8 or 200 mg/kg/day for 7 days
(Bruchajzer et al. 2010), or ≥25% after exposure to pentaBDE at ≥40 mg/kg/day for 14 days (Bruchazjer
et al. 2010). Hepatic enzyme induction (e.g., increased CYP1A and CYP2B activity and/or CYP1A1, 
CYP4A, and total cytochrome P450 protein levels) was observed at lower doses: ≥25 mg/kg in the single
dose study and ≥8 mg/kg/day in the 7- and 14-day studies (Bruchazjer et al. 2010, 2011).
Consistent with the findings of Bruchazjer and colleagues (Bruchajzer 2011; Bruchajzer et al. 2012), 
elevated liver weights have been reported following acute exposure to penta-, octa-, or tetraBDE in 
several other animal studies.  Significantly increased liver weights were reported in rats and mice exposed
to penta-, tetra-, or octaBDE via gavage at ≥10 and ≥18 mg/kg/day, respectively, for 1–14 days (Carlson 
1980b; Fowles et al. 1994; Hallgren et al. 2001; Mercado-Feliciano and Bigsby 2008a; Richardson et al. 
2008; Stoker et al. 2004, 2005; Zhou et al. 2001).  However, no exposure-related changes in relative liver
weight were observed in female rats exposed to tetraBDE at doses up to18 mg/kg/day for 14 days via 
   
 








    
      
         
   
   
  
     







   




     
  
     




   
 
    
 
     
  




gavage (Hallgren and Darnerud 2002).  In the studies that evaluated hepatic enzyme induction (e.g.,
elevated EROD, MROD, PROD, and UDPGT activity and/or increased CYP protein levels), significantly
increased enzyme levels and activities were observed in rats and mice at gavage doses of ≥6 and
≥3 mg/kg/day, respectively, and were always observed at doses at or below the dose causing elevated
liver weights in the same study (Carlson 1980b; Fowles et al. 1994; Hallgren and Darnerud 2002;
Hallgren et al. 2001; Richardson et al. 2008; Stoker et al. 2004; Zhou et al. 2001).  Exposure to a single
pentaBDE dose of 0.03 or 0.6 mg/kg on GD 6 via gavage caused significant induction of hepatic enzymes 
(EROD, UDPGT) in dams and pups from the 0.6 mg/kg group on PND 22; liver weight was not evaluated 
(Kuriyama et al. 2007).  Collectively, these findings support that elevated liver weight following exposure
to lower-brominated PBDEs is associated with hepatic enzyme induction.
Richardson et al. (2008) evaluated genomic changes in mice following exposure to tetraBDE at 0, 3, 10, 
or 100 mg/kg/day for 4 days via gavage.  The mRNA levels of several hepatic enzymes were significantly
elevated at ≥20 mg/kg/day (Cyp2b10, Ugt1a1, Ugt1a7, Ugt2b2).  In addition, several exposure-related
changes were observed in hepatic efflux transporter (Mrp3, Mdr1a) and thyroid hormone transporter (Ttr,
Mct8) mRNA expression levels in hepatic tissue (Richarson et al. 2008).
To determine if PBDE exposure alters vitamin A homeostasis in a manner similar to the related PBBs
(ATSDR 2004), hepatic vitamin A levels were measured in mice and rats exposed to pentaBDE at 0, 18,
or 36 mg/kg/day and mice exposed to tetraBDE at 0 or 18 mg/kg/day for 14 days via gavage (Hallgren et
al. 2001).  In pentaBDE-exposed animals, hepatic vitamin A levels were significantly decreased by
24 and 26% in rats in the 18 and 36 mg/kg/day groups, respectively, and 22% in mice in the
36 mg/kg/day group.  No changes in hepatic vitamin A levels were observed in mice exposed to penta- or
tetraBDE at 18 mg/kg/day. 
DecaBDE: Unlike the lower-brominated PBDEs, there is no evidence of hepatic toxicity following acute 
exposure to decaBDE.  Exposure to decaBDE at doses up to 1,000 mg/kg/day for 7 or 14 days via gavage
did not produce liver damage, as indicated by liver histology or clinical chemistry, nor did it produce
increased liver weight or hepatic enzyme induction in female rats (Bruchajzer et al. 2010).  Carlson 
(1980b) observed no changes in serum SDH activity in rats exposed to decaBDE at 95.9 mg/kg/day for
14 days via gavage; significantly elevated liver weights were found, but in the absence of hepatic enzyme 
induction.  In a shorter-duration study, exposure to decaBDE at doses up to 100 mg/kg/day for 4 days via
gavage did not cause changes in liver weight or hepatic enzyme induction in female rats; clinical
chemistry and histology were not examined (Zhou et al. 2001).  
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Sakamoto et al. (2013) evaluated both liver weight and hepatocyte proliferation in female rats following
exposure to decaBDE at 980 mg/kg/day for 1 week.  Consistent with other studies, no exposure-related
findings in absolute or relative liver weight were observed.  Additionally, no exposure-related changes in
hepatocyte proliferation were observed, as evaluated by labeling indices of proliferating cell nuclear
antigen (PCNA) in paraffin-embedded liver sections.
Intermediate-Duration Animal Studies
Lower-brominated PBDEs:  Histopathological effects in the liver have been consistently observed in 
animals exposed to lower-brominated PBDEs for 15–90 days at doses as low as 2 mg/kg/day.
Hepatocytomegaly (hepatocyte hypertrophy) was observed in rats exposed to dietary pentaBDE at doses
≥2 mg/kg/day (lowest dose tested) for 13 weeks (WIL Research Laboratories 1984).  The
hepatocytomegaly was dose-related with respect to severity (some affected hepatocytes at higher doses 
had vacuoles that likely contained lipid) and was not completely reversible, as it was still evident in
≥10 mg/kg/day males and 100 mg/kg/day females at 24 weeks postexposure in lessened severity and
incidence.  Females exposed to 2 or 100 mg/kg/day pentaBDE for 90 days also had an increased
incidence of degeneration and necrosis of individual liver parenchymal cells at 24 weeks postexposure;
the investigators concluded that this may represent the final loss of previously damaged cells and
probably should be considered compound-related (WIL Research Laboratories 1984).  Similarly, dietary
exposure to octaBDE at 0, 100, 1,000, or 10,000 ppm (0, 5, 50, or 600 mg/kg/day in males and 0, 7, 70, or
750 mg/kg/day in females) for 13 weeks caused liver lesions in 40% of males at 5 mg/kg/day and 100%
of both sexes at ≥50–70 mg/kg/day (IRDC 1977).  The lesions were dose-related in severity as well as 
incidence and characterized by cytomegaly, change in hepatocytic cytoplasm to a finely granular, 
homogeneous type, and cytoplasmic vacuolation.  At 600–750 mg/kg/day, many of the livers had
vacuolation of centrolobular hepatocytes and some had hepatocyte necrosis.  Examinations performed at
8 weeks and 6 months postexposure showed that the liver effects persisted in the rats exposed to ≥50– 
70 mg/kg/day for 13 weeks (IRDC 1977).
Hepatocellular hypertrophy was also observed in rats exposed to dietary penta- or octaBDE at
≥9 mg/kg/day for 28 days (IRDC 1976), in rats exposed to pentaBDE at ≥3 mg/kg/day for 15–28 days via
gavage (Becker et al. 2012; Fattore et al. 2001; Oberg et al. 2010), and in rats exposed to tetraBDE at
150 mg/kg/day via gavage for 12 weeks (only dose tested) (Zhang et al. 2015a, 2015b).  No
histopathological changes were observed in mice exposed to tetraBDE at 1 mg/kg/day via gavage for
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6 weeks (only dose tested) (McIntyre et al. 2015). In another gavage study, rats were exposed to 
pentaBDE at doses of 0, 0.27, 0.82, 2.47, 7.4, 22.2, 66.7, or 200 mg/kg/day for 28 days (Van der ven et al. 
2008b).  The study authors reported centrilobular hypertrophy and an increased ratio of binucleated 
hepatocytes; however, the incidence data and dose(s) at which effects were observed were not reported 
(Van der ven et al. 2008b).  Van der ven et al. (2008b) also reported a near-significant 5-fold increase in 
the number of apoptotic cells in males exposed to 200 mg/kg/day (p=0.067).  Rats exposed to pentaBDE
at 200 mg/kg/day for 21or 28 days via gavage showed “minor lesions” in the liver, but no further
information regarding the type or incidence of the lesion was reported (Bruchajzer et al. 2010).  In mice, 
exposure to dietary tetraBDE at 0.45 mg/kg/day for 28 days induced hepatocyte vacuolation, pyknotic
nuclei in the hepatocytes, and periportal lymphocytic infiltration; no lesions were observed in control
animals (Maranghi et al. 2013).  
In rats exposed to pentaBDE via gavage for 70 days prior to mating until PND 42, significantly increased 
incidences of hepatocellular hypertrophy were observed in F0 males at ≥5 mg/kg/day and F0 females and 
F1 offspring at 25 mg/kg/day; no exposure-related effects were observed at 0.5 mg/kg/day (Bondy et al. 
2013).  Similarly, all F1 rats exposed to pentaBDE at 50 mg/kg/day from GD 6 to PNW 16 via gavage 
showed hepatocellular hypertrophy characterized by enlarged hepatocytes with an increased amount of
cytoplasm, enlarged nuclei, and pale eosinophilic and granular cytoplasm.  Hepatocyte vacuolization was
also significantly increased in exposed F1 males, but not F1 females (Dunnick et al. 2012).  
No exposure-related changes were observed in serum chemistry markers (ALT, AST, ALP, LDH,
cholesterol, triglycerides, albumin, globulin) in rats exposed to dietary pentaBDE at doses up to 
100 mg/kg/day for 13 weeks (WIL Research Laboratories 1984), octaBDE at doses up to 750 mg/kg/day
for 90 days (IRDC 1977), or a penta-decaBDE mixture (52.1% pentaBDE, 44.2% decaBDE, 0.4%
octaBDE) at 20 mg/kg/day for 70 days (Ernest et al. 2012).  Similarly, no exposure-related changes were 
observed in serum ALP, ALT, AST, or gamma-glutamyl transferase (GGT) following exposure to 
pentaBDE at low doses up to 0.015 mg/kg/day via gavage for 90 days (Daubie et al. 2011).  Marginal
changes (<2-fold) were observed in shorter-duration rat gavage studies with higher doses.  A statistically
significant 51% increase in serum ALT level was observed in male rats exposed to pentaBDE at
250 mg/kg/day via gavage for 28 days; no changes were observed in males at 2.5 or 25 mg/kg/day or
females at any dose (Oberg et al. 2010).  No exposure-related changes were observed in serum ALP
(Oberg et al. 2010).  Similarly, in female rats exposed to pentaBDE at 200 mg/kg/day via gavage for 21 or
28 days, serum ALT levels were increased to 190% of control values at 21 or 28 days and serum AST
levels were increased to 185% of control values at 28 days; no changes were observed at ≤40 mg/kg/day
   
 








   
 
    
  
   
   
 
      
  
   
     
 
     
 
    
 
 
   
 
   
 
  
      
  
 
    
  
 
    
  
    




(Bruchajzer et al. 2010). Increases in serum cholesterol, total protein, and ALT and decreases in the
albumin/globulin ratio were observed in rats exposed to pentaBDE at 250 mg/kg/day, but the magnitudes
of these effects were not reported (Fattore et al. 2001). In another gavage study, rats were exposed to 
pentaBDE at doses of 0, 0.27, 0.82, 2.47, 7.4, 22.2, 66.7, or 200 mg/kg/day for 28 days (Van der ven et al. 
2008b).  The study authors reported a dose-related increase in serum ALT in male rats (maximal increase 
of 148.1%); however, the lowest dose at which the effect was observed was not reported.  Instead, results
were reported in terms of BMD analysis (BMD/BMDLRD10%=61.4/15.5 mg/kg/day).  No changes in 
serum ALT were observed in female rats, and no changes in serum ALP were observed in either sex,
although the authors noted procedural problems with their ALP assay (Van der ven et al. 2008b).  The
study authors reported dose-related increases in serum cholesterol in male and female rats (maximal
increases in males and females were 257 and 144%, respectively). Again, the lowest dose at which the 
effect was observed was not reported (BMD/BMDLRD10%=15.4/8.4 mg/kg/day in males and 
22.4/11.6 mg/kg/day in females) (Van der ven et al. 2008b). In mice, serum ALT levels were 
significantly elevated by approximately 2-fold in males exposed to tetraBDE at gavage doses of
150 mg/kg/day for 12 weeks, compared with control (only dose tested); no other serum biochemistry
endpoints were evaluated (Zhang et al. 2015a, 2015b).
Significant changes in hepatic oxidative stress parameters were observed in rats following exposure to
pentaBDE at doses ≥8 mg/kg/day via gavage for 21 or 28 days, including increased hepatic GSH and 
MDA levels (Bruchajzer et al. 2010).  Oxidative stress markers were also significantly altered in the livers
of rat offspring following exposure to pentaBDE from GD 6 to PND 21, including significantly increased 
activities of catalase (CAT) activity at ≥1 mg/kg/day and SOD at 2 mg/kg/day (Blanco et al. 2014).  There
was no change in total levels of thiobarbituric acid reactive substances (TBARS) in offspring (Blanco et
al. 2014).  In mice, exposure to diBDE at 1.2 mg/kg/day via gavage for 28 days caused significantly
decreased levels of GSH, decreased activities of SOD and glutathione peroxidase (GPx), and increased 
levels of MDA in the liver (Zhang et al. 2014).  
Female rats were examined for hepatic porphyria following exposure to pentaBDE or octaBDE at doses 
of 0, 2, 8, 40, or 200 mg/kg/day via gavage for 21 or 28 days (Bruchajzer 2011; Bruchajzer et al. 2012).  
PentaBDE caused significant dose-related elevations in total porphyrin levels in the liver following
exposure to ≥8 mg/kg/day for 21 days (~3–8-fold) or 28 days (~3–19-fold), compared to vehicle controls
(Bruchajzer 2011), OctaBDE cause significant elevations in liver concentrations of high carboxylated
porphyrins (octa- and hepta-) following exposure to ≥8 mg/kg/day for 21 days (~2–3-fold) or 2 or
8 mg/kg/day for 28 days (~3–4-fold) (Bruchajzer et al. 2012).  At 28 days, high carboxylated porphyrin 
   
 











    
 
  
     
 
  
    







    
    
    
   
     
       
    




   
    




levels in the 40 and 200 mg/kg/day groups were not were not significantly elevated compared to the 
vehicle control.  However, the vehicle controls at this duration had an unusually high hepatic porphyrin 
levels (4-fold increase compared with untreated control).  When compared with the untreated controls, 
porphyrin levels were significantly increased by ~10-, 14-, 4-, and 5-fold in the 2, 8, 40, and
200 mg/kg/day groups, respectively.  Lower carboxylated porphyrins were <1% of total liver porphyrins
measured, and were not further analyzed.  These studies also measured ALA-S and ALA-D activity, two
enzymes involved in heme biosynthesis. The results were mixed.  PentaBDE exposure caused a 
significant elevation in ALA-S activity at ≥8 mg/kg/day after 21 days and at ≥2 mg/kg/day after 28 days, 
while octaBDE exposure caused a significant decrease in ALA-S activity at 200 mg/kg/day after 21 days 
and at ≥40 mg/kg/day after 28 days.  ALA-D activity was also significantly decreased in rats exposed to 
octaBDE at ≥40 mg/kg/day for 21 or 28 days (ALA-D activity was not assessed in pentaBDE-exposed 
rats) (Bruchajzer 2011; Bruchajzer et al. 2012).  Hepatic porphyria was also observed in rats after
exposure to dietary pentaBDE for 90 days (WIL Research Laboratories 1984).  Liver porphyrins were
significantly elevated by 8.5- and 390-fold in males and females from the 100 mg/kg/day group, 
respectively, and 3-fold in females from the 20 mg/kg/day group; no significant changes were observed in 
the 2 mg/kg/day group (WIL Research Laboratories 1984).  
Elevated liver weights have been reported following intermediate-duration exposure to penta-, octa-, 
tetra-, or diBDE in several animal studies.  Significantly increased liver weights were reported in rats and
mice exposed to penta-, di-, or tetraBDE via gavage at ≥1.2, ≥50, and 150 mg/kg/day, respectively, for
15–84 days (Becker et al. 2014; Bruchajzer et al. 2010; Fattore et al. 2001; Mercado-Feliciano and Bigsby
2008a; Oberg et al. 2010; Stoker et al. 2004, 2005; Van der Ven et al. 2008b; Zhang et al. 2014, 2015a, 
2015b).  No exposure-related changes in liver weight were observed in mice exposed to tetraBDE at
1 mg/kg/day via gavage for 6 weeks (only dose tested) (McIntyre et al. 2015). In dietary studies, 
significantly increased liver weights were reported in rats exposed to penta- or octaBDE at ≥5 mg/kg/day 
for 28–90 days (IRDC 1976, 1977; WIL Research Laboratories 1984) or a penta-decaBDE mixture
(52.1% pentaBDE, 44.2% decaBDE, 0.4% octaBDE) at 20 mg/kg/day for 70 days (Ernest et al. 2012).  In 
mink exposed to dietary pentaBDE at 0, 0.08, 0.63, or 0.78 mg/kg/day for 90 days, increased absolute
liver weight was observed at 0.78 mg/kg/day and increased relative liver weight was observed at
≥0.08 mg/kg/day; however, these findings are confounded by significant body weight loss at
≥0.63 mg/kg/day (Martin et al. 2007).  No exposure-related changes in liver weight were observed in
mice exposed to dietary tetraBDE at 0.45 mg/kg/day for 28 days (Maranghi et al. 2013).  
   
 








    
   
 
    
   
     
 
  
    
 
       
       
    
    
    
   
 
   
    
  





   
 
     
   






In studies that evaluated hepatic enzyme induction (e.g., elevated EROD, MROD, PROD, and UDPGT
activity), significantly increased enzyme activities were observed in rats, mice, and mink at doses of ≥2.5, 
≥50, and ≥0.08 mg/kg/day, respectively, and were always observed at doses at or below the dose causing
elevated liver weights in the same study (Bruchajzer et al. 2010; Ernest et al. 2012; Fattore et al. 2001;
Martin et al. 2007; Mercado-Feliciano and Bigsby 2008a; Oberg et al. 2010; Stoker et al. 2004).  
Additionally, microsomal enzyme activity was induced in rats exposed by gavage to doses as low as 
0.6 mg/kg/day of octaBDE and 0.4 mg/kg/day of pentaBDE for 90 days as indicated by increases in
O-ethyl O-p-nitrophenyl phenylphosphonothioate (EPN) detoxification, p-nitroanisole demethylation, and 
cytochrome c reductase and cytochrome P-450 levels (Carlson 1980a).  Some of these changes were
persistent, lasting for 30–60 days after cessation of treatment.
Maternal and pup liver weights were significantly elevated in rats exposed to pentaBDE from GD 1 or
GD 6 to PND 21 via gavage or dosed cookies at 30 and ≥3 mg/kg/day, respectively (Bowers et al. 2015;
Ellis-Hutchings et al. 2006; Zhou et al. 2002).  In mice, elevated maternal liver weights were observed in
dams exposed to 452 mg/kg/day of the pentaBDE congener BDE 99, but not the pentaBDE commercial
mixture Bromkal 70-5DE, from GD 6 to PND 17 via gavage (Skarman et al. 2005).  Elevated liver
weights were not observed in mouse pups (Skarman et al. 2005).  In a one-generation study in rats (pre­
mating day 70 to PND 42), F0 males and F1 offspring showed significantly increased liver weights on 
PND 43 following exposure to 25 and ≥5 mg/kg/day via gavage (Bondy et al. 2011, 2013).  In other one-
generation studies, no changes were observed in maternal or pup liver weight in rats exposed to
pentaBDE-dose vanilla wafers at doses up to 11.4 mg/kg/day from pre-mating day 28 to PND 21 (Poon et
al. 2011) or adult F1 liver weight in rats exposed to pentaBDE at 50 mg/kg/day from GD 6 to PNW 16 
via gavage (Dunnick et al. 2012).  In mink, exposure to dietary pentaBDE from 4 weeks premating until
PNW 6 or 33 led to elevated liver weights in sows at 0.31 mg/kg/day (highest dose tested) and F1 
offspring at 0.06 mg/kg/day (Zhang et al. 2009).  In the studies that evaluated hepatic enzyme levels 
(e.g., EROD, PROD, UDPGT), significantly increased enzyme activities were always observed at doses 
at or below the dose causing elevated liver weights in the same study, with significant changes observed
in F0 and F1 rats at ≥0.3 mg/kg/day, F0 and F1 mice at 450 mg/kg/day, and F0 and F1 mink at ≥0.06 and 
0.01 mg/kg/day, respectively (Bowers et al. 2015; Skarman et al. 2005; Zhang et al. 2009; Zhou et al. 
2002).  Additionally, significant induction of hepatic enzymes was observed in male rat pups following
exposure to pentaBDE at ≥1.7 mg/kg/day from GD 6 to PND 21 via gavage (Szabo et al. 2009). 
Szabo et al. (2009) also evaluated genomic changes in F1 rats following exposure to pentaBDE at 0, 1.7, 
10.2, or 30.6 mg/kg/day from GD 6 to PND 4 or 21 via gavage.  Significant dose-related increases were 
   
 








   
 
        
     
     
  
     









    
   
 
 
     
    
  
  
    
   






observed in hepatic mRNA expression levels of phase I enzymes (Cyp1a1, Cyp2b1, Cyp2b2, Cyp3a1), 
phase II enzymes (Ugt1a6, Ugt1a7, Ugt2b, Sult1b1), phase III influx transporters (Oatp1a4), phase II
efflux transporters (Mdr1, Mrp2, Mrp3), the serum binding protein transthyretin (Ttr), and deiodinase 1 
(d1) during exposure (PND 4 and 21); the majority of which no longer differed from control at PND 60.  
Genomic changes were also evaluated in F1 rats following exposure to pentaBDE at 0, 1, or 2 mg/kg/day
via gavage (Blanco et al. 2014).  Various cytochrome isoforms were evaluated, but mRNA levels were 
only significantly elevated for CYP2B1 in pup liver tissue from the 2 mg/kg/day group.  Additionally, 
significant changes were observed in the thyroid hormone receptor, including decreased TRα1 mRNA in 
both dose groups, decreased TRβ1 mRNA at 2 mg/kg/day, and decreased TRα1 protein levels at
2 mg/kg/day.  Cylcin D1 protein expression was significantly decreased in both groups and the
phosphorylation levels of Akt and GSK3β were significantly decreased at 2 mg/kg/day.
To determine if PBDE exposure alters vitamin A homeostasis in a manner similar to the related PBBs
(ATSDR 2004), hepatic vitamin A levels were measured in rats following exposure to pentaBDE at 0, 
2.5, 25, or 250 mg/kg/day via gavage for 28 days (Oberg et al. 2010).  Hepatic liver vitamin A content 
was significantly decreased in females at 25 mg/kg/day and males and females at 250 mg/kg/day by up to 
36 and 47%, respectively (Oberg et al. 2010).  Hepatic vitamin A levels were also significantly decreased
by 13% in dams and 50% in F1 pups on PND 18 in rats exposed to pentaBDE at 0 or 18 mg/kg/day from
GD 6 to PND 18 via gavage (Ellis-Hutchings et al. 2006).  Additional pup sacrifices on PNDs 12 and 31 
showed significant 59 and 25% decreases in hepatic vitamin A level, respectively (Ellis-Hutchings et al. 
2006).  
DecaBDE:  Moderate hepatocellular hypertrophy was observed in all mice exposed to dietary decaBDE at
9,400 mg/kg/day for 28 days, but in none of the controls (Sakamoto et al. 2013).  Similarly, slight
centrilobular hypertrophy was “occasionally” observed in rats exposed to decaBDE at doses ranging from 
1.87 to 60 mg/kg/day for 28 days via gavage, which was most obvious in “some” of the 60 mg/kg/day
males (incidence data not reported) (Van der ven et al. 2008a). In an older study using an impure
decaBDE compound (77% purity), centrilobular cytoplasmic enlargement and vacuolation were observed 
in male rats exposed to dietary doses of 800 mg/kg/day for 30 days (incidences not reported); no changes
were observed at 8 or 80 mg/kg/day (Norris et al. 1973, 1975a).  However, no exposure-related changes 
in liver histology were observed in rats and mice exposed to dietary decaBDE at estimated doses as high
as 2,000–8,000 and 2,375–9,500 mg/kg/day for 13 weeks, respectively (NTP 1986), or in rats exposed to 
gavage doses up to 1,000 mg/kg/day for 21 or 28 days (Bruchajzer et al. 2010).  
   
 








    
   
   
  
  
   
     
   
   
  
   
   
 
   
      
  
  
   
   
   
  






       
    
   
       
   
    
PBDEs 151
3. HEALTH EFFECTS
Pregnant dams and developing rats and mice appear to be more susceptible to liver damage following
exposure to decaBDE than adult animals.  Hepatocyte degeneration and eosinophil changes were
observed in the livers of rat dams exposed to decaBDE at 300 mg/kg/day for 21 days prior to mating, 
through mating, gestation, and lactation (PND 21) (Liu et al. 2012).  Compared with control, the exposed
group had significantly increased “histological scores;” however, the method of histological scoring and
incidences of lesions were not reported (Liu et al. 2012).  Following exposure to dietary decaBDE from
GD 10 to PND 21, male and female rat pups showed significantly increased incidence of follicular cell
hypertrophy in the liver at ≥2 and 146 mg/kg/day, respectively (Fujimoto et al. 2011).  These findings
were transient, as they were no longer evident in male and female offspring evaluated at PNW 11
(Fujimoto et al. 2011).  Male offspring from mouse dams exposed to decaBDE from GD 0 to 17 via 
gavage showed dose-related histopathological changes in the liver on PND 71 at doses ≥10 mg/kg/day
(lowest dose tested) (Tseng et al. 2008).  Histological changes observed in exposed groups included acute
cell swelling of hepatocytes associated with pressure occlusion of hepatic sinusoids (Tseng et al. 2008).  
Young male rats exposed to decaBDE at doses of 0, 100, 300, or 600 mg/kg/day from PND 10 to 42 via
gavage showed fatty degeneration at ≥300 mg/kg/day (incidence data were not reported) (Lee et al. 2010).
Wang et al. (2010) found no exposure-related changes in serum ALT, AST, or ALP in male rats following
gavage exposure to decaBDE at 100 mg/kg/day for 90 days, but serum total cholesterol, high density
lipid-cholesterol, and total bile acid levels were significantly increased by 23, 26, and 98%, respectively.  
No biologically relevant, exposure-related changes were observed in either serum ALT or AST, or total
cholesterol or triglyceride levels, in rats exposed to decaBDE at doses up to 1,000 mg/kg/day for 21– 
56 days (Bruchazjer et al. 2010; Van der ven et al. 2008a; Zhang et al. 2013a).
No exposure-related changes were observed in hepatic markers of oxidative stress (GSH, MDA) in
female rats exposed to decaBDE up to doses of 1,000 mg/kg/day for 21 or 28 days (Bruchazjer et al. 
2010).
Significantly elevated liver weights were observed in male rats after exposure to decaBDE at
≥1 mg/kg/day for 8 weeks via gavage (Zhang et al. 2013a) and male mice after exposure to dietary
decaBDE at 9,400 mg/kg/day for 28 days (Sakamoto et al. 2013).  However, no exposure-related changes 
in liver weight were observed in rats exposed to decaBDE up to doses of 1,000 mg/kg/day via gavage for
21–90 days (Bruchazjer et al. 2010; Van der ven et al. 2008a; Wang et al. 2010, 2011b).  In an older study
using an impure decaBDE compound (77% purity), increased liver weights were observed at dietary
doses ≥80 mg/kg/day in male rats exposed for 30 days (Norris et al. 1973, 1975a).  Following exposure to 
   
 








    
  
   
 
    
   
   
 
     
    
    
   
 
    
   
   




   
   
  
   
   









dietary decaBDE from GD 10 to PND 21, male and female rat pups showed significantly increased liver
weights at ≥2 and 146 mg/kg/day, respectively (Fujimoto et al. 2011).  These findings were transient, as 
they were no longer evident in male and female offspring evaluated at PNW 11 (Fujimoto et al. 2011).
No liver weight changes were observed in dams or PND 71 male offspring exposed to decaBDE from
GD 0 to 17 via gavage at doses up to 1,500 mg/kg/day (Tseng et al. 2008).  Young male rats exposed to 
decaBDE at doses of 0, 100, 300, or 600 mg/kg/day from PND 10 to 42 via gavage showed elevated liver
weights at ≥300 mg/kg/day (Lee et al. 2010).
Hepatic enzyme induction (e.g., EROD, PRO activity, CYP protein levels) was significantly elevated in a
dose-related manner in adult male and female rats exposed to decaBDE at 1.87–60 mg/kg/day for 28 days 
via gavage (Van der ven et al. 2008a) and young male rats exposed to decaBDE at 100–600 mg/kg/day 
from PND 10 to 42 via gavage (Lee et al. 2010).  EROD activity was also significantly elevated in
PND 71 male mice exposed to 1,500 mg/kg/day during gestation (Tseng et al. 2008).  However, no 
exposure-related changes were observed in hepatic enzyme induction in female rats exposed to decaBDE
up to doses of 1,000 mg/kg/day for 21 or 28 days (Bruchazjer et al. 2010). Genomic analyses of liver
tissue reported elevated mRNA levels of CYP proteins in male mice exposed to dietary decaBDE at
9,400 mg/kg/day for 28 days (Sakamoto et al. 2013) and a dose-dependent elevation of Cyp2b2 mRNA in
male rats exposed to decaBDE at doses of 1.87–60 mg/kg/day for 28 days via gavage (Van der ven et al. 
2008a).
To determine if PBDE exposure alters vitamin A homeostasis in a manner similar to the related PBBs
(ATSDR 2004), hepatic vitamin A levels were measured in rats following exposure to decaBDE at 0, 
1.87, 3.75, 7.5, 15, 30, or 60 mg/kg/day for 28 days via gavage (Van der ven et al. 2008a).  In females, 
but not males, hepatic vitamin A levels were increased in a dose-dependent manner by up to 14.6%, 
compared with controls; however, the lowest dose at which the effect was observed was not reported.
The study authors conclude that the relevance of the effect is uncertain due to high variation in the data, 
as evidenced by a high BMD/BMDL ratio (BMD/BMDLRD10% =13.8/1.2 mg/kg/day).
Chronic-Duration Animal Studies
Lower-brominated PBDEs:  No chronic-duration studies analyzing hepatic effects were located for lower­
brominated PBDEs.
   
 









   
    
 
   
     
      
   
 
  
   
 
 
       
  
      
      
    
   
  









    
  
     
PBDEs 153
3. HEALTH EFFECTS
DecaBDE:  In chronic studies, exposure to 94–97% decaBDE for 103 weeks caused liver lesions that 
included neoplastic nodules in rats at ≥1,120 mg/kg/day, thrombosis and degeneration in rats at
2,240 mg/kg/day, and centrilobular hypertrophy and granulomas in mice at ≥3,200 mg/kg/day (NTP
1986).  The thrombosis in the rats was characterized by a near total occlusion of a major hepatic blood 
vessel by a dense fibrin coagulum.  A NOAEL was not identified in the rats or mice.  The only other
chronic study of decaBDE found that exposure to 1 mg/kg/day of a 77% pure mixture for 2 years caused
no liver effects in rats; higher doses were not tested, precluding identification of a LOAEL (Kociba et al.
1975; Norris et al. 1975a).
Summary. No studies are available on hepatic effects of PBDEs in humans.  Based on the evidence in
animals, including enzyme induction, liver enlargement, histological lesions, hepatic porphyria, and 
markers of hepatic oxidative stress, PBDEs are potentially hepatotoxic in humans, especially lower­
brominated PBDEs.
Renal Effects. Only one study was located that provides information on renal effects in humans 
following exposure to PBDEs.  A pilot study measured serum creatinine and urinary β2-microglobulin, as
indices of renal function, in 40 Chinese residents exposed to PBDEs in an electronic waste dismantling
area (Xu et al. 2015a).  Mean ΣPBDEs in serum from exposed subjects was almost twice that in a control
group, but the difference was not statistically significant.  The results showed that neither serum
creatinine nor β2-microglobulin were correlated with PBDEs.  However, congener analyses showed that
BDE 28, BDE 47, BDE 85, and BDE 153 were positively correlated with urinary levels of
β2-microglobulin, and that BDE 28 and BDE 85 were positively correlated with serum creatinine levels. 
PCBs also played a role in the findings reported.
Acute-Duration Animal Studies
Lower-brominated PBDEs:  Two studies examined renal effects in male rats 45 days after a single gavage 
administration of pentaBDE at doses of 0, 0.06, or 1.2 mg/kg (Albina et al. 2010; Alonso et al. 2010).  In 
urine, a 4-fold increase in total protein levels was observed at 1.2 mg/kg (Alonso et al. 2010).  Although 
this might suggest possible tubular damage, histopathological examination of the kidneys found no 
abnormalities other than a dose-related increase in phagolysosomes (incidence data not reported) (Albina
et al. 2010).  No other changes were observed in urinalysis or serum chemistry parameters (urea, 
creatinine, uric acid) (Alonso et al. 2010). Altered oxidative stress markers were found in the kidney after
   
 











    
  
   
 





     
  
    
     
   
      
   
 





   
  
       
 
 
   
    
 
   
PBDEs 154
3. HEALTH EFFECTS
exposure to 1.2 mg/kg/day, including significantly decreased CAT activity and increased GSSG and 
GSSG/GSH ratio (Albina et al. 2010). 
No exposure-related changes in kidney weight were observed in male rats exposed to pentaBDE at doses
up to 240 mg/kg/day for 9 days via gavage (Stoker et al. 2005) or female mice exposed to tetraBDE at
doses up to 100 mg/kg/day for 4 days via gavage (Richardson et al. 2008).  
DecaBDE:  No acute-duration studies analyzing renal effects were located for decaBDE.
Intermediate-Duration Animal Studies
Lower-brominated PBDEs:  Renal effects induced by dietary octaBDE included non-inflammatory
kidney changes in male rats exposed to 600 mg/kg/day for 13 weeks, but not females exposed to doses up
to 750 mg/kg/day (IRDC 1977).  The incidence and severity of the kidney lesions (tubule regeneration, 
intratubular casts, and cellular debris occurred in most 600 mg/kg/day males) suggested a compound-
related effect (IRDC 1977).  However, no histopathological lesions of the kidney were observed in male
or female rats exposed to pentaBDE at doses up to 250 mg/kg/day for 28 days via gavage (Oberg et al. 
2010; Van der ven et al. 2008b), dietary penta- or octaBDE at doses up to 90 mg/kg/day for 28 days
(IRDC 1976), or dietary pentaBDE doses up to 100 mg/kg/day for 90 days (WIL Research Laboratories 
1984).  Additionally, no histopathological kidney lesions were observed in F0 or F1 rats exposed to 
pentaBDE at doses up to 25 mg/kg/day from pre-mating through PND 42 (Bondy et al. 2013).
Statistically significant changes in blood urea and urea nitrogen levels were reported in some 
intermediate-duration studies; however, none of the changes were considered biologically relevant due to
the small magnitude of change (<2-fold) compared with control.  Following exposure to pentaBDE at 0, 
2.5, 25, or 250 mg/kg/day via gavage for 28 days, blood urea levels in male rats from the 25 or
250 mg/kg/day groups were significantly increased by 1.5- and 1.2-fold, respectively; no changes were 
observed in blood urea levels in females or blood creatinine in either sex (Oberg et al. 2010). In another
28-day study, rats were exposed to pentaBDE at 0, 0.27, 0.82, 2.47, 7.4, 22.2, 66.7, or 200 mg/kg/day via
gavage (Van der ven et al. 2008b).  Study authors reported dose-related increases in blood urea levels in
male and female rats (maximal increases in males and females were 61.2 and 33.1%, respectively);
however, the lowest dose at which the effect was observed was not reported.  Instead, results were
reported in terms of BMD analysis (BMD/BMDLRD10%=64.2/30.2 mg/kg/day in males and 
65.1/22.2 mg/kg/day in females) (Van der ven et al. 2008b). Again, no changes in serum creatinine were 
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3. HEALTH EFFECTS
reported in either sex at doses up to 200 mg/kg/day (Van der ven et al. 2008b).  Blood urea nitrogen 
(BUN) levels were elevated by 35% in male rats and 59% in female rats exposed to dietary octaBDE for
13 weeks at 600 and 750 mg/kg/day, respectively (IRDC 1977).  No changes in BUN levels were
observed in male or female rats exposed to dietary pentaBDE doses up to 100 mg/kg/day for 90 days
(WIL Research Laboratories 1984). 
Kidney weight changes following intermediate-duration exposure are inconsistent.  A significant 10%
decrease in relative kidney weight was observed in mice exposed to diBDE at 1.2 mg/kg/day for 28 days
via gavage (Zhang et al. 2014).  Absolute organ weights were not reported; however, no body weight
effects were observed.  In contrast, no change in kidney weight was reported in rats following exposure to 
pentaBDE at gavage doses up to 120 mg/kg/day for 20–90 days (Daubie et al. 2011; Stoker et al. 2004, 
2005) or dietary penta- or octaBDE at doses up to 750 mg/kg/day for 28–90 days (IRDC 1976, 1977;
WIL Research Laboratories 1984).  Similarly, no change in F0 or F1 kidney weight was observed in rats
exposed to pentaBDE at doses up to 25 mg/kg/day via gavage from 70 days prior to mating through 
PND 42 (Bondy et al. 2013) or mink exposed to dietary pentaBDE at doses up to 0.31 mg/kg/day from
4 weeks prior to mating to PNW 6 or 33 (Zhang et al. 2009).  In other studies, significantly increased 
kidney weights have been reported, including a dose-related increase in absolute liver weight in rats 
exposed to pentaBDE doses up to 200 mg/kg/day for 28 days via gavage (dose at which effect was first
observed was not reported; maximum increase of 11.5% in males and 15.6% in females) (Van der ven et
al. 2008b), a significant 15% increase in relative, but not absolute, kidney weight following exposure to 
pentaBDE at 250 mg/kg/day for 28 days via gavage (Oberg et al. 2010), and a significant 18% increase in
relative kidney weight following exposure to a dietary penta-decaBDE mixture (52.1% pentaBDE, 44.2%
decaBDE, 0.4% octaBDE) at 20 mg/kg/day for 70 days (absolute kidney weight not reported) (Ernest et
al. 2012).
To determine if PBDE exposure alters vitamin A homeostasis in rats in a manner similar to the related
PBBs (ATSDR 2004), vitamin A levels were measured in kidney tissue following exposure to pentaBDE
at 0, 2.5, 25, or 250 mg/kg/day via gavage (Oberg et al. 2010). No significant changes in kidney vitamin 
A levels were observed at any dose.
DecaBDE:  No renal histopathological changes were observed in rats or mice exposed to dietary
decaBDE at doses up to 8,000 or 9,500 mg/kg/day, respectively, for 13 weeks (NTP 1986).  A 28-day 
study that evaluated histology of “major organs” did not report any exposure-related kidney effects in rats 
exposed to decaBDE at doses up to 60 mg/kg/day via gavage (Van der ven et al. 2008a).  Studies of low
   
 








   
     
    
 
    
 
    




   







    
     
     
    
 
 
   
 
   
   




purity (≈77%) commercial decaBDE mixtures found kidney pathology (hyaline degenerative cytoplasmic
changes) in male rats exposed to dietary levels of 800 mg/kg/day for 30 days (Norris et al. 1973,1975a), 
but not in rats exposed to ≤90 mg/kg/day for 28–30 days (IRDC 1976; Norris et al. 1973, 1975a).  
Interpretation of this finding is complicated by the fact that hyaline degenerative cytoplasmic changes are 
not uncommon in adult male rats and might be induced by a mechanism specific to certain aged male rats.
No exposure-related changes were observed in serum urea or creatinine levels in rats exposed to
decaBDE at doses up to 100 mg/kg/day for 28–90 days via gavage (Van der ven et al. 2008a; Wang et al.
2010).  Additionally, no exposure-related changes were observed in kidney weights in rats exposed to
decaBDE at doses up to 600 mg/kg/day for 28–90 days via gavage (Lee et al. 2010; Van der ven et al. 
2008a; Wang et al. 2010, 2011b; Zhang et al. 2013b), F0 or F1 mice exposed to decaBDE at doses up to 
1,500 mg/kg/day from GD 0 to 17 via gavage (Tseng et al. 2008), or dietary decaBDE at doses up to 
800 mg/kg/day for 28–30 days (IRDC 1976; Norris et al. 1973, 1975a).
Chronic-Duration Animal Studies
Lower-brominated PBDEs:  No chronic-duration studies analyzing renal effects were located for lower­
brominated PBDEs.
DecaBDE:  No renal histopathological changes were observed in rats or mice exposed to dietary
decaBDE at doses up to 2,550 or 7,780 mg/kg/day, respectively, for 2 years (NTP 1986).  The only other
chronic study of decaBDE found that exposure to dietary doses up to 1 mg/kg/day of the 77% pure
mixture for 2 years caused no exposure-related changes in kidney histology or weight in rats (Kociba et
al. 1975; Norris et al. 1975a).  
Summary. No studies are available on hepatic effects of PBDEs in humans.  While there is limited
evidence from animal studies that lower-brominated PBDEs can cause kidney damage at high exposure 
levels, data are inconsistent and there is no evidence of impaired renal function.  Animal studies do not
indicate that decaBDE causes renal toxicity. Taken together, animals studies indicate that renal effects
are not likely to occur in humans at environmentally-relevant exposure concentrations.
   
 








     
 
    
    
  
     
     
    
     
     
   




    
  
     
 
 
   
    
 
 
   
    
  
   
    
    
      
  
  




Human Studies. Numerous studies have been performed to evaluate the relationship between 
concentrations of PBDE in body tissues and circulating hormone levels in human populations.  While
these studies have demonstrated that PBDE can perturb the human endocrine system and affect hormone
levels, the specific findings are not consistent across studies.  For example, even limiting the discussion to
studies that evaluated both PBDE concentrations and thyroid hormone levels in serum samples collected 
only from adult men, studies have reported positive associations with T4 (Turyk et al. 2008), negative
associations with T4 (Abdelouahab et al. 2011), and no association with T4 (Hagmar et al. 2001).  These
studies also reported either negative association with T3 (Turyk et al. 2008) or no association with T3 
(Abdelouahab et al. 2011; Hagmar et al. 2001), and either negative association with TSH (Hagmar et al.
2001; Turyk et al. 2008) or no association with TSH (Abdelouahab et al. 2011).  Populations in these
studies were 308 adult male consumers of sport fish from U.S. Great Lakes with serum ∑PBDE ranging
from 15.8 to 1,360 ng/g lipid (0.13–10.15 ng/g) with a median of 38.4 ng/g lipid (0.26 ng/g) (Turyk et al. 
2008), 48 adult men recruited through an infertility clinic in Quebec with median serum ∑PBDE of
0.302 ng/mL and maximum of 2.250 ng/mL (Abdelouahab et al. 2011), and 110 adult men from Latvia
and Sweden having varying consumption of Baltic Sea fish with serum BDE 47 ranging from 0.10 ng/g 
lipid (10th percentile) to 5.16 ng/g lipid (90th percentile) and a median of 1.04 ng/g lipid (Hagmar et al. 
2001).
Similarly, studies of serum PBDE and serum thyroid hormones in populations including adults of both 
sexes found: (1) a negative association with free T4 and no association with T4, T3, or TSH in 114 elderly
residents of the upper Hudson River area of New York State (∑PBDE range of 0.04–9.80 µg/L and 
median of 0.19 µg/L in 48 women; range of 0.04–4.74 µg/L and median of 0.16 µg/L in 66 men) (Bloom
et al. 2014); (2) a negative association with total T4 (BDE 47, BDE 99, and BDE 100) and a positive
association with TSH (BDE 153 only), but no association with free T4 or total T3, in a longitudinal study
of 51 healthy adult office workers from Boston with serum ∑PBDE geometric means ranging from 19 to 
23 ng/g lipid over 18 months (Makey et al. 2016); (3) no association with free or total T4, T3, or TSH in 
36 New York anglers living in counties adjacent to Lakes Erie or Ontario with median serum ∑PBDE of
15 ng/g lipid and maximum of 2,303 ng/g lipid (Bloom et al. 2008); (4) a positive association with T3 (for 
BDE 47 only) and no association with free T4 or TSH in 623 Nunavik Inuits with geometric mean BDE
47=2.16 and BDE 153=2.05 µg/kg lipid (Dallaire et al. 2009); (5) no association with T4, T3, or TSH in 
11 Swedish electronics recycling workers sampled repeatedly over 1.5 years (∑PBDE median=7.2 pmol/g
lipid weight at start of employment and 9.7 pmol/g lipid weight at the conclusion of the study) (Julander
   
 








    
   
       
       
    
  
  
      
   
     
    
  
  
   
  
  
   
     
        
    
    
  
    
        
   
      









et al. 2005); (6) a positive association with TSH in 23 Chinese e-waste workers (∑PBDE
median=382 ng/g lipid with range of 77–8,452 ng/g lipid) versus 26 controls (∑PBDE median=158 ng/g
lipid with range of 18–436 ng/g lipid) (Yuan et al. 2008); (7) a positive association with T4 (for BDE 126 
and BDE 205 only) and no association with free T4, T3, free T3, or TSH in another group of 239 Chinese
e-waste workers (∑PBDE median=189.79 ng/g lipid with range of 0–6,016 ng/g lipid) and 93 farmers
from the e-waste area (∑PBDE median=164.64 ng/g lipid with range of 0–8,600 ng/g lipid) versus
116 controls (∑PBDE median=122.37 ng/g lipid with range of 0–1,398 ng/g lipid) (Wang et al. 2010); 
(8) a negative association with T3 (for BDE 17 and BDE 153 only) and no association with free T4 or
TSH in 124 residents of northern China with serum ∑PBDE median=7.16 ng/g lipid with range of 2.09– 
160.3 ng/g lipid (Huang et al. 2014); (9) no associations between serum PBDEs or their methyoxylated or
hydroxylated metabolites and thyroid hormones in 77 residents living near an e-waste recycling site in
Vui Dau, Vietnam or 34 residents living in rural Doung Quang, Vietnam (median ∑PBDE serum
concentrations of 290 and 230 pg/g wet weight, respectively) (Eguchi et al. 2015); and (10) no 
associations between serum PBDEs and thyroid hormones in 40 residents living near an e-waste recycling
site in Luqiao, China or 15 residents living in rural Yunhe, China (median ∑PBDE serum concentrations
of 51.61 and 66.45 ng/g, respectively) (Xu et al. 2015a).  Similar studies performed in children found:
(1) a positive association with serum PBDE for serum TSH in 195 6–8-year-old children from an e-waste 
recycling area in China (∑PBDE mean=664.28 ng/g lipid) or 174 children from a control area (∑PBDE
mean=375.81 ng/g lipid) (Han et al. 2011); (2) a negative association with serum PBDE for free T3 and a
positive association with serum PBDE for TSH in 162 4–6-year-old children living in an e-waste area in
China (serum ∑PBDE median=189.99 ng/g lipid) (Xu et al. 2014b); (3) no association between free and 
total T3 and T4, TSH, and serum PBDE in 21 8-year-old children from an e-waste recycling area in China 
(∑PBDE median=31.86 ng/g lipid) or 24 children from a control area (∑PBDE median=6.97 ng/g lipid)
(Xu et al.2014a); (4) positive associations with T3 and free T4 (for BDE 99 only) and no association with 
T4 or TSH in 17 Dutch teenagers with serum ∑PBDE ranging from 4.9–22.1 ng/g lipid and a mean of
10.5 ng/g lipid (Leijs et al. 2012); and (5) and negative or no association with free T3 (depending on type
of analysis), positive or no association with TSH, and no association with free T4 in 515 Flemish 
teenagers with a median serum ∑PBDE of 7 ng/L and maximum of 125 ng/L (Kicinski et al. 2012). 
Oulhote et al. (2016) examined the potential association between PBDE exposure and hypothyroidism in 
Canadian women aged 30–79 years.  PBDE levels were not significantly different in women diagnosed
with hypothyroidism (n=90; geometric mean serum ∑PBDE=15.4 ng/g lipid) compared with women 
without hypothyroidism (n=655; geometric mean serum ∑PBDE=20.5 ng/g lipid).  In a model adjusted
for age, income, education, alcohol consumption, race/ethnicity, and history of breast-feeding, the
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prevalence ratio of hypothyroidism was marginally increased by 1.7 per 10-fold increase in ∑PBDEs 
(95% CI 1.0, 3.0) or BDE 47 (95% CI 1.0, 2.9) and marginally increased by 1.8 in individuals with 
detectable BDE 100 compared with those without detectable BDE 100 (95% CI 1.0, 3.3).  When models
were adjusted for age income, education, alcohol consumption, and lipid-standardized PCB-153, these
marginal associations were no longer observed.
A couple of studies were located in which exposure was estimated from concentrations of PBDE in house
dust, rather than serum samples.  In the earlier study, Meeker et al. (2009) found a positive association 
between PBDE in house dust and serum levels of free T4, but no association with T3 or TSH in 24 men 
recruited through an infertility clinic.  Median and maximum concentrations of PBDE in dust collected 
from houses of study subjects were 500 and 7,620 ng/g dust for BDE 47, 838,and 9,220 ng/g dust for 
BDE 99, and 180 and 2,830 ng/g dust for BDE 100.  A later study by these same researchers found 
positive associations between dust concentrations of pentaBDE (sum of BDE 47, BDE 99, and BDE 100;
median and maximum concentrations of 1,049 and 22,300 ng/g in dust) and octaBDE (sum of BDE 183 
and BDE 201; median and maximum concentrations of 30.5 and 1,181 ng/g in dust) and serum free T4, 
and also between pentaBDE and T3 and octaBDE and TSH in 38 additional men recruited through the
infertility clinic (Johnson et al. 2013).  There were no significant associations between thyroid hormones
and exposure to decaBDE (sum of BDE 206, BDE 207, BDE 208, and BDE 209; median and maximum 
concentrations of 1,800 and 38,483 ng/g in dust) in this study.
As in other populations, findings in pregnant women differed across studies.  Both free and total T4 were 
significantly and positively associated with PBDE (several individual congeners and their sum) in serum
collected during the 3rd trimester (>34 weeks) of pregnancy in a North Carolina cohort of 137 primarily
African-American expectant mothers with serum ∑PBDE ranging from 3.59 to 693.95 ng/g lipid and a
median of 36.56 ng/g lipid (Stapleton et al. 2011).  Associations for free and total T3 and TSH were not
significant in this cohort.  In contrast, a study of a California cohort of 270 mostly Latina women tested at
the 27th week of pregnancy (serum ∑PBDE range of 3.6–1338.6 ng/g lipid, median of 25.2 ng/g lipid)
found no association between PBDE and free or total T4 (Chevrier et al. 2010).  However, all PBDE
congeners identified and their sum were significantly negatively associated with TSH in this study.
Further analysis showed that women in the highest quartile of PBDE exposure had significantly increased 
odds of subclinical hyperthyroidism (defined as low TSH and normal free T4) relative to women in the
first quartile.  A study of 105 pregnant women in South Korean that looked at blood samples collected the 
day before delivery (serum ∑PBDE median=2.13 ng/g lipid with 25th–75th percentile range of 1.35– 
4.34 ng/g lipid) found significant negative associations for PBDE with free and total T3, a significant 
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positive association with free T4, and no association with T4 or TSH (Kim et al. 2013a).  There were no 
correlations between PBDE and free and total T4 and free and total T3 in maternal serum samples 
(∑PBDE range from 15 to 580 ng/g lipid, median=37 ng/g lipid) collected just prior to delivery in another
study of 12 patients from Indiana (Mazdai et al. 2003).
Abdelouahab et al. (2013) compared maternal serum concentrations of PBDE collected at <20 weeks of
pregnancy (for ∑PBDE, median=30.92 ng/g lipid, maximum=726.09 ng/g lipid, n=380) with thyroid 
hormone levels in maternal blood at <20 weeks of pregnancy and in maternal blood collected at delivery
for 260 pregnancies in Quebec.  At <20 weeks of pregnancy, they found significant negative associations
between PBDE and T3 and T4, but significant positive associations between PBDE and free T3 and free
T4. However, using the thyroid hormone levels from the maternal samples at delivery, they found 
negative associations between maternal serum PBDE at <20 weeks and maternal free and total T3 and T4 
at delivery.  There was no significant association with TSH for either of the samples. In a Swedish cohort
(n=166), a significant inverse relationship was observed between first trimester total T3 levels and
maternal body burden of BDE 153 (median breast milk concentration, 0.48 ng/g lipid); this relationship 
was not significant for third trimester total T3 levels (Lignell et al. 2016).  No significant associations
were observed between breast milk BDE 153 levels and free T4 or TSH in first or third trimester serum
samples.  No associations were observed between serum thyroid hormone levels and breast milk
concentrations of tetra-pentaBDE (BDE 47, BDE 99, BDE 100; median concentration, 2.3 ng/g lipid).
A few studies included analysis of maternal serum samples collected after delivery.  Kim et al. (2011d,
2012b) found significant positive relationships between serum PBDE (BDE 49 only) and free T4, and 
between PBDE (BDE 154 and BDE 153 only) and TSH, and a significant negative relationship between 
PBDE (BDE 153 only) and T3 in maternal blood samples collected from 12 South Korean mothers after
delivery (for ∑PBDE, range=1.88–53.54 ng/g lipid, mean=18.79 ng/g lipid). There were no such 
correlations between serum PBDE and thyroid hormone levels in post-delivery blood samples collected
from 26 mothers of infants born with congenital hypothyroidism (for ∑PBDE, range=3.81–1563 ng/g
lipid, mean=65.16 ng/g lipid) (Kim et al. 2011d, 2012b).  In a second study in which maternal blood 
samples were collected after delivery (for 21 South Korean mothers undergoing Cesarean section), there 
was no correlation between PBDE concentrations and thyroid hormone (free T4, T3, and TSH) levels in 
the maternal serum (Kim et al. 2012a).  In this study, ∑PBDE in maternal blood ranged from 1.8 to 
17.66 ng/g lipid, with a median of 7.81 ng/g lipid.  Kim et al. (2011a) reported a significant positive 
correlation between concentrations of BDE 153 in breast milk (mean ≈0.25 ng/g lipid) and serum TSH
collected post-delivery in another group of South Korean mothers.
   
 









   
  
    
  
 
    
   
    
      
   
 
   
      
    




     
  
   




   
       
      
    
   




In addition to the maternal effects, several of these studies and others reported on thyroid hormone
changes in developing offspring, as identified by umbilical cord or neonatal blood samples in relation to 
PBDE concentrations in maternal serum, cord serum, or breast milk.  The data on thyroid hormone effects
in developing offspring are presented in Section 3.2.2.6 on Developmental Effects.
Few human data were located on endocrine end points other than thyroid (discussed above) or sex
hormones (discussed in Section 3.2.2.5, Reproductive Effects).  Lim et al. (2008) performed an analysis
of cross-sectional U.S. NHANES 2003–2004 data that showed significant increases in risk of diabetes
and metabolic syndrome associated with serum concentrations of BDE 153 (but not BDE 28, BDE 47, 
BDE 99, or BDE 100) based on 156 and 237 cases, respectively, in a population of 1,367 adults examined 
for diabetes status and, for metabolic syndrome, a subset of 637 participants with a morning fasting blood 
sample.  In both analyses, the risk of disease was higher with exposure to 25th–50th percentile BDE 153 
concentrations (median=3.6 ng/g lipid) and 50–75th percentile BDE 153 concentrations (median=6.6 ng/g
lipid) than >75th percentile BDE 153 concentrations (median=24.6 ng/g lipid).  Adjusted ORs were 2.6, 
2.7, and 1.8 for diabetes and 2.5, 2.4, and 1.7 for metabolic syndrome in the respective quartiles. Serum 
BDE 153 concentrations (0.04 ng/g serum) were also shown to be significantly associated with increased 
odds of developing gestational diabetes in 258 pregnant women from the LIFE cohort in Michigan and 
Texas; no associations were observed for BDE 28, BDE 47, BDE 85, BDE 99, BDE 100, or BDE 154
(Smarr et al. 2016).  A report from the Great Lakes Fish Consumption Study in Wisconsin found no 
significant difference in total serum PBDE or BDE 47 concentrations between individuals who were
diagnosed with (n=64; Ln∑PBDEs reported as 0.31 ng/g) compared with non-diabetics (n=349;
Ln∑PBDEs reported as 0.30 ng/g) (Turyk et al. 2015).  In the Great Lakes cohort, established biomarkers
of diabetes (C-reactive protein [CRP], gamma glutamyl transferase [GGT] and adiponectin) were also not
associated with PBDE exposure; however, in stratified models, Ln∑PBDE and LnBDE47 were
significantly associated with LnGGT and Lnadiponectin in persons above the median age.
In elderly populations, cross-sectional and prospective studies have found no relationship between serum
PBDE (BDE 47 and BDE 153) concentrations and diabetes in cohorts from Finland (Airaksinen et al.
2011) or Sweden (Lee et al. 2011).  In the Finnish study, 308 participants with diabetes had median serum
concentrations of 2.7 ng/g lipid BDE 47 and 1.5 ng/g lipid BDE 153, while 1,680 nondiabetic participants
had median serum concentrations of 2.9 ng/g lipid BDE 47 and 1.7 ng/g lipid BDE 153 (Airaksinen et al. 
2011).  PBDE exposure levels for the Swedish study (n=725) were not available (Lee et al. 2011).
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In conclusion, although numerous studies have attempted to evaluate the relationship between tissue
concentrations of PBDE and endocrine changes in humans, no clear pattern has emerged. Studies have 
found different results even in similar populations (e.g., adult men or pregnant women) from the same 
part of the world (e.g., North America or Asia) exposed to similar concentrations of PBDE.  Although the
specific findings are not consistent across studies, the bulk of the data have demonstrated that PBDE can
interact with the human endocrine system to affect hormone levels.
Acute-Duration Animal Studies
Lower-brominated PBDEs:  No exposure-related changes in thyroid weight or histology were observed in 
female rats exposed to penta- or tetraBDE doses up to 36 mg/kg/day for 14 days via gavage (Darnerud 
and Sinjari 1996; Hallgren and Darnerud 1998; Hallgren et al. 2001).  No other acute studies evaluating
thyroid weight or histology were identified.
Altered thyroid hormone levels have been reported following acute exposure to lower-brominated 
PBDEs.  Significant reductions in serum T4 of 19–92% have been reported following gavage exposure to 
penta-, octa-, or tetraBDE at doses ≥10 and ≥0.8 mg/kg/day in rats and mice, respectively, for 1–14 days
(Darnerud and Sinjari 1996; Fowles et al. 1994; Hallgren and Darnerud 1998, 2002; Hallgren et al. 2001; 
Hoppe and Carey 2007; Richardson et al. 2008; Stoker et al. 2004, 2005; Zhou et al. 2001).  The
decreases in serum T4 were associated with reduced ex vivo binding of T4 to the plasma thyroid hormone
transporter protein TTR (Hallgren and Darnerud 1998).  Significant reductions in serum T3 were observed
in rats exposed to penta- and octaBDE at doses ≥100 and ≥60 mg/kg/day, with maximum reductions up to 
25–30% at 300 and 100 mg/kg/day, respectively, for 4 days via gavage (Zhou et al. 2001).  No changes in 
serum T3 were observed in rats exposed to pentaBDE at lower doses (≤60 mg/kg/day) for 5 days via
gavage (Stoker et al. 2004).  No compound-related changes were observed in serum TSH levels in rats or
mice exposed to penta- or octaBDE at doses up to 300 mg/kg/day for 4–14 days via gavage (Darnerud
and Sinjari 1996; Hallgren and Darnerud 1998, 2002; Hallgren et al. 2001; Stoker et al. 2004; Zhou et al. 
2001).  In a low-dose study, male rats did not show exposure-related changes in serum T4, T3, or TSH
levels measured 45 days after a single exposure pentaBDE at doses up to 1.2 mg/kg/day via gavage 
(Alonso et al. 2010).
Following a single gavage exposure to pentaBDE on GD 6, reductions in serum T4 levels were observed
at doses ≥0.06 mg/kg in rat dams on PND 1 (23–33%), but not PND 22, and F1 males and females at
0.3 mg/kg/day on PND 22 (19–23%), but not PND 1 or 14; no changes in serum T3 were observed in
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dams or F1 rats at any time-point at doses up to 1.2 mg/kg (Kuriyama et al. 2007).  Maternal serum T4 
was also reduced on GD 20 in rat dams exposed to pentaBDE doses ≥60 mg/kg/day from GD 6.5 to 19.5 
via gavage, but not on GD 12 in rat dams exposed to up to 120 mg/kg/day on GDs 6.5–11.5 (Ellis-
Hutchings et al. 2009).  Exposure to pentaBDE at doses up to 120 mg/kg/day on GDs 6.5–11.5 or 6.5– 
19.5 did not significantly alter maternal serum T3, TSH, or TTR levels (Ellis-Hutchings et al. 2009). 
A limited amount of information is available on hormonal effects of PBDEs other than thyroid.  There
were no clear chemical-related changes in serum corticosterone levels in female mice that were exposed
to pentaBDE at doses up to 72 mg/kg/day via gavage for 14 days (Fowles et al. 1994).  Limited data
regarding serum reproductive hormone levels after acute-duration exposure to lower-brominated PBDEs
are discussed in Section 3.2.2.5 (Reproductive Effects).
DecaBDE:  No exposure-related changes in serum T4, T3, or TSH were observed in female rats exposed
to decaBDE at doses up to 100 mg/kg/day via gavage for 4 days (Zhou et al. 2001).  In neonatal male rats 
exposed to doses of 0, 6, or 20 mg/kg/day from PND 2 to 15, serum T4 was reduced by ~8 and 22% at
6 and 20 mg/kg/day, respectively (Rice et al. 2007).  This finding was reported as a dose-related trend;
however, pair-wise statistics were not reported.  No exposure-related changes in serum T4 levels were 
observed in similarly exposed neonatal females (Rice et al. 2007).  In pregnant mice exposed to decaBDE
at 0, 150, 750, 1,500, or 2,500 from GD 7 to 9 via gavage, maternal serum T4 was significantly reduced
by ~11 and 14% on GD 16 in the 1,500 and 2,500 mg/kg/day groups, respectively (data reported
graphically) (Chi et al. 2011).  In the 2,500 mg/kg/day group, serum T3 levels were also significantly
reduced by ~40% (Chi et al. 2011).
Intermediate-Duration Animal Studies
Lower-brominated PBDEs:  In a comprehensive 90-day study in rats, incidences of thyroid follicular cell
hyperplasia were 0/10, 2/10, 2/10, and 5/10 in males and 0/10, 0/10, 1/10, and 4/10 in females exposed to
dietary pentaBDE at 0, 2, 10, and 100 mg/kg/day, respectively (WIL Research Laboratories 1984).  The
thyroid hyperplasia was mild and transient, as it was characterized as very slight in severity at all doses 
and was no longer observed at 24 weeks postexposure in any animals.  In a 28-day dietary study, thyroid 
hyperplasia was equivocally increased in male rats that were exposed to 90 mg/kg/day of penta- or
octaBDE (IRDC 1976).  Incidences of slight or moderate hyperplasia in the 0, 9, or 90 mg/kg/day dose
groups were 0/5, 1/5, and 3/5 in pentaBDE-exposed males and 0/5, 0/5, and 3/5 in the octaBDE-exposed 
males, respectively; no increases were seen in females (IRDC 1976).  In males rats exposed to pentaBDE
   
 








    
  
     
    
      
  
     
 
 
   
     
  
     
      
    
    
  
   
   
    
    
   
   
    
    
     
 
 








at doses of 0, 3, 30, or 60 mg/kg/day for 15 days via gavage, follicular cell hypertrophy and hyperplasia
were observed in the 30 and 60 mg/kg/day groups (13/15 and 10/15, respectively); however, incidences in
control and low-dose groups were not reported (Becker et al. 2012).  Additionally, when this study was
repeated in a different laboratory, no treatment-related histological changes were observed in the thyroid
from the 60 mg/kg/day group (animals from 3- and 30-mg/kg/day group were not evaluated) (Becker et
al. 2012).  Follicular cell hypertrophy was observed in 50% of F1 rats exposed to pentaBDE at
50 mg/kg/day for 18 weeks (GD 6 to PNW 16) via gavage; hypertrophy was not observed in any controls
(Dunnick et al. 2012).  
Other histological and morphological changes observed in the thyroid included increased epithelial
thickness of inner follicles of the thyroid in male rats exposed to a dietary penta-decaBDE mixture
(52.1% pentaBDE, 44.2 decaBDE, and 0.4% octaBDE) at 20 mg/kg/day for 70 days (incidence data not
reported) (Ernest et al. 2012); altered morphology of the epithelium (tall columnar rather than the normal
cuboidal type) in 4/35 male and 1/35 female rats exposed to estimated dietary octaBDE doses of 600 and
750 mg/kg/day, respectively, for 28 days (IRDC 1977); an increased incidence of cellular debris in the
follicular lumen of the thyroid in female mice exposed to dietary tetraBDE at 0.45 mg/kg/day for 28 days
(Maranghi et al. 2013); a significant 60–66% increase in the follicular epithelial height score, a 23–44%
decrease in the colloid area, and a 12.5–13.3% increased incidence of follicular degeneration in male and
female rats exposed to pentaBDE at 60 mg/kg/day via gavage for 31 or 20 days, respectively (Stoker et al.
2004); an increase in the observed degree of vacuolation in the thyroid of female mink exposed to 
0.31 mg/kg/day for 16–17 weeks (4 weeks pre-mating through PNW 6) (Zhang et al. 2009); and a
borderline significant (p=0.057) increase in thyroid follicular epithelial cell height in F1 mink exposed to 
0.06 mg/kg/day via gavage during a one-generation study (4 weeks pre-mating through PNW 33) (Zhang
et al. 2009).  Additionally, the epithelial height of the inner follicles of the thyroids showed a biphasic
response in rats following dietary exposure to a penta-decaBDE mixture (52.1% pentaBDE, 
44.2 decaBDE, and 0.4% octaBDE) at 0. 02, 0.2, 2, or 20 mg/kg/day for 70 days (Ernest et al. 2012).  
Compared with controls, the epithelial height was significantly decreased at 0.02 mg/kg/day and 
significantly increased at 20 mg/kg/day (other doses were not significantly different from controls; 
quantitative data not reported) (Ernest et al. 2012).  In contrast to findings in other studies, no exposure-
related changes in thyroid histology were observed in male or female rats exposed to pentaBDE doses up 
to 200 mg/kg/day for 28 days via gavage (Van der ven et al. 2008b).
Relative, but not absolute, thyroid weights were significantly elevated by 50% in male and females 
exposed to dietary pentaBDE at 100 mg/kg/day for 90 days (WIL Research Laboratories 1984).  Eight
   
 








    
     
   
      
   
   
  
   
     
 
   
   
 
    
  
      
 
  
   
 
  
   
 
     
      
   
   
  
 
   




weeks postexposure, thyroid weights were still significantly elevated by 40% in female, but not male, 
rats; no exposure-related changes were observed 24 weeks postexposure (WIL Research Laboratories 
1984).  Rats that were exposed to octaBDE in estimated dietary doses of 5, 50, or 600 mg/kg/day (males)
or 7, 70, or 750 mg/kg/day (females) for 13 weeks had increased absolute and relative thyroid weights of
15–31 and 32–56%, respectively, at ≥50/70 mg/kg/day (IRDC 1977).  The thyroid weight increases were
still observed at 8 weeks postexposure in the 600/750 mg/kg/day groups (increased 67 and 13% in males
and females, respectively).  However, no exposure-related thyroid weight changes were observed in rats 
exposed to pentaBDE at doses up to 200 mg/kg/day for 15–28 days via gavage (Becker et al. 2012; Van
der ven et al. 2008b), in rats exposed to dietary penta- or octaBDE at doses up to 90 mg/kg/day for
28 days (IRDC 1976), or in F0 or F1 mink exposed to dietary pentaBDE at doses up to 0.31 mg/kg/day in 
one generation studies (4 weeks pre-mating through PNW 6 or 33) (Zhang et al. 2009).
Following exposure to pentaBDE doses of 0, 0.27, 0.82, 2.47, 7.4, 22.2, 66.7, or 200 mg/kg/day for
28 days via gavage, hyperemia in the zona reticularis of the adrenal gland was observed in ~50% of
exposed male rats across all dose groups and occasionally in exposed female rats, but not in any control
rats (incidence data for exposed animals not reported) (Van der ven et al. 2008b).  In females, there was a 
dose-related increase in necrotic lesions in the zona reticularis, with pyknosis at 67 mg/kg/day and 
widespread necrosis at 200 mg/kg/day (Van der ven et al. 2008b). The authors reported that the
combined incidence of hyperemia and zona reticularis necrosis was statistically significantly increased at
the higher doses (precise doses not specified).  No histological changes were observed in the adrenal
gland of female mice exposed to dietary tetraBDE at 0.45 mg/kg/day for 28 days (Maranghi et al. 2013).
Mink that were exposed to dietary pentaBDE for 9 weeks had increased absolute and relative adrenal
weights at 0.78 mg/kg/day (25 and 67%, respectively); no changes were observed at ≤0.63 mg/kg/day
(Martin et al. 2007).  No exposure-related adrenal weight changes were observed in rats exposed to
pentaBDE at doses up to 240 mg/kg/day for 28–31 days via gavage (Stoker et al. 2005; Van der ven et al.
2008b), in rats exposed to dietary penta- or octaBDE at doses up to 90 mg/kg/day for 28 days (IRDC
1976), or in male or female rats exposed to dietary octaBDE doses up to 600 and 750 mg/kg/day, 
respectively, for 13 weeks (IRDC 1977).  Adrenal weight was not assessed in any other intermediate-
duration studies identified.
Serum T4 levels were significantly reduced by 22–91% in rats exposed to pentaBDE at gavage doses of
≥3 mg/kg/day for 15–125 days (Becker et al. 2012; Driscol et al. 2009; Hoppe and Carey 2007; Stoker et
al. 2004) or dietary pentaBDE at doses ≥20 mg/kg/day for 90 days (WIL Research Laboratories 1984).  
   
 








   
   
  
     
    
  
    
  
    
    
  
    
 
   
   
    
     
  
     
     
     
   
    
   
    
   
   
  
     
     




Similarly, serum T4 levels were significantly reduced by 22% in rats exposed to a dietary penta-decaBDE
mixture (52.1% pentaBDE, 44.2 decaBDE, and 0.4% octaBDE) at 20 mg/kg/day for 70 days (Ernest et al. 
2012).  In a 28-day study, rats were exposed to pentaBDE at 0, 0.27, 0.82, 2.47, 7.4, 22.2, 66.7, or
200 mg/kg/day via gavage (Van der ven et al. 2008b). Study authors report dose-related decreases in
serum T4 levels (maximal reduction of 88–89%); however, the doses at which these effects were observed
were not reported.  Instead, results were reported in terms of BMD analysis (BMD/BMDLRD10%= 
1.4/1.1 mg/kg/day in males and 2.7/1.8 mg/kg/day in females) (Van der ven et al. 2008b).  Serum T3 
levels were significantly reduced by 14–25% and serum TSH levels were significantly increased by 63– 
144% in male rats exposed to pentaBDE via gavage at ≥30 mg/kg/day for 15–31 days (Becker et al. 2012;
Stoker et al. 2004).  However, other studies reported no significant changes in serum T3 and/or TSH levels 
in rats exposed to pentaBDE at doses up to 200 mg/kg/day for 20–28 days via gavage (Stoker et al. 2004;
Van der ven et al. 2008b), dietary pentaBDE at doses up to 100 mg/kg/day for 90 days (WIL Research 
Laboratories 1984), or to a dietary penta-decaBDE mixture (52.1% pentaBDE, 44.2 decaBDE, and 0.4%
octaBDE) at doses up to 20 mg/kg/day for 70 days (Ernest et al. 2012).  
Altered thyroid hormone levels have also been reported in F0 animals following exposure to lower­
brominated PBDEs in one-generation and gestational/lactation exposure studies.  Following exposure to 
pentaBDE at 0, 0.5, 5, or 25 mg/kg/day via gavage for 70 days prior to mating through PND 42, serum T4 
levels were significantly reduced in F0 males at ≥5 mg/kg/day (50–87%) and females at 25 mg/kg/day
(67%) (Bondy et al. 2011, 2013).  In rat dams exposed to pentaBDE at 18 mg/kg/day via gavage from
GD 6 to PND 18, serum T4 levels were significantly decreased by 45%; no changes were observed in
serum T3, TSH, or TTR (Ellis-Hutchings et al. 2006).  Following exposure to pentaBDE via gavage from
GD 6 to PND 21, maternal serum T4 levels were significantly reduced by ≥31% at ≥10.2 mg/kg/day, and 
maternal serum TSH levels were significantly increased by 127% at 30.6 mg/kg/day (Kodavanti et al. 
2010; Zhou et al. 2002).  No exposure-related changes were observed in serum T3 (Kodavanti et al. 2010;
Zhou et al. 2002).  In dams exposed to 30 mg/kg/day via pentaBDE-dosed cookies from GD 1 to PND 21 
via dose-cookies, significant decreases were observed in serum T3 and T4 levels (quantitative data not
reported); no significant changes were observed in T3 and T4 levels at ≤3 mg/kg/day or TSH levels at
doses up to 30 mg/kg/day (Bowers et al. 2015).  In a similar study, a significant 25–50% decrease in 
maternal free and total T4 levels was observed in dams exposed to ≥10 mg/kg/day via pentaBDE-dosed 
cookie from GD 6 to PND 21; no exposure-related changes were observed in T3 or TSH levels at doses up
to 30 mg/kg/day (Bansal et al. 2014).  In rat dams exposed to tetraBDE via gavage from GD 1 to PND 14, 
maternal T4 levels were significantly reduced on PND 1 and 7 by 28–31% at doses ≥3.2 mg/kg/day; no 
changes were observed in serum T3 levels (Wang et al. 2011a).  In mice, no exposure-related changes 
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were observed in maternal serum T4 levels after exposure to pentaBDE at 452 mg/kg/day via gavage from
GD 4 to PND 17 (Skarman et al. 2005).  In one-generation dietary pentaBDE studies in mink (4 weeks 
premating through PNW 6), significant reductions in plasma T3, but not T4, were observed in F0 females 
exposed to 0.31 mg/kg/day (Zhang et al. 2009).
Numerous studies have also reported decreased serum T3 and/or T4 levels in pups after gestational and
lactational exposure to penta- or tetraBDE at doses as low as 0.3 mg/kg/day in rats and at 452 mg/kg/day
in mice (Bansal et al. 2014; Blanco et al. 2013; Bondy et al. 2011, 2013; Bowers et al. 2015; Ellis-
Hutchings et al. 2006; Kodavanti et al. 2010; Miller et al. 2012; Poon et al. 2011; Shah et al. 2011;
Skarman et al. 2005; Szabo et al. 2009; Wang et al. 2011a; Zhou et al. 2002).  Changes observed in mink
juveniles included decreases in serum T3, as in the adults, but also an increase in serum T4 in juvenile
females (Zhang et al. 2009).  See Section 3.2.2.6 (Developmental Effects) for more details. 
Consistent, exposure-related changes were not observed between studies that evaluated serum
reproductive hormone levels after intermediate-duration exposure to lower-brominated PBDEs; see 
Section 3.2.2.5 (Reproductive Effects) for more details. 
DecaBDE:  Dose-related increases in thyroid hyperplasia were reported for male Sprague-Dawley rats 
exposed to dietary decaBDE at 80 or 800 mg/kg/day for 30 days (Norris et al. 1973, 1975a), although not
in rats exposed to ≤90 mg/kg/day for 90 days, rats exposed to ≤8,000 mg/kg/day for 13 weeks, or mice 
exposed to ≤9,500 mg/kg/day for 13 weeks (IRDC 1976; NTP 1986).  The occurrence of thyroid 
hyperplasia in the rats exposed to ≥80 mg/kg/day for 30 days could be related to the low purity
composition of the older commercial decaBDE mixture tested by Norris et al. (1973, 1975a) (i.e., 77.4%
decaBDE, 21.8% nonaBDE, and 0.8% octaBDE, compared to the ≥94% decaBDE composition used in 
the NTP studies).  Similarly, observed incidences of diffuse follicular cell hypertrophy were not
significantly elevated in rat dams exposed to dietary decaBDE from GD 10 to PND 21 at doses up to 
146 mg/kg/day, compared with control (Fujimoto et al. 2011).  However, in young male rats exposed to 
decaBDE at doses of 0, 100, 300, or 600 mg/kg/day via gavage for 33 days (PNDs 10–42), multiple areas
of degenerated follicular epithelium and slight attenuation of the follicular epithelium were observed in
the thyroid glands of rat exposed to 300 or 600 mg/kg/day (incidence data not reported) (Lee et al. 2010). 
In young male rats exposed to decaBDE at doses of 0, 100, 300, or 600 mg/kg/day via gavage for 33 days
(PND 10–42), absolute and relative thyroid weights were significantly increased by 60 and 40%, 
respectively, in the 600 mg/kg/day group (Lee et al. 2010).  Increased absolute and relative thyroid 
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weights were also reported in rat dams exposed to dietary decaBDE at 2, 15, or 146 mg/kg/day from
GD 10 to PND 21; findings were significant at 2 mg/kg/day (21–22% decrease) and 146 mg/kg/day (21%
decrease) (Fujimoto et al. 2011).  No exposure-related changes in thyroid weight were observed in rats 
exposed to dietary decaBDE at doses up to 90 mg/kg/day for 28 days (IRDC 1976).  
Unlike the lower-brominated PBDEs, serum T4 levels were not altered in rats exposed to decaBDE at
gavage doses up to 600 mg/kg/day for 28–90 days (Lee et al. 2010; Van der ven et al. 2008a; Wang et al. 
2010, 2011b).  Serum T3 levels were significantly reduced by up to 25% in female, but not male, rats
exposed to decaBDE at 60 mg/kg/day via gavage for 28 days (Van der ven et al. 2008a), and no changes
in serum T3 levels were observed in male rats exposed to decaBDE at doses up to 100 mg/kg/day via
gavage for 90 days (Wang et al. 2010, 2011b).  In young male rats exposed to decaBDE for 33 days
(PNDs 10–45) via gavage, serum T3 was significantly reduced by up to 45% at doses ≥100 mg/kg/day and 
serum TSH was significantly increased by ~70% following exposure to ≥300 mg/kg/day decaBDE for
33 days (PNDs 10–42) (Lee et al. 2010).  In male mice, serum T4 and T3 were significantly reduced by
22 and 44%, respectively, following exposure to decaBDE at gavage doses of 950 mg/kg/day for 35 days, 
compared with controls; no exposure-related changes in serum thyroid hormone levels were observed at
750 mg/kg/day (Sarkar et al. 2015). In developing animals, significant reductions in serum T3 levels were 
observed following gestational and lactational exposure to decaBDE at 146 mg/kg/day in rats and 
1,500 mg/kg/day in mice; no changes were observed in serum T4 or TSH (Fujimoto et al. 2011; Tseng et
al. 2008); see Section 3.2.2.6 (Developmental Effects) for more details. 
In young male rats exposed to decaBDE at doses of 0, 100, 300, or 600 mg/kg/day via gavage for 33 days
(PNDs 10–42), absolute and relative adrenal weights were significantly increased by 14 and 20%, 
respectively, in the 600 mg/kg/day group (Lee et al. 2010).  No exposure-related changes in adrenal
weight were observed in rats exposed to dietary decaBDE at doses up to 90 mg/kg/day for 28 days (IRDC
1976).  In mice, no significant changes in adrenal weight were observed in dams exposed to decaBDE at
doses up to 1,500 mg/kg/day from GD 0 to 17 (Tseng et al. 2008).
Pancreatic effects were evaluated in rats exposed to decaBDE at doses of 0, 0.05, 1 or 20 mg/kg/day via
gavage for 8 weeks (Zhang et al. 2013a).  Serum insulin levels were significantly reduced by 50–60% at
≥1 mg/kg/day, and blood glucose levels were elevated by 12–21% at ≥0.05 mg/kg/day (Zhang et al.
2013a).  Consistent with these findings, morphological changes in the pancreas were observed at
≥1 mg/kg/day, including blurred boundaries among pancreatic islet cells (incidence not reported).
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Microarray analysis of liver tissue indicated significant alterations in genes from the canonical pathway
for type I diabetes mellitus (Zhang et al. 2013a).  
Chronic-Duration Animal Studies
Lower-brominated PBDEs:  No chronic-duration studies analyzing endocrine effects were located for
lower-brominated PBDEs,
DecaBDE:  Hyperplasia of the thyroid was observed in rats and mice following repeated dietary
exposures to decaBDE. Thyroid follicular cell hyperplasia was increased in male B6C3F1 mice that were 
exposed to ≥94% pure commercial decaBDE for 103 weeks (NTP 1986).  Incidences of the lesion were 
2/50 (4%), 10/50 (20%), and 19/50 (38%) in the 0, 3,200, and 6,650 mg/kg/day dose groups of this study.  
Slight increases in follicular cell tumors that were considered to be equivocal evidence of thyroid
carcinogenicity were also observed in the male mice (see Section 3.2.2.7, Cancer).  No decaBDE-related
histopathological changes in the thyroid were found after 103 weeks of exposure to ≤7,780 mg/kg/day in
female mice, ≤2,240 mg/kg/day in male Sprague-Dawley rats, or ≤2,550 mg/kg/day in female rats (NTP
1986). 
Summary.  While human data are inconsistent, they suggest that PBDEs can interact with thyroid
hormone homeostasis. These data, along with available animal studies, indicate that the thyroid is a target
of concern for PBDE exposure, especially lower-brominated PBDEs. One study reported pancreatic 
effects, including altered insulin regulation and pancreatic lesions, following intermediate decaBDE
exposure; however, no other animal studies evaluated these end points.  Limited human evidence is
inconclusive regarding potential associations between diabetes and PBDE exposure; however,
considering the animal data, the pancreas may be a target of concern for oral PBDE exposure. There is 
little evidence for endocrine effects other than those mediated by the thyroid and pancreas; data for
altered reproductive hormones in humans and animals exposed to PBDEs are inconclusive (see 
Section 3.2.2.5, Reproductive Effects).
Dermal Effects. No studies were located regarding dermal effects in humans after oral exposure to
PBDEs.
Histopathological examinations showed no dermal changes in rats following gavage exposure to 
≤200 mg/kg/day of pentaBDE for 28 days (Van der ven et al. 2008b), dietary exposure to 
   
 








     
     




       
 
 
    
     
      
   




      
 
 




   
  
   
  
   
 






≤100 mg/kg/day of pentaBDE for 90 days (WIL Research Laboratories 1984), or dietary exposure to
≤750 mg/kg/day of octaBDE for 13 weeks (IRDC 1977). No studies examining dermal effects after
exposure to decaBDE were located.
Based on animal studies, dermal effects are unlikely with oral exposure to PBDEs.
Ocular Effects. No studies were located regarding ocular effects in humans after oral exposure to
PBDEs.
Histopathological examinations showed no ocular effects in rats following dietary exposure to 
≤100 mg/kg/day of pentaBDE for 90 days (WIL Research Laboratories 1984) or ≤750 mg/kg/day of
octaBDE for 13 weeks (IRDC 1977). Similarly, histopathological examinations showed no ocular effects
in rats following dietary exposure to ≤1.0 mg/kg/day of 77.4% decaBDE (containing 21.8% nonaBDE
and 0.8% octaBDE) for 2 years (Kociba et al. 1975; Norris et al. 1975a).
Based on animal studies, ocular effects are unlikely with oral exposure to PBDEs.
Body Weight Effects. The only information located was that serum concentrations of BDE 47 in a
group of 36 metabolically healthy but obese women (MHO) were not significantly different than in a
group of 40 metabolically abnormal obese women (p=33 for comparison of the medians) (Gauthier et al. 
2014). The significance of this isolated finding is unknown
Acute-Duration Animal Studies
Lower-brominated PBDEs:  Percent body weight gain was significantly decreased by 2–19% in female 
rats following gavage exposure to pentaBDE at 2000 mg/kg for 1 day, pentaBDE at 200 mg/kg/day for
7 days, pentaBDE at 8–200 mg/kg/day for 14 days, or octaBDE at 40–200 mg/kg/day for 7 or 14 days
(Bruchajzer et al. 2010, 2011, 2012).  However, no changes in percent body weight gain were observed in 
female rats exposed to pentaBDE at doses up to 200 mg/kg/day for 7 or 14 days via gavage in another
study by the same investigators (Bruchajzer 2011).  Additionally, body weight effects were not reported 
in any other acute-duration study.  No changes in body weight or body weight gain were observed in rats 
exposed to penta- or tetraBDE at doses up to 240 mg/kg/day for 3–14 days via gavage (Bruchajzer 2011;
Hallgren and Darnerud 2002; Hallgren et al. 2001; Hoppe and Carey 2007; Stoker et al. 2004; Stoker et
al. 2005; Zhou et al. 2001) or in mice exposed to penta-, tetra-, or octaBDE at doses up to 100 mg/kg/day
   
 














   
 
   
  
   
   
 
 
   
      
   
     




     
 
    




     
   
  




for 4–14 days via gavage (Hallgren and Darnerud 2002; Fowles et al. 1994; Hallgren et al. 2001; 
Richardson et al. 2008; Zhou et al. 2001). 
In pregnant rats exposed to pentaBDE at 0, 10, 100, or 200 mg/kg/day via gavage from GD 6 to 15, 
maternal body weight gain was significantly decreased by 20 and 30% in the 100 and 200 mg/kg/day
groups (Argus Research Laboratories 1985a).  Pregnant rats exposed to octaBDE at 0, 2.5, 10, 15, 25, or
50 mg/kg/day via gavage from GD 6 to 15 showed a significantly 40% reduction in maternal body weight
gain at 50 mg/kg/day (WIL Research Laboratories 1986).  In pregnant rabbits, exposure to octaBDE at
15 mg/kg/day via gavage from GD 7 to 19 also resulted in a 7% decreased in maternal body weight gain 
(statistics not provided); no body weight effects were observed at ≤5 mg/kg/day (Breslin et al. 1989).  In 
other studies, maternal body weight was not affected in rats by gestational exposure via gavage to 
pentaBDE at doses up to 120 mg/kg/day (Blanco et al. 2012, Ellis-Hutchings et al. 2009; Zhao et al. 
2014) or tetraBDE at 0.7 mg/kg/day (Talness et al. 2008).  
DecaBDE:  No change in body weight or body weight gains were observed in rats exposed to decaBDE at
doses up to 1,000 mg/kg/day for 4–14 days via gavage (Bruchajzer et al. 2010; Zhou et al. 2001) or in rats
and mice exposed to dietary decaBDE doses up to 16,000 and 19,000 mg/kg/day, respectively, for 7– 
14 days (NTP 1986; Sakamoto et al. 2013). DecaBDE did not alter maternal body weight in mice
exposed to doses up to 1500 mg/kg/day from GD 0 to 17 via gavage (Tseng et al. 2006).
Intermediate-Duration Animal Studies
Lower-brominated PBDEs:  Percent body weight gain was significantly decreased by 8–19% in rats
exposed to pentaBDE at 8–200 mg/kg/day or octaBDE at 40–200 mg/kg/day for 21 or 28 days via gavage
(Bruchajzer 2011; Bruchajzer et al. 2012).  However, in another study by the same investigators that
exposed female rats to 0, 8, 40, or 200 mg/kg/day for 21 or 28 days via gavage, percent body weight gain 
was only significantly decreased at 200 mg/kg/day (Bruchajzer et al. 2010).  Another 28-day gavage
study reported no body weight gain changes in female rats at pentaBDE doses up to 200 mg/kg/day; 
however, significant changes were observed in male rats after the 28-day exposure to 0.27– 
200 mg/kg/day (Van der ven et al. 2008b).  The BMDRD10% and BMDLRD10% for decreased body weight
gain in male rats were 61.3 and 9.7 mg/kg/day, respectively (data were reported in terms of BMD analysis 
only; raw data were not reported).  At higher doses (≥600 mg/kg/day), rats exposed to dietary octaBDE
for 13 weeks showed ≥12% decreases in weight gain (IRDC 1977).  In mink, dietary pentaBDE exposure
at doses of 0.63 and 0.78 mg/kg/day for 9 weeks showed significant body weight decreases of 21 and 
   
 












   
  
   
 
    
   





   





       
     
  
   
 
   
   
   
    
 
     




28%, respectively; no body weight effects were observed in mink exposed to dietary concentrations of
0.08 mg/kg/day (Martin et al. 2007).  
Body weight effects were not reported in other intermediate-duration studies.  No changes in body weight
or body weight gain were observed in rats exposed to pentaBDE at doses up to 250 mg/kg/day for 15– 
90 days via gavage (Becker et al. 2012; Daubie et al. 2011; Hoppe and Carey 2007; IRDC 1976; Oberg et
al. 2010; Stoker et al. 2004, 2005; WIL Research Laboratories 1984), in mice exposed to tetra- or diBDE
at doses up to 30 mg/kg/day for 28–30 days via gavage (Wang et al. 2013; Zhang et al. 2014), in mice 
exposed to tetraBDE at doses up to 150 mg/kg/day for 6–12 weeks via gavage (McIntyre et al. 2015;
Zhang et al. 2015a, 2015b), in rats exposed to dietary penta- or octaBDE or a penta-decaBDE mixture
(52.1% pentaBDE, 44.2% decaBDE, and 0.4% octaBDE) at doses up to 90 mg/kg/day for 28–125 days
(Driscol et al. 2009; Ernest et al. 2012; IRDC 1976), or in mice exposed to dietary tetraBDE at doses up 
to 0.45 mg/kg/day (Maranghi et al. 2013).  
Maternal body weight effects were not observed following gavage exposure to pentaBDE during
gestation and lactation in rats at doses up to 30.6 mg/kg/day (Bowers et al. 2015; Ellis-Hutchings et al.
2006; Kodavanti et al. 2010; Zhou et al. 2002) or in mice at doses up to 452 mg/kg/day (Branchi et al. 
2005; Skarman et al. 2005).  In one-generation studies, no body weight effects were observed in F0 or F1
rats following pentaBDE exposure to gavage doses up to ≤50 mg/kg/day (Bondy et al. 2011, 2013;
Dunnick et al. 2012), in F0 dams following administration of doses up to 11.4 mg/kg/day via pentaBDE­
dosed vanilla wafers (Poon et al. 2011), in F0 or F1 mink exposed to dietary pentaBDE doses of
≤0.31 mg/kg/day (Zhang et al. 2009), or in female F0 mice fed cornflakes dosed with 1 mg/kg/day of
tetraBDE for 4 weeks prior to mating through PND 21 (Koenig et al. 2012; Ta et al. 2011)
DecaBDE:  One study reported significant decreases in growth in rats exposed to decaBDE via gavage for
90 days (Wang et al. 2011b).  “Whole-body growth rates,” defined by the study authors as the average 
growth rate after 90 days, were reported as 1.57, 0.59, and 0.76% in the 0, 10, and 50 mg/kg/day groups, 
respectively (Wang et al. 2011b).  No changes in body weight or body weight gain were observed in other
studies of rats exposed to decaBDE doses up to 1,000 mg/kg/day for 21–90 days via gavage (Bruchajzer
et al. 2010; Lee et al. 2010; Van der ven et al. 2008a; Wang et al. 2010; Zhang et al. 2013a), in mice
exposed to decaBDE at doses up to 1,500 mg/kg/day for 15–60 days via gavage (Heredia et al. 2012;
Liang et al. 2010; Sarkar et al. 2015; Tseng et al. 2006), or in rats and mice exposed to dietary decaBDE
at doses of ≤8,000 and ≤9,500 mg/kg/day, respectively, for 28–90 days (NTP 1986; Sakamoto et al. 2013;
Watanabe et al. 2010a).  Dietary ingestion of 77.4% decaBDE mixture (containing 21.8% nonaBDE and 
   
 








   
     
 
  
    




     








     
 
    















0.8% octaBDE) similarly caused no body weight changes in rats exposed to ≤800 mg/kg/day for 30 days 
or ≤1.0 mg/kg/day for 2 years (Kociba et al. 1975; Norris et al. 1973, 1975a).  
Mean maternal weight was suppressed by ~10% in mice exposed to dietary decaBDE doses of 290 or
2,900 mg/kg/day from GD 10 to PND 21; however, the study authors did not report whether or not this
finding was statistically significant (raw data not available for statistical analysis) (Watanabe et al.
2010b).  A significant 12% decrease in body weight was also reported in rat dams exposed to decaBDE at
300 mg/kg/day via gavage for 3 weeks prior to mating until PND 21 (Liu et al. 2012).  In other studies, 
decaBDE did not alter maternal body weight in rats exposed to doses up to 1,000 mg/kg/day from GD 10 
to PND 21 via gavage (Biesemeir et al. 2011; Fujimoto et al. 2011) or in mice exposed to dietary
decaBDE at doses up to 260 mg/kg/day from GD 10 to PND 21 (Watanabe et al. 2008). 
Chronic-Duration Animal Studies
Lower-brominated PBDEs:  No chronic-duration studies analyzing body weight effects were located for
lower-brominated PBDEs.
DecaBDE:  Body weight effects were not observed in rats and mice that were exposed to dietary
decaBDE doses of ≤2,550 and ≤7,780 mg/kg/day, respectively, for 103 weeks (NTP 1986).  
Summary. No studies are available on body weight effects of PBDEs in humans.  Although some acute-
and intermediate-duration animal studies reported decreased body weight, several others reported no 
exposure-related changes in body weight.  No changes in body weight were observed in chronic studies.  
Based on the body of evidence from animal studies, body weight effects are unlikely to occur following
oral exposure to PBDEs at environmentally-relevant doses.
Metabolic Effects. No studies were located regarding metabolic effects in humans after oral exposure 
to PBDEs.
Animal Studies
Lower-brominated PBDEs:  Exposure to pentaBDE via gavage for 28 days at doses of 0, 0.27, 0.82, 2.47, 
7.4, 22.2, 66.7, or 200 mg/kg/day caused significant, dose-related decreases in blood glucose levels in
male rats (Van der ven et al. 2008b).  Results, reported in terms of BMD analysis, indicated a BMD10 of
   
 








    
   
    
  
  





     




   
 
   
   
  
 
   
  
      
   
    
 
 
    
     
      
 




179.55 mg/kg/day and a BMDL10 of 66.7 mg/kg/day (raw data and statistics for individual dose groups
were not reported).  No significant changes in blood glucose levels were found in female rats exposed to 
doses up to 200 mg/kg/day (Van der ven et al. 2008b).  Reduced serum glucose levels were also reported 
in male rats exposed to 20 mg/kg/day of a dietary PBDE mixture containing 52.1% penta-decaBDE
(DE-71), 44.2% decaBDE (BDE 209), and 0.4% octaBDE (DE-79) for 70 days; no changes were
observed at ≤2 mg/kg/day (Ernest et al. 2012).
In wild-type mice exposed to tetraBDE at 0 or 1 mg/kg/day via gavage for 6 weeks, no exposure-related
changes in circulating insulin levels, glucose tolerance, insulin resistance, or lipogenesis in the liver were 
observed (McIntyre et al. 2015).  However, insulin sensitivity was significantly decreased in similarly-
exposed Pten -/- mice (mice hypersensitive to insulin), compared to control Pten -/- mice.  No exposure-
related effects were observed in Tsc1 -/- (mice with mild insulin resistance).
Exposure to pentaBDE via gavage at 250 mg/kg/day for 28 days caused hypercalcemia, hyper­
magnesemia, and hyperphosphatemia in male rats and hyperatremia and hypokalemia in female rats 
(Oberg et al. 2010).  No changes in blood calcium, magnesmium, potassium, phosphorus, or sodium
levels were observed at doses ≤25 mg/kg/day (Oberg et al. 2010).  No significant changes in blood 
calcium, magnesium, or phosphorus levels were observed in male rats exposed to ≤20 mg/kg/day of a
dietary penta-decaBDE mixture containing 52.1% pentaBDE (DE-71), 44.2% decaBDE (BDE 209), and 
0.4% octaBDE (DE-79) for 70 days (Ernest et al. 2012).
A single study evaluated fat pad weight and adipocyte number, size, viability, lipolysis, and glucose
oxidation in male rats following exposure to pentaBDE at 14 mg/kg/day via gavage for 2 or 4 weeks
(Hoppee and Carey 2007).  No exposure-related effects were noted at 2 weeks.  At 4 weeks, significant
observations included increased adipocyte lipolysis and decreased adipocyte glucose oxidation; however,
no changes in fat pad weight or the number, size, or viability of adipocytes were observed.
DecaBDE:  DecaBDE exposure via gavage for 8 weeks caused elevated blood glucose levels at
≥0.05 mg/kg/day in male rats (Zhang et al. 2013a).  Elevated glucose levels were increased 12–21%
compared with controls, and were accompanied by significantly decreased serum insulin levels at
≥1 mg/kg/day; see Section 3.2.2.2, Endocrine System Effects for more details.  
Summary.  Data regarding metabolic effects of PBDE are too limited to adequately characterize if PBDE
exposure could alter metabolism in humans.
   
 











    
       
 
      
 
       
   
     
       
      
 
   
      




   
   
     
  
    
 
  







3.2.2.3  Immunological and Lymphoreticular Effects 
Human Studies.  A significant negative statistical association (not further described) was found between 
serum concentrations of PBDE and number of circulating lymphocytes in a subset of 18 of a cohort of
33 children (18 girls and 15 boys) born in the Amsterdam/Zaandam area of the Netherlands and aged 14– 
19 years at the time of this study (Leijs et al. 2009).  Serum PBDE concentrations (determined as the sum
of congeners 28, 47, 85, 99, 100, 153, 154, and 183) ranged from 5 to 74 ng/g lipid with a mean of
13.9 ng/g lipid. Congener-specific analysis showed the main contributors to be BDE 183, BDE 154, and 
BDE 85.  There were no other effects on leukocyte count or differential.  Although dioxins and PCBs
were also assessed, no association with lymphocytes was found for these chemicals.  No effects on
pokeweed mitogen-stimulated DNA proliferation or IgG immunoglobulin synthesis were found in human 
lymphocytes exposed to BDE 47 or BDE 85 in vitro (Fernlof et al. 1997). A cross-sectional study of
992 subjects from Sweden aged 70 years reported that serum levels of BDE 47 (median 12.6 ng/g lipid)
were significantly (p=0.03) negatively associated with blood levels of protein complement 3 (C3), but not
with serum levels of C3a or C4 (Kumar et al. 2014a); no other BDE congener was assessed.  PCB levels 
were also negatively associated with protein complements. In a similar study of the same cohort, Kumar
et al. 2014b) found no association between serum levels of BDE 47 and multiple inflammatory markers.
Acute-Duration Animal Studies
Lower-brominated PBDEs:  Limited information is available on effects of acute-duration exposure to 
lower-brominated PBDEs on immunologic function in animals.  A single gavage dose of 0.8–500 mg/kg 
pentaBDE did not affect the plaque-forming splenic cell antibody response to injected sheep red blood 
cells in mice (Fowles et al. 1994).  Mice that were given 18, 36, or 72 mg/kg/day doses of pentaBDE via 
gavage for 14 days had significantly reduced antibody response to sheep red blood cells (63% of control
value, p<0.02) and decreased thymus weight at 72 mg/kg/day (Fowles et al. 1994).  There were no 
exposure-related effects of the 14-day exposure to ≤72 mg/kg/day on NKC activity to murine YAC-1 
target cells; NKC activity was not evaluated in the single-dose study.  Another 14-day study was
conducted in which mice and rats were administered pentaBDE at 0, 18, or 36 mg/kg/day via gavage and
were evaluated for spleen and thymus weights, numbers of splenic and thymic lymphocyte subsets
(CD4+, CD8+, and CD45R+ cells), and in vitro IgG immunoglobulin production in pokeweed mitogen­
stimulated splenocytes (Darnerud and Thuvander 1998).  The only exposure-related effect in either
species was significantly reduced in vitro production of IgG in pokeweed-stimulated splenocyte cultures 
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from the mice exposed to 36 mg/kg/day.  Mice that were similarly exposed to tetraBDE at 18 mg/kg/day 
via gavage for 14 days had significantly reduced numbers of total splenocytes as well as CD4+, CD8+,
and CD45R+ cells in spleen (Darnerud and Thuvander 1998), but no changes in spleen or thymic weight
(Hallgren et al. 2001).  
DecaBDE:  No acute-duration studies analyzing immune effects were located for lower-brominated 
PBDEs.
Intermediate-Duration Animal Studies
Lower-brominated PBDEs:  Immune function was evaluated in male mink exposed to dietary pentaBDE
for 9 weeks (Martin et al. 2007).  Initial exposure concentrations were 0, 1, 10, or 100 ppm; however, 
after the first week of exposure, the 100 ppm group was switched to 5 ppm for weeks 2–9 because of food 
avoidance and weight loss concerns.  Dose levels in the 1, 5/100, and 10 ppm groups were calculated to 
be 0.08, 0.63, and 0.78 mg/kg/day, respectively, based on estimated daily intake ranges (Martin et al. 
2007). Mink were assessed weekly during exposure for antibody-mediated immunity to KLH (a carrier
protein from keyhole limpet that binds to haptens and is used to stimulate a response from the immune
system in the form of antibody production) and at 9 weeks for PHA skin response. No dose-related
effects were observed for antibody production to KLH; however, at each time-point tested, antibody
production in the 0.63 mg/kg/day group (the 100 ppm/5 ppm group) was significantly increased compared 
with controls.  No exposure-related changes were observed in the skin response to PHA challenge.
Martin et al. (2007) also reported a significant increase in the incidence of spleen hyperplasia in mink
from the 0.63 and 0.78 mg/kg/day groups, with 25 and 40% incidence, respectively, compared with 0%
incidence in the controls.  In the 0.78 mg/kg/day group, the number of germinal centers in the spleen was
also significantly increased.  In mice, histological and morphometric changes were observed in the spleen
and thymus of females exposed to dietary tetraBDE at 0.45 mg/kg/day for 28 days (only dose tested;
males not evaluated) (Maranghi et al. 2013).  In the spleen, follicular hyperplasia with germinal center
development was observed in 9/10 exposed mice, compared with 4/10 controls, and lymphocytic
infiltration involving the red pulp was observed in 5/10 exposed mice, compared with 0/10 controls.  In 
the thymus, 7/9 exposed mice showed Hassal’s bodies, compared with 2/10 controls, and 5/9 showed 
lymphocytic apoptosis, compared with 0/10 controls.  The ratio between area of cortex and medulla in the
thymus was significantly increased by 43% in exposed mice, compared with controls.  In the thyroid, 
cellular debris was observed in the follicular lumen of 5/7 exposed mice, compared with 0/10 controls
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(Maranghi et al. 2013).  In other studies, no exposure-related changes were observed in spleen, thymus,
lymph node, and/or bone marrow tissue histology in rats exposed to pentaBDE at gavage doses up to 
250 mg/kg/day for 28 days (Oberg et al. 2010; Van der ven et al. 2008b), pentaBDE at dietary doses up to 
100 mg/kg/day for 90 days (WIL Research Laboratories 1984), or octaBDE at dietary doses up to
750 mg/kg/day for 13 weeks (IRDC 1977).  Additionally, no exposure-related changes were observed in
the histology of the spleen, thymus, Peyer’s patches, or mesenteric lymph nodes in rat dams exposed to
pentaBDE at doses up to 25 mg/kg/day via gavage for 70 days prior to mating through PND 21 
(~21 weeks) (Bondy et al. 2013).  In offspring, a significant dose-related trend was observed in the
incidence of apoptotic lymphocytes and tingible macrophages in the thymus of PND 43 males, but not
females (Bondy et al. 2013); see Section 3.2.2.6 (Developmental Effects) for more details.  
Martin et al. (2007) reported a significant 29% increase in relative, but not absolute, spleen weight in
mink exposed to dietary pentaBDE at 0.78 mg/kg/day for 9 weeks.  In a 28-day study, rats were exposed 
to pentaBDE at 0, 0.27, 0.82, 2.47, 7.4, 22.2, 66.7, or 200 mg/kg/day via gavage (Van der ven et al. 
2008b).  Study authors reported a dose-related decrease in thymus weight in male rats (maximal decrease 
of 19.4%); however, the lowest dose at which the effect was observed was not reported.  Instead, results
were reported in terms of BMD analysis (BMD/BMDLRD20%=194.2/110 mg/kg/day).  No dose-related
changes were reported for female thymus weight, male or female spleen weight, or T-cell, B-cell, or
macrophage population distribution in the spleen in either sex (Van der ven et al. 2008b). In other
studies, no exposure-related changes were observed in spleen or thymus weights in rats exposed to penta­
or diBDE at gavage doses up to 250 mg/kg/day for 28 days (Oberg et al. 2010; Zhang et al. 2014), in rats
exposed to pentaBDE at gavage doses up to 0.015 mg/kg/day for 90 days (Daubie et al. 2011), in rats
exposed to dietary penta- or octaBDE at doses up to 100 mg/kg/day for 28 or 90 days (IRDC 1976; WIL
Research Laboratories 1984), in rats exposed to a dietary penta-decaBDE mixture (52.1% pentaBDE
[DE-71], 44.2% decaBDE [BDE 209], 0.4% octaBDE [DE-79]) at doses up to 20 mg/kg/day for 70 days
(Ernest et al. 2012), in rats exposed to dietary octaBDE at doses up to 750 mg/kg/day for 13 weeks (IRDC
1977), or in mice exposed to dietary tetraBDE at 0.45 mg/kg/day for 28 days (Maranghi et al. 2013).  
Additionally, no exposure-related changes in spleen or thymus weights were observed in rat dams or
offspring exposed to pentaBDE at 18 mg/kg/day via gavage from GD 6 to PND 21  (Ellis-Hutchings et al. 
2006), in rat dams exposed to pentaBDE at doses up to 25 mg/kg/day via gavage for 70 days prior to 
mating through PND 21 (~21 weeks) (Bondy et al. 2013), or in mink sows exposed to dietary pentaBDE
at doses up to 0.31 mg/kg/day for 4 weeks prior to mating through PNW 6 (Zhang et al. 2009).  Although 
immune function was not altered, increased thymus weights, as well as altered serum immunoglobin 
levels and lymphocyte proliferation, were observed in the offspring of rat dams exposed to pentaBDE at
   
 








   
    
 
   
     
 
  
   
     
       





     




   
 
   
   
 
    
     
   
     
 




































































doses ≥5 mg/kg/day via gavage for 70 days prior to mating through PND 21 (~21 weeks) (Bondy et al.
2013); see Section 3.2.2.6 (Developmental Effects) for more details.  
In a poorly-reported study, immune end points were evaluated in mouse dams and offspring following
exposure to pentaBDE at 0, 50, 100, or 200 mg/kg/day via gavage from GD 6 to PND 21 (Hong et al. 
2010).  The absolute and relative spleen weights were significantly decreased in the 100 and 
200 mg/kg/day groups and the thymi of exposed dams were “weighed decreasingly” (quantitative data 
were not reported).  No histopathological alterations were observed in the spleen or thymus.  The study
abstract reports decreased cellularity of the spleen and thymus in dams; however, cellularity data for the 
dams are not reported in the results section of the paper.  No statistically significant increases in T- or
B-cell lymphocyte proliferation were observed, and no exposure-related changes in T-cell, B-cell, or
macrophage population distribution were observed in the spleen.  The study authors reported decreases in
serum IgM levels, but statistical significance was not reported.  No changes in serum IgG1 were 
observed.  The study authors also noted some immune effects in offspring, including decreased spleen 
weight and cellularity and altered serum immunoglobin levels on PND 21 in groups exposed to 
≥100 mg/kg/day and increased T-cell proliferation following in vitro exposure to concanavalin A (ConA)
at 200 mg/kg/day on PND 63; see Section 3.2.2.6 (Developmental Effects) for more details.  
DecaBDE:  One week following exposure to dietary decaBDE at 0 or 1,800 mg/kg/day for 28 days, mice
were intranasally infected with the RSV (Watanabe et al. 2010a).  No exposure-related differences in
pulmonary viral titers were observed 5 days post-infection (Watanabe et al. 2010a).  In contrast, 
pulmonary viral loads were increased post-infection in PND 28 offspring of mouse dams exposed to 
dietary decaBDE at doses ≥260 mg/kg/day from GD 10 to PND 21 (Watanabe et al. 2008, 2010b); see 
Section 3.2.2.6 (Developmental Effects) for more details. In another high-dose study, female mice 
exposed to decaBDE at 800 mg/kg every other day showed impaired CD4 T-cell function from 4 to 
10 months of exposure, compared with controls (Feng et al. 2016b).  Significant alterations in peripheral 
CD4 T-cells from exposed mice included significant decreases in in vitro cytokine production of TNF-α,
IFN-γ, and IL-2, decreased percentage of multi-functional CD4 T-cells (cells capable of producing
multiple cytokines following mitogen production), increased percentage of T regulatory cells
(CD4+CD25+Foxp3+), decreased percentage of proliferating CD4 T-cells, and decreased percentage of
antigen-specific CD4 T cells following in vivo Listeria monocytogenes infection.  
In rats exposed to decaBDE at 0 or 300 mg/kg/day via gavage for 21 days prior to mating through 
PND 21, the distribution of T-lymphocytes in the thymus was significantly altered in exposed rat dams, 
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with significantly decreased CD3+, CD4+, CD4+/CD8+, CC3+/CD8+, and CD3+/CD4+ T-cells and
significantly increased CD4-/CD8- T-cells compared with control dams (Liu et al. 2012).  CD161+ NKCs 
were also significantly decreased, compared with controls.  Additionally, the lymphocyte stimulation 
index in response to in vitro PHA exposure was significantly reduced by ~2-fold in lymphocytes
harvested from exposed rat dams, compared with control dams (Liu et al. 2012).  In another study, no 
dose-related changes were reported for T-cell, B-cell, or macrophage population distribution in the spleen 
of rats exposed to decaBDE at doses up to 60 mg/kg/day via gavage for 28 days (Van der ven et al. 
2008a).  
Following exposure to decaBDE at 300 mg/kg/day via gavage for 21 days prior to mating through 
PND 21, serum IgM and IgG were significantly decreased by 28 and 4%, respectively, compared with 
controls (Liu et al. 2012).  No exposure-related changes were observed in IFN- γ or IL-4 (Liu et al. 2012).  
Histopathological examinations of spleen, thymus, lymph node, and/or bone marrow tissues showed no 
effects in rats or mice exposed to dietary decaBDE at doses up 8,000 or 9,500 mg/kg/day, respectively, 
for 13 weeks (NTP 1986). In rat dams exposed to decaBDE at 0 or 300 mg/kg/day via gavage for 21 days
prior to mating through PND 21 (~11 weeks), the exposed group showed significantly increased 
“histological scores” in the spleen and thymus compared with controls (methods of histological scoring
and incidences of lesions were not reported) (Liu et al. 2012).  Lesions observed in the thymus of exposed 
rats included thickened thymus capsule, decreased lymphoid tissue in the cortex with adipose tissue 
replacement, increased medulla size, and obscured corticomedullary junction.  The spleen showed 
decreased size and number of lymphoid nodules, thinner lymphatic sheath around arteries, and fibrotic
tissue with macrophages in the medulla.
In a 28-day study, rats were exposed to decaBDE at 0, 1.87, 3.45, 7.5, 15, 30, or 60 mg/kg/day via gavage
(Van der ven et al. 2008a).  The study authors reported a dose-related decreased in thymus weight in
female rats (maximal decrease of 16.6%); however, the lowest dose at which the effect was observed was
not reported.  Instead, results were reported in terms of BMD analysis (BMD/BMDLRD20%=
75/43 mg/kg/day).  No dose-related changes were reported for male thymus weight or male or female 
spleen weight (Van der ven et al. 2008a).  Absolute and relative spleen weights were significantly
decreased by 12 and 27%, respectively, in rat dams exposed to decaBDE at 300 mg/kg/day via gavage for
21 days prior to mating through PND 21 (~11 weeks); no exposure-related changes were observed in
thymus weight (Liu et al. 2012).  In other studies, no exposure-related changes in spleen weight were 
observed in rats exposed to decaBDE at doses up to 20 mg/kg/day via gavage for 8 weeks (Zhang et al.
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2013a) or in mouse dams or PND 71 male offspring exposed to decaBDE at doses up to 1,500 mg/kg/day
from GD 0 to 17 via gavage (Tseng et al. 2008).
In a poorly-reported study, immune end points were evaluated in mouse dams and offspring following
exposure to decaBDE at 0, 500, 2,500, or 12,500 mg/kg/day via gavage on GD 6 to PND 21 (Hong et al. 
2010).  No exposure-related changes were reported for maternal spleen or thymus weight or histology.
T-cell lymphocyte proliferation (in response to ConA) was “slightly” increased.  No statistically
significant increases in B-cell lymphocyte proliferation were observed and no exposure-related changes in
T-cell, B-cell, or macrophage population distribution were observed in the spleen.  The study authors
reported increased serum IgG1 and IgM levels; however, statistics were not reported and changes do not
appear dose-related in graphically-presented data.  In offspring, altered spleen cell populations were noted 
on PND 21; see Section 3.2.2.6 (Developmental Effects) for more details.  
Chronic-Duration Animal Studies
Lower-brominated PBDEs:  No chronic-duration studies analyzing immune effects were located for
lower-brominated PBDEs.
DecaBDE:  Following chronic ingestion of decaBDE for 103 weeks, an increased incidence of splenic
hematopoiesis was observed in female rats at ≥1,200 mg/kg/day (12/49, 24/48, and 17/50 at 0, 1,200, and 
2,550 mg/kg/day, respectively); only the incidence in the mid-dose group was statistically significant.  In
male rats, the incidence of splenic fibrosis was significantly increased at 2,240 mg/kg/day (5/49, 8/50, and 
13/49 at 0, 1,120, and 2,240 mg/kg/day, respectively) (NTP 1983).  The incidence of lymphoid 
hyperplasia in the mandibular lymph node was also significantly increased in male rats at
2,240 mg/kg/day (4/50, 6/50, and 13/49 at 0, 1,120, and 2,240 mg/kg/day, respectively) (NTP 1983).  No 
exposure-related histopathological lesions were observed in male or female mice following chronic 
ingestion of decaBDE for 103 weeks at doses up to 6,650 and 7,780 mg/kg/day, respectively (NTP 1983).
Summary.  Evidence from animals suggest that PBDE exposure may cause immune suppression,
particularly in infants or children (see Section 3.2.2.6, Developmental Effects for more details), but data
are limited and inconsistent.  Additionally, comprehensive immunological evaluations have not been 
performed and human data are limited. Therefore, currently available information is insufficient to
adequately characterize the human immunotoxic potential of PBDEs. The highest NOAEL values and all
   
 













      
       
    
    
  
   
   
  
     
       
         
  
   
    





   
   
 
  







LOAEL values from each reliable study for immunological effects in each species and duration category
are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.4  Neurological Effects 
Human Studies.  No association was found between serum PBDE concentrations (BDE 28, BDE 47, 
BDE 66, BDE 85, BDE 99, BDE 100, BDE 138, BDE 153, BDE 154, and their sum) and 
neuropsychological function assessed by 34 tests of cognitive and motor function, affective state, and 
olfactory function in a study population of 144 volunteers (67 males and 77 females) between the ages of
55 and 74 who lived for at least 25 years in the upper Hudson valley of New York State (Fitzgerald et al. 
2012).  Median total serum PBDE concentration in the study population was 23.9 ppb (lipid weight), with 
the detection limit exceeded in 89% of the population.  Neurobehavioral function in adolescents was
studied by Kicinski et al. (2012).  The study population included 515 secondary school students
(271 boys) from Flanders, Belgium, with a mean age of 14.9 years. The students were given a 
computerized battery of neurological tests.  PBDE concentrations (BDE 28, BDE 47, BDE 99, BDE 100, 
BDE 153, BDE 154, BDE 183, and BDE 209) were measured in the serum.  The median concentration of
total PBDE in the serum was 7 ng/L.  Serum PBDE concentrations were not associated with most aspects 
of neurological performance investigated, but there was a significant deterioration in performance in the
finger tapping test with increasing PBDE level, suggesting an effect of PBDE on motor activity.  Studies
of neurological function in relation to PBDE concentrations in young children are discussed in Section
3.2.2.6 on Developmental Effects.
Acute-Duration Animal Studies
Lower-brominated PBDEs:  In a neurotoxicity screen, adult male rats were exposed once to pentaBDE at
0, 0.6, or 1.2 mg/kg via gavage (Belles et al. 2010).  Rats were assessed using a functional observation 
battery 3, 21, and 44 days after pentaBDE administration.  After 45 days, rats were assessed in a variety
of behavioral tests over 9 days, including open-field activity, passive avoidance test, and the Morris water
maze.  Following completion of behavioral tests, rats were sacrificed and brains were removed for
biochemical analysis of oxidative stress markers (right hemisphere) and histopathological (left 
hemisphere) examinations of the cortex, hippocampus, and cerebellum.  No exposure-related
neurobehavioral, histological, or biochemical effects were observed.
   
 












     
 
   
   
  
     
   
   
 
  




    
 
      
  
    
    
   
   
  
      





In developing animals, a series of studies evaluated neurobehavior at 2–8 months of age following single-
day exposure to lower-brominated PBDEs on PND 3, 10, or 19 in rats and mice.  Collectively, these
studies showed altered open-field activity, impaired habituation and altered learning and memory in rats
and mice exposed to penta-, hexa-, tetra-, or octaBDE at doses as low as 0.4, 0.45, 1, or 16.8 mg/kg, 
respectively (Eriksson et al. 2001, 2002b, 2006; Fischer et al. 2008; Hallgren et al. 2015; He et al. 2009, 
2011; Gee and Moser 2008; Sand et al. 2004; Viberg et al. 2002, 2003a, 2004a, 2004b, 2005, 2006).  No 
changes in open-field behavior were observed in mice exposed to heptaBDE at 15.2 mg/kg or nonaBDE
at 18.5 on PND 10 (Viberg et al. 2006).  Besides behavioral changes, other significant neuro­
developmental effects observed in these studies included ultrastructural changes, altered nicotinic receptor
density, and altered gene and protein expression levels in the hippocampus.  Altered open-field behavior
was also observed in PND 36 offspring following acute gestational exposure to pentaBDE at doses as low
as 0.06 mg/kg via gavage on GD 6 (Kuriyama et al. 2004).  See Section 3.2.2.6 (Developmental Effects)
for more details regarding neurodevelopmental effects of acute exposure to lower-brominated PBDEs. 
DecaBDE:  No studies evaluating neurobehavior or neuropathology in adult rats or mice following acute
exposure to decaBDE were identified; however, there were no overt signs of neurotoxicity in rats and
mice exposed to decaBDE in estimated dietary doses of ≤16,000 and ≤19,000 mg/kg/day, respectively, 
for 14 days (NTP 1986).  
In developing animals, a series of studies reported decreased spontaneous activity and impaired
habituation in open-field testing in 2–6-month-old mice that were exposed to decaBDE on PND 3 at
doses as low as 2.22 mg/kg (Buratovic et al. 2014; Johansson et al. 2008; Viberg et al. 2003b, 2007).  
These changes in open-field behaviors were not observed in animals exposed on PND 10 or 19.  In 
contrast, significantly increased locomotor activity during the first 1.5 hours of a 2-hour observation 
period was observed in PND 70 males following exposure to decaBDE at 20 mg/kg/day via micropipette
from PND 2 to 15 (Rice et al. 2007).  No changes in locomotor activity were observed at PND 70 in 
females or at 1 year in either sex at doses up to 20 mg/kg/day (Rice et al. 2007).  In operant training and 
visual discrimination tasks, learning impairments and impulsivity were observed in aging mice
(16 months old), but not young adult mice (3 months old), that had been exposed to decaBDE at
20 mg/kg/day from PND 2 to 15 (Rice et al. 2009).  See Section 3.2.2.6 (Developmental Effects) for more
details regarding neurodevelopmental effects of acute exposure to decaBDE.
   
 












   
  
      
  
     
  
  
   
   












      
  
     
  
  
   
  





Lower-brominated PBDEs:  No exposure-related changes were observed in open-field behavior, anxiety-
like behavior in the elevated plus-maze performance, or learning and memory in the Morris water maze in
male rats following exposure to pentaBDE at doses up to 0.015 mg/kg/day (highest dose tested) via
gavage for 90 days (Daubie et al. 2011).  In a higher dose study, impaired attention and inhibitory control
was observed in a series of 5-choice serial reaction time tasks assessed from PND 40 to 125 in male mice 
exposed to dietary pentaBDE at 26.2 mg/kg/day from PND 1 to 125; no exposure-related changes were 
observed at 17.5 mg/kg/day (Driscoll et al. 2009).  In adult male rats exposed to tetraBDE at 0, 0.1, 0.5, or
1 mg/kg/day via gavage for 30 days, rats in all exposure groups showed impaired learning and memory in 
the Morris water maze (Yan et al. 2012).  Exposed rats required significantly more time to find the hidden 
platform in the Morris water maze compared with control group, without showing any differences in
swim speed.  Additionally, significant decreases in the time spent in the target quadrant and the number of
crossings over the original platform location were observed during the retention trial on day 5 (Yan et al. 
2012).
No exposure-related changes in brain weight and/or histology were observed in rats exposed to pentaBDE
at gavage doses up to 250 mg/kg/day for 28 days (Oberg et al. 2010; Van der ven et al. 2008b), in rats
exposed to pentaBDE at gavage doses up to 0.015 mg/kg/day for 90 days (Daubie et al. 2011), in rats
exposed to penta- or octaBDE at dietary doses up to 750 mg/kg/day for 28 or 90 days (IRDC 1976, 1977;
WIL Research Laboratories 1984), in rat dams or pups exposed to pentaBDE at a gavage dose of
18 mg/kg/day from GD 6 to PND 18 (Ellis-Hutchings et al. 2006), or in mink sows or kits exposed to 
pentaBDE at dietary doses up to 0.31 mg/kg/day for 4 weeks prior to mating through PNW 6 or 33 
(Zhang et al. 2009).
The density of NMDA receptor subunits, NR1 and NR2B, and the glutamate receptor, Glu, was
determined in the CA1, CA3, and dentate gyrus of the hippocampus in adult male rats exposed to 
tetraBDE at 0, 0.1, 0.5, or 1 mg/kg/day via gavage for 30 days (Yan et al. 2012). Immunohistochemical
staining showed significant decreases in the density of NR1 and Glu in the hippocampus of all exposed 
rats and NR2B in the hippocampus of rats exposed to 0.5 and 1 mg/kg/day.  Additionally, significant
decreases in hippocampal mRNA levels were observed for NR1 and NR2C in all dose groups and NR2D 
in the 0.5 and 1 mg/kg/day groups.  No exposure-related changes were observed in NR2A or NR2B 
mRNA levels (Yan et al. 2012).
   
 








   
  
     
   
    
   
  
   
 
  
   
       
        
   
 
   
   
 














Cholinergic effects were evaluated in mink sows and kits exposed to dietary pentaBDE at 0, 0.01, 0.05, or
0.25 mg/kg/day from pre-mating day 28 to PNW 6 (Bull et al. 2007).  No exposure-related effects were 
observed in acetylcholinesterase concentration (ACh), acetylcholinesterase activity (ChE), or muscarinic 
receptor (mAChR) or nicotinic receptor (nAChR) binding in the cerebral cortices of sows or kits.  Plasma 
ChE activity in sows from the 0.25 mg/kg/day group was significantly increased by 3-fold, compared 
with controls.  Plasma ChE activity was not significantly correlated with cortical ChE activity; however, 
it was significantly correlated with absolute and relative liver weights. Therefore, altered ChE activity in
plasma in the high-dose sows may reflect exposure-related effects in the liver, rather than the central
nervous system.  No changes were observed in plasma ChE activity in kits (Bull et al. 2007).
Several studies have reported delayed ontogeny of reflexes, neurobehavioral impairments, and 
ultrastructural and biochemical changes in the hippocampus of offspring after gestational and lactational
exposure to penta- or tetraBDE in rats and mice at doses as low as 2 and 0.03 mg/kg/day, respectively
(Blanco et al. 2013; Bowers et al. 2015; Branchi et al. 2001, 2002, 2005; Cheng et al. 2009; Koenig et al. 
2012; Ta et al. 2011; Woods et al. 2012). See Section 3.2.2.6 (Developmental Effects) for more details
regarding neurodevelopmental effects of intermediate-duration exposure to lower-brominated PBDEs.
DecaBDE:  Following a 15-day exposure to decaBDE at 20 mg/kg/day via gavage, male mice showed
decreased anxiety behavior in the elevated zero maze, including decreased latency to first entry into the 
open region, increased time spent and number of entries into the open region, and increased number of
head dips, compared with controls (Heredia et al. 2012).  No exposure-related changes were observed in
anxiety behaviors in the light/dark test, in learning or memory in the Morris water maze, or in general
neurological behaviors assessed using a functional observation battery (Heredia et al. 2012).  In another
study, no changes were observed in open-field behavior of male rats exposed to decaBDE at doses up to 
50 mg/kg/day via gavage for 90 days (Wang et al. 2011b).  No overt signs of neurotoxicity were observed 
in rats and mice exposed to decaBDE in estimated dietary doses of ≤8,000 and ≤9,500 mg/kg/day, 
respectively, for 13 weeks (NTP 1986).  
Rats exposed to decaBDE at dietary doses up to 90 mg/kg/day for 28 days showed no change in brain 
weight (IRDC 1976).  No exposure-related changes in brain weight or AchE activity were observed in
mice exposed to decaBDE at doses up to 160 mg/kg/day via gavage for 15, 30, or 60 days (Liang et al. 
2010).
   
 










    
    
 
    
 









   
 
   
     
 
 
   
   
  
     
   
   
 
   
 




There is limited evidence for neurodevelopmental effects following gestational and lactational exposure 
to decaBDE.  No neurobehavioral changes were observed in rat offspring exposed to decaBDE at doses
up to 1,000 mg/kg/day from GD 6 to PND 21 (Biesemeier et al. 2011).  However, impaired spatial
learning was observed in offspring of rat dams exposed to decaBDE at doses ≥30 mg/kg/day from GD 1
to 14 (Chen et al. 2014).  Additionally, altered hippocampal electrophysiology was observed in mice 
offspring exposed to 20.1 mg/kg/day from GD 1 to PND 41 (Xing et al. 2009) and altered hippocampal
immunohistochemistry was observed in mice offspring exposed to ≥15 mg/kg/day from GD 10 to
PND 21 (Fujimoto et al. 2011).  See Section 3.2.2.6 (Developmental Effects) for more details regarding
neurodevelopmental effects of intermediate-duration exposure to decaBDE.
Chronic-Duration Animal Studies
Lower-brominated PBDEs:  No chronic-duration studies analyzing neurological effects were located for
lower-brominated PBDEs.
DecaBDE:  There were no indications of neurotoxicity in rats and mice in lifetime feeding studies of
decaBDE at doses as high as 2,550 and 7,780 mg/kg/day, respectively, as assessed by overt clinical signs 
and nervous system histopathology (NTP 1986).  Although the high doses and extended exposure
durations in the NTP (1986) studies provided opportunities for the induction and/or development of
effects, neurotoxicity is incompletely evaluated due to the lack of testing for subtle behavioral and other
sensitive neurological end points. 
Summary.  While the nervous system is a target of concern during early development (see 
Section 3.2.2.6, Development Effects for more details), it is unclear if the developed nervous system is a 
target of oral PBDE toxicity.  Animal data suggest the oral PBDE exposure may lead to neurobehavioral
changes; however, available information is insufficient to adequately characterize the neurotoxic potential
of PBDEs in adults and adolescents. The highest NOAEL values and all LOAEL values from each
reliable study for neurological effects in each species and duration category are recorded in Table 3-2 and 
plotted in Figure 3-2.
3.2.2.5  Reproductive Effects
Human Studies. Two studies have demonstrated reproductive effects in men associated with exposure to
PBDEs.  In a small study limited to 10 young adult Japanese males, strong, statistically significant inverse
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correlations were found between serum levels of BDE 153 and sperm concentration and testis size
(Akutsu et al. 2008).  Both blood and sperm were collected monthly and pooled for each participant over
1 year.  BDE 153 concentrations for the 10 participants ranged from 0.37 to 1.1 ng/g lipid.  There was no 
relationship to sperm concentration or testes size for other PBDE congeners or for the sum of the most
prevalent congeners, which included BDE 153 (BDE 47, BDE 99, BDE 100, and BDE 153) and ranged 
from 1.1 to 8.6 ng/g lipid for the 10 participants.  Among a group of 52 Canadian men recruited at a
fertility clinic, sperm mobility was significantly reduced in association with increased serum PBDE
concentrations (BDE 47, BDE 100, and total) (Abdelouahab et al. 2011).  Results for BDE 153 were
similar, but not statistically significant.  Relationships between PBDE and sperm concentration were 
consistently negative as well, but also not significant.  The median ∑PBDE concentration in this
population was 0.302 ng/mL and the maximum was 2.250 ng/mL. A study of 468 male partners of
couples discontinuing contraception for purposes of becoming pregnant from Michigan and Texas found
that, in general, serum concentrations PBDEs were negatively associated with parameters of semen
quality, specifically increased percentages of abnormal morphology (Mumford et al. 2015).  The study
evaluated 10 BDEs: BDE 17, BDE 28, BDE 47, BDE 66, BDE 85, BDE 99, BDE 100, BDE 153, 
BDE 154, and BDE 183.  BDE 153, however, was associated with increased sperm concentration.  The
95th percentile serum concentrations (unadjusted for lipid content) for the BDEs analyzed ranged from
0.007 ng/g serum for BDE 183 to 0.761 ng/g serum for BDE 47. Significant associations at the α=0.01 
level were found only for BDE 17 (increased sperm with coiled tail) and for BDE 28 (increased
bicephalic sperm). A cross-sectional study that included 99 men from Greenland, 100 from Poland, and 
100 from Ukraine found no association between serum levels of BDE 47 and BDE 153 with parameters
of semen quality including markers of DNA damage and apoptosis (Toft et al. 2014).  Among the three
groups, median concentrations of BDE 47 ranged from 0.2 to 2.0 ng/g lipid and median concentrations of
BDE 153 ranged from 0.3 to 2.7 ng/g lipid. 
Studies of hormone levels in men in relation to PBDE concentrations have not produced consistent
results. Concentrations of PBDE (BDE 47, BDE 99, and BDE 100) in house dust samples were
significantly associated with changes in some sex hormone levels (decreased FSH, LH, and free androgen
index, and increased Inhibin B and sex hormone binding globulin [SHBG]), although not testosterone or
estradiol, in 24 adult men recruited through a Massachusetts infertility clinic (Meeker et al. 2009).
Median and maximum concentrations of PBDE in dust collected from houses of study subjects were 
500 and 7,620 ng/g dust for BDE 47, 838 and 9,220 ng/g dust for BDE 99, and 180 and 2,830 ng/g dust
for BDE 100.  A larger subsequent study by the same researchers with 38 additional subjects using the 
same design found a significant negative correlation with FSH and significant positive correlations with
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estradiol and SHBG for pentaBDE (sum of BDE 47, BDE 99, and BDE 100; median and maximum
concentrations of 1,049 and 22,300 ng/g in dust), significant positive correlations with testosterone and
LH for octaBDE (sum of BDE 183 and BDE 201; median and maximum concentrations of 30.5 and 
1,181 ng/g in dust), and a significant negative correlation with testosterone for decaBDE (sum of BDE
206, BDE 207, BDE 208, and BDE 209; median and maximum concentrations of 1,800 and 38,483 ng/g
in dust) (Johnson et al. 2013).  No relationships were found between serum concentrations of BDE 47 and 
testosterone, FSH, LH, or prolactin in adult male Baltic Sea area residents of Sweden and Latvia with a 
wide range of fish consumption behavior and BDE 47 concentrations ranging from 0.10 ng/g lipid at the
10th percentile to 5.16 ng/g lipid at the 90th percentile (median=1.04 ng/g lipid) (Hagmar et al. 2001).  In a
study of serum PBDE and hormone levels in adult male sport fish consumers from the Great Lakes, a 
significant positive relationship was found for BDE 47 (but not other congeners) and serum testosterone 
levels (Turyk et al. 2008).  BDE 47 concentrations in this population ranged from 0.01 to 5.90 ng/g
(median=0.11 ng/g), while ∑PBDE concentrations ranged from 0.13 to 10.15 ng/g (median=0.26 ng/g).
Serum concentrations of FSH, LH, or estradiol were not associated with serum levels of BDE 47 or
BDE 153 in a study of 299 spouses of pregnant women from Greenland, Poland, and Ukraine (Toft et al. 
2014).  Median concentrations of BDE 47 ranged from 0.2 to 2.0 ng/g lipid and median concentrations of
BDE 153 ranged from 0.3 to 2.7 ng/g lipid.  
In women, Chao et al. (2007) found no significant relationship between concentrations of PBDE in breast
milk and pre-pregnancy menstrual cycle length (by questionnaire) in an analysis of 20 pregnant women 
from Taiwan with median PBDE concentrations in breast milk of 3.65 ng/g lipid, predominantly BDE 47 
and BDE 153.  However, in a larger study of 46 pregnant Taiwanese women recruited several years later,
Chao et al. (2010) found significant increases in average length of pre-pregnancy menstrual cycle with
increased breast milk concentrations of PBDE (total and multiple individual congeners).  Median breast
milk total PBDE concentration in this study group was 2.84 ng/g lipid, with predominant congeners being
BDE 47, BDE 153, and BDE 209.  A study of 42 Cree women of James Bay, Canada, reported that
concentrations of BDE 47 and BDE 153 in plasma were associated with increased menstrual cycle length
(Wainman et al. 2016).  Geometric mean plasma concentrations of BDE 47 and BDE 153 were 14.1 and 
4.5 ng/g lipid, respectively, which according to the investigators, were comparable to those reported for
women 20–39 years old from the general Canadian population; serum cadmium and selenium were also
associated with increased cycle length.  In the study by Chao et al. (2010), age at menarche was not
related to breast milk PBDE concentrations, but an analysis of data from a sample of 271 adolescent U.S.
girls age 12–19 years with serum total PBDE concentrations ranging from 6.4 to 636.5 ng/g lipid 
(median=44.7 ng/g lipid) from NHANES (2003–2004) found that higher serum PBDE concentrations
   
 









    
     
  
  
      
  
      
   
    
   
 
    
   
      
  
    
    
     
   
  
  
      
  
 
   
   
    
    
    
   




were associated with younger age of menarche in this population (Chen et al. 2011).  There was no 
relationship between mid-pregnancy serum PBDE concentrations and pre-pregnancy menstrual cycling in
a cohort of 223 pregnant low-income women from the Salinas Valley of California (part of the
CHAMACOS study) (Harley et al. 2010), but there were significant decreases in fecundability
(i.e., increases in time to pregnancy between stopping contraception and becoming pregnant) associated 
with increased serum concentrations of BDE 47 (geometric mean=14.9 ng/g lipid), BDE 99 (geometic
mean=4.4 ng/g lipid), BDE 100 (geometic mean=2.8 ng/g lipid), BDE 153 (geometic mean=2.5 ng/g
lipid), and their sum in this population and/or a subset comprising 107 women actively trying to become
pregnant.  However, fecundability was not significantly related to serum PBDE concentrations
(concentrations not reported) in a cohort of 501 Michigan and Texas couples followed prospectively for
1 year after discontinuing contraception for the purpose of becoming pregnant (Buck Louis et al. 2013).  
Blood was collected from both male and female partners in this study and fecundity of the couple was
assessed in relation to each partner’s exposure.  A study of 65 women undergoing in vitro fertilization
found no association between serum PBDE concentrations (median=12.6 ng/g lipid, maximum=113 ng/g
lipid) and risk of implantation failure, but did find a significantly increased risk of failure associated with
increased (i.e., detectable) concentrations of BDE 153 (but not other congeners or total PBDE) in 
follicular fluid (Johnson et al. 2012).  No significant relationship was found between concentrations of the
PBDE metabolite 6-OH-BDE-47, which ranged from <4 to 127 pg/g wet weight, with a median of
26 pg/g wet weight) and 17β-estradiol in umbilical cord serum collected from 26 births in South Korea
(Wan et al. 2010).  Serum PBDE concentrations had no effect on expression of genes for the sex steroid 
enzymes aromatase (CYP19A1) and 17-α-hydroxylase or estrogen receptors α and β (ESR1 and ESR2) in 
leukocytes collected from 139 adult daughters of Michigan fisheaters with serum total PBDE
concentrations ranging from 4.3 ng/g lipid at the 5th percentile to 209.5 ng/g lipid at the 95th percentile 
(median=33.8 ng/g lipid) (Karmaus et al. 2011).
Vagi et al. (2014 examined the association between blood levels of multiple environmental pollutants and 
Polycystic Ovary Syndrome (PCOS). Fifty-two PCOs patients and 50 controls were included in the
study.  PCOS is an endocrine- metabolic disorder characterized by ovulatory dysfunction, hirsutism, or
elevated levels of androgens in blood.  Eleven PBDEs were analyzed in blood, but only six had detectable
serum concentrations (however, only five are listed in the report: BDE 28, BDE 47, BDE 99, BDE 100, 
and BDE 153).  Cases and controls had comparable serum concentrations of these BDEs, and in both 
groups, BDE 47 had the highest concentration (~25.5 ng/g lipid).  After controlling for age, BMI, and 
ethnicity, none of the measured BDEs was associated with increased risk of PCOS.
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Concentrations of PBDEs in omental fat or serum were not associated with risk of uterine fibroids in 
women undergoing laparoscopy or laparotomy in a study conducted in Salt Lake City, Utah, and San 
Francisco, California (Trabert et al. 2015).  Ninety-nine women had fibroids and 374 had none.  Seven 
PBDEs were measured: BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, BDE 183, and BDE 209.  
Whether in omental fat or serum, geometric mean concentrations of PBDEs were comparable between
women who had fibroids and those who did not.  Odds of a fibroid diagnosis (and corresponding 95%
CIs) showed no association with PBDEs.
Acute-Duration Animal Studies
Lower-brominated PBDEs:  There are limited data regarding the reproductive effects of acute exposure to
lower-brominated PBDEs in females.  In rat dams exposed once to tetraBDE at 0, 0.14, or 0.7 mg/kg on 
GD 6 via gavage, a significant 17% increase in paired ovary weight was observed at 0.14 mg/kg, but not
0.7 mg/kg (Talsness et al. 2008).  No treatment-related changes in gravid uterine weight or number of
implantation or resorptions were observed in rat dams exposed to pentaBDE at doses up to 2 mg/kg/day
from GD 6 to 19 (Blanco et al. 2012).  In ovariectomized female mice, no exposure-related changes were 
observed in uterine wet weight, uterine epithelial height, or vaginal epithelium thickness following
exposure to pentaBDE at doses up to 300 mg/kg/day for 3 days via gavage, with or without co-exposure
to β-estradiol-3-benzoate (Mercado-Feliciano and Bigsby 2008a). 
The effects of acute pentaBDE exposure on androgen-dependent tissue weights was assessed in castrated
male rats supplemented with subcutaneous injections of testosterone (to ensure equal levels of circulating
testosterone in the exposed and control groups) in a Herschberger assay (Stoker et al. 2005).  Male rats
that were castrated on PND 42 were exposed to pentaBDE at 0, 30, 60, 120, or 240 mg/kg/day from
PND 53 to 61 via gavage, and daily gavage exposures were followed by daily subcutaneous injections of
0.4 mg/kg testosterone.  On PND 62, significant decreases in androgen-dependent tissue weights included
a ~20–55% decrease in ventral prostate weight at ≥30 mg/kg/day, a ~20–60% decrease in seminal vesicle 
weight at ≥60 mg/kg/day, a ~28–41% decrease in Cowper’s gland weight at ≥120 mg/kg/day, and a 22– 
29% decrease in the gland penis and levator ani bulbo cavernosus weight at 240 mg/kg/day (Stoker et al. 
2005). 
There is limited evidence for exposure-related effects on serum reproductive hormones levels in male rats 
following acute exposure to pentaBDE.  Serum testosterone levels were significantly decreased by ~40– 
45% in male rats 45 days after a single gavage exposure to pentaBDE at doses ≥0.6 mg/kg; serum
   
 









   
    
   





   
  
     
    
      
   
   
 
   
   
      
 
     
  
 
     
 
 
   





progesterone was significantly decreased by ~40% at 1.2 mg/kg (data presented graphically) (Alonso et
al. 2010).  Significantly increased serum levels of LH were reported in male rats (~65%, data reported 
graphically) following exposure to pentaBDE at 60 mg/kg/day for 3 days (Stoker et al. 2005).  No 
exposure-related changes were observed in serum testosterone, androsteridione, or estrone levels at doses 
up to 60 mg/kg/day (Stoker et al. 2005).  Following a single gavage administration of pentaBDE at 0, 
0.06, or 0.3 mg/kg on GD 6, no exposure-related changes in serum testosterone or LH levels were 
observed in F1 male rats on PND 140 (Kuriyama et al. 2005).  
As discussed in Section 3.2.2.6 (Developmental Effects), F1 reproductive success was assessed following
a single gavage administration of pentaBDE at 0, 0.06 or 0.3 mg/kg or tetraBDE at 0, 0.14, or 0.7 mg/kg
on GD 6 in rat dams (Kuriyama et al. 2005; Talsness et al. 2005, 2008).  Following pentaBDE exposure, 
no significant exposure-related effects were observed in F1 male fertility when exposed males were mated
with unexposed females, and the only mating behavior significantly altered was a 32% decrease in the
percent of males with two or more ejaculations in F1 males from the 0.3 mg/kg group (Kuriyama et al. 
2005).  Similarly, no changes in female pregnancy rate was observed in F1 females mated to unexposed 
males following exposure to pentaBDE or tetraBDE (Talsness et al. 2005, 2008).  F1 male reproductive
performance was not assessed following tetraBDE exposure.  Despite a lack of exposure-related
impairment in reproductive success following acute developmental exposure to penta- or tetraBDE, 
reductions in testicular weight, sperm/spermatid number, and daily sperm production were observed in F1
males exposed to pentaBDE at ≥0.06 mg/kg/day, and a decreased number of secondary follicles and
ultrastructural changes in the ovaries were observed in F1 females exposed to pentaBDE at
≥0.06 mg/kg/day or tetraBDE at ≥0.14 mg/kg/day (Kuriyama et al. 2005; Talsness et al. 2005, 2008). 
In a one-generation study in mink, females exposed to pentaBDE at doses ≥0.25 mg/kg/day from pre­
mating day 28 through PNW 6 did not whelp (Bull et al. 2007; Zhang et al. 2009).  It is not clear in the
Bull et al. (2007) study whether mink exposed to 0.25 mg/kg/day never became pregnant or had complete
litter loss.  However, Zhang et al. (2009) reported that females exposed to 0.31 mg/kg/day had no 
exposure-related changes in mating success; rather, sows showed complete litter loss with 70% showing
clear postimplantation loss.
DecaBDE:  In mouse dams exposed to decaBDE at 0, 150, 750, 1,500, or 2,000 mg/kg/day via gavage
from GD 7 to 9, the percentage of postimplantation loss per litter was significantly increased by 3, 2.7, 
and 9.8% at 750, 1,500, and 2,000 mg/kg/day, respectively, compared with control (Chi et al. 2011).  At
1,500 and 2,000 mg/kg/day, the percentage of resorptions per litter was also significantly increased by
   
 








    
    
    








    
    
 
   
    
   
   
      
   
  
      
 
 
   
    
    
 
  
   




2.7 and 8.6%, respectively.  Additionally, the percentage of live fetuses per litter was significantly
decreased by 10% in the high-dose group (Chi et al. 2011).  These effects could reflect reproductive
toxicity in the dams or developmental toxicity in the fetuses (see Section 3.2.2.6, Developmental Effects).
No other acute-duration studies analyzing reproductive effects were located for decaBDE.
Intermediate-Duration Animal Studies
Lower-brominated PBDEs:  No exposure-related changes were observed in reproductive end points
(number of pregnancies, gestation length, number, size, or sex ratio of litters) in rats exposed to 
pentaBDE at doses up to 25 mg/kg/day for 70 days prior to mating until PND 42 via gavage (Bondy et al. 
2013), in rats fed vanilla wafers containing pentaBDE at doses up to 11.4 mg/kg/day from pre-mating
day 28 through PND 21 (Poon et al. 2011), in mice exposed to tetraBDE at doses up to 0.1 mg/kg/day via
gavage from pre-mating day 28 through PND 21 (Woods et al. 2012), or in mice fed cornflakes
containing tetraBDE at doses up to 1 mg/kg/day from pre-mating day 28 through PND 21 (Koenig et al. 
2012; Ta et al. 2011).  Similarly, no exposure-related effects on litter parameters (successful delivery of
litters, gestation length, litter size, sex ratio, number of live pups) were observed in rats or mice exposed 
to pentaBDE at doses up to 2 or 10 mg/kg/day, respectively, from GD 1 or 6 to PND 21 via gavage
(Branchi et al. 2005; Cheng et al. 2009; Zhao et al. 2014), in rats exposed to pentaBDE at doses up to 
30 mg/kg/day from GD 1 to PND 21 via dosed cookies (Bowers et al. 2015), or rats exposed to dietary
tetraBDE at doses up to 32 mg/kg/day from GD 1 to PND 14 (Wang et al. 2011a). The number of litters
surviving until PND 8 was significantly decreased following exposure to tetraBDE at 0.1 mg/kg/day from
pre-mating day 28 through PND 21 in one study (Woods et al. 2012); however, reduced pup survival was
not reported in other studies (Bondy et al. 2013; Koenig et al. 2012; Poon et al. 2011; Ta et al. 2011;
Wang et al. 2011a).  
Male rats exposed to tetraBDE at 1 mg/kg/day via gavage for 8 weeks showed a significant 24% decrease 
in daily sperm production; no exposure-related effects were observed at doses ≤0.03 mg/kg/day (Zhang et
al. 2013b).  In another study, sperm morphology, motility, and capacitation were evaluated in mice
following gavage exposure to tetraBDE at 0, 0.0015, 0.045, 1.5, or 30 mg/kg/day for 30 days (Wang et al. 
2013).  No exposure-related changes in sperm morphology or sperm motility were observed.  A
significantly decreased rate of sperm capacitation (% B-type [mature] sperm) was observed in the 0.0015, 
0.045, and 30 mg/kg/day groups, but not in the 1.5 mg/kg/day group (Wang et al. 2013).  No exposure-
related changes in sperm counts, motility, or DNA damage were observed in rats exposed to a penta­
   
 








   
   
 
     
   
   
   
    
 
  
   
    
    
  
  
   
     
 
    
    
  
 
   
   
 
  
   
  
   




decaBDE mixture (52.1% pentaBDE, 44.2% decaBDE, 0.4% octaBDE) at dietary doses up to
20 mg/kg/day for 70 days (Ernest et al. 2012).
Microscopic changes in the testes of rats were observed following exposure to tetraBDE at
≥0.03 mg/kg/day via gavage for 8 weeks, including increased epithelial thickness, vacuolar spaces in the 
seminiferous epithelium, and increased number of multinucleated giant cells (arising from spermatocytes 
that aborted meiosis); no histopathological changes were observed at 0.001 mg/kg/day (Huang et al. 2015;
Zhang et al. 2013b).  Additionally, the number of apoptotic cells was significantly increased by 2- and 
3-fold in the testes of rats from the 0.03 and 1 mg/kg/day groups, respectively (Huang et al. 2015; Zhang
et al. 2013b).  In similarly-exposed rats, co-treatment with dexamethasone phosphate (DEX; a CYP3A1 
inducer) “aggravated” the observed histopathological effects (Zhang et al. 2013b).  Mice exposed to 
tetraBDE at 0, 0.0015, 0.045, 1.5, or 30 mg/kg/day via gavage for 30 days also showed testicular effects
at doses ≥0.045 mg/kg/day, including “some” seminiferous tubules with complete germ cell loss and a 
Sertoli cell-only phenotype (incidence not reported) and a dose-related increase in the number of
apoptotic cells (Wang et al. 2013).  No exposure-related changes were observed in testes weight at doses 
up to 30 mg/kg/day (Wang et al. 2013).  In other studies, exposure-related changes were not observed in
organ weight or histology in male or female reproductive tissues from mice exposed to tetraBDE at
dietary doses of 0.45 mg/kg/day for 28 days (Maranghi et al. 2013), rats exposed to penta- or octaBDE at
dietary doses up to 750 mg/kg/day for 28–90 days (IRDC 1976, 1977; WIL Research Laboratories), rats
exposed to a penta-decaBDE mixture (52.1% pentaBDE, 44.2% decaBDE, 0.4% octaBDE) at dietary
doses up to 20 mg/kg/day for 70 days (Ernest et al. 2012), rats exposed to pentaBDE at gavage doses up
to 250 mg/kg/day for 15–28 days (Becker et al. 2012; Oberg et al. 2010), or ovariectomized mice exposed 
to pentaBDE at 50 mg/kg/day for 34 days via gavage (with or without β-estradiol-3-benzoate co-
exposure) (Mercado-Feliciano and Bigsby 2008a).  Additionally, organ weight changes were not observed
in F0 or F1 rats exposed to pentaBDE at doses up to 25 mg/kg/day via gavage from pre-mating day 70 to
PND 42 (Bondy et al. 2013) or F0 or F1 mink exposed to dietary pentaBDE at doses up to 
0.31 mg/kg/day for 4 weeks prior to mating through PNW 6 or 33 (Zhang et al. 2009).
Following exposure to pentaBDE at 0, 3, 30, or 60 mg/kg/day for 15 days via gavage, serum prolactin 
was significantly decreased by 67% at 60 mg/kg/day in male rats (Becker et al. 2012). While testosterone 
and FSH levels were not significantly altered at any specific dose (based on pair-wise analysis), trend
tests showed significant dose-dependent increases in testosterone and FSH levels; LH and E2 were below
the detection limit in all groups (Becker et al. 2012).  In contrast, a repeat of the same study in a different
laboratory showed no exposure-related changes in serum testosterone, LH, FSH, E2, or prolactin in male
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rats exposed to pentaBDE at doses up to 60 mg/kg/day for 15 days (Becker et al. 2012).  Similarly, male
rats exposed to a penta-decaBDE mixture (52.1% pentaBDE, 44.2% decaBDE, 0.4% octaBDE) at dietary
doses up to 20 mg/kg/day for 70 days did not show altered serum testosterone levels (Ernest et al. 2012).
After exposure to tetraBDE for 8 weeks via gavage (6 days/week), male rats showed significant
reductions in serum testosterone of ~35, 54, and 63% at 0.001, 0.03, or 1 mg/kg/day, respectively (data 
reported graphically) (Zhang et al. 2013b).  No exposure-related changes were observed in serum E2,
FSH, or LH levels at doses up to 1 mg/kg/day (Zhang et al. 2013b).  In female mice exposed to dietary
tetraBDE for 28 days, serum testosterone and E2 were significantly increased by 57 and 18% at
0.45 mg/kg/day (only tested dose) (Maranghi et al. 2013).
Biochemical analysis of rat testes showed significant dose-related elevations of mRNA levels of several
apoptosis genes following exposure to tetraBDE at doses of 0.001–1 mg/kg/day via gavage for 8 weeks
(6 days/week) (Zhang et al. 2013b).  Additionally, elevated levels of ROS were observed at 1 mg/kg/day
(Zhang et al. 2013b).  Co-exposure to DEX (a CYP3A1 inducer) enhanced ROS-induction in the testes, 
with significant elevations observed at ≥0.001 mg/kg/day (Zhang et al. 2013b). No exposure-related
changes were observed in testicular mRNA expression levels for genes involved in steroidogenesis (Star,
Cyp17a1, Ar, Srd5a1, Srd 5a2, Cyp19a1, Esr1, Esr2) in rats following exposure to a penta-decaBDE
mixture (52.1% pentaBDE, 44.2% decaBDE, 0.4% octaBDE) at dietary doses up to 20 mg/kg/day for
70 days (Ernest et al. 2012).
Exposure to lower-brominated PBDEs has been reported to cause reproductive effects in developing rats.
Two companion studies evaluated reproductive system development following exposure to pentaBDE at
0, 3, 30, or 60 mg/kg/day via gavage during pubertal development (PNDs 23–53 in males or PNDs 22–41 
in females) (Stoker et al. 2004) or 0, 60 or 120 mg/kg/day via gavage during pubertal development in 
males (PNDs 23–53) (Stoker et al. 2005).  In males, preputial separation (PPS) was significantly delayed 
by 1.7–5 days at ≥30 mg/kg/day, absolute ventral and lateral prostate weights and seminal vesicle weights 
were significantly decreased 16–29% at ≥60 mg/kg/day (in the absence of body weight effects), and 
serum prolactin was increased 2-fold at 60 mg/kg/day (not evaluated in the 120 mg/kg/day group).  There
were no exposure-related changes in testicular weight or histology, epididymides histology, serum
testosterone or LH, or pituitary LH or prolactin levels at doses up to 60–120 mg/kg/day (Stoker et al. 
2004, 2005).  In females, vaginal opening was significantly delayed by 1.8 days in the 60 mg/kg/day
group.  No changes were observed in estrous cycling or ovarian or uterine weight or histology at doses up 
to 60 mg/kg/day (Stoker et al. 2004).  As summarized in Section 3.2.2.6 Developmental Effects, observed 
effects in F1 rats exposed to pentaBDE at 30.1 mg/kg/day from GD 6 to PND 21 included decreased 
   
 













   




   
   
   
  
   
     










      
   
  







anogenital distance, delayed PPS, and decreased serum testosterone in male offspring and decreased
mammary gland development in female offspring (Kodavanti et al. 2010).
DecaBDE:  Information on effects of intermediate-duration exposure to decaBDE on reproductive
function is limited to negative findings in a one-generation study in rats using a low-purity (77.4%)
decaBDE mixture (Dow Chemical Co. 1975; Norris et al. 1975a).  Male and female rats were exposed to
0, 3, 30, or 100 mg/kg/day doses in the diet for 60 days prior to mating through PND 21.  Parameters
monitored included length of time between first day of cohabitation and parturition, numbers of live and 
dead newborn, number of live pups (PNDs 1, 7, 14, and 21), litter weight (PNDs 1, 7, and 14), and 
weanling weight (PND 21).  Comprehensive histological examinations (adults and weanlings), skeletal
examinations (weanlings), and cytogenetic evaluation of bone marrow (adults and weanlings) were also 
performed on PND 21.  There were no exposure-related effects on reproductive parameters or any
indications of maternal or neonatal toxicity.  Additionally, no exposure-related changes were observed in
litter parameters in mice exposed to decaBDE at gavage doses up to 1,500 mg/kg/day from GD 0 to 17 
(Tseng et al. 2008), in rats exposed to decaBDE at gavage doses up to 1,000 mg/kg/day from GD 6 to
PND 21 (Biesemeier et al. 2011), or in rats or mice exposed to decaBDE at dietary doses up to 146 or
3,100 mg/kg/day, respectively, from GD 10 to PND 21 (Fujimoto et al. 2011; Watanabe et al. 2008, 
2010b).
Sperm parameters have been assessed in rats and mice following intermediate-duration exposure to 
decaBDE.  In the rat study, no exposure-related changes were observed in male epididymal sperm counts 
or morphology following exposure to decaBDE at gavage doses up to 60 mg/kg/day for 28 days (Van der
ven et al. 2008a).  In one mouse study, sperm count and viability were significantly reduced by about
40% in males exposed to 950 mg/kg/day via gavage for 35 days, compared with controls; no exposure-
related changes in sperm count and viability were observed at 750 mg/kg/day (Sarkar et al. 2015).  
In contrast, no exposure-related changes were observed in sperm count, sperm motility, or the percent of
abnormal sperm heads in mice exposed to decaBDE at doses up to 1,500 mg/kg/day via gavage for
50 days (Tseng et al. 2006).  For sperm velocity, the lateral head amplitude was significantly decreased in
the 500 and 1,500 mg/kg/day groups, compared with control; no exposure-related changes were observed
in curvilinear, average path, or straight line velocity or beat-cross frequency.  No exposure-related
changes were observed in sperm damage parameters; however, sperm H2O2 production was significantly
increased at 500 and 1,500 mg/kg/day (no change in O2- production).  The percentage of sperm with high 
mitochondrial membrane potential was significantly decreased in the 1,500 mg/kg/day group, compared 
with controls.  
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There is limited evidence of histopathological damage in reproductive organs following intermediate-
duration exposure to decaBDE.  Various degenerative changes were observed in the seminiferous tubules 
of mice exposed to decaBDE at gavage doses of 950 mg/kg/day for 35 days, including thinning of the
germinal epithelium, decreased diameter of the seminiferous tubules, depletion of germ cells, exfoliation
of germ cells, and intraepithelial vacuolation (Sarkar et al. 2015).  Both the height of the germinal 
epithelium and the diameter of seminiferous tubules were significantly decreased at 950 mg/kg/day, 
compared with controls.  No exposure-related testicular lesions were observed at 750 mg/kg/day. In
female rats exposed to decaBDE at 0 or 300 mg/kg/day from 3 weeks of age, through mating to untreated 
males, gestation, and lactation (~11 weeks), the ovaries in the exposed rats had significantly increased
“histological scores” than the ovaries from the control rats (methods of histological scoring and 
incidences of lesions were not reported) (Liu et al. 2012).  Observations in the ovaries of exposed rats
included atrophic changes, decreased number of follicles, and increased fibrotic tissue (Liu et al. 2012).  
F0 reproductive success and F1 developmental end points were not reported in this study.  However, in 
other intermediate-duration studies, no histopathological changes were observed following exposure to 
decaBDE in male or female reproductive tissues from rats exposed for 28–50 days at gavage doses up to
1,500 mg/kg/day (Tseng et al. 2006; Van der ven et al. 2008a), rats exposed for 28–30 days at dietary
doses up to 800 mg/kg/day (IRDC 1976; Norris et al. 1973, 1975a), or rats or mice exposed for 13 weeks
at dietary doses up to 8,000 or 9,500 mg/kg/day, respectively (NTP 1986).
In a 28-day study, rats were exposed to decaBDE at 0, 1.7, 3.75, 7.5, 15, 30, or 60 mg/kg/day via gavage
(Van der ven et al. 2008a).  The study authors reported a dose-related decrease in epididymis weight in
male rats (maximal decrease of 22.5%) and a dose-related increase in seminal vesicle/coagulation gland
weight (maximal increase of 38.3%); however, the lowest doses at which the effects were observed were 
not reported.  Instead, results were reported in terms of BMD analysis (BMDRD10% for epididymis=
4.0 mg/kg/day, BMDLRD10% was not determined; BMD/BMDLRD10% for seminal vesicle=
1.5/0.2 mg/kg/day).  No exposure-related changes in organ weight were reported for testes, ovaries, or
uterus at doses up to 60 mg/kg/day (Van der ven et al. 2008a).  In other rat studies, no exposure-related
changes in testes, epididymides, or seminal vesicle weights were observed following exposure to dietary
decaBDE doses up to 800 mg/kg/day for 28–30 days (IRDC 1976; Norris et al. 1973, 1975a).  In mice, 
one study reports a significant 13–18% decrease in relative testis and epididymides weight following
exposure to decaBDE at 950 mg/kg/day via gavage for 35 days, compared with controls; no exposure-
related changes in male reproductive organ weights were observed at 750 mg/kg/day (Sarkar et al. 2015).  
In contrast, no exposure-related changes in testes, epididymides, or seminal vesicle weights were 
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observed in another mouse study that exposed animals to decaBDE at gavage doses up to 
1,500 mg/kg/day for 50 days (Tseng et al. 2006). 
In a 35-day study, serum testosterone levels were significantly decreased by 65% in mice following
exposure to decaBDE at gavage doses of 950 mg/kg/day, compared with controls; testosterone levels at
750 mg/kg/day were comparable to control (Sarkar et al. 2015).
There is limited evidence that exposure to decaBDE in developing animals results in reproductive effects.
In male rats exposed during pubertal development, exposure to decaBDE at doses up to 600 mg/kg/day 
did not cause exposure-related changes in testes, epididmides, or prostate organ weight, testicular
histology, or testicular mRNA expression levels of steriodogensis-related genes (Lee et al. 2010).  As 
summarized in Section 3.2.2.6 (Developmental Effects), only one intermediate-duration gestational
exposure study reported reproductive effects in mouse offspring exposed to decaBDE doses of 10– 
1,500 mg/kg/day from GD 0 to 17 via gavage, including testicular lesions, decreased AGD, and altered
sperm parameters (Tseng et al. 2013).  No exposure-related changes in AGD, onset of puberty (PPS or
vaginal opening), estrous parameters, or reproductive organ weight and histology were reported in 
offspring exposed to decaBDE at doses up to 1,000 mg/kg/day during gestation and lactation (Biesemeier
et al. 2011; Fujimoto et al. 2011) or doses up to 20 mg/kg/day from PND 2 to 15 (Rice et al. 2007).
Chronic-Duration Animal Studies
Lower-brominated PBDEs:  No chronic-duration studies evaluating reproductive system effects were 
located for lower-brominated PBDEs.
DecaBDE:  No histopathological changes were observed in male or female reproductive tissues from rats 
or mice that were exposed to decaBDE at dietary doses up to 2,550 or 7,780 mg/kg/day, respectively, for
103 weeks (NTP 1986).  In the only other chronic-duration study, a low-purity mixture (77.4% purity) did 
not cause histopathological changes in male or female reproductive tissues from rats at doses up to
1.0 mg/kg/day for 2 years (Kociba et al. 1975; Norris et al. 1975a),
Summary.  Based on the evidence in humans and animals, lower-brominated PBDEs are potentially toxic 
to the male reproductive system in humans, including the developing reproductive system in children (see
Section 3.2.2.6, Developmental Effects for more details).  Available data for decaBDE provide very
limited evidence of male reproductive damage, and are insufficient to determine if oral decaBDE
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exposure can damage the male reproductive system in humans.  For female reproductive end points, data
are inconsistent in humans and animals; therefore, it is unclear whether PBDEs affect the female 
reproductive system in adults or developing infants/children.  The highest NOAEL values and all LOAEL
values from each reliable study for reproductive effects in each species and duration category are 
recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.6  Developmental Effects 
Human Studies. Numerous studies have investigated potential relationships between developmental
PBDE exposure and birth outcomes (e.g., birth weight, length, head circumference, gestational age) 
and/or postnatal development of various systems (neurological, reproductive, endocrine, immune).
Physical Growth and Development and Related Birth Outcomes
Robledo et al. (2015a) studied potential relationships between pre-conception maternal and paternal
serum levels of 10 PBDEs (BDE 17, BDE 28, BDE 47, BDE 66, BDE 85, BDE 99, BDE 100, BDE 153, 
BDE 154, and BDE 183) and birth weight and length, head circumference, and ponderal index 
(100x[birth weight in g/birth length in cm3]) in a prospective cohort study in Michigan and Texas (LIFE
study).  Geometric means of maternal and paternal serum PBDE levels (n=234 pairs) were 0.001– 
0.116 ng/g serum and 0.001–0.113 ng/g serum, respectively.  The relative concentrations of PBDEs was 
similar in maternal and paternal serum, with BDE 47 having the highest level (Robledo et al. 2015b).  
Levels were not reported in terms of ng/g lipid.  Maternal serum BDE 28 and BDE 183 levels and 
paternal serum BDE 183 were significantly associated with lower birth weight in female infants, with a
decrease of 84.6–151.33 g per 1 standard deviation (SD) increase in ln- transformed chemical
concentration. Maternal serum BDE 28 was also significantly associated with smaller birth length
(-1.14 cm per 1-SD increase) and head circumference (-1.05 cm per 1-SD increase) in female infants.
However, in male infants, maternal serum BDE 66 and BDE 99 were significantly associated with higher
birth weight (+85.21–125.04 g per 1-SD increase) and larger head circumference (+0.6–0.91 cm per 1-SD 
increase. Maternal serum BDE 99 was also significantly associated with larger birth length in boy infants 
(+0.76 cm per 1-SD increase).  No other significant associations were observed.
Maternal serum concentrations were studied in a population of 286 low-income women living in the
Salinas Valley of California (a subset of the CHAMACOS study) (Harley et al. 2011). The main PBDEs
detected in maternal blood, collected during the second trimester of pregnancy, were BDE 47, BDE 99, 
BDE 100, and BDE 153 (median concentrations of 14.57, 3.85, 2.45 and 2.03 ng/g lipid, respectively).  
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Serum concentrations of each of these congeners, and their sum, were significantly inversely related to
infant birth weight in crude analysis.  After adjustment for covariates, regression analysis showed that
each 10-fold increase in BDE 47, BDE 99, or BDE 100 was associated with roughly a 115-g decrease in
birth weight.  These associations were no longer statistically significant when maternal weight gain was 
included in the models. There were no significant relationships between maternal serum PBDE and infant
birth length or head circumference, or length of gestation. In a follow-up study of the CHAMACOS
cohort, the potential association between obesity indices (BMI, waist circumference, obesity/overweight
status) at 2–7 years of age and maternal serum PBDE levels was evaluated (BDE 47, BDE 99, BDE 100, 
BDE 153, and their sum); child serum PBDE levels were also determined at age 7.  The geometric means 
of the total maternal (n=224) and child (n=216) serum PBDE concentration were 25.35 and 83.03 ng/g
lipid, respectively (Erkin-Cakmak et al. 2015).  No significant associations were observed between
obesity measures and maternal serum concentrations of individual or summed PBDEs at any age when 
both sexes were examined together; however, statistical analysis revealed a significant effect modification
by sex.  When evaluated separately, a significant negative relationship was observed between BMI
z-score in 3.5-year-old females and a 10-fold increase in summed maternal serum PBDE levels (adjusted 
β -0.64, 95% CI -1.23, -0.06), and a significant positive relationship was observed between BMI z-score 
in 3.5-year-old males and a 10-fold increase in summed maternal serum PBDE levels (adjusted β 0.99,
95% CI 0.32, 1.66).  This sex difference was also observed at 7 years of age, with a significant negative
association in females (adjusted β -0.41, 95% CI -0.87, -0.05) and a near-significant positive association
in males (adjusted β 0.26, 95% CI: -0.19, 0.72).  Similar trends were observed for waist circumference
and obesity status (data not reported). When evaluating child serum PBDE levels, significant associations 
after adjustment for potential cofounders included a negative association between BDE 153 and ∑PBDEs
and BMI and waist circumference and a reduced risk for being overweight. There was no significant
effect by sex modification in the analysis of child serum levels.  This follow-up study suggests possible
obesogenic effects of in utero PBDE exposure in boys.  In contrast, Vuong et al. (2016b) found no 
significant association between PBDEs (BDE 28, BDE 47, BDE 99, BDE 100, BDE 153, and their sum) 
measured in maternal serum at 16 weeks of gestation (geometric mean 39.1 ng/g lipid) and height or
weight of boys and girls at 1–8 years of age.  However, BDE 153 was associated with lower BMI at 2– 
8 years, smaller waist circumference at 4–8 years, and lower percent body fat at 8 years.  The Vuong et al. 
(2016b) study comprised 318 mother-child pairs in the Health Outcomes and Measures of the
Environment (HOME) Study in Cincinnati, Ohio. Agay-Shay et al. (2015) also evaluated the potential 
association between maternal PBDE exposure and childhood obesity.  This study did not find significant 
associations between maternal PBDE colostrum levels (BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, 
BDE 209, and their sum) and BMI z-scores or risk of being overweight (BMI >85th percentile) in
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470 7-year-old boys and girls from a Spanish birth cohort study; however, sex-specific analyses were not
conducted. Geometric mean concentrations of BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, and 
BDE 209 in colostrum were 0.5, 0.3, 0.2, 0.7, 0.7,and 0.8 ng/g lipid, respectively.
Results from other studies evaluating potential associations between maternal serum PBDE levels during
pregnancy and/or at delivery and birth outcomes are inconsistent between studies and congeners.  The
Healthy Pregnancy, Healthy Baby (HPHB) birth cohort in North Carolina also evaluated potential
associations between third trimester maternal serum PBDE concentrations and birth weight, length, head
circumference, and birth weight percentile for gestational age (Miranda et al. 2015).  Serum was
evaluated for 27 PBDE congeners and 6 OH-PBDEs; however, only congeners and metabolites detected
in >50% of the subjects (n=137) were included in the analysis, including BDE 47, BDE 99, BDE 100, 
BDE 153, 4’-OH-BDE-49, and 6’-OH-BDE-47 (median serum concentrations of 18.87, 5.5, 4.61, 5.65, 
0.12, and 0.19 ng/g lipid, respectively).  The only significant finding was a negative association between 
maternal BDE 153 and head circumference (0.32 cm decrease per 2-fold increase in BDE 153); however, 
this association was no longer significant after adjustment for maternal risk factors.  Similarly, Serme-
Gbedo et al. (2016) did not find a statistically significant relationship between birth weight and BDE 47, 
BDE 99, BDE 100, BDE 153, or their sum in maternal serum collected during early pregnancy
(~12 weeks; median concentration of 32.99 ng/g lipid for total PBDE).  This study evaluated 
349 Canadian women (GESTE birth cohort), and utilized both unadjusted models and multivariate
regression models adjusted for a full range of clinical risk factors known to affect fetal growth as well as 
other environmental pollutants that are likely to impact fetal growth (PCBs, mercury, lead, cadmium, 
manganese). In contrast, Chen et al. (2015) reported negative associations between lower levels of
maternal serum PBDEs and birth weight and length in the prospective Laizhou Wan birth cohort (LWBC)
in 215 Chinese women.  In this study, median maternal serum levels of PBDEs, collected at delivery,
were 2.27, 2.26, 3.53, 2.13, and 4.87 ng/g lipid for BDE 28, BDE 47, BDE 99, BDE 100, and BDE 153, 
respectively (median concentration of total PBDEs was 21.68 ng/g lipid).  After adjustment for potential 
covariants, a near-significant negative association was observed between birth weight and maternal serum
BDE 28; when stratified by sex, this decrease was significant for males (253.76 g decreased per 10-fold 
increase in BDE 28), but not females.  A negative association was observed between birth length and 
maternal serum levels of all congeners; however, the association was only statistically significant for
BDE 28 and BDE 100 when males and females were combined (0.92–0.97 cm decrease per 10-fold BDE
increase).  When stratified by sex, BDE 99 was significantly negatively associated with male infant length
and BDE 100 was significantly negatively associated with female infant length (1.47–1.50 cm decrease 
per 10-fold BDE increase). There were no significant relationships between maternal serum PBDE and
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infant head circumference or length of gestation. In a case-control study of 197 full-term births and 
82 pre-term births, identified at the Centennial Women’s Hospital in Nashville, serum BDE 47 levels
were divided into the following ordinal scale: 25–135, 136–200, 200–321, 322–1,000, and >1,000 pg/mL
(Peltier et al. 2015).  The distribution for controls into the five bins was 23, 22, 21, 22, and 12%, 
respectively, while the distribution for cases was 10, 6, 20, 35, and 29%, respectively; these distributions
are statistically significantly different.  When cases and controls were combined for analysis, women from
the two higher exposure bins (>323 pg/mL BDE 47) showed a significantly increased risk for preterm
birth.
Several investigators have also evaluated associations between serum maternal and umbilical cord PBDE
levels, and their potential associations with birth indices.  As observed in maternal serum studies, data are 
inconsistent between studies and congeners.  In a study of 97 Canadian women (a subset of the FAMILY 
study), Foster et al. (2011) found no significant relationship between infant birth weight and maternal
serum PBDE (BDE 17, BDE 28, BDE 47, BDE 66, BDE 99, BDE 100, BDE 153, BDE 154, BDE 183, 
and their sum), whether the serum was collected during the second trimester of pregnancy or at delivery.
PBDE concentrations in this study were relatively high (median concentrations of 52.1 and 50.1 ng/g lipid 
for total PBDE at mid-pregnancy and delivery).  Foster et al. (2011) also evaluated the potential
relationship between umbilical cord serum PBDE (BDE 17, BDE 28, BDE 47, BDE 66, BDE 99, 
BDE 100, BDE 153, BDE 154, BDE 183, and their sum) and birth weight.  They found a significant
negative association between birth weight and concentrations of one PBDE congener (BDE 99) in 
umbilical cord serum.  PBDE concentrations in umbilical cord serum were 1.7–3.4 times higher than in 
maternal serum at delivery (median concentration of 100.0 ng/g lipid for total PBDE). These results are 
in contrast to Mazdai et al. (2003), who found umbilical cord concentrations of PBDE (BDE 47, BDE 99, 
BDE 100, BDE 153, BDE 154, BDE 183, and their sum) to be similar to maternal serum concentrations
at delivery (median concentrations of 39 and 37 ng/g lipid for total PBDE, respectively) in a small study
of 12 women recruited upon presenting in labor to Indianapolis hospitals.  In this study, no relationship of
maternal or cord blood serum to infant birth weight was observed. In contrast to these findings, a low
exposure study in 686 Spanish women (INMA cohort; median total serum PBDE concentrations in 
maternal blood collected at gestational week 12 and umbilical cords of 10.74 and 7.51 ng/g lipid, 
respectively) reported a significant relationships between PBDE levels and some birth indices (Lopez-
Espinosa et al. 2015). While concentrations were similar between maternal and umbilical cords serum,
Pearson’s correlations between maternal and cord log2(PBDEs) were low (0.18, 0.06, 0.04, 0.09, and 0.07 
for BDE 47, BDE 99, BDE 153, BDE 159 and BDE 209, respectively).  Potential associations were
examined between maternal or cord serum and birth weight, length, and head circumference for each 
   
 








   
   





    
 
 
    
    
   
    
  
  
   
     
      
    
 
    
  
 
   
      
    
    







congener and their sum.  A significant inverse association was observed between birth weight and 
maternal serum BDE 99 levels (Lopez-Espinosa et al. 2015).  After adjustment for covariates, regression 
analysis showed that each 2-fold increase in BDE 99 was associated a 1.4% decrease (~46.8 g) decrease
in birth weight.  Maternal serum BDE 99, as well as the sum of all PBDEs, was also significantly
associated with a 2.1–2.9% decrease in head circumference per 2-fold increase in PBDE concentration 
(~0.7–1.0 cm).  No significant associations were observed between birth weight or head circumference 
for other maternal serum congeners or any cord serum congeners, and no significant associations were 
observed for birth length. Lopez-Espinosa et al. (2015) also evaluated fetal growth indices during
pregnancy using ultrasound measurements in mid-pregnancy (gestational weeks 12–20) and late
pregnancy (gestational weeks 20–34), including abdominal circumference, fetal length, biparietal
distance, and estimated fetal weight. Significant associations, observed only during gestational weeks
20–34, included inverse relationships between maternal BDE 99 and biparietal distance, abdominal
circumference, and estimated fetal weight; cord BDE 99 and ∑PBDEs and fetal abdominal circumference
and estimated fetal weight; and maternal ∑PBDEs and biparietal distance (1.3–3.5% decrease per 2-fold 
increase in PBDE concentration). In another low-exposure study, Tan et al. (2009) also found no 
relationship between PBDE in umbilical cord blood and infant birth weight (or length, head 
circumference, or sex) in babies from 41 native mothers admitted to the Singapore National Hospital for
Cesarean section. Median PBDE concentrations in this study population 3.3 ng/g lipid for total PBDE in 
cord blood. There was reported to be a small positive association between cord blood concentrations of 
the PBDE congeners BDE 47 and BDE 99 and Apgar score at 1 minute in this study.  
Wu et al. (2010) also studied cord blood, but did not assess effect on birth weight alone, using instead a
composite of adverse birth outcomes, including low birth weight but also premature delivery and 
stillbirth. These researchers reported significant associations between umbilical cord PBDE (BDE 28, 
BDE 47, BDE 99, BDE 153, BDE 183, and total) and adverse birth outcomes in a comparison of
128 normal births and 25 cases of adverse birth outcomes from two towns (Guiyu and Chaonan) in China.  
The two towns represent an e-waste recycling area (Guiyu, with a median total PBDE concentration of
13.8 ng/g lipid [n=102]) and a control area with no e-waste recycling workshops (Chaonan, with a median
total PBDE concentration of 5.2 ng/g lipid [n=51]). In a companion study, neonatal physiological indices
were compared between 69 births in Guiyu (e-waste recycling) and 86 births in Haojiang (no e-waste re 
cycling), using placental PBDE concentrations as an exposure metric (Xu et al. 2015b).  Median total
placental PBDE concentrations were 32.25 ng/g lipid in Guiyu and 5.13 ng/g lipid in Haojiang; measured
congeners included BDE 29, BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, BDE 183, and BDE 209 
(mean placental concentrations of 11.66, 1.61, 0.32, 0.14, 3.17, 0.34, 2.20, and 3.30 ng/g lipid, 
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respectively). Head circumference, BMI, and Apgar1 score were significantly decreased by 4–8% and 
body length significantly increased by 4% in the Guiyu cohort, compared with the Haojiang cohort.  No 
differences were observed in birth weight between the two cohorts. When data from both cohorts were
combined for multiple linear regression analysis, significant negative associations were observed between
∑PBDEs and BDE 47 and head circumference; ∑PBDEs, BDE 47, and BDE 99 and neonatal BMI, and 
∑PBDEs, BDE 29, BDE 47, BDE 153, and BDE 183 and Apgar1 score. A significant positive
association was observed between BDE 47 and body length.  
Concentrations of PBDE in breast milk have also been studied in relation to adverse birth outcomes.  A
study of births from 20 healthy pregnant women in Taiwan found that increased PBDE (BDE 47, BDE
99, BDE 100, and BDE 209) in breast milk was associated with significantly reduced infant birth weight, 
length, chest circumference, and Quetelet’s index (BMI) (Chao et al. 2007).  The median total PBDE
concentration in breast milk was 3.65 ng/g lipid in the study population.  A significant negative
association between breast milk PBDE concentrations (BDE 47, BDE 99, BDE 100, BDE 153, and their
sum) and birth weight was also identified in a Swedish cohort of 254 women with a median total PBDE
concentration of 2.4 ng/g lipid (Lignell et al. 2013).  In contrast, a significant positive association was 
observed between colostrum (breast milk collected in the first week after delivery) PBDE concentrations 
(BDE 47, BDE 99, BDE 100, BDE 153, and their sum) and birth weight and birth length in a Tanzanian 
cohort of 95 women with a median total PBDE concentration of 19.8 ng/g lipid (Müller et al. 2016).  
When stratified by sex, the only significant finding was a positive association between birth weight and 
PBDE concentration in female infants.  The high PBDE levels were attributed to the consumption of
Pemba (clay soil), which is sold in Tanzanian markers to pregnant women as a mineral supplement and 
nausea-relieving aid. Women who ate Pemba (64%) had significantly higher PBDE concentrations in 
colostrum, compared to non-Pemba eating women.  
Reproductive System Development
Main et al. (2007) found a significant positive relationship between concentrations of PBDE in breast
milk and congenital cryptorchidism (undescended testes) in male offspring.  The study compared 
concentrations of 14 PBDE congeners in breast milk of mothers of 62 Danish and Finnish boys with 
cryptorchidism to mothers of 68 controls from the same population.  Significant increases were seen for
the sum of the 7 most prevalent congeners (found in all mothers), for several of the individual congeners, 
and for the sum of all 14 congeners in cases versus controls.  No such relationship was found, however, 
when placental blood PBDE concentrations, rather than maternal breast milk PBDE concentrations, were 
   
 








     
   
     
    
   
    
   
 
  
     
 
 
    
  
    




    
   
     
     
  
  
    
   
    








used to represent exposure.  In a comparison of 86 paired samples from this study, PBDE concentrations
in placenta and breast milk were correlated, but absolute PBDE concentrations were 3–4 times higher in 
breast milk (median of 3.23 ng/g fat for total PBDE) than in placenta (median of 1.19 ng/g fat for total
PBDE).  The researchers hypothesized that while breast milk PBDE concentrations reflect the
accumulated body burden of the mother, placental PBDE concentrations may resemble measurements in
single blood samples, reflecting the situation at delivery, but not the long-term exposure. In another case-
control study in Danish and Finnish boys, no significant difference was observed in the concentrations of
14 PBDE congeners in subcutaneous tissue samples from the inguinal region during orichidopexy surgery
(44 cases) or hernia surgery (38 controls) (Koskenniemi et al. 2015).  Mean age at surgery was 2.3 and 
2.9 years for cases and controls, respectively.  Median concentrations of total PBDEs in adipose tissue 
were 4.90 ng/g in cases and 5.54 ng/g in controls.
Other studies of reproductive development found no relationship between PBDE concentrations in mid-
pregnancy serum samples from California mothers (median ∑PBDE=33.7 ng/g lipid for 20 cases and 
38.6 ng/g lipid for 28 controls) and hypospadias in their male offspring (Carmichael et al. 2010) and no 
relationship between current serum concentrations of PBDE (range of 4.9–73.6 ng/g lipid, with median of
9.9 ng/g lipid) and various measures of sexual maturation (e.g., initiation of breast development, current
breast development, age at menarche), in a small cohort of 18 (9 boys and 9 girls) teen-aged Dutch 
children (Leijs et al. 2008). A study of 55 Dutch boys found significant positive associations between 
maternal serum concentrations of BDE 154 (median=0.5 ng/g lipid) collected on week 35 of pregnancy
(but not other congeners measured, including BDE 47 and BDE 153 that occurred at higher
concentrations [medians of 0.9 and 1.6 ng/g lipid, respectively]) and serum concentrations of the sex 
hormones, E2, free E2, and inhibin B (but not testosterone, LH, FSH, or sex hormone binding globulin),
in the baby boys at 3 months of age and testes volume in the boys at 18 months of age, but no effect on 
penile length at either age (Meijer et al. 2012).  In a French birth cohort (n=262 mother-child pairs; 
141 male infants, 141 female infants), cord blood total testosterone was significantly decreased in male 
infants with detectable BDE 209 levels (>0.05 ng/g lipid) compared with male infants without detectable
BDE 209 levels (Warembourg et al. 2016).  No associations were observed for female total testosterone
or other sex hormones measured in male and/or female infants (sex hormone-binding globulin, E2, free
testosterone, aromatase index, or Anti-Müllerian hormone).
Delayed onset of puberty was significantly associated with higher PBDE concentrations in serum in a 
cohort of 645 ethnically diverse girls (recruited at 6–8 years of age and followed annually) from
California and Ohio (Breast Cancer and the Environment Research program [BCERP] cohort) (Windham
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et al. 2015a).  A cross-sectional analysis, conducted at enrollment, showed a significant decrease in the 
percentage of females showing Tanner stage 2 breast development per quartile increase in serum ∑PBDE 
levels; no association was observed with pubic hair development. Median serum ∑PBDE levels at
enrollment were 78.3 ng/g lipid (Windham et al. 2015b).  In follow-up evaluations, the longitudinal 
analysis showed a significant increase in age at pubertal transition (both breast and pubic hair Tanner
stages) with per quartile increase in serum ∑PBDE levels. When analyzed by individual congener,
significant delays in pubic hair development were observed for all congers evaluated (BDE 28, BDE 47, 
BDE 99, BDE 100, BDE 153, and BDE 154) and significant delays in breast development were observed 
for BDE 47, BDE 99, BDE 100, and BDE 153 (associations were marginal for BDE 28 and BDE 154).
Neurodevelopment
Numerous studies have reported results suggestive of an effect of PBDE on neurodevelopment in
children.  Associations are more consistent when blood concentrations were used as a biomarker of
exposure, compared with studies utilizing breast milk concentrations as a biomarker of exposure.
A series of studies evaluated neurodevelopmental outcomes in a longitudinal study of the HOME study
cohort from Cincinnati, Ohio (full sample 349 mother-child pairs) (Braun et al. 2014; Chen et al. 2014;
Donauer et al. 2015; Vuong et al. 2016a).  Several environmental chemicals, including PBDEs, were 
quantified in maternal blood collected at approximately 16 weeks of gestation. In 5-week-old infants
(n=326), no associations were observed between neonatal neurobehavior and maternal serum PBDEs 
(Donauer et al. 2015).  The geometric mean of the sum of the most frequently detected PBDEs 
(sum4BDE=BDE 47, BDE 99, BDE 100, and BDE 153) in maternal serum from mother-child pairs in the
neonatal study was 37.12 ng/g lipid (Donauer et al. 2015).  The majority of children from the HOME
cohort (n=309) were examined for cognitive and motor abilities at 1, 2, and 3 years of age, intelligence at
5 years of age, and general behavior at 2, 3, 4, and 5 years of age (Behavioral Assessment System for
Children 2 [BASC-2]) (Chen et al. 2014).  This analysis focused primarily on maternal BDE 47 exposure
(geometric mean=20.1 ng/g lipid; median=18.9 ng/g lipid); however, some analysis were conducted for
sum4BDE (geometric mean=37.7 ng/g lipid; median=34.6 ng/g lipid).  Maternal serum levels of BDE 47
or sum4BDE were not significantly associated with Bayley mental or psychomotor development indices at
1–3 years of age. At 5 years, however, adjusted regression analysis showed a significant 4.5-point
decrease in full-scale IQ per 10-fold increase in maternal serum BDE 47 (95% CI -8.8, -0.1). For the
sum4BDE analysis, a marginal decrease in full-scale IQ was observed (β [95% CI] -4.38 [-8.9, 0.14]). In
the BASC-2 behavioral assessments at 2–5 years of age, significant associations observed included a 
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positive association between maternal BDE 47 serum levels and the Externalizing Problems score at
2 and 3 years of age (~2–3-point increase per 10-fold increase in serum BDE 47) and a positive 
association between maternal BDE 47 serum levels and the Hyperactivity subscore at 2, 3, and 5 years of
age (~2–3-point increase per 10-fold increase in serum BDE 47); other ages showed marginal positive
associations in these domains.  Similar trends were observed in BASC-2 analysis of sum4BDE analysis.
Further analysis of neurodevelopment at 4 and 5 years of age in a subset of the HOME cohort (n=175)
was reported by Braun et al. (2014), with a specific focus on autistic behaviors (social, repetitive, and
stereotypic behaviors). Specific analysis were conducted for BDE 28, BDE 47, BDE 85, BDE 99, BDE
100, BDE 153, and BDE 154 (maternal serum geometric mean of 0.8, 20.1, 3.1, 4.7, 3.8, 5.1, and 2.6 ng/g
lipid, respectively).  A marginal positive association was observed between maternal serum BDE 28
levels and autistic behaviors (β [95% CI] 2.5 [-0.6, 5.6]).  In contrast, a significant negative association 
was observed between maternal serum BDE 85 levels and autistic behaviors (β [95% CI] -3.2 [-5.9, 
-0.5]); however, BDE 85 was detected in <50% of the maternal serum samples. In the most recent report,
Vuong et al. (2016a) evaluated potential associations between maternal PBDE levels and executive
function at 5 and/or 8 years in 256 children from the HOME cohort. Specific analysis were conducted for
BDE 28, BDE 47, BDE 99, BDE 100, BDE 153, and their sum (maternal serum geometric mean of 1.2, 
21.5, 5.0, 4.2, 5.5, and 41.3 ng/g lipid, respectively). After adjusted regression analysis, a significant 
positive association was observed between impaired behavior regulation and maternal serum BDE 153.  
Increased BDE 153 was also significantly associated with higher odds of having a behavior regulation 
(OR, 3.92 95% CI 1.76, 8.73) or a global executive function score (OR 2.34, 95% CI 1.05, 5.23) greater
than 1 standard deviation above the mean, indicating increased risk of impaired behavior regulation 
and/or executive function deficits. No significant associations were observed for other congeners or their
sums.
In another longitudinal birth cohort of predominantly Mexican-American families in the Salinas Valley of
California (CHAMACOS), PBDE levels were analyzed in maternal serum (collected at mid-pregnancy or
at delivery) and child serum at 7 years of age (Eskenazi et al. 2013). Significant negative associations 
were found for both maternal serum PBDE and current child serum PBDE and measures of attention, fine
motor coordination, and cognitive function (particularly verbal comprehension) in children evaluated at
5 (n=249) and/or 7 (n=270) years of age.  PBDE concentrations for this subset of the CHAMACOS
cohort are not available. A follow-up study in the CHAMACOS birth cohort (n=622) evaluated potential 
associations between PBDE levels in maternal serum (collected at mid-pregnancy or delivery) and current
child serum (collected at age 9) and numerous measures of attention and executive function at 9, 10.5, and
12 years of age (Sagiv et al. 2015). Significant negative associations were observed between several
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measures of attention and executive function at 9–12 years of age and maternal serum PBDE (geometric 
mean of BDE 47, BDE 99, BDE 100, and BDE 153 of 26.3 ng/g lipid), but not current child serum PBDE 
(geometric mean of BDE 47, BDE 99, BDE 100, and BDE 153 of 63.2 ng/g lipid).
Several studies in infants and toddlers report associations between neurodevelopmental deficits and
umbilical cord serum PBDE levels. Taiwanese infants (n=36) evaluated for neurological development at
age 8–12 months by Bayley Scales of Infant and Toddler Development and parental questionnaire showed
significant deficits in cognitive score and adaptive behavior associated with umbilical cord blood
concentrations of total PBDE (range of 2.24–49.1 ng/g lipid, with median of 4.63 ng/g lipid) and 
concentrations of several individual congeners (Shy et al. 2011).  Children from a New York City cohort
(n=152) who had higher cord blood concentrations of PBDE congeners BDE 47, BDE 99, and BDE 100 
scored significantly lower on tests of mental and physical development at ages 12, 24, and 36 months
(Bayley Scales of Infant Development) and ages 48 and 72 months (Wechsler Preschool and Primary
Scale of Intelligence) than children with lower cord blood concentrations (Herbstman et al. 2010). 
Median and maximum concentrations of BDE congeners in cord blood were 11.2 and 613.1 ng/g lipid for
BDE 47, 3.2 and 202.8 ng/g lipid for BDE 99, and 1.4 and 71.9 ng/g lipid for BDE 100. Ding et al.
(2015) evaluated the potential association between motor, adaptive, language, and social developmental
quotients in Chinese children at 12 months (n=192) and 24 months (n=149) and cord blood concentrations
of BDE 28, BDE 47, BDE 85, BDE 99, BDE 100, and BDE 153 (median concentrations of 2.05, 3.71, 
1.47, 6.70, 2.63, and 2.19 ng/g lipid, respectively) and the sum of BDE 47, BDE 99, BDE 100, and 
BDE 153 (the four congeners detected in >80% of samples).  No significant associations were observed at
12 months. At 24 months, a 10-fold increase in cord blood BDE 99 was significantly associated with a
2.16-fold decrease in the language domain developmental quotient and a 10-fold increase in cord blood
BDE 47 was significantly associated with a 1.89-fold decrease in the social domain developmental
quotient.  No significant associations were observed for the other congeners or the sum of BDE 47, 
BDE 99, BDE 100, and BDE 153.
Studies in preschool and school-aged children (≥4 years of age) also report associations between
neurodevelopmental impairments and maternal, child, or umbilical cord serum/plasma PBDEs. Both cord 
and current blood concentrations of BDE 47 (cord blood median and maximum of 2.10 and 16.8 ng/g
lipid [n=88], current blood median and maximum of 0.12 and 130.2 ng/g lipid [n=244]) were also 
negatively associated with cognitive and motor functions in 4-year-old children from a Spanish cohort
(McCarthy Scales of Children’s Abilities), although in this study, the results were not statistically
significant, except for associations with symptoms of poor social competence and ADHD (Gascon et al.
   
 









   
 
     
 
      
   
     




      
     
 
 




     
  
  
    
 
   
   
    
  
      
 
     
PBDEs 207
3. HEALTH EFFECTS
2011).  Positive associations between attention problems (Child Behavior Checklist) and cord plasma 
levels of BDE 47, BDE 99, BDE 100, and BDE 153 were also observed in 4-year-old children (n=109)
from a New York City cohort of mothers pregnant during the September 11, 2001 World Trade Center
terrorist attacks; however, associations were only significant for BDE 47 and BDE 153 (Cowell et al.
2015).  No significant associations were observed in 6-year-old children.  Median BDE 47, BDE 99, 
BDE 100, and BDE 153 cord plasma levels were 11.2, 3.2, 1.4, and 07 ng/g lipid, respectively.
Significant negative correlations were observed for maternal serum PBDE (median ∑PBDE=3.4 ng/g 
lipid, n=62) in the 35th week of pregnancy and fine manipulative abilities, verbal memory, and sustained 
attention in a cohort of Dutch children tested at age 5–6 years (Roze et al. 2009), although some aspects
of neurodevelopment appeared to be improved with higher PBDE concentrations in this study, including
coordination, visual perception, and behavioral outcome reported by parents and teachers.  A case-control
study of 100 California children, including 51 with autism/autism spectrum, 26 developmentally delayed
but not autistic, and 23 with typical development, found no association of autism or developmental delay
with concentrations of PBDE in serum collected from the children after assessment of developmental
status at 36 months (Hertz-Picciotto et al. 2011).  PBDE concentrations for this study were not available 
numerically.  
Studies attempting to discern relationships between PBDE concentrations in breast milk, rather than
blood, and neurodevelopmental end points produced more uncertain results.  A study of 70 infants in 
Taiwan found no correlation between total PBDE concentrations in breast milk collected within 1 month 
of delivery (range=1.44–118 ng/g lipid, median=2.92 ng/g lipid) and neurodevelopment as assessed in 
infants at 8–12 months of age using the Bayley Scales (Chao et al. 2011).  There was, however, a
significant inverse association between BDE 209 concentration in breast milk and cognitive score, 
suggesting delayed cognitive development associated with that particular congener.  Gascon et al. (2012)
reported similar findings in a Spanish cohort of 290 infants.  In this study, total PBDE concentrations in 
colostrum collected at the hospital within 4 days of delivery (range=0.31–32.66 ng/g lipid, median= 
4.05 ng/g lipid) were negatively, but not significantly, associated with the Bayley score for cognitive
development in children assessed at age 12–18 months, but again, a significant negative relationship was
found for BDE 209, the congener found at the highest concentrations in this population (median of
1.02 ng/g lipid).  Studies of a North Carolina cohort found modest and imprecisely estimated associations
between PBDEs (BDE 28, BDE 47, BDE 99, BDE 100, BDE 153, and their sum) in breast milk collected 
3 months postpartum (median ∑PBDE=47.3 ng/g lipid, n=222) and (1) increased extermalizing
behaviors, primarily driven by activity/impulsivity behaviors, in children assessed at 24–36 months for
social and emotional development; (2) higher anxiety and withdrawal in children assessed at 36 months
   
 









   
 
 
   
       
  
        














   
   
     
       
    
      
    





for behavioral development using a parental rating scale; and (3) improved cognitive skills in children
assessed at 36 months for cognitive development using the Mullen Scales of Early Learning (Adgent et al. 
2014; Hoffman et al. 2012).
Potential associations between household BDE 99 and BDE 209 dust and cognitive ability of 6-year-old 
children (verbal comprehension, working memory) were evaluated in French birth cohort (n=246);
potential associations with cord blood BDE 209 were also evaluated (Chevrier et al. 2016). After
adjustment for potential covariates, children from homes with BDE 99 dust levels above the median value 
(54 ng/g) or BDE 209 dust levels in the 2nd or 3rd exposure tertile (≥257 ng/g) had significantly increased
risk of poor performance on verbal comprehension assessments.  No association was observed between
dust BDE 99 or BDE 209 levels and working memory, and no association was observed between cord 
BDE 209 and cognitive function.
A case-control study of a Chinese population found no relationship between risk of neural tube defects
and placental PBDE concentrations (median ∑PBDE=0.55 ng/g lipid for 80 cases and 0.54 ng/g lipid for
50 controls) (Ma et al. 2012b; Ren et al. 2011). 
Endocrine System Development
A number of studies evaluated effects on thyroid hormones in neonatal serum or cord blood associated
with developmental exposure to PBDEs; however, findings are inconsistent between studies and 
congeners.
Abdelouahab et al. (2013) evaluated the potential associations between thyroid hormone levels in the
umbilical cord blood and maternal serum concentrations of PBDEs collected at <20 weeks of pregnancy
(for ∑PBDE, median=30.92 ng/g lipid, maximum=726.09 ng/g lipid, n=380).  Significant negative 
associations were observed between maternal PBDE levels and both free and total T4 in cord blood, but
not free or total T3 or TSH in cord blood.  Similarly, neonatal TSH assessed in blood samples collected
24 hours after birth (on average) was not related to PBDE concentrations (median ∑PBDE=25.4 ng/g
lipid) in maternal serum collected at the start of the third trimester or at delivery from 289 expectant 
mothers living in the Salinas Valley of California (Chevrier et al. 2011). In a low-exposure Korean birth
cohort (n=104), no significant associations were observed between neonatal free or total T3, free or total
T4, or TSH and maternal PBDE concentrations in maternal serum collected at delivery (median
∑PBDE=2.2 ng/g lipid) (Kim et al. 2015)
   
 









     
   
   
   
 
    
      
    
    
    
    
   
 
    
     
  
     
 
 
     
    
  
  
    
    
  
    
     
  





Other studies of thyroid hormone changes in infants looked at hormone levels in umbilical cord or
neonatal blood in relation to PBDE concentrations in maternal breast milk.  Kim et al. (2011a) reported a 
significant negative correlation between breast milk PBDE (BDE 28 only, mean ≈0.1 ng/g lipid) and free
T4 in cord blood.  Other studies that measured PBDEs in breast milk to assess exposure found no 
association with TSH in neonatal blood collected 3 days after delivery in a Norwegian population of
239 mother-baby pairs (median ∑PBDE in breast milk=1.91 ng/g lipid) (Eggesbo et al. 2011), no
association with T3, T4, free T4, or TSH in cord blood in a population of 149 Taiwanese mothers (median
∑PBDE in breast milk=3.38 ng/g lipid from 42 mothers in Central Taiwan and 3.13 ng/g lipid from
107 mothers in Southern Taiwan) (Shy et al. 2012), and no association with free T4, total T3, or TSH in 
infant serum at 3 weeks or 3 months in 186 Swedish mother-child pairs (median breast milk
concentrations of tetra-pentaBDE [BDE 47, BDE 99, BDE 100] of 2.3 ng/g lipid and BDE 153 of
0.48 ng/g lipid) (Lignell et al. 2016).
Inconsistent findings were also observed when thyroid hormones and PBDEs levels were evaluated in
infant serum and/or cord blood. For example, Mazdai et al. (2003) found no correlations between PBDE
concentrations (for ∑PBDE, range=14–460 ng/g lipid, median=39 ng/g lipid, n=12) and thyroid hormone
levels (free and total T4 and free and total T3) in umbilical cord blood.  Similarly, there was no correlation 
between PBDEs and thyroid hormone levels in umbilical cord blood in another study of 21 South Korean 
mothers undergoing Cesarean section (Kim et al. 2012a).  In this study, ∑PBDE in cord blood ranged 
from 2.28 to 30.94 ng/g lipid, with a median of 12.04 ng/g lipid. Both T3 and free T3 in cord blood were
significantly inversely related to PBDE in cord blood (median ∑PBDE=3.49 ng/g lipid) in another study
of 54 Taiwanese births (Lin et al. 2011).  T4, free T4, and TSH were unaffected in this study.  Wan et al. 
(2010) found no significant relationship between the PBDE metabolite, 6-OH-BDE-47 (which ranged 
from <4 to 127 pg/g wet weight, with a median of 26 pg/g wet weight), and T4 in cord serum in 
26 pregnant South Korean women.  In an analysis of 289 births at Johns Hopkins Hospital in Maryland, 
PBDE in cord blood (median ∑PBDE=18.7 ng/g lipid) was compared to T4, free T4, and TSH in cord
blood and T4 from blood spots collected from newborns at 2 and 18 days of age (on average) (Herbstman 
et al. 2008). There were consistent negative associations between PBDEs and free and total T4 in cord 
blood and/or spot samples, although these were primarily nonsignificant. Kim et al. (2011d, 2012b)
analyzed blood samples collected from infants in neonatal screening tests.  They found a positive
relationship between PBDEs with TSH (BDE 197 and BDE 196 only), a negative association with T3 
(BDE 154 only) for control babies (for ∑PBDE, range=1.61–252.9 ng/g lipid, mean=56.70 ng/g lipid, 
n=12), and no significant relationships between PBDEs and thyroid hormones in babies with congenital 
   
 








     
  
    












    
 
  
   
      
      
      
   
   
 
   
  




    




hypothyroidism (for ∑PBDE, range=2.22–861.0 ng/g lipid, mean=59.84 ng/g lipid, n=26). In another
Korean birth cohort (n=104), significant positive associations were observed between neonatal serum
TSH and cord BDE 99 levels and cord TSH and cord BDE 47 levels; no significant associations were 
observed for free or total T3 or T4 and ∑PBDE, BDE 47, or BDE 99 levels in cord blood (median ∑PBDE 
in cord=8.8 ng/g lipid) (Kim et al. 2015).
Immune System Development
A study of developmental immunity found reduced risk of atopic dermatitis in Japanese infants
(diagnosed at 7 months of age by questionnaire) with higher concentrations of PBDE in umbilical cord 
blood (median ∑PBDE=41 pg/g wet weight for 27 cases and 54.5 pg/g wet weight for 54 controls)
(Ochiai et al. 2014).  
Animal Studies
Teratology, Fetotoxicity, and Physical Growth and Development
Lower-brominated PBDEs: No exposure-related developmental changes were observed following
gestational exposure to pentaBDE in GD 12 rat embryos from dams exposed to doses up to 
120 mg/kg/day via gavage from GD 6.5 to 11.5 (Ellis-Hutchings et al. 2009), in GD 20 rat fetuses from
dams exposed to doses up to 120 mg/kg/day via gavage from GD 6.5 to 19.5 (Ellis-Hutchings et al.
2009), or in GD 20 rat fetuses from dams exposed to doses up to 200 mg/kg/day via gavage from GD 6 to 
15 (Argus Research Laboratories 1985a).  End points evaluated included fetal/embryo survival,
resorptions, fetal weight and length, gross abnormalities, and skeletal and soft tissue abnormalities.  In
these studies, maternal toxicity (significantly decreased maternal weight gain) was observed at doses 
≥100 mg/kg/day (Argus Research Laboratories 1985a; Ellis-Hutchings et al. 2009).  Similarly, rat dams
exposed to pentaBDE at doses up to 30.6 mg/kg/day from GD 6 to 21 did not show any exposure-related
changes in pregnancy or birth indices (Branchi et al. 2001, 2002, 2005; Kodavanti et al. 2010; Zhou et al. 
2002).  Zhou et al. (2002) also reported no change in offspring viability and growth, as assessed by
numbers of pups at birth and on PNDs 4–21, body weight of pups on PNDs 4–90, and eye opening status
on PNDs 11–18; however, Kodavanti et al. (2010) observed significantly decreased body weight from
PND 29 to 58 in female offspring at ≥10.2 mg/kg/day (8–10% reduction at PND 60).  No exposure-
related changes were observed in litter size, live births per litter, sex ratio, implantation sites, timing of
eye opening, or body or organ weights (brain, liver, thymus) on PND 21 in offspring from rat dams fed 
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vanilla wafers dosed with commercial pentaBDE (DE-71) at doses up to 11.4 mg/kg/day from 28 days
pre-mating through PND 21 (Poon et al. 2011). In a similar study, no exposure-related changes were 
observed in litter size, live pups per litter, sex ratio, offspring survival, or timing of eye opening or pinna
detachment in offspring from rat dams fed cookies dosed with DE-71 at doses up to 30 mg/kg/day from
GD 1 to PND 21; however, a significant decrease in offspring body weight was observed during early 
development (up through PND 30) at 30 mg/kg/day, but not at doses ≤3 mg/kg/day (Bowers et al. 2015).  
Several studies examined developmental effects of very low doses of pentaBDE. Following maternal
exposure to pentaBDE at doses of 0, 0.5, 1, or 2 mg/kg/day via gavage from GD 6 to 19, GD 20 rat
fetuses showed delayed ossification and an increased incidence of internal variations at 2 mg/kg/day
(Blanco et al. 2012).  Significantly increased skeletal variations included delayed ossification of parietal
and occipital bones, caudal vertebrae, and floating ribs.  Soft tissue variations included significant
increase in the size of the ventricles of the heart and liver enlargement.  No significant changes were 
observed in the number of live fetuses, the sex ratio, the average fetal body weight/litter, or external
malformations (Blanco et al. 2012).  In another study, incisor eruption was delayed in offspring from rat
dams exposed on GD 6 to a single gavage dose of pentaBDE at 0.3 mg/kg, but not 0.06 mg/kg (average
age at eruption was not reported) (Kuriyama et al. 2005).  No exposure-related delays were reported for
fur development or eye opening (Kuriyama et al. 2005).  Following single gavage doses of pentaBDE up 
to 0.3 mg/kg or tetraBDE up to 0.7 mg/kg/day in F0 rats on GD 6, no significant, exposure-related
changes were observed in F1 body weights through PND 100 or F2 fetal end points (implantation sites,
implantation sites/dam, number of live fetuses, fetuses/dam, mean fetal weight, resorption rate, or
incidence of skeletal anomalies) on GD 21 (Talsness et al. 2005, 2008).
In several other studies assessing offspring body weight following developmental exposure to pentaBDE
(without assessing any teratogenic or fetotoxic end points), no consistent body weight effects were found.
No dose-related body weight changes were observed in offspring of male and female rats exposed to
pentaBDE at doses up to 25 mg/kg/day via gavage for 70 days pre-mating through PND 42 (Bondy et al. 
2011, 2013).  No exposure-related body weight effects were observed in rat pups from dams exposed to 
pentaBDE at doses up to 30 mg/kg/day via gavage or pentaBDE-dosed cookies from GD 6 to PND 18 or
21 (Bansal et al. 2014; Cheng et al. 2009; Ellis-Hutchings et al. 2006; Miller et al. 2012; Zhao et al. 
2014), or in mouse pups from dams exposed to pentaBDE at 452 mg/kg/day every third day from GD 4 to
PND 17 via gavage (Skarman et al. 2005).  A poorly-reported study indicated that pup weight was
significantly decreased at PND 21 by 8, 16, and 15% following maternal exposure to pentaBDE at 50, 
100, at 200 mg/kg/day, respectively, from GD 6 to PND 21 via gavage; by PND 63, no body weight
   
 








   
   
   
 
   
  
 
     
 




   
  
   
   
  
    
    
 
 
   
  
     
   
    







effects were observed (Hong et al. 2010).  Another study reported significantly elevated pup body weight
on PND 21 in rat offspring from dams exposed to pentaBDE at 2 mg/kg/day via gavage from GD 6 to 
PND 21; no changes were observed at 1 mg/kg/day (Blanco et al. 2014).  
Three studies exposed rat dams to different commercial octaBDE mixtures at 0, 2.5, 10, or 25 mg/kg/day
via gavage on GDs 6–15, including FR-1208 (Life Science Research Israel Ltd. 1987), Saytex 111 (Argus
Research Laboratories 1985b), and DE-79 (WIL Research Laboratories 1986).  Following exposure to 
FR-1208, postimplantation loss was significantly elevated at 10 and 25 mg/kg/day when Freeman-Tukey 
arcsine transformed values were tested as normally distributing data (Student’s t-test); however, no 
statistical differences were observed with untransformed data and values were within the range of
laboratory historical control values. There were no indications of skeletal malformation or variations or
delayed or retarded ossification in any dose group (Life Science Research Israel Ltd. 1987).  Following
exposure to Saytex 111, the number of resorptions per litter was significantly increased by 8-fold and the
number of live fetuses per litter was decreased 6.6% in the 25 mg/kg/day group (Argus Research 
Laboratories 1985b).  Average fetal body weights were also significantly reduced at 25 mg/kg/day (Argus
Research Laboratories 1985b).  Following exposure to DE-79, effects observed at 50 mg/kg/day included 
significantly reduced mean maternal body weight gain during the post-treatment period (GDs 16–20) and 
fetotoxicity as indicated by increased postimplantation loss due to late resorptions (not significantly
increased compared to control group but exceeded historical control range), 39% reduced mean fetal
weight (p<0.01), skeletal variations (e.g., reduced ossification of the skull and various unossified bones)
that were associated with the reduced fetal weights in this group, and single instances of malformations 
(fetal anasarca, bent limb bones, unilateral absence of 13th rib) commonly associated with maternal
toxicity (WIL Research Laboratories 1986). 
In rabbit does exposed to octaBDE (Saytex 111) at 0, 2, 5, or 15 mg/kg/day on GDs 7–19 via gavage, the 
15 mg/kg/day group showed slight fetotoxicity, as indicated by a significantly (p≤0.05) increased 
incidence of delayed ossification of the sternebrae (Breslin et al. 1989). This finding was accompanied by
evidence of slight maternal toxicity as indicated by decreased body weight gain during GDs 7–20 and 7– 
28 (not statistically identified), reduced body weight on GD 28 (7% less than controls, p≤0.05), and 
significantly increased absolute and relative liver weights on GD 28 (Breslin et al. 1989).
Developmental effects were assessed in mice from dams fed cornflakes containing tetraBDE at doses of
0, 0.03, 0.1, or 1 mg/kg/day from 28 days premating to PND 21 (Ta et al. 2011).  At PND 21, a
significant decrease in crown-rump length of pups was observed in the 0.1 mg/kg/day group, compared 
   
 








   




   
     
     
  
    
  
 






   
    
 
     
    
   
     
     
     
 
 
    
     
   




with controls; however, no other dose-group showed this effect and the ponderal index (weight/crown­
rump length) was not statistically different among treatment groups.  Similarly, body weight was
significantly decreased by ~13–17% from PND 14 to 18 in the 0.1 mg/kg/day group, compared with 
controls, but not in the 0.03 or 1 mg/kg/day groups.  No changes were observed in gestation length, litter
size, or sex ratio (Ta et al. 2011).  In another study using the same protocol, no changes were observed in 
the number of pups per litter, the sex ratio, or pup body weight (Koenig et al. 2012).  Pre-weaning
weights were significantly reduced by ~10% in female offspring of female mice exposed to tetraBDE at
0.03 mg/kg/day via gavage for 28 days premating through PND 21, but only in one of two experimental
replicates (Woods et al. 2012).  In a dietary study, no exposure-related changes were observed in
pregnancy length, litter sizes, pup mortality, sex ratio, or pup weight in rats exposed to tetraBDE at doses
up to 32 mg/kg/day from GD 1 to PND 14 (Wang et al. 2011a).
DecaBDE:  Developmental effects were assessed in mice following maternal exposure to decaBDE at
gavage doses of 0, 150, 750, 1,500, or 2,000 mg/kg/day from GD 7 to 9 (Chi et al. 2011).  No gross
external malformations were observed; however, significant exposure-related changes were observed in
postimplantation loss, resorptions, number of live litters, and fetal body weight on GD 16.  The
percentage of postimplantation loss per litter was significantly increased by 3, 2.7, and 9.8% at 750, 
1,500, and 2,000 mg/kg/day, respectively, compared with control.  At 1,500 and 2,000 mg/kg/day, the
percentage of resorptions per litter was also significantly increased by 2.7 and 8.6%, respectively.
Additionally, the percentage of live fetuses per litter was significantly decreased by 10% in the high-dose
group.  Fetal body weight was significantly decreased by 10, 10, and 22% at 750, 1,500, and 
2,000 mg/kg/day, respectively, compared with controls (Chi et al. 2011).  A significant 15% reduction in 
pup body weight was observed in offspring of mouse dams fed dietary decaBDE at 260 mg/kg/day from
GD 10 through PND 21 (Watanabe et al. 2008); however, another study using the same protocol did not
observe body weight effects in PND 21 pups at doses up to 2,900 mg/kg/day (Watanabe et al. 2010b). No
exposure-related changes were observed in the number of liters or survival rate of pups in either study at
doses up to 3,100 mg/kg/day (Watanabe et al. 2008, 2010b).  In other studies, no exposure-related
teratogenic, fetotoxic, or body weight effects, and/or delays in attainment of developmental landmarks, 
were observed following decaBDE exposure in rat offspring from dams exposed to gavage doses up to 
146 mg/kg/day from GD 10 to PND 20 or 21 (Fujimoto et al. 2011; Saegusa et al. 2012), in rat offspring 
from dams exposed to gavage doses up to 1,000 mg/kg/day from GD 0 to 19 or from GD 6 to PND 21
(Hardy et al. 2001, 2002; Biesemeier et al. 2011), in mouse offspring from dams exposed to gavage doses 
up to 1,500 mg/kg/day from GD 0 to 17 (Tseng et al. 2008, 2013), or in mouse offspring from dams
exposed to doses up to 20 mg/kg/day via micropipette from PND 2 to 15 (Rice et al. 2007).  In a poorly­
   
 








   
       
   
 
 
   
       
     
  
    
 
   
      
   
 
 
     
     
   









   
  




reported study, the study authors reported that pup weight was significantly decreased in mouse offspring 
at PND 21 following maternal exposure to decaBDE at 500, 2,500, and 12,500 mg/kg/day via gavage
from GD 6 to PND 21; however, the included graph and table do not support that statement (Hong et al. 
2010).
A lower purity commercial decaBDE product (77% decaBDE, 22% nonaBDE, 0.8% octaBDE) used in 
the 1970s was fetotoxic in rats at high, albeit not maternally toxic, dose levels.  Developmental effects 
were investigated in GD 21 rat fetuses from dams exposed to decaBDE at doses of 10, 100, or
1,000 mg/kg/day by gavage on GDs 6–15 (Dow Chemical Co. 1985; Norris et al. 1975a).  The numbers
of fetuses with subcutaneous edema and delayed ossification of normally developed skull bones were 
significantly increased at 1,000 mg/kg/day.  Resorptions were significantly increased at ≥10 mg/kg/day,
but the increases were not dose-related and rates in the high dose group were comparable to historical
control values.  As discussed in Section 3.2.2.5 (Reproductive Effects), a one-generation study of the 77% 
commercial decaBDE mixture at ≤100 mg/kg/day in rats found no effects on numbers of live pups at birth 
or during lactation, body weights of pups at birth or weaning, or skeletal development or soft-tissue 
histology of pups at weaning (Dow Chemical Co. 1975; Norris et al. 1975a).
An additional study evaluated developmental effects in neonatal mice engineered to express neonatal
human apolipoprotein E (three genotypes: apoE2, apoE3, and apoE4) exposed once to decaBDE at 0, 10, 
or 30 mg/kg via micropipette on PND 10 (Reverte et al. 2014).  Investigators were assessing the potential
effect of different human apoE genotypes on susceptibility to decaBDE exposure during development, as
apolipoprotein is a genetic factor that is associated with varied vulnerability for the development of
neurodegenerative disease.  No exposure-related changes were observed in survival, body weight gain, 
ontogeny of reflexes, pinna detachment, or incisor eruption.  However, eye opening was significantly
delayed in apoE2 mice exposed to 30 mg/kg, compared with apoE2 controls.
Neurodevelopment
Lower-brominated PBDEs
Neurobehavior: In a series of one-day exposure neonatal gavage studies using similar experimental
designs, mice exposed to pentaBDE at doses ≥0.8 mg/kg on PND 3 or PND 10 consistently showed 
alterations in open-field behavior at 2–8 months of age, characterized by decreased activity during the
first 20-minute period followed by increased activity during the third 20-minute period; exposure-related
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effects were not observed in any study at ≤0.4 mg/kg/day or following exposure to pentaBDE at 8 mg/kg
on PND 19 (Eriksson et al. 2002b, 2006; Fischer et al. 2008; Hallgren et al. 2015; Sand et al. 2004;
Viberg et al. 2002, 2004a, 2004b).  These findings indicate an initial decrease in activity, but also a lack
of habituation to new surroundings.  The study authors noted that this nonhabituating behavior profile
(i.e., decreased activity early in the test period and increased activity late in the test period) has also been
reported in adult mice neonatally exposed to certain ortho-PCB congeners (Eriksson and Fredriksson 
1996a, 1996b).  Several other 1-day exposure studies report similar findings in rats and mice following
exposure to various lower-brominated PBDEs.  Decreased spontaneous activity and/or impaired 
habituation was observed in rats exposed to pentaBDE at 8 mg/kg on PND 10, mice exposed to hexaBDE
at ≥0.45 mg/kg on PND 10, mice exposed to tetraBDE at 10.5 mg/kg on PND 10, mice exposed to 
heptaBDE at 15.2 mg/kg on PND 3, and mice exposed octaBDE at 16.8 mg/kg on PND 3 or 10 (Eriksson 
et al. 2001; Viberg et al. 2003a, 2005, 2006).  Increased vertical activity was significantly increased at
4 months, but not 2 months, in mice exposed to tetraBDE at ≥1 mg/kg on PND 10; no changes were 
observed in horizontal activity or habituation (Gee and Moser 2008).  No changes in open-field behavior
were observed in mice exposed to heptaBDE at 15.2 mg/kg or nonaBDE at 18.5 on PND 10 (Viberg et al. 
2006).  The observed effects may be modulated by the cholinergic system, as mice exposed to pentaBDE
at 8 mg/kg on PND 10 showed significantly altered responses in a nicotine-induced behavior task
(decreased instead of increased activity) (Viberg et al. 2002).
Evidence for exposure-related changes in open-field behavior is less consistent in pre- and perinatal
studies. Male offspring from mouse dams exposed to pentaBDE at 18 mg/kg/day via gavage or “self­
administration” from a modified syringe from GD 6 to PND 21 showed significantly increased motor
activity during the 3rd 10-minute block of an open field test on PND 34, indicating decreased habituation 
(female offspring not evaluated) (Branchi et al. 2005).  This effect was transient, as it was no longer
observed in male offspring at PND 60 to 120.  No exposure related changes were observed in the amount
of time spent in the center versus the middle of the open field (Branchi et al. 2005).  However, male and
female offspring from mouse dams exposed to pentaBDE at 0, 0.6, 6, or 30 mg/kg/day via gavage from
GD 6 to PND 21 showed changes suggestive of an age-dependent alteration in activity at ≥6 mg/kg/day;
effects included hyperactivity (increased locomotion and rearing) and impaired habituation at PNDs 34 
and 60, altered thigmotaxis (reduced time near walls) at PND 60, and a tendency to hypoactivity (reduced 
locomotion) at PND 120 (Branchi et al. 2001, 2002).  In 24-hour observations of open-field behavior, 
total activity, time spent active, duration of activity per active phase, and total activity per active phase 
were all significantly increased in PND 36 male rat offspring following a single maternal exposure to
0.3 mg/kg on GD 6 via gavage (Kuriyama et al. 2005).  At PND 71, the increases in total activity and 
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time spent active persisted in the 0.3 mg/kg group, and were also significantly increased at 0.06 mg/kg
(Kuriyama et al. 2005).  Bowers et al. (2015) reported a significant increase in rearing behavior in rats at
PND 110 following maternal exposure to pentaBDE at doses up to 30 mg/kg/day via dosed cookie intake 
from GD 1 to PND 21; however, rearing behavior did not differ from control on PND 16, 55, or 230, and 
no other changes in motor activity or habituation behavior were observed in open-field testing at any
time-point.  Kodavanti et al. (2010) also reported a lack of exposure-related changes in open-field
behavior in rats at PND 100, 114, or 273 following maternal exposure to pentaBDE at doses up to 
30.6 mg/kg/day via gavage from GD 6 to PND 21.  Similarly, no exposure-related changes were observed
in general motor activity in an open field in PND 22 male and female offspring of rat dams exposed to 
pentaBDE at doses up to 2 mg/kg/day via gavage from GD 6 to PND 21; however, the offspring exposed 
to 2 mg/kg/day spent a significantly greater percentage of time in the center of the open field, indicating
decreased anxiety (anxiolytic effect) (Blanco et al. 2013).  However, no effect on anxiety behavior was
observed in the emergence latency assay in PND 35 or 80 rat offspring of dams fed pentaBDE-dosed 
cookies at intake levels up to 30 mg/kg/day from GD 1 to PND 21 (Bowers et al. 2015).  In offspring of
mouse dams fed cornflakes containing tetraBDE at doses up to 1 mg/kg/day from pre-mating day 28 
through PND 21, no changes in locomotor activity were observed at PNW 8 or 17 (Koenig et al. 2012).
In contrast, a second study using the same protocol reported significantly decreased locomotion and 
distance travelled in open-field testing of PND 60 females exposed to ≥0.1 mg/kg/day; at 0.03 mg/kg/day,
PND 60 female mice showed decreased activity in the center of the open field (Ta et al. 2011).  No
exposure-related changes in open-field behavior were observed at PND 60 in males or PND 42 in either
sex (Ta et al. 2011). Open field behavior was not significantly altered in PND 21 male offspring of
mouse dams administered tetraBDE at 0.2 mg/kg/day from GD 8 to PND 21, compared with control (Kim
et al. 2015).
In 1-day exposure neonatal gavage studies, significant impairments were also observed in learning and 
memory in the Morris water maze test in mice exposed to pentaBDE at 0.8 mg/kg on PND 10, mice
exposed to hexaBDE at ≥0.9 mg/kg on PND 10, and mice exposed to octaBDE at 16.8 mg/kg on PND 10, 
or in rats exposed to tetraBDE at ≥1 mg/kg on PND 10 (Fischer et al. 2008; He et al. 2009, 2011; Viberg
et al. 2003a, 2006).  Observed changes included increased latencies to find a hidden platform during a
4-day training period and decreased distance travelled in the quadrant containing the hidden platform 
compared with controls; no changes were observed during a reversal phase on the 5th day (when the
platform was moved to a new quadrant).  Similarly, impairments in learning and memory were observed 
in the radial arm maze in mice exposed to pentaBDE at 0.8 mg/kg on PND 10, as evidence by the
increased number of re-entries into maze arms from which the food pellet had already been eaten (Fischer
   
 








    
  
     
   
  
   
    
    
 
   
 
  
      
   
   
    
  
   
 
    
   
     
   
   
   
    









et al. 2008).  No exposure-related effects on learning or memory were observed in the Morris water maze 
in mice exposed to octaBDE at 16.8 mg/kg on PND 3 or nonaBDE at 18.5 mg/kg on PND 10 (Viberg et
al. 2006).  Based on the observed deficits, some of the studies evaluated the density of nicotinic
cholinergic receptors in the hippocampus.  Significant decreases in receptor density of 7–31% were
observed in mice exposed to penta- or hexaBDE at ≥9 mg/kg on PND 10 (Viberg et al. 2003a, 2004b, 
2005).  Another study reported a significant 23% decrease in cortical density of nicotinic cholinergic
receptors in mice exposed to pentaBDE at 0.8 mg/kg on PND 10; hippocampal density was not altered at
this dose (Fischer et al. 2008). The observed effects may be modulated by the cholinergic system, as 
mice exposed to pentaBDE at 8 mg/kg on PND 10 showed significantly altered responses in a nicotine-
induced behavior task (decreased instead of increased activity) (Viberg et al. 2002).
Learning and memory impairments have also been reported following pre- and perinatal exposures. 
Following maternal exposure to pentaBDE at 0, 1, or 2 mg/kg/day via gavage from GD 6 to PND 21, a
nonsignificant trend toward increased time to locate the hidden platform in the Morris water maze was 
observed on days 2–4 in PND 22 rat offspring from both dose groups; however, the increase was only
significant on day 4 in the 2 mg/kg/day group (Blanco et al. 2013).  In another study, significantly
increased latency to find the escape platform was observed in the Morris water maze on training days 2–3 
in PND 34 offspring of rat dams exposed to pentaBDE at 2 mg/kg/day from GD 6 to PND 21 (Cheng et
al. 2009).  In a low-dose study, maternal exposure to 0.2 mg/kg/day from GD 1 to PND 21 via gavage did 
not impair spatial learning in PND 34–36 offspring (Zhao et al. 2014).  Effects observed at higher doses
may be transient, as no exposure-related changes were observed in the Morris water maze in PND 235 rat
offspring following maternal exposure to pentaBDE at doses up to 30 mg/kg/day via dosed cookie intake
from GD 1 to PND 21 (Bowers et al. 2015).  No exposure-related deficits in the Morris water maze were 
observed during PNW 7 or 11 in offspring of mouse dams exposed to tetraBDE at 0.03 mg/kg/day via
gavage from pre-mating day 28 to PND 21 (Woods et al. 2012).  Similarly, offspring of mouse dams fed 
cornflakes containing tetraBDE at 0, 0.03, 0.1, or 1 mg/kg/day from pre-mating day 28 through PND 21 
did not show exposure-related impairments in the Morris water maze at PNW 8 (Ta et al. 2011).
However, another study using the same protocol reported a significant increase in the latency to find a 
hidden escape hole in the Barnes maze on the first day of training at ≥0.03 mg/kg/day in PNW 8 offspring 
(Koenig et al. 2012).  No exposure-related effects were observed during trial days 2–4 or during reversal
learning on day 5 (escape hole placed in a different location) at doses up to 1 mg/kg/day (Koenig et al.
2012).  Other studies assessed learning and attention using 5-choice visual learning and attention tasks 
conducted from PND 30 to 95 in offspring of rat dams exposed to pentaBDE via gavage from PND 6 to 
12 (Driscoll et al. 2012; Dufault et al. 2005).  Offspring exposed to 30 mg/kg/day required significantly 
   
 








     
   
 
   
     
 
 
     
   
   
     
       
    
 
   
    
      
     
   
   
  
 
    
    
       
 
   
  
   
    
 




more trials to reach “passing” criterion in the visual discrimination task, and committed significantly
more errors than controls prior to reaching the criterion (Dufault et al. 2005).  The number of omission 
errors (no choice made) was also significantly increased in rats exposed to 30 mg/kg/day.  No exposure-
related impairments were observed in the visual discrimination task at doses ≤15 mg/kg/day, and no 
exposure-related impairments were observed in the sustained attention task at doses up to 30 mg/kg/day
(Driscoll et al. 2012; Dufault et al. 2005).  
In the three-chambered sociability task, general sociability (time spent in the chamber with a social target)
was decreased in female offspring of mouse dams exposed to tetraBDE at 0.03 mg/kg/day via gavage
from pre-mating day 28 to PND 21 (only dose evaluated); no exposure-related changes were observed in
male offspring (Woods et al. 2012).  No changes were observed in social novelty (time spent in the
chamber with a new social target vs. a familiar social target) or barrier social interaction tests (time spent
interacting with social target) in either sex (Woods et al. 2012).  No exposure-related changes in social
interaction were observed in offspring of mouse dams fed cornflakes containing tetraBDE at 0, 0.03, 0.1, 
or 1 mg/kg/day from pre-mating day 28 through PND 21 (Ta et al. 2011).  No performance deficits were
observed in additional neurobehavioral tests in these studies, including the elevated plus maze, acoustic
startle and prepulse inhibition, and fear conditioning (Ta et al. 2011; Woods et al. 2012). Similarly, no
significant, exposure-related changes were observed in social interaction or social novelty indices in
PND 70 offspring of dams administered tetraBDE at 0 or 0.2 mg/kg/day via gavage from GD 8 to 
PND 21 (Kim et al. 2015).  Additionally, no exposure-related effects were observed in social dominance
testing (tube test, urine marking test).
Sensory and motor development. Sensory and motor development (righting reflex, forelimb stick
grasping reflex, forelimb placing reflexes, negative geotaxis, screen grasping and climbing, pole grasping, 
ultrasonic vocalizations, homing test) were assessed in male and female offspring of mouse dams exposed 
to pentaBDE at doses of 0, 0.6, 6, or 30 mg/kg/day via gavage from GD 6 to PND 21 (Branchi et al. 2001,
2002).  The screen climbing response was delayed by approximately 2 days in the 30 mg/kg/day group, 
compared with controls; no other exposure-related changes were observed in reflex development (Branchi
et al. 2001, 2002).  However, in rats, development of the cliff drop and negative geotaxis reflexes was
significantly delayed in male pups following maternal exposure to pentaBDE at 2 mg/kg/day via gavage
from GD 6 to PND 21; no delays were observed in the development of the righting reflex (Cheng et al. 
2009).  Similarly, development of the cliff drop reflex was significantly delayed in male rat pups
following a single maternal exposure to pentaBDE at 0.3 mg/kg on GD 6, but not at 0.06 mg/kg (average
age at which the reflex developed was not reported) (Kuriyama et al. 2005).  However, no exposure­
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related changes were observed in the ability of male offspring to stay on a rotating rod for 3 minutes at
doses up to 0.3 mg/kg (Kuriyama et al. 2005).  In a low-dose study, no exposure-related changes in reflex 
maturation or motor coordination were observed in PND 3–30 offspring of dams exposed to pentaBDE at
0.2 mg/kg/day from GD 1 to PND 21 via gavage (Zhao et al. 2014). Similarly, no changes in grip 
strength or motor coordination (beam test) were observed in PND 12–60 rat offspring of dams fed 
pentaBDE-dosed cookies at intake levels up to 30 mg/kg/day from GD 1 to PND 21 (Bowers et al. 2015). 
However, the acoustic startle response was significantly increased at the highest intensity levels in rats on
PND 9, but not PND 20 (Bowers et al. 2015).  
Sensory and motor development was also tested in offspring of mouse dams fed cornflakes containing
tetraBDE at doses of 0, 0.03, 0.1, or 1 mg/kg/day from pre-mating day 28 to PND 21 (Ta et al. 2011).  No 
significant exposure-related effects were found in the Wahlsten battery for sensory and motor
development (righting reflex, cliff aversion, needle grasp, visual placing, vibrissa placing, eye opening, 
ear opening, ear twitch response, screen pull, screen cling/climb, startle reflex) on PNDs 8–18 or rotarod 
performance on PNDs 35–36; however, significant differences in ultrasonic pup vocalization (UPV)
measures were observed between the 1 mg/kg/day group and control, including increased duration of
UPVs on PND 13 and increased UPV bout duration on PND 9 and 13.  A nonsignificant trend was also 
observed in the 1 mg/kg/day group in the number of UPVs on PNDs 13 and 17 (Ta et al. 2011).  
Similarly, female offspring of mouse dams exposed to tetraBDE at 0 or 0.03 mg/kg/day via gavage from
pre-mating day 28 to PND 21 showed significantly decreased UPV between PND 8 and 16; no exposure-
related deficits were observed in male or female offspring in sensory or motor test batteries from PND 8
to 21 or rotarod performance at PNDs 29–30 or 66–68 (Woods et al. 2012).  Koenig et al. (2012) also 
reported a lack of exposure-related changes motor tests (grip strength, ladder walk, gait analysis) in
PND 14–42 offspring of mouse dams fed cornflakes containing tetraBDE at doses up to 1 mg/kg/day
from pre-mating day 28 through PND 21 (Koenig et al. 2012).
In other studies, no exposure-related changes were observed in functional observation batteries in male
offspring of rat dams exposed to pentaBDE at doses up to 30.6 mg/kg/day via gavage from GD 6 to
PND 21 (assessed at PND 24 or 60) or male mice exposed to single tetraBDE doses up to 30 mg/kg via
gavage on PND 10 (assessed at PNDs 12–18 or at 1 or 3 months of age) (Gee and Moser 2008; Kodavanti
et al. 2010).  
Electrophysiology. Following a single exposure to tetraBDE at 0, 6.8, or 68 mg/kg via gavage on 
PND 10, hippocampal slices from PND 17 to 19 male mice were prepared for field-excitatory
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postsynaptic potential (fEPSP) recordings (Dingemans et al. 2007).  No exposure-related differences in
the stimulus-response relation were seen in fEPSPs.  However, post-tetanus potential (PTP) and long-term 
potential (LTP) were significantly decreased in the hippocampus of exposed mice, compared with 
controls.  No exposure-related effects on paired-pulse inhibition were observed.
To assess auditory function, distortion product otoacoustic emissions (DPOAEs) were measured in adult
offspring of rat dams fed vanilla wafers containing pentaBDE at doses of 0, 5.7, or 11.4 mg/kg/day from
pre-mating day 28 to PND 21 (Poon et al. 2011).  No exposure-related changes were observed in DPOAE
amplitudes, frequencies, or thresholds.
Histology and organ weight. Ultrastructural changes were observed in the hippocampus of 2-month-old 
rats exposed once to tetraBDE on PND 10 at ≥5 mg/kg, but not at 1 mg/kg (He et al. 2009).  At 5 mg/kg, 
the endoplasmic reticulum appeared increasing swollen and degranulated, and at 10 mg/kg, the neurons
were acutely affected, with puffed periplast, dissolved cell organelles, and vacuolized mitochondria (no 
incidence data reported) (He et al. 2009).  No exposure-related changes in hippocampal histology were
observed in PND 70 offspring of mouse dams fed cornflakes containing tetraBDE at 0, 0.03, 0.1, or
1 mg/kg/day from pre-mating day 28 through PND 21 (Ta et al. 2011).
No exposure-related changes in brain weight were observed in neonatal, weanling, or adult offspring
following maternal exposure to pentaBDE at 18 mg/kg/day via gavage on GD 6 to PND 21 (Ellis-
Hutchings et al. 2006), maternal exposure to pentaBDE-dosed cookies at doses up to 30 mg/kg/day from
GD 1 to PND 21 (Bowers et al. 2015), or maternal exposure to pentaBDE-dosed vanilla wafers at doses
up to 11.4 mg/kg/day from pre-mating day 28 to PND 21 (Poon et al. 2011).  Similarly, cerebrum weight
was unaffected in 2-month-old rats exposed once to tetraBDE at doses up to 10 mg/kg via gavage on 
PND 10 (He et al. 2011).
Biochemical, proteomic, genomic, and epigenetic changes. Hippocampal and cortical tissues of rat pups
were evaluated for mRNA and protein expression levels of several T3-mediate proteins (BDNF, NCAM1, 
and GAP-43) following maternal exposure to tetraBDE at 0, 3.2, or 32 mg/kg/day via gavage from GD 1 
to PND 14 (Wang et al. 2011a).  At PNDs 1, 7, and 14, multiple alterations in mRNA and protein levels
were observed; however, magnitude, direction, and significance of the changes were time- and region-
dependent, with no clear exposure-related pattern (Wang et al. 2011a).  In another study, hippocampal
and cortical tissues were evaluated for gene expression levels of TRα1, TRα2, TRβ1, and BDNF in 
PND 21 offspring of rat dams exposed to pentaBDE at 0, 1, or 2 mg/kg/day via gavage from GD 6 to
   
 









   
 
     
 
   
    
  
 








   
       
 
   
    
   
  
   
  
    
     
     
   
    
 




PND 21 (Blanco et al. 2013).  The only exposure-related change observed was a significant decrease in
BDNF expression in the hippocampus at 2 mg/kg/day (Blanco et al. 2013).  
In 2-month-old rats exposed once to tetraBDE at 0, 1, 5, or 10 mg/kg on PND 10, various dose-related
changes were observed in the mRNA and protein expression levels of apoptotic proteins in the
hippocampus, including induction of caspase3, caspase12, and cytochrome C (He et al. 2009).  Costa et
al. (2015) reported similar induction of caspase3 in mice sacrificed 24 hours following exposure to 
20 mg/kg of tetraBDE on PND 10, compared with control.  Markers of oxidative stress were also elevated
in exposed mice, including malondialdehyde (MDA), 8-isoprostane, and reactive protein carbonyls, and 
tetraBDE-mediated induction of caspase3 was significantly greater in glutathione-deficient knockout mice
(Gclm -/-) than in wild-type mice (Costa et al. 2015).  In another 1-day neonatal exposure study, brain 
levels of calcium/calmodulin-dependent protein kinase II (CaMKII), NMDA interacting proteins PSD-95 
and SAP97, AMPA receptor subunit GluR1, and NMDA receptor subunits NR1, NR2A, and NR2B were
measured in PNDs 17–19 mice exposed to tetraBDE at 0, 6.8, or 68 mg/kg on PND 10 (Dingemans et al. 
2007).  Protein expression levels of NR2B, GluR1, and the autophosphorylated-active form of CaMKII
were significantly decreased in exposed mice compared with control.  No exposure-related changes were 
observed for total CaMKII, NR1, NR2A, PSD-95, or SAP97 protein expression levels.  Additionally, 
K+-evoked catecholamine release was evaluated from chromaffin cells isolated from mice in the 0 and
68 mg/kg groups; no significant exposure-related effects were observed (Dingemans et al. 2007).
Hippocampal, cortical, and cerebellar tissues were evaluated for markers of oxidative stress in PND 37
male offspring of rat dams exposed to pentaBDE at 0 or 2 mg/kg/day via gavage from GD 6 to PND 21 
(Cheng et al. 2009).  In the hippocampus of offspring of exposed dams, the specific activities of SOD and
GSH-Px were significantly decreased, lipid peroxidase, H2O2, and NO generation were significantly
increased, and the number of free radicals was significantly increased, compared with controls.  No 
significant changes were observed for these measures in the cerebral cortex or cerebellum, with the 
exception of significantly increased H2O2 generation in the cerebellum.  No changes in brain GSH
concentrations were observed (Cheng et al. 2009). Increased markers of apoptosis and oxidative stress
were also observed in the hippocampus of offspring of rat dams exposed to the commercial pentaBDE
mixture DE-71 at 30.6 mg/kg/day via gavage from GD 6 to PND 14 (Kodavanti et al. 2015).  In a low-
dose study, no exposure-related changes were observed in cortical, cerebellar, or hippocampal levels of
SOD, GSH-Px, GSH, H2O2, NO, or lipid peroxidation in PND 37 male offspring of dams exposed to
0.2 mg/kg/day via gavage from GD 1 to PND 21, compared with controls (Zhao et al. 2014).
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DNA methylation and mRNA levels of DNA methyltransferase (Dmnt1) were measured in adult
offspring of mouse dams exposed to tetraBDE at 0 or 0.03 mg/kg/day via gavage from pre-mating day 28 
to PND 21 (Woods et al. 2012).  Global DNA methylation was significantly decreased in female, but not
male, offspring; no changes were observed in Dmct1 transcript levels.
Cortical and hippocampal cholinergic gene transcription was evaluated in 2-month-old mice exposed to 
pentaBDE at 12 mg/kg via gavage on PND 10 (Hallgren et al. 2015).  Significant transcriptional findings
included increased cortical nAchR-β2, AChR5, and nAChR-α4 in exposed mice, compared with controls;
a near-significant increase in cortical AchE transcription was also observed.  No exposure-related
cholinergic gene transcription changes were observed in the hippocampus of 2-month-old mice.  
Additionally, no exposure-related cholinergic gene transcription changes were observed in the cortex or
hippocampus of mice sacrificed 24 hours postexposure (i.e., PND 11).  Cholinergic effects were also
evaluated in offspring from a one-generation study in mink (Bull et al. 2007). F0 females were exposed 
to dietary pentaBDE at 0, 0.01, 0.05, or 0.25 mg/kg/day from pre-mating day 28 to PNW 6.  No kits were
born in the 0.25 mg/kg/day group; for the other groups, 6 kits/group were sacrificed at PNW 6 and 10 
kits/group continued dietary exposure until PNW 27 and were sacrificed at PNW 45.  In both PNW 6 and 
45 kits, ChE was determined in blood plasma and cerebral cortex.  In the cerebral cortex, ACh, mAChR,
and nAChR binding were also measured.  No exposure-related effects were observed in any cholinergic 
measures in 6-week-old kits or 27-week-old juveniles.
DecaBDE
Neurobehavior. As seen in the lower-brominated PBDE neurobehavioral section, decreased spontaneous
activity and impaired habituation in open-field testing were observed at 2 and 4 months in mice exposed 
once to decaBDE on PND 3 at doses ≥2.22 mg/kg (Buratovic et al. 2014; Johansson et al. 2008; Viberg et
al. 2003b, 2007).  Also as observed with pentaBDE, decaBDE-exposed mice showed significantly altered
responses in a cholinergic-induced behavior task (decreased instead of increased activity) at ≥5.76 mg/kg 
on PND 3 (Buratovic et al. 2014; Johansson et al. 2008).  Following exposure on PND 10 or 19, however,
no exposure-related changes in open-field behavior were observed in mice exposed to decaBDE at doses 
up to 20.1 mg/kg (Viberg et al. 2003b).  In contrast, significantly increased locomotor activity during the
first 1.5 hours of a 2-hour observation period was observed in PND 70 males following exposure to 
decaBDE at 20 mg/kg/day via micropipette from PND 2 to 15 (Rice et al. 2007).  No changes in 
locomotor activity were observed at PND 70 in females or 1 year in either sex at doses up to 20 
mg/kg/day (Rice et al. 2007).  In a perinatal exposure study, no exposure-related changes in motor
   
 








     
      
 
   
 




    
   
    
   
   
     
  
   
   
 
 
    
     
   
 
 
    
      
 
        
  
   
    




activity were observed in neonatal, weanling, juvenile, or adult offspring of rat dams exposed to decaBDE
at doses up to 1,000 mg/kg/day via gavage from GD 6 to PND 21 (Biesemeier et al. 2011).
Operant training and visual discrimination were assessed in young adult (3-month-old) and aging
(16-month-old) mice following exposure to decaBDE at 0, 6, or 20 mg/kg/day via micropipette on 
PNDs 2–15 (Rice et al. 2009). Neurobehavioral tasks included lever-press training followed by a series 
of operant procedures, including a fixed-ratio (FR) schedule of reinforcement, a fixed-interval (FI) 
2-minute schedule, and a light-dark visual discrimination.  No significant, exposure-related effects were 
observed in the young adult cohort; however, learning impairment and impulsivity were observed in the
aging cohort.  In the FR task, exposure did not lead to impaired performance; however, there was a
significant main effect of decaBDE exposure on the slope parameter for the number of earned food 
pellets.  The control group earned the fewest reinforcers at the beginning of the task, and the high-dose
group earned the most; by the end of the 10 sessions, all dose groups earned about the same number of
reinforcers.  In the FI task, there were significant main effects of decaBDE exposure on the fitted mean
for the overall response rate, with the high-dose having a marginally higher response rate than the control
group (p=0.06).  This means that the exposed mice were emitting more responses for the same number of
reinforcers. No significant exposure-related changes were observed for other parameters measured in the 
FI task (pause time, run rate, index of curvature, or number of responses during the feed cycle).  A
number of significantly altered parameters were observed during the visual discrimination task (41 trials).  
Significantly decreased number of first choice errors and shorter response latencies were observed in
6 and 20 mg/kg/day females and 20 mg/kg/day males; these findings were particularly pronounced in the 
earlier trials.  However, mice in the 20 mg/kg/day group showed a significantly higher rate of error in the
last 15 trials, compared with controls.  Additionally, after an initial error, mice in the 20 mg/kg/day group 
made significantly more “perseverative” errors than controls.
Altered spatial learning and memory have been reported in the Morris water maze following prenatal or
neonatal exposure to decaBDE.  While initial spatial learning was not impaired in mice exposed to 5.76 or
13.4 mg/kg on PND 3, reversal learning (ability to find the escape platform in a new location after initial 
training) was significantly impaired at ≥5.76 mg/kg at 5 and 7 months (Buratovic et al. 2014).  Following 
gestational exposure from GD 1 to 14, rat offspring showed significantly impaired spatial learning on 
PND 25 at ≥30 mg/kg/day, but not at 10 mg/kg/day, compared with controls; reversal learning was not
assessed in this study (Chen et al. 2014).  An additional study evaluated spatial learning and memory in 
neonatal mice engineered to express neonatal human apolipoprotein E (three genotypes: apoE2, apoE3, 
and apoE4) exposed once to decaBDE at 0, 10, or 30 mg/kg via micropipette on PND 10 (Reverte et al.
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2013).  Investigators were assessing the potential effect of different human apoE genotypes on 
susceptibility to decaBDE exposure during development, as apolipoprotein is a genetic factor that is
associated with varied vulnerability for the development of neurodegenerative disease.  Impaired learning
and memory were observed at 4 months in apoE3 and apoE4 male mice at ≥10 mg/kg/day and at
12 months in apoE3 females exposed to 30 mg/kg (lack of preference for target quadrant).  No wild-type
mice were evaluated.
In other behavioral tests, no exposure-related changes were observed in auditory startle responses, or
learning and memory in the water-filled T-maze in weanling, juvenile, or adult offspring from rat dams
exposed to decaBDE at doses up to 1,000 mg/kg/day via gavage from GD 6 to PND 21 (Biesemeier et al. 
2011) or in the elevated plus maze in 4-month-old mice exposed once to decaBDE at doses up to
20.1 mg/kg via gavage on PND 3 (Johansson et al. 2008). No changes in were observed in surface-
righting or geotaxis reflexes or motor function assays (tail pull, cling and climb test) at PNDs 12–16 in 
mice engineered to express neonatal human apolipoprotein E (three genotypes: apoE2, apoE3, and 
apoE4) exposed once to decaBDE at 0, 10, or 30 mg/kg via micropipette on PND 10 (Reverte et al. 2014).
Sensory and motor development. A comprehensive functional observation battery was conducted every
other day from PND 2 to 20 in mice exposed to decaBDE at 0, 6, or 20 mg/kg/day via micropipette from
PND 2 to 15 (Rice et al. 2007).  The only exposure-related changes observed were a significant reduction
in the number of male and female pups performing the palpebral reflex on PND 14 and a significant
reduction in the number of male pups performing an effective forelimb grip on PNDs 14 and 16 in the
20 mg/kg/day group.
Electrophysiology. Five groups of developing mice were exposed to decaBDE at 0 or 20.1 mg/kg/day via
gavage during the following periods: gestational (GDs 1–21, via dam), lactational (PNDs 1–21, via dam), 
neonatal (PNDs 3–21, direct), post-weaning (PNDs 22–41), or gestational, lactational, and post-weaning
(GD 1–PND 21, via dam, and PNDs 22–41, direct) (Xing et al. 2009).  In the control group, dams were
administered the vehicle only from GD 1 to PND 21 and offspring were administered the vehicle from
PND 22 to 41.  The dams and pups in all exposure groups were administered the vehicle during non-
exposure periods (e.g., the group exposed to decaBDE during gestation only was administered the vehicle
daily from PND 1 to 41).  In all groups, in vivo extracellular recording of synaptic transmission in the 
hippocampus was measured on PND 60 by placing the anesthetized mice in a stereotaxic head holder.  
Significantly decreased synaptic potency, short-term plasticity, and long-term potentiation were observed 
in exposed mice from the neonatal, post-weaning, and gestation+lactation+post-weaning groups. In the
   
 








   
   
 
 
       
      
       
    
   
   
   
  
 
    
  
    
  
   
  
 
     








   
   




lactation-only group, long-term potentiation was significantly decreased, but no exposure-related changes 
were observed in synaptic potency or short-term plasticity.  No exposure-related changes were observed
in the gestation-only exposure group.
Histology and organ weight. No exposure-related changes were observed in brain weight, histology, or
morphometry in weanling or juvenile offspring from rat dams exposed to decaBDE at doses up to
1,000 mg/kg/day via gavage from GD 6 to PND 21 or PND 10 to 21 (Biesemeier et al. 2011; Fujimoto et 
al. 2011; Saegusa et al. 2012) or juvenile offspring from rat dams exposed to decaBDE at doses up to 
1,500 mg/kg/day via gavage from GD 0 to 17 (Tseng et al. 2008).  Absolute brain weight was
significantly decreased in GD 16 fetuses following maternal exposure to decaBDE at 2,000 mg/kg/day via
gavage on GDs 7–9; however, the difference was no longer significant once brain weights were adjusted
for body weight (Chi et al. 2011).
Biochemical, proteomic, and genomic changes. Seven months following exposure to decaBDE at 0 or
13.4 mg/kg on PND 3, the cortical and hippocampal expression of CaMKII, Gap-43, Tau, and 
synaptophysin were evaluated in male and female mice (Buratovic et al. 2014).  Significant increases in 
protein levels of CaMKII, Gap-43, and Tau were observed in the cortex and hippocampus in exposed 
male mice and increased levels of Tau were observed in the cortex and hippocampus of exposed female 
mice, compared with control.  No changes in synaptophysin were observed.
Neonatal mice engineered to express neonatal human apolipoprotein E (three genotypes: apoE2, apoE3, 
apoE4) were exposed once to decaBDE at 0, 10, or 30 mg/kg via micropipette on PND 10 and evaluated 
for BDNF levels in the hippocampus (Reverte et al. 2013).  When all genotypes were combined for
analysis, hippocampal BDNF levels were significantly elevated in males and females (combined) in the 
30 mg/kg group.  No wild-type mice were evaluated.
Following exposure to decaBDE at 0, 2, 15, or 146 mg/kg/day from GD 10 to PND 21, brains from
offspring sacrificed on PND 20 and 77 were fixed for hippocampal immunohistochemistry (reelin, 
flutamic acid decarboxylase 67 [GAD67], EphA5, Tacr3, and neuron-specific nuclear protein [NeuN])
and cresyl violet staining of apoptotic bodies (Saegusa et al. 2012).  Significant, exposure-related findings 
included an increase in the number of reelin-immunoreactive cells in the dentate hilus in groups exposed
to ≥15 mg/kg/day on PND 20, an increase in the number of EphA5-postive cells in the CA1 layer on
PND 20, and a minimal increase in the number NeuN-immunoreactive cells in the hilus in the
146 mg/kg/day group on PND 77. 
   
 











   
  
     
   
   
  
     
 
     
   
   
  
    
   
     
  
   
    
    
 
 
   
      
    
     
    
  






Lower-brominated PBDEs:  Reproductive performance was assessed in F1 male and female offspring
from rat dams exposed to single pentaBDE doses of 0, 0.06, or 0.3 mg/kg or tetraBDE doses of 0, 0.14, or
0.7 mg/kg on GD 6 via gavage (Kuriyama et al. 2005; Talsness et al. 2005, 2008).  Following pentaBDE
exposure, no significant exposure-related effects were observed in F1 male fertility or F2 litter parameters 
when exposed males were mated with unexposed females (Kuriyama et al. 2005).  Additionally,
ejaculatory and mounting latencies, intromission frequency and latency, and number of penetrations were 
not altered in F1 exposed mice, compared with controls; however, the percent of males with two or more
ejaculations was significantly decreased by 32% in the F1 males from the 0.3 mg/kg group (Kuriyama et
al. 2005).  In pentaBDE-exposed F1 females mated to unexposed males, there were no exposure-related
changes in female pregnancy rate, total implantation sites, implantation sites/dam, F2 fetuses/gravid dam,
or total number of live F2 fetuses (Talsness et al. 2005).  However, the resorption rate was 12 and 15% in 
the 0.06 and 0.03 mg/kg groups, respectively, compared with the control rate of 9%, and the percentage of
litters with resorptions was 69 and 72% in the 0.06 and 0.3 mg/kg groups, respectively, compared with 
the control percentage of 47% (Talsness et al. 2005). Following tetraBDE exposure, reproductive
performance of F1 females was unaltered by developmental tetraBDE exposure (Talsness et al. 2008).
No exposure-related changes were observed for the following F2 litter parameters: total number of
implantation sites, implantation sites/dam, number of live fetuses, fetuses/dam, mean fetal weight, or
resorption rate.  In the 0.7 mg/kg group, the sex ratio was significantly altered; however, comparison of
the altered sex ratio with controls from two different historical experiments (n=24 and 43 litters) revealed
no differences (Talsness et al. 2008).  F1 male reproductive performance was not assessed following
tetraBDE exposure.
Male offspring of rat dams exposed to pentaBDE at 0, 1.7, 10.2, or 30.6 mg/kg/day via gavage from GD 6 
to PND 21 showed a significant 1.8-day delay in PPS (an external sign of pubertal development), 
compared with controls (Kodavanti et al. 2010).  A 5.5% decrease in AGD was also observed at PND 7 in 
the 30.6 mg/kg/day group; although not statistically significant, the study authors argue that this finding
may be biologically relevant, as the findings were not confounded by body weight effects and were
accompanied by the delay in PPS and a 20% decrease in mean testosterone concentration on PND 60 
(Kodavanti et al. 2010).  After maternal exposure to a lower pentaBDE dose (2 mg/kg/day) from GD 6 to 
PND 21 via gavage, no exposure-related changes in AGD were observed in male offspring on PND 1
(Cheng et al. 2009).  Female offspring of rat dams exposed to pentaBDE at 0, 1.7, 10.2, or
   
 








     




   
      
  
   
    
  
  





        
   
    
     
     
 
  
   
      
   
  
   
  




30.6 mg/kg/day via gavage from GD 6 to PND 21 showed a significant reduction in mammary gland 
development on PND 21 at 10.2 and 30.6 mg/kg/day, showing lack of outgrowth, fewer lateral branches
and limited terminal end bud development, compared with controls (Kodavanti et al. 2010).  Vaginal
opening was not assessed.  
As discussed in Section 3.2.2.5 (Reproductive Effects), delays in reproductive development also occurred 
in male and female rats that were exposed to pentaBDE at 0, 3, 30, or 60 mg/kg/day via gavage during
pubertal development (PNDs 23–53 in males or PNDs 22–41 in females) (Stoker et al. 2004).  PPS was
significantly delayed by 1.7 and 2.1 days in the 30 and 60 mg/kg/day groups, respectively, and vaginal
opening was significantly delayed by 1.8 days in the 60 mg/kg/day group.  However, no changes were
observed in estrous cycling at doses up to 60 mg/kg/day (Stoker et al. 2004).
Following a single gavage administration of pentaBDE at 0, 0.06 or 0.3 mg/kg on GD 6 to rat dams, 
various exposure-related sperm effects were observed in male offspring on PND 140 in both dose groups
(Kuriyama et al. 2005).  Spermatid number and daily sperm production were significantly decreased by 
31 and 34%, and sperm number was significantly decreased by 29 and 18%, at 0.06 and 0.3 mg/kg, 
respectively (Kuriyama et al. 2005).
Following a single gavage administration of pentaBDE at 0, 0.06 or 0.3 mg/kg on GD 6 to rat dams, 
multiple ultrastructural changes were noted in the ovaries of female offspring at PND 90 in both exposure
groups, including destruction of the surface of the serosal epithelial cells, necrosis, and numerous
vesicular structures with dense granular material within the cytoplasm (Talsness et al. 2005).  Additional
changes observed in the 0.3 mg/kg group included degenerative changes and aggregates of small and
large vesicles filled with homogeneously dense granular material in the cytoplasm and clumped
chromatin within the condensed nucleus.  No statistically significant, exposure-related histological 
changes were observed at the light microscopic level in the ovary, uterus, or vagina of female offspring,
and no exposure-related effects were observed on the number of ovarian follicles (Talsness et al. 2005).
Following a single gavage administration of tetraBDE at 0, 0.14, or 0.7 mg/kg on GD 6 to rat dams, the
mean number of secondary follicles in the ovaries of female offspring was significantly decreased by 43%
in both exposure groups at PND 38, and the mean number of tertiary follicles was significantly decreased
by 38% in the 0.7 mg/kg group, compared with controls (Talsness et al. 2008).  No exposure-related
changes were observed in the number of primordial, primary, or atretic follicles.  No histopathological
lesions or organ weight changes were observed in the ovary, uterus, or vagina at PND 38 or 100 (Talsness
et al. 2008).  However, ultrastructural changes of the ovaries were observed on PND 200 in F1 females
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from both exposure groups, including an accumulation of vesicular structures with homogeneously dense
granular material in the cytoplasm of the stromal cells, which appeared to fuse together to form large 
vacuoles (Talsness et al. 2008).  No exposure-related histopathological changes were observed in the uteri
or ovaries from female rats exposed to pentaBDE at gavage doses up to 60 mg/kg/day for 20 days during
pubertal development (PNDs 22–41) (Stoker et al. 2004).
In 2-month-old females exposed to tetraBDE on PND 10, relative uterine weights were significantly
decreased by 23–36% at doses ≥1 mg/kg and relative ovary weights were significantly increased by 27– 
35% at doses ≥5 mg/kg (He et al. 2011).  In other studies, no exposure-related changes were observed in 
ovary or uterus weights in PND 100 offspring of rat dams exposed to tetraBDE at doses up to 0.7 mg/kg
via gavage on GD 6 (Talsness et al. 2008), in PND 31 offspring of rat dams exposed to pentaBDE at
18 mg/kg/day from GD 6 to PND 18 via gavage (Ellis-Hutchings et al. 2006), in PND 43 offspring of rat
dams exposed to pentaBDE at doses up to 25 mg/kg/day from pre-mating day 70 to PND 42 (Bondy et al. 
2013), or in PND 42 rats exposed to pentaBDE at doses up to 60 mg/kg/day for 20 days during pubertal
development (PNDs 22–41) (Stoker et al. 2004).
No exposure-related histopathological changes were observed in the epididymides or left testis from male 
rats exposed to pentaBDE at gavage doses up to 60 mg/kg/day for 31 days during pubertal development
(PNDs 23–53) (Stoker et al. 2004).  No other developmental studies examined male reproductive
histology following exposure to lower-brominated PBDEs.
Relative testes weights were significantly increased by 1.3-fold in PND 31 male offspring of rat dams 
exposed to pentaBDE at 18 mg/kg/day from GD 6 to PND 18 via gavage (absolute weights not reported);
no exposure-related changes were observed on PND 12 and 18 (Ellis-Hutchings et al. 2006).  In contrast, 
following a single maternal exposure to pentaBDE on GD 6, adult male rat offspring showed significant
10 and 11% decreases in relative testes weights at 0.06 and 0.3 mg/kg, respectively, as well as a 
significant 5% decrease in relative epididymis weight at 0.3 mg/kg (Kuriyama et al. 2005).  Neither
absolute organ weights nor body weight were significantly altered (Kuriyama et al. 2005).  In other
studies, no exposure-related weight effects were observed in male reproductive organs (seminal vesicles,
prostate, epididymides, or testes) in PND 60 offspring of rat dams exposed to pentaBDE at doses up to
30.6 mg/kg/day from GD 5 to PND 21 (Kodavanti et al. 2010), in 2-month-old rats exposed to tetraBDE
at doses up to 10 mg/kg on PND 10 (He et al. 2011), in PND 43 offspring of rat dams exposed to
pentaBDE from pre-mating day 70 to PND 42 at doses up to 25 mg/kg/day (Bondy et al. 2013), or in 
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PND 53 rats exposed to pentaBDE at doses up to 60 mg/kg/day for 31 days during pubertal development
(PNDs 23–53) (Stoker et al. 2004). 
After a single maternal gavage exposure to tetraBDE on GD 6, serum E2 levels in female rat offspring
were significantly decreased on PND 28 by ~38% at 0.7 mg/kg; no change was observed in the
0.14 mg/kg group (Talsness et al. 2008).  No exposure-related changes in serum testosterone or LH were 
observed in adult F1 males after a single exposure to pentaBDE at doses up to 0.3 mg/kg via gavage on 
GD 6 (Kuriyama et al. 2005).  Exposure-related effects on serum testosterone levels were also not
observed in male offspring of rat dams on PND 60 following exposure to pentaBDE at doses up to
30.6 mg/kg/day from GD 6 to PND 21 (Kodavanti et al. 2010).  In male rats exposed to pentaBDE at 0, 3, 
30, or 60 mg/kg/day via gavage during pubertal development (PNDs 23–53), serum prolactin was
increased 2-fold in the 60 mg/kg/day group approximately 2 hours after the final exposure on PND 53;
however, no exposure-related changes were observed in serum testosterone, serum or pituitary
luteinizing, or pituitary prolactin levels (Stoker et al. 2004).  
DecaBDE:  Male offspring of mouse dams exposed to decaBDE at 0, 10, 500, or 1,500 mg/kg/day via
gavage from GD 0 to 17 were assessed for reproductive system effects on PND 71 (Tseng et al. 2013).
The mean AGD and AGI (anogenital index; corrected for body weight) were significantly reduced in the
1,500 mg/kg/day group, compared with control.  No exposure-related changes were observed in testicular
index ([testicular length x testicular width]/body weight) or male reproductive organ weights (testis,
epididymis, cauda epididymis, or seminal vesicles). However, increased incidences of testicular lesions 
were observed in male offspring, with increased incidence of slight/moderate vacuolization in interstitial
cells in all treated groups (0/5, 4/5, 3/5, or 5/5 at 0, 10, 500, or 1,500 mg/kg/day, respectively) and
increased incidence of slight-severe vacuolization in seminiferous tubules at 1500 mg/kg/day (4/5; control
incidence 0/5).  Additionally, in the 1,500 mg/kg/day group, seminiferous tubules had lost almost all
spermatozoa and spermatids.  Analysis of male offspring sperm parameters (from the seminiferous 
tubules) showed a significant increase in percentage of abnormal sperm heads in the 1,500 mg/kg/day
group (18.2%) compared with controls (10.3%). No changes were observed in abnormal sperm heads at
lower doses, and no changes were observed in sperm count, motility, or velocity at any dose.  However, 
evidence of sperm damage was observed in all exposed groups.  The DNA fragmentation index (DFI) and 
level of sperm with DNA damage (X αT) were significantly elevated in all exposed groups in a dose-
related manner.  Sperm H2O2 generation was significantly elevated in a dose-related manner; however,
only the values in the 10 and 1,500 mg/kg/day groups reached statistical significance in pairwise 
   
 








    
 
 
   
    
   
    
      
  
      






   
  
   
     
 
    






   
    
    
   




comparisons with controls.  No changes were observed in sperm O2- generation. No changes in serum
testosterone levels were observed.
In other studies, no exposure-related changes were observed in AGD, onset of puberty (PPS or vaginal
opening), estrous parameters, and/or reproductive organ weight and histology in offspring of rat dams 
exposed to dietary decaBDE at doses up to 146 mg/kg/day from GD 10 to PND 21 (Fujimoto et al. 2011)
or gavage doses up to 1,000 mg/kg/day from GD 6 to PND 21 (Biesemeier et al. 2011).  Similarly, no 
exposure-related changes were observed in AGD or the onset of puberty (vaginal opening or descent of
the testes) in mice exposed to decaBDE at doses up to 20 mg/kg/day via micropipette from PND 2 to 15 
(Rice et al. 2007). No changes in were observed in vaginal opening or testicle descent in mice engineered
to express neonatal human apolipoprotein E (three genotypes: apoE2, apoE3, and apoE4) exposed once
to decaBDE at 0, 10, or 30 mg/kg via micropipette on PND 10 (Reverte et al. 2014).
Endocrine System Development
Lower-brominated PBDEs:  Histological, ultrastructural, and morphometric changes of the thyroid were
observed at PND 100 in female offspring of dams exposed once to tetraBDE via gavage on GD 6 at 0, 
0.14, or 0.7 mg/kg; however, a clear dose-response pattern cannot be determined from the available data 
(Talsness et al. 2008).  The study authors reported “occasional” follicular cyst formation in the 
0.14 mg/kg group with multiple areas of degenerated follicular epithelium.  In the 0.7 mg/kg group, only
mild cyst formation was observed.  Ultrastructural changes observed in both exposure groups included 
irregular, non-typical follicular shape and detached and swollen follicular cells.  Incidence data were not
reported for any of these end points.  Morphometric analysis showed that the colloid area of the thyroid 
was also significantly increased in offspring, but only in the 0.14 mg/kg group (Talsness et al. 2008).  In 
mink, no exposure-related changes were observed in thyroid histology in PNW 6 offspring of sows
exposed to pentaBDE at doses up to 0.06 mg/kg/day from pre-mating week 4 to PNW 6 (Zhang et al. 
2009).
In rats exposed once to tetraBDE via gavage on PND 10 at doses of 0, 1, 5, or 10 mg/kg, relative thyroid 
weights were significantly decreased by 11% in the 10 mg/kg group at 2 months of age (He et al. 2011).  
In other studies, no exposure-related changes in thyroid weight were observed in rat offspring of dams
exposed once to tetraBDE at gavage doses up to 0.7 mg/kg on GD 6 (Talsness et al. 2008) or in mink
offspring of sows exposed to pentaBDE at doses up to 0.06 mg/kg/day from pre-mating week 4 to PNW 6
(Zhang et al. 2009).
   
 









     
  
     
     
    
        
     
   
   
    
  
  
   
  
 
    
    
     
      
     
   
     
     
  
   
   
   
    
   
 




Significant reductions in serum T4 ranging from 12 to 90% were observed in male and female offspring of
rat dams exposed once to pentaBDE on GD 6 at 0.3 mg/kg (Kuriyama et al. 2007), exposed to pentaBDE
or commercial pentaBDE mixtures from GD 6 to PND 18 or 21 via gavage at doses as low as
2 mg/kg/day (Blanco et al. 2013; Ellis-Hutchings et al. 2006; Kodavanti et al. 2010; Miller et al. 2012;
Shah et al. 2011; Szabo et al. 2009; Zhou et al. 2002), exposed to pentaBDE from GD 1 or 6 to PND 21 
via dosed cookies at intake levels ≥3 mg/kg/day (Bansal et al. 2014; Bowers et al. 2015), or exposed to
dietary tetraBDE from GD 1 to PND 14 at doses ≥3.2 mg/kg/day (Wang et al. 2011a).  These reductions
were observed in offspring between PND 7 and 22.  In studies described above that also evaluated
offspring at older ages, it was found that the effects were no longer observed at PNDs 31–60 (Bowers et
al. 2015; Ellis-Hutchings et al. 2006; Kodavanti et al. 2010; Szabo et al. 2009; Zhou et al. 2002), 
indicating that serum T4 changes in offspring may be transient.  In one-generation studies, offspring from
rat dams fed pentaBDE-dosed vanilla wafers from pre-mating day 28 to PND 21 showed significant 43– 
55% reductions in serum T4 on PND 21 at ≥5.7 mg/kg/day (Poon et al. 2011) and male and female 
offspring from rat dams exposed to pentaBDE via gavage from pre-mating day 70 to PND 42 showed 
significant 65–70% reductions in serum T4 on PND 21 at 25 mg/kg/day (but not ≤5 mg/kg/day) (Bondy et
al. 2011, 2013).  In rats and mice exposed once to tetraBDE via gavage on PND 10 at doses up to 10 or
20 mg/kg, respectively, no exposure-related changes were observed in serum T4 levels (Costa et al. 2015;
Gee et al. 2008; He et al. 2011).  In other mouse studies, maternal exposure to the pure pentaBDE
congener BDE 99 at doses up to 452 mg/kg/day via gavage from GD 6 to PND 21 or from GD 4 to
PND 17 did not lead to altered serum T4 levels in offspring at PNDs 11–37 (Branchi et al. 2005; Skarman 
et al. 2005).  In contrast, maternal exposure to the commercial pentaBDE mixture Bromkal 70-5DE at
452 mg/kg/day via gavage from GD 4 to PND 17 caused a significant 29–32% reduction in serum T4 in 
PND 11 mouse offspring (Skarman et al. 2005). This effect was transient, as it was no longer observed at
PND 18 (Skarman et al. 2005).  In mink, no exposure-related changes were observed in serum T4 levels in
PNW 6 offspring of sows exposed to dietary pentaBDE at doses up to 0.06 mg/kg/day from pre-mating
week 4 to PNW 6 (Zhang et al. 2009).  In mink offspring that continued exposure through PNW 33, 
serum T4 levels were significantly increased by 31% compared with control; however, this response was 
entirely attributable to the females, which were significantly elevated by 71% compared to males at the
same dose (change compared with female controls was not reported) (Zhang et al. 2009).
Evidence for exposure-related serum T3 changes is less consistent.  In a one-generation study, male and 
female offspring from rat dams exposed to pentaBDE via gavage from pre-mating day 70 to PND 42
showed significant 16–27% reductions in serum T3 on PND 21 at 25 mg/kg/day (but not ≤5 mg/kg/day)
   
 








     
        
 
     
    
       
    
   
    
  
      






      
   
     
    
  
 
    
      
  
   
    
     
    
   





(Bondy et al. 2013).  Similarly, offspring of rat dams exposed to pentaBDE at ≥2 mg/kg/day via gavage
from GD 6 to PND 21 showed a significant 19–25% reduction in serum T3 levels on PNDs 21–23 and 
offspring from dams fed cookies dosed with ≥3 mg/kg/day pentaBDE from GD 1 to PND 21 showed a
significant 5–40% reduction in serum T3 levels on PND 21; no exposure-related effect was observed at
doses ≤1.7 mg/kg/day (Blanco et al. 2013; Bowers et al. 2015; Shah et al. 2011). This effect was 
transient, as it was no longer observed at PND 50 or later (Bowers et al. 2015; Shah et al. 2011). In
contrast, exposure-related changes in serum T3 levels were not observed in offspring of rat dams exposed 
to pentaBDE at doses up to 30.6 mg/kg/day via gavage or pentaBDE-dosed cookies from GD 6 to PND 
18 or 21 (Bansal et al. 2014; Ellis-Hutchings et al. 2006; Kodavanti et al. 2010; Szabo et al. 2009) or
offspring of rat dams exposed to a single pentaBDE dose up to 0.3 mg/kg on GD 6 via gavage (Kuriyama
et al. 2007).  In rats and mice exposed once to tetraBDE via gavage on PND 10 at doses up to 10 or
20 mg/kg, respectively, no exposure-related changes were observed in serum T3 levels (Costa et al. 2015;
Gee et al. 2008; He et al. 2011).  In mink, no exposure-related changes were observed in serum T3 levels 
in PNW 6 offspring of sows exposed to pentaBDE at doses up to 0.06 mg/kg/day from pre-mating week 4
to PNW 6; however, in offspring that continued exposure through PNW 33, serum T3 levels were 
significantly reduced by ~31% at 0.06 mg/kg/day (Zhang et al. 2009).
No exposure-related changes in serum TSH were observed in offspring of rat dams exposed to a single 
pentaBDE dose up to 0.3 mg/kg on GD 6 via gavage (Kuriyama et al. 2005), offspring of rat dams
exposed to pentaBDE at doses up to 30.6 mg/kg/day via gavage or pentaBDE-dosed cookies from GD 6
to PND 21 (Bansal et al. 2014; Kodavanti et al. 2010), or rats exposed once to tetraBDE via gavage on 
PND 10 at doses up to 10 mg/kg (He et al. 2011).
DecaBDE:  Following maternal exposure to decaBDE at 0, 2, 15, or 146 mg/kg/day via gavage from
GD 6 to PND 21, the incidences of diffuse follicular cell hypertrophy in the thyroid of rat offspring on 
PND 21 were 0/10, 1/10, 3/10, and 9/10 in males and 0/10, 3/10, 2/10, and 4/10 in females, respectively
(Fujimoto et al. 2011).  No change was observed in thyroid weight (Fujimoto et al. 2011).  Following
maternal exposure to decaBDE at 0, 10, 500, or 1,500 mg/kg/day via gavage on GDs 0–17, histological
evaluation of the thyroid glands in male offspring at PND 71 showed that a few acini were slightly
enlarged in the 1,500 mg/kg/day group, compared to the controls (female offspring were not evaluated)
(Tseng et al. 2008).  The normal cuboidal epithelium had dose-dependently transformed into squamous
epithelium, with the most notable change found in the 1,500 mg/kg/day group.  Incidence data for
histological lesions were not reported (Tseng et al. 2008).  
   
 








     
   
      
    
    
     
   
    
    
  
    






    
  
   
  
    
  
   
    
      
    
    






Serum T3 levels were significantly reduced by 16% on PND 21 in male offspring of rat dams exposed to 
decaBDE at 146 mg/kg/day via gavage from GD 6 to PND 21; no change was observed in serum T3 levels 
in female offspring or serum T4 or TSH levels in either sex at doses ≤146 mg/kg/day (Fujimoto et al. 
2011).  Following maternal exposure to decaBDE at 0, 10, 500, or 1,500 mg/kg/day via gavage on 
GDs 0–17, serum T3 levels were significantly decreased by 21% in the 10 and 1,500 mg/kg/day groups in 
male mouse offspring examined on PND 71 (female offspring not examined); serum T3 levels were not
significantly altered in the 500 mg/kg/day group and serum T4 levels were not altered in any group (Tseng
et al. 2008).  In neonatal male mice exposed to 0, 6, or 20 mg/kg/day from PND 2 to 15, serum T4 was 
reduced by ~8 and 22% at 6 and 20 mg/kg/day, respectively (Rice et al. 2007).  This finding was reported
as a dose-related trend; however, pair-wise statistics were not reported.  No exposure-related changes in
serum T4 levels were observed in similarly exposed neonatal female mice (Rice et al. 2007).  Serum T3 
levels were not examined by Rice et al. (2007).
Immune System Development
Lower-brominated PBDEs:  In a one-generation study, F0 rats were exposed to pentaBDE at 0, 0.5, 5, or
25 mg/kg/day via gavage for 70 days prior to mating, through mating, gestation, and lactation (PND 21)
(Bondy et al. 2013).  F1 rats continued exposure to their respective doses from PND 22 to 42.  Half of the
F1 rats were sacrificed on PND 43 and assessed for serum immunoglobin levels, B and T lymphocyte
quantification in the spleen, spleen cell proliferation in vitro, and immune organ weight and histology.  
The remaining F1 rats were assessed for immune function at PND 56 using the KLH antigen immune
challenge.  Serum IgE and IgG1 levels were significantly reduced by 77 and 53%, respectively, in 
females at 25 mg/kg/day; no changes were observed in serum IgE or IgG1 levels in males or serum IgM, 
IgA, IgG2a, IgG2b, or IgGc levels in either sex.  All exposed groups showed a significant, dose-related
reduction in the proportion of B cells and a significant concomitant increase in the proportion of T cells in 
the spleen (7–18%).  In vitro, increased proliferation of unstimulated spleen cells was observed in cells
harvested from F1 males and females from the 25 mg/kg/day group; however, the proliferative response 
to ConA or lipopolysaccharide (LPS) stimulation was not affected by pentaBDE exposure.  In the thymic
cortex from F1 rats, mild increases in apoptotic lymphocytes and tingible macrophages were observed in
F1 males (0/14, 1/19, 3/13, and 3/13) and F1 females (0/13, 3/17, 0/13, and 4/14) in control, 0.5, 5, and 
25 mg/kg/day groups, respectively. Trend test analysis indicated that the increase was significantly dose-
related in males, but not females.  No treatment-related histopathological changes were observed in the 
Peyer’s patches, mesenteric lymph nodes, or spleen of F1 rats.  Absolute thymus weights were 
significantly increased in the 5 mg/kg/day males and females and relative thymus weight was only
   
 









   






    
   
     
   




    
  
   
    




    
      
  
 
    
   
 




increased in the 5 mg/kg/day females; no changes were observed in thymus weights at 25 mg/kg/day.  
These organ weight changes reflect observed body weight changes (significantly increased in the
5 mg/kg/day group).  In the immune challenged rats, no exposure-related changes were observed in
KLH-specific IgG levels or changes in delayed-type hypersensitivity responses to KLH injections (Bondy
et al. 2013).  In another one-generation study (pre-mating day 28 to PND 21), maternal exposure to 
pentaBDE-dose vanilla wafers at doses up to 11.4 mg/kg/day had no effect on thymus weight in PND 21 
offspring (Poon et al. 2011).
In a poorly-reported study, mouse dams were exposed to pentaBDE at 0, 50, 100, or 200 mg/kg/day via
gavage from GD 6 to PND 21 (Hong et al. 2010).  In PND 21 offspring, study authors report exposure-
related decreases in serum IgM and IgG1, decreased absolute and relative spleen weights at
≥100 mg/kg/day, and reduced cellularity levels at ≥100 mg/kg/day.  No statistically significant increases
in T- or B-cell lymphocyte proliferation were observed in vitro. The only significant effect observed in 
PND 63 offspring was increased T-cell proliferation following in vitro exposure to ConA at
200 mg/kg/day.
In another study, absolute spleen weight was significantly increased by 9% in PND 140 male offspring of
rat dams exposed to single pentaBDE doses of 0.06 and 0.3 mg/kg on GD 6; relative spleen weight was
only significantly increased in the 0.06 mg/kg group (12%) (Kuriyama et al. 2005).  No organ weight
changes were observed in the thymus of PND 140 male rats (Kuriyama et al. 2005).  Following maternal
exposure to pentaBDE at 0 or 18 mg/kg/day via gavage from GD 6 to PND 18, no exposure-related
changes were observed in spleen or thymus weights measured in rat offspring on PNDs 3, 12, 18, and 31 
(Ellis-Hutchings et al. 2006).
DecaBDE:  Immune function in PND 28 mice was assessed using the RSV intranasal infection test
following maternal exposure to decaBDE from GD 10 to PND 21 at doses of 0, 3.3, 34, 260, or
3,100 mg/kg/day (Watanabe et al. 2008). Typical features of pneumonia due to RSV infection were
observed in all RSV-infected mice; however, exacerbation of histopathological changes in the lung was
observed in 50% of mice exposed to 3,100 mg/kg/day, including hypertrophy and/or hyperplasia.  Five
days after the RSV infection, pulmonary viral titers of RSV and bronchoalveolar lavage fluid (BALF)
levels of IFN-γ were significantly increased in the 260 mg/kg/day group (titers and BALF fluid not
assessed in the 3,100 mg/kg/day group).  Additionally, mRNA expression of RANTES (a characteristic 
marker of severity of inflammation in the lungs due to an RSV infection) was significantly elevated at
34 and 260 mg/kg/day (Watanabe et al. 2008).  In a second study, immune function in PND 28 mice was
   
 








     
    
   
   




    
       
    
    
    
   
   
     




   
  
      
   
    
  
   
 
      
   
 




also assessed using the RSV infection test following maternal exposure to decaBDE from GD 10 to
PND 21 at doses of 0, 290, or 2,900 mg/kg/day (Watanabe et al. 2010b).  In this study, pulmonary viral
titers of RSV were significantly increased in the 2,900 mg/kg/day group 1 and 5 days post-infection.  
BALF levels of TNF-α, IL-6, and IL1β were significantly decreased one day post-infection (cytokine
levels at 5 days postexposure were not reported).  No exposure-related changes were observed in BALF
cell TNF-α production in vitro in response to LPS.  
In a poorly-reported study, mouse dams were exposed to decaBDE at 0, 500, 2,500, or 12,500 mg/kg/day
via gavage from GD 6 to PND 21 (Hong et al. 2010).  Absolute and relative thymus weights were
significantly increased in offspring the 2,500 mg/kg/day group at PND 21, but not the 500 or
12,500 mg/kg/day groups.  At PND 21, no exposure-related changes were reported for spleen weight,
spleen, or thymus cellularity, serum IgM or IgG1 levels, or T- or B-cell lymphocyte proliferation in vitro. 
The study authors report an increase in the relative B cell population and a decrease in the relative 
distribution of macrophage cells in spleens from pups exposed to decaBDE (no statistics provided).  No
exposure-related effects were observed at PND 63.  In another study, no exposure-related changes in
spleen weight were observed in PND 71 male offspring of mouse dams exposed to decaBDE at doses up
to 1,500 mg/kg/day from GD 0 to 17 (Tseng et al. 2008).
Summary
Teratology, fetotoxicity, and physical growth and development: No human studies have evaluated
associations between embryotoxicity or fetotoxicity and PBDE exposure.  Evidence for altered physical
grown and development from human studies is inconsistent. Available data from animal studies do not
indicate that PBDEs are embryotoxic or fetotoxic at PBDE doses below doses that elicited maternal
toxicity, although occasional observations of reduced pup weight were reported.  Taken together, it is
unlikely that oral PBDE exposure will cause embryotoxicity or fetoxicity in humans; however, data
indicate that PBDE exposure could potentially lead to low birth weight.
Neurodevelopment: Evidence from both human and animal studies indicates that oral PBDE exposure
can lead to adverse effects in neurodevelopment, leading to altered neurobehavior later in life.
Reproductive system development: Based on limited human and adequate animal data, it is possible that
that oral PBDE exposure during development may adversely affect the developing reproductive system, 
   
 









      
 
      
     
   
   
 





     
 
   
 
   
     
    
    
    
       
     
  
    
    
     






particularly the male reproductive system.  However, data are too limited to adequately determine 
whether or not PBDE exposure in infants and children will lead to altered reproductive performance.
Endocrine system development: While human data are inconsistent, they suggest that PBDEs can interact
with thyroid hormone homeostasis in infants and children. These data, along with available animal
studies, indicate that the thyroid is a target of concern for PBDE exposure, especially lower-brominated 
PBDEs.
Immune system development: Animal data suggest that oral PBDE exposure during development may
lead to immunosuppression; however, data are too limited to adequately assess the immunotoxic potential
of PBDE exposure in infants and children.
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in
each species and duration category are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.7  Cancer
Human Studies.  There was no clear association between risk of non-Hodgkin’s lymphoma (NHL) and 
exposure to 2,2'4,4'-tetraBDE in a case-control study of 77 Swedish men and women who were recruited
in 1995–1997 and ranged in age from 28 to 85 years (Hardell et al. 1998; Lindstrom et al. 1998).  Adipose
tissue concentrations of 2,2',4,4'-tetraBDE (BDE 47) (used as a marker for total PBDE exposure) were 
compared in 19 patients with NHL, 23 patients with malignant melanoma, 8 patients with other cancers or
in situ changes, and 27 persons with no cancer diagnosis.  The highest concentrations were seen in the
patients with NHL. The mean concentration of BDE 47 was 13.0 ng/g (ppb) lipid (range 1.0–98.2 ppb) in 
the 19 NHL patients and 5.1 ppb (range 0.6–27.5 ppb) in the 27 persons without known malignancies.  
Logistic regression, adjusted for age, gender, sum of PCBs, and sum of chlordanes, was performed on 
cases and controls in three concentration groups (<2.05, 2.05–<5.43, and ≥5.43 ppb).  A nonsignificantly
elevated risk with a suggestive dose-response was found for NHL in the two highest concentration groups
compared with the lowest group; the ORs and 95% CIs were 1.9 (0.3–14) and 3.8 (0.7–26) in the middle
and high groups, respectively.  Although the risk was highest in the group with the highest concentration
of 2,2'4,4'-tetraBDE (p=0.09 for trend), there was no significant difference between cases and controls 
(p=0.14).  The results for patients with malignant melanoma did not differ from controls.
   
 








    
      
   
    
  
  
    
      
      
     
   
 
     
 
   
       
 
    
   
     
   
     
  
   
  
      
 
 
   
    
   
  




Hardell et al. (2006) found no association between testicular cancer risk and serum PBDE (sum of
congeners 47, 99, and 153, but concentrations not reported) in a study of 58 cases recruited from hospitals
in Sweden and age-matched controls.  Blood was also collected from the mothers of the cases and
controls (44 of the case mothers and 45 of the control mothers agreed to participate).  There was a 
marginally significant relationship between maternal PBDE and the risk of testicular cancer in sons (OR
2.5, 95% CI 1.02–6.0 using median concentration in mothers of controls as a cut-off) and some evidence 
of a dose-response (OR 3.2, 95% CI 1.1–11 for those with high concentrations of PBDE in blood 
[>75th percentile] and OR 1.8, 95% CI 0.6–7.9 for those with low concentrations of PBDE in blood 
[median–75th percentile]). The relevance of this finding is uncertain, as it is unclear the extent to which 
the case mothers’ body burden of PBDE at the time of the study might relate to body burden when giving
birth to the cases (approximately 30 years previously, as median age of the cases was 30 years). A case-
control study of Singaporean males found no significant association between serum levels of BDE 47 and 
risk of prostate cancer (Pi et al. 2016).  The study included 240 prostate cancer incident cases and
268 controls.  Serum concentrations of BDE 47 were 37 ng/g lipid in cases and 58 ng/g lipid in controls.  
Other BDEs analyzed in serum included BDE 99, BDE 100, BDE 153, BDE 154, and BDE 183, but the
concentrations were below the limit of detection of the analytical method (0.3–20 pg/g lipid). 
PBDE concentrations in adipose tissue (sum of congeners 28, 47, 66, 100, 99, 85, 154, 153, 138, and 183)
were significantly higher in 21 cases with exocrine pancreatic cancer recruited in Sweden 1996–1999
(median 3.1 ng/g lipid) than in 59 controls comprising 20 males undergoing transurethral resection for
benign prostate hyperplasia and 39 females undergoing hysterectomy 1997–1998 in the same
geographical area (median 1.6 ng/g lipid) (Hardell et al. 2007).  Case-control analysis found that the risk
of pancreatic cancer was not significantly increased with lipid PBDE (OR 3.90, 95% CI 0.93–16.3) using
median concentration in controls as a cut-off after adjustment for age, sex, and BMI at tissue sampling,
but that the increase in risk was significant when the BMI adjustment was performed for the year before 
tissue sampling (OR 7.67, 95% CI 1.53–38.5, body weight 1 year before tissue sampling obtained by
questionnaire).
Serum concentrations of PBDEs (10 tri- to hepta-BDEs) were not associated with risk of thyroid cancer in
a nested case-control study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a large 
multicenter clinical trial in the United States (Aschebrook-Kilfoy et al. 2015).  The study included 
104 case of thyroid cancer and 208 controls matched to cases by race, sex, birth date, center, and blood 
collection date.  Median lipid adjusted concentrations of ΣPBDEs (sum of BDE 47, 99, 100, and 153)
were 12.8 ng/g for cases and 19.4 ng/g for controls.  For ΣPBDEs, the OR for the fourth versus the first
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3. HEALTH EFFECTS
quartile was 0.62 (95% CI 0.29–1.30). Restricting the analyses to cases with the papillary subtype (75%
of the cases) did not alter the findings. 
A case-control study found no evidence of an association between adipose concentrations of PBDE (BDE
47, BDE 99, BDE 100, BDE 153, BDE 154, and their sum) and breast cancer risk in women from the San 
Francisco Bay area of California (Hurley et al. 2011).  The study population included 78 cases with 
histologically confirmed invasive breast cancer and 56 controls with benign histological changes 
undergoing surgical breast biopsies.  PBDE concentrations in both cases and controls were relatively high
(median values of 56.32 and 72.25 ng/g lipid in cases and controls, respectively, for total BDE). Another
case-control study of 170 native Alaskan women reported that cases (n=75) had significantly higher
serum levels of BDE 47 (38.8 ng/g lipid) than controls (n=95, 25.1 ng/g lipid) (Holmes et al. 2014).  The
result of univariate logistic regression analysis showed increase risk that approached statistical 
significance (OR 1.79, 95% CI 0.97–3.32); no statistical significance was apparent in multivariable
analysis (OR 1.58, 95% CI 0.75–3.33).  
Animal Studies.  Information on carcinogenic effects of PBDEs in animals is limited to results of chronic
bioassays of decaBDE mixtures in rats and mice (Kociba et al. 1975; Norris et al. 1975a; NTP 1986).  As
summarized below, these studies provide limited evidence for the carcinogenicity of decaBDE in animals.  
No carcinogenicity studies of octaBDE or pentaBDE were located in the available literature.
NTP evaluated the carcinogenicity of commercial-grade decaBDE (94–97% pure, no detected brominated 
dioxins or furans) in Sprague-Dawley rats (50/sex/dose) and B6C3F1 mice (50/sex/dose) that were
exposed in the diet for 103 weeks and observed for an additional 0–1 weeks (NTP 1986).  Comprehensive
gross and histological examinations were performed on all animals in all dose groups including those that
were moribund or died during the study.  Reported estimated dose levels in the rats were 1,120 and 
2,240 mg/kg/day in males and 1,200 and 2,550 mg/kg/day in females.  Incidences of liver neoplastic 
nodules in low- and high-dose male rats (7/50 and 15/49, respectively) and high-dose female rats (9/50)
were significantly greater than in controls (1/50 in both males and females) (p≤0.03, Fisher Exact test)
and showed positive dose-related trends (p<0.001, Cochran-Armitage trend test). Incidences of
hepatocellular carcinoma alone (1/50, control males; 1/50, low-dose males; 1/49, high-dose males; 0/50, 
control females; 2/49, low-dose females; and 0/50, high-dose females) were not significantly increased in
the treated rat groups compared to controls. The increased incidences of neoplastic nodules were 
considered as “some evidence of carcinogenicity” in both sexes.  However, although it was concluded 
that there was some evidence of carcinogenicity in male and female rats based on “neoplastic nodules,” 
   
 













   







    
   
     
    





       
    
    
     
   
 
     
     




this is a poorly defined and understood term that is no longer used by NTP to characterize
hepatoproliferative lesions in rats.  A dose-related trend for mononuclear cell leukemia was observed in 
treated male rats but was not considered to be biologically significant because of a high incidence in
control animals.
Reported estimated doses in the mice were 3,200 and 6,650 mg/kg/day in males and 3,760 and 
7,780 mg/kg/day in females (NTP 1986).  Hepatocellular adenoma or carcinoma (combined) occurred at
significantly increased incidences in low-dose male mice (22/50, p=0.002) and high-dose male mice 
(18/50, p=0.019) in comparison to controls (8/50) and showed a positive dose-related trend (p=0.021).  
Incidences of hepatocellular carcinoma alone were not significantly increased in either the low- or high-
dose male mice.  Slightly elevated incidences of thyroid gland follicular cell adenoma or carcinoma 
(combined) were additionally observed in exposed male mice but the increases were not statistically
significant (control, 0/50; low dose, 4/50; high dose, 3/50).  Incidences of follicular cell hyperplasia were 
significantly increased in male mice as summarized in the subsection on Endocrine Effects in
Section 3.2.2.2.  No significantly increased incidences of neoplastic lesions were observed in the female 
mice.  NTP (1986) concluded that the significant increase in liver tumors and equivocal increase in
thyroid tumors represented equivocal evidence of carcinogenicity in male mice. The evidence of
carcinogenicity in the male mice was considered limited by an early loss of control animals.  Losses of
control male mice were significant during the first year of the study, but were subsequently comparable to
the dosed mice; the early losses were presumed to be due to fighting among animals in both control and 
treatment groups.
The carcinogenicity of decaBDE was also evaluated in Sprague-Dawley rats (25/sex/dose) that were 
exposed to dietary doses of 0, 0.01, 0.1, or 1.0 mg/kg/day for approximately 2 years (702 days for males,
735 days for females) (Kociba et al. 1975; Norris et al. 1975a).  The commercial mixture was comprised
of 77.4% decaBDE, 21.8% nonaBDE, and 0.8% octaBDE and therefore differs from typical decaBDE
formulations containing ≥97% decaBDE.  Comprehensive histological examinations showed no 
exposure-related neoplastic effects. The ability of this study to detect carcinogenic changes is limited by
the very low dose levels in comparison to those tested in the NTP (1986) bioassay.
Summary.  With the exception of one small case-control study reporting possible associations between
adipose PBDE concentrations and risk of pancreatic cancer, there is no evidence for carcinogenicity of
PBDEs in human studies. There is limited evidence of carcinogenicity in animals in a NTP bioassay with
decaBDE (significantly increased incidences of neoplastic liver nodules in rats and combined 
   
 









     
 
    
 
  
     
   
  
    
  







    
   
  
 






   
  
 






hepatocellular adenomas and carcinomas in mice). The Cancer Effect Levels (CELs) for decaBDE in the 
NTP (1986) study are recorded in Table 3-3 and plotted in Figure 3-3.
3.2.3 Dermal Exposure 
A few studies have examined groups of chemical workers involved in the manufacture and distribution of
PBDEs (Bahn et al. 1980; Brown et al. 1981; Chanda et al. 1982; Landrigan et al. 1979; Rosenman et al. 
1979; Stross et al. 1981).  Although the route of exposure (inhalation relative to dermal) of these workers 
has not been well defined, they appear to have had a high potential for dermal exposure (Anderson et al.
1978).  Results from these studies are discussed in this section, as well as in Section 3.2.1.  Dermal
exposure may not be an important route of concern for PBDEs because dermal absorption is likely to be 
low, particularly for the highly brominated congeners, based on in vitro dermal absorption assays (Hughes
et al. 2001; Roper et al. 2006).
3.2.3.1  Death 
No reports of death in humans after dermal exposure to PBDEs were located in the available literature.
No deaths occurred in rabbits that were observed for 14 days following a single ≤2,000 mg/kg dermal
dose of decaBDE, octaBDE, or pentaBDE (IRDC 1974, 1975a, 1975b).  The PBDEs were applied to 
clipped intact skin, covered with an occlusive barrier, and washed from the treatment site 24 hours later. 
3.2.3.2  Systemic Effects
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological,
musculoskeletal, hepatic, or renal effects in humans or animals after dermal exposure to PBDEs.
Systemic effects that have been observed in humans and animals following dermal exposure to PBDEs 
are described below. The highest NOAEL and all LOAEL values from each reliable study for systemic 
end points in each species and duration category are recorded in Table 3-4.
Endocrine Effects. There is suggestive evidence of hypothyroidism in a small group of workers who 
were occupationally exposed to decaBDE (Bahn et al. 1980) as summarized above and detailed in 
Section 3.2.1.2.






(Route) System NOAEL 
Reference 
Chemical Form Comments Less Serious Serious 
ACUTE EXPOSURE 
Systemic 
Rabbit 24 hr 
(New 
Zealand) 






Rabbit 24 hr 
(New 
Zealand) 




















Note on chemical form: The chemical forms included technical octaBDE and pentaBDE mixtures (exact compositions were not reported). 
Bd Wt = body weight; hr = hour(s); LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level 
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3. HEALTH EFFECTS
No studies were located regarding endocrine effects in animals after dermal exposure to PBDEs.
Dermal Effects. No studies evaluating dermal exposure of PBDEs were located.
There was no evidence of primary irritation in intact skin of rabbits that were dermally exposed to a
former commercial decaBDE mixture (500 mg as dry solid was applied to clipped skin and occluded for
24 hours) (IRDC 1974).  A similar application of 77.4% decaBDE (containing 21.8% nonaBDE and 0.8%
octaBDE) (dry solid, amount not reported), octaBDE (500 mg as dry solid), or pentaBDE (0.5 mL as a 
viscous liquid) was also non-irritating to intact rabbit skin (IRDC 1975a, 1975b).  
OctaBDE and pentaBDE were non-sensitizing in maximization tests in guinea pigs (Microbiological 
Associates Inc. 1996).  The induction doses consisted of three pairs of interscapular region intradermal
injections of (1) a 50:50 solution of Freund’s adjuvant and corn oil, (2) 2.5% octaBDE or 5% pentaBDE
solutions in corn oil, and (3) 2.5% octaBDE or 5% pentaBDE in the 50:50 corn oil/Freund’s adjuvant
solution.  Control groups received the same regimen without PBDEs.  After 7 days, the PBDE-treated
animals received topical applications of neat octaBDE or pentaBDE on the previously treated
interscapular sites. Two weeks later, the animals were challenged with topical doses of neat octaBDE or
pentaBDE on the left flank.  Subsequent examination of the test sites at 24, 48, 72, 96, or 120 hours after
the challenge dose showed no erythema or edema responses in any of the animals, indicating that the 
PBDEs did not cause delayed contact hypersensitivity.
A 10% chloroform solution of 77.4% decaBDE (containing 21.8% nonaBDE and 0.8% octaBDE) did not
induce bromacne when applied to the ear of rabbits for 30 days (Norris et al. 1975a).  A slight 
erythematous response and slight exfoliation were the only observed effects.  No additional information 
was reported on the design and results of this acnegenesis study.
Ocular Effects. No studies were located regarding ocular effects in animals after dermal exposure to
PBDEs.
Ocular effects were investigated in rats that had 100 mg decaBDE (solid), 100 mg octaBDE (solid), or
0.1 mL pentaBDE (viscous liquid) instilled into the conjunctival sac (IRCD 1974, 1975a, 1975b). The
eyes were examined for irritation after 24, 48, and 72 hours and 7 days and corneal injury after 72 hours.  
There were no exposure-related effects with decaBDE or octaBDE, although pentaBDE caused slight
evidence of corneal damage in one of six rats (IRDC 1975b).
   
 













     
   
  
 





   
  
   
 
   
 
      
  
     




   
      
     
   
    
 
  




Body Weight Effects. No studies were located regarding body weight effects in humans after dermal
exposure to PBDEs.
There were no adverse effects on body weight in rabbits that were observed for 14 days following a single
≤2,000 mg/kg dermal dose of decaBDE, octaBDE, or pentaBDE (IRDC 1974, 1975a, 1975b).  The
PBDEs were applied to clipped intact skin, covered with an occlusive barrier, and washed from the 
treatment site after 24 hours.
No studies were located regarding the following effects in humans or animals after dermal exposure to
PBDEs:
3.2.3.3  Immunological and Lymphoreticular Effects 
3.2.3.4  Neurological Effects 
3.2.3.5  Reproductive Effects
3.2.3.6  Developmental Effects 
3.2.3.7  Cancer
3.3  GENOTOXICITY
Limited information exists regarding the in vivo genotoxicity of PBDEs. The frequency of micronuclei in 
peripheral lymphocytes was significantly higher in 23 Chinese workers who dismantled electronic waste
(median PBDE serum concentrations 382 ng/g lipid weight) compared with 26 unexposed workers (median 
PBDE serum concentrations 158 ng/g lipid weight) (Yuan et al. 2008). Multivariate logistic regression
analysis of several risk factors showed that only history of engaging in dismantling electronic waste was a 
significant predictor of micronuclei frequencies.  The investigators also noted that pollutants other than 
PBDEs also may have played a role in the increased frequency of micronuclei.  No evidence of oxidative
DNA damage was found in peripheral lymphocytes from exposed workers.  A study of 84 healthy Korean 
subjects from the general population reported that serum concentrations of BDE 47 and BDE 99 were not
associated with telomere length in peripheral lymphocytes (Shin et al. 2010); actual concentrations of
PBDEs were not provided.  Telomers are complex structures consisting of repeat DNA sequences and 
associated proteins located at the end of chromosomes which protect chromosomes from end-to-end fusions.  
Dosing of mice with up to 1,250 mg/kg/day pentaBDE (mixed congeners) by gavage once per day for
3 consecutive days did not increase the frequency of micronuclei in blood or bone marrow cells (Witt et al. 
2008).  In another gavage study, dosing of pregnant mice with ≥10 mg/kg/day decaBDE (the lowest dose
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tested) on GDs 0–17 resulted in significant sperm chromatin DNA damage in male offspring examined at
71 days of age, as indicated by DNA denaturation induction and increased DNA fragmentation index in 
the sperm chromatin structure analysis (Tseng et al. 2013).  The investigators suggested that hydrogen
peroxide, which was increased in sperm cells, may have been involved in induction of oxidative DNA
damage.  A summary of in vivo genotoxicity studies of PBDEs is presented in Table 3-5.
Results from in vitro assays for gene mutation in various Salmonella typhimurium strains and in
Escherichia coli WP2 uvrA conducted with 2,2’,4,4’,5-pentaBDE and decaBDE yielded negative results 
in the presence or absence of metabolic activation (Evandri et al. 2003; NTP 1986).  Assays conducted in 
mammalian cells yielded mixed results.  Tests of decaBDE (BDE 209) for sister chromatid exchange and 
chromosomal aberrations in Chinese hamster ovary cells were negative and the same was reported for
gene mutation in mouse lymphoma L5178Y cells (NTP 1986).  These tests were conducted with and 
without metabolic activation.  However, decaBDE induced DNA damage (Comet assay) in human
SK-N-MC neuroblastoma cells (Pellacani et al. 2012) and SW 480 colon carcinoma cells (Curcic et al.
2014).  Several congeners (BDE 47, 99, 253, 183, and 209) induced micronuclei in human mammary
carcinoma cells (Barber et al. 2006). Both BDE 32 and BDE 47 caused DNA damage (Comet assay) in 
HepG2 hepatocellular carcinoma cells (Saquib et al. 2016). The congener 2,2',4,4'-tetraBDE (BDE 47) 
also induced micronuclei formation and DNA damage (Comet assay) in human neuroblastoma cells (Gao
et al. 2009; He et al. 2008a; Pellacani et al. 2012) and DNA damage (Comet assay) in rat primary
hippocampal neurons (He et al. 2008b).  However, BDE 47 did not cause DNA damage in normal human 
hepatocytes, as assessed by the Comet assay (An et al. 2011).  BDE 47 also induced gene recombination 
in Chinese hamster SPD8/V79 cells, but not Sp5/V79 cells (Helleday et al. 1999).  In the same study,
3,4-diBDE (BDE 12) and 2-monoBDE (BDE 1) produced positive results for gene recombination in both 
Chinese hamster SPD8/V79 cells and Sp5/V79 cells (Helleday et al. 1999).  Experiments conducted by Ji
et al. (2011) in chicken DT40 cell lines showed that BDE 47 and 2,2,4’,5-tetraBDE (BDE 49) could
induce DNA damage (double strand breaks; identified by γ-H2AX focus formation) and that BDE 47 
could also induce chromosomal aberration.  Ji et al. (2011) also reported that tetraBDEs had a greater
genotoxic potential than PBDEs with a higher number of bromine substitutes and that hydroxylated 
analogs of tetraBDEs were more genotoxic than tetraBDEs.  These investigators suggested that DNA
damage caused by tetraBDEs and hydroxylated analogs is mediated through ROS, which leads to 
replication blockage and subsequent chromosomal breaks.  However, Song et al. (2009) did not find 
evidence of DNA damage (Comet assay) in human adreno cortical carcinoma cells exposed to the 
hydroxylated metabolite OH-BDE-47 or OH-BDE-85. DNA damage by PBDEs could be mediated via
covalent binding of PBDE quinone metabolites, as both Lai et al. (2011) and Huang et al. (2015) have
   
 









   
 
     
 
 
     
 
 
     
 
 
    
 
 





    









Table 3-5.  Genotoxicity of Polybrominated Diphenyl Ethers (PBDEs) In Vivo
Species (test system) Compound End point Results Reference
Human peripheral Total PBDEs Micronucleous assay ± Yuan et al. 2008
lymphocytes
Human peripheral Total PBDEs Oxidative DNA damage − Yuan et al. 2008
lymphocytes
Human peripheral BDE 47 Telomere length − Shin et al. 2010
lymphocytes
Human peripheral BDE 99 Telomere length − Shin et al. 2010
lymphocytes
Mouse blood and bone PentaBDE Micronucleous assay − Witt et al. 2008
marrow (unspecified)
Mouse sperm BDE 209 DNA damage (sperm + Tseng et al. 2013
chromatin structure analysis)
+ = positive result; – = negative result; ± = inconclusive result; BDE = brominated diphenyl ether
   
 








   
   
   
 
 
    
  
 
   
 






   
    
   
    
      
    
 
  
     
    
     
 
   
 




reported that PBDE quinone metabolites covalently bind to DNA in vitro to form DNA adducts.  These
metabolites would result from oxidation of hydroxylated metabolites to dihydroxylated metabolites by
microsomal cytochrome P450s.  A summary of the in vitro genotoxicity data for PBDEs is presented in
Table 3-6.
Overall, the information available from in vivo and in vitro studies with a few PBDE congeners is 
insufficient to make generalizations regarding the genotoxicity of PBDEs.
3.4  TOXICOKINETICS
3.4.1 Absorption 
3.4.1.1  Inhalation Exposure 
No studies were located regarding absorption of PBDEs in humans after inhalation exposure.  
Evidence for the inhalation absorption of lower-brominated PBDEs in animals was provided by
observations of systemic toxicity in rats that were intermittently exposed to a commercial octaBDE
product (bromine content 78.7%) as dust aerosol for 13 weeks (Great Lakes Chemical Corporation 2000).  
The absorption of the lower-brominated BDE congeners was indicated by the occurrence of hepatic,
thyroid, and ovarian effects in rats following exposure to 16 or 202 mg/m3 for 6 hours/day, 5 days/week,
for 13 weeks.
No studies were located that quantified absorption of inhaled PBDEs, but Staskal et al. (2005) reported 
absorption efficiencies of 91% in mice given single intratracheal doses of 14C-BDE 47 in corn oil.  This
estimate was derived by comparing the radioactivity profiles in urine, feces, and tissues 5 days after
intratracheal or intravenous administration of 1 mg/kg doses of 14C-BDE 47.
3.4.1.2  Oral Exposure
Human Data.  No information was located regarding absorption of PBDEs in humans following
controlled oral exposure.  
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Table 3-6.  Genotoxicity of Polybrominated Diphenyl Ethers (PBDEs) In Vitro
Results
With Without
Species (test system) Compound End point activation activation Reference
Prokaryotic organisms:






BDE 99 Gene mutation – – Evandri et al. 2003
Escherichia coli, WP2
uvrA




BDE 47 DNA damage 
(Comet assay)






Micronuclei No data + Barber et al. 2006
Human SW 480 colon 
carcinoma cells
BDE 209 DNA damage 
(Comet assay)
No data + Curcic et al. 2014
Human SH-SY5Y 
neuroblastoma cells
BDE 47 DNA damage 
(Comet assay)
No data + Gao et al. 2009




BDE 47 DNA damage
(Comet assay)
No data + He et al. 2008a
Human SK-N-MC
neuroblastoma cells
BDE 47 DNA damage
(Comet assay)
No data + Pellacani et al. 2012
Human SK-N-MC
neuroblastoma cells
BDE 209 DNA damage
(Comet assay)




BDE 32, 47 DNA damage 
(Comet assay)








NA – Song et al. 2009
Rat primary
hippocampal neurons
BDE 47 DNA damage
(Comet assay)
No data + He et al. 2008b
Mouse lymphoma 
L5178Y cells
BDE 209 Gene mutation – – NTP 1986
Chinese hamster
Sp5/V79 cells
BDE 47 Gene 
recombination
No data – Helleday et al. 1999
Chinese hamster
SPD8/V79 cells
BDE 47 Gene 
recombination
No data + Helleday et al. 1999
Chinese hamster
Sp5/V79 cells
BDE 12 Gene 
recombination
No data + Helleday et al. 1999
   
 








   
 
     





























   
      
     
 
 
    
    
 
 
    
    
 
    
 






Table 3-6.  Genotoxicity of Polybrominated Diphenyl Ethers (PBDEs) In Vitro
Results
With Without
Species (test system) Compound End point activation activation Reference
Chinese hamster
SPD8/V79 cells
BDE 12 Gene 
recombination
No data + Helleday et al. 1999
Chinese hamster
Sp5/V79 cells
BDE 1 Gene 
recombination
No data + Helleday et al. 1999
Chinese hamster
SPD8/V79 cells
BDE 1 Gene 
recombination
No data + Helleday et al. 1999
Chinese hamster ovary
cells
BDE 209 Sister chromatid 
exchange





− − NTP 1986
Other cells
Chicken DT40 cell line BDE 47 DNA damage
(γ-H2AX focus
formation)
No data + Ji et al. 2011
BDE 49 DNA damage
(γ-H2AX focus
formation)
No data + Ji et al. 2011
BDE 47 Chromosomal
aberrations
No data + Ji et al. 2011
+ = positive result; C = negative result; BDE = brominated diphenyl ether; DNA = deoxyribonucleic acid; NA = not
applicable
   
 











    
  
    
      




    
     
   
     
 
   
   
  
   
   
 
    
 
   
     
    
  
 
     
 





Overview: Information regarding oral absorption in animals is available from studies of commercial
PBDE mixtures and individual 14C-labeled tetra-, penta-, hexa-, and decaBDE congeners.  As summarized
below, the most recent and best available estimates of oral absorption efficiencies following gavage 
administration in lipophilic vehicles indicate a range of 70–85% for tetra- (BDE 47), penta- (BDE 99, 
BDE 100), and hexa- (BDE 153, BDE 154) congeners, and 10–26% for decaBDE (BDE 209).
Information on oral absorption of the commercial pentaBDE mixture DE-71 and the commercial
octaBDE mixture DE-79 is available from studies in which male Sprague-Dawley rats were fed diets 
containing 0 or approximately 32–33 ng/day (≈120 ng/kg/day) of either mixture in peanut oil for 21 days
(Hakk et al. 2001; Huwe et al. 2002b, 2007).  The doses were designed to mimic environmental exposure
concentrations.  Liver, carcass, and feces were analyzed for major congeners in the penta- and octaBDE
formulations 24 hours after the final feeding; urine was not evaluated. The study of the pentaBDE
mixture (DE-71) assessed the following six congeners:  BDE 47, BDE 85, BDE 99, BDE 100, BDE 153, 
and BDE 154 (Hakk et al. 2001; Huwe et al. 2007).  Based on liver, carcass, and unrecovered 
concentrations of congeners, and assuming that excretion in the urine was negligible, absorption is
estimated to have been 44.3% for penta congener BDE 85 and 84.3–92.4% for the other tetra- to 
hexaBDE congeners.  The study of the octaBDE mixture (DE-79) assessed the following eight congeners:
BDE 153, BDE 154, BDE 183, BDE 190, an unknown heptaBDE, and three unknown octaBDEs (Huwe
et al. 2002b).  Based on liver, carcass, and unrecovered concentrations of congeners, and assuming that
excretion in the urine was negligible, absorption is estimated to have been 84.2–95.1% for the hexaBDEs, 
68.5–79.1% for the heptaBDEs, and 55.7–83.3% for the octaBDEs.  
Early studies with 14C-decaBDE (BDE 209) indicated that gastrointestinal absorption efficiency was low
(~9 or <1%) in rats (El Dareer et al. 1987; Norris et al. 1973, 1975b; NTP 1986). Following treatment
with a single 1 mg/kg dose of 14C-decaBDE in corn oil, administered as a low purity commercial mixture 
(77.4% decaBDE, 21.8% nonaBDE, 0.8% octaBDE) by gavage, 90.6 and >99% of the dose was
eliminated in the feces within 24 and 72 hours post-dosing, respectively (Norris et al. 1973, 1975a).  An 
oral absorption efficiency estimate of about 9% is indicated, assuming that fecal radioactivity excreted in
24 hours was nonabsorbed, and fecal radioactivity excreted between 24 and 72 hours was from biliary
excretion of absorbed material. Two feeding studies were conducted in which rats were exposed to a
commercial mixture as unlabeled decaBDE (92% pure) on days 1–7 and 14C-decaBDE (98.9% pure) on 
day 8, followed by unlabelled decaBDE on days 9, 9–10, or 9–11 (El Dareer et al. 1987; NTP 1986).  In 
   
 








   
   
  
  
       
     
     
   
      
 
 
     
  




     
     
      
      
      
   
  
   
    
   
    
  
  
   




the first study, dietary concentrations ranged from 238 to 51,100 ppm (six levels) (≈20–4,500 mg/kg/day).  
Recovery of radioactivity in the feces ranged from 91.3±4.0 to 101±4% of the administered dose and was
not related to dose level.  In the second study, rats were exposed to dietary concentrations of 277 or
48,000 ppm (≈20 or 4,300 mg/kg/day).  Recovery of radioactivity in the feces ranged from 82.5±4.7 to 
86.4±8.5% of the dose and was not related to dose level or time of sacrifice (24, 48, or 72 hours after 
14C-decaBDE intake).  For both dose levels, the percent of 14C dose remaining in the gut contents (<4%)
and gut tissue (<0.04%) decreased with time.  Of the radioactivity recovered, >99% was in the feces and 
gut contents.  Based on a comparison of average tissue concentrations following intravenous and oral
administration, NTP (1986) estimated that oral absorption was 0.33±0.19% at the highest dietary level
(50,000 ppm).
More recent studies indicated that absorption efficiency of 14C-decaBDE (BDE 209) in rats can be 
influenced by vehicle and have reported absorption efficiencies in the 10–26% range using lipophilic
vehicles (Hakk et al. 2002b; Morck and Klasson Wehler 2001; Morck et al. 2003; Riu et al. 2008;
Sandholm et al. 2003).  In normal and bile duct-cannulated male Sprague-Dawley rats administered single 
3-µmol/kg (≈3 mg/kg) doses of 14C-decaBDE (>98% pure) in Lutrol F127/soya phospholipone (34:16, 
w/w)/water, radioactivity in feces collected for 72 hours accounted for about 90% of the administered 
dose in conventional rats (Morck and Klasson Wehler 2001; Morck et al. 2003).  In bile duct-cannulated
rats, averages of 88 and 9.5% of the dose were recovered in feces and bile, respectively, within 3 days.  
Radioactivity recovered in urine was <0.1% of the dose in normal and bile-duct cannulated rats. The
radioactivity in bile indicates that at least 10% of the dose was absorbed (Morck and Klasson Wehler
2001; Morck et al. 2003).  Hakk et al. (2002b) reported similar results in another study in which four bile
duct-cannulated male Sprague-Dawley rats were orally administered single 3-µmol/kg doses of
14C-decaBDE (>98% pure) in Lutrol 127, soyaphospholipone, and water.  Radioactivity in bile and urine 
collected for 72 hours accounted for 9.2 and <0.1% of the administered dose, respectively.  Sandholm et
al. (2003) reported an oral bioavailability of 26% for decaBDE from plasma concentration-time curves for
144 hours following gavage and intravenous administration of single 2-µmol/kg doses of unlabeled
decaBDE (purity >98%) in a DMA/polyethylene glycol/water vehicle (4:4:1) to Sprague-Dawley rats.
DecaBDE concentrations in plasma samples were quantified by gas chromatography/mass spectrometry
(GC/MS).  Oral bioavailability was calculated by dividing the area under the plasma concentration-time
curve for oral exposure (AUCoral) by the AUCi.v.  Qualitative analysis by GC/MS of pooled plasma 
samples determined 3 major metabolites among 13 hydroxylated metabolites: a hydoxy-octaDDE, a
hydroxyl-nonaBDE and a hydoxy-methoxy-hexaBDE.  The presence of these phenolic metabolites in the 
plasma samples indicates that the oral bioavailability (and hence oral absorption efficiency) of decaBDE 
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may have been higher than the calculated value of 26% based on parent-compound plasma concentration-
time curves (Sandholm et al. 2003).  Riu et al. (2008) reported that >19% of administered radioactivity
was recovered in tissues (including fetuses) and carcasses, 24 hours after oral administration of 2-mg/kg 
doses of 14C-labeled decaBDE (>99.8% radiopurity) dissolved in peanut oil to pregnant Wistar rats on 
GDs 16, 17, 18, and 19.  This finding indicates an absorption efficiency of about 20%, assuming that
radioactivity recovered in the feces (about 66% of the administered dose) was not absorbed.  Because 
biliary excretion of decaBDE has been demonstrated in rats, this value may underestimate the actual oral
absorption that occurred in this study.  However, the aqueous fraction (which would contain hydroxylated
metabolites and conjugates) accounted for only 4% of the radioactivity in the collected feces, and 97% of
the radioactivity in the organic-solvent fraction of the feces was determined by high-performance liquid 
chromatography (HPLC) to be unchanged decaBDE.
Estimates of oral absorption efficiencies for BDE 47 in rats and mice have ranged from about 75 to 95%, 
depending on species and employed measurement techniques (Örn and Klasson-Wehler 1998; Sanders et
al. 2006a; Staskal et al. 2005).  A single 14.5-mg/kg (30-µmol/kg) gavage dose of 14C-BDE 47 in corn oil
was well absorbed by male Sprague-Dawley rats and male C57Bl mice (Örn and Klasson-Wehler 1998).  
Approximately 5% of the dose in rats and 7% of the dose in mice was excreted as parent congener in the 
feces in 24 hours. The investigators concluded that these values represented the non-absorbed doses, 
indicating that absorption of BDE 47 was 93–95%.  Later studies with male F344 rats and male B6C3F1 
mice reported oral absorption efficiency estimates for BDE 47 of 75% in rats and 85% in mice (Sanders et
al. 2006a).  Sanders et al. (2006a) used a more refined technique that compared profiles of radioactivity in 
urine, feces, and tissues 24 hours after gavage and intravenous administration of single 1-µmol/kg doses
of 14C-BDE 47 in corn oil. Using a similar technique comparing radioactivity profiles in excreta and
tissues 5 days after gavage and intravenous administration of single 1-mg/kg doses of 14C-BDE 47 in corn 
oil, Staskal et al. (2005) reported that oral absorption efficiency was approximately 82% in female
C57BL/6J mice.  
Evidence for extensive oral absorption of pentaBDE congeners (BDE 99 and BDE 100) in rats and mice 
comes from studies that administered single oral doses of about ~28 µmol/kg 14C-BDE 100 (~98% pure) 
in peanut oil to male Sprague-Dawley rats (Hakk et al. 2006), about 2.2 mg/rat (~15 µmol/kg) of
14C-BDE 99 (~98% pure) in corn oil to male Sprague-Dawley rats (Hakk et al. 2002a), or 1 µmol/kg body
weight of 14C-BDE 99 (~96% pure) in corn oil to male F344 rats and male B6C3F1 mice (Chen et al. 
2006).  Seventy-two hours after administration of BDE 100, about 73 and 41% of the administered 
radioactivity remained in tissues of conventional and bile-duct cannulated rats, respectively; fecal
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radioactivity accounted for about 20 and 26% of administered radioactivity in conventional and bile-duct
cannulated rats, respectively (Hakk et al. 2006).  Assuming that radioactivity excreted in feces within
24 hours was non-absorbed, reported values of 11.5% in conventional rats and 16.8% in bile duct­
cannulated rats indicate oral absorption for BDE 100 of about 89 and 84%, respectively.  In the studies
with BDE 99, radioactivity in 24-hour feces accounted for 22.3 and 52.5% of administered radioactivity
in conventional and bile-cannulated rats, respectively, indicating absorption efficiencies for BDE 99 of at
least 78 and 48% (Hakk et al. 2002a).  Chen et al. (2006) compared radioactivity profiles in 24-hour
excreta and tissues after gavage and intravenous administration of 14C-BDE 99 to arrive at estimated oral 
absorption efficiencies of approximately 85% in both male rats and male mice.  
Results from rat and mouse studies with 14C-labeled hexaBDEs (BDE 153 and BDE 154) administered as 
single doses in oil vehicles also indicate extensive oral absorption (Hakk et al. 2009; Sanders et al.
2006b). Hakk et al. (2009) estimated an oral absorption efficiency for BDE 154 of about 77% in male
Sprague-Dawley rats, based on radioactivity profiles in 72-hour excreta and tissues after gavage 
administration of single 11.3-µmol/kg 14C-BDE 154 (>98% pure) to conventional and bile duct­
cannulated rats.  Sanders et al. (2006b) estimated oral absorption efficiencies for BDE 153 of about 70%
in male F344 rats and male B6C3F1 mice, based on comparison of radioactivity profiles in 24-hour
excreta and tissues after gavage and intravenous administration of single 1-µmol/kg doses 14C-BDE 153
(96% pure).  
3.4.1.3  Dermal Exposure 
No information was located regarding dermal absorption of PBDEs in humans. 
A dermal absorption efficiency of 62% was reported for female mice exposed to an occluded dermal dose 
of 1 mg/kg 14C-BDE 47) (Staskal et al. 2005).  Profiles of radioactivity in urine, feces, and tissues 5 days
after dermal or intravenous administration were compared to estimate dermal absorption efficiency.
Approximately 15% of the administered dose remained at the site of application 5 days after application.  
No other in vivo studies of dermal absorption with PBDE congeners or mixtures were located.
In in vitro studies with human breast skin and mouse dorsal skin samples exposed to 14C-BDE 147 
(radiochemical purity=96.5%) for 24 hours in a flow-through diffusion cell apparatus, reported mean 
absorption efficiencies (percent of applied radioactivity collected in receptor compartment) were 1.88%
for human skin (n=10) and 14.58% for rat skin (n=12) (Roper et al. 2006).  
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Limited dermal absorption of 14C-decaBDE by mouse skin was indicated in an in vitro study in which
14C-decaBDE dissolved in tetrahydrofuran was applied (three dose levels) to dorsal skin excised from
adult hairless female mice, and fractions of receptor fluid were collected over a 24-hour period (Hughes et
al. 2001). Transfer of radioactivity to the receptor fluid was minimal, accounting for only 0.07–0.34% of
the applied radioactivity.  Two to 20% of the radioactivity was found in the skin. The highest percentage
of the dose in the skin was associated with application of the lowest dose.  Washing the skin with solvent
24 hours after application removed 77–92% of the applied dose.
3.4.2 Distribution 
3.4.2.1  Inhalation Exposure 
No information was located regarding distribution of PBDEs in humans following controlled inhalation 
exposure. 
The distribution of bromine was examined in tissues of rats after inhalation exposure to octaBDE (Great
Lakes Chemical Corporation 1978).  Groups of rats were exposed to 0, 1.2, 12, 120, or 1,200 mg/m3 of
dusts of octaBDE 8 hours/day for 14 days.  At necropsy, sections of the lungs, adipose tissue, and liver
were collected for bromine analysis using a neutron activation technique. The results showed
concentrations of bromine in the lungs and adipose tissue significantly higher in all groups relative to 
controls; the amounts of bromine detected were concentration-related.  In the liver, the concentration of
bromine was also elevated in all groups relative to controls except in the 1.2 mg/m3 exposure group; the
elevated concentrations in the liver were not as marked as in the lungs or in adipose tissue.
3.4.2.2  Oral Exposure
Human Studies.  
Overview: No studies were located that examined tissue distribution of PBDEs in humans following 
controlled oral exposure.  Evidence for the transfer of PBDEs from pregnant mothers to the developing
fetus and for the transfer of PBDEs from maternal blood to breast milk and then to nursing infants comes 
from a number of studies of PBDE concentrations in maternal and cord serum samples and breast milk
samples from groups of non-occupationally exposed women.  Although the contributions of different
possible exposure routes experienced by these women are uncertain, it is thought that ingestion of PBDEs
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in dust and food represented a significant exposure route.  In general, the tetra- and penta-brominated 
PBDEs have been the predominant congeners detected in maternal and cord serum samples and breast
milk samples, but some recent studies assaying for a wider range of PBDE congeners have found 
evidence for distribution of hepta-, octa-, or decaBDEs into cord serum and breast milk. In evaluation of
these studies, the location where the study was performed (e.g., Asia, Europe or North America) is very
important, as the patterns of exposure to various congeners were different due to different usage patterns
of commercial mixtures (see Section 6.5, General Population and Occupational Exposure, for more
information).
A number of studies have examined concentrations of PBDEs or hydroxylated PBDEs in maternal and 
cord blood samples in non-occupationally exposed groups of women from the United States (Chen et al. 
2013; Mazdai et al. 2003; Qiu et al. 2009), France (Antignac et al. 2009, 2008), China (Li et al. 2013a), 
Japan (Kawashiro et al. 2008), Spain (Vizcaino et al. 2011), the Netherlands (Meijer et al. 2008), and 
Korea (Wan et al. 2010). In the most recent of the U.S. studies, BDE 28, BDE 47, BDE 99, BDE 100, 
and BDE 153 were detected in 90, 90, 95, 85, and 100% of 20 maternal and 65, 65, 80, 90, and 85% of
20 matched cord serum samples, respectively (Chen et al. 2013).  Percentages of samples above the limit
of detection were lower for BDE 209 (55% maternal and 40% cord) and BDE 154 (25% maternal and 5%
cord).  Chemical analyses for other PBDE congeners were not conducted in this study.  Median 
concentrations of congeners in maternal serum samples (ng/g lipid) were in the following order: BDE 47 
> BDE 153 > BDE 209 > BDE 99 > BDE 100 > BDE 28 > BDE 154. In cord serum samples, the order
was: BDE 47 > BDE 99 > BDE 209 > BDE 28 > BDE 153 > BDE 100 > BDE 154.  Concentrations of
four hydoxylated PBDEs (6-OH-BDE-47, 5-OH-BDE-47, 4'-OH-BDE-49 and 6'-OH-BDE-99) were also
determined.  Geometric mean concentrations (ng/g lipid) of total BDEs and total OH-BDEs in cord 
samples were higher than those in maternal serum samples (~52% and 42 higher for OH-BDEs and 
BDEs, respectively).  Equal or higher concentrations of total OH-BDEs or total BDEs in cord serum, 
compared with maternal serum, were found in 85 and 80% of the matched mother-neonate pairs. The 
results suggest that each of the seven BDEs and four OH-BDEs can cross the placenta and distribute to
the fetus, and that internal exposure via blood is equal to or higher in fetuses, compared with their
mothers.  In contrast, BDE 209 was the most abundant congener detected in both maternal and cord blood
samples from China, where industrial production of BDE 209 may result in exposure (Li et al. 2013a).
Similar evidence for transplacental transfer of a set of PBDE congeners more enriched in higher­
brominated PBDEs was reported in a recent study that measured concentrations of 19 PBDE congeners in 
maternal and cord serum samples from 29 mother-neonate pairs from a Wenzhou region of China that is
   
 








    
 
      
      
      
     
 
  
     
 
    
      
     
    
    
 
      
 
   
    
     
   
      
    
  
   
    




      




the major region for electronics dismantling and recycling in China (Li et al. 2013a).  In both maternal
and cord serum samples, the congeners with the highest geometric mean concentrations (ranging from
3.32 to 1.78 ng/g lipid in maternal samples) were BDE 207 > BDE 208 > BDE 209 > BDE 28.  
Geometric means for total cord serum concentrations of lower-brominated congeners (BDE 17 to
BDE 154), higher-brominated congeners (BDE 183 to BDE 209), and all BDEs were higher than 
respective concentrations in maternal blood by about 15, 47, and 41%, respectively (Li et al. 2013a).
Frederiksen et al. (2010) utilized a human ex vivo placenta perfusion system to study the kinetics of
placental transfer of BDE 47, BDE 99, and BDE 209 to the fetus.  Placentas were perfused for 4 hours 
with 1 ng/mL concentrations of the non-labeled congeners.  Samples of maternal and fetal compartments 
were taken during the perfusion, and concentrations in samples were determined by GC/MS.  Placental
transfer of BDE 47 and BDE 99 was demonstrated, and transfer of BDE 47 was faster and more extensive 
than BDE 99.  Transfer of BDE 209 across the placenta to the fetal compartment was not demonstrated
with the detection limits of the techniques employed.  Frederiksen et al. (2010) proposed that future
perfusion studies with BDE 209 should use 14C-labeled BDE 209 to increase sensitivity. 
Evidence for the transfer of PBDEs from maternal blood to breast milk and hence to nursing infants
comes from a number of studies examining PBDE concentrations in breast milk samples.  Most studies of
PBDEs in breast milk samples through 2002 measured concentrations of only lower-brominated
congeners (tetra, penta and hexaBDEs) used in many commercial products up to that time: BDE 47, 
BDE 99, BDE 100, BDE 153, and BDE 154 (Hites 2004).  Additionally, higher brominated PBDEs
(e.g., decaBDE; BDE 209) were often omitted from early human biomonitoring due to the inability to 
accurately measure them at that time. In these early studies, BDE 47 was the congener detected at the 
highest concentration.  A number of more recent studies have included chemical analysis for a greater 
number of PBDE congeners (including hepta-, octa- and deca-brominated congeners) in breast milk
samples collected in the United States (Daniels et al. 2010; Park et al. 2011; Schecter et al. 2010, 2006), 
France (Antignac et al. 2009, 2008), and Philippines (Malarvannan et al. 2013).  The detection of higher­
brominated congeners in some of these recent studies indicates that both lower and higher-brominated
congeners can be distributed to breast milk (Antignac et al. 2008, 2009; Malarvannan et al. 2013; Park et
al. 2011; Schecter et al. 2010). 
Further support for the transfer of PBDEs from mothers to nursing children comes from a report that
average concentrations of BDE 47 and BDE 99 were statistically significantly (p < 0.05) increased by
~5-fold in serum samples from 4-year-old Spanish children (n=202) who had been breastfed, compared 
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with formula-fed 4-year-old children (n=42) (Carrizzo et al. 2007). This study analyzed serum samples 
for 13 PBDE congeners including tri- (BDE 17, BDE 28), tetra- (BDE 47, BDE 66, BDE 71), penta­
(BDE 85, BDE 99, BDE 100), hexa- (BDE 138, BDE 153, BDE 154), and hepta-brominated congeners
(BDE 183, BDE 190).  BDE 47 and BDE 99 were the predominant congeners detected in both breastfed 
and formula-fed children; concentrations of BDE 47 and BDE 99 in breastfed children were about 16 and 
6 times higher than the congener with the next highest concentration, BDE 100.  The following congeners
were not detected in the collected serum samples: BDE 17, BDE 28, BDE 66, BDE 71, BDE 85, BDE
183, and BDE 190.  This study did not control for potential differences in other PBDE exposure
pathways, such as ingestion of contaminated dusts or food. 
Animal Studies.  
Overview: Tissue distribution studies in animals orally exposed to 14C-labeled BDE 47, BDE 99, 
BDE 100, BDE 153, BDE 154, and BDE 209 indicate that decaBDE is distributed among tissues 
somewhat differently than tetra-, penta- and hexaBDEs.  While lower-brominated BDE congeners, 
following absorption and an initial wide distribution, are preferentially accumulated in adipose tissues, 
absorbed decaBDE is less readily distributed to adipose tissues and appears to preferentially distribute to
highly perfused tissues.  Although less likely to partition to adipose tissues, decaBDE was still found in 
low quantities in adipose tissues in these studies, and has been shown to transfer from dams to fetuses and 
neonates from exposure during gestational and nursing periods.  Two studies with female Sprague-
Dawley rats given oral doses of nonlabeled BDE 209 in corn oil from GD 7 to postpartum day (PPD) 4 or
8 demonstrated maternal transfer to developing fetuses and neonates by examining whole-body BDE 209
concentrations in offspring, but another study with similarly exposed Sprague-Dawley rats found no clear
evidence for maternal transfer by examining BDE 209 concentrations in blood from dams and offspring.
Results from studies of rats or mice orally exposed to 14C-labeled decaBDE (BDE 209) indicate that
decaBDE is not as readily distributed to adipose tissues as the lower-brominated BDEs and more readily
distributed to highly perfused tissues (El Dareer et al. 1987; Morck and Klasson-Wehler 2001; Morck et
al. 2003; Norris et al. 1975a; NTP 1986; Riu et al. 2008).  In male rats administered single gavage doses
of 1 mg/kg of a 14C-labeled commercial decaBDE mixture (77.4% pure containing 21.8% nonaBDE and 
0.8% octaBDE), radioactivity could be detected on day 1 in all sampled tissues (adipose, skin, liver, heart, 
adrenals, spleen, pancreas) (Norris et al. 1975a).  On day 16 after dosing, radioactivity was only detected 
in adrenals and spleen (0.01 and 0.06% of the administered dose per gram of tissue, respectively).  In 
F344 rats fed diets containing a commercial mixture as unlabeled decaBDE (92% pure) on days 1–7,
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14C-decaBDE (98.9% pure) on day 8, and unlabelled decaBDE on days 9, or 9–10, or 9–11, the levels of
radioactivity remaining in tissues 72 hours after the exposure period ended had the following order:
gastrointestinal tract > liver > kidney > lung > skin > adipose (El Dareer et al. 1987; NTP 1986).  In 
Sprague-Dawley rats given single 3-µmol/kg (≈3 mg/kg) gavage doses of 14C-decaBDE (>98% pure) in 
Lutrol F127/soya phospholipone (34:16, w/w)/water, concentrations of radioactivity remaining in tissues
3 days after dose administration had the following order (14C nmol equivalents/g lipid concentrations in
parentheses):  plasma (22 nmol/g) > liver (14.9 nmol/g) > heart ~ small intestine wall ~ adrenal (ranging
from 5.6 to 4.0 nmol/g) > lung ~thymus ~ kidney (ranging from 2.1 to 1.8 nmol/g) > adipose
(0.17 nmol/g) (Morck and Klasson-Wehler 2001; Morck et al. 2003).  In pregnant Wistar rats given single
2-mg/kg doses of 14C-decaBDE (>99.8% pure) in peanut oil daily on GDs 16–19, concentrations of
radioactivity on a wet weight basis (µg 14C-decaBDE equivalents/g tissue) were highest in adrenals 
(33 µg/g), ovaries (16 µg/g), and liver (11 µg/g); intermediate in kidneys > stomach > heart ~ placentas >
lung > spleen > plasma > uterus > carcass (ranging from 3.90 to 1.11 µg/g); and lowest in adipose tissue 
(0.79 µg/g), fetuses (0.46 µg/g), brain (0.11 µg/g), and amniotic fluid (0.11 µg/g) (Riu et al. 2008).  
Results from studies of rats and mice exposed to oral doses of 14C-labeled BDE 47 indicate wide
distribution to tissues following absorption with preferential accumulation in fatty tissues, contrasting the 
preferential distribution of decaBDE to highly perfused tissues (Örn and Klasson-Wehler 1998; Sanders 
et al. 2006a; Staskal et al. 2005, 2006a).  Five days after gavage administration of single 30-µmol/kg 
doses of 14C-BDE 47 in corn oil to male Sprague-Dawley rats, concentrations of radioactivity had the 
following order (14C-BDE 47 equivalent nmol/g wet tissue): adipose (706) > lung (12) > kidney (11) >
liver (5) > brain (1.9) > plasma (0.76) (Örn and Klasson-Wehler 1998).  A similar order of wet tissue
concentrations (nmol/g wet tissue) was observed in male C57Bl mice exposed to 14C-BDE 47: adipose
(79) > liver (7) > lung (5) > kidney (3) > brain (1) > plasma (not detected) (Örn and Klasson-Wehler
1998).  In another study that gave single 1-µmol/kg doses of 14C-BDE 47 to male and female F344 rats in
corn oil, the following order of amounts of radioactivity remaining in tissues was observed 24 hours after
dose administration (percentages of administered dose for male rats): adipose (24.6%) > skin (13.0%) >
muscle (3.0%) > liver (1.3%) > blood (0.2%) > brain ~ kidney ~ lung (0.1% each) (Sanders et al. 2006a).  
A similar order was observed in female rats, but the amount of radioactivity in adipose in females (37%)
was higher than in male rats (24.6%) (Sanders et al. 2006a).  Tissue distribution in male and female
B6C3F1 mice exposed to 14C-BDE 47 was similar to distribution in F344 rats, with females showing
higher accumulation of radioactivity in adipose than male mice (Sanders et al. 2006a).  Staskal et al.
(2005) reported similar patterns for tissue distribution in female C57BL/6J mice 5 days after
administration of single oral doses of 0.1, 1.0, 10, or 100 mg/kg 14C-BDE 47 in corn oil.  For all doses, 
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the reported order of remaining radioactivity in tissues was: adipose (8–14% of administered dose) > skin
and muscle (~2–3%) > liver (~1%) > brain ~ kidneys ~ lungs (<0.05% each) (Staskal et al. 2005).  The
same tissue distribution pattern was also observed in female C57BL/6J mice given nine 1-mg/kg/day 
doses of unlabeled BDE 47 in corn oil followed by single 1-mg/kg doses of 14C-BDE 47 (Staskal et al.
2006a).  Using percent of dose/g of tissue as the dose metric to compare single-dose levels in rats reported 
by Staskal et al. (2005) with repeated-dose levels in tissues, the tissue concentrations from the repeated-
dose scenario with 1 mg/kg were comparable to tissue concentrations from single 10-mg/kg doses and 
about 2 times greater than concentrations from single 1-mg/kg doses (Staskal et al. 2006a).  The results 
indicate the potential for incremental accumulation of BDE 47 in fat with continued exposure.
Results from studies of 14C-BDE 99 (Chen et al. 2006; Hakk et al. 2002a) and 14C-BDE 100 (Hakk et al.
2006) indicate an initial wide distribution of penta-brominated congeners to tissues following absorption 
with preferential accumulation in fatty tissues, similar to results from studies with BDE 47.  In male F344 
rats given single doses of 0.1 µmol/kg 14C-BDE 99 (~96% pure) in corn oil, levels of radioactivity
remaining in tissues 24 hours after dose administration had the following order (percent of administered 
dose): adipose (20.8%) > skin (7.0%) > muscle (5.2%) > liver (2.1%) > blood = brain (0.3% each) > lung
= brain (0.1% each) (Chen et al. 2006).  Similar orders of tissue concentrations were seen 24 hours after
oral administration in male rats given single 1, 10, 100, or 1,000 µmol/kg doses, and in female F344 rats
and male and female B6C3F1 mice given single 1 µmol/kg doses (Chen et al. 2006).  Preferential
accumulation in adipose also was found in male Sprague-Dawley rats 24 hours after administration of
14.5 µmol/kg doses of 14C-BDE 99 (>98% pure) in corn oil (Hakk et al. 2002a).  In male Sprague-Dawley
rats 72 hours after administration of single 25.2 µmol/kg doses of 14C-BDE 100 (>95% pure) in peanut
oil, the adipose, gastrointestinal tract, and skin had the highest concentrations of radioactivity
(>35 nmol/g fresh tissue weight), liver and lung had intermediate concentrations (~10–15 nmol/g), and 
other tissues, including lung, adrenals, testes, and muscle, had the lowest concentrations (<10 nmol/g)
(Hakk et al. 2006). 
Preferential distribution and accumulation in adipose also has been found for hexa-brominated BDEs in 
studies with rats or mice exposed orally to 14C-BDE 153 (Sanders et al. 2006b) and 14C-BDE 154 (Hakk 
et al. 2009).  In male F344 rats given single doses of 1 µmol/kg 14C-BDE 153 (~96% pure) in corn oil, 
levels of radioactivity remaining in tissues 24 hours after dose administration had the following order of 
percent of administered dose: adipose (16.7%) > muscle (13.4%) > skin (8.3%) > liver (5.8%) > blood 
(0.9%) > kidney (0.4%) > lung = brain (0.2% each) (Sanders et al. 2006b).  Similar orders of tissue
concentrations were observed in similarly exposed female F344 rats and male and female B6C3F1 mice 
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(Sanders et al. 2006b).  During repeated daily applications of 1-µmol/kg 14C-BDE 153 doses to male rats,
supralinear increases in concentrations of radioactivity (nmol 14C equivalents/g wet tissue) were observed
in adipose and skin (e.g., average concentrations in adipose after 1, 3, and 10 consecutive doses were 
1.57, 9.21, and 30.38 nmol/g, respectively) (Sanders et al. 2006b).  This observation suggests that adipose
and skin serve as sinks for radioactivity initially distributed to other tissues.  In male Sprague-Dawley rats 
sampled 72 hours after administration of single 12.3 µmol/kg doses of 14C-BDE 154 (>95% pure) in
peanut oil, levels of radioactivity remaining in tissues had the following order (percent of administered 
dose): carcass (24.3%) > gastrointestinal tract (3.77%) > adipose (1.82%) > liver (0.68) > thymus ~ testis 
~ lung ~ adrenal ~ kidney ~ plasma ~ heart ~ spleen (≤0.1% each) (Hakk et al. 2009).  Expression of the
data on a concentration basis (nmol 14C equivalents/g wet tissue weight) showed the highest
concentrations in lipid rich tissues: adrenals (29.56 nmol/g), adipose (21.79 nmol/g), skin (7.55 nmol/g), 
gastrointestinal tract (4.58 nmol/g), and thymus (4.48 nmol/g).  Concentrations in carcass, lung, and liver
were intermediate (3.58, 2.26, and 1.80 nmol/g), and concentrations in testis, kidney, heart, spleen, and 
muscle ranged from 1.01 to 0.45 nmol/g.  The concentration in plasma was very low (0.04 nmol/g) (Hakk
et al. 2009). 
Maternal transfer of decaBDE (BDE 209) has been demonstrated in female Sprague-Dawley rats given
oral 5 µmol/kg/day doses of nonlabeled BDE 209 in peanut oil from GD 7 to PPD 4 (Cai et al. 2011).  
BDE 209 concentrations in blood of dams increased with duration of exposure: mean concentrations 
(standard error [SE]) were 358.17 (210.49) and 701.17 (63.43) µg/g lipid weight on GD 15 and PPD 4, 
respectively (Cai et al. 2011). Whole-body concentrations of BDE 209 in fetuses and neonates also 
increased with duration: mean BDE 209 concentrations (and SE) were 20.53 (7.9), 28.95 (3.57), and 
45.04 (10.23) µg/g lipid on GD 15, GD 21, and PPD 4, respectively (Cai et al. 2011).  Nona-brominated 
congeners (BDE 208, BDE 207, and BDE 206) were detected in dam blood samples and whole-bodies of
fetuses and neonates at lower concentrations than BDE 209 and higher concentrations than octa­
brominated BDEs (BDE 196, 197/204, 198/203).  In a related study by the same group of investigators,
female Sprague-Dawley rats were exposed to 5 µmol/kg/day doses of nonlabeled BDE 209 from GD 7 to 
PPD 8 and from PPD 1 to 8 (Zhang et al. 2011).  Whole-body BDE 209 concentrations in pups exposed 
during gestation and lactation were about 2 times greater than concentrations of pup exposed only during
lactation, suggesting that BDE 209 exposure and accumulation can occur during gestational and nursing
periods (Zhang et al. 2011).
In another study with female Sprague-Dawley rats given 1, 10, 100, 300 or 1,000 mg/kg/day of
nonlabeled BDE 209 in corn oil from GD 7 to PPD 4, measurements of BDE 209 concentrations in blood
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samples of dams and offspring gave no clear evidence of maternal transfer, but whole-body
concentrations in offspring were not measured (Biesemeier et al. 2010).  BDE 209 concentrations in 
blood (reported as ng/mL blood) collected on GD 20 were generally higher in exposed dams than in 
exposed fetuses, but mean concentrations of dams and fetuses in the 100-, 300-, and 1,000-mg/kg groups
did not increase with increasing dose. Mean BDE 209 concentrations in maternal or offspring blood 
collected on PPD 4 also did not increase with increasing dose levels, but mean BDE 209 concentrations in 
exposed groups of PPD 4 pups were mostly higher than mean concentrations in dams from the same
exposed groups (Biesemeier et al. 2010). 
Further evidence for different tissue distributions of decaBDE and lower-brominated congeners comes 
from a study in which neonatal NMRI mice were given single 0.7 mg/kg doses of 14C-decaBDE or
0.8 mg/kg doses of 14C-BDE 99 in a 20% fat emulsion to simulate milk on PND 3, 10, or 19 (Eriksson et
al. 2002b; Viberg et al. 2003a).  Neonatal mice exposed to 14C-BDE 209 on PND 3, 10, or 19 had about
0.48, 0.40, and 0.06% of the total administered radioactivity in the brain, 24 hours after dose
administration (Viberg et al. 2003a).  Seven days after exposure, radioactivity in the brain had increased
approximately 2-fold in mice exposed on PND 3 or 10 (to 0.74 and 1.05% of the administered dose), but
remained the same as previously measured in mice exposed on PND 19 (0.06% of administered dose).  
Mice exposed to 14C-BDE 99 on PND 3, 10, or 19 had about 0.37, 0.51, and 0.51% of the administered 
dose in the brain, 24 hours after dose administration; 7 days after dose administration, decreased levels in
brains were seen in mice exposed on PNDs 3, 10, and 19 (about 0.18, 0.28, and 0.15% of the
administered dose) (Eriksson et al. 2002b). 
3.4.2.3  Dermal Exposure 
No studies were located regarding distribution of PBDEs in humans or animals after controlled dermal
exposure.
3.4.3 Metabolism
Oxidative hydroxylation of PBDEs is a principal metabolic transformation that occurs in humans and 
laboratory animals.  Hydroxylated PBDEs have been identified in samples of human biological fluids,
including blood (Athanasiadou et al. 2008; Hovander et al. 2002; Lacorte and Ikonomou 2009; Qiu et al.
2009; Rydén et al. 2012; Wan et al. 2009, 2010; Wang et al. 2012; Yu et al. 2010a) and breast milk
(Lacorte and Ikonomou 2009).  Hydroxylated PBDEs also have been identified in feces or bile of
laboratory rodents exposed to 14C-labeled tetra-, penta-, hexa- or decaBDEs, including:
   
 









    
  
 
     
  
 
      
  
 
    
 
     
 
 
   
     




    
  
 
      
     
   
 
   
    
 



















• rats orally exposed to BDE 47 (Marsh et al. 2006; Orn and Klasson-Wehler 1998; Sanders et al. 
2006a);
• female mice given single intravenous doses of BDE 47, BDE 99, BDE 100, or BDE 153 (Staskal
et al. 2006b)
• conventional or bile-duct cannulated male rats given oral or intravenous doses of BDE 99 (Chen 
et al. 2006; Hakk et al. 2002a);
• conventional or bile-duct cannulated rats given oral doses of BDE 154 (Hakk et al. 2009); and
• conventional or bile-duct cannulated rats given oral doses of BDE 209 (Morck et al. 2003; Riu et
al. 2008).  
Hydroxylated metabolites have also been identified in feces and carcasses of male rats fed a commercial
pentaBDE mixture (DE-71) for 21 days (Huwe et al. 2007), in plasma of rats given single intraperitoneal
injections of an equimolar mixture of BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, and BDE 183 
(Malmberg et al. 2005), and in plasma of mice after oral and subcutaneous exposure to DE-71 for 34 days
(Qiu et al. 2007).  Oxidative hydroxylation of PBDEs also has been demonstrated and studied in in vitro
metabolic systems with human liver microsomes or primary hepatocytes (Cheng et al. 2008; Erratico et
al. 2012, 2013; Feo et al. 2013; Lupton et al. 2009; Stapleton et al. 2009) and rat liver microsomes or
primary hepatocytes (Dong et al. 2010; Erratico et al. 2011).
Metabolic cleavage of the ether bond in PBDEs to form brominated phenols and debromination to form
lower-brominated PBDEs are other metabolic fates of PBDEs in mammals. Evidence for cleavage of the 
ether bond includes the identification of:
• glucuronide- and sulfate-conjugates of 2,4-dibromophenol in male rats given single oral doses of
14C-BDE 47 (2,2',4,4'-tetraBDE) (Sanders et al. 2006a);
• unconjugated 2,4,5-tribromophenol in feces and urine and glucuronide-, sulfate-, and 
glutathionyl-conjugates of 2,4,5-tribromophenol in bile and urine in conventional and bile duct­
cannulated male rats given single oral doses of 14C-BDE 99 (2,2',4,4',5-pentaBDE) (Chen et al. 
2006); and 
• 2,4-dibromophenol and 2,4,5-tribromophenol as metabolites of BDE 47 and BDE 99 following in
vitro incubation with human liver microsomes (Erratico et al. 2013, 2012).
   
 








   
 
    
  
 
    
   
 
      
 
 
     
  
 
    
   
 
    
   
 
      
       
     
   
     
     
   
   
    
   
  
 






   















Evidence for debromination includes the identification of:
• hydroxylated triBDEs in feces of rats given single oral doses of 14C-BDE 47 (2,2',4,4'-tetraBDE)
(Marsh et al. 2006);
• hydroxylated tetraBDEs in feces of male rats given single oral doses of 14C-BDE 99
(2,2',4,4',5-pentaBDE) (Hakk et al. 2002a);
• mono- and di-hydroxylated tetraBDEs in feces of rats given single oral doses of 14C-BDE 100
(2,2',4,4',6-pentaBDE) (Hakk et al. 2006);
• hydroxylated tetra- and pentaBDEs in feces of rats given single oral doses of 14C-BDE 154
(2,2',4,4',5,6'-hexaBDE) (Hakk et al. 2009);
• several hydroxylated BDEs with five to seven bromines per molecule in feces of rats given single 
doses of 14C-BDE 209 (Morck et al. 2003); and 
• several hydroxylated BDEs with eight or nine bromines per molecule in male rats given single
doses of 14C-BDE 209 (Sandholm et al. 2003). 
Information from in vivo toxicokinetic studies with rodents exposed to the best studied congeners
(i.e., BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, and BDE 209) is inadequate to describe detailed 
metabolic pathways, but is adequate to propose that cytochrome P450s are likely to be involved in the
formation of hydroxylated metabolites and hydoxylated debrominated metabolites of BDE 47 (Sanders et
al. 2006a), BDE 99 (Chen et al. 2006), BDE 100 and BDE 154 (Hakk et al. 2006, 2009), and BDE 209
(Morck et al. 2003; Sandholm et al. 2003).  Recent in vitro studies with human or rat liver microsomes or
hepatocytes, and human or rat recombinant CYPs, provide more detailed information adequate for
proposing metabolic pathways for BDE 47, BDE 99, and BDE 100 in humans showing CYP2B6 
mediation for hydroxylation, debromination, and ether bond cleavage for BDE 47, hydroxylation and
ether bond cleavage for BDE 99, and hydroxylation for BDE 100 (see Figures 3-4, 3-5, and 3-6); 
however, no clear metabolic pathways were identified for BDE 153 or BDE 209 using these methods.
• BDE 47 was metabolized, principally by CYP2B6, in human liver microsomes (Erratico et al.
2013; Feo et al. 2013; Lupton et al. 2009), producing 5-OH-BDE-47, 6-OH-BDE-47, an 
unidentified dihydroxylated tetrabrominated BDE and 2,4-dibromophenol as major metabolites,
and several minor metabolites including three other hydroxylated tetrabrominated BDEs and two 
hydroxylated tribrominated BDEs (Erratico et al. 2013; see Figure 3-4).  The predominance of
CYP2B6 involvement was demonstrated by inhibition of the production of all metabolites by a
specific antibody to CYP2B6 (Erratico et al. 2013) and comparison of capabilities of 11 or
12 recombinant human CYPs (Erratico et al. 2013; Feo et al. 2013).  
   
 













      
    
       
     











Figure 3-4.  Structures and General Metabolic Scheme for Hydroxylated



















































*M1 and M2 refer to general structures of unidentified hydroxylated and dihydroxylated tetrabrominated 
BDEs. Structures of other metabolites were determined with authentic chemical standards and ultra-
performance liquid chromatography-mass spectrometry techniques. Bold arrows indicate major
metabolites. CYP2B6 is proposed to be involved in production of all metabolites, based on inhibition of
BDE 47 metabolism by a specific antibody to CYP2B6, and higher rates of BDE 47 metabolism in human 
liver microsomes incubated with specific human recombinant CYP2B6, compared with 11 other human 
recombinant CYPs.
Reprinted (adapted) with permission from Erratico et al. (2013).  Copyright 2013 American Chemical
Society.
   
 















    
    
      
    
    
 







Figure 3-5.  Structures and General Metabolic Scheme for Hydroxylated















































2-OH-BDE-123 4'-OH-BDE-101 6'-OH-BDE-99 
*M1-3 and M4 refer to general structures of unidentified hydroxylated and dihydroxylated 
pentabrominated BDEs. Structures of other metabolites were determined with authentic chemical
standards and ultra-performance liquid chromatography-mass spectrometry techniques. CYP2B6 is
proposed to be involved in production of all metabolites, based on inhibition of BDE 99 metabolism by a
specific antibody to CYP2B6, and higher rates of BDE 99 metabolism in human liver microsomes
incubated with human recombinant CYP2B6, compared with11 other human recombinant CYPs.
Source: Erratico et al. 2012
   
 

















    
   
  
 
    
 
   
 











Figure 3-6.  Structures and General Metabolic Scheme for Hydroxylated










































































*Structures of 3-OH-BDE-100, 5’-OH-BDE-100, 6’OH-BDE-100, and 4’-OH-BDE-103 were determined 
using commercial reference standards and ultra-performance liquid chromatography-mass spectrometry
techniques.  The two remaining mono-OH-pentaBDE metabolites were hypothesized using mass spectral
fragmentation characteristics of derivatized OH-BDEs. Additional information based on theoretical boiling 
point calculations using COnductor-like Screening MOdel for Realistic Solvents (COSMO-RS) and 
experimental chromatographicretention times were used to identify the hypothesized metabolites as
2′-hydroxy-2,3′,4,4′,6-pentabromodiphenyl ether (2′-OHBDE-119) and 4-hydroxy-2,2′,4′,5,6-penta­
bromodiphenyl ether (4-OH-BDE-91), respectively.  CYP2B6 is proposed to be involved in production of
all metabolites, based on inhibition of BDE 99 metabolism by a specific antibody to CYP2B6, and higher
rates of BDE 100 metabolism in human liver microsomes incubated with human recombinant CYP2B6,
compared with nine other human recombinant CYPs.
Source: Gross et al. 2015
   
 













    







    




   
   
 
 










   
  
  






   
  










• BDE 47 was metabolized by liver microsomes from phenobarbital (PB)-induced and 
dexamethasone (DEX)-induced rats, producing five hydroxylated tetrabrominated BDEs with PB-
induction and two hydroxylated tetrabrominated BDEs with DEX induction (Erratico et al. 2011).  
The major metabolites identified were 4'-OH-BDE-49 and 3-OH-BDE-47 (with PB or DEX
induction), and 4-OH-BDE-42 (PB induction only).  No evidence for debromination or ether
bond cleavage was found. These data and a comparison of metabolic capabilities of
14 recombinant rat CYP enzymes indicate that rat liver metabolism of BDE 47 involves 
CYP1A1, CYP2A2, and CYP3A1 (Erratico et al. 2011), 
• BDE 99 was metabolized, principally by CYP2B6, in human liver microsomes (Erratico et al. 
2012; Lupton et al. 2009; Stapleton et al. 2009), producing 2,4,5-tribromophenol, 5'-OH-BDE-99 
and 4'-OH-BDE-101 as major metabolites and seven minor hydroxylated pentaBDEs (4-OH­
BDE-90, 6'-OH-BDE-99, and 2-OH-BDE-123, three unidentified monohydroxy pentabrominated 
BDEs, and one dihydroxy pentabrominated BDE) (Erratico et al. 2012; see Figure 3-5).  No 
evidence for debromination of BDE 99 was found.  CYP2B6 was the only CYP among a panel of
12 human recombinant CYPs showing metabolic activity with BDE 99, and a specific antibody to 
CYP2B6 inhibited the production of all BDE 99 metabolites by human liver microsomes
(Erratico et al. 2012).
• BDE 99 was metabolized to hydroxylated metabolites in primary rat hepatocytes (Dong et al. 
2010) and in liver microsomes from DEX- and PB-induced rats (Erratico et al. 2011).  Liver
microsomes from DEX- and PB-induced rats produced 4-OH-BDE-99 as the major metabolite 
and lesser amounts (in decreasing order) of 5'-OH-BDE-99, 6'-OH-BDE-99, 2,4,5-tribromo­
phenol, 4'-OH-BDE-101, and 2-OH-BDE-123.  No evidence for debromination was found.  
These data and a comparison of metabolic capabilities of 14 recombinant rat CYP enzymes 
indicated that rat liver metabolism of BDE 99 involves CYP1A1, CYP2A2, CYP2B1, and 
CYP3A1 (Erratico et al. 2011).
• BDE 100 was metabolized by recombinant human P450s and pooled human liver
microsomes (Gross et al. 2015).  As with BDE 47 and BDE 99, human CYP2B6 was found 
to be the predominant enzyme responsible for nearly all formation of six mono-OH­
pentaBDE and two di-OH-pentaBDE metabolites.  Four metabolites were identified as 
3-hydroxy-2,2′,4,4′,6-pentabromodiphenyl ether (3-OH-BDE-100), 5′-hydroxy­
2,2′,4,4′,6-pentabromodiphenyl ether (5′-OHBDE-100), 6′-hydroxy-2,2′,4,4′,6-penta­
bromodiphenyl ether (6′-OH-BDE-100), and 4′-hydroxy-2,2′,4,5′,6-pentabromodiphenyl
ether (4′-OH-BDE-103) through use of reference standards (see Figure 3-6).  The two 
remaining mono-OH-pentaBDE metabolites were hypothesized using mass spectral
fragmentation characteristics of derivatized OH-BDEs, which allowed prediction of an 
ortho-OH-pentaBDE and a para-OH-pentaBDE positional isomer.  Additional information 
based on theoretical boiling point calculations using COnductor-like Screening MOdel for
Realistic Solvents (COSMO-RS) and experimental chromatographic retention times were
used to identify the hypothesized metabolites as 2′-hydroxy-2,3′,4,4′,6-penta­
bromodiphenyl ether (2′-OHBDE-119) and 4-hydroxy-2,2′,4′,5,6-pentabromodiphenyl
ether (4-OH-BDE-91), respectively (Simpson et al. 2015).  Kinetic studies of BDE 100 
metabolism using P450 2B6 and HLMs revealed Km values ranging from 4.9 to 7.0 μM
and 6−10 μM, respectively, suggesting a high affinity toward the formation of OH-BDEs.
Compared to the metabolism of BDE 47 and BDE 99 reported in previous studies,
BDE 100 appears to be more slowly metabolized by P450s due to the presence of a third 
ortho-substituted bromine atom.
   
 


















   
  
   
   
       
 
     
 
 
   
     
     
     
   
  
    
   
 










• BDE 153 was not metabolized by human liver microsomes under conditions that produced 
hydroxylated metabolites from BDE 47 (a dihydroxylated BDE 47 and 2,4-dibromophenol), and 
BDE 99 (2,4,5- tribromophenol, a dihydroxlated BDE 99, and 1,3-dibromo benzene) (Lupton et
al. 2009).
• BDE 209 was not metabolized by human primary liver hepatocytes under conditions that
produced 2,3,5-tribromophenol, two hydroxylated pentabrominated BDE metabolites and an 
unidentified hydroxylated tetrabrominated metabolite from BDE 99 (Stapleton et al. 2009).  
In summary, Feo et al. (2013) and Gross et al. (2015) characterized the in vitro metabolism of BDE 47 
and BDE 100 by pooled human liver microsomes and recombinant human CYPs, identifying a number of
hydroxylated BDE metabolites; however, no brominated phenols were detected by the methods utilized 
by these investigators.  In other studies, CYP2B6-mediated metabolism of BDE 47 and BDE 99 produces
multiple hydroxylated metabolites via hydroxylation and ether bond cleavage, based on in vitro studies
with human liver microsomes or hepatocytes and human recombinant CYPs (Erratico et al. 2012, 2013).  
The major metabolites of BDE 47 and BDE 99 formed by human liver microsomes were not the same as 
those identified using rat liver microsomes (Erratico et al. 2013, 2012, 2011).  It is important to note that 
all studies consistently identified CYP2B6 as the primary human CYP responsible for the formation of
hydroxylated metabolites of BDE 47, BDE 99, and BDE 100 (Erratico et al. 2012, 2013; Feo et al. 2013;
Gross et al. 2015), while different classes of CYP enzymes appear to be involved in in vitro rat liver
metabolism of BDE 47 and BDE 99: CYP1A1, CYP2A2, and CYP3A1 for BDE 47 and CYP1A1, 
CYP2A2, CYP2B1, and CYP3A1 for BDE 99 (Erratico et al. 2011).  Production of hydroxylated 
metabolites of BDE 153 (Lupton et al. 2009) and BDE 209 (Stapleton et al. 2009) has not been 
demonstrated with human liver microsomes or hepatocytes, respectively.  It is uncertain if these latter
findings are reflective of a limited in vivo capacity of humans to metabolize these BDE congeners or
because the proper in vitro conditions for metabolizing these congeners were not provided.  Currently, 
studies of metabolism of BDE 47 and BDE 99 with in vitro human and rat systems have found evidence 
of metabolic oxidative debromination only with BDE 47 in human liver microsomes.  In contrast, a
number of in vivo studies have found evidence for oxidative debromination in feces collected from rats
exposed to BDE 47 (Marsh et al. 2006), BDE 99 (Hakk et al. 2002a), BDE 100 (Hakk et al. 2006), 
BDE 154 (Hakk et al. 2009), and BDE 209 (Morck et al. 2003; Sandholm et al. 2003).
3.4.4 Elimination and Excretion 
3.4.4.1  Inhalation Exposure 
No studies were located regarding excretion of PBDEs in humans or animals after inhalation exposure.
   
 









   
 
   
    
 
   
   
 
     





    
   
   
   
   
     
     
 
     
      
 
     
 
     
 
      
     




3.4.4.2  Oral Exposure
Oral Exposure Elimination Overview. Apparent half-lives of PBDE congeners in blood of PBDE-
exposed workers during non-exposed vacation periods ranged from 15 days for BDE 209, 18–39 days for
nonabrominated congeners, and 37–94 days for octabrominated congeners. The detection of PBDEs in 
human breast milk samples indicates that elimination via milk is an elimination route for women, but
several studies examining PBDE concentrations during lactation do not provide a clear account of the
degree to which PBDEs are cleared from the body during lactation.  Results from animal studies given 
single oral doses of 14C-labeled PBDE congeners or PBDE mixtures indicate that biliary excretion into the
feces is the principal route of elimination in rats, and that the urine and feces are principal routes of
elimination of orally absorbed PBDEs in mice.
No studies were located regarding excretion of PBDEs in humans after controlled oral exposure.
Apparent half-lives of several PBDEs in blood were estimated for eight PBDE-exposed workers (four
electronics dismantlers and four workers in a factory making flame-retarded rubber) from measurements 
of hepta-, octa-, nona- and decaBDE concentrations in blood collected during 28–29-day vacation periods
without occupational exposure (Thuresson et al. 2006).  After fitting the data to a single-phase 
exponential model, calculated apparent half-lives were: 15 days for BDE 209; 28, 39, and 18 days for
nonabrominated congeners BDE 208, BDE 207, and BDE 206; 37, 72, 85, and 91 days for BDE 203 and 
three other octabrominated congeners of uncertain chemical structure; and 94 days for BDE 183.
The detection of PBDEs in human breast milk samples suggests that breast milk represents an elimination
route of absorbed PBDEs in women (see Jakobsson et al. 2012 and Frederiksen et al. 2009 for reviews of
PBDE levels in breast milk).  Several studies have examined changes in PBDE concentrations (and other
persistent lipophilic chemicals) in breast milk during lactation, but the results do not provide a clear
account of the degree to which PBDEs are cleared from the body during breast feeding (Hooper et al. 
2007; Jakobsson et al. 2012; LaKind et al. 2009; Thomsen et al. 2010).
Studies with rats given single oral doses of 14C-labeled PBDE congeners or PBDE mixtures indicate that
ingested PBDEs are principally excreted in the feces with <2% of administered radioactivity excreted in 
the urine within 3 days of dose administration. This pattern has been observed in male and female rats 
exposed to BDE 47 (Orn and Klasson-Wehler 1998; Sanders et al. 2006a), male and female rats exposed 
   
 








      
     
   
   
    
     
  
  
    
 
     
   
     
   
   
    
 
   
  
      




     
    
    
   
  
     





to BDE 99 (Chen et al. 2006; Hakk et al. 2002a), male rats exposed to BDE 100 (Hakk et al. 2006), male
and female rats exposed to BDE 153 (Sanders et al. 2006), male rats exposed to BDE 154 (Hakk et al.
2009), pregnant female and male rats exposed to BDE 209 (Morck et al. 2003; Riu et al. 2008), and male 
and female rats exposed to a mixture with 77.4% 14C-BDE 209, 21.8% nonabrominated BDE, and 0.8%
octabrominated (Norris et al. 1973, 1975b).  Studies with bile duct-cannulated male rats indicated that
radioactivity excreted in feces of conventional rats included bile duct-delivered metabolites (i.e., absorbed
material) and unabsorbed compound.  Cumulative biliary excretion represented about 3.9% of
administered dose with BDE 99 (Hakk et al. 2002a), 1.7% with BDE 100 (Hakk et al. 2006), 1.3% with 
BDE 154, and about 10% with BDE 209 (Morck et al. 2003).  
A different elimination pattern has been observed in mice, especially with BDE 47.  In mice given single 
oral doses of 14C-labeled PBDE congeners, fecal and urinary elimination were principal routes of
elimination for BDE 47 (Orn and Klasson-Wehler 1998; Sanders et al. 2006a), whereas fecal elimination 
appeared to be more important than urinary elimination with BDE 99 (Chen et al. 2006) and BDE 153
(Sanders et al. 2006b).  Male C57Bl mice excreted 20% of administered radioactivity in feces and 33% in 
urine within 5 days of administration of 14C-BDE 47 (Orn and Klasson-Wehler 1998). Male and female 
B6C3F1 mice excreted about 30 and 20% of administered 14C-BDE 47 dose in urine and about 22% and 
25% in feces, within 24 hours (Sanders et al. 2006a).  In B6C3F1 mice given 14C-BDE 99, males excreted
7.8% in urine and 27.1% in feces within 24 hours, and females excreted 4.1% in urine and 32.4% in feces
(Chen et al. 2006). Twenty-four hours after administration of 14C-BDE 153, male B6C3F1 mice excreted
1% of administered dose in urine and 31.5% in feces, and females excreted 0.3% in urine and 26.0% in 
feces (Sanders et al. 2006b).
Complementary studies with female C57BL/6J given single intravenous 1-mg/kg doses of 14C-labeled
BDE 47, BDE 99, BDE 100, or BDE 153 also indicate that the degree of urinary excretion in mice is
congener specific (Staskal et al. 2006b).  Cumulative percentages of administered radioactivity excreted
in urine within 5 days were 40, 16, 6, and 2% for BDE 47, BDE 99, BDE 100, and BDE 153, 
respectively.  Relatively greater amounts of parent compound were found in urine from BDE 47-exposed 
mice, compared with mice exposed to the other congeners.  Ratios of cumulative percentage dose 
excreted as parent compound or metabolite in urine were 1.5, 0.5, 0.4, and 0.2 for BDE 47, BDE 99, 
BDE 100, and BDE 153, respectively.  In feces, respective ratios of parent compound:metabolite were 
0.7, 0.2, 0.2, and 0.3 for these congeners, respectively. 
   
 








      
  





   
 




     
   
     
 
  
   
 
  
    
    
 
     
  
   
   
 
       
  






The mechanism for the relatively high elimination of BDE 47 in the urine of mice is unknown, but has
been hypothesized to involve binding to mouse major urinary protein (m-MUP) in the blood (Sanders et
al. 2006a; Staskal et al. 2006b) and other membrane transporting polypeptides (Emond et al. 2013;
Pacyniak et al. 2010, 2011).
3.4.4.3  Dermal Exposure 
No studies were located regarding excretion of PBDEs in humans or animals after dermal exposure.
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
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numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-7 shows a conceptualized representation of a PBPK model.
If PBPK models for PBDEs exist, the overall results and individual models are discussed in this section in 
terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.
Emond et al. (2010) developed a PBPK model for BDE 47 in male and female (nonpregnant and 
pregnant) adult rats.  The model included eight compartments: liver, brain, adipose tissue, kidney, 
placenta, fetus, blood, and the remaining body.  The model was calibrated with tissue concentration data 
from adult male and maternal-fetal toxicokinetic studies. Other data sets were then used to evaluate the 
model’s performance.  Model evaluations indicated that simulated BDE 47 tissue concentrations in adult
male, adult female, and fetal compartments were within the standard deviations of the empirical data.
Emond et al. (2013) developed a PBPK model for BDE 47 in adult mice to describe the distribution of
BDE 47 in tissues and its elimination in feces and urine, and to evaluate the role of transporters in 
elimination of BDE 47. The structure of the model was similar to the rat model developed by Emond et
al. (2010), without the gestational submodel.  In addition, binding to transporters proposed to facilitate
   
 


























Figure 3-7.  Conceptual Representation of a Physiologically Based
Pharmacokinetic (PBPK) Model for a 
Hypothetical Chemical Substance













































Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  Krishnan and Andersen 1994
   
 













   
 





   
    
 
    




    
   
 
     
  
  
   
 
 
    
      




urinary excretion in mice were added:  mouse major urinary protein (m-MUP) in blood and 
P-glycoprotein, a membrane transporter in brain, liver, and kidneys.  The model was used to investigate
the roles that m-MUP and P-glycoprotein may play in BDE 47 elimination in mice.
No reports were located on the development of PBPK models for PBDEs in humans.
3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
Absorption.  Information regarding oral absorption in animals is available from studies of commercial
PBDE mixtures and individual 14C-labeled tetra-, penta-, hexa-, and decaBDE congeners.  The most
recent and best available estimates of oral absorption efficiencies following gavage administration in
lipophilic vehicles indicate a range of 70–85% for tetraBDE (BDE 47), pentaBDE (BDE 99, BDE 100),
and hexaBDE (BDE 153, BDE 154) congeners, and 10–26% for decaBDE (BDE 209) (Hakk et al. 2001, 
2002b, 2006, 2009; Huwe et al. 2002b, 2007; Morck and Klasson Wehler 2001; Morck et al. 2003; Örn 
and Klasson-Wehler 1998; Riu et al. 2008; Sanders et al. 2006a, 2006b; Sandholm et al. 2003; Staskal et
al. 2005).  Underlying mechanisms for oral absorption (e.g., active transport, diffusion, protein binding)
have not been described.
Studies using in vitro gastrointestinal digestion models have evaluated bioaccessibility of PBDEs in
environmentally relevant sources.  In a study by Yu et al. (2010b), the bioaccessibility of lower­
brominated PBDEs in 13 types of food (fish, meat, rice, flour, and vegetables) ranged from 2.6 to 41.3%
in food.  Dietary fat was the most important factor affecting the bioaccessibility of PBDEs, with
bioavailability increasing with increased fat content, likely due to the lipophilic nature of PBDEs (Yu et 
al. 2010b).  Bioavailability was also increased with increasing carbohydrate content, potentially due to the
formation of micelles (Yu et al. 2010b).  However, bioavailability decreased with increasing protein and
fiber content, potentially due to adsorption to dietary fiber and ionic strength effect of amino acids leading
to decreased partition of PBDEs in the aqueous phase (Yu et al. 2010b).  Lepom et al. (2010) evaluated 
the bioaccessibility of PBDEs in ingested dust, which is expected to be the predominant source of human 
exposure in the United States (EPA 2010).  In this study, the bioavailability of PBDEs in ingested dust
was <50%, with higher bioavailability for the lower-brominated PBDEs (27–42%) compared with 
BDE 209 (10%) (Lepom et al. 2010).  A similar study by Abdallah et al. (2012) showed comparable
results for the bioaccessibility of PBDEs in ingested dust, with higher bioavailability for the lower­
brominated PBDEs (32–58%) compared with BDE 209 (14%).
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A dermal absorption efficiency of 62% was reported for female mice exposed to an occluded dermal dose 
of 1 mg/kg 14C-BDE 47) (Staskal et al. 2005). In vitro studies have evaluated diffusion of PBDEs across 
human, rat, and mouse skin.  For 14C-BDE 47, the mean absorption efficiencies (percent of applied
radioactivity collected in receptor compartment) were 1.88% for human skin and 14.58% for rat skin 
(Roper et al. 2006).  For 14C-decaBDE, mean absorption efficiency for mouse skin in vitro was reported
to be only 0.07–0.34% of the applied dose (Hughes et al. 2001). Underlying mechanisms for dermal
absorption (e.g., active transport, diffusion, protein binding) specific to PBDEs have not been described.
Distribution. Evidence for the transfer of PBDEs from pregnant mothers to the developing fetus and for
the transfer of PBDEs from maternal blood to breast milk and then to nursing infants comes from a
number of studies of PBDE concentrations in maternal and cord serum samples and breast milk samples 
from groups of non-occupationally exposed women (Antignac et al. 2009, 2008; Chen et al. 2013;
Kawashiro et al. 2008; Li et al. 2013b; Malarvannan et al. 2013; Mazdai et al. 2003; Meijer et al. 2008;
Park et al. 2011; Qiu et al. 2009; Schecter et al. 2010; Vizcaino et al. 2011; Wan et al. 2010).  In general, 
the tetra- and penta-brominated PBDEs have been the predominant congeners detected in maternal and
cord serum samples and breast milk samples, but some recent studies analyzing a wider range of PBDE
congeners have found evidence for distribution of hepta-, octa-, or decaBDEs into cord serum and breast
milk. Frederiksen et al. (2010) utilized a human ex vivo placenta perfusion system to study the kinetics of
placental transfer of BDE 47, BDE 99, and BDE 209 to the fetus.  Placentas were perfused for 4 hours
with 1 ng/mL concentrations of the nonlabeled congeners.  Samples of maternal and fetal compartments
were taken during the perfusion, and concentrations in samples were determined by GC/MS.  Placental
transfer of BDE 47 and BDE 99 was demonstrated, and transfer of BDE 47 was faster and more extensive
than BDE 99.  Transfer of BDE 209 across the placenta to the fetal compartment was not demonstrated 
with the detection limits of the techniques employed.  Frederiksen et al. (2010) proposed that future
perfusion studies with BDE 209 should use 14C-labeled BDE 209 to increase sensitivity.
Tissue distribution studies in animals orally exposed to 14C-labeled BDE 47, BDE 99, BDE 100, 
BDE 153, BDE 154, and BDE 209 indicate that decaBDE is distributed among tissues somewhat
differently than tetra-, penta- and hexaBDEs.  While lower-brominated BDE congeners, following
absorption and an initial wide distribution, are preferentially accumulated in adipose tissues, absorbed
decaBDE is less readily distributed to adipose tissues and appears to preferentially distribute to highly
perfused tissues (Chen et al. 2006; El Dareer et al. 1987; Eriksson et al. 2002b; Hakk et al. 2002a, 2006;
Morck and Klasson-Wehler 2001; Morck et al. 2003; Norris et al. 1975a; NTP 1986; Örn and Klasson­
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Wehler 1998; Riu et al. 2008; Sanders et al. 2006a, 2006b; Staskal et al. 2005, 2006a; Viberg et al.
2003a).  Although less likely to partition to adipose tissues, decaBDE was still found in low quantities in 
adipose tissues in these studies, and has been shown to transfer from dams to fetuses and neonates from
exposure during gestational and nursing periods (Cai et al. 2011; Zhang et al. 2011).  
Metabolism. Oxidative hydroxylation of PBDEs is a principal metabolic transformation that is thought to 
occur in humans and laboratory animals.  Hydroxylated PBDEs have been identified in samples of human 
biological fluids including blood (Athanasiadou et al. 2008; Hovander et al. 2002; Lacorte and Ikonomou 
2009; Qiu et al. 2009; Rydén et al. 2012; Wan et al. 2009, 2010; Wang et al. 2012; Yu et al. 2010a) and 
breast milk (Lacorte and Ikonomou 2009).  Hydroxylated PBDEs also have been identified in feces or
bile of laboratory rodents exposed to 14C-labeled tetra-, penta-, hexa- or decaBDEs (Chen et al. 2006;
Hakk et al. 2002a, 2009; Marsh et al. 2006; Morck et al. 2003; Orn and Klasson-Wehler 1998; Riu et al. 
2008; Sanders et al. 2006a; Staskal et al. 2006b). Oxidative hydroxylation of PBDEs also has been 
demonstrated and studied in in vitro metabolic systems with human liver microsomes or primary
hepatocytes (Cheng et al. 2008; Erratico et al. 2012, 2013; Feo et al. 2013; Lupton et al. 2009; Stapleton 
et al. 2009) and rat liver microsomes or primary hepatocytes (Dong et al. 2010; Erratico et al. 2011).  
Metabolic cleavage of the ether bond in PBDEs to form brominated phenols and debromination to form
lower-brominated PBDEs are other metabolic fate processes for PBDEs in mammals (Chen et al. 2006;
Erratico et al. 2013, 2012; Hakk et al. 2002a, 2006, 2009; Marsh et al. 2006; Morck et al. 2003; Sanders 
et al. 2006a; Sandholm et al. 2003).
Information from in vivo toxicokinetic studies with rodents exposed to the best studied congeners
(i.e., BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, and BDE 209) is inadequate to describe detailed 
metabolic pathways, but is adequate to propose that cytochrome P450s are likely to be involved in the
formation of hydroxylated metabolites and hydoxylated debrominated metabolites.  In vitro studies with
human liver microsomes or hepatocytes and human recombinant CYPs indicate that CYP2B6-mediated
metabolism of BDE 47, BDE 99, and BDE 100 produced multiple metabolites via hydroxylation (Erratico 
et al. 2012, 2013; Feo et al. 2013; Gross et al. 2015) and ether bond cleavage (Erratico et al. 2012, 2013).  
The major metabolites of BDE 47 and BDE 99 formed by human liver microsomes were not the same as 
those identified using rat liver microsomes (Erratico et al. 2011, 2012, 2013).  Different sets of CYP
enzymes appear to be involved in in vitro rat liver metabolism of BDE 47 and BDE 99: CYP1A1, 
CYP2A2, and CYP3A1 for BDE 47 and CYP1A1, CYP2A2, CYP2B1, and CYP3A1 for BDE 99 
(Erratico et al. 2011).  Production of hydroxylated metabolites of BDE 153 (Lupton et al. 2009) and BDE
209 (Stapleton et al. 2009) has not been demonstrated with human liver microsomes or hepatocytes.  It is
   
 









     
  
    
 
 
   
  
  
   
      
    
   
 
    
 
    
     
  
     




     
 
    
  
 
   
     





uncertain if these latter findings are reflective of a limited in vivo capacity of humans to metabolize these 
BDE congeners or because the proper in vitro conditions for metabolizing these congeners were not
provided.  While rat studies provide evidence for metabolic oxidative debromination of BDE 47, BDE 99,
BDE 100, BDE 154, and BDE 209, studies with human liver microsomes only found evidence supporting
the oxidative debromination of BDE 47.
Elimination. Apparent half-lives of PBDE congeners in blood of PBDE-exposed workers during non-
exposed vacation periods ranged from 15 days for BDE 209, 18–39 days for nonabrominated congeners, 
and 37–94 days for octabrominated congeners (Thuresson et al. 2006).  The detection of PBDEs in human 
breast milk samples indicates that elimination via milk is an elimination route for women, but several
studies examining PBDE concentrations during lactation do not provide a clear account of the degree to 
which PBDEs are cleared from the body during lactation (Hooper et al. 2007; Jakobsson et al. 2012;
LaKind et al. 2009; Thomsen et al. 2010).  Results from animal studies given single oral doses of
14C-labeled PBDE congeners or PBDE mixtures indicate that biliary excretion into the feces is the 
principal route of elimination in rats (Chen et al. 2006; Hakk et al. 2002a, 2006; Morck et al. 2003; Norris
et al. 1973, 1975b; Orn and Klasson-Wehler 1998; Riu et al. 2008; Sanders et al. 2006a), and that the
urine and feces are principal routes of elimination of orally absorbed PBDEs in mice (Chen et al. 2006;
Orn and Klasson-Wehler 1998; Sanders et al. 2006a).  In mice, the importance of urinary excretion is
congener-specific, with BDE 47 showing the greatest ratio of cumulative percentage dose excreted as 
parent compound or metabolite (Staskal et al. 2006b). The mechanism for the relatively high elimination
of BDE 47 in the urine of mice is unknown, but has been hypothesized to involve binding to mouse major
urinary protein (m-MUP) in the blood (Sanders et al. 2006a; Staskal et al. 2006b) and other membrane
transporting polypeptides (Emond et al. 2013; Pacyniak et al. 2010, 2011).
3.5.2 Mechanisms of Toxicity
Overview. As summarized in Section 2.2 (Summary of Health Effects) and detailed in Chapter 3 (Health 
Effects), the main targets of concern following PBDE exposure in humans are the developing nervous and 
reproductive systems, the developing and mature endocrine system, the liver, and the male reproductive 
system.  Other potential targets are the female reproductive system, the adult nervous system, and the 
developing and adult immune system; however, evidence for these end points is limited. Numerous
studies have been conducted to identify potential mechanisms of toxicity for PBDE exposure. These 
studies include evaluations of general mechanisms (e.g., hepatic enzyme induction, AhR-mediated
effects) as well as target-specific mechanisms.  For specific targets, the majority of mechanistic studies 
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have focused on endocrine disruption and neurological effects; however, definitive mechanisms
underlying these effects have not been elucidated.  For other effects, including reproductive toxicity,
immunotoxicity, and hepatotoxicity, only limited mechanistic data are available. Mechanistic data 
relevant to toxic effects of PBDEs are reviewed below.
General Mechanisms of Toxicity.  PBDEs share some toxicological properties with other structurally
similar polyhalogenated aromatic compounds, particularly PBBs, PCBs, PCDDs, and PCDFs (ATSDR
1994, 1998, 2000).  Although these chemicals are structurally similar in two dimensions, PBDEs (and 
polychlorinated diphenyl ethers or PCDEs) differ from the other classes on a three-dimensional basis.  In 
particular, the oxygen bridge of the ether linkage in the diphenyl ether molecule increases the distance 
between the biphenyl rings, introduces a 120° bend in the alignment of the biphenyl rings, and serves as a
barrier to rotation that inhibits the two aromatic rings from assuming a coplanar configuration (Hardy
2002a; Howie et al. 1990). Furthermore, halogen substitution of the ortho positions in the diphenylether
molecule, as occurs for some congeners, pushes the aromatic rings to be orthoganol to each other (i.e., 
offset by 90°) (Hardy 2002a).  Because the toxicity of TCDD and related compounds is related to their 
ability to assume a coplanar configuration for binding to AhR, this suggests that PBDEs are unlikely to 
display similar toxic potency (Hardy 2002a).  Assays conducted by Chen et al. (2001) to compare AhR
binding affinity and EROD activity of PBDE congeners and mixtures found that activities were very low
relative to TCDD and related compounds, but also that, unlike for PCBs, AhR binding affinity was not
correlated with planarization energies of the congeners (the calculated energy needed to force coplanarity 
of the PBDE molecule). The researchers speculated that the large size of the bromine atoms may distort
the AhR binding site so that coplanar configuration is not required.  However, even in studies of
chlorinated analogs (PCDEs), it was found that increasing ortho substitution is less effective in decreasing
the activity of these congeners than for PCBs (Howie et al. 1990).  The authors attributed this difference
to the increased bond length between the phenyl rings in PCDEs relative to PCBs.
In other words, the ether bridge makes PBDEs more non-coplanar in nature, which reduces AhR binding 
affinity relative to similar compounds, but also less sensitive to the influence of ortho substitutions that
inhibit AhR binding of PBBs or PCBs.  This has implications not only for dioxin-type toxicities, which
are mediated by the AhR pathway, but also for non-dioxin-type effects.  For example, Chen et al. (2001)
found that the induction of CYP1A1 by PBDEs is AhR-mediated, as it is for numerous organochlorines, 
even though PBDEs do not readily adopt the coplanar conformation usually considered characteristic of
AhR ligands.  Structure-activity relationships have been incompletely elucidated for non-dioxin-like
effects of PBDEs such as neurotoxicity.  However, based on limited available data, it can be speculated
   
 











   
    
    
   





   
 




    
     
     
    
   
    




    
 
    




that di-ortho-substituted PBDEs might follow the neurotoxic potency of ortho-PCBs (Eriksson et al. 
2002b; Kodavanti and Derr-Yellin 2002; Mariussen and Fonnum 2002, 2003).
There are also geometrical differences in PCBs, PBBs, and PBDEs due to the higher atomic weight and
considerably larger molecular volume of bromine compared to chorine (Hardy 2000a, 2002a).  These
differences contribute to dissimilar physical/chemical properties that can influence the relative
bioavailability, absorption, tissue accumulation, receptor interactions, and toxicities of the chemicals.  For
example, a comparison of a series of isosteric 3,3',4,4'-tetrahalobiphenyls in rats showed that relative 
toxicity (growth rate and thymic atrophy), AhR binding affinity, and aryl hydrocarbon hydroxylase
(AHH) and EROD induction potencies increased with increasing bromine substitution (Andres et al. 
1983).  Possible explanations for this effect included the increased polarizability of bromine versus
chlorine and differences in the electronic, hydrophobic, and hydrogen bonding characteristics of bromine
and chlorine (Andres et al. 1983). 
The enzyme induction properties of PBDEs have been studied to a lesser extent than the enzyme 
induction properties of other structurally similar chemicals.  Existing information suggests that PBDEs 
can be classified as mixed-type inducers of hepatic microsomal monooxygenases, although the mixed 
induction properties of the commercial mixtures are likely due to contamination with polybrominated­
p-dibenzodioxins (PBDDs) and polybrominated dibenzofurans (PBDFs) (Darnerud et al. 2001; de Wit
2002; Hardy 2002b).  Few studies have examined the structure-induction relationships for PBDEs. Chen 
et al. (2001) examined the ability of 12 PBDE congeners and 3 commercial mixtures to induce EROD
activity in chick and rat hepatocytes, in liver cell lines from rainbow trout, rat, and human, and in a
human intestinal cell line.  The number of bromine substitutions in the congeners tested ranged from 3 to 
7. In all cell types, BDE 77, 2,2',4,4',6-pentaBDE, BDE 66, and BDE 126 were the strongest inducers.  
BDE 153 and 2,2',3,4,4',5',6-heptaBDE were weak inducers in all cell types, whereas BDE 66 and 
BDE 85 were very weak inducers in rat hepatocytes and inactive in the other cells.  BDE 47 and 
2,2'4,4',5-pentaBDE, which are prominent in the environment, were not inducers in any cell line, and 
neither were BDE 28, 2,2',4,4',5,6'-hexaBDE, or the penta-, octa-, or decaBDE mixtures.  For those
congeners that had measurable EROD induction activity, their relative potencies were 10-3–10-6 that of
2,3,7,8-TCDD.  In general, the EROD induction activity paralleled the strength of the AhR binding with 
the notable exception of BDE 85, which despite its relatively strong AhR binding affinity (see above),
showed no evidence of activating the AhR to its DRE binding form and was only a weak EROD inducer. 
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As discussed in the introduction to this section, bromination at the ortho position does not appear to
significantly change the biological effects of PBDE molecules.  Structure-activity studies have shown that
some PBDE congeners can bind to the AhR, although binding affinities and induction of AhR-mediated
responses are very weak or negligible, particularly for commercial PBDE mixtures and environmentally
relevant congeners.
For example, Meerts et al. (1998) indirectly examined the AhR-mediated (dioxin-like) properties of
17 PBDE congeners in a recombinant H4II rat hepatoma cell line showing AhR-mediated expression of a
luciferase reporter gene.  The tested congeners varied from dibromo- to heptabromo- substituted
compounds, and with the exception of BDE 15 and BDE 77, all had at least one ortho substitution.  Seven 
of the congeners showed luciferase expression, indicating their ability to activate the AhR.  The only
discernable pattern of receptor activation that appeared to emerge from these results was that greater
receptor activation was obtained with the penta- and hexaBDEs than with tri- and tetraBDEs.
Another study also examined the AhR induction potency of PBDE congeners using the in vitro luciferase
assay with H4IIE-luc recombinant rat hepatoma cells (Villeneuve et al. 2002).  Only 1 of 10 tested
congeners (BDE 126) induced a significant response for AhR-mediated gene expression in the H4IIE-luc
cells, but the magnitude of induction was 87% less compared with the response induced by 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).  With the exception of BDE 105, which induced a response
of 1.7% of the TCDD maximum, no other congener, including the environmentally prominent congeners,
BDE 47, BDE 99, and BDE 153, yielded a response greater than 1% of TCDD.  Overall, the tested PBDE
congeners were at least 200,000 times less potent than TCDD for inducing AhR-mediated gene 
expression in this test system.  Using the same test system (H4IIE-luc recombinant rat hepatoma cells),
Behnisch et al. (2003) reported AhR activities 5–6 orders of magnitude lower than TCDD for BDE 77, 
BDE 105, BDE 126, BDE 119, BDE 190, and BDE 209; BDE 47, BDE 66, BDE 85, BDE 99, BDE 100, 
BDE 153, and BDE 183 were inactive.  Similarly, Hamers et al. (2006) reported AhR activities 6 orders 
of magnitude lower than TCDD for 7/19 PBDE congeners tested (BDE 38, BDE 49, BDE 79, BDE 99, 
BDE 181, BDE 183, and BDE 190), as well as the hydroxylated metabolite, 6OH-BDE-47.  In another
study, several hydroxylated and methoxylated PBDEs (19 out of 34 tested) were also shown to activate 
the AhR receptor in the H4IIE-luc assay, with potencies 4–12 orders of magnitude less than TCDD (Su et
al. 2012).
Chen et al. (2001) studied the affinities of a series of 18 PBDE congeners and 3 commercial PBDE
mixtures for rat hepatic AhR by using competitive AhR-ligand and EROD induction assays. The analysis 
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showed that both the congeners and octa- and pentaBDE commercial mixtures had binding affinities of
10-2–10-5 times that of 2,3,7,8-TCDD.  The congener with the highest affinity among the tested congeners
was BDE 85, although its relative binding affinity was only 2% that of 2,3,7,8-TCDD.  No binding
activity could be determined for the decaBDE mixture.  In contrast with PCBs, the binding affinities did 
not appear to relate to the planarity of the molecule, which according to Chen et al. (2001), was possibly
due to the fact that the large size of bromine atoms expands the receptor binding site.  The dioxin-like
activity of the PBDE congeners and commercial mixtures was subsequently more completely
characterized, by determining whether they act as AhR agonists or antagonists at sequential stages of the 
AhR signal transduction pathway leading to CYP1A1 expression in rat hepatocytes (Chen and Bunce 
2001).  BDE 77, BDE 119, and BDE 126 were moderately active towards dioxin-response element (DRE)
binding and induced responses of both CYP1A1 mRNA and CYP1A1 protein analogous to the maximal 
response of TCDD, although at concentrations 3–5 orders of magnitude greater than TCDD.  These 
congeners showed additive behavior towards DRE binding with TCDD (i.e., an increased response
compared to TCDD alone), whereas most of the other congeners antagonized the action of TCDD.  BDE
100, BDE 153, and BDE 183 were very weak activators of DRE binding, and other congeners and the
three commercial BDE mixtures were inactive.  In particular, the environmentally prominent congeners
BDE 47 and BDE 99 were among the least active with respect to dioxin-like behavior (i.e., were inactive
at all stages of signal transduction), and the commercial pentaBDE mixture had negligible EROD
induction activity.  The PBDE congeners that bound most strongly to the AhR were also the strongest
inducers of CYP1A1 mRNA and CYP1A1 protein, indicating that the induction of CYP1A1 was AhR­
mediated.  Considering all of the end points evaluated in the Chen et al. (2001) and Chen and Bunce
(2001) studies, it was concluded that the relative induction potencies (REPs) of the most active PBDEs 
toward CYP1A1 are ≈10-4 that of TCDD, which is similar to some mono-ortho-PCBs and two orders of 
magnitude less than those of coplanar PCBs, but the REPs for the environmentally prominent congeners
are essentially zero.  Consistent with these findings, Behnisch et al. (2003) also reported REPs of 10-4– 
10-6 that of TCDD for BDE 25, BDE 77, BDE 100, BDE 126, and BDE 183 in the H4IIE-EROD 
bioassay, while BDE 154, BDE 99, BDE 47, and BDE 28 were inactive.
Mechanism of Endocrine Disruption.  PBDE-induced endocrine disruption is likely to involve multiple
mechanisms, including altered synthesis/clearance, transport, and/or receptor binding of endocrine
hormones.
The apparent lack of effect of PBDEs on serum TSH suggests that direct effects on the thyroid leading to 
inhibition of T4 synthesis are unlikely.  However, Wu et al. (2016) present in vitro data that BDE 47 
   
 








   






   
 
    
     
    
    
    
   
   
   
   
     
  
    
 
    
    
    
    
  
 
     
      





inhibits iodide uptake in rat thyroid follicular FRTL-5 cells via non-competitive inhibition of the
sodium/iodide symporter (NIS).  Additionally, mRNA expression levels of thyroid peroxidase (TPO) was
decreased by BDE 47.  Together, NIS and TPO are considered critical molecules in thyroid hormone
synthesis, and are targets of many thyroid disruptors (e.g., perchlorate and thiocyanate) (Wu et al. 2016).  
No additional data regarding the potential for PBDEs to interfere with thyroid hormone synthesis were
located.
PBDEs are hepatic microsomal enzyme inducers, but there is little evidence that increased enzyme 
activity leads to greater clearance of thyroid hormones.  The induction of hepatic UDPGT by PBDEs has 
been demonstrated in several studies (Fowles et al. 1994; Hallgren and Darnerud 2002; Hallgren et al.
2001; Skarman et al. 2005; Stoker et al. 2004; Szabo et al. 2009; Zhou et al. 2001, 2002) and this could 
increase the UDPGT-catalyzed deactivation and excretion of T4 (i.e., the conjugation of T4 with
glucuronic acid).  An indication that increased UDPGT activity may not be the main mechanism for the
reduced T4 levels is provided by Hallgren et al. (2001), who found that exposure to ≥18 mg/kg/day 
pentaBDE for 14 days caused serum T4 reductions in both mice and rats with no effect on UDPGT
activity in the mice, and increased UDPGT in the rats only at higher dose levels.  In contrast, the 
decreases in serum T4 correlated with the induction of microsomal phase I enzymes (EROD and MROD).  
Increased microsomal enzyme activity (discussed above) could also increase the formation of
hydroxylated PBDE metabolites that can bind to T4 plasma transport proteins. This would serve to
increase the number of occupied sites on T4-binding proteins and subsequently result in decreased serum
levels of T4; however, this mechanism is not fully elucidated.  
Several studies have demonstrated that PBDE metabolites compete with T4 for binding thyroid hormone
transport proteins (TTR, thyroxine-binding globulin [TBG]). Meerts et al. (1998, 2000) tested 17 PBDE 
congeners and 3 hydroxylated PBDEs for possible interaction with T4 binding to human TTR, a plasma
transport protein of thyroid hormones, in an in vitro competitive binding assay.  None of the pure
congeners competed with T4 for binding to human TTR without metabolic activation.  Incubation of the
congeners with rat liver microsomes induced by PB (CYP2B enriched), β-napthoflavone (CYPIA
enriched), or clofibrate (CYP4A3 enriched) indicated that 9 of the 17 pure congeners generated
metabolites (not identified) that were able to displace T4 from TTR (>60% competition):  BDE 15, 
BDE 28, BDE 30, BDE 47, BDE 51, BDE 75, BDE 77, BDE 100, and BDE 119.  Testing of the three
known hydroxylated PBDEs, used for their structural resemblance with the thyroid hormones
3,5-diiodothyronine (3,5-T2), 3,3',5-triiodothyronine (T3), and 3,3',5,5'-tetraiodothyronine (T4) showed 
that the T4-like (2,6-dibromo-4-[2,4,6-tribromophenoxy]phenol) and T3-like (2-bromo-4-[2,4,6-tri­
   
 









   
  
       
    
    
  
    
  
   
 
     
  
  
    
   
       
 
   
   
    
    
      
      
   
 
  
   
    
  






bromophenoxy]phenol) hydroxylated PBDEs were 1.42- and 1.22-fold more potent, respectively, than T4; 
the T2-like hydroxylated PBDE (4-[2,4,6-tribromophenoxy]phenol) showed low affinity for TTR
(0.41-fold less potent than T4).  Consistent with these findings, Hamers et al. (2006) reported that 
6OH BDE-47, but none of the 19 PBDE congeners, competed with the natural ligand T4 for TTR binding
(4-fold less potent than T4).  Additionally, Ren and Guo (2012) reported that 5 of the 11 OH-PBDEs
tested bound to TTR with 1.2–2-fold greater potency than T4 and 1 of the 11 OH-PBDEs tested bound to 
TBG with 1.5-fold greater potency than T4. In another study, all OH-PBDEs tested were considered
strong binders of TTR (relative potency compared with T4 between 0.1 and 1) and moderate-to-strong
binders of TBR (relative potency compared with T4 between 0.01 and 1), including 3-OH-BDE 47, 
5-OH-BDE 47, 6-OH-BDE 47, 4-OH-BDE 49, and 6-OH-BDE 99 (Marchesini et al. 2008). Parent
compounds (BDE 47, BDE 49, BDE 68, and BDE 99) and MeO-PBDEs (6-MeO BDE 57, 
2’-MeO-BDE 68) showed no-to-weak binding (<0.01 relative potency compared with T4). Marsh et al.
(1998) tested the affinity of 4'-hydroxyl derivatives of 1,3,5-triBDE, 1,3,3',5'-tetraBDE, and 
1,3,3',5,5'-pentaBDE were tested for human thyroid hormone receptor subunits THR-α and THR-β in 
vitro. These congeners were tested because they theoretically show the highest structural similarity to T4 
and T3. None of the hydroxylated derivatives effectively competed with the thyroid hormones for binding
to either receptor (affinities were 41–>1,000 times less than for T4 and T3).
Studies also suggest that PBDEs and/or their metabolites can alter thyroid hormone binding to thyroid
receptors.  In a reporter gene assay in Chinese hamster ovary (CHO) cells, 4OH-BDE-90 was antagonistic 
to both THR-α and THR-β receptors, with a potency 2-fold less potent in the THR-α assay and ~30%
more potent in the THR-β assay than the reference compound tetrabrominated bisphenol A (TBBPA)
(Kojima et al. 2009). However, receptor antagonism was not observed for the other three OH-PBDEs
tested (4OH-BDE-17, 4OH-BDE-42, 4OH-BDE-49) or any of the eight PBDEs or four MeO-PBDEs
tested (Kojima et al. 2009).  In another reporter gene assay in fibroblast-derived CV-1 cells, T3-dependent
THR-α- and THR-β-responsive gene expression was decreased by BDE 100, BDE 153, BDE 154, 
BDE 290, and DE-71 in fibroblast-derived CV-1 cells by 35–45% (Ibhazehiebo et al. 2011).  Thyroid 
responsive element (TRE) dissociation from TRs was also significantly increased by BDE 100, BDE 154, 
and BDE 290 by 30–45%; however, no changes in THR-α and THR-β cofactor recruitment were 
observed for 11 PBDEs, 2 OH-PBDEs, or DE-71 (Ibhazehiebo et al. 2011). In contrast, in a THR-α and 
THR-β cofactor recruitment assay, 4 of the 10 OH-PBDEs tested were TR agonists (2OH-BDE-28, 
3OH-BDE-28, 5OH-BDE-47, 6OH-BDE-47), showing 70–90% of the maximal response induced by T3 
(Ren et al. 2013). 
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In general, lower-brominated PBDEs, and their hydroxylated (OH-PBDEs) and methoyxylated 
(MeO-PBDEs) metabolites, show estrogenic activities 5–7 orders of magnitude lower than the natural
ligand 17β-estradiol (E2) in reporter gene assays, and higher-brominated PBDEs and their metabolites
show anti-estrogenic activities that are 1–6 orders of magnitude lower than reference antiestrogenic 
compounds (Hamers et al. 2006; Kojima et al. 2009; Li et al. 2013b; Meerts et al. 2001; Mercado-
Feliciano and Bigsby 2008b).  A good correlation has been shown between estrogenic activity and ER
binding affinity of low-brominated PBDEs (Li et al. 2013b; Mercado-Feliciano and Bigsby 2008b).  One
study reported no estrogenic activity in an ER-dependent gene transcriptional activation assay for
“PBDEs” in human HeLa 9903 cells stably transfected with the human ERα receptor; however, the 
specific congener(s) were not identified (Kim et al. 2011b).
For two OH-PBDEs that have bromine substitution patterns similar to the thyroid hormones T2 
[3,5-diiodothyronine] and T3 [3,3’,5-triiodothyronine] (i.e., 4-(2,4,6-tribromophenoxy)phenol and 
2-bromo-4-(2,4,6-tribromophenoxy) phenol, respectively), estrogenic activities were 2–10 times more
potent than E2 (Meerts et al. 2001).  The T2-like hydoxylated PBDE 4-(2,4,6-tribromophenoxy)phenol
also showed estrogenic activity in ERα- and ERβ-like human embryonic kidney cells, with maximum
inductions of 50–95% of the maximum induction by E2 (Meerts et al. 2001). 
Estrogenic effects were also demonstrated using cell proliferation assays in breast cancer cells exposed to
the commercial pentaBDE mixture DE-71 (Mercado-Feliciano and Bigsby 2008b).  Basal cell
proliferation was significantly increased by up to 10-fold with DE-71 exposure (compared with increases
up to 15-fold with exposure to the natural ligand E2).  Co-exposure of cells to DE-71 and E2 significantly
decreased proliferation relative to E2-only exposure in a concentration-dependent manner, suggesting an 
antagonistic effect of DE-71 on E2-induced cell proliferation (Mercado-Feliciano and Bigsby 2008b).  
However, neither basal nor E2-induced cell proliferation were altered in breast cancer cells exposed to
BDE 47, BDE 99, BDE 100, or BDE 209 (Kwiecińska et al. 2011).  Caspase-9 activity (apoptotic marker)
was significantly decreased by ~40–60% in tests with all congeners compared with decreases of ~25%
with exposure to E2 (Kwiecińska et al. 2011).
Estrogenic effects have also been reported in other in vitro and in vivo assays, including increased uterine 
mRNA expression of ERα and ERβ in adult female offspring of rats given subcutaneous injections of
BDE 99 at 1 mg/kg/day (but not 10 mg/kg/day) from GD 10 to 18 (Ceccatelli et al. 2006); increased
uterine mRNA and protein levels of calbindin-D9k, a biomarker for estrogenic compounds, in immature
female rats exposed to BDE 47 at 50–200 mg/kg/day from PND 16 to 18 (Dang et al. 2007); increased
   
 








    




     
     
  







     
  
   
 
      
         
      
    
 
  
    
  
    
   
     





gene and protein expression of ERα and ERβ in porcine ovarian follicles by 5-OH-BDE-47 and 
6-OH-BDE-47 (Karpeta et al. 2014); inhibition of E2 metabolism in rat liver microsomes by
11 OH-PBDEs and 1 MeO-BDE (Lai and Cai et al. 2012); inhibition of E2 sulfation (E2SULT) in
V79 cells by 6-OH-BDE-47, BDE 19, BDE 47, and BDE 49 (Hamers et al. 2006); and increased 
production of vitellogenin in trout hepatocytes exposed to BDE 47, BDE 99, or BDE 205 (Nakari and 
Pessala 2005).  However, estrogenic effects were not observed with exposure to BDE 47, BDE 99, or
BDE 205 in recombinant yeast assays with human estrogen receptor (hER) (Nakari and Pessala 2005). In
a human cohort study, total serum PBDE in adult females were positively associated with ERα and ERβ
mRNA expression levels in the blood; however, BDE 47 serum levels were negatively associated with
ERα and ERβ mRNA expression levels (Karmaus et al. 2011). Similarly, ERβ gene and protein
expression were decreased in porcine ovarian follicles exposed go BDE 47; however, no change was
observed in ERα gene or protein expression levels (Karpeta et al. 2014).
Anti-androgenic and anti-prostagenic activity was observed in reporter gene assays in human osteoblast
cells following exposure to 16 different PBDE congeners, 6OH-BDE-47, and 2 commercial PBDE
mixtures (DE-71, Octa LM) (Hamers et al. 2006).  The most potent antiandrogens, BDE 19 and BDE 100,
were 21 and 13 times less potent than the reference antiandrogenic drug flutamide.  BDE 19 was also the
most potent antiprostagen, and was 3 orders of magnitude lower in potency than the reference compound 
RU-486 (Hamers et al. 2006).  Neither antiandrogenic nor antiprogestagenic activity were observed for
BDE 169, BDE 206, or BDE 209 (Hamers et al. 2006).  Antiandrogenic activity was also observed in two
of five PBDEs tested (BDE 47, BDE 100) and the commercial pentaBDE mixture DE-71 tested in human 
breast cells (Stoker et al. 2005), and in five of eight PBDEs tested, three of four OH-PBDEs tested, and 
four of four MeO PBDEs (all low-brominated) tested in CHO cells (Kojima et al. 2009).  In contrast, 
Christen et al. (2010) reported that BDE 100 and BDE 155 enhanced DHT-dependent activation of
androgen receptor (AR)-responsive gene expression in human breast cells (no other congeners tested).  
However, findings were not concentration-dependent, with the greatest enhancement (~50%) at 10 nM
(highest concentration used was 10 µM) (Christen et al. 2010). This suggests that very low
concentrations of PBDEs may be androgenic, while higher concentrations appear to be antiandrogenic.  
No changes in AR gene or protein expression were observed in porcine ovarian follicular cells exposed to
BDE 47, 5-OH-BDE-47 or 6-OH-BDE-47 (Karpeta et al. 2014).  Anti-progestagenic activity was also
observed in an in vivo study, where adult female offspring of rats given subcutaneous injections of PBDE
99 at 1 or 10 mg/kg/day from GD 10 to 18 had significantly decreased uterine mRNA expression levels of
progesterone receptor (Ceccatelli et al. 2006).
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The ability of the commercial pentaBDE mixture DE-71 and the pure congeners, BDE 47, BDE 99, 
BDE 100, BDE 153, and BDE 154 to compete with 1.0 nM [3H]R1881 for binding to the rat AR was
evaluated using a cytosolic extract prepared from rat ventral prostate tissue (Stoker et al. 2005).  Relative 
binding curves suggested that all of the compounds competed with [3H]R1881 for binding to the AR, with 
inhibition up to 80 and 98% for DE-71 and BDE 100, respectively.  In order to determine if this inhibition 
was competitive, additional in vitro binding tests for BDE 100 were conducted to calculate the inhibition 
constant (Ki).  These experiments showed that BDE 100 was a competitive inhibitor with a Ki value of
1 µM (Stoker et al. 2005).  
Anti-glucocortogenic activity was observed in 3/8 PBDEs (PBDE 85, PBDE 99, PBDE 100), 
2/4 OH-PBDEs (4OH-BDE-17, 4OH-BDE-49), and 1/4 MeO-PBDEs (4MeO-BDE-49) in a
glucocorticoid receptor-mediated reporter gene assay with CHO cells (Kojima et al. 2009).  Anti­
glucocortogenic potencies were 3 orders of magnitude lower than for the reference compound RU-486.
In summary, the mechanistic studies show that PBDEs and/or their metabolites are capable of acting as 
thyroid hormone transporters or receptors and are weakly estrogenic, anti-androgenic, anti-prostagenic,
and anti-glucocortogenic.  However, these findings were not always consistent between different
congeners, metabolites, and studies. Therefore, mechanisms of endocrine disruption by PBDEs have not
been fully elucidated.
Mechanisms of Neurotoxicity.  As detailed in Section 3.2.2.4 Neurological Effects, developmental
exposure to PBDEs has been associated with altered neurodevelopment and behavior later in life in both
humans and animals. The mechanisms for these behavioral and cognitive effects have not been
elucidated; however, proposed mechanisms include neuroendocrine disruption (including altered thyroid 
hormone homeostasis), alterations in neurotransmitter systems (cholinergic, dopaminergic, glutamatergic,
and/or gabaergic), altered calcium homeostatic mechanisms, altered intracellular communication,
oxidative stress, and cell death. Additionally, monohydroxylated metabolites are more potent than the
parent BDE in several of the mechanistic assays, suggesting that bioactivation by oxidative metabolism
contributes to the neurotoxic potential of PBDEs.
Since altered thyroid hormone levels have been reported in both animals and humans (see Section 3.2.2.2 
Systemic Effects, Endocrine subsection), one possible mechanism of neurotoxicity involves the well-
documented key role of thyroid hormones in brain development.  In support of this mechanism, BDE 99 
down-regulates the transcription of the thyroid receptors α1 and α2 (TRα, TRα2) in cultured rat cerebellar
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granular cells, leading to disruption in the expression of T3-mediated genes, including decreased brain-
derived neurotrophic factor (BDNF) (Blanco et al. 2011).  BDE 99 and hydroxylated PBDE metabolites
(3-OH-BDE-47, 6-OH-BDE-47, and 5’-OH-BDE-99) have also been shown to significantly decrease the 
activity of the selenodeiodinase type 2 iodothyronine deiodinase (DIO2), which converts T4 to T3 in the
brain, in primary human astrocytes and H4 glioma cells; BDE 47 did not affect DIO2 activity (Roberts et
al. 2015).  Decreased DIO2 activity associated with exposure to BDE 99 and OH-PBDEs was attributed
to multiple mechanisms, including observed downregulation of DIO2 mRNA, competitive inhibition of
DIO2, and enhance post-translational degradation of DIO2. Ibhazehiebo et al. (2011) showed that the
TR-antagonist, BDE 209 (see Mechanisms of Endocrine Disruption section above), inhibits T4-induced 
dendritic arborization in cultured rat cerebellar Purkinje cells.  However, BDE 47, which was not found to
be a TR-antagonist (see Mechanisms of Endocrine Disruption section above), did not alter dendritic
arborization (Ibhazehiebo et al. 2011).  Study authors indicate that other PBDEs and OH-PBDEs were 
evaluated for dendritic developmental effects; however, results were not reported (Ibhazehiebo et al.
2011).  Additionally, Schreiber et al. (2010) showed that reduced migration and differentiation observed 
in cultured fetal human neural progenitor cells (hNPCs) following exposure to BDE 47 and BDE 99 was
prevented with co-exposure to T3.  These findings indicate that in vitro neurodevelopmental changes were 
due to disruption of cellular thyroid hormone signaling. However, BDE 209 did not significantly
interfere with the T3-mediated response in either a human embryonic kidney reporter cell line expressing
mouse TRα (HEK293-Gal4TRα) or a mouse cerebellar neural reporter cell line expressing TRα
(C17.2α-HRLuc), with or without metabolic activation (Guyot et al. 2014).  Preliminary studies also did 
not show altered T3-mediated responses in C17.2α-HRLuc cells incubated with a commercial PBDE
mixture (BDE-CM, AccuStandard, Inc.; according to manufacturer datasheet, the mixture contains equal
parts BDE 28, 47, 99, 100, 153, 154, 183, and 209) (Guyot et al. 2014).  Additionally, only slight, but 
statistically significant, changes were observed in the expression of T3-responsive genes in C17.2α cells 
following exposure to BDE 209 and T3, compared with T3 exposure alone (Guyot et al. 2014).
Some studies suggest that the neurological effects of PBDEs might be related to alterations in cholinergic
functions.  For example, neonatal exposure to a single oral dose of BDE 99 (8 mg/kg) on PND 10 or a
single oral dose of BDE 209 (≥5.76 mg/kg) on PND 3 altered the behavioral response to cholinergic 
agents (nicotine or paraoxen) in adult mice (Buratovic et al. 2014; Johansson et al. 2008; Viberg et al.
2002, 2007).  Neonatal exposure to nicotine and adult exposure to BDE 99 (single 8 mg/kg oral dose at
age 5 months) also affected behavior in mice, although the change was not seen in mice only exposed to
BDE 99 as adults or mice only exposed to nicotine as neonates (Ankarberg et al. 2001).  Additionally, the
densities of cholinergic nicotinic receptors in the brain hippocampus and/or cortex were decreased by 7– 
   
 








     
    
 
 
    
  
    
    
  
    
     
     
 
   
   
 
    
   
     
   
   
  
     
    
     
   
 
   
   






31% in adult mice exposed once to BDE 99 or BDE 153 at ≥0.8 mg/kg on PND 10 (Fischer et al. 2008; 
Viberg and Eriksson 2011;Viberg et al. 2003a, 2004b, 2005) and increased transcription of cholinergic 
receptors nAchR-β2, AChR5, and nAChR-α4 were observed in the cortex of 2-month-old mice exposed 
to BDE 99 at 12 mg/kg on PND 10 (Hallgren et al. 2015). However, no exposure-related effects were 
observed in any cholinergic parameters in 6- or 27-week-old mink from mink sows exposed to dietary
pentaBDE at 0, 0.01, 0.05, or 0.25 mg/kg/day from pre-mating day 28 to PNW 6 (Bull et al. 2007).  In rat
neuroendocrine pheochromocytoma (PC12) cells and rat neuroblastoma (B35) cells, BDE 209 
significantly decreased the Ach-evoked response in vitro (Hendriks et al. 2014).  Additionally, in vitro
exposure to BDE 99 led to altered neurotransmitter phenotype differentiation in rat PC12 cells, resulting
in a decreased number of cholinergic cells and a greater number of dopaminergic cells; this was not
observed with exposure to BDE 47 (Dishaw et al. 2011; Slotkin et al. 2013). BDE 47 also did not
modulate human α4β2 nicotinic acetylcholine (nACh) receptor function (expressed in Xenopus oocytes); 
however, its hydroxylated metabolite, 6-OH-PBDE-47, was a nACh antagonist (Hendriks et al. 2010).  
Other studies have reported alterations in the dopaminergic system.  Alterations have been observed in the
striatum of mice exposure to 30 mg/kg/day of the pentaBDE mixture DE-71 for 30 days via gavage,
including reductions in dopamine levels, altered dopamine handling (i.e., altered dopamine breakdown 
into DOPAC and HVA), and reductions in the striatal dopamine transporter (DAT) and 
vesicularmonoamine transporter 2 (VMAT2) (Bradner et al. 2013).  DE-71 also inhibited the in vitro
uptake of the neurotransmitter dopamine into rat brain synaptic vesicles; however, inhibition was not
observed with commercial mixtures of octaBDE (DE-79) or decaBDE (DE-83R) (Mariussen and Fonnum
2002, 2003; Mariussen et al. 2003).  Similarly, DE-71 reduced synaptosomal dopamine concentrations
and increased medium dopamine concentrations in striatal synaptosomes derived from PND 7–21 rats
(Dreiem et al. 2010). However, in contrast to the cholinergic system, acute neonatal exposure to BDE 99
(12 mg/kg) on PND 10 did not significantly affect dopaminergic gene transcription in the cortex or
hippocampus on PND 11 or at 2 months of age; genes evaluated included tyrosine hydroxylase (TH), 
DAT, and dopamine receptors D1, D2, and D5 (DRD1, DRD2, and DRD5) (Hallgren and Viberg 2016).
Additional evidence suggests that alterations in the glutamatergic system may also contribute to observed 
neurological effects following PBDE exposure. Neonatal exposure to BDE 209 via gavage doses of
20 mg/kg/day from PND 3 to 10 resulted in significant upregulation of NR1 mRNA in the frontal cortex 
and hippocampus of PND 11 and PND 60 mice, as well as decreased binding of the regulatory complex
REST/NRST (Repressor Element Silencing Transcription Factor/Neuron-Restrictive Silencer Factor) to
the NR1 promotor (Verma et al. 2015).  Additionally, extracellular glutamate levels (along with oxidative
   
 









   
  
  




       
  
      
     
     
 
  
    
 
  
   
  
 
   
  
  
   
   
   
    
       
     
   




stress and cell death) were significantly elevated in cultured mouse cerebellar neurons following in vitro 
exposure to BDE 47 (Costa et al. 2016).  Antagonists of ionotropic glutamate receptors, but not
metabotropic, prevented BDE 47-induced oxidative stress and cell death, providing additional evidence
for a role of glutamatergic signaling in PBDE neurotoxicity (Costa et al. 2016).  In rats, exposure to BDE
47 at doses ≥0.1 mg/kg/day for 30 days via gavage resulted in altered mRNA expression of the glutamate 
receptor subunits NR(1), NR(2)B, and NR(2)C (Yan et al. 2012).
Limited evidence suggests that alterations in the gabaergic system may also contribute to observed
neurological effects following PBDE exposure.  A commercial pentaBDE mixture (DE-71) caused a 
slight inhibition of in vitro uptake of the neurotransmitter GABA into rat brain synaptic vesicles, but
commercial mixtures of octaBDE (DE-79) or decaBDE (DE-83R) did not alter GABA uptake (Mariussen 
and Fonnum 2003).  Additionally, the metabolite, 6-OH-PBDE-47, was a partial agonist for the human 
GABAA receptor expressed in Xenopus oocytes; however, its parent compound (BDE 47) did not
modulate GABAA receptor activity (Hendriks et al. 2010).
Effects of PBDEs on the function and development of the nervous system could also involve disruption of
calcium homeostatic mechanisms and intracellular signaling events. In human neural progenitor cells
(hNPCs), in vitro exposure to BDE 47 or 6-OH-BDE-47 led to transient increases in intracellular Ca+2 
levels due to increased influx of extracellular Ca+2 as well as intracellular release from the endoplasmic
reticulum (Gassmann et al. 2014).  Based on additional studies using multiple inhibitors/stimulators of
presumably involved signaling pathways, the increase in extracellular influx appears to be due to 
interference with the cell membrane, rather than alterations of Ca+ ion channel dynamics, and the
increased ER release was associated with activation of protein lipase C and inositol 1,4,5-trisphophate
receptor, independent of the ryanodine receptors (Gassmann et al. 2014).  A series of studies evaluated
the effects of in vitro exposure to PBDEs and their metabolites on calcium homeostasis in rat PC12 cells 
(Dingemans et al. 2008, 2010a, 2010b).  Collectively, these studies show that hydroxylated metabolites of
PBDEs lead to increased basal Ca+2 levels due to Ca+2 release from the endoplasmic reticulum and
mitochondria as well as decreased depolarization-evoked Ca+2 levels.  BDE 47 was shown to have
similar, but less potent effects, while no effects on calcium homeostasis were observed with BDE 49,
BDE 99, BDE 100, BDE 153, or methylated metabolites (Dingemans et al. 2008, 2010a, 2010b). In a
similar study, BDE 209 did not alter calcium homeostasis in rat PC12 or B35 cells (Hendriks et al. 2014).  
BDE 49, OH-BDE-47, and 4’OH-BDE-49 have also been shown to be potent modulators of ryanodine
receptors type 1 and 2, which regulate essential aspects of Ca+2 signaling; BDE 47 was without activity in
this assay (Kim et al. 2011c; Pessah et al. 2010).  In culture systems, BDE 47 and BDE 209 were shown 
   
 









   
 
    
  
    
  
     
     
       
    
    
 
 
   
   
        
    
  
     
   
     
     
     
  
    
   
 
    
 
  




to increased intracellular Ca+2 content in mouse cerebellar granule cells and rat neonatal hippocampal
neurons, respectively (Chen et al. 2010; Costa et al. 2016).  In vitro exposure to DE-71 or BDE 47 also
stimulated arachidonic acid release in rat cerebellar granule neurons; this effect was not seen with DE-79 
(Kodavanti 2003; Kodavanti and Derr-Yellin 2002).  The release of arachidonic acid appeared to be 
mediated by the activation of both Ca+2-dependent and Ca+2-independent cytosolic phospholipase A2. In 
vitro exposure to DE-71and BDE 47 also caused translocation of protein kinase C, as indicated by
increased phorbol ester binding; DE-79 did not induce this effect (Kodavanti and Derr-Yellin 2002; Rao 
et al. 2003).  Other effects of penta mixture DE-71 and tetra congener BDE 47 included decreases in 
intracellular calcium buffering by microsomes and mitochondria (Kodavanti and Derr-Yellin 2002).  The
tetra- congener BDE 47 was generally more potent than the DE-71 mixture (mainly comprised of tetra-
and penta- congeners) in these tests. All commercial mixtures and congeners tested (DE-71, DE-79, BDE
47, BDE 77, BDE 99, BDE 153) elevated phosphorylated extracellular signal-regulated kinase (pERK) ½, 
with congeners having a greater effect than mixtures (Fan et al. 2010).  pERK ½ is a widely studied
MAPK cascade known to be involved in learning and memory.  
Neurotoxicity may be mediated by cell death, perhaps in response to oxidative stress, as increased
apoptosis and upregulation of apoptotic proteins and markers of oxidative have been observed in the
hippocampus, cortex, and cerebellum of rats following developmental exposure to PBDEs (He et al.
2009; Chen et al. 2014; Cheng et al. 2009; Costa et al. 2015; see Section 3.2.2.6, Developmental Effects
for more details).  In support, ROS were increased in rat cerebellar granular cells exposed to 25 µM 
BDE 99, and this increase was correlated with a decrease in the gene expression of the anti-apoptotic
protein Bcl-2 (Blanco et al. 2011). Another study found that DE-71 was more toxic than octa- and deca­
congeners in inducing cell death and free radical formation in cerebellar granule cells (Reistad et al.
2002).  In cultured rat cortical cells, a high concentration of BDE 99 (30 µM) induced cell death without
any apparent increase in caspase-3 activity (Alm et al. 2008).  BDE 47 also induced apoptosis in primary
cultured rat hippocampal neurons; changes in oxidative stress parameters included increased ROS levels,
malondialdehyde content, glutathione peroxidase levels and decreased glutathione and superoxide
dismutase levels (He et al. 2008c).  BDE 47-induced apoptosis in human SH-SY5Y was shown to be
mediated via the mitochondrial p53 pathway, as evidenced by up-regulation of p53 and Bax, down-
regulation of Bcl-2 and Bcl-2/Bax ratio, enhancement of Cyt c release from mitochondria into the cytosol, 
and activation of caspase-3, as well as by ultrastructural abnormalities of mitochondria (Zhang et al. 
2013c).  In mouse cerebral granule cells, PBDE exposure caused decreased cell viability, induced 
apoptotic cell death, and increased ROS and lipid peroxidation following exposure to BDE 47, BDE 99, 
BDE 100, BDE 153, and BDE 209 (Costas et al. 2015, 2016; Huang et al. 2010).  Huang et al. (2010)
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reported a congener potency ranking of BDE 100 > BDE 47 > BDE 99 > BDE 153 >> BDE 209. 
Similarly, in cultured rat neonatal hippocampal neurons, BDE 209 decreased cell viability and increased
the rate of apoptosis, ROS levels, malondialdehyde (MDA) content, and NO content (MAPKs) (Chen et
al. 2010). In rat B35 cells, increased ROS generation in the absence of decreased cell viability was 
observed following exposure to BDE 209; no changes in ROS generation or cell viability were observed 
in rat PC12 cells (Hendriks et al. 2014).
Proteomic and genomic studies have identified multiple systems/pathways in the brain that can be altered
following PBDE exposure; however, strong conclusions regarding mechanisms of neurotoxicity from
these studies cannot be made at this point.  In laboratory animals, in vivo exposure to ≥12 mg/kg/day of
DE-71, BDE 99, BDE 203, BDE 206, or BDE 209 for 1–30 days has been shown to alter expression of
proteins involved in mediating GABA and glutamate neurotransmission in the frontal cortex; neuronal
survival, growth, and synaptogenesis in the cortex, hippocampus, cerebellum, and striatum; cytoskeletal
proteins in the cortex and hippocampus; oxidative stress and apoptosis in the cerebellum and 
hippocampus; and metabolism and energy production in the hippocampus and cerebellum (Alm et al.
2008, 2006; Buratovic et al. 2014; Bradner et al. 2013; Kodavanti et al. 2015; Verma et al. 2015; Viberg 
2009a, 2009b; Viberg and Eriksson 2011; Viberg et al. 2008). In mice exposed to 0.45 mg/kg/day for 
28 days, combined analysis of proteomic and genomic data using biological network analysis indicated
disturbances in the following functional categories: nervous system development and function, 
neurological disease, and behavior (Rasinger et al. 2014). Gene ontogeny analysis showed significant
changes in mitochondrion morphogenesis, Wnt receptor signaling pathway, ʟ-glutamate transport, and 
calcium ion transport into cytosol, while proteomics identified differential expression of dynamin 1, 
calcium/calmodulin-dependent protein kinase II delta, and alpha 4a tubulin (Rasinger et al. 2014).  In
culture systems, proteomic analysis of neonatal hippocampal neural stem/progenitor cells following
exposure to BDE 47 and/or BDE 209 showed differential expression of 19 proteins, including proteins
involved in metabolism, signal transduction, transcription, transport, and cell structures (Song et al. 
2014).  Key proteins showing downregulation were cofilin-1, which is associated with cell cycle and 
neuronal migration, and vimentin, which is implicated in nervous system repair mechanisms.
Epigenetic changes may also contribute to neurotoxicity following exposure to PBDEs.  Byun et al. 
(2015) examined this hypothesis in mice exposed perinatally to BDE 47 by evaluating DNA methylation
patterns in mitochondrial genes involved in respiration (cytochrome c oxidase I, II, and III), nuclear
genome methylation markers (5hmc, L1Rn), and nuclear candidate genes related to behavioral and brain
functions (BDNF, corticotropin releasing hormone receptor 1, melanocortin 2 receptor, nuclear receptor
   
 








    
     
 
   
 
 
    
 





    
  
   








   
   
    
    




subfamily 3 group C member 1, and alpha-synuclein). Significant changes in methylation were not
observe in DNA methylation patterns for the majority of genes examined, although slight (<2-fold), but
statistically significant, methylation decreases were observed in cytochrome c oxidase II, L1Rn, BDNF, 
and nuclear receptor subfamily 3 group C member 1 (NR3CL) in mice exposed to BDE 47, compared 
with control (Byun et al. 2015).  However, global DNA methylation was significantly decreased in
female, but not male, offspring of mouse dams exposed to tetraBDE from premating day 28 to PND 21 
(Woods et al. 2012).  
Mechanisms of Reproductive Toxicity.  As discussed above (see Mechanisms of Endocrine Disruption), 
PBDEs have been shown to be weakly estrogenic and anti-androgenic.  Additionally, altered
steroidogenesis has been observed in vitro. Limited data are available regarding other potential
mechanisms of reproductive toxicity, such as altered placental function due to increased prostaglandin
synthesis and impaired mitochondrial function in sperm cells.
Testosterone secretion was increased by up to 3-fold in cultured rat Leydig cells exposed to a mixture of
tetra- and pentaBDEs (PBDE-710) (Wang et al. 2011c) or BDE 47 alone (Zhao et al. 2011).  These
studies suggest that PBDEs may stimulate testosterone secretion by acting directly on Leydig cells to
activate the cAMP pathway and increased expression of steroidogenic acute regulatory protein (StAR), as 
evidence by increased gene and protein expression of StAR (Wang et al. 2011c, Zhao et al. 2011) as well
as increased intracellular levels of cAMP, increased PKAα nuclear translocation, and increased activity of
CYP 11A1 (Wang et al. 2011c).  In support, the observed increase in testosterone secretion was blocked
in the presence of the adenylyl cyclase inhibitor SQ22536 (Wang et al. 2011c).  However, gene 
expression of StAR was not upregulated in mouse Leydig cells exposed to BDE 47 (testosterone secretion
was not evaluated) (Schang et al. 2016).
Testosterone production was also significantly increased by ~2–4.5-fold in porcine ovarian follicles
exposed in vitro to BDE 47, BDE 99, or BDE 100 (Karpeta et al. 2011).  Androstenedione (A4) and 
progesterone production was also significantly increased, but responses were not concentration-
dependent.  No exposure-related changes were observed in E2 production.  Potential mechanisms 
underlying increased testosterone production were judged to be congener-specific.  For BDE 47, observed 
increases in 17β-HSD protein expression and activity and decreases in CYP19 (aromatase) activity
suggest that increased testosterone production is due to increased conversion of A4 to testosterone by
17β-HSD and decreased conversion of testosterone to E2 by CYP 19.  For BDE 100, observed increases
in CYP17 protein expression and activity and decreases in CYP19 activity suggest increased testosterone
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production is due to increased conversion of progesterone to A4 by 17β-HSD (which is later converted
into testosterone) and decreased conversion of testosterone to E2 by CYP 19.  BDE 99 did not alter
protein expression or activity of 17β-HSD, CYP 17, or CYP 19.  The study authors suggest that the
mechanism of action for BDE 99 is prior to the secretion of progesterone (i.e., StAR or 3β-HSD). In
contrast, OH-PBDEs (5OH-BDE-47, 6OH-BDE-47) did not alter testosterone or A4 production in 
porcine ovarian follicles; however, E2 production was significantly increased for both metabolites by 2.4– 
2.9-fold (Karpeta et al. 2013).  Additionally, the OH-PBDEs increased protein expression and activity of
CYP 19, suggesting that the increase in E2 may be due to increased aromatase-mediated conversion of
testosterone to E2.  Similarly, changes in E2 secretion in mid-phase porcine luteal cells (increased) and
late-phase porcine luteal cells (decreased) following in vitro exposure to BDE 47 was significantly
correlated with CYP 19 activity, although neither 5-OH-BDE-47 nor 6-OH-BDE-47 altered E2 secretion
(Gregoraszczuk et al. 2015).  In an in vivo study, CYP 19 activity in the ovaries of female rats was not 
altered with exposure to BDE 209 doses up to 60 mg/kg/day for 28 days via gavage; however, CYP 17 
activity in the adrenal glands was significantly decreased by up to 97% in females, but not males (Van der
Ven et al. 2008a). 
Progesterone production was significantly increased by 1.3–2.1-fold in mid-phase porcine luteal cells 
exposed to BDE 47 (≥250 ng/mL) or BDE 99 (≥50 ng/mL) for 24 hours, but not 48 hours (Gregorasczuk
et al. 2012). Exposure to BDE 100 did not alter progesterone levels at concentrations up to 500 ng/mL at
either time point.  Following exposure for 24 hours, cells exposed to BDE 99 also showed a significant
increase in the activity and protein level of 3β-HSD (which converts pregnenolone into progesterone); no 
changes in protein levels or activity of CYP11A1 (which converts 25-hydroxycholesterol into 
progesterone) were observed for any congener.  Increased gene expression of 3β-HSD was also observed 
in mouse Leydig cells exposed to BDE 47; however, no exposure-related changes were observed in
progesterone secretion (Schang et al. 2016).  Another study did not observe increased progesterone
production in early-, mid-, or late-phase porcine luteal cells exposed to BDE 47 for 24 hours at doses up 
to 50 ng/mL (lower than the lowest effective dose in the previous study) (Gregorasczuk et al. 2015).  
However, metabolites of BDE 47 (5-OH-BDE-47 and 6-OH-BDE-47) significantly decreased
progesterone secretion in mid- and late-phase cells, respectively; 6-OH-BDE-47 also significantly 
inhibited 3β-HSD activity in late-phase cells (Gregorasczuk et al. 2015).  Gregorasczuk et al. (2012) also 
measured activity of caspases 3, 8, and 9 in porcine luteal cells collected during the middle luteal phase 
following exposure to BDE 47, 99, or 100.  Increased activation of both intrinsic (caspase 9) and extrinsic
(caspase 8) apoptotic pathways was observed at 24 hours, with additional activation of caspase 3 at
48 hours, was observed with all congeners, indicating premature apoptosis of middle luteal cells 
   
 








   
    
  
 
    
     
 




    








    
 
    
     
    
    
 
  
    





(apoptosis should occur during late luteal phase).  The study authors proposed that the combined effects 
of altered steroidogenesis and premature apoptosis observed following in vitro exposure to PBDEs could 
negatively impact the estrous cycle by shortening the luteal phase, and potentially fecundability.  
Several studies have also evaluated steroidogenesis in human adrenocortical carcinoma cells following
exposure to PBDEs or their metabolites.  The parent compound, BDE 47, did not alter testosterone, 
androstenedione, E2, pregnenolone, 17α-OH-pregnenolone, progesterone, or 17α-OH- progesterone 
levels in human adrenocortical carcinoma cells (van den Dungen et al. 2015).  As observed in porcine
follicular cells, increased E2 production accompanied by increased CYP 19 gene expression and activity
was observed in human adrenocortical carcinoma cells following exposure to the methyoxylated 
metabolites 6Cl-2MeO-BDE-68 and 6MeO-BDE852/10 (He et al. 2008c).  However, other tested 
metabolites (6Cl-2OH-BDE-7, 5Cl-6OH-BDE-47, 2MeO-BDE-28) showed decreased E2 production (He
et al. 2008c). Testosterone production was increased by 2/10 tested MeO-PBDEs (6MeO-BDE85, 
6MeO-BDE137), but 0/10 tested OH-PBDEs (He et al. 2008c).  The activity of the steroidogenic enzyme
CYP 19 was also evaluated in cultured H295R human adrenocortical carcinoma cells exposed to
19 PBDEs, 5 OH-PBDEs, and one methoxylated (MeO-)PBDE (Canton et al. 2005).  Two low­
brominated PBDEs (BDE 19, BDE 28) induced CYP 19 by 200%, while two higher-brominated PBDEs
(BDE 206, BDE 209) inhibited CYP 19 by 61–64%.  6OH-BDE-99 and 6MeO-BDE-47 also inhibited 
CYP 19 by 46–67%.  The 6OH-BDE-47 metabolite showed minimal inhibition accompanied by
cytotoxicity.  In another study evaluating 11 OH-PBDEs and 11 MeO-PBDEs, all OH-PBDEs inhibited 
CYP 19 (Canton et al. 2008).  The most potent aromatase inhibitors were 6OH-BDE-49 and 
3OH-BDE-47, which decreased CYP 19 activity by 54 and 27%, respectively.  No CYP 19 inhibition was
observed with the MeO-PBDEs.
Park and Loch-Caruso (2015) evaluated the effects of BDE 47 exposure on prostaglandin E2 synthesis in 
first trimester human extravillous trophoblast cells (HTR-8/SVneo), as prostaglandin E2 is a pro-
inflammatory regulator of trophoblast cellular functions critical for successful placentation.  Significantly 
increased prostaglandin E2 release was following in vitro exposure to BDE 47.  mRNA expression of
enzymes involved in prostaglandin synthesis and catabolism were also significantly altered, including
increases in prostaglandin synthase 2 and COX-2 (rate-limiting enzyme of prostaglandin synthesis) and 
decreased 15-hydroxyprostaglandin dehydrogenase and prostaglandin E synthase. Prostaglandin changes
were completely blocked following treatment with a COX-2 inhibitor, confirming that prostaglandin 
upregulation was COX-dependent.  Additionally, significant ROS generation was observed following
BDE 47 exposure.  The peroxyl radical scavenger, α-tocopherol, blocked both ROS generation and 
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prostaglandin release; however, it had no effect on COX-2 mRNA levels.  The study authors proposed
that generation of ROS in the placenta following BDE 47 exposure stimulates prostaglandin E2 
production via post-translational modifications of a COX-2-dependant pathway, and may lead to placental
dysfunction (Park and Loch-Caruso 2015).  
Following 8-week oral exposure to BDE 47, increased apoptosis was observed in early leptotene 
spermatocytes of adult male rats (Huang et al. 2015). Proteomic analysis of testicular tissue indicated
differential expression of 64 proteins, including 20 proteins related to apoptosis.  Of these 15/20 apoptotic
proteins were located in the mitochondria.  Protein expression data from cultured testicular mouse cells 
(GC1-spg cells) were consistent with in vivo results, showing significant decreases in Uqcrc1, Atp5b, 
Tufm, Sucla2, and Lap3, indicating mitochondrial dysfunction and apoptosis, and a significant decrease
in the anti-apoptotic factor Bcl-2 (Huang et al. 2015).
Mechanisms of Immunotoxicity.  As discussed in Section 3.2.2.3, Immunological and Lymphoreticular
Effects, limited evidence from animal studies suggest that PBDEs may cause immunosuppression
(Darnerud and Thuvander 1998; Feng et al. 2016b; Fowles et al. 1994; Watanabe et al. 2008, 2010b).  
Lundgren et al. (2009) suggested that decreased immune response to infection may be due to suppression 
of cytokines by PBDE exposure.  In mice infected with human coxsackievirus B3 (CVB3), serum levels
of IL-12, MIP-1β, RANTES, IFN-γ, and KC were markedly decreased (or completely lacking) in mice
exposed to BDE 99 or Bromkal 70-5 DE (37% BDE 47, 35% BDE 99), compared with infected controls.
No information regarding potential mechanisms of immunotoxicity for PBDEs were located.  Howie et al.
(1990) examined the immunotoxic potencies of various polychlorinated diphenyl ether congeners on the
inhibition of the plaque-forming splenic cell response to sheep red blood cell antigen in mice. The
observed potency order (2,3,3',4,4',5-hexaCDE > 3,3',4,4',5-pentaCDE > 2,3',4,4',5-pentaCDE >
3,3',4,4'-tetraCDE > 2,2',4,4',5,5'-hexaCDE > 2,2',4,5,5'-pentaCDE > 2,2',4,4',5,6'-hexaCDE) generally
paralleled the congener-specific potencies for induction of hepatic microsomal AHH and EROD.  Worth 
noting is the fact that the resulting ranking order of potency did not follow the order that would have been 
expected for a response known to be AhR-mediated, such as the inhibition of the plaque-forming splenic
cell response to challenge with sheep red blood cells antigen.  For example, the laterally substituted
congeners 3,3',4,4'-tetraCDE and 3,3',4,4',5-pentaCDE were less immunotoxic than their respective
monoortho-substituted analogs; this was true also for their enzyme induction potencies.  These findings
showed that increasing ortho- substitution is less effective in reducing the “dioxin-like” activity of these
compounds.  Howie et al. (1990) suggested that the ether bridge in the polychlorinated diphenyl ether
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molecules increases the bond length between the two phenyl rings, thus diminishing the effects of ortho
substituents on the biochemical and toxic potencies of these compounds. However, these findings may or
may not be relevant to immunotoxic activities of PBDEs because of the considerable difference in the
molecular size of brominated and chlorinated analogues, which may influence receptor-mediated effects,
as well as potential toxicokinetic differences.
Mechanisms of Hepatotoxicity. As discussed in Section 3.2.2.2 Systemic Effects (hepatic subsection),
liver effects have been reported in adult, pregnant, and developing animals exposed to lower-brominated 
PBDEs.  Evidence for hepatic effects in animals following exposure to decaBDE is less consistent.
Existing information suggests that PBDEs can be classified as mixed-type inducers of hepatic microsomal
monooxygenases (see General Mechanisms of Toxicity Section).  Observed effects of liver enlargement
and hepatocellular hypertrophy are consistent with enzymatic induction. However, oxidative stress,
inflammatory processes, and induction of apoptosis may also contribute to hepatotoxicity of PBDEs.  In
12-week gavage studies in mice, administration of troxerutin, an antioxidant and anti-inflammatory agent, 
prevented tetraBDE-induced hepatotoxicity (increased liver weight, increased serum ALT, hepatocyte
hypertrophy and vacuolization, and inflammatory cell infiltration) (Zhang et al. 2015a, 2015b).
Moreover, tetraBDE-mediated induction of protein and genetic markers of oxidative stress, inflammation, 
proteasomal subunits, ER-stress pathways, and apopotisis are prevented by troxerutin.  Zhang et al. 
(2015b) proposed that upregulation of NF-kB via the tetraBDE-induction of histone 3 acetylation at 
lysine 9 (H3K9) is due to tetraBDE-mediated decreases in SirT1 (which mediates deacetylation), and that
this upregulation of NF-kB leads to the observed increases in mRNA levels of inflammation-related
genes. Additionally, Zhang et al. (2015a) suggested that oxidative stress leads to apoptosis via 
proteasome dysfunction-mediated ER stress. Taken together, the therapeutic mechanism of actions for
troxerutin could include antioxidant actions and restoration of proteasomal function, as well as the 
activation of SirT1. These are supported by similar decreases in markers of oxidative stress following
vitamin E treatment as well as the blunting of troxerutin-mediate effects with concurrent EX527
injections (a SirT1-specific inhibitor) or epoxomicin injections (a selective proteasome inhibitor) (Zhang
et al. 2015a, 2015b).  In vitro studies also report elevated ROS levels, depleted GSH levels, mitochondrial 
damage and dysfunction, and apoptosis in HepG2 human hepatocellular carcinoma cells exposed to BDE
47 (Liu et al. 2015; Saquib et al. 2016; Yeh et al. 2015).  As observed in vivo, known antioxidants
(eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) protect cultured HepG2 human 
hepatocellular carcinoma cells from BDE-47-induced oxidative stress and mitochondrial dysfunction 
(Yeh et al. 2015). However, Pereira et al. (2014) suggest that apoptosis may be mediated via direct
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interaction of PBDEs with mitochondria, rather than secondary to PBDE-mediated oxidative stress.  In
isolated rat liver mitochondria, BDE 154 directly interacted with the mitochondrial membrane, 
permeabilizing the membrane and leading to ATP depletion.  These events occurred in the absence of
ROS accumulation in the mitochondria, suggesting that BDE 154 impairs mitochondrial bioenergetics
and permeabilizes the mitochondria, potentially leading to cell death, in the absence of oxidative stress 
(Pereira et al. 2014). BDE 47 and BDE 99 have also been shown to directly interact with the 
mitochondrial membrane in isolated rat liver mitochondria, resulting in altered mitochondrial
bioenergetics and ATP depletion (Pazin et al. 2015).
3.5.3 Animal-to-Human Extrapolations 
Residues of PBDEs in humans reflect multiple exposure pathways and congener-specific elimination and 
thus, in general, represent steady-state body burdens that do not match the congener profiles in the
original exposure sources.  For example, profiles of PBDE congeners in human milk do not resemble the
pattern of any of the previously used commercial mixtures, which were predominantly pentaBDE, 
octaBDE, and/or decaBDE, as illustrated by the finding that the major PBDE congener in milk from
Swedish mothers was 2,2',4,4'-tetraBDE (BDE 47), which comprised approximately 55% of the total
PBDEs (Darnerud et al. 1998).  As discussed in Chapter 6, residue analyses indicate that tetra- to hexa­
congeners predominate in humans, aquatic mammals, birds, fish, and other biota, indicating that the
biological fate of PBDE congeners is qualitatively similar in various animal species. The wildlife residue 
data also indicate that different species have different tissue ratios of congeners, possibly reflective of
interspecies differences in metabolic capabilities as well as potential differences in exposure.  The 
likelihood of interspecies differences in the quantitative disposition of PBDEs is illustrated by the
observation that metabolism and urinary excretion of a single oral dose of BDE 47 was significantly 
slower in rats than in mice (Orn and Klasson-Wehler 1998; Staskal et al. 2006b).
While alterations in thyroid hormone levels are consistently altered in in PBDE-exposed animals, human 
data are less consistent.  Humans are possibly less sensitive than rats to effects of PBDEs on circulating
levels of thyroid hormones.  This difference is thought to derive from the rat thyroid having a smaller
store of iodinated thyroglobulin that is more easily depleted when the availability of iodide is limited, and
from a more rapid clearance of T4 from the rat circulation; the latter resulting from rats not having a high
affinity binding protein for T4 in serum analogous to TBG in humans (Capen 1997).  If the production of
T4 and T3 is impaired sufficiently to deplete the thyroid of stored iodinated thyroglobulin, the thyroid 
cannot produce or secrete amounts of T4 and T3 needed to support physiological demands, circulating
   
 








      
   
  
    
     
    






    
    
 
    
 
   
   
   
    
  
 
   
 
  
   
      
  
   
 
   
    
PBDEs 297
3. HEALTH EFFECTS
levels of T4 (free T4) and T3 decrease, and a state of thyroid hormone insufficiency ensues. TTR is the 
major thyroid hormone binding protein in rats, but not in man.  In most mammals, including humans, 
TBG is the principal thyroid hormone binding protein; 74% of the total bound-T4 is bound to TBG, and 
TTR and albumin bind only 11 and 15%, respectively, of the total (Schussler 2000).  In contrast to most
mammals, the rat utilizes TTR as the major T4 plasma binding protein; approximately 75% of T4 in rat 
serum is bound to TTR and only 25% to albumin.  Both circulating T3 and T4 are highly protein bound 
with only a small fraction of their total present as free hormone, and this high degree of protein binding
serves to maintain equilibrium between the extracellular and intracellular pools of these hormones
(O’Connor et al. 1999).  
Less is known about the relative sensitivities of humans and experimental animals to developmental
effects of PBDEs.  Outstanding uncertainties include potential differences in kinetics of maternal-fetal 
and maternal-infant transfer of PBDEs, as well as potential differences in the degree to which the fetus of
the human, in comparison to experimental animals, is dependent on maternal thyroid hormone for
development, particularly during the period of gestation prior to the onset of fetal hormone production.
3.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
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(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
Concern has been raised that many industrial chemicals, including PBDEs, are endocrine-active 
compounds capable of having widespread effects on humans and wildlife (Colborn et al. 1993; Crisp et al.
1998; Daston et al. 1997; Safe and Zacharewski 1997).  Particular attention has been paid to the
possibility of these compounds mimicking or antagonizing the action of estrogen.  Estrogen influences the
growth, differentiation, and functioning of many target tissues, including female and male reproductive
systems, such as mammary gland, uterus, vagina, ovary, testes, epididymis, and prostate.  In addition, 
there is evidence that some of these environmentally-persistent chemicals alter the thyroid hormone
system, which is a very important system for normal structural and functional development of sexual
organs and the brain. 
As discussed in Chapter 2 and Section 3.2.2.2. (Systemic Effects), the thyroid is a target of concern
following exposure to PBDEs, with adverse effects including altered thyroid hormone expression 
(predominantly reduced serum T4) and histological changes in the thyroid indicative of glandular
stimulation (e.g., follicular cell hyperplasia similar to that induced by a hypothyroid state).  Additionally, 
as discussed in Chapter 2 and Section 3.2.2.6 (Developmental Effects), the developing nervous system
and the developing reproductive system are also targets of concern.  Since these effects could be mediated
by the neuroendocrine axis, several studies have tested PBDEs and their metabolites in in vitro endocrine
disruption screens and in vivo gene expression assays. These studies, and their results, are summarized in 
Section 3.5.2 (Mechanisms of Toxicity) in the subsections on Mechanisms of Endocrine Disruption 
(thyroid hormone assays; anti-estrogenic, -androgenic, -progestagenic, and -glucocortogenic assays) and
Mechanisms of Reproductive Toxicity (steroidogenesis assays).  While results are not always consistent
between studies, the data collectively indicate that there is a potential for some PBDEs to disrupt thyroid
and other endocrine system functions in humans.
   
 










    
   
 
 
    
  
      
    
    
    
    







   
 
  
       
 
   
    
 
    
   
   
 




Additionally, a few studies specifically evaluated neuroendocrine disruption in vitro. BDE 47 and 
BDE 99 altered neurodevelopment of cultured fetal hNPCs (Schreiber et al. 2010).  The migration
distance of the hNPCs was reduced by up to 30% by BDE 47 and up to 35% by BDE 99.  Differentiation 
of hNPCs into neurons was reduced up to 50% by BDE 47 and up to 68% by BDE 99, and differentiation 
of hNPCs into oligodendrocytes was reduced up to 51% by BDE 47 and up to 93% by BDE 99.  Co-
exposure with T3 prevented the effects of PBDE exposure on migration and differentiation, indicating that
neurodevelopmental changes were due to endocrine disruption of cellular thyroid hormone signaling.  
Similarly, Ibhazehiebo et al. (2011) showed that the TR-antagonist, BDE 209 (see discussion in 
Mechanisms of Endocrine Disruption), inhibits T4-induced dendritic arborization in cultured rat cerebellar
Purkinje cells.  However, BDE 47, which was not found to be a TR-antagonist (see discussion in 
Mechanisms of Endocrine Disruption), did not alter dendritic arborization (Ibhazehiebo et al. 2011). 
Study authors indicate that other PBDEs and OH-PBDEs were evaluated for dendritic developmental
effects, but results were not reported (Ibhazehiebo et al. 2011). In another study, hyperosmotic-stimulated
somatodendritic vasopressin release in supraoptic tissue from the hypothalamus of rats was significantly
reduced by 40–50% by BDE 46, BDE 77, and the commercial pentaBDE mixture DE-71 (no other
PBDEs tested) (Coburn et al. 2007).  The neuropeptide vasopressin, which is synthesized in 
magnocellular neuroendocrine cells, functions to maintain body fluid homeostasis, cardiovascular control, 
learning and memory, and nervous system development.
3.7  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less
   
 








   
  
   
  
   
     
   




     
  
   
    
 
 










     
    
   




susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are
critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage
may not be evident until a later stage of development. There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
1966; Widdowson and Dickerson 1964).  The fetus/infant has an immature (developing) blood-brain 
barrier that past literature has often described as being leaky and poorly intact (Costa et al. 2004).  
However, current evidence suggests that the blood-brain barrier is anatomically and physically intact at 
this stage of development, and the restrictive intracellular junctions that exist at the blood-CNS interface 
are fully formed, intact, and functionally effective (Saunders et al. 2008, 2012).
However, during development of the blood-brain barrier, there are differences between fetuses/infants and
adults which are toxicologically important. These differences mainly involve variations in physiological 
transport systems that form during development (Ek et al. 2012).  These transport mechanisms (influx and 
efflux) play an important role in the movement of amino acids and other vital substances across the
blood-brain barrier in the developing brain; these transport mechanisms are far more active in the 
developing brain than in the adult.  Because many drugs or potential toxins may be transported into the
brain using these same transport mechanisms—the developing brain may be rendered more vulnerable 
than the adult.  Thus, concern regarding possible involvement of the blood-brain barrier with enhanced 
susceptibility of the developing brain to toxins is valid.  It is important to note however, that this potential
selective vulnerability of the developing brain is associated with essential normal physiological
mechanisms; and not because of an absence or deficiency of anatomical/physical barrier mechanisms.
The presence of these unique transport systems in the developing brain of the fetus/infant is intriguing; as
it raises a very important toxicological question as to whether these mechanisms provide protection for
the developing brain or do they render it more vulnerable to toxic injury.  Each case of chemical exposure
should be assessed on a case-by-case basis.  Research continues into the function and structure of the 
blood-brain barrier in early life (Kearns et al. 2003; Saunders et al. 2012; Scheuplein et al. 2002).
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Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of
growth and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion,
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
Body burden data, as well as intake modeling, suggest that infants and toddlers have higher exposures to
PBDEs as compared to older children or adults (EPA 2010; Lorber 2008; Trudel et al. 2011; Wong et al. 
2013).  Exposure during development may occur by transfer of PBDEs that have accumulated in women’s
bodies to the fetus across the placenta (Antignac et al. 2009, 2008; Chen et al. 2013; Kawashiro et al. 
2008; Li et al. 2013a; Mazdai et al. 2003; Meijer et al. 2008; Qiu et al. 2009; Vizcaino et al. 2011; Wan et
al. 2010).  Placental transfer, although it may be limited in absolute amounts (Frederiksene et al. 2010), is
a concern because of possible effects of PBDEs on sensitive immature tissues, organs, and systems, with
potentially serious long-lasting consequences.  Because PBDEs are lipophilic substances, they can
additionally accumulate in breast milk and be transferred to nursing infants (Antignac et al. 2008, 2009; 
Malarvannan et al. 2013; Park et al. 2011; Schecter et al. 2010).  Transfer of PBDEs via breast milk could 
be considerable and, like prenatal exposure, has the potential to contribute to altered development. 
Toddlers and older children are exposed to PBDEs in the same manner as the general population,
primarily via ingestion of contaminated dust and consumption of contaminated foods (EPA 2010; Lorber
2008).  However, exposure from these sources may be greater in young children due to: (1) greater hand-
to-mouth behavior, increasing the risk of ingestion of contaminated dust and/or residues from PBDE­
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treated materials; and (2) increased exposure relative to their body weight via diet due to increased caloric
intake normalized to body weight and a higher general intake of animal fats. Additionally, children may 
be particularly vulnerable to PBDEs because, compared to adults, they are growing more rapidly and are 
generally expected to have lower and distinct profiles of biotransformation enzymes, as well as much
smaller fat depots for sequestering these lipophilic chemicals.
In human studies, significant associations between umbilical cord and placental PBDE (BDE 28, BDE 47, 
BDE 99, BDE 153, BDE 183, and total) and adverse birth outcomes were reported in a comparison of
128 normal births and 25 cases of adverse birth outcomes (low birth weight, premature birth, still birth)
(Wu et al. 2010; Xu et al. 2015a).  Elevated maternal serum BDE 47 levels were also significantly
associated with an increased risk of preterm birth in a case-control study of 197 full-term births and 
82 pre-term births in Nashville, Tennessee (Peltier et al. 2015).  A study of births from 20 healthy
pregnant women in Taiwan found that elevated PBDE concentrations (BDE 47, BDE 99, BDE 100, and 
BDE 209) in breast milk was associated with significantly reduced infant birth weight, length, chest
circumference, and Quetelet’s index (i.e., BMI) (Chao et al. 2007).  A significant negative association 
between breast milk PBDE concentrations (BDE 47, BDE 99, BDE 100, BDE 153, and their sum) and 
birth weight was also identified in a Swedish cohort of 254 women with median total PBDE levels of
2.4 ng/g lipid (Lignell et al. 2013).  Several studies have also reported a negative association between one 
or more PBDE congeners in maternal serum and birth weight, length, and/or head circumference: a 
prospective reproduction study of 234 couples in Michigan and Texas (Robledo et al. 2015a), a birth 
cohort of 215 Chinese women with a median total PBDE level of 21.68 ng/g lipid (Chen et al. 2015), and 
a birth cohort of 686 Spanish women (Lopez-Espinosa et al. 2015).  In other studies, no significant
associations were observed between birth weight, length, or head circumference and maternal or cord
serum PBDE concentrations (Foster et al. 2011; Harley et al. 2011; Mazdai et al. 2003; Miranda et al.
2015; Serme-Gbedo et al. 2016; Tan et al. 2009).  In another study, a positive association between birth 
weight and length and colostrum PBDE (BDE 47, BDE 99, BDE 100, BDE 153, and their sum) was
observed in a Tanzanian cohort of 95 women with a median total PBDE concentration of 19.8 ng/g lipid 
(Müller et al. 2016).  
In general, available data from animal studies do not indicate that PBDEs are embryotoxic or fetotoxic at
PBDE doses below doses that elicited maternal toxicity, although occasional observations of reduced pup 
weight were reported (Argus Research Laboratories 1985a, 1985b; Biesemeier et al. 2011; Bowers et al.
2015; Branchi et al. 2001, 2002, 2005; Breslin et al. 1989; Ellis-Hutchings et al. 2009; Fujimoto et al. 
2011; Hardy et al. 2001, 2002; Kodavanti et al. 2010; Koenig et al. 2012; Life Science Research Israel
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Ltd. 1987; Poon et al. 2011; Rice et al. 2007; Saegusa et al. 2012; Ta et al. 2011; Talsness et al. 2005, 
2008; Tseng et al. 2008, 2013; Wang et al. 2011a; Watanabe et al. 2008, 2010b; WIL Research 
Laboratories 1986; Woods et al. 2012; Zhou et al. 2002).  At PBDE doses that elicited maternal toxicity
(15 mg/kg/day in rabbits, 50 mg/kg/day in rats), developmental effects observed included increased post-
implantation loss due to late resorptions and skeletal variations commonly associated with maternal 
toxicity (Breslin et al. 1989; WIL Research Laboratories 1986).  A few studies did report effects at doses
below maternal toxicity, including delayed ossification and an increased incidence of internal variations
in GD 20 rat fetuses exposed to pentaBDE at 2 mg/kg/day from GD 6 to 19 (Blanco et al. 2012), 
increased postimplantation loss and number of resorptions and decreased number of live fetuses/litter in 
mice exposed to decaBDE at ≥750 mg/kg/day from GD 7 to 9 (Chi et al. 2011), and subcutaneous edema
and delayed ossification in rats exposed to a low purity (77%) decaBDE mixture at 1,000 mg/kg/day from
GD 6 to 15 (Dow Chemical Co. 1985; Norris et al. 1975a).
A major target of concern in infants and children is the developing nervous system.  Numerous studies 
have reported results suggestive of an effect of PBDE on neurodevelopment in children.  PBDE levels in
cord blood, maternal or infant serum, and/or breast milk have been correlated with cognitive score and
adaptive behavior deficits in infants (Chao et al. 2011; Gascon et al. 2012; Shy et al. 2011); mental and 
physical development deficits in infants/toddlers at ages 12, 24, and 36 months (Herbstman et al. 2010);
language and social developmental score deficits in toddlers at 24 months (Ding et al. 2015); increased
impulsivity in toddlers at 24–36 months (Adgent et al. 2014; Hoffman et al. 2012); poor social
competence and ADHD or increased attention problems in 4-year-old children (Cowell et al. 2015;
Gascon et al. 2011); decreased IQ and increased hyperactivity in 5-year-old children (Chen et al. 2014);
impaired fine motor coordination, verbal memory and comprehension, and sustained attention in 5– 
7-year-old children (Eskenazi et al. 2013; Roze et al. 2009); and poor attention and executive function 
deficits in 9–12-year-old children (Sagiv et al. 2015).  In one birth cohort, no associations were observed 
between maternal serum PBDEs and neonatal behavior in 5-week-old infants (Donauer et al. 2015) or
autistic behaviors at 4–5-year-old children (Braun et al. 2014); however, children from the same cohort
showed associations between maternal serum PBDEs and decreased IQ and increased hyperactivity at
5 years of age (Chen et al. 2014) and executive function deficits at 5–8 years of age (Vuong et al. 2016a).  
Pre- and peri-natal studies in animals also consistently reported neurodevelopmental effects following
exposure to lower-brominated PBDEs and decaBDE at doses ≥0.06 and ≥2.22 mg/kg/day, respectively, 
including neurobehavioral alterations, delayed ontogeny of reflexes, ultrastructural changes, altered
nicotinic receptor density, altered electrophysiology, and altered gene and protein expression levels
(Biesemeier et al. 2011; Blanco et al. 2013; Bowers et al. 2015; Branchi et al. 2001, 2002, 2005;
   
 








   
       
    
     
 
 
   
   
 
    
 
      
    




    
     
   
    
    
    
       
    
 
     
     
   
     





Buratovic et al. 2014; Chen et al. 2014; Cheng et al. 2009; Eriksson et al. 2001, 2002b, 2006; Fischer et
al. 2008; Fujimoto et al. 2011; Gee and Moser 2008; He et al. 2009, 2011; Johansson et al. 2008; Koenig
et al. 2012; Kuriyama et al. 2004, 2005; Rice et al. 2007; Sand et al. 2004; Ta et al. 2011; Viberg et al. 
2002, 2003a, 2003b, 2004a, 2004b, 2005, 2006, 2007; Woods et al. 2012; Xing et al. 2009).  Consistent
reports of neurological effects have not been found in adult animal studies, and the only studies that did 
report neurological effects in adults observed altered neurobehavior at doses above those that cause 
neurodevelopmental effects in pre- and peri-natal studies (26.2 mg/kg/day of pentaBDE and 
≥0.1 mg/kg/day of tetraBDE) (Driscoll et al. 2009; Yan et al. 2012).
Neurodevelopmental effects may be mediated through the neuroendocrine axis, as thyroid hormones
regulate cell proliferation, migration, and differentiation during development, and maintenance of normal 
levels is essential to normal growth and development.  In support, neuronal migration and differentiation 
of fetal human neural progenitor cells (hNPCs) were significantly impaired following in vitro exposure to
tetraBDE (Schreiber et al. 2010), and decaBDE was shown to be a thyroid hormone receptor antagonist
that significantly inhibited T4-induced dendritic arborization in cultured rat cerebellar Purkinje cells
(Ibhazehiebo et al. 2011).  Additionally, PBDE-induced alterations in thyroid hormone binding to 
transport proteins and receptors have been demonstrated in several in vitro studies (Hamers et al. 2006;
Ibhazehiebo et al. 2011; Marsh et al. 1998; Meerts et al. 1998, 2000; Ren and Guo 2012; Ren et al. 2013).  
In humans, evidence for thyroid hormone disruption in infants is inconclusive.  Some studies reported
negative associations between developmental exposure to PBDEs and infant serum or cord blood T4 
levels (Abdelouahab et al. 2013; Herbstman et al. 2010; Kim et al. 2011a); however, other studies 
reported no association (Kim et al. 2011d, 2012a, 2012b, 2015; Lignell et al. 2016; Lin et al. 2011;
Mazdai et al. 2003; Shy et al. 2012).  Associations between developmental PBDE exposure and infant
serum or cord blood T3 and TSH were similarly inconsistent (Abdelouahab et al. 2013; Eggesbo et al.
2011; Kim et al. 2011d, 2012a, 2012b, 2015; Lignell et al. 2016; Lin et al. 2011; Mazdai et al. 2003; Shy
et al. 2012; Stapleton et al. 2011; Turyk et al. 2008).  In contrast, reduced serum T4 levels have been
consistently reported in animals exposed to lower-brominated PBDEs during development (Bansal et al.
2014; Blanco et al. 2013; Bondy et al. 2011, 2013; Bowers et al. 2015; Ellis-Hutchings et al. 2006;
Kodavanti et al. 2010; Kuriyama et al. 2007; Miller et al. 2012; Poon et al. 2011; Shah et al. 2011;
Skarman et al. 2005; Szabo et al. 2009; Wang et al. 2011a; Zhang et al. 2009; Zhou et al. 2002).  Some
studies also reported reduced serum T3 levels, although findings are less consistent (Blanco et al. 2013;
Bondy et al. 2013; Bowers et al. 2015; Shah et al. 2011; Zhang et al. 2009).  Consistent changes in
thyroid hormones were not found in animals exposed to decaBDE during development (Fujimoto et al. 
2011; Rice et al. 2007; Tseng et al. 2008).  
   
 











    
 
    
    
   
     
  
    
      
   
     
 




    
         
   
   
 
  
   
     
  
    






Disruption of circulating hormone levels can have markedly different effects, depending on the stage of
development, and even transient disruptions can produce permanent effects, such as mental retardation, 
impaired motor skills, and hearing and speech impediments (Boyages 2000; Fisher and Brown 2000).  
Several factors might contribute to a high vulnerability of the fetus and neonate to PBDEs.  Relatively
brief periods of thyroid hormone insufficiency (e.g., 14 days) can produce measurable neurological 
deficits in newborn infants (van Vliet 1999).  Furthermore, unlike the adult thyroid gland, which contains
a relatively large store of T4 that is sufficient to support circulating levels of hormone for several months, 
the neonatal thyroid contains only enough hormone to support circulating levels of hormone for ≥1 day 
(van den Hove et al. 1999; Vulsma et al. 1989).  Thus, even acute exposures to a dose of lower­
brominated PBDEs sufficient to suppress thyroid hormone production could potentially result in thyroid 
insufficiency in the neonate.  The absorbed dose of lower-brominated PBDEs per unit of body mass is 
also likely to be higher in infants compared to adults exposed to similar levels of PBDEs because of
higher intakes per unit of body mass and exposure from breast milk.  It should be noted that screening of
all newborn children for hypothyroidism is already a widely accepted and legislatively mandated practice 
(LaFranchi 1999; Landenson et al. 2000).  Newborns are tested for thyroid hormone levels within the first 
few days of life in the United States and most other developed countries, and treatment is started
immediately if indicated (LaFranchi 1999; Landenson et al. 2000).
The human relevance of the thyroid effects of lower-brominated BDEs in animals is unclear.  Humans are 
generally regarded as being less sensitive than rats to effects of PBDEs on circulating thyroid hormones.
This is thought to be related to a smaller and more rapid turnover of the hormone pool in the rat thyroid, 
and to a more rapid clearance of secreted hormone in the rat; the latter being, in part, related to the
absence of TBG in rats (Capen 1997).  TTR is the major thyroid hormone binding protein in rats, whereas
TBG is the main binding protein in man and most other mammals.  However, although TTR is a minor
thyroid hormone binding protein in humans, it is the principal protein involved in T4 transport to the brain 
in both rats and man (Blay et al. 1993; Sinjari et al. 1998).  TTR does not transport T4 from the
bloodstream to the brain, but rather is the main T4 binding protein in cerebral spinal fluid (CSF) in rats
and humans.  In the rat, T4 is transported to the brain primarily through the blood-brain barrier, and not
via the choroid plexus and CSF (Blay et al. 1993).  Also, the mechanism by which lower-brominated
BDEs cause decreased serum T4 might involve hepatic microsomal enzyme induction and consequent
increased metabolic formation of hydroxy signaling-metabolites, but humans are not particularly sensitive 
to this effect.
   
 








   
 
   
 
  
      
    
  
  
    
 
 
    
  
  
   
      
      
    
       







   
   
     




Based on limited findings from human and animal studies, another target of concern in infants and 
children exposed to PBDEs is the developing reproductive system.  Main et al. (2007) found a significant
positive relationship between levels of PBDE in breast milk and congenital cryptorchidism (undescended 
testes) in male offspring. The study compared levels of 14 PBDE congeners in breast milk of mothers of
62 Danish and Finnish boys with cryptorchidism to mothers of 68 controls from the same population.  
Significant elevation of concentrations in cases versus controls were seen for the sum of all 14 congeners, 
for the sum of the 7 most prevalent congeners found in all mothers (BDE 28, BDE 47, BDE 66, BDE 99, 
BDE 100, BDE 153, BDE 154), and for 5 of the 7 most prevalent congeners.  No significant associations
were observed between PBDE concentrations in children’s adipose tissue and cryptorchidism
(Koskenniemi et al. 2015). Other studies of reproductive development found no relationship between 
concentrations of individual PBDE congeners (BDE 28, BDE 47, BDE 99, BDE 100, BDE 153) in mid-
pregnancy serum samples from California mothers and hypospadias in their male offspring (Carmichael
et al. 2010) and no relationship between current serum levels of PBDE and various measures of sexual
maturation (e.g., age at thelarche, current breast development, age at menarche) in a small cohort of teen-
aged Dutch children (Leijs et al. 2008).  However, serum PBDE levels in 6–8-year-old females were 
significantly associated with delayed onset of puberty in a longitudinal cohort of U.S. girls (Windham et
al. 2015a). A study of 55 Dutch boys found significant positive associations between maternal serum
levels of BDE 154 collected on week 35 of pregnancy (but not other congeners measured, including
BDE 47 and BDE 153, that occurred at higher levels) and serum levels of the sex hormones, E2, free E2, 
and inhibin B (but not testosterone, LH, FSH, or sex hormone binding globulin) in the baby boys at
3 months of age and testes volume in the boys at 18 months of age, but no effect on penile length at either
age (Meijer et al. 2012).  Additionally, Warembourg et al. (2016) reported an inverse association between 
cord serum BDE 209 and total testosterone (but not free testosterone, E2, aromatase index, sex hormone
binding globulin, or Anti-Müllerian hormone) in 141 French boys.
In animal studies, reproductive effects were observed in adult F1 offspring exposed to a single dose of
pentaBDE at 0.06 mg/kg on GD 6, including reductions in testicular weight, sperm/spermatid number, 
and daily sperm production in males and a decreased number of secondary follicles and ultrastructural
changes in the ovaries in females (although F1 fertility when mated to an unexposed animal was not
impaired) (Kuriyama et al. 2005; Talsness et al. 2005, 2008).  In animals exposed pre- or perinatally to
decaBDE, one study reported reproductive effects in adult male offspring exposed to decaBDE doses of
10–1,500 mg/kg/day from GD 0 to 17, including testicular lesions, decreased AGD, and altered sperm
parameters (Tseng et al. 2013); however, no exposure-related changes in AGD, onset of puberty, or
reproductive organ weight and histology were reported in offspring exposed to decaBDE at doses up to 
   
 












   
   
    
     
 
   
 
   
 
 
   
     
   
   
  
  
    




   




1,000 mg/kg/day during gestation and lactation (Biesemeier et al. 2011; Fujimoto et al. 2011) or doses up 
to 20 mg/kg/day from PND 2 to 15 (Rice et al. 2007).  In females, no exposure-related changes in
reproductive development were reported in offspring exposed to decaBDE at doses up to 
1,000 mg/kg/day during gestation and lactation (Biesemeier et al. 2011; Fujimoto et al. 2011) or doses up 
to 20 mg/kg/day from PND 2 to 15 (Rice et al. 2007).  In in vitro assays, lower-brominated PBDEs have
been shown to be mildly estrogenic, anti-androgenic, anti-progestagenic, and anti-glucocorticogenic and 
higher-brominated PBDEs have been shown to be mildly anti-estrogenic (Hamers et al. 2006; Kojima et
al. 2009; Meerts et al. 2001; Mercado-Feliciano and Bigsby 2008a, 2008b; Stoker et al. 2005).  PBDEs
have also been shown to alter expression and activity of steroidogenic enzymes in vitro (Canton et al. 
2005, 2008; He et al. 2008a; Karpeta et al. 2011, 2013; Wang et al. 2011c; Zhao et al. 2011).  
The developing immune system may also be a target of concern in infants and children exposed to
PBDEs.  In a one-generation study in rats, F0 rats were exposed to pentaBDE at 0, 0.5, 5, or
25 mg/kg/day via gavage for 70 days prior to mating, through mating, gestation, and lactation (PND 21),
and PND 43 F1 rats were assessed for serum immunoglobin levels, B and T lymphocyte quantification in 
the spleen, spleen cell proliferation in vitro, and immune organ weight and histology and PND 56 rats
were assessed for immune function in the KLH antigen immune challenge (Bondy et al. 2013).  Observed 
effects at PND 43 included reduced serum IgE and IgG1 levels in females; a significant, dose-related
reduction in the proportion of B cells and a significant concomitant increase in the proportion of T cells in
the spleen in males and females; increased proliferation of unstimulated spleen cells harvested from males 
and females; and histopathological changes in the thymic cortex in males.  No exposure-related changes 
were observed in immune function in PND 56 rats (Bondy et al. 2013).  Two studies examined immune
function in PND 28 mice was assessed using the RSV intranasal infection test following exposure to 
decaBDE from GD 10 to PND 21 at doses ranging from 3.3 to 3,000 mg/kg/day (Watanabe et al. 2008, 
2010b).  At doses ≥260 mg/kg/day, RSV pulmonary viral titers were elevated at 1–5 days post-infection, 
and exposure to 3,100 mg/kg/day exacerbated the histopathological changes in the lung caused by RSV
infection.  In the only developmental immune study in humans, a reduced risk of atopic dermatitis was
found in Japanese infants (diagnosed at 7 months of age by questionnaire) with higher PBDE
concentrations in umbilical cord blood (Ochiai et al. 2014).  
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3. HEALTH EFFECTS
3.8  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment
of an organism (NAS/NRC 1989).  The preferred biomarkers of exposure are generally the substance
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  However, several
factors can confound the use and interpretation of biomarkers of exposure.  The body burden of a
substance may be the result of exposures from more than one source. The substance being measured may
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from
exposure to several different aromatic compounds).  Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken.  It may be difficult to
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids
(e.g., essential mineral nutrients such as copper, zinc, and selenium).  Biomarkers of exposure to PBDEs
are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by PBDEs are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism’s ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
   
 









      
 
 
   
   
  
      
    




      
   
      
      
      
   
    
     
     
  
 
    
   
      
 
    






3.8.1 Biomarkers Used to Identify or Quantify Exposure to PBDEs
PBDEs are persistent environmental contaminants that accumulate in adipose tissue, serum, and breast
milk serum of the general population (see Section 3.4, Toxicokinetics).  Therefore, PBDE concentrations 
in these tissues are indicators of general exposure for PBDEs, and PBDE concentrations in maternal
adipose tissue, serum, breast milk, and cord serum are useful as markers of maternal body burdens as well
as lactational and in utero exposures (Ahn et al. 2009; CDC 2015; Huwe et al. 2008; Kim et al. 2012a; 
Marchitti et al. 2013; Mazdai et al. 2003; Meironyté Guvenius et al. 2001). The National Report on 
Human Exposure to Environmental Chemicals (CDC 2015) has methods for many PBDE congeners to 
identify exposure and provides reference values representative of U.S. population for comparison with 
exposures to potentially more exposed populations; it is continually updated on-line (see 
http://www.cdc.gov/exposurereport/ to look for the most recent U.S. human PBDE exposure
information). Studies have also proposed that PBDE concentrations in hair are also useful markers of
exposure (Aleksa et al. 2012a, 2012b; Kucharska et al. 2015; Liu et al. 2016; Malarvannan et al. 2013; 
Poon et al. 2014), although Zheng et al. (2011) reported that PBDE concentrations in hair were not
correlated with PBDE concentrations in indoor dust from urban, e-waste, and rural areas in South China.
It is not clear if the lack of correlation between PBDE concentrations in indoor dust and hair reported by
Zheng et al. (2011) indicates that hair is a poor monitor of exposure or if exposure via dust was not
significant for the Chinese subjects involved in the study.  Other potential exposure sources, including
outdoor dust for individuals living near an e-waste area or ingestion of contaminated food, were not
controlled for in this study. Urinary bromophenols have also been suggested as potential biomarkers of
human exposure to PBDEs (Feng et al. 2016a; Ho et al. 2015). 
Estimates of PBDE serum concentrations among electronics-dismantling workers before and after 
exposure-free vacation (median duration 28 days, range 21–35 days) indicate that the higher-brominated
congeners have shorter half-lives than lower-brominated congeners (Sjödin et al. 1999b).  The medians
and ranges of percentage decreases in serum concentrations, based on 5–11 measurements per congener,
were 14 (range 3.5–39), 14 (2.1–38), 14 (6.7–42), 30 (7.9–52), and 66 (47–100) for BDE 47, BDE 153, 
BDE 154, BDE 183, and BDE 209, respectively.  Although actual half-lives were not calculated, the data
suggest that the half-lives of the lower-brominated congeners were <1 year.  Similar findings were found 
in another study of eight PBDE-exposed workers (four electronics dismantlers and four workers in a
factory making flame-retarded rubber), where calculated apparent half-lives were: 15 days for BDE 209;
28, 39, and 18 days for nonabrominated congeners BDE 208, BDE 207, and BDE 206; 37, 72, 85, and 
   
 








    
    
 
   
     
   
  
     
     
  




    
  




    
 
   
  
   
 
     
   
   
    
  
   




91 days for BDE 203 and three other octabrominated congeners of uncertain chemical structure; and 
94 days for BDE 183 (Thuresson et al. 2006).
A study in Sweden examined the feasibility of using feces as a noninvasive matrix to determine serum
concentrations of PBDEs in toddlers for biomonitoring purposes (Sahlström et al. 2015).  The cohort
consisted of 22 healthy toddlers 11–15 months of age. Twelve (tri- to decabrominated) BDEs were 
analyzed, but only nine could be quantified; not detected were BDE 28, BDE 99, and BDE 100.  Median 
concentrations of BDEs in feces ranged from 18 ng/g lipid for BDE 209 to 0.055 ng/g lipid for BDE 196.
Concentrations of tetra- to octaBDE in serum were significantly higher than in feces; the highest
difference was for BDE 153.  BDE 209 was significantly more concentrated in feces than in serum.  
Significant correlations in concentrations were found for all BDEs detected, except BDE 197 and
BDE 203.
Congener patterns in humans may provide information on the nature or pathway of PBDE exposures
(Hooper and McDonald 2000).  Low tetra:deca congener ratios are suggestive of direct, recent, or
occupational exposures to the parent PBDE mixture.  Higher ratios may indicate an environmental
pathway where exposures result from PBDEs that have leached from the parent mixtures and have been
degraded in the environment, although they may also reflect metabolic debromination following exposure
to parent PBDE mixtures.
3.8.2 Biomarkers Used to Characterize Effects Caused by PBDEs
Biomarkers of effects for PBDEs are likely to be common to the general class of halogenated aromatic 
hydrocarbons, rather than specific for PBDEs, because PBBs, PCBs, and other structurally similar
chemicals cause generally similar effects.
As discussed in Chapter 2, the thyroid, nervous system, and reproductive system are critical targets of
exposure to lower-brominated PBDEs in animals, and evidence from human studies also suggests that
these systems may be a target of human toxicity.  Critical effects used for derivation of the MRLs for
lower-brominated PBDEs include: endocrine effects in rats (reduced serum T4) for the intermediate 
inhalation MRL (Great Lakes Chemical Corporation 2000); endocrine effects in F0 rat dams (reduced 
serum T4) and reproductive and neurobehavioral effects in F1 adult offspring (impaired spermatogenesis,
ultrastructural changes in ovaries, increased resorptions in F1 females mated to unexposed males, and
increased spontaneous motor activity) for the acute oral MRL (Kuriyama et al. 2005, 2007; Talsness et al. 
   
 








   
     
   
   
 
    
    
    
    
    
     
      
   
  
   
 




    
       
  
      
   
    
  
 
   
  
     




2005); and reproductive effects in male rats (decreased serum testosterone) for the intermediate oral MRL
(Zhang et al. 2013b). There are several potential biomarkers for these effects, such as alterations in serum
thyroid or reproductive hormone levels or changes in neurobehavioral screens; however, none of these
effects are specific to PBDE exposure.
Similarly, the nervous system and pancreas are critical targets of exposure to decaBDE in animals.  There
are two human studies suggesting delayed cognitive development in children exposed to decaBDE (Chao
et al. 2011; Gascon et al. 2012) and limited evidence for an association between BDE 153 and diabetes
(BDE 209 was not assessed) in humans (Airaksinen et al. 2011; Lee et al. 2011; Lim et al. 2008; Smarr et
al. 2016).  Critical effects used for derivation of the MRLs for decaBDE include altered neurobehavior in 
juvenile mice following neonatal exposure for the acute oral MRL (Johansson et al. 2008; Viberg et al. 
2003b) and altered insulin homeostasis (elevated serum glucose levels) in rats for the intermediate oral 
MRL (Zhang et al. 2013a).  Again, there are potential biomarkers for these effects, such as alterations in
serum glucose levels or changes in neurobehavioral screens; however, none of these effects are specific to
decaBDE exposure.
3.9  INTERACTIONS WITH OTHER CHEMICALS
Only one study was located that provided information regarding interactions between PBDE and other
chemicals in humans.  Fitzgerald et al. (2012) examined the association between exposure to PBDEs and 
neuropsychological function among 144 adult men and women residents of upper Hudson River
communities and also studied the possible interactive effects of exposure to PCBs.  A series of 34 tests to
assess cognitive and motor function, affective state, and olfactory function were conducted.  Serum
samples were collected and analyzed for concentrations of nine of the most commonly detected PBDE
congeners in human serum (ΣPBDE) and 30 PCB congeners that usually constitute 95% of the congeners 
found in human serum (ΣPCB).  After adjustment for relevant confounders, the results of multiple linear
regression analyses showed no significant associations between ΣPBDE and scores on the
neuropsychological tests.  However, in subjects with a ΣPCB concentration above the median of 467 ppb 
(on a lipid basis), an increase in ΣPBDE concentration from the 25th to the 75th percentile was 
significantly associated with decreases between 7 and 12% in scores of some tests of memory and 
learning. Tests also showed that the interaction was greater than additive.  No specific mechanism was 
proposed for the interaction between PBDEs and PCBs.
   
 








   
 
 
   
     
     





     
     
    
    
      
 
   
       
     
  
   
    
    
  










A few animal studies have examined the effects of the interaction of PBDEs and other chemicals on
thyroid-related parameters.  For example, Hallgren and Darnerud (2002) reported that daily oral
administration of 18 mg/kg/day BDE 47 and 4 mg/kg/day Aroclor 1254 to female rats for 14 days
resulted in a significant decrease in plasma free T4 that suggested additive effects compared to
administration of either compound alone.  The reduction in free T4 coincided with a decrease in ex vivo
binding of 125I-T4 to the hormone transporter TTR and induction of the microsomal enzymes EROD and 
MROD, and led the investigators to suggest that the reduced free T4 could be explained by alterations in 
serum binding to TTR caused by metabolites of Aroclor 1254 or BDE 47. In the same study, co-
administration of BDE 47 and a technical mixture of chlorinated paraffins resulted in a reduction in 
plasma free T4 and induction of EROD that were greater than the effects of the single compounds, 
indicating synergistic effects.  Consistent with the findings of Hallgren and Darnerud (2002), Miller et al. 
(2012) reported that oral co-administration of equimolar doses of the commercial PBDE mixture DE-71 
and a mixture of various Aroclors to pregnant rats from GD 6 until PND 21 significantly reduced
circulating levels of total T4 in male and female offspring from PND 7 to 21 in a manner that indicated 
additive effects.  The reduction in total T4 was dose-dependent over a wide range of doses, 3– 
40 µmol/kg/day.  The mixture of Aroclors resembled the PCB congener pattern found in contaminated 
fish consumed by residents near the Fox River in Wisconsin.
Wang et al. (2011a) found little evidence of interactions between perfluorooctane sulfonate (PFOS) and 
BDE 47 on postnatal levels of total T3 and T4 in serum from rats (dams and their offspring) administered
the chemicals in the diet on GD 1 through PND 14. The investigators also examined the transcriptional
and translational expression of several thyroid hormone-mediated genes in neonates’ brains and found 
that PFOS and BDE 47 had interactive effects on only levels of brain-derived neurotrophic factor
(BDNF); the chemicals showed a synergistic effect on PND 1 in the cortex and an antagonistic effect on 
PND 14 in the hippocampus.  A possible mechanism for the interaction was not discussed.  He et al.
(2011) also found lack of interactive effects between BDE 47 and 2,2’,4,4’-tetrachlorobiphenyl 
(PCB 153) on serum T4 levels in rats.  In this study, 10-day-old pups received a dose of up to 10 mg/kg 
BDE 47 and/or 5 mg/kg PCB 153.  At 2 months of age, there was no evidence of any interaction between 
the chemicals on serum levels of T4.  However, performance on a Morris water maze was significantly
impaired in the group dosed with 5 mg/kg BDE 47 and PCB 153 and in the group dosed with 10 mg/kg
BDE 47 and PCB 153 relative to the groups dosed with either chemical alone.  The effect of the combined
action of BDE 47 and PCB 153 on performance on a Morris maze had been reported also in an earlier
study (He et al. 2009). 
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3. HEALTH EFFECTS
Two studies by Eriksson and coworkers (Eriksson et al. 2006; Fischer et al. 2008), examined the
interactive effects of BDE 99 and 2,2’,5,5’-tetrachlorobiphenyl (PCB 52) or BDE 99 and methyl mercury
on neurodevelopmental parameters in mice. In the first study, combined administration of equimolar
amounts of BDE 99 and PCB 52 (1.4 µmol/kg each; 0.8 mg/kg BDE 99, 0.4 mg/kg PCB 52) to 10-day­
old male mice resulted in reductions in spontaneous activity and habituation capability at 4 and 6 months
of age that were significantly more pronounced than those obtained with a single much higher dose
(14 µmol/kg) of PCB 52.  This led the investigators to suggest that the interaction was greater than
additive and that different mechanisms may be involved and/or different regions of the brain are 
differently affected.  Using the same protocol, Fischer et al. (2008) reported that coexposure to BDE 99 
and methyl mercury exacerbated neurobehavioral defects manifested as alterations in spontaneous 
behavior, lack of habituation, and impaired learning/memory in male mice tested during the first 6 months
of life.  BDE 99 and methyl mercury also interacted to promote a significant reduction in the density of
cholinergic nicotinic receptors in the hippocampus, suggesting that the neurobehavioral alterations may
involve the cholinergic system.  The interactive properties of BDE 99 and methyl mercury were also
assessed in a study in rats (Zhao et al. 2014).  Combined administration of these chemicals to pregnant
rats during gestation and up to PND 21 resulted in enhanced methylmercury-induced neurotoxicity in the
pups compared to treatment with methylmercury alone.  Specifically, tests showed delayed appearance of
negative geotaxis reflexes, impaired motor coordination, and induction of oxidative stress in the
cerebellum from pups.  While retention of mercury was not affected by co-exposure to BDE 99, 
combined exposure to methylmercury and BDE 99 seemed to increase the concentrations of BDE 99 in 
selected brain regions from pups.  The investigators concluded that combined exposure to methylmercury
and BDE 99 produced oxidative stress due to inhibition of antioxidant enzymes and production of free
radicals. In a study of the mechanism(s) of neurotoxicity of BDE 47, He et al. (2009) reported that the
combined administration of BDE 47 and PCB 153 to 10-day-old rats induced ultrastructural alterations in
neurons in the hippocampal CA1 region, assessed at the age of 2 months, in a manner that suggested a
synergistic mode of action.  These alterations were associated with changes in expression of mRNA and
proteins involved in three apoptosis pathways.  For the most part, the changes in expression levels of the
various factors due to the combined action of BDE 47 and PCB 153 were consistent with an additive
interaction between the two chemicals.
A study in rats reported that gestational and lactational exposure to 5.7 or 11.4 mg/kg/day of the
commercial PBDE mixture DE-71 did not alter cochlear function in adult offspring and neither did 
exposure to 3 mg/kg/day of an environmental PCB mixture (equimolar to 5.7 mg/kg/day of the PBDE
mixture) (Poon et al. 2011).  Exposure to 6 mg/kg/day of the PCB mixture did impair cochlear function.  
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3. HEALTH EFFECTS
However, exposure of the rats to the combined two low doses of the chemicals, neither of which alone
affected cochlear function, resulted in a deficit in cochlear function in the offspring similar to that in the
high-dose PCB group, suggesting an additive effect of the mixture on the outcome measured.  The
mechanism of the interaction was not elucidated, but it did not appear to be directly related to reductions
in serum T4. The PCB mixture used in this study was the Fox River mixture (see above Miller et al. 
2012).
It should be noted that the alterations in health outcomes in humans or animals summarized in
Section 3.2, Discussion of Health Effects by Route of Exposure, that were caused by exposure to
commercial or environmental PBDE mixtures, are in fact the result of interactions between the individual
components of the particular PBDE mixture.
3.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to PBDEs than will most persons
exposed to the same level of PBDEs in the environment.  Reasons may include genetic makeup, age,
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These 
parameters result in reduced detoxification or excretion of PBDEs, or compromised function of organs
affected by PBDEs.  Populations who are at greater risk due to their unusually high exposure to PBDEs
are discussed in Section 6.7, Populations with Potentially High Exposures.
Information was located on a small part of the U.S. population that might be unusually susceptible to 
PBDEs.  As indicated in Section 3.4.4.2, the detection of PBDEs in human breast milk samples suggests
that breast milk represents an elimination route of absorbed PBDEs in women.  Both lower and higher­
brominated congeners have been detected in breast milk (Antignac et al. 2008, 2009; Malarvannan et al.
2013; Park et al. 2011; Schecter et al. 2010).  Therefore, women with high body burdens of PBDEs who 
breastfeed may be placing their infants at a higher risk of potential health effects, although it is unclear
the degree to which PBDEs are cleared from the body during breast feeding (Hooper et al. 2007;
Jakobsson et al. 2012; LaKind et al. 2009; Thomsen et al. 2010).  In general, however, any risks from
exposures in mother’s milk are outweighed by the benefits of breastfeeding.
Pregnant women and developing infants and fetuses should be viewed as possibly sensitive populations
for exposure to lower-brominated PBDEs, as they are for other thyroid hormone disrupting chemicals
(Glinoer 1990; McDonald 2002; Morreale de Escobar et al. 2000).  The condition of pregnancy normally
   
 








   
   
   
 
    
  
  
    
     
 




   
   
   
     
   
  
     
 
   
   








puts a significant strain on the maternal thyroid system, which can be exacerbated by iodine deficiency;
according to data from 1988 to 1994, iodine deficiency is prevalent in approximately 12% of the general
population and 15% of women of child-bearing age in the United States (Hollowell et al. 1998).  Thyroid 
hormones are essential for normal development of the nervous system, lung, skeletal muscle, and possibly
other organ systems, and the fetus is dependent on maternal thyroid hormones at least until the fetal 
thyroid begins to produce T4 and T3, which occurs in humans at approximately 16–20 weeks of gestation
(Zoeller and Crofton 2000).  As discussed in Section 3.2.2.2 (Endocrine Effects subsection), human 
studies have found inconsistent associations between PBDE levels in maternal/infant serum, cord blood, 
or breast milk and thyroid hormone levels in pregnant women and infants.  However, decreased maternal, 
fetal, and neonatal serum T4 levels have been consistently reported in animals exposed to lower­
brominated PBDEs (but not decaBDE). Therefore, it is unclear whether or not exposure to lower
brominate PBDEs will cause thyroid hormone disruption in humans, and mechanistic differences may
account for the observed interspecies differences (as discussed in Section 3.5.3, Animal-to-Human
Extrapolations).
Developing fetuses, infants, and children should also be regarded as a possibly sensitive population with
regards to neurodevelopmental effects.  As discussed in Section 3.7 (Children’s Susceptibility), numerous
studies have reported results suggestive of an effect of PBDE on neurodevelopment in children.  PBDE
levels in cord blood, maternal or infant serum, and/or breast milk have been correlated with cognitive
deficits (including impaired verbal memory and comprehension), adaptive behavior deficits, increased 
impulsivity and impaired attention, poor social competence, and impaired fine motor coordination in 
infants and children.  Additionally, pre- and peri-natal studies in animals consistently report 
neurodevelopmental effects following exposure to lower-brominated PBDEs and decaBDE (at higher
doses). The susceptibility of the developing nervous system may be due to neuroendocrine effects, as 
discussed in Section 3.6 (Toxicities Mediated Through The Neuroendocrine Axis).  For example, 
neuronal migration and differentiation of fetal hNPCs were significantly impaired following in vitro 
exposure to tetraBDE (Schreiber et al. 2010), and decaBDE was shown to be a thyroid hormone receptor
antagonist that significantly inhibited T4-induced dendritic arborization in cultured rat cerebellar Purkinje
cells (Ibhazehiebo et al. 2011).
People with exposure to anti-thyroid drugs (e.g., lithium), thyroid disease, or otherwise compromised 
thyroid function might have a more pronounced response to PBDEs because of their underlying
limitations in thyroid hormone production.  Similarly, people with compromised function of other organs,
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such as those with liver or kidney diseases (e.g., liver cirrhosis or hepatitis), could be considered more
susceptible to health effects of PBDEs.
3.11  METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to PBDEs.  However, because some of the treatments discussed may be experimental and
unproven, this section should not be used as a guide for treatment of exposures to PBDEs.  When specific
exposures have occurred, poison control centers and medical toxicologists should be consulted for
medical advice.  No texts were located that provide specific information about treatment following
exposures to PBDEs; however, recommendations based on experiences with PCBs are relevant.  The
following texts provide specific information about treatment following exposures to PCBs:
Caravati EM, Mcguigan MA, Whyte IM, et al. 2004. Polyhalogenated biphenyls.  In: Dart RC, ed.  
Medical toxicology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1342-1343.
Leikin JB, Pauloucek FP.  2008. Polychlorinated biphenyls.  In:  Leikin JB, Pauloucek FP, eds.  
Poisoning and toxicology handbook. 4th ed.  Boca Raton, FL:  CRC Press, Taylor & Francis Group, 840.
The treatment methods discussed below are general methods that would apply to any persistent, lipophilic
chemical, and have not been tested for efficacy, indicating that they might not be effective in reducing the 
toxic effects of PBDEs. There is no indication of hazards associated with the treatments.  The methods 
are particularly appropriate for trying under conditions of acute exposure, but PBDEs are not acutely toxic
chemicals.  Scenarios where life-threatening acute exposure would occur are unlikely, although accidental
or intentional ingestion of the commercial products is a conceivable concern. The relevance of the 
methods to common background environmental exposures to these chemicals is unclear, and it is
questionable whether current exposure and tissue levels in the general population are a health concern.
3.11.1 Reducing Peak Absorption Following Exposure 
Ingested PBDEs are absorbed by the gastrointestinal tract of humans and animals (see Section 3.4).  
Although there are no specific recommendations for clinical treatment of acute intoxication from ingested 
PBDEs, recommendations based on experiences with PCBs are relevant. Treatments for acute poisonings 
from PCBs and related substances include the induction of emesis or gastric lavage and stomach pumping
to decrease gastrointestinal absorption of the chemicals (Lemesh 1992). These procedures would not be
beneficial if performed too long after exposure occurred.  Administration of activated charcoal as a slurry, 
   
 









   
  
     
  
     
 
   
   
  
    
   
  
   
 
 




   
     
 
 
   
      









either aqueous or mixed with a saline cathartic or sorbitol, is frequently recommended to decrease the 
gastrointestinal absorption of PCBs, but the value of this treatment for reducing absorption of PCBs,
PBBs, and PBDEs is unknown (HSDB 2012).  Repetitive administration of activated charcoal might be 
useful in preventing reabsorption of metabolites.  Rice bran fiber decreased absorption of PCBs in the 
gastrointestinal tract and had a stimulatory effect on fecal excretion of PCBs in rats (Takenaka and 
Takahashi 1991), but it is unclear if rice bran would be of benefit in poisoned humans.
The detection of PBDEs in the serum and fat of people who were occupationally exposed to these
chemicals indicates that PBDEs can be absorbed by the lungs, skin, and/or orally by hand-to-mouth 
contact.  Although no specific methods to reduce absorption of dermally applied or inhaled PBDEs were
located, multiple washings of contaminated skin with soap and water immediately following exposure
have been suggested to reduce the dermal absorption of PCBs (HSDB 2012).  Studies with monkeys
showed that soap and water was as effective as or better than such solvents as ethanol, mineral oil, or
trichlorobenzene in removing PCBs from skin (Wester et al. 1990).  Personal protective equipment
(e.g., long sleeves, gloves, safety glasses, respiratory protection) and industrial hygiene programs 
generally help to limit occupational exposures. 
3.11.2 Reducing Body Burden
As discussed in Section 3.4, while decaBDE is absorbed to a lesser degree than lower-brominated 
PBDEs, all PBDE congeners can accumulate in lipid-rich tissues. However, lower-brominated PBDEs 
are more likely to accumulate as they are more slowly metabolized and eliminated from the body. No
studies evaluating methods to reduce body burden of PBDEs were located.
Several methods to enhance the elimination of PBBs from the body have been examined in animals and 
may be applicable to PBDEs.  Methods for increasing the elimination of these chemicals include the
restriction of caloric intake (to reduce total body fat), and the administration of various agents that interact
with bile acids including activated charcoal, mineral oil, and bile-binding resins such as cholestyramine
(Kimbrough et al. 1980; McConnell et al. 1980; Polin and Leavitt 1984; Polin et al. 1985, 1991; Rozman 
et al. 1982).  It should be mentioned, however, that based on the pharmacokinetic considerations
discussed in Section 3.8.1, a rapid breakdown of fat, as might occur in dieting, might lead to a transient 
increase in PBDE levels in serum and other body tissues, possibly posing a significant re-exposure
problem.  Although some of the studies observed no enhanced elimination (Kimbrough et al. 1980;
McConnell et al. 1980), others identified treatments that were effective in enhancing the biliary and
   
 









      
    




      
    
 
  
      
   
 
   
    
  
   
   
    
    
   
  
  
   
    
 
 
       
 




intestinal elimination of PBB residues (Polin et al. 1991; Rozman et al. 1982).  Polin et al. (1991) found 
that dietary intervention to reduce PBBs was dose dependent; treatment with 10% mineral oil and a 45%
reduction in food intake resulted in a 69 and 23% reduction in body burden in rats fed PBBs at dietary
concentrations of 0.1 and 100 ppm, respectively (Polin et al. 1991).  A combination of mineral oil, 
colestipol, and dietary restriction was successful in reducing the PBB body burdens in chickens (Polin 
and Leavitt 1984; Polin et al. 1985), while each treatment alone had no effect in reducing PBB body
burden.  A 3-week treatment regimen that included dietary supplements of polyunsaturated oil, vitamins, 
and minerals, and heat stress has been applied in a pilot study to seven human subjects that were known to
have been exposed to PBBs; following treatment, statistically significant reductions were measured in
PBB concentrations in fat (Schnare et al. 1984).  Although the lack of a separate control group 
complicates interpretation of the results of this study (each subject served as his/her own control), this 
treatment was developed for the purpose of reducing body burdens of fat-soluble psychoactive drugs
(Schnare et al. 1984).
Additionally, a few human studies that have evaluated methods to reduce body burden of PCBs, another
class of lipophilic compounds, may be applicable to PBDEs.  A liquid diet was used for 16 individuals
who developed symptoms following exposure to PCBs and polychlorinated dibenzofurans (Imamura and 
Tung 1984).  Symptoms were reduced several months after the fasting period. This study is limited in 
that a control group was not used, and body burdens were not measured.  Based on information for PCBs, 
mobilization of PBDEs from adipose tissue is not recommended in individuals with hepatic or renal
disease (Lemesh 1992). More recently, 14 individuals administered 15 g/day of dietary olestra (a non­
absorbable lipid in potato crisps) for 1 year showed a steady decline in serum lipid concentrations of
PCBs (Jandacek et al. 2014).  At the end of 1 year, PCB concentrations were significantly decreased by
~8% compared with pre-trial values.  However, PCB concentrations were not significantly decreased
compared with 14 concurrent controls administered 15 g/day of dietary olive oil (which showed a
nonsignificant ~4% decrease in PCB concentration compared with pre-trial values). Further studies need
to be conducted with larger study groups to determine the efficacy of olestra for reducing body burden of
PCBs and/or other lipophilic compounds. 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
There are no known methods for interfering with the mechanism of action of PBDEs.  Although the
mechanism of action of PBDEs is not completely understood, PBDEs share some toxicological properties 
with other structurally similar polyhalogenated aromatic compounds, particularly PBBs, PCBs, CDDs, 
   
 








    
   
   
   
     
   
   
    
     
    
    
    
 
  




   
   
   
       
    
   
 
  
   
      
    




and CDFs (ATSDR 1994, 1998, 2000).  Experimental evidence indicates that some PBB congeners exert
toxic actions by a process involving several steps (Safe 1984).  This process begins with the binding of
particular congeners to the AhR and leads to enhancement of the CYP1A1 gene expression (see 
Section 3.5).  The toxicity of specific congeners is related to their ability to assume a coplanar
configuration for binding to AhR (Hardy 2002a).  It may be inferred that interfering with the initial step,
binding to the receptor, or with any of the subsequent steps, would possibly prevent the expression of the
toxic effects.  Several compounds have been identified that partially antagonize one or more AhR­
mediated responses (Bannister et al. 1989); their use, however, has been limited to experimental studies in 
animals. These compounds were successful antagonists when given before or at the same time as the
potent AhR activator TCDD (Bannister et al. 1989).  In contrast to PBBs, PCBs, and related compounds, 
AhR binding affinity of PBDE congeners is not correlated with planarity (Chen et al. 2001).  This may be
due, in part, to increased distance between the phenyl rings relative to PBBs and PCBs.  It has also been
speculated that the large size of the bromine atoms of PBDEs relative to chlorine atoms of PCBs may
distort the AhR binding site so that coplanar configuration is not required (Chen et al. 2001).  Because 
AhR binding by PBDEs apparently differs in some respects from AhR binding by PBBs and other related 
compounds, AhR antagonists identified via experiments with PBBs, TCDD, and related compounds
might not effectively antagonize AhR binding and effects of PBDEs.
PBDEs may also cause toxicity by other mechanisms of action.  PBDE-induced decreases in thyroid T4 
hormone, which can affect neurobehavioral development, are likely to involve multiple mechanisms (see
Section 3.5.3).  These include induction of hepatic microsomal enzymes, particularly UDPGT, which can 
increase the rate of T4 conjugation and excretion, and metabolic formation of hydroxy-metabolites of
PBDEs.  PBDEs and their hydroxy metabolites can bind with high affinity to thyroid transport proteins
because they are structurally similar to T4 hormone (i.e., are also hydroxy-halogenated diphenyl ethers)
(see Section 3.5.2).  Effects of PBDEs on thyroid status via induction of hepatic enzymes, however, are
unlikely to occur in humans, and the impact of hydroxy-metabolites on serum T4 needs further
clarification.  Effects of PBDEs on the function and development of the nervous system could also
involve disruption of calcium homeostatic mechanisms and intracellular signalling events (Chen et al.
2010; Dingemans et al. 2008, 2010a, 2010b; Fan et al. 2010; Kodavanti 2003; Kodavanti and Derr-Yellin
2001, 2002; Smolnikar et al. 2001; Wiegand et al. 2001), altered cholinergic or dopaminergic functions
(Ankarberg et al. 2001; Bradner et al. 2013; Dreiem et al. 2010; Fischer et al. 2008; Mariussen and 
Fonnum 2002, 2003; Mariussen et al. 2003; Slotkin et al. 2013; Viberg and Eriksson 2011; Viberg et al.
2002, 2003a, 2004b, 2005), and/or free radical-induced neuronal death (Chen et al. 2010; He et al. 2008b; 
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Huang et al. 2010; Reistad et al. 2002).  Clinical interventions designed to interfere with the
aforementioned mechanisms have yet to be developed.
3.12  ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of PBDEs is available.  Where adequate information is not
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the
initiation of a program of research designed to determine the health effects (and techniques for developing
methods to determine such health effects) of PBDEs.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of PBDEs
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
PBDEs are summarized in Figure 3-8.  The purpose of this figure is to illustrate the existing information
concerning the health effects of PBDEs.  Each dot in the figure indicates that one or more studies provide
information associated with that particular effect. The dot does not necessarily imply anything about the
quality of the study or studies, nor should missing information in this figure be interpreted as a “data
need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific Data 
Needs Related to Toxicological Profiles (ATSDR 1989), is substance-specific information necessary to
conduct comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly
as any substance-specific information missing from the scientific literature.
Studies on the systemic and carcinogenic effects of PBDEs in humans are based primarily on tissue 
PBDE levels without knowledge of route of exposure; in most cases exposure was attributed to the oral
route (Figure 3-8).  Information on health effects of PBDEs in animals is available for all effect
categories, but is mainly limited to oral exposure studies in animals.
   
 


























































































































   
 









    
 
     
     
  
   
  




    
     
   
  
      
      




   
     
   
       
     
  
     




3.12.2 Identification of Data Needs 
Acute-Duration Exposure. Acute-duration studies of lower-brominated PBDEs have documented 
effects mainly on the developing nervous system, the developing reproductive system, the thyroid, and 
the liver of orally exposed rats and mice (Bruchajzer 2011; Bruchajzer et al. 2010, 2011; Darnerud and 
Sinjari 1996; Dingemans et al. 2007; Dufault et al. 2005; Eriksson et al. 2001, 2002b, 2006; Fischer et al. 
2008; Fowles et al. 1994; Gee and Moser 2008; Hallgren and Darnerud 2002; Hallgren et al. 2001, 2015; 
He et al. 2009, 2011; Hoppe and Carey 2007; Kuriyama et al. 2005, 2007; Richardson et al. 2008; Sand et
al. 2004; Stoker et al. 2004; Talsness et al. 2005, 2008; Viberg et al. 2002, 2003a, 2004a, 2004b, 2005, 
2006; Zhou et al. 2001, 2002).  The most sensitive effects were observed in F0 and F1 rats exposed to 
≥0.06 mg/kg of pentaBDE on GD 6, including decreased maternal serum T4 in dams, decreased number of
spermatids and sperm and daily sperm production in F1 males, decreased relative epididymis weight in 
F1 males, altered neurobehavior in F1 males, ultrastructural changes in ovaries of F1 females, and
increased resorptions in F1 females mated to unexposed males (Kuriyama et al. 2005, 2007; Talsness et
al. 2005).  Collectively, these end points were selected as a basis for an acute MRL for lower-brominated 
PBDEs.  While hepatic effects were consistently observed, they occurred at much higher doses 
(≥8 mg/kg/day). Two studies in mice indicate that immunosuppression is a potentially critical health end
point for acute exposure to lower-brominated PBDEs; additional studies may provide more support for
this end point (Darnerud and Thuvander 1998; Fowles et al. 1994; see discussions of data needs for
Immunotoxicity).  
Several acute-duration studies of decaBDE have also documented effects on the developing nervous
system in rats (Chen et al. 2014; Viberg et al. 2007) and mice (Buratovic et al. 2014; Johansson et al. 
2008; Rice et al. 2007, 2009; Viberg et al. 2003b).  The most sensitive neurobehavioral effects, decreased 
open field activity and impaired habituation, were observed in 2–6-month-old male mice that were 
exposed once to decaBDE at doses ≥2.22 mg/kg on PND 3 (Buratovic et al. 2014; Johansson et al. 2008;
Viberg et al. 2003b). This effect was not observed at 1.34 mg/kg (Buratovic et al. 2014; Johansson et al.
2008).  These neurobehavioral end points were selected as the basis for an acute MRL for decaBDE. The 
remaining acute database for decaBDE provides only limited data regarding hepatic, endocrine, body
weight, and developmental effects in rats and mice (Bruchajzer et al. 2010; Carlson 1980b; Chi et al.
2011; IRDC 1974; NTP 1986; Sakamoto et al. 2013; Zhou et al. 2001).  Additional studies, specifically
neurodevelopmental studies in species other than mice and immunotoxicity screens, would help to clearly
   
 








     
    
 
   
   
      
     
 
    
    
 
       
  
      
 
   
    
    
  
    
   
  
   
 
        
  
   
   
 
 
   
   




establish the most sensitive target and species for acute exposure, as well as which animal toxicity data 
are the most relevant to humans and useful for assessing acute health risks of decaBDE.
The inhalation database for acute-duration exposure to lower-brominated PBDEs is essentially limited to
a single 14-day unpublished industry-sponsored studies of octaBDE in rats (Great Lakes Chemical
Corporation 1978).  A liver effect level was identified in this study, but MRL estimation is precluded by
small animal groups and incomplete assessment of other toxicological end points, particularly a lack of
information on thyroid hormone levels.  Additional dose-response studies may provide an adequate basis 
for derivation of an acute inhalation MRL for lower-brominated PBDEs.  Acute-duration inhalation 
exposure toxicity studies of decaBDE were not located.
Intermediate-Duration Exposure. Available intermediate-duration oral studies in animals indicate
that the male reproductive system, the developing nervous system, the thyroid, and the liver are the main
systemic targets of repeated exposures to lower-brominated PBDEs. The most sensitive end points were
reproductive effects in male rats exposed to tetraBDE for 8 weeks, which identified a minimal LOAEL of
0.001 mg/kg/day for a 34% decrease in serum testosterone levels (Zhang et al. 2013b). Histological 
changes in the testes were also observed at ≥0.03 mg/kg/day in the study by Zhang et al. (2013b) and a
similar study in rats by Huang et al. (2015).  The minimal LOAEL for decreased serum testosterone was 
selected as the basis for an intermediate-duration MRL for lower-brominated PBDEs.  A study in mice
supports that the male reproductive system is a target for tetraBDE toxicity, reporting histological
changes in the testes at tetraBDE doses ≥0.045 mg/kg/day for 30 days (Wang et al. 2013).  As observed 
with acute exposure, altered neurobehavior was consistently observed in animals exposed to lower­
brominated PBDEs for intermediate durations during development, with effects occurring at or above the
doses of observed male reproductive effects (≥2 and ≥0.03 mg/kg/day in rats and mice, respectively)
(Blanco et al. 2013; Bowers et al. 2015; Branchi et al. 2005; Cheng et al. 2009; Koenig et al. 2012; Ta et
al. 2011; Woods et al. 2012).  Liver effects, including increased liver weight, hypertrophy, and 
histopathological changes, were observed following exposure to lower-brominated PBDEs at doses as 
low as 0.45 mg/kg/day (Becker et al. 2012; Bondy et al. 2011, 2013; Bruchajzer 2011; Bruchajzer et al. 
2012; Dunnick et al. 2012; IRDC 1976, 1977; Maranghi et al. 2013; Oberg et al. 2010; WIL Research 
Laboratories 1984; Zhang et al. 2014, 2015a, 2015b).
The thyroid is also a critical target in both adult and developing animals, with consistent observations of
reduced serum T4 levels at doses as low as 2.85 mg/kg/day and enlargement and histological alterations to 
the thyroid at doses as low as 0.45 mg/kg/day (Bansal et al. 2014; Becker et al. 2012; Bondy et al. 2011,
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2013; Bowers et al. 2015; Driscoll et al. 2009; Dunnick et al. 2012; Ellis-Hutchings et al. 2006; Ernest et
al. 2012; Hoppe and Carey 2007; IRDC 1977; Kodavanti et al. 2010; Maranghi et al. 2013; Miller et al. 
2012; Poon et al. 2011; Skarman et al. 2005; Stoker et al. 2004, 2005; Szabo et al. 2009; Wang et al.
2011a; WIL Research Laboratories 1984; Zhou et al. 2002).  Essentially all of the available data on
thyroid effects of lower-brominated PBDEs have been obtained from oral studies in rats.  It is speculated
that the extent that PBDEs affect circulating levels of thyroid T4 or T3 might vary with species, and rats 
are often regarded as more sensitive than humans.  Studies designed to elucidate the mechanism(s) of
action for thyroid and other effects of lower-brominated PBDEs would help to better understand how the
animal toxicity data can best be used to identify target end points and assess health risks in humans.
Available intermediate-duration oral studies provide limited evidence for effects in the pancreas, nervous
system, liver, immune system, reproductive system, and several organ systems in developing animals 
following repeated exposures to decaBDE.  The most sensitive end points were pancreatic effects from a 
study in male rats exposed to decaBDE for 8 weeks, which identified a minimal LOAEL of
0.05 mg/kg/day based on a 12% increase in serum glucose levels (Zhang et al. 2013a). The increase in
serum glucose is considered to be part of a spectrum of effects indicative of altered insulin homeostasis
and toxicity to the pancreas, including decreased serum insulin and morphological changes in pancreatic 
islet cells, following decaBDE exposure to doses ≥1 mg/kg/day (Zhang et al. 2013a).  This minimal 
LOAEL for elevated serum glucose levels was used as a basis for the intermediate-duration oral MRL for
decaBDE.  Other effects observed following intermediate-duration exposure to decaBDE were observed 
at higher doses.  In animals exposed during development, adverse effects included histopathological 
changes in the liver, kidney, and testes of rats exposed to ≥2 mg/kg/day (Fujimoto et al. 2011; Tseng et al.
2008, 2013); altered hippocampal electrophysiology in rats exposed to 20.1 mg/kg/day (Xing et al. 2009);
and impaired immunity in mice exposed to 2,900 mg/kg/day (Watanabe et al. 2010b).  In adult animals, 
observed effects following intermediate-duration decaBDE exposure included decreased anxiety in mice
at doses 20 mg/kg/day (Heredia et al. 2012); histopathological changes in the ovaries, liver, spleen, and
thymus and altered immune end points (T-cell distribution, lymphocyte proliferation, serum
immunoglobulins) in rats exposed to 300 mg/kg/day (Liu et al. 2012); altered CD4 T-cell function in mice 
exposed to 800 mg/kg/day (Feng et al. 2016b); reduced serum testosterone, reduced sperm count and 
viability, and degenerative changes in the seminiferous tubules in mice exposed to 950 mg/kg/day (Sarkar
et al. 2015); and histopathological changes in the liver in mice exposed to 9,400 mg/kg/day (Lee et al.
2010; Liu et al. 2012; Sakamoto et al. 2013).  Since the majority of the observed effects lack supporting
evidence from other studies, and many were single-dose studies, additional intermediate-duration studies
evaluating these end points following decaBDE exposure at multiple doses would help to better
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understand how the animal toxicity data can best be used to identify target end points and assess health 
risks in humans. Of particular interest would be additional studies evaluating altered insulin homeostasis,
the critical effect that serves as the basis for the current intermediate-duration oral MRL for decaBDE.
The inhalation database for intermediate-duration exposure to PBDEs consists of one well-conducted
13-week unpublished industry study of octaBDE in rats (Great Lakes Chemical Corporation 2000).  
Hepatic, nasal, lung, thyroid, and ovarian effects were observed, and a NOAEL for changes in thyroid 
hormone levels was used as the basis for estimation of an intermediate-duration inhalation MRL. 
Intermediate-duration inhalation exposure toxicity studies of decaBDE were not located.  
Chronic-Duration Exposure and Cancer. One chronic study of high purity decaBDE has been 
conducted.  In this study, a commercial decaBDE product (94–97% pure) was fed to rats and mice for
103 weeks (NTP 1986).  Comprehensive gross and histological examinations were performed on all
animals, but no hematology, clinical chemistry, or urine indices, or thyroid hormone levels, were
evaluated. The lowest tested dose in the study, 1,120 mg/kg/day in male rats, was a LOAEL for a liver
lesion (neoplastic nodules) that is precancerous and associated with thrombosis in the same tissue, 
precluding estimation of an MRL.  Additional chronic dose-response information would provide
information on the NOAEL/LOAEL threshold and an appropriate basis for derivation of a chronic MRL
for decaBDE.  Neoplastic effects in this study included increased incidences of neoplastic nodules in the
liver in the male and female rats and hepatocellular adenoma or carcinoma (combined) in the male mice.
Slightly elevated incidences of thyroid gland follicular cell tumors were additionally observed in exposed 
male mice, although the increases were equivocal.
In the only other chronic oral study available, rats were fed a 77.4% pure commercial decaBDE mixture
(containing 21.8% nonaBDE and 0.8% octaBDE) for approximately 2 years (Kociba et al. 1975; Norris et
al. 1975a).  Evaluations that included clinical signs, body weight, food consumption, hematology, clinical
chemistry, urine indices, and comprehensive histological examinations showed no exposure-related
effects.  The highest tested dose (1 mg/kg/day) was a NOAEL, but this effect level is not an appropriate 
basis for MRL estimation due to insufficient sensitivity of the study.  In particular, a chronic oral MRL
based on this study would be higher than the intermediate MRL.  No exposure-related neoplastic changes 
were found, but the power of this study to detect carcinogenic effects is limited by the low dose levels.
Considering the limitations of the available data, well-designed chronic toxicity studies of lower­
brominated PBDEs may provide adequate bases for MRL derivation and cancer assessment for lower­
brominated PBDEs.  Evaluations that include the thyroid and neurobehavioral end points would be
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particularly informative because acute and intermediate-duration oral studies indicate that the thyroid and 
developing central nervous system are particularly sensitive targets for lower-brominated PBDEs.
Genotoxicity. Limited information was located regarding the genotoxicity of PBDEs in humans.  A
study of Chinese workers exposed to PBDEs suggested an association between levels of total PBDEs in 
blood and frequency of micronuclei in peripheral lymphocytes, but no causality was demonstrated (Yuan
et al. 2008).  Moreover, other pollutants could have played a role.  A study of the general population from
Korea did not find an association between serum levels of 2,2’,4,4’-tetraBDE and 2,2’,4,4’,5-pentaBDE
and chromosome telomere length in peripheral lymphocytes (Shin et al. 2010).  Cytogenetic examination 
of additional populations previously or currently exposed to PBDEs would provide valuable information.  
A study in mice reported that maternal exposure to decaBDE during gestation resulted in sperm DNA
damage in male offspring examined at 71 days of age (Tseng et al. 2013).  Additional studies trying to 
replicate these results would be helpful.  Testing the offspring for fertility would also be informative.
DecaBDE and 2,2’,4,4’,5-pentaBDE have been tested in prokaryotic organisms and both yielded negative
results in gene mutation tests (Evandri et al. 2003; NTP 1986).  Relatively few PBDE congeners have 
been examined for genetic effects in mammalian cells.  DNA damage and increased recombination 
activity have been reported (He et al. 2008a, 2008b; Helladay et al. 1999; Ji et al. 2011; Pellacani et al. 
2012).  Further studies with the PBDE congeners that are most frequently found in the environment and 
in human blood and tissues would be valuable.  Studies designed to explore possible mechanisms of
genotoxicity of PBDEs and also of metabolites would also be valuable.
Reproductive Toxicity. Reports of five one-generation studies in rats and mice were located.  No
exposure-related changes were observed in reproductive end points (number of pregnancies, gestation
length, number, size, or sex ratio of litters) at pentaBDE doses up to 25 mg/kg/day or tetraBDE doses up 
to 1 mg/kg/day (Bondy et al. 2011, 2013; Koenig et al. 2012; Poon et al. 2011; Ta et al. 2011; Woods et
al. 2012).  No fertility impairments were observed in F1 males or females that were exposed once to
pentaBDE on GD 6 at doses up to 0.3 mg/kg/day, when mated to unexposed animals (Kuriyama et al. 
2005; Talsness et al. 2005, 2008).  However, in a one-generation study in mink, females exposed to 
pentaBDE at doses ≥0.25 mg/kg/day from pre-mating day 28 through PNW 6 did not whelp (Bull et al. 
2007; Zhang et al. 2009).  It is not clear in the study reported by Bull et al. (2007) whether mink exposed 
to 0.25 mg/kg/day never became pregnant or had complete litter loss.  However, Zhang et al. (2009)
reported that female mink exposed to 0.31 mg/kg/day had no exposure-related changes in mating success;
rather, sows showed complete litter loss with 70% showing clear postimplantation loss.  Despite a lack of
effects from most one-generation studies, reduced serum testosterone and testicular damage (increased
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multinucleated giant cells, germ cell loss, and apoptotic cells) was reported in adult male rats and mice 
exposed to tetraBDE doses as low as 0.001 and 0.045 mg/kg/day, respectively (Huang et al. 2015; Wang
et al. 2013; Zhang et al. 2013b).  Reduced serum testosterone in rats exposed to ≥0.001 mg/kg/day for 
8 weeks was selected as the critical effect for the intermediate-duration MRL for lower-brominated 
PBDEs; therefore, additional studies with other congeners evaluating testicular damage may better
characterize the reproductive toxic potential of PBDEs and assure the adequacy of the intermediate oral
MRL.  Also, studies in other species (e.g., rabbits) may be warranted to investigate species-specific 
reproductive effects and two-generation studies designed to assess effects on fertility in both sexes would
better characterize the potential for reproductive toxicity as a result of exposure to lower-brominated
PBDEs.
For decaBDE, information on the reproductive toxicity is limited to a single one-generation oral study in 
rats that found no exposure-related functional effects following exposure to an impure decaBDE mixture 
containing lower-brominated PBDEs (77% decaBDE, 22% nonaBDE, 0.8% octaBDE) at dietary doses up 
to 100 mg/kg/day for 60 days prior to mating through PND 21 (Dow Chemical Co. 1975; Norris et al.
1975a). Studies that evaluated reproductive organ histology following exposure to decaBDE generally
did not report detectable effects.  As suggested for lower-brominated PBDEs, studies in other species may
be warranted to investigate species-specific reproductive effects and two-generation studies designed to 
assess effects on fertility in both sexes would better characterize the potential for reproductive toxicity as 
a result of exposure to decaBDE.
Developmental Toxicity. Numerous oral developmental toxicity studies have shown no evidence of
teratogenicity in rats or rabbits exposed to lower-brominated PBDEs or decaBDE, although fetotoxic
effects, including skeletal ossification variations at maternally toxic doses, have occurred with exposures
to lower-brominated mixtures (Argus Research Laboratories 1985a, 1985b; Biesemeier et al. 2011; 
Blanco et al. 2012; Breslin et al. 1989; Chi et al. 2011; Dow Chemical Co. 1975, 1985; Ellis-Hutchings et
al. 2009; Hardy et al. 2002; Life Science Research Israel Ltd. 1987; Norris et al. 1975a; WIL Research
Laboratories 1986). The available evidence adequately shows that teratogenicity and fetal toxicity is not
a critical effect of concern for either lower-brominated PBDEs or decaBDE.  However, there is evidence
that the developing nervous and endocrine systems, and potentially the developing reproductive and 
immune systems are sensitive targets of particular PBDE congeners.  Numerous studies show that
developmental exposure can lead to neurological changes at later life stages, as rats and mice exposed 
pre- or peri-natally to lower-brominated PBDEs or decaBDE show neurobehavioral alterations following
exposure to lower-brominated PBDEs and decaBDE at doses ≥0.06 and ≥2.22 mg/kg/day, respectively, as 
   
 












       
  
      
     
   
   
       
  
    
    
  
   
 
         
     
    
    
    
    






    





well as several other neurological effects at higher doses, including delayed ontogeny of reflexes, 
ultrastructural changes, altered nicotinic receptor density, altered electrophysiology, and altered gene and
protein expression levels (Biesemeier et al. 2011; Blanco et al. 2013; Branchi et al. 2001, 2002, 2005;
Cheng et al. 2009; Eriksson et al. 2001, 2002b, 2006; Fischer et al. 2008; Fujimoto et al. 2011; Gee and 
Moser 2008; He et al. 2009, 2011; Johansson et al. 2008; Koenig et al. 2012; Kuriyama et al. 2004, 2005;
Rice et al. 2007; Sand et al. 2004; Ta et al. 2011; Viberg et al. 2002, 2003a, 2003b, 2004a, 2004b, 2005, 
2006, 2007; Woods et al. 2012; Xing et al. 2009).  Developing animals exposed to lower-brominated
PBDEs, but not decaBDE, also consistently showed decreased serum T4 levels, although these effects 
may be transient (Blanco et al. 2013; Bondy et al. 2011, 2013; Ellis-Hutchings et al. 2006; Kodavanti et
al. 2010; Kuriyama et al. 2007; Miller et al. 2012; Poon et al. 2011; Shah et al. 2011; Skarman et al. 2005;
Szabo et al. 2009; Wang et al. 2011a; Zhang et al. 2009; Zhou et al. 2002). There is limited evidence that
developmental exposure to lower-brominated PBDEs may effect reproductive system development
(Kuriyama et al. 2005; Talsness et al. 2005, 2008) and that both lower-brominated PBDEs and decaBDE
may effect immune system development (Bondy et al. 2013; Watanabe et al. 2008, 2010b).  Additional
studies evaluating reproductive and immune system development following exposure to PBDEs would 
better characterize the developmental toxic potential of PBDEs on these systems.
Immunotoxicity. Information regarding the immunosuppressive potential of PBDEs is limited.
Immune function assays in adult animals are limited to lower-brominated PBDEs. Acute-duration oral
studies in animals exposed to pentaBDE reported that plaque-forming splenic cell antibody response to 
injected sheep red blood cells was significantly reduced in mice exposed to 72 mg/kg/day pentaBDE for
14 days (Fowles et al. 1994) and in vitro production of IgG immunoglobulin from pokeweed mitogen­
stimulated splenocytes was reduced in mice, but not in rats, exposed to 36 mg/kg/day pentaBDE for
14 days (Darnerud and Thuvander 1998).  The only intermediate-duration immune function assay
reported no exposure-related immune effects in the KLH antibody production assay or the PHA skin 
challenge in mink exposed to pentaBDE at doses up to 0.78 mg/kg/day for 9 weeks (Martin et al. 2007).  
The majority of studies report no histological changes in immune tissues with acute- or intermediate-
duration exposure to PBDEs.  However, as discussed in the Developmental section above, exposure to 
lower-brominated PBDEs or decaBDE during development may lead to impaired immune function 
(Bondy et al. 2013; Watanabe et al. 2008, 2010b). Additional oral studies using a battery of
immunological tests and a lower range of doses for several congeners, including decaBDE, would serve
to better characterize the immunotoxic potential of PBDEs.
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Neurotoxicity. While a large body of evidence indicates that the developing nervous system is a target
for PBDE toxicity, a limited amount of information is available on neurological effects of PBDEs in adult
animals.  In a comprehensive neurotoxicity screen, no adverse effects were observed in rats exposed once
to pentaBDE at doses up to 1.2 mg/kg/day (Belles et al. 2010).  In a neurobehavioral study, no exposure-
related changes were observed in open-field behavior, anxiety-like behavior, or learning and memory in 
male rats exposed to low doses of pentaBDE at doses up to 0.015 mg/kg/day for 90 days (Daubie et al. 
2011).  In a higher dose study, impaired attention and inhibitory control were observed in male mice
exposed to pentaBDE at 26.2 mg/kg/day for 125 days; no exposure-related changes were observed at
17.5 mg/kg/day (Driscoll et al. 2009).  Impaired learning and memory were observed in male rats exposed 
to tetraBDE at doses ≥0.1 for 30 days (Yan et al. 2012).  
For decaBDE, no studies evaluating neurological end points in adult rats or mice following acute
exposure were identified. Decreased anxiety behavior was observed in male mice exposed to decaBDE
for 15 days; however, no exposure-related changes were observed in a functional observation battery or
learning and memory (Heredia et al. 2012).  In another study, no changes were observed in open-field
behavior of male rats exposed to decaBDE at doses up to 50 mg/kg/day 90 days (Wang et al. 2011b).  No 
overt signs of neurotoxicity were observed in rats and mice exposed to decaBDE in estimated dietary 
doses as high as 16,000–19,000 mg/kg/day for 14 days, 8,000–9,000 mg/kg/day for 13 weeks, or 2,550– 
7,780 mg/kg/day for 103 weeks (NTP 1986).  Although the high doses and extended exposure durations
provided opportunities for the induction and/or development of clinical signs, the study is limited by lack
of testing for subtle behavioral changes and neurodevelopmental effects.  Additional comprehensive
neurotoxicity batteries in adult animals exposed orally to repeat doses of PBDEs would better characterize 
the potential for PBDEs to cause neurotoxic effects in adults.
Epidemiological and Human Dosimetry Studies. There are numerous epidemiological studies
evaluating potential associations between tissue PBDE concentrations and adverse health effects;
however, none of the studies provided quantitative exposure information.  Therefore, the available
epidemiological studies are not useful for quantitative risk assessment.  Available studies indicate that
PBDE exposure may lead to neurodevelopmental effects (Adgent et al. 2014; Chao et al. 2011; Chen et al. 
2014; Chevrier et al. 2016; Cowell et al. 2015; Ding et al. 2015; Eskenazi et al. 2013; Gascon et al. 2012;
Herbstman et al. 2010; Hoffman et al. 2012; Roze et al. 2009; Sagiv et al. 2015; Shy et al. 2011; Vuong et
al. 2016a).  Evidence for associations between PBDE exposure and other effects in humans are 
inconsistent between studies, including observations of altered thyroid hormone levels (Abdelouahab et
al. 2011, 2013; Bloom et al. 2008, 2014; Chevrier et al. 2010; Dallaire et al. 2009; Eggesbo et al. 2011;
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Eguchi et al. 2015; Hagmar et al. 2001; Herbstman et al. 2008; Huang et al. 2014; Julander et al. 2005;
Kicinski et al. 2012; Kim et al. 2011a, 2011d, 2012a, 2012b, 2013a; Leijs et al. 2012; Lignell et al. 2016; 
Makey et al. 2016; Mazdai et al. 2003; Shy et al. 2012; Stapleton et al. 2011; Turyk et al. 2008; Yuan et
al. 2008; Wan et al. 2010; Wang et al. 2010; Xu et al. 2014a, 2014b, 2015a), male reproductive effects
(Abdelouahab et al. 2011; Akutsu et al. 2008; Hagmar et al. 2001; Johnson et al. 2013; Meeker et al. 
2009; Mumford et al. 2015; Turyk et al. 2008), female reproductive effects (Buck Louis et al. 2013; Chao 
et al. 2007, 2010; Chen et al.2011; Harley et al. 2010; Johnson et al. 2012; Karmaus et al. 2011; Wainman 
et al. 2016), non-neurological developmental effects (Agay-Shay et al. 2015; Carmichael et al. 2010;
Chao et al. 2007; Chen et al. 2015; Erkin-Cakmak et al. 2015; Foster et al. 2011; Harley et al. 2011; Kim 
et al. 2011d, 2012a, 2012b, 2015; Koskenniemi et al. 2015; Leijs et al. 2008; Lopez-Espinosa et al. 2015;
Ma et al. 2012a; Main et al. 2007; Mazdai et al. 2003; Meijer et al. 2012; Miranda et al. 2015; Müller et
al. 2016; Ochiai et al. 2014; Peltier et al. 2015; Ren et al. 2011; Robledo et al. 2015a; Serme-Gbedo et al. 
2016; Tan et al. 2009; Vuong et al. 2016b; Warembourg et al. 2016; Windham et al. 2015a; Wu et al.
2010; Xu et al. 2015b), and risk for diabetes (Airaksinen et al. 2011; Lee et al. 2011; Lim et al. 2008; 
Smarr et al. 2016; Turyk et al. 2015).  In other epidemiological studies, serum PBDE levels were not
significantly associated with carotid atherosclerosis, risk of stroke, bone mineral density, immune
function, non-Hodgkin’s lymphoma (Fernlof et al. 1997; Hardell et al. 1998; Kumar et al. 2014a, 2014b;
Lee et al. 2012; Lind et al. 2012; Lindstrom et al. 1998;Weiss et al. 2006), breast cancer (Holmes et al.
2014; Hurley et al. 2011), thyroid cancer (Aschebrook-Kilfoy et al. 2015), prostate cancer (Pi et al. 2016), 
reproductive effects in men (Toft et al. 2014), Polycystic Ovary Syndrome (Vagi et al. 2014), or uterine
fibroids (Trabert et al. 2015).  
Epidemiological studies with quantitative estimates of exposure would be useful for quantitative risk
assessment.  Considering the possibility that PBDEs can be transferred to the fetus across the placenta and
that greater amounts might be transferred to nursing infants via breast milk, as well as evidence that
perinatal exposure to PCBs and other similar chemicals may induce subtle neurological damage and
immunological and thyroid effects in children, transgenerational studies would be particularly
informative. Additional studies evaluating the potential link between pre- and peri-natal PBDE exposure 
and childhood behavior disorders, such as Autism Spectrum Disorder (ASD) and ADHD, have been 
specifically requested by the scientific community based upon potential links between these disorders and
endocrine disruption (de Cock et al. 2012; Messer 2010).  However, limitations that are likely to constrain
epidemiological investigations, such as unmeasured PBDE exposure concentrations and lack of controls 
for confounding co-exposures, may be difficult to address. Studies that assess PBDE concentrations in
serum or breast milk along with concentrations of other persistent organic pollutants (POPs), such as 
   
 











     
 
 
     
      
    
   
    
   
   
       
  
    
   
      
     
 
    
    
  
   
   




    
 




PCBs, PCDDs, and /or PCDFs, would be useful to evaluate responses that may be co-dependent on other
persistent lipophilic agents.
Biomarkers of Exposure and Effect.
Exposure.  PBDEs accumulate in adipose tissue, serum, and breast milk of the general population due to 
their lipophilic characteristics.  Concentrations of PBDEs in breast milk are useful, non-invasive markers 
of maternal body burdens and of in utero and lactational exposures, but body burden assessments are 
limited by a lack of time-trend data for PBDEs in the milk of U.S. populations (Hooper and McDonald 
2000). Breast milk monitoring programs would provide time-trend data that would verify whether
regulatory action to limit the use of PBDEs is reversing the previous trend of an exponential increase in 
PBDE concentrations in breast milk (Norén and Meironyté 1998, 2000).  Studies on the predictive value
of concentrations of PBDEs in serum and adipose tissue could provide useful information for detection 
and monitoring of exposure.  It should be noted, however, that solubilities in adipose and breast milk are
likely to vary with the congener. For example, decaBDE is much less soluble in adipose than pentaBDE.
These differences must be considered when designing studies evaluating PBDE exposure.  Recent studies 
have indicated that PBDE concentrations in hair may also be useful to estimate exposure levels (Aleksa et
al. 2012a, 2012b; Malarvannan et al. 2013), although Zheng et al. (2011) reported that PBDE 
concentrations in hair were not correlated with PBDE concentrations in indoor dust from urban, e-waste,
and rural areas in South China.  Additional studies would be useful to validate this approach.
A potential biomarker of exposure to PBDEs relates to their effect on the thyroid gland.  Thyroid changes
in rats and mice include reduced serum T4 levels, with no changes in serum TSH (Darnerud and Sinjari
1996; Fowles et al. 1994; Hallgren and Darnerud 1998; WIL Research Laboratories 1984; Zhou et al. 
2001, 2002).  However, using thyroid changes as a biomarker may not be reliable, as thyroid changes are
not specific to exposure to PBDEs and the effects associated with the thyroid in non-clinical studies are
likely specific to the rodent and may or may not be directly relevant to the human.  Additional studies
could characterize thyroid effects of PBDEs in humans and develop specific correlations between levels 
and duration of exposure and alterations in serum levels of T4.
Effect. Biomarkers that could be used to characterize health effects caused specifically by exposure to 
PBDEs have not been identified.  Additional information on the mechanisms of toxicity may suggest a
useful biomarker of effect; however, at this time, there is little to suggest that such biomarkers exist.
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Absorption, Distribution, Metabolism, and Excretion. No information was located regarding
the toxicokinetics of PBDEs in humans following controlled oral exposure, although information of
toxicokinetics has been gathered based on levels of PBDEs and metabolites in tissues of environmentally
exposed individuals and numerous animal studies and in vitro studies.  
Absorption studies in animals indicate that decaBDE is absorbed to a lesser degree than lower-brominated 
PBDEs.  The most recent and best available estimates of oral absorption efficiencies indicate a range of
70–85% for the tetraBDE (BDE 47), pentaDE (BDE 99, BDE 100), and hexaBDE (BDE 153, BDE 154), 
and 10–26% for decaBDE (BDE 209) (Chen et al. 2006; Hakk et al. 2002a, 2002b, 2009; Klasson Wehler
et al. 2001; Morck and Klasson Wehler 2001; Morck et al. 2003; Örn and Klasson-Wehler 1998; Riu et 
al. 2008; Sandholm et al. 2003; Sanders et al. 2006a, 2006b; Staskal et al. 2005).  Quantitative absorption 
studies in humans could corroborate the conclusions on oral uptake in animals that are based on
elimination and excretion data.
Distribution studies in animals indicate that lower-brominated BDE congeners, following absorption and 
an initial wide distribution, are preferentially accumulated in adipose tissues (Chen et al. 2006; El Dareer
et al. 1987; Hakk et al. 2002a, 2009; Morck and Klasson-Wehler 2001; Morck et al. 2003; Norris et al. 
1975a; NTP 1986; Örn and Klasson-Wehler 1998; Riu et al. 2008; Sanders et al. 2006a, 2006b; Staskal et
al. 2005, 2006a).  In comparison, decaBDE is more readily distributed to highly perfused tissues and less
readily distributed to adipose tissues.  Evidence for the transfer of PBDEs from pregnant mothers to the
developing fetus and for the transfer of PBDEs from maternal blood to breast milk and then to nursing
infants comes from a number of studies of PBDE concentrations in maternal and cord serum samples and 
breast milk samples from groups of non-occupationally exposed women.  In general, the tetra- and penta­
brominated PBDEs have been the predominant congeners detected in maternal and cord serum samples
and breast milk samples, but some recent studies assaying for a wider range of PBDE congeners have 
found evidence for distribution of hepta-, octa-, or decaBDEs into cord serum and breast milk (Antignac
et al. 2009, 2008; Chen et al. 2013; Daniels et al. 2010; Hites 2004; Kawashiro et al. 2008; Li et al. 
2013a; Malarvannan et al. 2013; Mazdai et al. 2003; Meijer et al. 2008; Park et al. 2011; Qiu et al. 2009;
Schecter et al. 2010, 2006; Vizcaino et al. 2011; Wan et al. 2010).  Maternal transfer of both lower­
brominated PBDEs and decaBDE has also been shown in animal studies (Cai et al. 2011; Zhang et al. 
2011).  The available studies appear adequate to characterize distribution of PBDEs.
Current evidence indicates that CYP2B6-mediated metabolism of BDE 47 and BDE 99 produces multiple
hydroxylated metabolites via hydroxylation and ether bond cleavage, based on in vitro studies with
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human liver microsomes or hepatocytes and human recombinant CYPs (Erratico et al. 2012, 2013; Feo et
al. 2013). The major metabolites of BDE 47 and BDE 99 formed by human liver microsomes were not
the same as those identified using rat liver microsomes (Erratico et al. 2013, 2012, 2011).  Different
classes of CYP enzymes appear to be involved in in vitro rat liver metabolism of BDE 47 and BDE 99:
CYP1A1, CYP2A2, and CYP3A1 for BDE 47 and CYP1A1, CYP2A2, CYP2B1, and CYP3A1 for BDE
99 (Erratico et al. 2011).  Production of hydroxylated metabolites of BDE 153 (Lupton et al. 2009) and 
BDE 209 (Stapleton et al. 2009) has not been demonstrated with human liver microsomes or hepatocytes.
It is uncertain if these latter findings are reflective of a limited in vivo capacity of humans to metabolize 
these BDE congeners or because the proper in vitro conditions for metabolizing these congeners were not
provided.  Currently, studies of metabolism of BDE 47 and BDE 99 using in vitro human and rat systems 
have found evidence of metabolic oxidative debromination only with BDE 47 in human liver
microsomes.  In contrast, a number of in vivo studies have found evidence for oxidative debromination by 
analysis of feces collected from rats exposed to BDE 47 (Marsh et al. 2006), BDE 99 (Hakk et al. 2002a), 
BDE 100 (Hakk et al. 2006), BDE 154 (Hakk et al. 2009), and BDE 209 (Morck et al. 2003; Sandholm et
al. 2003). Additional metabolism studies would help to characterize the enzymes involved as well as the 
transformation of some congeners to biologically active hydroxylated BDEs.  There are still data gaps in 
the toxicokinetics of decaBDE, including an incomplete understanding of the debromination of decaBDE
to lower-brominated BDEs.
The detection of PBDEs in human breast milk samples suggest that breast milk represents an elimination
route of absorbed PBDEs in women (see Jakobsson et al. 2012 and Frederiksen et al. 2009 for reviews of
PBDE levels in breast milk); however, studies do not provide a clear account of the degree to which
PBDEs are cleared from the body during breastfeeding (Hooper et al. 2007; Jakobsson et al. 2012;
LaKind et al. 2009; Thomsen et al. 2010).  Rat studies indicate that ingested PBDEs are principally
excreted in the feces with <2% of administered radioactivity excreted in the urine within 3 days of dose
administration (Chen et al. 2006; Hakk et al. 2002a, 2006; Morck et al. 2003; Norris et al. 1973, 1975b; 
Orn and Klasson-Wehler 1998; Sanders et al. 2006a; Riu et al. 2008). However, a different elimination 
pattern has been observed in mice, especially with BDE 47. In mice given single oral doses of
14C-labeled PBDE congeners, fecal and urinary elimination were principal routes of elimination for
BDE 47 (Orn and Klasson-Wehler 1998; Sanders et al. 2006a), whereas fecal elimination appeared to be
more important than urinary elimination with BDE 99 (Chen et al. 2006) and BDE 153 (Sanders et al.
2006b).  Complementary studies with female C57BL/6J given single intravenous 1-mg/kg doses of
14C-labeled BDE 47, BDE 99, BDE 100, or BDE 153 also indicate that the importance of urinary
excretion in mice is congener specific (Staskal et al. 2006b).  Quantitative studies in humans could
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determine which excretion route is more relevant for humans (feces or urine) for different congeners
based on elimination and excretion data.  Additionally, further studies regarding the degree of elimination 
in breast milk during breast feeding could better characterize exposure risks for breastfeeding infants.
Comparative Toxicokinetics. Insufficient data are available to determine whether there are 
qualitative differences in the toxicokinetic disposition of PBDEs between humans and animals and among
animal species.  However, elimination studies in rats and mice (discussed above) highlight that
toxicokinetics may differ between species.  Differences are likely to be dependent on the specific 
congener or mixture studied, and pharmacokinetic modeling studies could help to determine the validity
of extrapolating data.  Most of the available toxicokinetic studies of PBDEs have been performed in rats,
and studies in other species could help to ascertain the most relevant animal model.
Methods for Reducing Toxic Effects. The mechanism by which PBDEs enter the blood stream is 
not known, there are no established methods for reducing body burden of PBDEs, and the mechanisms of
toxic action of PBDEs are incompletely understood.  A more complete characterization of the cytosolic
AhR protein and understanding of physiological effects of receptor blockage would be useful for the
possible identification of blockers of AhR-mediated toxic effects.  Further studies aimed at elucidating the
nonreceptor-mediated mechanism of action of some PBDEs would also be valuable.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
Body burden data, as well as intake modeling, suggest that infants and toddlers have higher exposures to
PBDEs as compared to older children or adults (EPA 2010; Lorber 2008; Trudel et al. 2011; Wong et al. 
2013).  Several epidemiological studies have reported results suggestive of an effect of PBDE on
neurodevelopment in children (Adgent et al. 2014; Chao et al. 2011; Chen et al. 2014; Chevrier et al.
2016; Cowell et al. 2015; Ding et al. 2015; Eskenazi et al. 2013; Gascon et al. 2012; Herbstman et al.
2010; Hoffman et al. 2012; Roze et al. 2009; Sagiv et al. 2015; Shy et al. 2011; Vuong et al. 2016a), and 
these findings are supported by developmental studies in animals (Biesemeier et al. 2011; Blanco et al. 
2013; Branchi et al. 2001, 2002, 2005; Cheng et al. 2009; Eriksson et al. 2001, 2002, 2006; Fischer et al. 
2008; Fujimoto et al. 2011; Gee and Moser 2008; He et al. 2009, 2011; Johansson et al. 2008; Koenig et
al. 2012; Kuriyama et al. 2004, 2005; Rice et al. 2007; Sand et al. 2004; Ta et al. 2011; Viberg et al. 2002,
2003a, 2003b, 2004a, 2004b, 2005, 2006, 2007; Woods et al. 2012; Xing et al. 2009).  Epidemiological 
   
 









   
     
   
      
 
      
   
     
 
   
   
    
   
   
    
   
 
     
   
   
     
    
 
    
   
   
    
      
 





studies in infants are inconclusive regarding thyroid effects and exposure to PBDEs (Abdelouahab et al. 
2013; Herbstman et al. 2010; Kim et al. 2011a, 2012a; Lin et al. 2011; Mazdai et al. 2003; Shy et al. 
2012); however, numerous animal studies indicated that developmental exposure to lower-brominated
PBDEs result in thyroid hormone alterations (Blanco et al. 2013; Bondy et al. 2011, 2013; Ellis-
Hutchings et al. 2006; Kodavanti et al. 2010; Kuriyama et al. 2007; Miller et al. 2012; Poon et al. 2011;
Shah et al. 2011; Skarman et al. 2005; Szabo et al. 2009; Wang et al. 2011a; Zhang et al. 2009; Zhou et al.
2002).  Additional studies would better characterize the potential susceptibility of children to the effects 
of PBDEs on the thyroid and neurodevelopment, particularly considering the possibility that these effects
are related to the dependence of central nervous system development on thyroid hormones.
Data from two human epidemiological studies suggest that PBDE exposure may alter reproductive system
development in boys (Main et al. 2007; Meijer et al. 2012).  In contrast, other studies found no 
associations between serum or adipose tissue PBDE concentrations and reproductive development
(Carmichael et al. 2010; Koskenniemi et al. 2015; Leijs et al. 2008).  These findings, along with limited 
evidence of reproductive effects in animals exposed to lower-brominated PBDEs during development
(Kuriyama et al. 2005; Talsness et al. 2005, 2008), indicate that additional studies of reproductive
development in young animals would help to more fully assess children’s susceptibility to PBDEs.
No information is available regarding the immunosuppressive potential of PBDEs in children, but serum
levels of BDE 28 and 209 were found associated with an increased risk of asthma in a study of 3–6-year­
old Chinese children (Meng et al. 2016). Limited evidence in young animals exposed to PBDEs (Bondy
et al. 2013; Watanabe et al. 2008, 2010b) indicates that additional studies of immune competence in 
developing animals would also help to more fully assess children’s susceptibility to PBDEs.
A recent small study of Swedish toddlers (n=22) found good correlations between concentrations of some
PBDEs in serum and in feces, suggesting that fecal analysis, a noninvasive test, might be a good 
alternative for biomonitoring PBDEs in toddlers (Sahlström et al. 2015).  Larger studies would be
valuable to improve the predictive power of the statistical analyses performed in this study.  In addition, it
would be helpful to determine whether the method is applicable to infants and children of different ages.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
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3.12.3 Ongoing Studies 
Fifty-six ongoing research efforts have been identified that may provide data related to the toxic actions
of PBDEs in humans (RePORTER 2014, 2016). These projects are summarized in Table 3-7.
Animal Studies. Dr. Charles Herbert of the Southern Research Institute is conducting chronic studies of
the commercial pentaBDE mixture DE-71 in rats and mice under contract with NTP and Dr. Lu Taylor of
the Battelle Memorial Institute is conducting a perinatal study BDE 47 in CB6F1-Tg(HRAS2) transgenic 
mice under contract with NTP.
Several animal studies are investigating neurobehavioral changes in animals exposed to PBDEs. Four
ongoing studies are investigating behavioral and biochemical end points relevant to ADHD (Drs. Susan 
Schantz and Paula Eubig, University of Illinois Urbana-Champaign; Dr. Richard Seegal, Wadsworth 
Center). To assess the role of the immune system and its interaction with environmental contaminants in
autism and other neurodevelopmental disorders, Dr. Isaac Pessah of the University of California at Davis 
is investigating the effects of perinatal PBDE exposure on brain development, complex social behaviors,
and immune system function in mouse strains with low (C57BL/6J) or high (SJL mice) susceptibility to 
autoimmunity.  Using an established mouse model, Dr. Margarita Behrens, from the Salk Institute for
Biological Sciences, will examine the effects of exposure to PBDE on autism spectrum disorder. Dr.
Helen Sable of the University of Memphis is examining if developmental PBDE exposure in rats alter
dopamine receptor expression and enhance behavioral sensitization following psychostimulant exposure
(as seen with PCBs).
Dr. Deena Small of the University of New England is examining bone growth and remodeling in mice 
exposed to pentaBDE from PND 1 to 60.  In addition, Dr. Small will use cell culture-based assays that
measure gene expression, enzyme activity and calcium deposition in cultured bone cell lines exposed to 
the pentaBDEs.
Toxicokinetic Studies. Dr. Tracey Woodruff of the University of California, San Francisco is measuring
concentrations of PBDEs and OH-PBDEs in human maternal and fetal biological specimens from women 
undergoing voluntary, second trimester pregnancy terminations and generating original human data on 
whether fetal exposures to PBDEs alter gene expression of cytochrome P450 (CYP) enzymes in the
second-trimester human fetal liver and placenta.  Dr. James Olson of SUNY Buffalo is conducting a 
qualitative and quantitative characterization of the human CYP-specific in vitro metabolism of
   
 



































































   
 


























Table 3-7.  Ongoing Research for PBDEs in Humans
Investigator Affiliation Research description 	 Sponsor
Baccarelli, A Harvard School of Public Prenatal exposure to PBDEs and visual skills, NIEHS
Health attention, and fine motor skills in children
Barr, DB Emory University Prenatal exposure to PBDEs and birth NIHES
outcomes
Blumberg, B University of California- Endocrine disrupter modulation of the steroid NIEHS
Irvine and xenobiotic receptor, SXR, in development
and lymphomagenesis
Caudle, WM Emory University Vesicular monoamine transporter 2 as a NIEHS
mediator of PBDE neurotoxicity
Chen, A University of Cincinnati Longitudinal study of exposure to PBDEs and NIEHS
child neurobehavior
Chen, S Beckman Research Determine role and mechanism of PBDEs on NIEHS
Institute/City of Hope development of breast cancer during the 
menopausal transition
Costa, LG University of Washington Low-level exposure to PBDEs: Testing the NIEHS
hermetic and epigenetic hypotheses
Croen, LA Kaiser Foundation Research Prenatal and neonatal biologic markers for NIEHS
Institute autism
Darrow, L Emory University 	 PBDE body burdens, house dust NIEHS
concentrations, and associations with thyroid 
hormone
Di Giulio, R Duke University Thyroid metabolism disruption key in toxicant- NIEHS
induced development
Eskenazi, B University of California Pesticides and PBDEs on neurobehavior NIEHS
Berkeley
Eskenazi, B University of California PBDEs, DDT, and neurodevelopment in NIEHS
Berkeley school-aged Mexican-American children
Eskenazi, B University of California DDT and PBDE exposure, puberty onset, and NIEHS
Berkeley neurodevelopment in Mexican-American girls
Eubig, P University of Illinois Urbana- Effects of PCBs and PBDEs on three distinct NIEHS
Champaign components of response inhibition
Ferguson, PL University of South Carolina Mechanisms of xenoestrogen stress: a NIEHS
at Columbia proteomic and functional genomic approach
Fitzgerald, EF State University of New York Persistent organic pollutants and cognitive NIEHS
at Albany decline in the elderly
Getahun, D Kaiser Foundation Research Flame retardant and adverse perinatal NIEHS
Institute outcome
Giese, RW Northeastern University Discovery of xenobiotics associated with NIEHS
preterm birth
Hauser, RB Harvard School of Public Maternal and paternal flame retardant NIEHS
Health exposure, impact on fertility and pregnancy
Herbert, C Southern Research Institute Studies to evaluate the toxicologic and NIEHS
carcinogenic potential
Herbstman, JB Columbia University Pre- and postnatal PBDE exposure, thyroid NIEHS
hormones, and neurodevelopment
   
 









































































































Table 3-7.  Ongoing Research for PBDEs in Humans
Investigator Affiliation Research description Sponsor
Epidemiology and the environment in autism NIEHS
The CHARGE study: Childhood Autism Risk
from Genetics and Environment
NIEHS
Autism risk, prenatal environmental
exposures, and pathophysiologic markers
NIEHS
Epigenetic effects of DDT/E and PBDEs on
puberty
NIEHS
Environmental determinants of autoimmunity
among African Americans in coastal South 
NIEHS
Carolina
Developmental exposure to PBDEs and long- NIEHS
lasting modifications of drug metabolism in 
children
Epigenetic interaction of MECP2 and organic NIEHS
pollutants in neurodevelopment
Methylomic and genomic impacts of organic NIEHS
pollutants in Dup15q syndrome
Mechanisms of inflammation in gestational NIEHS
membranes
Longitudinal investigation of fertility and the NICHD
environment
Protecting the health of future generations: NIEHS
assessing and preventing exposures
Effects of endocrine disrupting chemicals and NIEHS
chronic psychosocial stress on fetal growth
Bioactivation of PBDEs by human cytochrome NIEHS
P-450
Calcium signaling defects in autism NIEHS
Neurodevelopmental toxicology of autism NIEHS
Environment chemicals and gynecologic NICHD
health 
Exposure Assessment for childhood leukemia NIEHS
Polybrominated diphenyl ether effects on NIEHS
human neuronal development
Assessment of psychostimulant addiction risk NIEHS
following developmental PCB exposure 
Mechanisms of xenoestrogen stress: a NIEHS






















University of California at
Davis
University of California at
Davis
University of California at
Davis
University of California 
Berkeley
Medical University of South
Carolina
University of Washington
University of California at
Davis




National Institute of Child 




University of California, San 
Francisco
State University of New York
at Buffalo
University of California at
Davis
University of California at
Davis
University of Utah
Rappaport, SM University of California 
Berkeley
Robinson, JF University of California, San 
Francisco
Sable, HJ University of Memphis
Sabo-Attwood, University of South Carolina 
TL at Columbia
   
 




























   
 
 
    
 
 















































































Table 3-7.  Ongoing Research for PBDEs in Humans

















University of Illinois Urbana-
Champaign
University of Illinois Urbana-
Champaign
Wadsworth Center




University of Illinois at
Chicago






University of California, San 
Francisco





PCBs, PBDEs, hearing loss, and 
attention/impulsivity: mechanistic studies in
animals
Health effects of PCB exposure from
contaminated fish
Developmental neuroendocrine effects of
PCBs and PBDEs
Effect of polybrominated diphenyl ether flame 
retardant exposure on osteogenesis
Children’s exposure to flame retardants:
effects on thyroid hormone regulation
Deiodinase activity as a biomarker of
response to brominated flame retardants
Studies to evaluate the toxicological potential
of test articles
Diabetes and persistent organic pollutants
Immune environment interaction and 
neurodevelopment
Endocrine disruption in pregnant women:
thyroid disruption and infant development
Measuring human exposure to PBDEs
Human maternal/fetal exposures to PBDEs
and their metabolites during development
Mid-gestational exposure to endocrine 
disrupting chemicals and effects on placental
development
Polyhalogenated aromatic hydrocarbons and 
thyroid cancer risk in the Department of
Defense Serum Repository (DoDSR) cohort
Role of endocrine-disrupting chemicals and 
















Source: RePORTER 2014, 2016
NIEHS = National Institute of Environmental Health Sciences; PBDE = polybrominated diphenyl ether;
PCB = polychlorinated biphenyl
   
 








      
      
    
  
  
    
   
    
  












   
    







    





2,2',4,4'-tetraBDE (BDE 47), 2,2',4,5'-tetraBDE (BDE 49), 2,2',4,4',5-pentaBDE (BDE 99), and 
2,2',4,4',6- pentaBDE (BDE 100) as well as quantify OH-PBDEs in human milk and serum and assess the
potential impact of CYP2B6 genotype on the body burden of PBDEs.  Dr. Heather Stapleton of Duke
University is identifying the products of hepatic metabolism of PBDEs (no further details available).
Mechanistic Studies. Several studies are investigating mechanisms of neurotoxicity.  At the University
of California at Davis, Dr. Janine Lasalle is investigating epigenetic changes in the genome of Mecp2
mutant mouse models of Rett syndrome and autism following in vivo exposure to BDE 47, Drs. Janine
Lasalle and Isaac Pessah are investigating potential mechanisms of PBDE toxicity in susceptible neuronal
cell models (chromosome 15q11-13 duplication syndrome [Dup15q] or fragile X syndrome [FMRI]), and 
Dr. Judy Van de Water is investigating mechanisms of PBDE toxicity in peripheral blood mononuclear
cells from children with autism.  Dr. Joshua Robinson of the University of California San Francisco is
investigating the effects in vitro exposure to BDE 47 and BDE 99 on neuronal differentiation and gene
expression in human embryonic stem cells.  Dr. Lucio Costa of University of Washington is investigating
genetic and epigenetic changes in cultured mouse neurons exposed to low, environmentally-relevant
concentrations of BDE 47. Dr. William Caudle of Emory University is investigating the potential 
mechanisms by which the commercial pentaBDE mixture DE-71 disrupts VMAT2, which is a key
mediator of cytosolic dopamine.
Additional studies are investigating mechanisms of thyroid hormone disruption.  Dr. Heather Stapleton of
Duke University is investigating the effects of PBDEs and their metabolites on intra- and extra-cellular
thyroid hormone regulation in vitro to elucidate the mechanisms of action for thyroid toxicity.  Dr. Deena
Small of the University of New England is measuring thyroid hormone receptor- mediated transcription 
and thyroid hormone receptor binding of pentaBDEs in vitro. Dr. Richard Di Guilio of Duke University
is investigating the potential role of inhibition of diodinases by PBDEs in altered thyroid hormone
homeostasis, using zebrafish as a model.
Other mechanistic studies are investigating mechanisms of xenoestrogen stress (Drs. P. Lee Ferguson and
Tara Sabo-Attwood of the University of South Carolina at Columbia), potential mechanisms behind the 
etiology of inflammation of extra-placental gestational membranes and associated release of cytokines 
and prostaglandins (which are associated with preterm birth) (Dr. Rita Loch-Caruso of the University of
Michigan), the potential role of the steroid and xenobiotic receptor SXR in the development of lymphoma
and leukemia in individuals exposed to PBDEs (Dr. Bruce Blumberg of the University of California-
Irvine), and development of biomarkers of mitochondrial function in primary mouse hepatocytes exposed 
   
 













to BDE 47 using metabolomic analysis (Dr. Hockenberry from the Fred Hutchison Cancer Research
Center.
   
 













This page is intentionally blank.












   
 
   








   
 
  
     
  
  
     
  
    
  
       
   
    
       
    
    
PBDEs 343
4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
PBDEs are a class of structurally similar brominated hydrocarbons, in which 2–10 bromine atoms are 
attached to the diphenyl ether molecule.  Monobrominated structures (i.e., one bromine atom attached to 
















where m + n = 1 to 10
It can be seen from the structure that a large number of brominated compounds are possible.  The
209 possible compounds for PBDEs are called “congeners”.  However, the number of PBDE congeners
that actually exist in commercial PBDE mixtures are much less compared to PCBs.  Typically, only a
subset of the 209 possible congeners is observed for PBDEs.  PBDEs can also be categorized by degree of
bromination.  The term “homolog” is used to refer to all PBDEs with the same number of bromines (e.g., 
tribromodiphenyl ether or triBDE refers to PBDEs containing only three bromine atoms).  Based on the
number of bromine substituents, there are 10 homologous groups of PBDEs (monobrominated through 
decabrominated).  Each homologous group contains one or more congeners. The mono-, di-, tri-, tetra-, 
penta-, hexa-, hepta-, octa-, nona-, and decabromo-congeners can exist in 3, 12, 24, 42, 46, 42, 24, 12, 3, 
and 1 forms, respectively. Homologs with different substitution patterns are referred to as isomers.  For
example, the group of dibromodiphenyl ether or diBDE homologs contains 12 isomers.  The numbering
system for PBDEs is also shown above. The structures of representative PBDE molecules appear similar
when drawn in one dimension.  However, there are important three-dimensional differences in their
structures due to the ether linkage and location/number of halogen atoms.  The ortho positions of the
aromatic rings must be nonhalogen-substituted for a diphenyl ether molecule to assume a planar or near
planar configuration.  Halogen substitution of the diphenyl ether molecule in the ortho position (2,2’,6,6’)
will force the aromatic rings orthogonal to one another (e.g., the phenyl rings will be positioned in space
with a dihedral angle >0°).  This is particularly evident for decabromodiphenyl ether, which is predicted 
to have a dihedral angle of ~90° and a high barrier to rotation around the ether linkage preventing this














    
   
    
   
    






       
     
    
    





     
     
     




4.  CHEMICAL AND PHYSICAL INFORMATION
molecule from assuming a planar configuration.  The benzene rings of non-ortho substituted PBDEs may
assume a small dihedral angle (in which the dihedral angle is small, but >0°) or “near” planar
configuration.  These molecules are referred to as planar or coplanar congeners (Hardy 2002a).  
Like PCBs, the 209 congeners for PBDEs are arranged in ascending numerical order using a numbering
system developed by Ballschmiter and Zell (1980) that follow the IUPAC rules of substituent
characterization in biphenyls. The resulting numbers assigned by Ballschmiter and Zell (which are also
referred to as congener, IUPAC, or BZ numbers) are widely used for identifying individual congeners of
PBDEs.  For example, the PBDE congener, 2,2',4,4'-tetraBDE may be referred to as BDE 47 in this
document. The identities of several PBDE congeners are shown in Table 4-1 (WHO 1994a, 1994b).
In the United States, Albemarle Corporation and Great Lakes Chemical Corporation previously marketed
mixtures of PBDEs under trade names (e.g., DE-60F, DE-61, DE-62, DE-71, for pentaBDE mixtures;
DE-79 for octaBDE mixtures; and DE 83R, Saytex 102E for decaBDE mixtures).  The Great Lakes 
Corporation merged with Crompton Chemical Corporation and was renamed Chemtura, which produced 
decaBDE under the brand names AZUB DB-40, AZUB DB-65, AZUB 2DA-65, and AZUB 3DA-65 
(EPA 2010).  There were also several trade names used by producers from Europe and Japan for the BDE
mixtures. The chemical identities of commercial mixtures of penta-, octa-, and decaBDEs are listed in
Table 4-2 (WHO 1994a). La Guardia et al. (2006) published detailed congener composition profiles of 
penta-, octa-, and decaBDE flame retardant mixtures; 39 discrete PBDEs were found in the six 
commercial products evaluated by GC/MS electron ionization (EI) and electron-capture negative 
ionization (ECNI).
Various synonyms and abbreviations for PBDEs exist in the literature and are shown below:
polybrominated biphenyl ethers = polybromobiphenyl ethers = PBBE
polybrominated biphenyl oxides = polybromobiphenyl oxides = PBBEs
polybrominated diphenyl ethers = polybromodiphenyl ethers = PBDEs or PBDPEs
polybrominated diphenyl oxides = polybromodiphenyl oxides = PBDOs or PBDPOs














   
   

























































































4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Polybrominated Diphenyl Ether (PBDE)
Congenersa





























































































   



























































































4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Polybrominated Diphenyl Ether (PBDE)
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Polybrominated Diphenyl Ether (PBDE)
Congenersa











































































































   



























































































4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Polybrominated Diphenyl Ether (PBDE)
Congenersa



































































































   

























































































4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Polybrominated Diphenyl Ether (PBDE)
Congenersa
































































































   
   












4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Polybrominated Diphenyl Ether (PBDE)
Congenersa




bBallschmiter and Zell 1980
cNo CAS numbers were identified for the individual PBDE congeners.
BDE = brominated diphenyl ether; CAS = Chemical Abstracts Service; IUPAC = International Union of Pure and 
Applied Chemistry





























































    
   
     
     
  
 
    
     
  
 
   
     
     
 








4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Chemical Identity of Technical Polybrominated Diphenyl Ethers
(PBDEs)





















DE 71; Bromkal 70-5 DE;
FR 1205/1215; Bromkal 70;
Bromkal G1;
Pentabromprop; Tardex 50;
Tardex 50 L; Saytex 115
Bromkal 79-8DE; DE 79;
FR 143; Tardex 80;
FR 1208; Adine 404;
Saytex 111
FR-300 BA; DE-83-RTM;
Saytex 102; Saytex 102E;
FR-1210; Adine 505;
AFR 1021; Berkflam B10E;
BR55N; Bromkal 81;
Bromkal 82-0DE; 
Bromkal 83-10 DE; Caliban
F/R-P 39P; Caliban F/R-P 
44; Chemflam 011; DE 83;
DP 10F; EB 10FP;
EBR 700; Flame Cut
BR 100; FR P-39; BR 100;
FR 330BA; FR P-39;












CAS registry 32534-81-9 32536-52-0 1163-19-5
NIOSH RTECS No data No data No data
EPA hazardous No data No data No data
waste
OHM/TADS No data No data No data
DOT/UN/IMCO
shipping
No data No data No data
HSDB 7109 7110 2911
NCI No data No data No data
Source: WHO 1994a
CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System;
RTECS = Registry of Toxic Effects of Chemical Substances











    
 
     
     
     
     
     
     
     
     
     
 
   
 
   
     
    
 
   
    
  





     
   
   
     
   




















4.  CHEMICAL AND PHYSICAL INFORMATION
For consistency in this document, polybrominated diphenyl ethers or PBDEs will be used to identify this
class of chemicals. The PBDE homologs are abbreviated as follows in this document:
dibromodiphenyl ether = DiBDE = diBDE
tribromodiphenyl ether = TrBDE = triBDE
tetrabromodiphenyl ether = TeBDE = tetraBDE
pentabromodiphenyl ether = PeBDE = pentaBDE
hexabromodiphenyl ether = HxBDE = hexaBDE
heptabromodiphenyl ether = HpBDE = heptaBDE
octabromodiphenyl ether = OcBDE = octaBDE
nonabromodiphenyl ether = NoBDE = nonaBDE
decabromodiphenyl ether = DeBDE = decaBDE
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
Information found in the literature regarding the physical and chemical properties of selected technical
PBDE mixtures is presented in Table 4-3.  Recent information regarding the vapor pressure, water
solubility, Henry’s Law constant, and log Kow of some PBDE congeners is presented in Table 4-4.  
Commercially available product mixtures of PBDEs (see Table 4-2) are not pure substances, but instead 
are mixtures of congeners. For example, the commercial mixture pentaBDE denotes the main component
of the mixture contains the pentaBDE homolog.  However, the commercial pentaBDE mixture actually
contains tetraBDE (24–38%) and pentaBDE (50–62%) homologs with small amounts of hexaBDE (4– 
8%) and trace amounts of triBDE (0–1%) homologs.  In this document, the commercial mixture of
pentabromodiphenyl ether may be called “the commercial pentaBDE mixture,” “technical pentaBDE,” or
“technical PeBDE” to distinguish this mixture of homologs from the pentaBDE homolog, which refers to 
PBDEs with only five bromine atoms (see Section 4.1).  Commercial octaBDE is a mixture of hexa-, 
hepta-, octa-, and nonaBDE homologs with trace amounts of decaBDE (i.e., BDE 209).  In this document, 
the commercial mixture of octabromodiphenyl ether may be called “the commercial octaBDE mixture,” 
“technical octaBDE,” or “technical OBDE” to distinguish this mixture of different homologs from the
octaBDE homolog, which refers to PBDEs with only eight bromine atoms (see Section 4.1).  The
composition of commercial decabromodiphenyl ether is 97% of the decaBDE (i.e., BDE 209); the
remainder is nonaBDE homologs and trace amounts of octaBDE homologs (WHO 1994a).  In this
document, commercial decabromodiphenyl ether may be called “the commercial decaBDE mixture,”














    




      









    
    
    
     
     















   
   
 
  





   
  






   
 

























4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-3.  Physical and Chemical Properties of Technical Polybrominated
Diphenyl Ether (PBDE) Mixtures

























Clear, amber to pale 
yellowa 
Highly viscous liquid
-7 to -3°C (commercial)b 
>300°C (decomposition 
starts above 200°C)a,b 




13.3 µg/L (commercial)b,d; 
2.4 µg/L (pentabromodi­
phenyl ether component)b; 
10.9 µg/L (tetrabromodi­
phenyl ether component)b





2.2x10-7–5.5x10-7 mm Hg 





















<1 ppb at 25°C (com­










Hg at 25°Cd; 4.9x10-8 mm








































    
   
 
  

















4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-3.  Physical and Chemical Properties of Technical Polybrominated
Diphenyl Ether (PBDE) Mixtures
Property Pentabromodiphenyl ether Octabromodiphenyl ether Decabromodiphenyl ether
Conversion factors 1 ppm=23.48 mg/m3 at No data No data
20°Cd 
Explosive limits Noneb,f Nonec No data




eEstimated values were calculated using EPIWIN v4.10 (EPA 2014e).
fHardy 2002a
gEstimated value was calculated using vapor pressure and water solubility values in table.


















   
      
      
      
      
      
      
      
      
      
      
      
      
      
      














4.  CHEMICAL AND PHYSICAL INFORMATION








(atm m3/mol)a Log Kow c Log KOAd
BDE 3 1.94x10-3 – – – –
BDE 15 1.30x10-4 130 2.07254x10-4 – –
BDE 17 – – – 5.74 9.30
BDE 28 1.64x10-5 70 5.03331x10-5 5.94 9.50
BDE 47 1.40x10-6 15 1.48038x10-5 6.81 10.53
BDE 66 9.15x10-7 18 4.93461x10-6 – 10.82
BDE 77 5.09x10-7 6 1.18431x10-5 – 10.87
BDE 85 7.40x10-8 6 1.08562x10-6 – 11.66
BDE 99 1.32x10-7 9 2.26992x10-6 7.32 11.31
BDE 100 2.15x10-7 40 6.80977x10-7 7.24 11.13
BDE 138 1.19x10-8 – – – –
BDE 153 1.57x10-8 1 6.61238x10-7 7.90 11.82
BDE 154 2.85x10-8 1 2.36862x10-6 7.82 11.92
BDE 183 3.51x10-9 2 7.30323x10-8 8.27 11.96
BDE 190 2.12x10-9 – – – –
aTittlemier et al. 2002.
bLiquid sub-cooled vapor pressures.
cBraekevelt et al. 2003.
dHarner 2001.
– = no data reported; BDE = brominated diphenyl ether










   
   
  
 
   
  
   
   
  
  
      
    













4.  CHEMICAL AND PHYSICAL INFORMATION
“technical decaBDE,” or “technical DeBDE” which represents 97% BDE 209 congener with 3% nona­
and octaBDE homolog impurities.  The compositions of commercial product mixtures of PBDEs
(e.g., technical penta-, octa-, and decaBDE) are given in Table 4-5.  
Trace analysis of these commercial mixtures for 15 different 2,3,7,8-substituted brominate dibenzo­
p-dioxins and dibenzofurans revealed no detectable amounts of these substances (Hardy 2002a).  The
commercial decaBDE product has been analyzed for trace quantities of 15 2,3,7,8-substituted PBDDs and 
PBDFs.  None of the analytes were present at or above the quantization limits established under an EPA
test rule (BFRIP 2002).  While in today’s commercial PBDE samples, there are no measurable quantities
of PBDDs/PBDFs, there are some materials that have reported quantifiable concentrations of these 
contaminants.  For example, hexabromodibenzofurans have been detected in commercial decaBDE
mixtures at concentrations as high as 200 μg/kg.  In other PBDE mixtures (e.g., tetra- to hexaBDEs), the
sum of tetra-, penta-, and hexabromodibenzofurans were reported at a concentrations of 8,000 μg/kg. In
addition, tetra- and pentabromo-p-dibenzodioxins have been measured in commercial decaBDE at
concentrations of 0.05 and 0.35 μg/kg, respectively (WHO 1998). 
When pyrolyzed up to 900°C, PBDEs may produce PBDFs and PBDDs (Buser 1986; EU 2001).  The
amount of PBDFs and PBDDs formed depends upon the conditions of pyrolysis.  For example, 
2,3,7,8-tetrabromodibenzofuran in ppm concentrations can be generated during pyrolysis of decaBDE in 
the temperature range of 400–700°C (Bieniek et al. 1989).  PBDFs may also be produced during the
pyrolysis of polymers containing PBDEs as flame retardants (Brenner and Knies 1993; Dumler et al. 
1989, 1990; Lenoir et al. 1994).  However, studies performed in the late 1980s may have suffered from
analytical methods that could not differentiate between PBDDs/PBDFs formed (e.g., 2,3,7,8-substituted 
congeners) and decaBDE, which might have artificially elevated the concentrations of PBDEs detected
(Hamm et al. 2001).  














     
    
    
    
    
    
    
    
    
    
    
    
    









4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-5.  Typical Congener Composition of Penta-, Octa-, and Deca-
Brominated Diphenyl Ether (BDE)




BDE 153 3–5% 5–10%






BDE 207 7% 0.24%
BDE 208 10% 0.06%
BDE 209 97%
Source:  EPA 2010
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
The commercial production of PBDEs generally involves bromination of diphenyl oxide to varying
degrees. The degree of bromination is controlled either through stoichiometry or through control of
reaction kinetics (Pettigrew 1993).  
The commercial production of PBDEs began in late 1970s (WHO 1994a).  There are no current
manufacturers of technical PBDEs in the United States. About 98% of the global demand for the
technical pentaBDE mixture resided in North America (Hale et al. 2003).  PentaBDE and octaBDE
mixtures were voluntarily withdrawn from the U.S. marketplace by their manufacturers at the end of
2004, leaving only decaBDE being marketed for use in commercial products in the United States (EPA
2010).  In December of 2009, the two remaining U.S. producers of decaBDE, Albemarle Corporation and 
Chemtura Corporation (formerly known as the Great Lakes Chemical Corporation), and the largest U.S.
importer, ICL Industrial Products, Inc., announced commitments to phase out manufacture and 
importation of decaBDE for most uses in the United States by December 31, 2012, and to end 
manufacture and import for all uses by the end of 2013 (EPA 2013j).  In 2003, the EU passed a Directive
to ban the marketing and use of penta- and octaBDE that took effect in 2004.  In 2008, the use of
decaBDE was restricted by an EU Directive on the Restriction of the use of certain Hazardous Substances 
(RoHS) (EC 2014; EPA 2010).
Table 5-1 lists the facilities in each state that manufactured or processed technical decaBDE in 2014, the 
intended use, and the range of maximum amounts of technical decaBDE that are stored on-site (TRI14 
2016).  The data from the Toxics Release Inventory (TRI) listed in Table 5-1 should be used with caution, 
however, since only certain types of facilities were required to report. The TRI is not an exhaustive list.
Facilities are only required to report to the TRI if they manufacture or process more than 25,000 pounds
of a TRI listed chemical during the year, or otherwise use more than 10,000 pounds, and have the
equivalent of more than 10 full-time employees.  According to the EPA, TRI data have certain
limitations. TRI data reflect releases and other waste management of chemicals, and not exposures of the 
public to those chemicals.  TRI data alone are not sufficient to determine exposure or calculate potential
adverse effects on human health and the environment.
   
 














     
     
      
     
     
     
      
     
     
     
     
     
     
     
      
      
     
     
     
 
  































































5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1. Facilities that Produce, Process, or Use Decabromodiphenyl Ether
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AR 2 1,000 99,999 7
CA 1 10,000 99,999 2, 3, 7, 8, 10
CT 1 10,000 99,999 8
GA 3 1,000 99,999 7, 8
IL 3 10,000 99,999 7
IN 1 50,000,000 99,999,999 2, 3, 4, 8
KS 1 1,000 9,999 8
MA 2 10,000 999,999 7
MS 1 10,000 99,999 7, 8
NH 1 Not reported Not reported Not reported
NJ 1 10,000 99,999 7
NV 1 10,000 99,999 7
NY 1 1,000 9,999 7
OH 4 1,000 99,999 2, 3, 7, 8
PA 3 100,000 999,999 1, 3, 7, 8
SC 5 10,000 99,999 7, 8
TX 2 1,000 9,999 7
VA 3 0 99,999 7
aPost office state abbreviations used.
bAmounts on site reported by facilities in each state.
cActivities/Uses:
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI14 2016 (Data are from 2014)
   
 
















    
   
  
 




   
    
  
   
 
   
   
 
    
   
 
   
   





5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.2  IMPORT/EXPORT
Production and importation of the final commercial PBDE, decaBDE, ended on December 31, 2013. 
5.3  USE 
PBDEs were used as additive flame retardants in thermoplastics.  Additive flame retardants are physically
combined with the polymer material being treated rather than chemically combined (as in reactive flame 
retardants).  This means that there is a possibility that the flame retardant may diffuse out of the treated
material to some extent.  PBDEs were used in different resins, polymers, and substrates at levels ranging
from 5 to 30% by weight (EU 2001).  
The commercial pentaBDE product was used predominantly (95–98%) for flame retardant purposes as an
additive in consumer products manufactured by the furniture industry (ENVIRON 2003a).  It was used 
almost exclusively to flame retard flexible polyurethane foam (FPUF), which is used in bed mattresses 
and cushioning in upholstered products.  The commercial pentaBDE was typically used in FPUF as an 
additive mixture with aromatic phosphate esters (e.g., mixture of 75% pentaBDE and 25% aromatic
phosphate esters). Mattress FPUF contains approximately 2–3% flame retardant mixture and cushion 
FPUF contains 3–5% flame retardant mixture (ENVIRON 2003a).  Scrap materials from both industries
have been used as padding beneath carpets, and as a result, carpet padding likely contained 3–5% flame 
retardant mixture.  However, not all of the FPUF found in cushion, mattress, and carpet padding products
were treated with commercial pentaBDE.  Approximately 7.5% of the more than 2.1 billion pounds of
FPUF produced annually in the United States used the commercial pentaBDE product as a flame retardant
additive (ENVIRON 2003a).  The majority of FPUF products treated with the commercial pentaBDE
product were sold in California, the only state requiring by law that upholstered products achieve a 
prescribed level of ignition resistance (ENVIRON 2003a).  A small percentage of pentaBDE was used in
commercial adhesive products.  Other former uses of commercial pentaBDE included coatings for
specialty textiles, printed circuit board components, hydraulic and oilfield completion fluids, and rubber
products.  In the past, automotive and airplane seating cushions contained FPUF with commercial
pentaBDE.  However, this use was discontinued in the early 1990s.  Prior to approximately 1990, the
commercial pentaBDE product may have been used in small quantities as a flame retardant in specialty
fire-resistant clothing using polyurethane treatment and in polyurethane coatings in carpets (ENVIRON
2003a).  Commercial pentaBDE product was used in rigid polyurethane elastomers for instrument
casings, and applied in printed circuit boards and microprocessor packaging previously (Betts 2006;
   
 








   
   
 
  
   
    
   
 
 
     
  
   
  
 
   
    
  
   
   
   
  




   
 
   
 





5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Hazrati and Harrad 2007).  Electronic equipment containing pentaBDE produced in other countries
(principally Asian) could also find its way into the United States (EU 2001).  
The commercial octaBDE was used by the plastics industry as an additive flame retardant for
manufactured products.  It was used almost exclusively to flame retard ABS terpolymers used in 
computer casings and monitors (ENVIRON 2003b).  In the EU, approximately 95% of the total
commercial octaBDE product sold to the electronics and plastics industries was used in ABS before it was
banned (EU 2003a).  Although data are not available in the United States, similar volumes were likely
(ENVIRON 2003b).  The commercial octaBDE product formerly used in ABS products was 12–18%
weight loadings of flame retardant.  OctaBDE was always used as a flame retardant in conjunction with
antimony trioxide.  Other minor uses for octaBDE, were high impact polystyrene (HIPS), polybutylene
terephthalate (PBT), and polyamide polymers (EU 2003a).  Other former applications of octaBDE
included use as additive flame retardant in polycarbonate, phenol-formaldehyde resins, and unsaturated
polyesters (EU 2003a).
The commercial decaBDE product was an additive flame retardant used in a variety of polymer
applications.  Industry information indicates that decaBDE was used at loadings of 10–15% weight in 
polymers and always in conjunction with antimony trioxide (EU 2002).  The major application for
decaBDE was in HIPS, which is used in the television industry for cabinet backs.  It was also used for a 
large number of other polymers with end-uses in electrical and electronic equipment (e.g., computers, 
connectors, electrical boxes, wire, cable, etc.).  Examples include polypropylene (for electronics), acetate 
copolymers (ethylene-vinyl acetate [EVA] and other copolymers for wire and cable), ethylene-propylene­
diene terpolymer (EPDM) and thermoplastic elastomers (for wire and cable), and polyester resins (for
electronics).  Other minor uses included styrenic rubbers, polycarbonates, polyamides, and terephthalates,
and small amounts are reported to be used in hot-melt adhesives (EU 2002).  
5.4  DISPOSAL
PBDEs were used as flame retardants in a wide range of consumer products (see Section 5.3).  In the
United States, waste disposal of PBDE-containing consumer products is described as transfers to disposal
(landfill), recycling, energy recovery (incineration), or publicly owned treatment works (POTWs)
(Darnerud et al. 2001).  No other information was located on the past or present volumes of PBDE-
containing consumer products disposed of by each method of waste transfer.
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Landfill disposal of plastic consumables containing pentaBDE (e.g., polyurethane foams), octaBDE (e.g., 
computer monitors), and decaBDE (e.g., televisions) to landfills is likely to increase in the United States 
due to their limited useful lifespan.  Given that all PBDEs have low water solubility (see Table 4-4), the
potential for leaching of PBDE from landfills appears to be small (EU 2002).  Well-designed landfills will
include measures to minimize leaching and those measures would also be effective in minimizing the 
leaching of any PBDE particulates present (EU 2002). PBDEs have been detected in landfill leachate and
landfill related aqueous samples worldwide (Daso et al. 2013; Kwan et al. 2013; Odusanya et al. 2009;
Oliaei et al. 2010; Stubbings and Harrad 2014).  The presence of hydrophobic compounds like PBDEs in 
leachate is expected to be a result of enhanced leachability due to the presence of other constituents 
present in the leachate (Stubbings and Harrad 2014).  Mass transfer evaluation of PBDEs from e-waste 
solids found that lower pH conditions resulted in higher transfer of PBDEs to the aqueous phase, with the
highest concentration of PBDEs detected at pH 5 and 25°C (Danon-Schaffer et al. 2013). The levels of
PBDEs in the aqueous phase did show a trend with temperature at the temperature range evaluated, 10– 
25°C.
Incineration of waste materials containing PBDEs is thought to be a potential source of PBDFs and/or
PBDDs.  The formation of PBDFs/PBDDs as a result of uncontrolled landfill fires is also a possibility,
although no data are available on the scale of this source.  The results of pyrolysis experiments showed 
that PBDEs can form PBDFs and PBDDs (in much smaller quantities) under a wide range of heating
conditions.  If chlorine is present, mixed halogenated furans/dioxins can be formed (Oberg et al. 1987;
Zier et al. 1991).  Unless sufficiently high temperatures and long residence times are maintained, 
PBDFs/PBDDs can be generated during the incineration of products containing PBDEs.  When heavy
metals are present, the concentration of PBDDs and PBDFs are higher than when no metals are present.
Sakai et al. (2001) measured residues of PBDFs/PBDDs in effluents from a municipal incineration plant
burning domestic waste materials.  Flue gases, fly ash, and bottom ash reportedly contained 
PBDFs/PBDDs at concentration ranges of 0.28–3.3 ng/N m3, 0.082–13 ng/g, and 0.0058–27 ng/g, 
respectively.  However, modern, properly operated municipal waste incineration should not emit
significant quantities of PBDFs/PBDDs, regardless of the composition of municipal waste (WHO 1994a). 
In the United States, waste disposal of industrial by-products containing PBDEs may also be described as 
transfers to disposal (landfill), recycling, energy recovery (incineration), industrial treatment works, or
POTWs. The types of waste transfer may be different for manufacturing versus processing sectors, and
also from within different types of processing.  Waste disposal from manufacturing processes is 
predominantly to secure chemical landfills (e.g., those built with liners and leachate collection).  Plastic 
   
 


















    
   




5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
processors typically transfer most waste to disposal (landfill), recycling, energy recovery (incineration), 
and industrial treatment works, while minimal releases are to POTWs.  In contrast, textile processors 
typically transfer most waste to POTWs. This difference in waste transfers between the plastic and textile 
sectors is because textile processors use water in their processing operation and other processors (e.g.,
processors of plastic) do not. 
Recycling of plastic materials containing PBDEs is a common practice in industry.  It has been
demonstrated that decaBDE-containing resins can be successively recycled without generation of
PBDDs/PBDFs (Brenner and Knies 1990; Donnelly et al. 1987; McAllister et al. 1990).  For example, 
virgin HIPS resins (containing antimony trioxide [Sb2O3] and decaBDE) and repeatedly ground and 
injected molded (e.g., “recycled”) HIPS/decaBDE/Sb2O3 resins both met the requirements of the German
Chemicals Banning Ordinance with respect to 2,3,7,8-substituted PBDD/PCDF congeners. These resins 
were at least 1 order of magnitude below the regulated limit values for PBDDs/PCDFs (1 ppb for the sum
of four congeners, 5 ppb for the sum of all eight regulated congeners).
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
PBDEs have not been identified in any of the 1,832 hazardous waste sites that have been proposed for
inclusion on the EPA National Priorities List (NPL) (ATSDR 2015).  However, the number of sites
evaluated for PBDEs is not known.  
The widespread use of PBDEs since the late 1970s has resulted in their presence in the environment.  
PBDEs were released into the environment from their manufacture and use as additive flame retardants in
thermoplastics in a wide range of products (WHO 1994a).  Waste containing PBDEs may be incinerated 
as municipal waste, deposited in landfills, discharged to municipal sewage-treatment plants, or emitted
directly to the atmosphere as particulates (Darnerud et al. 2001).  
Adsorption of PBDEs generally increases as bromination of PBDEs and organic carbon content of soil
and sediment increase.  As a result, most PBDEs have little or no mobility in soil and are not expected to 
leach (e.g., into groundwater).  PBDEs, particularly lower BDE homologs (e.g., tri- and tetraBDE), have 
the potential for long-range transport in the atmosphere (Dodder et al. 2000).  The detection of PBDEs in 
remote regions of the world suggests that long-range transport of these congeners is occurring (Dickhut et
al. 2012; Hung et al. 2010).  Biodegradation is a slow environmental fate process for PBDEs, but under
certain conditions, some PBDEs compounds (e.g., decaBDE) may degrade by direct photolysis to form
lower-brominated congeners.  However, determining the rate and extent of degradation processes (e.g., 
biodegradation and photolysis) for PBDEs, such as decaBDE and pentaBDE commercial mixtures, is still
an active area of research.
Studies of the biota indicate that lower-brominated congeners (e.g., BDE 47) are being preferentially
bioconcentrated.  Lower-brominated diphenyl ether (e.g., tetra- and pentaBDE) concentrations increase 
with respect to trophic level; thus, organisms that reside higher on food chains tend to have higher
concentrations of these brominated diphenyl ethers (Shaw et al. 2009).  Body-burden data indicate that
the general population is exposed to PBDEs through a variety of pathways (CDC 2015; Lorber 2008;
Trudel et al. 2011).  The primary exposure pathway to PBDEs for residents of North America is through 
indoor dust contact (ingestion and dermal exposure) (EPA 2010; Lorber 2008.  Dust contact is also the 
primary exposure pathway for BDE 209 in the United Kingdom.  For Europeans, food consumption 
appears to be the primary exposure pathway for most congeners (Abdallah and Harrad 2014; Law et al.
2008; Trudel et al. 2011).  Body burden data, as well as intake modeling, suggest that infants and toddlers
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6.  POTENTIAL FOR HUMAN EXPOSURE
have higher exposures to PBDEs as compared to older children or adults.  PBDE levels increase from
infant to toddler and then PBDE concentrations gradually decrease at older ages. Most studies indicate 
that concentrations of PBDEs in body fluids and tissues are a factor of 10–100-fold higher for individuals
living in the United States compared to individuals living in other regions of the world (e.g., Europe).  
6.2  RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing 
facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces,
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
The widespread use of PBDEs from the 1970s until 2013 resulted in their presence in the environment.  
PBDEs were released into the environment from their manufacture and use in a wide range of consumer
products (WHO 1994a).  PBDEs were used as additive flame retardants in thermoplastics.  Additive 
flame retardants are physically, rather than chemically, combined with polymers.  Thus, there is a 
possibility that some PBDEs congeners may diffuse out of the treated materials to some extent (EU
2001).  Although these substances are no longer manufactured in the United States and Europe, the
disposal of consumer products that contain penta-, octa-, and decaBDE will result in their continued 
release to the environment.  Waste from products containing PBDEs may be incinerated as municipal
waste, deposited in landfills, or discharged to municipal sewage-treatment plants (Darnerud et al. 2001).
6.2.1 Air
Estimated releases of 2,180 pounds (~0.9 metric tons) of decaBDE to the atmosphere from 34 domestic
manufacturing and processing facilities in 2014, accounted for about 1.5% of the estimated total
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6.  POTENTIAL FOR HUMAN EXPOSURE
environmental releases from facilities required to report to the TRI (TRI14 2016).  These releases are 
summarized in Table 6-1. There are no TRI data for penta- or octaBDE.
The estimated release of decaBDE from the 2014 TRI continues to reflect a decreasing trend as 
production slowed and was eventually discontinued in 2013.  The total on-site and off-site releases of
decaBDE since 1998 are illustrated in Figure 6-1 (TRI14 2016).  
No quantitative information was located on the releases of the pentaBDE technical mixtures to the 
atmosphere from its former production and use.  However, the release of pentaBDE technical mixtures to
air had the potential to occur during the curing phase, since the polyurethane foam was at elevated
temperatures (e.g., up to 160°C) for several hours during this phase.  Since pentaBDE technical mixtures
were additive flame retardants, they are subject to volatilization or leaching from the polymer matrix 
during the lifetime of the use of the foam article.  Losses of foam particles containing the substance (e.g.,
due to abrasion) may also occur.  However, most congeners in pentaBDE technical mixtures have very
low vapor pressures (see Table 4-3) and therefore, losses from polyurethane foam due to volatilization 
would be expected to be low.  Migration of pentaBDE technical mixtures from consumer products may be
a significant diffuse source of lower-brominated congeners of pentaBDE technical mixtures to the
atmosphere.  Although no studies were found that determined the migration rate of pentaBDE technical
mixtures from polymers into the air, estimates have been made.  The estimated migration rate for
pentaBDE technical mixtures is 0.39% per year (Danish EPA 1999).
Similarly, no quantitative information is available on emissions of octaBDE technical mixtures to the
atmosphere from production operations. The major sources of air emissions of octaBDE technical
mixtures were thought to be a result of grinding and bagging operations.  
The EPA National Center for Environmental Assessment (NCEA), Office of Research and Development
completed a comprehensive exposure assessment of PBDEs (EPA 2010).  A series of studies were
summarized that estimated the release of PBDEs from various products under laboratory conditions.  Two
computer workstations manufactured after 2000 consisting of a monitor, computer, keyboard, mouse, and 
printer were used for 93 and 150 days and PBDE concentrations were monitored during their operation.  
BDE 47, BDE 100, BDE 99, and BDE 85 concentrations in surrounding air were <0.3 ng/m3 for one of
the workstations; however, concentrations of BDE 47, BDE 100, and BDE 99 were 150, 28, and 
61 ng/m3, respectively, in air monitored for the second workstation.  An emission test was summarized
that used the back panel of a television set treated with octaBDE manufactured before 1979.  Maximum











   
 
 
   
       
 
    
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
 









   
   











































6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or
Use Decabromodiphenyl Ethera
Reported amounts released in pounds per yearb 
Total release
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek On- and off-site
AR 2 120 0 0 5,374 0 120 5,374 5,494
CA 1 1 0 0 139 0 1 139 140
CT 1 0 0 0 0 1,747 0 1,747 1,747
GA 3 347 0 0 2,917 0 347 2,917 3,264
IL 3 0 0 0 5 0 0 5 5
IN 1 5 0 0 0 0 5 0 5
KS 1 NR NR NR NR NR NR NR NR
MA 2 18 5 0 84 1 23 85 108
MS 1 28 0 0 0 0 28 0 28
NH 1 NR NR NR NR NR NR NR NR
NJ 1 0 0 0 0 150 0 150 150
NV 1 NR NR NR NR NR NR NR NR
NY 1 0 0 0 137 0 0 137 137
OH 4 505 0 0 75 112,501 505 112,576 113,081
PA 3 1,152 0 0 6,919 0 1,152 6,919 8,070
SC 5 0 0 0 67 0 0 67 67
TX 2 5 0 0 6,182 0 5 6,182 6,187
VA 1 0 0 0 2,504 0 0 2,504 2,504
Total 34 2,180 5 0 24,403 114,399 2,185 138,802 140,987
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 
exhaustive list.  Data are rounded to nearest whole number.
bData in TRI are maximum amounts released by each facility.
cPost office state abbreviations are used.
dNumber of reporting facilities.
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 
impoundments, other land disposal, other landfills.
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
kTotal amount of chemical transferred off-site, including to POTWs.
NR = not reported; RF = reporting facilities; UI = underground injection
Source:  TRI14 2016 (Data are from 2014)






















6.  POTENTIAL FOR HUMAN EXPOSURE
Figure 6-1.  Total On- and Off-Site Releases of Decabromodiphenyl Ether, 1998–
2014
Source: TRI14 (2016) 











     
    
 
   
 




    
   
 
     
     









   
    
     
 
     
 
    
    





6.  POTENTIAL FOR HUMAN EXPOSURE
concentrations of BDE 28, BDE 47, BDE 66, BDE 100, and BDE 99 were reported as 0.5, 8, 0.24, 0.27, 
and 0.84 ng/m3, respectively (EPA 2010). These data suggest that older treated consumer products may
continue to release PBDEs long after they were originally treated.
More generalized approaches were summarized that could be used to estimate the possible total
volatilization of PBDEs from treated plastic products (EPA 2010).  The EU utilized a regression derived 
equation to estimate the percentage loss of PBDE that volatilizes from plastic components treated with 
PBDEs:
PercentVolatilized =1.1×106 ×VP × SL 
where VP is the vapor pressure in units of mm Hg and SL is the
service life of the product, assumed to be 10 years
For instance, using a vapor pressure of 3.47x10-8 mm Hg for decaBDE, the volatilization loss after
10 years would be approximately 0.38% (EPA 2010).  Since approximately 6,710 metric tons of
decaBDE were used in plastics the EU before it was banned, the total loss to air over the assumed 10-year
lifetime would be approximately 25.5 metric tons (EPA 2010).  
Breivik et al. (2002) developed a regression-derived equation using the octanol-air partition coefficient 
(KOA) to estimate emission factors of PCBs from commercial sealants, which was also applied to estimate 
the emission factors of PBDEs
log EF = −0.839 × log KOA + 4.83 
The emission factor (EF) is the ratio of the mass of PBDE emitted divided by the mass PBDE used per
year.  Both equations above were used to estimate total emissions of penta-, octa-, and decaBDE from
products used in the United States (EPA 2010). 
6.2.2 Water
Estimated releases of 5 pounds (~0.002 metric tons) of decaBDE to surface water from 34 domestic 
manufacturing and processing facilities in 2014, accounted for <1% of the estimated total environmental
releases from facilities required to report to the TRI (TRI14 2016). These releases are summarized in
Table 6-1.
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Industrial and urban effluents are sources of PBDEs to surface waters and sediments.  Limited data on
industrial and urban effluents were located for the United States.  Hale et al. (2002) measured the 
concentration of PBDEs in soil and stream sediments collected near a polyurethane manufacturing plant
(near the Dan River, Virginia).  Summed concentrations of BDE 47, BDE 99, and BDE 100, the dominant
congeners in these samples, ranged from <1 to 132 µg/kg (ng/g) dry weight.  In 1995, sediment samples
were collected up- and downstream near an area where the Swedish plastics industry used brominated
flame retardants (Sellström and Jansson 1995; Sellström et al. 1998a).  Samples were analyzed for 
tetraBDEs (50 ng/g dry weight) and pentaBDEs (sum of three congeners, 2,300 ng/g dry weight).  These
PBDEs were found in higher concentrations downstream of the plant than upstream, which indicates that
the plastics industry was the most likely source of these compounds.  Surficial sediment samples were 
collected at eight locations along River Viskan near several textile manufacturing facilities that used
various brominated flame retardants in the production of textiles.  The concentrations of BDE 47,
BDE 99, BDE 100, and BDE 209 in sediments increased as samples were collected further downstream
where additional industries were located (Sellström et al. 1998a).  The lowest concentrations of PBDEs
were found upstream of the textile industries.  The combined concentration of BDE 47, BDE 99, and
BDE 100 ranged from not detected to 120 ng/g (µg/kg) dry weight; the concentration of BDE 209 ranged 
from not detected to 16,000 ng/g (µg/kg) dry weight.  Allchin et al. (1999) surveyed the concentrations of
PBDEs in sediments from several rivers and estuaries in Great Britain.  Sediments were collected
upstream and downstream of suspected sources of pentaBDE and octaBDE, including a manufacturer, 
several industries, landfills, and a reference site. The highest concentrations of BDE 47, BDE 99, 
pentaBDE (as BDE 71), and octaBDE (as BDE 79) were in sediments near or downstream from a 
manufacturing site at Newton Aycliffe in River Skerne.  The highest concentrations of decaBDE (as 
BDE 83) were found downstream of a sewage-treatment plant on River Calder.  High concentrations were 
also detected on River Skerne downstream of a manufacturing site.  BDE 99 concentrations were identical
or slightly higher than BDE 47 in most sediments (Allchin et al. 1999).  The sum of five pentaBDE
congeners (BDE 47, BDE 99, BDE 100, BDE 153, and BDE 209) ranged from 0.07 to 10.6 ng/g (μg/kg)
dry weight in freshwater sediments from Denmark (Christensen and Platz 2001).  The highest
concentrations were found in sediment close to populated areas.
A study conducted by the U.S. Geological Survey (USGS) analyzed waste water treatment plant (WWTP)
effluent from nine cities located in Oregon and Washington for anthropogenic compounds, including
PBDEs (USGS 2012).  Detectable levels in the low ng/L range were observed at every WWTP, and the 
highest concentrations measured were for congeners BDE 47, BDE 99, and BDE 100.  The greatest











     
  
     




     
    
      
 
 
   
  
  
       
  
    
    
    
    
  
  
   
 
    
 
    
  




6.  POTENTIAL FOR HUMAN EXPOSURE
PBDE concentrations were observed in Richland and Portland, Oregon.  The Portland PBDE values
showed varying concentrations as a function of the time of the day that samples were obtained. The 
lowest PBDE levels were observed in the morning hours and afternoon and then increased 2–4 times by
evening hours.  Shreder and LaGuardia (2014) measured PBDEs in the effluent of laundry waste water
from 20 residences located near the Columbia River in Washington state.  BDE 47 and BDE 209 were
detected in the laundry waste water effluent of all 20 homes at median levels of 1,230 and 140 ng/L, 
respectively.  The median concentration of total PBDE (sum of BDE 28, 47, 66, 85, 99, 100, 153, 154, 
183, 206, and 209) in the laundry waste water was reported as 2,550 ng/L.  BDE 47, BDE 49, and 
BDE 209 were also detected in the influents of two WWTPs near the Columbia River, Washington that
primarily serve residential households.  The sum total levels of BDE 47, BDE 49, and BDE 209 in the
influents of the WWTPs ranged from 35 to 206 ng/L.  Effluent PBDE levels were below the detection
limit at one WWTP and 28.2 ng/L at the other facility (Shreder and LaGuardia 2014).  
Although the available information indicates that leaching of PBDEs from landfills is minimal, movement
of polymer particles containing pentaBDE, octaBDE, and decaBDE commercial mixtures within the
landfill could lead to entry into leachate water of groundwater.  PBDEs have been detected in landfill
leachate and landfill related aqueous samples (Daso et al. 2013; Kwan et al. 2013; Odusanya et al. 2009;
Oliaei et al. 2010; Stubbings and Harrad 2014).  The presence of hydrophobic compounds like PBDEs in 
leachate is expected to be a result of enhanced leachability due to the presence of other constituents 
present in the leachate (Stubbings and Harrad 2014).  Mass transfer evaluation of PBDEs from e-waste 
found that lower pH conditions resulted in higher transfer of PBDEs to the aqueous phase, with the
highest concentration of PBDEs detected at pH 5 (Danon-Schaffer et al. 2013).  It is not currently
possible to assess the significance of this type of process.  Well-designed landfills already include 
measures to minimize leaching in general, and these measures would also be effective in minimizing
leaching of any PBDEs present (EU 2002, 2003a).
6.2.3 Soil 
Estimated releases of 24,403 pounds (~11.1 metric tons) of decaBDE to soils from 34 domestic
manufacturing and processing facilities in 2014, accounted for about 17% of the estimated total
environmental releases from facilities required to report to the TRI (TRI14 2016).  These releases are
summarized in Table 6-1.










    
     
 
  
   
    
    
 
    
    
     
    
     
  
   
     
   
  
 
   
 
     
 




   
   





6.  POTENTIAL FOR HUMAN EXPOSURE
PBDEs are released to land (i.e., landfills) as waste from their manufacture (both raw material and 
polymer) and as municipal wastes with the disposal of consumer products.  The disposal of consumer
products containing PBDEs is likely to increase worldwide due to rapid obsolescence of plastic products.
PBDEs may be present in biosolids and may therefore be inadvertently released to soils from the use of
biosolids as a nutrient amendment to agricultural soils.  Biosolids are sewage sludge that has been treated
to meet regulatory requirements for land application and must adhere to concentration limits and loading
rates for chemical pollutants, treatment and use requirements for controlling and reducing pathogens and 
the attraction of vectors, and management practices (NRC 2002).  PBDEs were detected in biosolids
destined for land applications in four different regions of the United States (Hale et al. 2001c).  The total
concentrations of pentaBDE in biosolids ranged from 1,100 to 2,290 μg/kg dry weight.  The concentration 
of decaBDE (BDE 209) varied widely among biosolids from different regions; the concentration of
BDE 209 ranged from 84.8 to 4,890 μg/kg dry weight in the biosolid samples.  Kim et al. (2013b)
analyzed 288 samples of sludge and biosolids from 15 WWTPs in Canada. Total PBDE levels were 230– 
82,000, 530–8,800, and 420–6,000 μg/kg, in primary sludge, waste biological sludge and treated biosolids 
respectively.  BDE 209, BDE 99, and BDE 47 were reported as the predominant congeners.  In the
biosolids, these three congeners accounted for approximately 80% of the total.  The median percentages
of BDE 209, BDE 99, and BDE 47 were 47, 16, and 16%, respectively, of the total amount of all PBDE
congeners in the biosolids.
6.3  ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
PBDEs exist in both the vapor phase and the particulate phase in the atmosphere. Particulate-phase 
PBDEs will be removed from the atmosphere by wet and dry deposition.  A vapor phase–particulate 
phase analysis of indoor air samples obtained from Birmingham, United Kingdom found that 66–86% of
BDE 47, 54–65% of BDE 99, 63–74% of BDE 100, <20–48% of BDE 153, and 37–48% of BDE 154 
existed in the vapor phase (Harrad et al. 2004).  Strandberg et al. (2001) performed a vapor phase– 
particulate phase analysis of outdoor air samples obtained from the Great Lakes region and found that
about 80% of BDE 47, 55–65% of BDE 100 and BDE 99, and 30% of BDE 154 and BDE 153 existed in 
the gas phase.  Several PBDE congeners have been detected in Arctic regions, suggesting that these
substances undergo aerosol-mediated, long-range atmospheric transport.  BDE 47, BDE 99, BDE 100, 
and BDE 209 were measured in air, snow, and sea ice samples throughout western Antarctica between 
2001 and 2007 (Dickhut et al. 2012).  Fourteen PBDE congeners are monitored for, and have been 
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detected at, Alert and Nuuk monitoring stations as part of the Arctic Monitoring and Assessment
Programme (Hung et al. 2010), indicating the importance of long-range transport as an environmental fate
process for these substances. 
In water, PBDEs are expected to adsorb strongly to suspended solids and sediment, and bioconcentrate in 
aquatic organisms.  The volatilization of PBDEs from water to air is expected to be attenuated by
adsorption in the water column.  In soil, PBDEs are adsorbed strongly and will be immobile.  They are
not likely to leach into groundwater.  Volatilization of PBDEs from soil to air is limited by the low
volatility of PBDEs and strong adsorption of PBDEs to soil.  There is potential for PBDEs to volatilize
from soil to air, particularly if the organic carbon content of the soil is low, as demonstrated by PBDEs
being monitored in air as described in Section 6.4.1.
PBDEs adsorb strongly onto suspended solids and sediments in the water column.  Volatilization of
PBDEs from water surfaces will be attenuated by adsorption, and is thus not an important fate process.  
Sediment-water partition coefficients (Kp) have been measured for several components of commercial
pentaBDEs (Watanabe 1988).  Kp values for tetra-, penta-, and hexaBDEs are 28,300, 49,200, and 
62,700 L/kg, respectively, which suggest strong partitioning to sediment.  Log organic carbon-water
partition coefficients (Koc) were estimated for PBDEs:  di- (4.11); tri- (4.35–4.41); tetra- (4.57–4.73);
penta- (4.89–5.17); hexa- (5.11–5.69); octa- (5.92–6.22); and deca- (6.80) (Lyman et al. 1990).
DecaBDE and octaBDE commercial products do not bioconcentrate in fish to the same extent as
congeners from the penta mixture. Monitoring data show that higher-brominated congeners such as BDE
209 are taken up in marine organisms.  The reported bioconcentration factors (BCFs) for commercial
decaBDE mixtures are typically <50 (Hardy 2002b). A single study on a mixed range of PBDEs, 
between hexaBDE and decaBDE, indicated little bioconcentration in carp (e.g., Cyprinus carpio) with a
BCF of <4 after 8 weeks of exposure (WHO 1994a). A bioconcentration study was carried out with 
rainbow trout under static conditions.  The concentration of 14C-decaBDE/L in water was 20 μg.  Fish 
were exposed to decaBDE for 0, 0.5, 1, 2, 4, 6, 12, 24, or 48 hours.  For each of the exposure periods, 
there was no measurable accumulation of decaBDE in flesh, skin, or viscera (WHO 1994a). The
bioconcentration of BDE 209 was studied by exposing zebrafish embryos to BDE 209 at concentrations
of 0, 0.08, 0.38, and 1.92 mg/L until 14 days post-fertilization (Chen et al. 2012).  BCFs of 29, 9, and 
20 were calculated for exposure of 0.08, 0.38, and 1.92 mg/L, respectively.  Several lower-brominated 
congeners were also detected in the larvae, with the main metabolite being nonaBDE.  These results are 
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consistent with other finding that indicate that BDE 209 was bioavailable and taken up by zebrafish larvae
from spiked sediments (Garcia-Reyero et al. 2014).  
An abundance of monitoring data illustrates the uptake of lower-brominated diphenyl ethers by aquatic
organisms, which results in bioconcentration (see Section 6.4.4).  The commercial pentaBDE product
undergoes bioconcentration with a BCF of approximately 14,000 (Hardy 2002b).  Congener components
of pentaBDE commercial product bioconcentrate to different extents.  For example, approximately 50– 
70% of PBDEs detected in fish is a single isomer (BDE 47).  The next most prominent isomer is typically
BDE 99 followed by BDE 100.  In a laboratory study of Baltic blue mussels (Mytilus edulis L), BCFs
from water absorption were found to be 1,300,000 for BDE 47, 1,400,000 for BDE 99, and 1,300,000 for 
BDE 153 (Gustafsson et al. 1999).  At several sites along the coast and in the Schelde Estuary (the 
Netherlands), BCFs for blue mussels were determined (Booij et al. 2000).  The maximum BCFs were
1x109 for BDE 99 and BDE 100, ≈2.5x107 for BDE 28, ≈2.5x108 for BDE 47 and ≈1.6x108 for BDE 153.  
Biomagnification of PBDE congeners BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, and BDE 155 in
the marine food chain was demonstrated by comparing concentrations in the blubber of harbor seals with 
their prey fish (Shaw et al. 2009).  Biomagnification factors (BMFs) from fish to seals were 21.4–109, 
17.9–213, 6.9–29.8, 148–700, 11.3–447, and 12.4–236 for BDE 47, BDE 99, BDE 100, BDE 153, BDE
154, and BDE 155, respectively (Shaw et al. 2009).  BDE 209 was detected at measurable concentrations
in fish and seal tissue, although it did not appear to biomagnify like the other congeners.  A laboratory
study was conducted using juvenile carp fed BDE 209 amended food over a 60-day period (Stapleton et
al. 2004).  BDE 209 was not highly accumulated in the carp; however, seven debrominated lower
congeners not initially present (penta- to octaBDEs) were detected in whole fish samples and liver tissue,
suggesting that while BDE 209 did not accumulate in the fish, it may be a source of lower-brominated 
metabolites in aquatic organisms. 
Other studies have demonstrated the biomagnification of lower-brominated PBDE congeners.  Haglund et
al. (1997) examined the concentrations of tetra- to hexaBDEs in herring, salmon muscle, and gray and 
ringed seals collected along the Swedish coast of the Baltic Sea between 1981 and 1988.  The
concentrations of tetraBDEs (e.g., BDE 47) were found to increase with trophic level.  Concentrations of
PBDEs in herring and their predators, grey seal and guillemot, all collected at the same location of the 
Baltic Sea, have been compared to estimate potential biomagnification (de Wit 2002).  The herring were
caught in the autumn of the same year as guillemot egg collection (1987).  BMFs for guillemot egg versus 
herring were 19, 17, and 7.1 for BDE 47, BDE 99, and BDE 100, respectively.  Burreau et al. (2000)
analyzed small herring and salmon from the Atlantic Ocean (near Iceland) for several PBDEs. The 
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calculated biomagnification factors for Atlantic salmon versus small herring were 3.5, 3.8, and 6.0 for 
BDE 47, BDE 99, and BDE 100, respectively.  These authors concluded that biomagnification was
occurring for the lower-brominated congeners.
Biosolids from the Metropolitan Water Reclamation District of Greater Chicago, Stickney WWTP,
collected between 2004 and 2007, were applied at two sites at a depth of 15−20 cm (Hale et al. 2012). 
Maximum total soil PBDE concentrations were 565 and 1,810 μg/kg for high clay soil and sandy soil,
respectively.  Corn grown at the two sites after the third year of annual biosolid application was evaluated 
for PBDEs using GC/MS with ENCI.  PBDEs were not detected in the 46 grain, stover, or root samples
examined, suggesting little uptake by corn from soils amended using biosolids.  However, earthworms
exposed to PBDE containing biosolids were shown to accumulate these substances (Gaylor et al. 2013).  
Earthworms were exposed to a Class B anaerobically digested biosolid (ADB) containing
5,560±440 μg/kg dry weight total penta congeners (BDE 47, 99, 100, 153, 154, and 183) and a composted 
biosolid (CB) containing 1,130±79 μg/kg dry weight total penta congeners over the course of a 28-day 
incubation period.  Total penta PBDE body burdens in worms exposed to ADB amended soils were about
5 times greater than those in the substrate, and worms exposed to CB amended soils had body burdens
about 4 times greater than in the substrate.
6.3.2 Transformation and Degradation
Photolysis appears to be the dominant transformation process for PBDEs.  However, the importance of
photochemical transformation reactions in the environment cannot be determined due to lack of
information.  Based on a very limited number of studies, biodegradation does not appear to be significant
for PBDEs.
6.3.2.1  Air
In air, PBDEs may undergo indirect photolysis with hydroxyl radicals or direct photolysis with sunlight.  
Vapor-phase PBDEs may be degraded in the atmosphere by reaction with photochemically produced
hydroxyl radicals.  The half-lives for this reaction in air are estimated to be 29, 140, and 476 days, 
respectively, for penta-, octa-, and decaBDE homologs, calculated using a structure estimation method 
(Meylan and Howard 1993).  This estimation is calculated using an atmospheric concentration of
5x105 hydroxyl radicals per cm3 and is based on a 24-hour day of sunlight.  The half-lives of PBDEs that 
are expected to be present in the particulate phase in the air will be longer than the estimated half-lives 
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calculated for the gas-phase reaction.  Thus, for the higher-brominated PBDEs (e.g., octa- and 
decaBDEs), indirect photolysis with hydroxyl radicals will be less important.  
In water, some PBDEs have been reported to undergo direct photolysis (Hua et al. 2003).  Likewise,
PBDEs present in the vapor phase (e.g., tetraBDE) or as particulates (e.g., decaBDE) may also undergo
photolysis in the atmosphere.  However, the rate and extent of the photolysis of PBDEs in air cannot be
evaluated due the lack of information.
6.3.2.2  Water
PBDEs absorb light in the environmental spectrum. Hua et al. (2003) found that decaBDE and the
commercial octaBDE absorbed light up to 325 nm, which indicates that these compounds may be
susceptible to photodegradation at environmental wavelengths (Hua et al. 2003).  Di- and tetraBDEs were 
reported to absorb minimal light at wavelengths >300 nm.  This trend suggests that the lower-brominated 
diphenyl ethers (e.g., pentaBDE commercial mixtures) will be less susceptible to photolysis compared to
octaBDE and decaBDE commercial mixtures.
PBDEs undergo debromination by direct photolysis in organic solvents and organic solvent:water
mixtures.  Laboratory studies of the photolytic breakdown of decaBDE in toluene have shown that it is
debrominated by ultraviolet (UV) light to hexaBDE and that photolysis occurs very rapidly (Sellström et
al. 1998b).  The photolysis half-life in toluene was <15 minutes. However, the amounts of lower­
brominated congeners appear to be small (EU 2002).  The photolysis of decaBDE (and tetra-, penta-, 
hexa-, hepta-, and octaBDEs) was reported in an 80:20 mixture of methanol:water at wavelengths
>290 nm (EU 2002). The rate of photodegradation was found to increase with increasing degree of
bromination.  DecaBDE was found to degrade with a half-life of around 30 minutes, while half-lives for
tetra-, penta-, hexa-, hepta-, and octaBDEs were 12–16 days, 2.4 days, 1.2 days, 1.2 days, and 5 hours, 
respectively.  The decomposition products of decaBDE were identified to be PBDEs (with >6 bromine
atoms per molecule) and polybrominated furans (with <6 bromine atoms per molecule).  Results of this
study indicate that the photochemical stability of PBDEs increases with decreasing bromination (EU
2002).  Rayne et al. (2003b) reported that BDE 15 photodegraded in organic (acetonitrile-methanol) and
aqueous (H2O:acetonitrile; 1:1 v/v) solvent systems at a wavelength of 300 nm.  Reductive bromination
was reported to be much slower in the aqueous system (e.g., 73% remained after 300 minutes) compared 
to the organic system (where 51 and 41% remained after 30 minutes).  However, these studies were 
conducted in the presence of organic solvents, which are not representative of conditions found in the
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environment.  Organic solvents can act as hydrogen donors in photolysis reactions, which will potentially
affect the distribution of products formed.
The photolysis of PBDEs was examined under environmentally relevant conditions.  Hua et al. (2003)
studied the degradation of decaBDE in several different experiments:  (1) on humic acid-coated silica 
particles; (2) on glass surfaces in contact with aqueous humic acid solutions; and (3) on glass surfaces in
contact with water.  DecaBDE dissolved in toluene was deposited on the solid substrate under a stream of
nitrogen (to evaporate the solvent) and then desiccated to remove any residual toluene.  The adsorbed 
decaBDE on the solid substrate was then inundated with the aqueous test solution, followed by irradiation 
for the duration of the test period.  In all experiments, natural sunlight (location, 40° 26’ N, 86° 55’ W) 
was used.  The extent of degradation was determined using HPLC with UV detection or by GC/MS.  In 
the first experiment, solar irradiation of decaBDE adsorbed onto humic acid-sand indicated that the 
photolysis of decaBDE was slow.  After 96 hours of exposure to sunlight, 88% of initial decaBDE
remained on the coated sand.  There is some evidence that lower-brominated congeners (e.g., BDE 155)
were formed in the experiment (EU 2002).  In the second experiment, decaBDE was adsorbed on glass
tubes containing a humic acid.  In this study, the concentration of decaBDE decreased relatively quickly
over the first 24 hours of exposure, after which, the concentration remained stable.  Bromide ion 
accumulated at an almost linear rate from start to end of the 72-hour exposure period.  Approximately
70% of the initial decaBDE remained after the 72-hour exposure.  The difference in kinetics (for the
disappearance of decaBDE vs. the appearance of bromide ion) suggests that after the initial degradation of
decaBDE, bromide ion was generated by the degradation of lower-brominated diphenyl ether congener
products (possibly octa- and nonaBDEs).  Bromide ion mass balance for the system indicated that 70% of
the total bromine present was accounted for by decaBDE or bromide, with the remaining 30% present as
unidentified compounds.  In the third experiment, Hua et al. (2003) investigated the photodegradation of
decaBDE adsorbed on glass tubes, which were filled with aqueous solutions (without humic acid).  The
result of this test showed a much more rapid loss of decaBDE than found in the analogous test using
humic acid solutions.  Approximately 29% of the initial decaBDE present remained after 72 hours.  The
rate of decaBDE loss and bromide ion accumulation was relatively constant over the entire 72-hour test
period.  Mass balance indicated that approximately 50% of the total bromine was present as either
decaBDE or bromide ion, while the remaining 50% was possibly unidentified nona- and octaBDE
congeners.  The difference between the tests using glass tubes with and without humic acid solution is 
possibly due to the absorption of light by humic acids, which may attenuate the degradation process.  
These studies indicate that adsorbed decaBDE may undergo photolysis forming octa- and nonaBDEs
under somewhat environmentally relevant conditions.  Lower-brominated diphenyl ether congeners are
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also formed although only to a minor extent.  These tests do not provide evidence that lower-brominated 
diphenyl ethers (e.g., tetra- and pentaBDEs) are a major degradation product of decaBDE (EU 2002).  
There is also insufficient information from these studies to estimate the rate of photolysis or if
intermediate degradation products build up after long-term exposures (EU 2002). 
Söderström et al. (2004) examined the time course of photolysis of decaBDE (BDE 209) in toluene, on 
silica gel, sand, sediment, and soil using artificial sunlight and on the natural matrices (e.g., sediment, 
soil, and sand) using natural sunlight.  On natural samples, BDE 209 was first dissolved in toluene and 
then deposited on the natural matrix. The toluene was allowed to evaporate, and then the sample was 
reconstituted with water to resemble natural conditions.  BDE 209 was photolytically labile and formed 
debromination products in all matrixes studied.  Nona- to tetraBDEs were formed as well as some 
PBDFs.  The half-lives in toluene and on silica gel were <15 minutes, and half-lives on other matrices 
ranged from 40 to 200 hours.  No differences were observed in the debromination patterns under different
matrices or light conditions. These experiments show that photolytic debromination of BDE 209 is a
possible pathway for the formation of more bioavailable, lower-brominated PBDEs.  However, the most
commonly found BDEs in environmental samples (e.g., BDE 47, BDE 99, and BDE 100) were only
formed to a minor degree (Söderström et al. 2004). 
Following the methodology described for decaBDE, photolysis experiments were conducted on BDE 47
(EU 2002).  BDE 47 was adsorbed on glass tubes filled with an aqueous solution and exposed to natural
sunlight.  After 72-hours of exposure, 30% of the initial BDE 47 remained.  The rate of disappearance of
BDE 47 was comparable to that found for decaBDE under similar test conditions. Accumulation of
bromide was initially slow with the rate increasing after 24 hours while the disappearance of BDE 47 was
initial rapid over the first 24 hours.  Using GC/MS, the authors concluded that 2,4,4’-triBDE was being
formed during this reaction and that removal of bromine atoms ortho to the ether functionality may be a
significant reaction pathway for removal of bromine atoms under the conditions of this study.  This study
suggests that adsorbed BDE congeners, like decaBDE, may undergo photolysis under somewhat
environmentally relevant conditions (EU 2002).
PBDEs are not expected to undergo abiotic hydrolysis under environmental conditions due to the lack of
hydrolysable functional groups (Wolfe and Jeffers 2000).
PBDEs are unlikely to biodegrade rapidly in the environment under aerobic conditions.  PentaBDE did 
not undergo biodegradation (determined by CO2 evolution) after 29 days in an Organisation for Economic
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Co-operation and Development (OECD) 301B ready biodegradation test (EU 2001).  The substance tested
was a composite sample from two producers with the following composition:  33.7% tetraBDE, 54.6%
pentaBDE, and 11.7% hexaBDE.  The test was extended to 93 days to allow sufficient opportunity for
adaptation to occur. At the end of 93 days, 2.4% of the theoretical amount of CO2 had been evolved.  
Thus, pentaBDE was determined to be not readily biodegradable.  No degradation (as oxygen uptake) was 
seen for octaBDE after 28 days in an OECD 301D ready biodegradation test (EU 2003a).  Thus, octaBDE
was determined to be not readily biodegradable.  The biodegradability of decaBDE has been studied 
under aerobic conditions using an activated sludge inoculum (EU 2002).  DecaBDE at 100 mg/L was 
incubated with activated sludge (at 30 mg/L) over a 2-week period using a method similar to an OCED 
301C MITI test.  No degradation (as measured by biochemical oxygen demand) was observed.  Thus, 
decaBDE was determined to be not readily biodegradable.
No data on biodegradation of pentaBDE and octaBDE commercial mixtures under anaerobic conditions
are available.  An anaerobic degradation study was carried out with BDE 47 using a mixture of
14C-labeled and unlabeled compound (EU 2003a).  The test was carried out using a sediment-water
(Schuykill River, Pennsylvania) inoculum.  After 32 weeks, it appeared that no significant degradation of
BDE 47 had occurred.  However, the analytical method (i.e., HPLC using radiometric detection) used in 
this test indicated that some unidentified products had been formed in samples taken after 32 weeks.
From these results, it is clear that BDE 47 has the potential to degrade slowly under anaerobic conditions
(EU 2003a).  Rayne et al. (2003b) reported that 4,4’-diBDE undergoes reductive debromination under
anaerobic conditions.  Debromination proceeds with replacement of a bromine atom by a hydrogen atom.  
The authors suggest that anaerobic debromination may sequentially debrominate BDE 15 to the parent
diphenyl ether. 
The anaerobic biodegradability of 14C-labeled decaBDE was studied over a period of 32 weeks (EU 
2002).  The test chambers consisted of 500 mL bottles containing 300 mL of sediment (Schuykill River, 
Pennsylvania) prepared under anaerobic conditions. The test chambers were incubated at 25°C and in the 
dark during the test.  After the 32-week period, <1% of the total radioactivity added was found as 14CO2 
and 14CH4 indicating that essentially no mineralization had occurred.  GC/MS results showed no evidence
for the formation of lower-brominated congeners from decaBDE under the conditions of this test (EU
2002). 
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6.3.2.3  Sediment and Soil
Information on the transformation and degradation of PBDEs in soil is limited.  The extent to which 
PBDEs undergo direct photolysis in soils and sediment is unknown.  However, sunlight would only
penetrate the uppermost few millimeters of soil and will not impact sediment.  Photolysis of PBDEs is
possibly important for land-applied sewage sludge contaminated with PBDEs.  However, no information 
was available on this possibility.  Based on studies in water, most PBDEs biodegrade slowly in soils or
sediment under aerobic or anaerobic conditions.  The anaerobic biodegradation of BDE 47, BDE 99, and 
BDE 209 was studied using microcosms prepared from loam sediment (pH 6.3, 16.4% organic carbon)
obtained from a pond located in West Lafayette, Indiana (Tokarz et al. 2008).  After an 8-month 
incubation period, microcosms containing BDE 47 showed variable losses (up to 30% of the initially
applied amount) of the parent congener without concurrent increases in expected debromination products, 
suggesting that other degradation mechanisms other than reductive debromination may have occurred.  
Only about 3% degradation of BDE 99 was observed after 8 months, with BDE 28 being the most
important debromination product.  After 10 months, only slight decreases in the initial BDE 209 
concentration was observed in six microcosms, and the half-life of this congener was estimated to range 
from 6 to 50 years; however, some aged microcosms exhibited greater degradation after 3.5 years, 
yielding nine degradation products (Tokarz et al. 2008).  
6.3.2.4  Other Media
The bacteria, Pseudomonas aeruginosa, that was isolated from an electronic waste dismantling area was 
capable of degrading BDE 209 under aerobic conditions, especially in the presence of co-metabolic 
substrates such as glucose (Shi et al. 2013).  Nonabromodiphenyl ethers (BDE 208, BDE 207), four
octabromodiphenyl ethers (BDE 203, BDE 202, BDE 197, BDE 196), and one heptabromodiphenyl
ethers (BDE 183) were noted as degradation products.
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to PBDEs depends in part on the reliability of
supporting analytical data from environmental samples and biological specimens.  Concentrations of
PBDEs in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits 
of current analytical methods.  In reviewing data on PBDEs levels monitored or estimated in the
environment, it should also be noted that the amount of chemical identified analytically is not necessarily
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equivalent to the amount that is bioavailable. The analytical methods available for monitoring PBDEs in
a variety of environmental media are detailed in Chapter 7.
Monitoring studies indicate that PBDEs are transported globally.  Atmospheric, water, and biota
concentrations of PBDEs tend to be dominated by lower-brominated congeners (e.g., BDE 47).  
Sediments tend to be dominated by higher-brominated congeners (e.g., BDE 209).  Biota monitoring
studies indicate that PBDE concentrations have increased since the late 1970s, with lower-brominated
congeners (e.g., BDE 47) being preferentially bioconcentrated.  Studies indicate that PBDE
concentrations increase with respect to trophic level; organisms that reside higher on the food chain tend 
to have higher concentrations of PBDEs. 
6.4.1 Air
PBDEs will exist in both the vapor and particulate phase in both indoor and outdoor air (Harrad et al. 
2004).  The higher-brominated congeners (hepta-deca) have lower vapor pressures and partition more to 
the particulate phase, while the lower-brominated substances have a greater tendency to partition to the 
vapor phase.  Concentrations of PBDEs in outdoor air in the United States are typically in the range of
20–200 pg/m3, with BDE 47 and BDE 99 being the congeners most often detected (EPA 2010).  
Monitoring data from the 1990s showed infrequent detections of decaBDE; however, more recent
monitoring data have shown an increase in the frequency of detection of this substance both in outdoor
and indoor air samples (EPA 2010; Hoh and Hites 2005).  Monitoring data from Europe and Asia suggest
lower concentrations of PBDE in air samples as compared to data obtained in the United States.  
Representative concentrations of PBDEs in outdoor air samples obtained at various locations are
summarized in Table 6-2.  Air samples obtained from urban (Chicago, Illinois), rural (Sleeping Bear
Dunes, Michigan and Sturgeon Point, New York), and remote (Eagle Harbor, Michigan) shorelines of the
U.S. Great Lakes all contained quantifiable concentrations of BDE 47, BDE 99, BDE 100, BDE 153, and 
BDE 154 (Dodder et al. 2000; Strandberg et al. 2001).  The most significant congeners were BDE 47 and 
BDE 99.  Air measurements were averaged over a 3-year period between 1997 and 1999.  The
concentration of total PBDEs ranged from 5.5 pg/m3 in rural environments to 52 pg/m3 in urban air from
Chicago, Illinois.  The concentration of BDE 47 was 48 pg/m3 observed near Chicago, Illinois.  The
average concentration of decaBDE at the remote and rural locations was <0.10 pg/m3 for each of the years 
investigated. The average concentration of decaBDE in the particulate phase at the urban location ranged
from 0.20 to 0.35 pg/m3 (Strandberg et al. 2001).














       
 
       
 
 
        
 
       
 
 
      
 
 
      
         
 
 
       
 
 
       
         
 
 
       
 
 
      
 
 
      
       
 
 
      
 
 
      
 
 
      
 
      
 
 
      
        
 










6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-2.  Concentrations (pg/m3) of Several Polybrominated Diphenyl Ethers
(PBDEs) in Air Samples
Location BDE 47 BDE 99 BDE 100 BDE 209 ΣPBDEsa Reference
Urban, United 
States
48 25 3.0 No data 77* Dodder et al. 2000
Rural, United
States
6.2–9.2 4.3–5.0 0.6–0.9 No data 2–4.8* Dodder et al. 2000
Remote, United 
States
3.7 2.6 0.33 No data 6.9* Dodder et al. 2000
Alert, Northwest
Territories Canada
No data No data No data No data 1–28 Alaee et al. 1999
Eagle Harbor,
Wisconsin
2.9 2.1 0.28 <0.10 5.5* Strandberg et al. 2001
Chicago, Illinois 3.9–42 2.4–15 0.68–3.3 1.5–878 13–980 Hoh and Hites 2005
Sleeping Bear
Dunes, Michigan
0.51–27 0.32–23 0.030–5.1 <0.29–21 1.4–61* Hoh and Hites 2005
Bloomington,
Indiana
1.9–21 1.2–11 0.26–2.75 <0.29–21 6.4–44* Hoh and Hites 2005
Rohwer, Arkansas 1.2–42 0.87–35 0.17–3.7 <0.10–135 2.7–165* Hoh and Hites 2005
Cocodrie,
Louisiana
2.0–24 0.89–11 0.21–2.7 <0.10–14 5.1–42* Hoh and Hites 2005
Sturgeon Point,
New York
3.8 2.8 0.39 <0.10 7.2* Strandberg et al. 2001
Sleeping Bear
Dunes, Michigan
8.4 5.3 0.80 <0.10 15* Strandberg et al. 2001
Chicago, Illinois 33 16 2.0 0.20–0.35 52* Strandberg et al. 2001
Ammarnäs,
Sweden
6.3 1.6 0.4 No data 8.3 de Wit 2000, 2002
Hoburgen,
Sweden
0.7 0.35 0.07 No data 1.1 de Wit 2000, 2002
Stoke Ferry,
United Kingdom
4.7–50 5.5–13 1.1–3.9 No data 6.7–58 Peters et al. 1999
Hazelrigg, United 
Kingdom
3.2–61 3.1–22 0.62–5.4 No data 4.1–69 Peters et al. 1999
Dunai Island,
Russia
No data No data No data No data 1–8* Alaee et al. 1999
Arctic 2.2–2.8 2.0–2.3 0.40–0.47 1.0–1.8 6.7–8.6* Hung et al. 2010
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).
BDE = brominated diphenyl ether
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6.  POTENTIAL FOR HUMAN EXPOSURE
PBDEs were monitored at five different locations (Chicago, Illinois; Sleeping Bear Dunes, Michigan;
Bloomington, Indiana; Rohwer, Arkansas; and Cocodrie, Louisiana) across the United States from 2002 
to 2003 (Hoh and Hites 2005).  Total PBDE concentrations at the urban site (Chicago, Illinois) were 3– 
6 times greater than the other locations, with BDE 47, BDE 99, BDE 100, and BDE 209 being the most
abundant congeners at all five locations.  DecaBDE concentrations as high as 960 and 410 pg/m3 were 
observed in Chicago on two dates in 2003.
Throughout the year of 1997, air samples were taken from a rural site in southwestern England called
Stokes Ferry and a semirural site in northwestern England called Hazelrigg and analyzed for PBDEs 
(Peters et al. 1999).  Tri- and heptaBDEs were detected; the combined concentrations of BDE 47,
BDE 99, and BDE 100 ranged from 7 to 69 pg/m3 at Hazelrigg and from 6 to 58 pg/m3 at Stoke Ferry (de 
Wit 2002).  PBDEs have also been measured in air samples taken from remote stations in the Arctic (e.g.,
Alert, Northwest Territories, Canada; Dunai Island, eastern Siberia, Russia) between January 1994 and 
January 1995 (de Wit 2002).  The total concentration of several di- to hexaBDEs ranged from 1 to 
4 pg/m3 at Alert for the majority of the year; however, in July 1994, the concentration was 28 pg/m3.  At
Dunai, the major congeners found were BDE 47 and BDE 99.  In Sweden during 1990–1991, air samples
collected from Ammarnäs in the northern mountains and Hoburgen on the southern tip of Gotland in the
Baltic Sea, had measurable amounts of BDE 47, BDE 99, and BDE 100 (de Wit 2002).  Total PBDE
concentrations were approximately 1 and 8 pg/m3, respectively.  The concentration of BDE 47 was found 
to be highest in the gas phase, while BDE 99 and BDE 100 were highest in the particulate phase.  No 
decaBDE was found, although the limit of detection limit for decaBDE is much higher than for the lower­
brominated diphenyl ethers.
Indoor air concentrations of PBDEs vary depending upon potential sources such electronics or foams used
in upholstery stuffing for furniture that were treated with PBDEs (EPA 2010; Harrad et al. 2006; Hazrati
and Harrad 2006).  Harrad et al. (2004) found a significant positive correlation between PBDE
concentrations in indoor air and both the number of electrical appliances and the number of chairs
containing FPUF.  Concentrations of tetra- and pentabrominated congeners (BDE 47, BDE 99, and BDE
100) in indoor air were always higher than those detected in outdoor air.  On average, indoor air
concentrations were 150, 120, and 140 times higher than outdoor air for BDE 47, BDE 99 and BDE 100, 
respectively.  Indoor air concentrations of PBDEs also tended to be higher in workplace environments as 
compared to domestic residences; however, these concentrations could vary substantially from one room
to another (Harrad et al. 2004).  Air samples collected from 31 homes, 33 offices, and 25 automobiles in 
the West Midlands, United Kingdom were analyzed for the presence of PBDEs (Harrad et al. 2006).
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Total PBDE concentrations in samples obtained from homes ranged from 4 to 245 pg/m3 (24 pg/m3, 
median), while concentrations in offices and cars ranged from 10 to 1,416 (71 pg/m3, median) and from
4 to 1,416 pg/m3 (41 pg/m3, median), respectively.  PBDE congeners 47 and 99 were reported as the
major contributors to the overall total (Harrad et al. 2006). Although the previous study reported a
statistically significant positive correlation between the PBDE concentrations and the number of electrical
devices and FPUF-containing chairs (Harrad et al. 2004), no clear statistical evidence of such correlations 
were reported in these indoor air environments (Harrad et al. 2006; Hazrati and Harrad 2006).  PBDE
concentrations in the air of one office did drop dramatically after an older computer was replaced by a 
relatively newer one and a statistically significant positive correlation was observed between automobile 
age and PBDE concentrations when two highly contaminated outliers were removed from the analysis.  
Further observations indicated a seasonal variation of the PBDE concentrations in indoor air, with higher
concentrations being observed during the summer months (Hazrati and Harrad 2006).  BDE 47, BDE 99, 
BDE 100, BDE 183, and BDE 209 were detected in 63, 22, 29, 32, and 42% of air samples taken aboard 
aircraft during routine flights (Allen et al. 2013).  Concentrations ranged from below the detection limits
to a maximum concentration of 2,100,000 pg/m3 for BDE 209.
Concentrations of PBDEs were measured in floor dust, indoor air, ventilation filter dust and carpets in 
10 buildings located in Michigan (Batterman et al. 2010).  Median concentrations of total PBDEs were
reported as 8,754 ng/g in settled dust, 1,250 pg/m3 vapor-phase air, and 155 pg/m3 particulate-phase air.
The highest concentrations of PBDEs were generally noted in rooms that contained sources such as
computer servers.  Monitoring data from one building that was built in 2006 indicated a very low
concentration of PBDEs in settled dust at the time it was constructed (145 ng/g); however, these 
concentrations increased exponentially to >10,000 ng/g 5–8 months after the building was opened.  
Despite the voluntary phase-out of pentaBDE and octaBDE in 2004, high concentrations of congeners
associated with these mixtures (BDE 47, BDE 99, BDE 100, BDE 153, and BDE 203) were detected in 
dust and air samples, suggesting that there are significant sources of these PBDEs in products that remain
in the market and that were used in this building even after the phase out in 2004.
6.4.2 Water
Due to the hydrophobic nature of PBDEs, this class of compounds is expected to be present in water at
very low concentrations or at concentrations below the limit of detection of acceptable analytical
methods.  In 1999, the concentration of PBDEs in Lake Ontario surface waters ranged between 4 and 
13 pg/L with ~90% in the dissolved phase (Luckey et al. 2001).  BDE 47 and BDE 99 were the most
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abundant congeners, together making up >70% of the total PBDEs.  Streets et al. (2006) reported 18 and 
3.1 pg/L average concentration of ƩPBDEs (BDE 47, BDE 66, BDE 100, BDE 99, BDE 85, BDE 154, 
and BDE 153 of pg/L) in Lake Michigan Water for the dissolved phase and particulate phase, 
respectively.  In Japan, PBDEs were not detected in 75–200 water samples (ENVIRON 2003a).  In nine
English freshwater lakes grab samples were obtained from April 2008 to February 2012, average
concentrations of the sum total of PBDEs, which included BDE 17, BDE 28, BDE 49, BDE 47, BDE 66, 
BDE 100, BDE 99, BDE 85, BDE 154, and BDE 153, ranged from 41.5 to 73.3 pg/L (Yang et al. 2014).  
The EPA utilized data from the San Francisco Monitoring Program for Trace Substances in surface water
to estimate possible concentrations of PBDEs that might be found in drinking water.  Thirty-three water
samples were obtained from the San Francisco Estuary, with total PBDEs concentrations ranging from
3 to 513 pg/L, and a mean concentration of 146.2 pg/L (Oros et al. 2005).  It was reported that the most
frequently detected congeners were BDE 47, BDE 99, and BDE 209. The source of these PBDEs was 
most likely effluent from municipal treatment plants.  Concentrations of PBDEs monitored in the
Spokane River in the state of Washington exhibited seasonal variation (Furl and Meredith 2010).  
Dissolved PBDE concentrations collected in the fall of 2005 were approximately 6 times greater
(926 pg/L) as compared to concentrations observed in the spring of 2006 (146 pg/L).  The variation in 
PBDE concentrations were likely a result of dilution of local sources in the spring from increased flow
due to snowmelt in the upper watershed.  
6.4.3 Sediment and Soil
Hale et al. (2002) reported the concentration of PBDEs in soil samples collected in the vicinity of a
polyurethane foam-manufacturing facility.  Concentrations in these soils are likely to be higher than those 
to be expected in rural and potentially urban areas of the United States.  Total PBDE concentrations in 
these samples ranged from not detected to 76 μg/kg dry weight.  BDE 99 was the predominant congener
in soil followed by BDE 47 and BDE 100.  Concentrations of total PBDEs in soil obtained from a large
automotive shredding and metal recycling facility in Brisbane, Australia ranged from 29 to 726 ng/g dry
weight as compared to background concentrations at an uncontaminated site (0.2–2 ng/g dry weight)
(Hearn et al. 2013).  BDE 209 was the predominant congener in dust, soil, and air at the facility.
In Eastern China, near dismantling areas for waste electrical and electronic equipment that are considered
a potential exposure source of PBDEs, 45 farmland soil samples were collected from 12 locations (Dong
et al. 2014).  The farmland soil PBDE concentrations ranged from 2.96 to 200 ng/g and air concentrations
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ranged from 884 to 2,791 pg/m3.  The PBDE concentrations in high-mountain pasture soil, grass, and 
milk from grazing cows in the Italian Alps were analyzed (Parolini et al. 2012). Thirteen BDE congeners 
were investigated, including BDE 17, BDE 28, BDE 71, BDE 47, BDE 66, BDE 100, BDE 99, BDE 85, 
BDE 154, BDE 153, BDE 138, BDE 183, and BDE 190.  Average ƩPBDE concentrations in soil from
0 to 7 cm soil depth were 0.43–1.55 ng/g dry weight, 1.7–8.2 ng/g dry weight in grass vegetation, and 
0.659–1.576 ng/g dry weight in milk.  The average total PBDE concentration in soil samples collected 
from the Ny-Alesund region of the Arctic was reported as 0.042 ng/g dry weight (Wang et al. 2015).  
BDE 99 was the predominant congener, with an average value of 0.0097 ng/g dry weight.
The EPA used 33 surface soil measurements taken from 15 states in the United States to estimate 
ingestion rates and dermal exposure rates of PBDEs from soil.  The concentration of 30 total BDEs in the
soils was reported to average 103 ng/g dry weight, with a geometric mean (GM) concentration of 5.3 ng/g
(EPA 2010).  BDE 47 (1.9 ng/g), BDE 99 (3.6), BDE 100 (0.4), BDE 153 (5.7), BDE 154 (4.8), BDE 183 
(37.4), and BDE 209 (15.3) were included in this evaluation.
Sediment concentrations of PBDEs tend to be dominated by higher-brominated congeners (e.g., 
BDE 209) (deWit 2002).  Temporal trends suggest that concentrations of PBDEs in sediments are
increasing.  Burdens of PBDEs in sediment appear to be a function of distance from the source and their
organic carbon content (Hale et al. 2003).  Representative concentrations of PBDEs in sediment samples 
are summarized in Table 6-3.  
A 20-year field study regarding the land application of Class B biosolids to a site located in Arizona was 
discussed by Quanrud et al. (2011).  Risk assessments were made based on the intake of compounds via
inhalation, dermal sorption, or ingestion.  PBDE concentrations were detected, primarily in the surface
30-cm depth sample, and surface accumulation of PBDEs occured due to their hydrophobic nature, which 
resulted in sorption to colloids.  The maximum amount of PBDE detected was 80 ng/g soil as congener
BDE 209.  A risk evaluation of PBDEs based on Hazard Indices indicated that the health risk to humans
of PBDEs was negligible when all three routes of exposure were considered.  
Li et al. (2006) collected 199 sediment samples from 16 locations of Lake Superior, Lake Michigan, Lake 
Huron, Lake Erie, and Lake Ontario and analyzed these samples for PBDE concentrations.  The
concentrations of PBDEs in surface sediment ranged from 0.5 to 6.7 ng/g dry weight tri- to heptaBDE
congeners and from <4 to >240 ng/g dry weight for BDE 209.  PBDEs were detected in 100% of
sediment samples obtained from the San Francisco Bay with total PBDE concentrations ranging from
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Table 6-3.  Concentrations (ng/g) of Several Polybrominated Diphenyl Ethers
(PBDEs) in Sediment and Suspended Particulate Samples
Sample type Location BDE 47 BDE 99 BDE 100 ΣPBDEs BDE 209 Reference
Sediment Lake Superior No data No data No data No data 12 Zhu and Hites
2005
Sediment Lake Michigan No data No data No data 2.6a 320 Zhu and Hites
2005
Sediment Lake Michigan No data No data No data 1.67–3.97a 43.9–95.6 Song et al. 2005
Sediment Lake Huron No data No data No data 1.02–1.87a 21.5–36.0 Song et al. 2005
Sediment Lake Erie No data No data No data 1.1a 40 Zhu and Hites
2005
Sediment Lake Ontario No data No data No data 2.8a 14 Qui et al. 2007
Sediment Hadley Lake,
Indiana


















780 1,200 270 2,250 No data Sellström and 
Jansson 1995
Sediment River Viskan 
(Sweden), up­
stream and 




























No data No data <4–510
(dw)






<2–9 (dw) <0.1–23 
(dw)
No data No data <9–4,600 
(dw)
de Boer et al.
2000b
aTri- to hepta-PBDE congeners.
bIncludes sum of BDE 47, BDE 99, BDE 100, BDE 209, and other congeners (not specified).
BDE = brominated diphenyl ether; dw = dry weight; ND = not detected
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2.1 to 8.0 ng/g dry weight and a median concentration of 4.3 ng/g dry weight (Klosterhaus et al. 2012).  
BDE 209 was the primary congener of each sample, accounting for approximately 38–68% of the total
PBDE amount.  
In the United States, Dodder et al. (2002) analyzed four surficial sediments from Hadley Lake (Indiana).  
This lake is in the vicinity of a production point source.  DecaBDE (BDE 209) was the major congener
detected at concentration ranging from 19 to 36 μg/kg (ng/g) dry weight.  Other congeners detected (in 
decreasing order: BDE 99, BDE 153, BDE 154, BDE 47, and BDE 100) were <5 μg/kg (ng/g) dry weight.  
PBDEs were above the detection limit (i.e., 0.5 μg/kg [ng/g] dry weight) in 22% of surficial sediment
samples (from 133 sites) in freshwater tributaries of Virginia (Hale et al. 2001b).  BDE 47 was the 
predominant congener followed by BDE 99 and BDE 100.  The maximum concentration detected in 
sediment was 52.3 μg/kg (ng/g) dry weight.  Hale et al. (2002) reported that stream sediment adjacent to a 
former polyurethane foam production facility in North Carolina contained up to 132 μg/kg (ng/g) dry 
weight of pentaBDE.  Since the phase out of PBDE-containing flame retardants, levels of these 
substances have begun declining in sediment and other environmental media.  Sutton et al. (2015)
reported that levels of BDE 47 have declined by over one-third in sediment samples obtained from the
San Francisco Bay from 2000 to 2012; however, no decline of BDE 209 was evident, presumably since 
decaBDE was not phased out until 2013.  
In Japan, tetra-, penta-, hexa-, and decaBDEs have been detected in river sediments (Watanabe et al.
1986, 1987, 1995). The combined concentrations of tetra- and pentaBDEs ranged from 21 to 59 ng/g 
(μg/kg) dry weight.  The concentration of decaBDE (BDE 209) ranged from <25 to 11,600 ng/g (μg/kg)
dry weight (deWit 2002).  In 1999, sediment samples from several locations in the Netherlands contained 
BDE 47, BDE 99, and BDE 209 (de Boer et al. 2000b).  Concentrations ranged from 0.3 to 7.1 ng/g 
(μg/kg) dry weight for BDE 47, not detected to 5.5 ng/g (μg/kg) dry weight for BDE 99, and not detected 
to 510 ng/g (μg/kg) dry weight for BDE 209. The concentration of PBDEs in suspended particulate
matter ranged from not detected to 9 ng/g (μg/kg) dry weight for BDE 47, not detected to 23 ng/g (μg/kg)
dry weight for BDE 99, and not detected to 4,600 ng/g (μg/kg) dry weight for BDE 209 (de Boer et al. 
2000b). The concentration of several brominated flame retardants was measured in sediments collected
from the mouths of major European rivers (de Wit 2002).  Elevated concentrations of BDE 47 and 
BDE 99 were found in Humber and Mersey rivers (Great Britain).  In two rivers of the Netherlands, the 
sum of BDE 47 and BDE 99 ranged from 1.61 to 13.1 ng/g (μg/kg) dry weight.  The highest hexaBDE
concentrations (as BDE 153) were found in the river Seine (France), three rivers in the Netherlands, and 
the rivers Schelde (Belgium), Forth (Great Britain) and Ems (Germany); the concentration of
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BDE 153 ranged from 0.013 to 0.056 ng/g (μg/kg) dry weight in these sediments.  The concentrations of
decaBDE were highest in sediment from the Seine, ranging from 2.4 to 3.9 ng/g (μg/kg) dry weight.  The
concentrations of decaBDE in River Mersey (Great Britain), Schelde, and River Liffey (Ireland) ranged
from 34 to 1,800 ng/g (μg/kg) dry weight.  In the southern Baltic Sea (Bornholm Deep), the upper layer of
sediment was analyzed for BDE 47, BDE 99, and BDE 100; the combined concentration of these three 
congeners was 0.52 ng/g (μg/kg) dry weight (Nylund et al. 1992). 
A well-studied sediment core collected from the southern part of the Baltic Sea proper was analyzed for
PBDEs and a number of organochlorine contaminants (Nylund et al. 1992).  The retrospective temporal
trend from 1939 to 1987 showed that the PBDE concentrations (i.e., sum of BDE 47, BDE 99, and 
BDE 100) have increased with a sharp increase after 1980.  The PBDE concentration in the sample from
1989 was 2.9 ng/g (Nylund et al. 1992).  Measurable amounts of BDE 28, BDE 47, BDE 66, BDE 99, and 
BDE 100 were found in sediment cores from a freshwater lake in Germany, the Wadden Sea (the 
Netherlands), and Drammenfjord (Oslo Fjord, Norway) (Zegers et al. 2000).  Samples from the 
Drammenfjord and freshwater lake also contained BDE 153 and BDE 154, and the Wadden Sea and 
freshwater lake samples contained BDE 209.  The lower-brominated PBDEs appear in the 1960s, and 
BDE 209 appears about 10 years later. The Drammenfjord sediment core shows increasing
concentrations of BDE 47 starting in the 1940s (range, 0.02–0.18 ng/g dry weight) and increasing 
concentrations of BDE 99 (range, 0.5–0.28 ng/g dry weight), BDE 100 (range, not detected–0.07 ng/g dry 
weight), and BDE 154 (range, not detected–0.06 ng/g dry weight) beginning in the 1950s up to 1999.  In 
the sediment core from Lake Woserin, lower-brominated PBDE congeners were detected in the sediment
horizons beginning in the late 1950s, and the concentrations increased until the late 1970s, and then 
leveled off when residues of BDE 209 first appeared.  A similar leveling-off trend is also observed in the
Wadden Sea core (Zegers et al. 2000).  It is important to note that this study identified the presence of
PBDEs compounds in sediments from the late 1950s and early 1960s.  This is nearly a decade prior to any
significant commercial production of these substances.  The existence of PBDEs at these early dates may
be a result of vertical mixing of sediment cores or blurring of core horizons through burrowing activity of
benthic organisms, or may lend some credibility to the likelihood that either the substances identified in
the environment as PBDEs are not necessarily PBDEs.
6.4.4 Other Environmental Media 
Dust. The predominant PBDE exposure pathway for the general population of the United States is from
indoor dust (EPA 2010; Lorber 2008).  Total PBDE (sum of BDE 28, 47, 66, 85, 99, 100, 153, 154, 183, 
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206, and 209) levels in dust samples obtained from 20 residences located near the Columbia River in 
Washington state ranged from 311 to 19,700 ng/g, with BDE 209 being the predominant congener
(Shreder and LaGuardia 2014).  Total PBDE concentrations in settled dust from 10 office buildings
located in Michigan ranged from 1,340 to 38,900 ng/g (median, 15,800 ng/g) (Batterman et al. 2010).  
BDE 47, BDE 99, and BDE 209 had the highest concentrations for the individual congeners, with a
maximum value of 29,000 ng/g measured for BDE 209 in one of the office buildings.  A study of eight
office buildings in Boston, Massachusetts had even greater PBDE concentrations in settled dust.  BDE
209 was detected in 100% of the samples at concentrations ranging from 912 to 106,204 ng/g (Watkins et
al. 2011).  Total pentaBDE congeners ranged from 141 to 61,264 ng/g in these office buildings.  Lower
concentrations of the lesser brominated congeners, Σtri–hexaBDE, were detected in dust samples in 
Europe as compared to the United States and Canada (Harrad et al. 2008).  Concentrations of BDE 209 in 
dust samples are similar in the United States and the United Kingdom.  Congener pattern analysis of
indoor dust suggests that North American dusts are contaminated with decaBDE and pentaBDE
commercial formulations, whereas U.K. dusts are predominantly contaminated with decaBDE.  For
example, the average concentration of total PBDE congeners in eight homes located in West Midlands,
United Kingdom was about 215 ng/g, with a range of 16.2–625.4 ng/g (Harrad et al. 2006).  Dust samples
obtained from Spain and Belgium had total PBDE ranges of 2.9–380.2 and 6.2–384.8 ng/g, respectively
(Harrad et al. 2006).  Concentrations in North America also seem to be greater than even source-
dominated areas in other parts of the world. The mean total concentration of 10 PBDE congeners in dust
samples obtained from an office building located near a large automotive shredding and metal recycling
facility in Brisbane, Australia was 2,014 ng/g (Hearn et al. 2013).  
Food.  Food ingestion typically accounts for <20% of the total PBDE intake for adults in North America
(EPA 2010; Lorber 2008); however, it accounts for the majority of intake for the European population, 
with the exception of BDE 209 where dust exposure is the primary source (Abdallah and Harrad 2014;
Trudel et al. 2011).  Schecter et al. (2006) measured concentrations of 13 PBDE congeners in 62 food 
samples in the United States.  Concentrations of total PBDEs ranged from 7.9 pg/g in milk to 3,762 pg/g 
in canned sardines.  Fish, meat, and dairy products tended to have the highest concentrations of PBDEs. 
The results of these measurements for meat and fish are reproduced in Table 6-4.  A survey of three
categories of baby food (formula, cereal, and puree) from the United States and China found the median 
concentrations of total PBDE (sum of BDE 17, BDE 28, BDE 47, BDE 49, BDE 100, BDE 153, BDE
183, and BDE 209) were 21 and 36 pg/g in foods purchased in the United States and China, respectively
(Liu et al. 2014). 


















             
 
  
     
 
       
 
   
 
      
 























    
 






















     
 
 
     


















         
   
 














   
 





    
    
 

















       
 
 
                
                
                
                
 
 
         
 








     
                
      
 
       
 
 
      
 











6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-4.  PBDE Concentrations (pg/g Wet Weight) in 18 U.S. Meat and Fish 
Samplesa
Lipid BDE BDE BDE BDE BDE BDE BDE BDE BDE BDE BDE BDE BDE Total
Sample (%) 17 28 47 66 77 85 99 100 138 153 154 183 209 PBDEsb 
U.S. meat samples
Bacon A 52.3 ND ND ND ND ND ND ND ND ND ND ND ND ND 165
(5.2) (7.1) (78.8) (5.2) (5.2) (5.2) (28.8) (6.8) (5.2) (5.2) (5.2) (5.2) (166.6)
Bacon B 43.4 ND ND ND ND ND NA ND ND ND ND ND ND ND 39
(0.4) (2.1) (19.9) (0.4) (0.2) (15.6) (2.8) (0.4) (1.1) (0.9) (1.7) (32.8)
Bacon C 35.3 0.7 ND 30.1 NA NA 1.4 16.8 4.8 ND 4.5 2.8 14.3 28.4 105
(2.0) (0.7)
Beef 30.7 ND 59.7 87.5 ND ND ND 35.5 6.2 ND 6.8 4.6 ND ND 258
(ground) A (3.1) (3.1) (3.1) (3.1) (3.1) (4.2) (95.7)
Beef 13.6 0.2 ND 23.4 0.5 NA NA 32.3 4.5 0.4 4.7 2.5 NA 9.7 79
(ground) B (0.7)
Beef 13.7 ND ND 35.1 ND NA 1.7 40.3 6.9 ND 4.9 3.7 3.8 ND 105
tenderloin (1.4) (1.5) (1.4) (1.4) (11.1)
Chicken 4.9 ND 0.5 60.5 NA NA NA 128 17.1 2.2 12.0 10.8 3.2 48.5 283
breast (0.04)
Duck 75.1 ND ND 286 2.7 ND 15.2 609 122 7.3 52.3 42.9 31.6 113 1,283
(0.5) (3.0) (0.3)
Ground 7.3 ND ND 11.0 ND NA ND 18.9 4.6 ND 4.1 2.6 5.8 80 129
chicken (0.7) (1.5) (0.7) (0.7) (0.7)
Ground 19.7 ND ND ND ND ND 3.2 56.8 16.8 ND 9.6 6.3 ND ND 186
lamb (2.0) (2.1) (23.0) (2.0) (2.0) (2.0) (2.0) (150.6)
Ground 21.5 ND ND 53.8 ND NA 3.1 74.2 12.9 4.3 18.7 15.0 19.9 ND 221
pork (2.2) (3.5) (2.2) (31.3)
Ground 11.1 0.2 ND 98 0.8 ND NA 217 54.4 3.9 32.9 24.1 36.8 245 713
turkey (0.5) (0.1)
Pork 8.9 0.1 ND 6.9 NA NA NA 16.3 1.8 0.2 1.0 1.2 1.3 11.7 41
(0.5)
Pork 23.7 ND ND 387 ND ND 16.8 688 74.5 5.6 81.6 55.3 14.6 49.7 1,378
sausage A (1.3) (6.9) (1.0) (0.3)
Pork 24.4 ND ND 39.4 ND ND 2.6 71.6 8.3 ND 22.0 13.7 10.7 ND 244
sausage B (2.4) (3.4) (2.4) (2.4) (2.4) (139)
Sausage 26.2 ND ND ND ND NA 3.1 40.1 6.4 ND 5.9 4.9 6.9 ND 1,426
A (2.6) (5.5) (34.8) (2.6) (2.6) (51.0)
Sausage 28.5 ND ND 94.1 ND ND ND 43.7 8.3 ND 8.5 9.2 ND ND 195
B (2.9) (3.2) (3.5) (2.9) (2.9) (2.9) (2.9) (41.7)
Wieners 32.9 ND ND 386 1.4 ND 11.1 703 53.9 7.2 106 49.8 14.3 ND 1,348
(0.3) (1.5) (0.2) (28.7)
Mean 26.3 0.76 4.59 93.2 1.19 0.83 4.93 157 22.7 2.33 21.1 14 10.1 53.3 383
Median 24.1 0.66 1.03 39.4 1.08 0.57 2.62 42 7.57 1.37 7.68 5.63 5.83 38.1 190
Minimum 4.87 0.02 0.24 6.93 0.21 0.06 0.36 7.79 1.39 0.16 0.53 0.44 0.86 5.53 39
Maximum 75.1 2.62 59.7 387 2.74 2.62 16.8 703 121 7.28 106 55.3 36.8 245 1,426
U.S. fish samples
Canned 0.3 0.1 0.6 5.1 0.2 NA 0.2 3.2 0.6 ND 0.3 0.2 1.1 4.9 16.6
tuna A (0.0)
Canned 0.5 ND 0.2 2.1 0.2 NA ND 1.1 0.4 ND 0.2 0.3 2.1 8.8 15.5
tuna B (0.1) (0.1) (0.1)
Catfish A 11.1 4.6 6.4 372 4.3 NA NA 589 116 5.1 37.1 39.6 7.3 1269 2,450
Catfish B 5.3 4.6 5.1 438 13.5 ND 41.6 834 102 7.9 49.9 45.8 4.9 ND 1,547
(0.1) (15.9)
Catfish C 5.2 2.2 3.7 137 0.7 ND 11.7 184 39.5 ND 15.8 15.2 ND ND 437
(0.5) (2.7) (1.6) (49.4)
















         
 
     




     




   
 
 
   
 
      
 
   
 
 
      
 
   
 
   
 
 
      
 



















     








         
 
     
 
 




     







                
          
 










       
 
      
 
 
     
   
  
 





   
  
 
   
   
  
 




     
                
                
                
                
 






















6.  POTENTIAL FOR HUMAN EXPOSURE

































Catfish 5.7 1.1 3.7 197 6.3 NA 16.4 282 53.0 ND 18.4 21.3 3.8 22.7 627
fillet (farm) (4.1)
Halibut 0.2 0.6 4.1 76.6 2.8 NA ND 10.6 12.4 ND 1.1 2.6 1.8 11.4 124
(0.1) (0.1)
Herring 9.1 4.1 56.3 2,072 69.4 3.6 ND 267 221 ND 29.3 69.9 2.5 ND 2,809
(0.9) (0.9) (26.4)
Mahi 0.5 0.6 ND 24.1 2.0 NA 0.6 13.0 5.1 ND 1.4 4.9 4.3 ND 66
(2.0) (0.8) (16.6)
Salmon A 8.0 79.2 92.6 1,222 30.6 ND NA 93.2 348 ND 27.7 98.8 1.4 ND 1,999
(0.2) (0.2) (9.0)
Salmon B 13.9 118 142 2,081 59.1 ND NA 147 353 ND 36.6 142 ND ND 3,082
(0.1) (0.2) (1.2) (7.0)
Salmon C 10.3 18.4 49.4 1,103 35.3 ND ND 239 217 ND 18.3 45.1 ND ND 1,732
(0.1) (0.1) (0.1) (1.3) (11.2)
Salmon D 6.3 1.4 5.2 94.7 5.2 ND ND 15.4 7.1 ND 1.4 5.0 ND ND 141
(0.9) (0.6) (0.6) (0.8) (9.1)
Salmon E 12.3 1.7 20.4 356 ND ND ND 84.4 84.2 ND 10.1 29.8 ND ND 605
(2.1) (1.2) (1.2) (1.2) (1.4) (29.2)
Salmon 7.4 11.1 50.5 1,000 63.1 NA 7.9 410 210 ND 37.4 104 3.7 20.5 1,919
fillet (farm) (1.4)
A




Sardines 9.6 3.3 53.6 2,748 85.6 ND ND 358 257 ND 51.9 139 ND ND 3,726
(5.0) (1.0) (1.0) (3.2) (51.4)
Shark 0.4 1.1 29.8 784 29.5 0.3 NA 57.8 608 0.4 112 291 2.0 5.4 1,920
Shrimp 0.6 0.3 3.6 75.6 NA NA NA 9.4 14.3 ND 1.2 2.6 0.2 ND 108
(0.1) (1.3)




5.9 NA NA 0.1 1.3 0.6 ND 
(0.1)





Trout A 4.2 4.8 22.2 320 NA NA ND 79.8 66.5 0.2 11.8 26.3 4.4 ND 549
(0.2) (26.7)
Trout B 10.1 4.3 49.3 826 ND ND ND 128 198 ND 24.7 61.3 2.5 ND 1,319
(5.6) (1.0) (1.0) (1.0) (42.9)
Tuna 0.2 ND ND 16.6 0.7 NA ND ND 2.9 ND ND ND 0.5 23.4 48
(0.1) (1.0) (0.0) (4.6) (0.1) (0.4) (1.0)
Wild perch 1.2 ND 
(0.1)
0.7 10.2 0.4 NA ND 
(0.1)
2.3 2.1 ND 
(0.1)
0.7 2.4 0.6 5.9 25
Mean 5.43 11.01 26.19 603 20.8 0.78 4.29 166 126 0.89 21 49.3 2.08 91.8 1,120
Median 5.52 1.97 5.77 338 5.23 0.30 0.35 88.8 75.3 0.33 15.9 28. 1.68 10.1 616
Minimum 0.15 0.03 0.20 2.11 0.18 0.06 0.02 1.15 0.43 0.02 0.21 0.21 0.12 0.63 11.14
Maximum 13.9 118 142 2,748 85.6 3.60 41.6 834 608 7.94 112 291 7.32 1,269 3,726
aLimits of detection (LODs) are shown in parentheses. Total PBDE concentrations and statistics for each congener were calculated by
assuming that nondetected concentrations were one-half the LOD; for calculations, these were treated as zero.
bTotals rounded to the nearest whole number for hundreds and to the nearest decimal place for tens.
NA = not available; ND = not detected
Source:  Adapted from Schecter et al. (2006)










   
  
  
   
  
     
  
    
  
   
 
  
   
     
    
   
    
   
 
    
   
  
   
        
    
    
    
    
  
     
   
   
 
PBDEs 394
6.  POTENTIAL FOR HUMAN EXPOSURE
Huwe et al. (2002a) reported total PBDE concentrations in farm chickens raised in two different regions
of the United States. The total PBDE concentration of discrete samples of chickens raised in Arkansas 
was 39.4 ng/g whole weight, while one composite sample of chickens raised in North Dakota was 
1.7 ng/g whole weight.  In the United States, chickens fed ball clay (a sedimentary, kaolinite clay) and
chickens bought in the grocery store were analyzed for total PBDEs (ENVIRON 2003b).  BDE 99 was 
the dominant congener in all samples. Total PBDEs ranged between 4 and 35 ng/g lipid weight in 
chickens fed ball clay and 0.5 ng/g lipid weight in store-bought chicken.  Ohta et al. (2002) determined 
the concentration of total PBDEs in vegetables and meat samples from Japan. The concentrations of
PBDEs in spinach, potato, and carrot were 134, 47.6, and 38.4 pg/g fresh weight, respectively.  The
highest concentrations of total PBDEs and BDE 47 were found in spinach.  Interestingly, different
congener patterns were found among the vegetables analyzed.  Compared to root vegetables, which had
high concentrations of BDE 153, spinach (representing a leafy vegetable) might be strongly influenced by
PBDE contamination in air.  The concentrations of PBDEs in pork, beef, and chicken were 63.6, 16.2, and 
6.25 pg/g fresh weight, respectively.  PBDE concentrations were highest in pork samples; however, the 
reason for this is unknown (Ohta et al. 2002).  Bocio et al. (2003) determined the concentrations of
PBDEs in food samples from Catalonia, Spain during 2000.  The highest concentration of total PBDEs
was found in oils and fats (587.7–569.3 pg/g), followed by fish and shellfish (333.9–325.3 pg/g), meat
and meat products (109.2–102.4 pg/g), and eggs (64.5–58.3 pg/g).  In all of these food groups, a
predominance of the tetra- and pentaBDE homologs, followed by hexaBDE, was observed in the sum
total PBDEs.  By contrast, PBDEs were not detected in the groups of fruits, cereals, or tubers.  Four types
of commercial fish oils sold in Sweden were found to contain PBDEs (0.2–28.1 ng/g lipid weight)
(Haglund et al. 1997).  The highest concentration of PBDEs was found in the cod liver oil.  These oils
were from products marketed as dietary supplements for humans.  The concentrations of PBDEs in 
seafood from the Inland Sea of Japan were determined for samples collected in 1998 (Hori et al. 2000).  
BDE 28, BDE 47, BDE 66, BDE 99, BDE 100, BDE 153, and BDE 154 were detected in all analyzed 
seafood samples.  BDE 47 was detected as the predominant congener, with concentrations ranging from
58 to 2,100 pg/g wet weight.  Harrad et al. (2004) determined the concentrations of several PBDE
congeners in omnivorous and vegan diet samples from the United Kingdom.  Median concentrations of
BDE 47, BDE 99, BDE 100, BDE 153, and BDE 154 in omnivorous diet samples were 66.8, 63.8, 10, 20, 
and 20 pg/g dry weight, respectively.  In vegetarian samples, median concentrations of BDE 47, BDE 99, 
BDE 100, BDE 153, and BDE 154 were 47.2, 56.7, 10.0, 20, and 20 pg/g dry weight, respectively.
Concentrations of BDE 47, BDE 99, and total PBDE were found to be statistically higher in omnivorous
diet samples compared to vegetarian diet samples.
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6.  POTENTIAL FOR HUMAN EXPOSURE
Biosolids and Effluents.  The concentrations of PBDEs in biosolids (sewage sludge) and effluents are 
summarized in Table 6-5.  PBDEs were detected in 11 biosolids obtained from Virginia, New York, 
Maryland, and California (Hale et al. 2001c). The total concentrations of pentaBDE in biosolids ranged 
from 1,100 to 2,290 ng/g dry weight.  The concentration of decaBDE (BDE 209) varied widely among 
biosolids from the four states; the concentration of BDE 209 ranged from 84.8 to 4,890 ng/g dry weight in
the biosolid samples.
Levels of PBDEs in biosolids were analyzed using samples from the EPA 2001 National Sewage
Sludge Survey (NSSS) (Venkatesan and Halden 2014).  Thirty-two PBDEs were detected in the samples 
analyzed.  The total mean±standard deviation PBDE concentration detected in biosolids composites was
9,388±7,778 µg/kg dry weight.  Deca, nona, and penta BDE congeners accounted for roughly 57, 18, and 
13% of the total, respectively.  Using these data and the estimated annual biosolids production and 
disposal figures in the United States, the annual mean loading rate of PBDEs was estimated to range from
47,900 to 60,100 kg/year.  Analysis of samples collected between August 2006 and March 2007 (2– 
3 years after the voluntary phase-out of penta and octa PBDE formulations) indicated that the levels of
8 out of 11 major congeners in biosolids had declined approximately 10–57 % when compared to 2001 
levels.
Sewage sludge in the vicinity of the Dan River (Virginia) were collected and analyzed for PBDEs (Hale 
et al. 2002).  Congener patterns suggestive of both penta- and decaBDE commercial products were 
present at concentrations of 1,370 ng/g dry weight (sum of BDE 47 to BDE 154) and from 1,470 ng/g dry 
weight, respectively.  While no known industrial source of pentaBDE discharged to this plant, the
distribution pattern for lower-brominated congeners matched the pentaBDE commercial product. 
Sewage sludge samples from 13 WWTPs in Germany were sampled (Hagenmaier et al. 1992). The mean
concentration of tri- to heptaBDEs was 8.37 ng/g, with tri-, tetra-, penta-, hexa-, and heptaBDEs at
concentrations of 0.65, 3.06, 3.02, 0.49, and 0.22 ng/g, respectively.  Concentrations of penta- and 
hexaBDEs were highest in these samples.  de Boer et al. (2000b) determined the concentration of PBDEs
in sewage treatment plant effluents from the Netherlands.  The concentration of total PBDEs (the sum of
BDE 47, BDE 99, and BDE 100) ranged from 11 to 35 ng/g dry weight with the overwhelming majority 
as BDE 47, while the concentrations of BDE 209 ranged from 310 to 920 ng/g dry weight.  Kohler et al. 
(2003) determined the concentrations of decaBDE in sewage sludge from Switzerland between 1993 and 
2002. These authors reported that the average concentration of decaBDE increased with time from 220 to 
1,100 ng/g dry weight, corresponding to an average increase of 560%.


























   
 






















      
 
 






      
 
 














6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-5.  Concentrations (ng/g Dry Weight) of Several Polybrominated Diphenyl
Ethers (PBDEs) in Biosolids (Sewage Sludge) and Effluents














No data No data No data 1,100– 
2,290*






































11–35 <1 No data 11–35 310–920 de Boer et al.
2000b
plant effluents
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).
BDE = brominated diphenyl ether











     
    
     
     
      
      
   
 
     
    
    
   
    
  
       
     
   
       
    
   
    
 
    
  
 
   
 
 
   
   
  






























































6.  POTENTIAL FOR HUMAN EXPOSURE
World Trade Center Site. In 2001, PBDEs were detected in dust and smoke samples taken near the
World Trade Center disaster site (Lioy 2002).  The highest concentration was for decaBDE (i.e., 
BDE 209), which was present in thermoplastics (e.g., computers).  Concentrations of PBDE congeners 
were 107–174 μg/kg dry weight basis for BDE 47, 51.1–74.1 μg/kg dry weight basis for BDE 100, 155–
293 μg/kg dry weight basis for BDE 99, 42.0–53.5 μg/kg dry weight basis for BDE 153, 219–305 μg/kg 
dry weight basis for BDE 154, and 1,330–2,660 μg/kg dry weight basis for decaBDE (BDE 209).  
Concentrations of PBDEs were found to be similar to concentrations found in sewage sludge (Lioy 2002).  
Freshwater Fish. Monitoring data indicated that the concentrations of PBDEs were historically
increasing in freshwater organisms, with higher concentrations near point sources.  The congener profiles
show the highest concentrations for BDE 47. The presence of PBDEs in freshwater aquatic organisms 
taken from remote regions suggests that diffuse sources of PBDEs are also important.  A sampling of
concentrations of PBDEs in freshwater fish samples in the United States are summarized in Table 6-6.  
Fish were sampled from two U.S. lakes, Hadley Lake, Indiana near a possible PBDE point source, and 
Lake of the Ozarks, Missouri, with no known sources (Dodder et al. 2000).  Mean total PBDE
concentrations (sum of BDE 47, BDE 99, BDE 100, BDE 153, and BDE 154) were higher in crappie
(Pomoxis annularis) and bluegill (Lepomis macrochirus) from Hadley Lake (1,500 and 1,900 ng/g lipid
weight, respectively) than from Lake of the Ozarks (340 and 390 ng/g lipid, respectively).  BDE 47, 
BDE 99, BDE 153, and BDE 154 were the primary congeners.  From the Lake of Ozarks, BDE 47 was 
the dominant congener in fish.  The total PBDE concentrations in smelt (Osmerus mordax) from Lakes 
Superior and Ontario were 150±9 and 240±30 ng/g lipid, respectively (Dodder et al. 2002).  The
dominant congeners in these fish were BDE 47 and BDE 99.  
An analysis of fish tissue samples from selected locations in Washington State showed that total PBDE
concentrations ranged from 29 ng/g lipid in rainbow trout from a remote spring-fed stream (Douglas 
Creek, Washington) to 19,000 ng/g lipid in rainbow trout from the urbanized Spokane River, Washington 
(Johnson and Olson 2001).  The tetra- and pentaBDE isomers were the major compounds present.  
TetraBDE to hexaBDE were found in carp (Cyprinus carpio) from the Buffalo River (New York), a
polluted area around the Great Lakes (Loganathan et al. 1995). TetraBDEs dominated the congener
pattern with 94–96% of total PBDEs.  TetraBDE and pentaBDE concentrations ranged from 13 to 22 ng/g 
fresh weight.  Asplund et al. (1999a) found tri- to hexaBDEs in steelhead trout (Oncorhynchus mykiss) 
sampled in 1995 from Lake Michigan.  The combined concentration of BDE 47, BDE 99, BDE 100, 
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Table 6-6.  Concentrations (ng/g Lipid Weight, Except as Noted) of Several
Polybrominated Diphenyl Ethers (PBDEs) in Freshwater Fish Samples
from the United States
Sample 
type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Lake trout Lake Michigan 93–230 9.0–48 12–45 120–350* No data Streets et al. 
2006
Lake trout Lake Superior 22–79 8.5–53 5.2–19 39–180* No data Streets et al. 
2006
Lake trout Lake Huron 32–59 7.8–13 6.5–12 50–94* No data Streets et al. 
2006
Lake trout Lake Ontario 45–140 6.5–34 7.7–24 64–230* No data Streets et al. 
2006
Lake Trout Lake Ontario 4.3–114 59–680 7.4–1,285 269–3,339* 2.3–12 Ismail et al.
2009
Alewife Grand Traverse 16 No data No data 36 No data Stapleton and
Bay, Lake Baker 2003
Michigan
Bloater Grand Traverse 11 (fw) No data No data 23 (fw) No data Stapleton and
chub Bay, Lake Baker 2003
Michigan
Bluegill Hadley Lake, 420 320 240 1,900 No data Dodder et al.
Indiana 2000
Bluegill Lake of the 200 91 59 390 No data Dodder et al.
Ozarks, Missouri 2000
Burbot Grand Traverse 43 (fw) No data No data 86 (fw) No data Stapleton and
Bay, Lake Baker 2003
Michigan
Carp United States No data No data No data 13–22* No data Loganathan et
(fw) al. 1995
Carp Detroit River, 3.0 (fw) 0.50 (fw) 0.48 (fw) 40.7* No data Rice et al. 2002
Grosse Isle,
Michigan
Carp Des Plaines 2.54 (fw) 0.5 (fw) 0.44 (fw) 281* No data Rice et al. 2002
River, Joliet,
Illinois
Carp Des Plaines 1.34 (fw) 0.50 (fw) 0.49 (fw) 78.3* No data Rice et al. 2002
River, Joliet,
Illinois
Carp (fillet) Yakima River, No data No data No data 22 (fw) No data Johnson and 
Washington Olson 2001
Crappie Hadley Lake, 250 430 150 1,500* No data Dodder et al.
Indiana 2000
Crappie Lake of the 190 78 59 340* No data Dodder et al.
Ozarks, Missouri 2000
Deepwater Grand Traverse 2.8 (fw) No data No data 3 (fw) No data Stapleton and
sculpin Bay, Lake Baker 2003
Michigan
Lake trout Grand Traverse 75 (fw) No data No data 126 (fw) No data Stapleton and
Bay, Lake Baker 2003
Michigan
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Table 6-6.  Concentrations (ng/g Lipid Weight, Except as Noted) of Several
Polybrominated Diphenyl Ethers (PBDEs) in Freshwater Fish Samples
from the United States
Sample 
type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Lake trout Lake Ontario, No data No data No data 540* No data Alaee et al. 1999
United States
Lake trout Lake Ontario, 58 (fw) 14 (fw) 5.7 (fw) No data No data Luross et al.
United States 2002
Lake trout Lake Huron, No data No data No data 240* No data Alaee et al. 1999
United States
Lake trout Lake Huron, 27 (fw) 7.7 (fw) 3.8 (fw) No data No data Luross et al.
United States 2002
Lake trout Lake Superior, No data No data No data 140* No data Alaee et al. 1999
United States
Lake trout Lake Superior, 29 (fw) 12 (fw) 4.1 (fw) No data No data Luross et al.
United States 2002
Lake trout Lake Erie, No data No data No data 117* No data Alaee et al. 1999
United States
Lake trout Lake Erie, 16 (fw) 2.0 (fw) 2.5 (fw) No data No data Luross et al.
United States 2002
Largescale Yakima River, No data No data No data 64 (fw) No data Johnson and 
sucker Washington Olson 2001
(whole)
Largescale Spokane River, No data No data No data 105 (fw) No data Johnson and 
sucker Washington Olson 2001
(whole)
Mountain Spokane River, No data No data No data 1,250 (fw) No data Johnson and 
whitefish Washington Olson 2001
(whole)
Rainbow Douglas Creek, No data No data No data 1.5 (fw) No data Johnson and 
trout Washington Olson 2001
(whole)
Rainbow Spokane River, No data No data No data 20–174 No data Johnson and 
trout Washington (fw) (fillet) Olson 2001
297 (fw)
(whole)
Northern Spokane River, 59–160 0.3–<0.4 17–47 No data Not Furl and 
pike Washington detected Meredith 2010
minnow
Mountain Spokane River, 127–942.6 81–942.6 26.3– No data Not Furl and 
whitefish Washington 368.1 detected Meredith 2010
Largescale Spokane River, 87–270 0.2–<4.4 13–45 No data Not Furl and 
sucker Washington detected Meredith 2010
Salmon Grand Traverse 34 (fw) No data No data 95 (fw) No data Stapleton and
Bay, Lake Baker 2003
Michigan
Salmon Lake Michigan, 52.1 (fw) 9.3 (fw) 9.7 (fw) 2,440 No data Manchester-
United States Neesvig et al.
2001
Smelt Lake Superior, 5.7 (fw) 1.8 (fw) 0.98 (fw) 150 <1.5 (fw) Dodder et al.
United States 2002












   
 
        
  
 




















      
 
 










6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-6.  Concentrations (ng/g Lipid Weight, Except as Noted) of Several
Polybrominated Diphenyl Ethers (PBDEs) in Freshwater Fish Samples
from the United States
Sample 
type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Smelt Lake Ontario, 10 (fw) 5.3 (fw) 1.6 (fw) 240 <1.6 (fw) Dodder et al.
United States 2002
Starry Columbia River, No data No data No data 30 (fw) No data Johnson and 
flounder Washington Olson 2001
(whole)
Steelhead Lake Michigan, 1,700 600 360 3,000* No data Asplund et al.
trout United States 1999b
Whitefish Columbia River, No data No data No data 72 (fw) No data Rayne et al.
United States 2003a
Whitefish Grand Traverse 9.8 (fw) No data No data 18 (fw) No data Stapleton and
Bay, Lake Baker 2003
Michigan
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).
BDE = brominated diphenyl ether; dw = dry weight; fw = fresh weight
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BDE 153, and BDE 154 was 3,000 ng/g lipid weight (Asplund et al. 1999b).  Lake trout (Salvelinus
namaycush) from Lakes Ontario, Huron, and Superior were also found to have di- to heptaBDEs with
combined concentrations of 545, 237, and 135 ng/g lipid weight, respectively (Alaee et al. 1999).  
Lake trout from Lake Erie had 117 ng/g lipid weight (Luross et al. 2000).  Variations in local sources, 
combined with atmospheric transport, may explain differences that were seen in congener profiles for the
different lakes.  A retrospective temporal study for the years 1978, 1983, 1988, 1993, and 1998 using
archived trout samples from Lake Ontario show a dramatic increase in total PBDE concentrations over
time (Luross et al. 2000).  At 50 freshwater sites in Virginia, muscle samples from 253 fish samples were 
collected and analyzed for PBDEs (Hale et al. 2000, 2001b).  Approximately 85% of the samples
contained BDE 47, the predominant congener, at measurable concentrations.  Concentrations were
>1,000 ng/g lipid weight at 9 of 50 sites. The highest combined PBDE concentrations (up to 57,000 ng/g 
lipid weight) were observed in carp downstream of textile and furniture facilities.  BDE 47 concentrations
were greater than 2,2’,4,4’,5,5’-hexachlorobiphenyl (PCB 153) concentrations in 58% of the samples
analyzed.  PBDEs were identified in fish collected from the Detroit River (Michigan) and Des Plaines 
Rivers (Illinois).  In Detroit River fish (carp and largemouth bass), the congener patterns were dominated
by BDE 47; however, in the Des Plaines River carp, the dominant congeners were heptaBDE congeners 
(BDE 181 and BDE 183), lesser amounts of BDE 190, and two hexaBDEs (BDE 154 and BDE 153).  
Possible sources for the heptaBDE congeners were not obvious Ozarks (340 and 390 ng/g lipid,
respectively).  BDE 47, BDE 99, BDE 153, and BDE 154 were the primary congeners.  From the Lake of
Ozarks, BDE 47 was the dominant congener in fish.  The total PBDE concentrations in smelt (O. mordax) 
from Lakes Superior and Ontario were 150±9 and 240±30 ng/g lipid, respectively (Dodder et al. 2002).  
The dominant congeners in these fish were BDE 47 and BDE 99. An analysis of fish tissue samples from
selected locations in Washington State showed that total PBDE concentrations ranged from 29 ng/g lipid 
in rainbow trout from a remote spring-fed stream (Douglas Creek, Washington) to 19,000 ng/g lipid in
rainbow trout from the urbanized Spokane River, Washington (Johnson and Olson 2001).  The tetra- and 
pentaBDE isomers were the major compounds present.  TetraBDE to hexaBDE were found in carp 
(C. carpio) from the Buffalo River (New York), a polluted area around the Great Lakes (Loganathan et al. 
1995).  TetraBDEs dominated the congener pattern with 94–96% of total PBDEs.  TetraBDE and 
pentaBDE concentrations ranged from 13 to 22 ng/g fresh weight.  Asplund et al. (1999a) found tri- to 
hexaBDEs in steelhead trout (O. mykiss) sampled in 1995 from Lake Michigan.  The combined 
concentration of BDE 47, BDE 99, BDE 100, BDE 153, and BDE 154 was 3,000 ng/g lipid weight
(Asplund et al. 1999b).  Lake trout (S. namaycush) from Lakes Ontario, Huron, and Superior were also 
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found to have di- to heptaBDEs with combined concentrations of 545, 237, and 135 ng/g lipid weight,
respectively (Alaee et al. 1999).
The National Study of Chemical Residues in Lake Fish Tissue (1998–2009) is one of the statistically-
based surveys conducted by EPA that analyzed the concentrations of PBDEs and other contaminants in
fish from 500 lakes in the continental United States (EPA 2009c, 2013k).  The most prevalent PBDE
congeners detected in both predator and bottom dweller fish were reported as BDE 47, BDE 99, and
BDE 100 (EPA 2013k).  
Ismail et al. (2009) studied the temporal trends of PBDE congeners in trout obtained from Lake Ontario 
from 1979 to 2004.  Concentrations of most PBDE congeners (BDE 28, BDE 47, BDE 99, BDE 100, 
BDE 153, and BDE 154) increased dramatically from 1979 to the mid-1990s and then either leveled off
or decreased from 1998 to 2004; average concentration and standard error values are presented in
Figure 6-2.  The temporal trend of BDE 209 was different than for the other congeners, however.  
Concentrations of BDE 209 in lake trout increased more slowly from 1979 until the mid-1990s, but its
concentrations increased dramatically from the late 1990s (3.3±0.8 ng/g in 1998) until 2004 (12±5.3 ng/g
in 2004), corresponding to its increased use in consumer products.
The concentrations of PBDEs in freshwater fish samples from Europe are summarized in Table 6-7.  
Between 1986 and 1988, concentrations of BDE 47, BDE 99, and BDE 100 were measured in whitefish
(Coregonus spp.) from a remote mountain lake in Northern Sweden (Lake Storvindeln), in Arctic char
(Salvelinus alpinus) from a heavily populated lake (Lake Vättern) in south-central Sweden with numerous
municipal and industrial point sources, and in trout (Salmo trutta) and pike (Esox lucius) from several
sites along Dalslands Canal in west central Sweden (Jansson et al. 1993).  No point sources of PBDEs
were identified from these sites.  Whitefish from the remote lake contained the lowest concentrations
(26 ng/g lipid weight) of PBDEs, whereas the Arctic char, from a heavily populated lake, contained 
520 ng/g lipid weight PBDEs.  In both samples, BDE 47 was the predominant congener.  PBDE
concentration in pike and trout from the Dalslands Canal ranged from 180 to 210 ng/g lipid weight and
from 280 to 1,200 ng/g lipid weight, respectively.  The congener pattern in these samples was similar to
the technical mixture, Bromkal 70-5DE, with equal quantities of both BDE 47 and BDE 99.  The
concentrations in pike and trout are of the same order of magnitude as in the Arctic char, indicating the
spread of PBDEs from diffuse sources (de Wit 2002).  In 1979 and 1980, high concentrations of tri- to 
hexaBDEs (range, 950–27,000 ng/g lipid weight in muscle tissues) were measured in fish sampled along
a river in Sweden (Viskan) where numerous textile industries are located (Andersson and Blomkvist
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Figure 6-2.  Temporal Trends in the Concentrations (ng/g Lipid Weight) of PBDE
Congeners in Lake Trout from Lake Ontario, Canada
Source: Ismail et al. 2009 
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Table 6-7.  Concentrations (ng/g Lipid Weight Except as Noted) of Several
Polybrominated Diphenyl Ethers (PBDEs) in Freshwater Fish Samples 
from Europe
Sample 
type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Freshwater Pyrenees 0.40–0.51 0.24 0.16–0.18 No data No data Gallego et al.
fish Mountains 2007
Freshwater Tatras 0.20–0.26 0.17–0.21 0.043 No data No data Gallego et al.
fish Mountains 2007
Arctic char Lake Vättern, 400 64 51 520 No data Sellström et al.
Sweden 1993
Bream Netherlands 0.2–130 Not No data No data No data de Boer et al.
(several sites) (dw) detected 2000b
Eels Netherlands <20–1,400 No data No data <50–1,700 No data de Boer 1990
Osprey Sweden 1,800 140 200 2,140 No data Sellström et al.
1993
Pike Dalslands canal, 94–98 60–79 25–36 180–210 No data Sellström et al.
Sweden 1993
Pike River Viskan, <46–2,000 <37– <14– <130– Trace Sellström et al.
Sweden, 1,600 1,000 4,600 1998a
upstream and 
downstream
Several Germany No data No data No data 19–983* No data Krüger 1988
fish
species
Trout Dalslands canal, 120–460 130–590 33–150 280–1,200 No data Sellström et al.
Sweden 1993
Whitefish Lake 15 7.2 3.9 26 No data Sellström et al.
Storvindeln, 1993
Sweden
Whitefish Lake Geneva, 26 13 2.5 44* No data Zennegg et al.
Switzerland 2003
Whitefish Lake Greifen, 96 52 9.1 165* No data Zennegg et al.
Switzerland 2003
Whitefish Lake Biel, 75.9 39 7.1 128* No data Zennegg et al.
Switzerland 2003
Whitefish Lake Lucerne, 56 46 10 121* No data Zennegg et al.
Switzerland 2003
Whitefish Lake Zürich, 56 25 4.5 89* No data Zennegg et al.
Switzerland 2003
Whitefish Lake Nauchatel 41 20 4.0 68* No data Zennegg et al.
Switzerland 2003
Whitefish Lake Constance, 32 15 2.9 52* No data Zennegg et al.
Switzerland 2003
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Table 6-7.  Concentrations (ng/g Lipid Weight Except as Noted) of Several
Polybrominated Diphenyl Ethers (PBDEs) in Freshwater Fish Samples 
from Europe
Sample 
type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Whitefish Lake Thun,
Switzerland
19 12 2.5 36* No data Zennegg et al.
2003
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).
BDE = brominated diphenyl ether
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1981).  These textile industries have used PBDEs in the production of textiles.  BDE 47 was the 
predominant congener at 70–80% of the total PBDEs.  In 1977, the PBDEs were not detected in fish 
sampled at the same sites. The elevated concentrations of BDE 47, BDE 99, and BDE 100 were later
confirmed in a follow-up study in which fish were caught from approximately the same locations 
(Sellström et al. 1993).  In the current study, BDE 47 was the predominant congener at 65–96% of total
PBDEs.  Several fish species were sampled (pike, perch, bream, eel, tench, and sea trout) in these studies.
In 1995, fresh samples of pike and sediments were collected at four of eight sites along River Viskan in
order to search for point sources of contaminants.  The combined concentrations of BDE 47, BDE 99, and 
BDE 100 ranged from not detected to 4,600 ng/g lipid weight; with BDE 47 being the predominant
congener (50–90% of total).  DecaBDE (BDE 209) was found in a few fish at trace amounts.  The lowest
concentrations of the PBDEs were found upstream of the industries.  The concentrations of PBDEs
increased further downstream as more industries were passed (Sellström et al. 1998a).  Concentrations of
BDE 47 ranged from <20 to 1,700 ng/g lipid in eels (Anguilla anguilla) from Dutch rivers and lakes (at
10 locations); BDE 47 comprised 70% of the total PBDEs (de Boer 1990). Bream (Abramis brama) 
sampled from several sites in the Netherlands had concentrations of BDE 47 ranging from 0.2 to 130 ng/g 
dry weight (de Boer et al. 2000b).  BDE 99 was below the detection limits. BDE 153 ranged from
<0.04 to 4.1 ng/g dry weight.  Allchin et al. (1999) conducted a study of PBDEs in plaice (Pleuronectes 
platessa), flounder (Platichthys flesus), and dab (Limanda limanda) collected in the estuaries of rivers in
the United Kingdom.  Suspected sources of PBDEs in the estuaries include a manufacturer of pentaBDE
and octaBDE, several industries using pentaBDE, and several landfills receiving wastes suspected to
contain PBDEs.  Concentrations of BDE 47, BDE 99, pentaBDE (as technical mixture DE-71), and 
octaBDE (as technical mixture DE-79) in fish ranged from not detected to 9,500 ng/g lipid weight, not
detected to 370 ng/g lipid weight, 47–1,200 ng/g lipid weight, and not detected to 1,200 ng/g lipid weight.
The highest concentrations were at Tees Bay downstream from a manufacturing plant on the River Tees.
These results are similar to the situation found in Sweden along the River Viskan (Andersson and 
Blomkvist 1981; Sellström et al. 1993).  Freshwater mussels (Dreissena polymorpha) were collected at
several locations in the Netherlands and analyzed for BDE 47, BDE 99, BDE 153, and BDE 209 (de Boer
et al. 2000b).  Concentration ranges for the congeners were 0.7–17, 0.4–11, and <0.1–1.5 ng/g dry weight
for BDE 47, BDE 99, and BDE 153, respectively; BDE 209 was below the detection limit.  Poma et al.
(2014) analyzed freshwater zebra mussels in Lake Maggiore, Northern Italy for the presence of PBDEs 
and other brominated flame retardants. Total tri- to heptaBDE concentrations ranged from 1.0 ng/g for
samples obtained in in May 2011 to 144.6 ng/g for samples collected in September 2012.  The authors
noted that even though penta- BDE was banned in Europe in 2004, increasing concentrations of tri- to 
heptaBDE congeners in mussels from 2011 to 2012 were observed in the samples obtained.  Average
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values of hepta to decaBDE congeners in zebra mussels ranged from 88.2 to 182.8 ng/g and tended to be
dominated by BDE 209, with average concentrations of 71.2–144.7 ng/g (Poma et al. 2014).  The
presence of the lower brominated octa and hepta congeners was likely due to metabolism of BDE 209 
within the organism or the environmental debromination of BDE 209 followed by uptake by the zebra
mussels.
Saltwater Fish. Spatial trends show higher concentrations of lower-brominated BDE congeners found
near human populated areas.  The congener profiles show the highest concentrations for BDE 47.  
Representative concentrations of several PBDEs in marine aquatic species are summarized in Table 6-8.  
BDEs were detected in 10/10 white croakers and 8/8 shiner surfperch obtained from the San Francisco 
Bay at concentrations of (total PBDEs) 470–2, 260 and 730–3,930 ng/g lipid, respectively (Klosterhaus et
al. 2012).  Mean levels of total PBDEs in halibut, jack smelt, leopard shark, northern anchovy, shiner
surfperch, striped bass white croaker, and white sturgeon collected from the San Francisco Bay in 2009 
ranged from 1.5 to 8.3 ng/g wet weight (Sutton et al. 2015).  In the year 2000, sole liver collected from
five sites along the Canadian west coast (Crofton, Bamfield, Kitimat, Trincomali, and Vancouver) were 
analyzed for 14 BDE congeners (Ikonomou et al. 2002); the total PBDE concentrations were 64–340 ng/g 
lipid while the three highest congener concentrations were 27–160 ng/g lipid (BDE 47), 8.5–54 ng/g lipid
(BDE 100), and 9.5–46 ng/g lipid (BDE 99).  The highest concentrations were found in sole samples
collected near Vancouver, Canada.  DecaBDE was not detected in these samples at the level of procedural
blank.  Farmed salmon collected at two locations in Canada were analyzed for PBDE congeners (Easton 
et al. 2002).  Forty-one congeners were detected with BDE 47 at the highest concentration (690 and 
2,600 ng/g wet weight) followed by BDE 99 and BDE 100; total BDE congener concentrations were
1,188 and 4,147 ng/g wet weight for the two samples. Likewise, wild salmon from four locations in 
Canada were analyzed for BDE congeners.  Concentrations were a factor of 10 lower for these samples 
compared to farmed salmon samples.  The total PBDE concentration for the 41 detected congeners ranged 
from 38.7 to 485.2 ng/g wet weight. The concentration of the highest congener, BDE 47, ranged from
29 to 280 ng/g wet weight (Easton et al. 2002).  PBDE concentrations in skipjack tuna from Asian 
offshore waters, off-Seychelles, off-Brazil, and open seas were determined for samples collected during
1996–2001 (Ueno et al. 2003).  The concentration of total BDEs in muscles tissues ranged from not
detected (<0.05 ng/g lipid) to 53 ng/g lipid.  The concentration of the highest congener in muscle tissues, 
BDE 47, ranged from <0.1 to 15 ng/g lipid.  BDE 99, BDE 100, BDE 153, and BDE 154 also were
detected; BDE 209 was below the detection limit (<5.0 ng/g lipid) for these samples.  Samples collected
off the coast of the Seychelles (relatively pristine area) did not have detectable concentrations of any
PBDEs, while samples collected in industrial areas of southeast Asia had the highest.  Fall-caught
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Table 6-8.  Concentrations (ng/g Lipid Weight) of Several Polybrominated 
Diphenyl Ethers (PBDEs) in Marine Aquatic Species
Sample type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference













No data No data No data 5.0±1.2* 
(ww)
ND Sutton et al.2015








Striped bass San 
Francisco 
Bay
No data No data No data 5.0±2.6* 
(ww)
ND Sutton et al.2015








Winter Northwest 35 2.5 6.4 52* ND Shaw et al. 2009
Flounder Atlantic
Atlantic Northwest 40 6.9 6.8 82* ND Shaw et al. 2009
Herring Atlantic
American Northwest 42 4.0 7.0 69* 1.9 Shaw et al. 2009
Plaice Atlantic
White Hake Northwest 25 0.63 7.2 42* 0.91 Shaw et al. 2009
Atlantic
Alewife Northwest 8.3 3.6 1.7 18* ND Shaw et al. 2009
Atlantic
Atlantic Northwest 20 7.5 4.1 69* 1.6 Shaw et al. 2009
Mackerel Atlantic













Easton et al. 2002
Salmon Canada 29–280 ND–97 4.2–43 38.7–485.2 No data Easton et al. 2002
(wild) (ww) (ww) (ww) (ww)












        
 
 






       
 
  





       
        
 
 
         
        
 
          
  
 
       
 
 






     
 
         
         
         
       
 
         
 
 
       
 
 
        
         
 
        






6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-8.  Concentrations (ng/g Lipid Weight) of Several Polybrominated 
Diphenyl Ethers (PBDEs) in Marine Aquatic Species
Sample type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Sole liver West coast, 27–160 9.5–46 8.5–54 64–340* ND Ikonomou et al.
Canada 2002
Skipjack Seychelles, <0.1 <0.05 <0.05 ND <5.0 Ueno et al. 2003
tuna Indian 
Ocean
Skipjack East China 9.0–15 2.4–4.7 3.4–4.4 23–34 <5.0 Ueno et al. 2003
tuna Sea
Skipjack Pacific 2.9–7.9 0.18–3.0 0.56–2.1 5.8–21 <5.0 Ueno et al. 2003
tuna Ocean
Herring Baltic Sea 19–38 7.8–17 3.4–6 30–61 No data de Wit 2002 
Sellström et al.
1993
Herring Baltic Sea 3.2–27 ND–2.9 1.3–1.9 3.2–32 No data Haglund et al. 1997
Herring Baltic Sea 7.6–24 4.3–3.9 No data 12.9–28.3* No data Strandman et al.
1999
Herring Baltic Sea 6.3 0.6 0.8 12* No data Burreau et al. 1999
Herring Kattegatt, 12 3.4 1.6 17 No data de Wit 2002;
Sweden Sellström et al.
1993
Herring North Sea 8.4–100 No data No data No data No data de Boer 1990
Sprat Baltic Sea 17.5– 1.9–9.5 No data 21–149* No data Strandman et al.
(different 140.8 1999
age groups)
Sprat Baltic Sea 4.3 0.7 0.8 8.4* No data Burreau et al. 1999
Cod liver North Sea 170 No data No data 1.9–360 No data de Boer 1989
Salmon Baltic Sea 167 52 44 220 No data Haglund et al. 1997
Salmon Baltic Sea 190 52 46 290 No data Asplund et al. 
1999b
Salmon Baltic Sea 46 7.3 6.4 86* No data Burreau et al. 1999
Several fish Japan No data No data No data 0.1–17* No data Watanabe et al.
species 1987
Yellowfin Japan 0.5 0.4 0.25 1.9* No data Ohta et al. 2000
tuna
Yellowtail Japan 17 4.5 4.0 30.5* No data Ohta et al. 2000
Yellowtail Japan 29 3.3 5.3 44* No data Ohta et al. 2000
(cultured)
Salmon Japan 22 8.1 5.3 46* No data Ohta et al. 2000
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Table 6-8.  Concentrations (ng/g Lipid Weight) of Several Polybrominated 
Diphenyl Ethers (PBDEs) in Marine Aquatic Species











<0.01–4.6 No data No data No data de Boer et al.
2000b
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).
BDE = brominated diphenyl ether; dw = dry weight; ND = not detected; ww = wet weight
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herring (Clupea harengus) muscle from five sites along the Swedish coast was analyzed for BDE 47, 
BDE 99, and BDE 100; the combined concentration of these three congeners ranged from 17 to 61 ng/g 
lipid, with BDE 47 being the dominant congener (Sellström et al. 1993).  Likewise, the concentration of
BDE 47 in Baltic herring ranged from 3.2 to 27 ng/g lipid in different age groups; the combined 
concentration of BDE 47, BDE 99, and BDE 100 ranged from 3.2 to 32 ng/g lipid (Haglund et al. 1997);
2-year-old herring had the lowest concentrations and 5-year-old herring had the highest concentrations.  
Similarly, Strandman et al. (1999) observed increasing concentrations with age of BDE 47, BDE 99, and 
BDE 153 in Baltic sprat (Sprattus sprattus, age 3–13 years).  However, this trend was not evident for
herring.  BDE 47 was the primary congener with concentrations ranging from 7.6 to 24 ng/g lipid weight 
for 1–3-year-old sprat, 17–140 ng/g lipid weight for 3–13-year-old sprat, and 7.6–24 ng/g lipid weight in
herring.  The concentrations of BDE 47, BDE 99, and BDE 100 in whole-body composites of herring
were 6.21, 0.62, and 0.81 ng/g lipid, respectively; in sprat, the concentrations were 4.32, 0.71, and 
0.80 ng/g lipid, respectively (Burreau et al. 1999).  Baltic sea herring had similar concentrations of
BDE 47 (46.3 ng/g lipid) compared to 8.4–100 ng/g lipid of BDE 47 found by de Boer (1990) for herring
collected from three regions of the North Sea.  BDE 47, BDE 99, and BDE 153 concentrations in Baltic
salmon (Salmo salar) muscle were 167, 52, and 4.2 ng/g lipid, respectively (Haglund et al. 1997).  
BDE 47, BDE 99, and BDE 100 concentrations were 47, 7.2, and 6.3 ng/g lipid, respectively, in whole-
body composites (Burreau et al. 1999).  In another study, the concentrations of BDE 47, BDE 99, and 
BDE 100 were determined in muscle, ripe eggs, and blood plasma from Baltic salmon (Asplund et al. 
1999a).  The mean concentrations of PBDEs in tissues from Baltic salmon (ng/g lipid weight) were as
follows: BDE 47 (muscle, 190; ripe eggs, 64; blood, 190), BDE 99 (muscle, 52; ripe eggs, 16; blood, 55), 
and BDE 100 (muscle, 46; ripe eggs, 18; blood, 59).  Cod (Gadus morhua) liver samples at three
locations of the North Sea had combined concentrations of BDE 47 and BDE 99 of 1.9–360 ng/g lipid (de
Boer 1989).  BDE concentrations in flounder were 0.6–20 ng/g dry weight for BDE 47 and <0.01– 
4.6 ng/g dry weight for BDE 99 from several sites in the Netherlands (de Boer et al. 2000b). 
Concentrations of BDE 153 and BDE 209 were below the detection limit.  In 1996, de Boer et al. (2001)
measured the concentrations of two BDE congeners in flounder liver samples from the Amsterdam and
Rotterdam harbors, and off the Dutch coast; BDE 47 and BDE 99 ranged from 15 to 280 and from <2 to 
24 ng/g lipid weight, respectively.  Olsson et al. (1999) detected BDE 47 in perch (Perca fluviatilis) from
Latvia in a study examining environmental contamination in coastal areas of the former Soviet Union; the
concentration of BDE 47 ranged from 6.4 to 10 ng/g lipid weight in the perch.  
Watanabe et al. (1987) detected PBDEs in numerous marine fish and shell fish in Japan. TetraBDE and
pentaBDE concentrations ranged from 0.1 and 17 ng/g fresh weight, with tetraBDE being the major
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congener.  DecaBDE was also detected in a mussel sample from Osaka Bay (at 1.4 μg/kg wet weight).  
Japanese market fish were analyzed for PBDEs. The highest combined PBDE concentrations (BDE 28, 
BDE 47, BDE 66, BDE 99, BDE 100, BDE 153, and BDE 154) were in salmon, cultured yellowtail, and 
wild yellowtail muscle (46, 44, and 30.5 ng/g lipid weight, respectively) and lowest concentrations in
yellowfin tuna (1.9 ng/g lipid weight) (Ohta et al. 2000).  BDE 47 was major congener in all samples.  In
another study, several fish species from Japan were analyzed for 15 BDE congeners (Hori et al. 2000).  
The PBDE concentrations ranged from 0.00136 to 2.1 ng/g fresh weight, with BDE 47 as the predominant
congener.  Seven species of marine fish (conger eel, flounder, gray mullet, horse mackerel, red sea bream,
sea bass, and yellowtail) were collected from the Inland Seas near Seto, Japan (Akutsu et al. 2001). 
Seven PBDEs (BDE 28, BDE 47, 2,3’,4,4’-tetraBDE [BDE 66], BDE 99, BDE 100, BDE 153, and 
BDE 154) were detected in all samples, with BDE 47 being the most abundant congener.  Concentrations
of total PBDEs in gray mullets and yellowtails were 63 and 15 ng/g lipid weight, respectively.
Marine Aquatic Organisms. Marine mussels (Mytilus edulis) collected at several locations in the 
Netherlands and analyzed for BDE 47, BDE 99, BDE 153, and decaBDE (BDE 209) (de Boer et al.
2000b).  Concentrations of BDE 47 and BDE 99 were 0.9–4.3 and 0.3–1.6 ng/g dry weight, respectively.  
BDE 153 and BDE 209 were not detected.  Di- to heptaBDE were analyzed for in hepatopancreas 
samples from Dungenes crab from several sites on the Strait of Georgia, British Columbia, Canada 
(Ikonomou et al. 1999).  The primary congener detected was BDE 47.  The combined concentration of
BDE 47 and BDE 99 was approximately 100–350 ng/g lipid weight.
Marine Animals. In marine animals, temporal trends show increasing concentrations of lower­
brominated BDE congeners with higher concentrations found near human-populated areas.  In all marine
animal studies, the congener profiles show the highest concentrations for BDE 47.  The concentrations of
several PBDEs in marine animals are summarized in Table 6-9.  Frouin et al. (2011) reported PBDE
concentrations measured from serum and blubber samples obtained from six harbor seal pups (Phoca
vitulina) live captured in May 2007, six harbor seal pups (Phoca vitulina) live captured in May 2008, six 
grey seal pups (Halichoerus grypus) live captured early January 2008, and six harp seal pups (Phoca 
groenlandica) live captured in March 2008 from the Gulf of St. Lawrence or the St. Lawrence Estuary.
The ƩPBDEs in serum (BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, and BDE 155) and blubber
(BDE 28, BDE 47, BDE 49, BDE 66, BDE 99, BDE 100, BDE 153, BDE 154, BDE 155, and BDE 183)
were strongly correlated.  BDE 47 was detected in all serum samples and accounted for 66–73% of
ƩPBDEs.  ƩPBDE concentrations in lipid ranged from 21 to 530 ng/g lipid weight and from 34 to 
600 ng/g lipid weight in serum.  PBDEs have been detected in several species of seal from several













        
 




       
 
 





































































6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-9.  Concentrations (ng/g Lipid Weight) of Several Polybrominated 
Diphenyl Ethers (PBDEs) in Marine Animals
Sample type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Bottlenose Gulf of Mexico No data No data No data 8,000 No data Kuehl and
dolphin Haebler 1995
Harbor seal Northwest 904 134 49 1,385* 1.2 Shaw et al. 2009
Atlantic
Harbor seal San Francisco No data No data No data 530–5,075* No data Klosterhaus et al.
Bay, California 2012
Cormorant San Francisco No data No data No data 3,425–5,550* No data Klosterhaus et al.
eggs Bay, California 2012
Harbor seal San Francisco 46– 17–303 No data No data No data She et al. 2000
Bay, California 6,682
Cormorant Suisan Bay, No data No data No data 19,000±4,000* No data Sutton et al. 2015
eggs CA (2002)
Cormorant Suisan Bay, No data No data No data 6,100±5,200* No data Sutton et al. 2015
eggs California 
(2006)
Cormorant Suisan Bay, No data No data No data 440±1708 No data Sutton et al. 2015
eggs California 
(2009)
Cormorant Suisan Bay No data No data No data 1,300±900* No data Sutton et al. 2015
eggs California 
(2012)
Cormorant Central Bay, No data No data No data 9,100±2200 No data Sutton et al. 2015
eggs California 
(2002)
Cormorant Central Bay, No data No data No data 3,700±500 No data Sutton et al. 2015
eggs California 
(2004)
Cormorant Central Bay, No data No data No data 1,800±400 No data Sutton et al. 2015
eggs California 
(2006)
Cormorant Central Bay, No data No data No data 1,800±300 No data Sutton et al. 2015
eggs California 
(2009)
Cormorant Central Bay, No data No data No data 1,100±200 No data Sutton et al. 2015
eggs California 
(2012)
Cormorant South Bay No data No data No data 4,200±400 No data Sutton et al. 2015
eggs California 
(2002)
Cormorant South Bay No data No data No data 3,300±300 No data Sutton et al. 2015
eggs California 
(2004)



























      
 
  































   











    





































       
  











6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-9.  Concentrations (ng/g Lipid Weight) of Several Polybrominated 
Diphenyl Ethers (PBDEs) in Marine Animals
Sample type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Cormorant South Bay No data No data No data 4,400±2,100 No data Sutton et al. 2015
eggs California 
(2006)
Cormorant South Bay No data No data No data 2,100±1,200 No data Sutton et al. 2015
eggs California 
(2009)
Cormorant South Bay No data No data No data 1,100±100 No data Sutton et al. 2015
eggs California 
(2012)
Harbor seal San Francisco 1,304 112 87.1 1,730* No data She et al. 2002 

(blubber) Bay, California 

Herring Gull Lake Superior, 253–323 202–284 83.6–113 664–887 (fw)* No data Norstrom et al. 

Eggs United States (fw) (fw) (fw) 2002 

Herring Gull Lake Michigan, 522–602 323–459 167–203 1,366–1,400 No data Norstrom et al. 

Eggs United States (fw) (fw) (fw) (fw)* 2002 

Herring Gull Lake Huron, 146–291 74.6–161 37.3–89.5 308–652 (fw)* No data Norstrom et al. 

Eggs United States (fw) (fw) (fw) 2002 

and Canada
Herring Gull Detroit River, 322 (fw) 130 (fw) 92.6 (fw) 639 (fw)* No data Norstrom et al.
Eggs United States 2002
Herring Gull Lake Erie, 70–163 52–55.9 24.6–51.8 192–340 (fw)* No data Norstrom et al.
Eggs United States (fw) (fw) (fw) 2002
Herring Gull Niagara River, 168 (fw) 111 (fw) 53 (fw) 432 (fw)* No data Norstrom et al.
Eggs United States 2002
Herring Gull Lake Ontario, 220–401 113–322 66.5–102 530–1,003 No data Norstrom et al.
Eggs Canada (fw) (fw) (fw) (fw)* 2002
Herring Gull St. Lawrence 220 (fw) 89.8 (fw) 56.6 (fw) 453 (fw)* No data Norstrom et al.
Eggs River, United 2002
States












Beluga Canadian No data No data No data 81–160* No data Alaee et al. 1999
whale Arctic
Beluga Southeast 10 0.9 1.6 15* No data Stern and
whale Baffin, Canada Ikonomou 2000




































       
         
 
 
          
 














     













     
 
 
       
 
        
 
         
 

















6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-9.  Concentrations (ng/g Lipid Weight) of Several Polybrominated 
Diphenyl Ethers (PBDEs) in Marine Animals
Sample type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Bottlenose South Atlantic No data No data No data 180–220 No data Kuehl et al. 1991
dolphin Ocean
Brunnich’s Svalbard, No data No data No data 130 No data Jansson and 
guillemot Sweden Asplund 1987
Cormorant England, 170– 50–250 50–1,500 300–6,400* No data Allchin et al. 2000
United 3,500
Kingdom
Cormorant Rhine delta, No data No data No data 28,000 (fw) No data de Boer 1990
liver Germany
Galaucous Bear Island, 290–634 160 No data No data No data de Wit 2002
gull Norway (Arctic)
Grey seal Baltic Sea 650 40 38 730 No data de Wit 2002;
Sellström et al.
1993
Grey seal Baltic Sea 308 54 57 419 No data Haglund et al.
1997
Grey seal Baltic Sea No data No data No data 208 No data Andersson and 
Wartanian 1992
Harbor British 50– No data No data 350–2,300* No data Ikonomou et al.
porpoise Columbia, 1,200 2000
Canada
Harbor England and 227– No data No data 440–7,670 No data Law et al. 2000
porpoise Wales, United 6,790
Kingdom
Harbor seal Baltic Sea No data No data No data 90 No data Jansson and 
Asplund 1987
Harbor seal Skagerrak, No data No data No data 230 No data Andersson and 
Norway and Wartanian 1992
Sweden
Harbor seal North Sea 390– 42–660 25–450 600–6,000 No data de Boer et al.
4,900 1998b
Long-finned Faeroe Islands 410– 160–600 87–280 843–3,160* No data Lindström et al.
pilot whale 1,780 1999
Long-finned Faeroe Islands 66–860 24–170 12–98 126–1,250* No data van Bavel et al.
pilot whale 1999
Minke whale Netherlands 630 160 79 870 No data de Boer et al.
1998b
Ringed seal Baltic sea 256 33 61 350 No data Haglund et al.
1997
Ringed seal Baltic sea No data No data No data 320 No data Andersson and 
Wartanian 1992
Ringed seal Svalbard, 47 1.7 2.3 51 No data de Wit 2002;
Sweden Sellström et al.
1993












        
 
 









       
 
 
       
 
 













6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-9.  Concentrations (ng/g Lipid Weight) of Several Polybrominated 
Diphenyl Ethers (PBDEs) in Marine Animals
Sample type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Ringed seal Canadian 
Arctic
No data No data No data 25.8–50* No data Alaee et al. 1999
Ringed seal Holman Island,
Northwest










Netherlands 5,500 1,000 1,200 7,700 No data de Boer et al.
1998b
dolphin
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).
BDE = brominated diphenyl ether; fw = fresh weight
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6.  POTENTIAL FOR HUMAN EXPOSURE
different sites.  In San Francisco Bay, California, the concentrations of PBDEs in harbor seals have 
increased dramatically based on samples obtained from 1989 to 1998.  The samples from 1998 had PBDE
concentrations among the highest reported for this species (She et al. 2002). The concentration of total
PBDEs (sum of BDE 47, BDE 99, BDE 100, BDE 153, and BDE 154) in harbor seal blubber increased 
by over a factor of 50 from a concentration of 88 ng/g lipid for species samples collected in 1988 to a 
concentration of 2,985–8,325 ng/g lipid for species samples collected in 1998.  The highest
concentrations reported were for BDE 47, which increased from 45.6 ng/g lipid for blubber samples in 
1989 to 2,343–6,682 ng/g lipid for blubber samples collected in 1998. The dominance of the tetraBDE
congeners over other congeners may indicate that tetraBDEs bioaccumulate more than the higher­
brominated congeners (She et al. 2002).  
In the Baltic Sea, female grey seals (Halichoerus grypus) sampled in 1979–1985 contained 730 ng 
PBDE/g lipid in their blubber (sum of BDE 47, BDE 99, and BDE 100) (Jansson et al. 1993); male grey
seals had 280 ng PBDE/g lipid weight (Andersson and Wartanian 1992).  Male ringed seals (Pusa
hispida) from the Baltic Sea had 320 ng PBDE/g lipid weight (Andersson and Wartanian 1992).  Baltic
gray and ringed seal blubber sampled between 1981 and 1988 contained 419 and 350 ng PBDEs/g lipid
(total of BDE 47, BDE 99, and BDE 100), respectively (Haglund et al. 1997).  In 1981, female ringed 
seals from Svalbard in the Swedish Arctic contained 40–51 ng PBDEs/g lipid in blubber (Jansson and 
Asplund 1987, Jansson et al. 1993; Sellström et al. 1993).  Higher concentrations of PBDEs are generally
evident in Baltic Sea ringed seals (320–350 ng/g lipid) (Andersson and Wartanian 1992; Haglund et al.
1997) compared to Arctic ringed seals (26–51 ng/g lipid) (Alaee et al. 1999; Jansson et al. 1987).  The
concentration of PBDEs in harbor seals from Skagerrak on the Swedish west coast was 230 ng PBDE/g 
lipid (Andersson and Wartanian 1992).
She et al. (2000) analyzed the concentration of BDE 47, BDE 99, and BDE 153 in harbor seals from the
San Francisco Bay area. Mean concentrations for BDE 47, BDE 99, and BDE 153 were 1,124, 107, and 
50 ng/g lipid weight, respectively.  Alaee et al. (1999) found that ringed seals from the Canadian Arctic
had mean PBDE concentrations (sum of di- to hexaBDEs) of 25.8 ng/g lipid weight (females) and 
50.0 ng/g lipid weight (males). The lower concentrations in female seals suggest that PBDEs are 
transferred to young through breast milk.  On Holman Island, Northwest Territory, Canada (Arctic) in 
1996, ringed seals had total PBDE concentrations of 2.4–4.9 ng/g lipid for males. The concentrations of
PBDEs were found to increase with age (Ikonomou et al. 2000).  In a temporal trend study, archived 
samples of blubber from ringed seals from Holman Island, Northwest Territory, Canada were analyzed
for PBDE concentrations. The concentration of PBDE in samples collected between 1981 and 1996 
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6.  POTENTIAL FOR HUMAN EXPOSURE
increased from approximately 0.3 ng/g lipid weight in 1981 to 3.6 ng/g lipid weight in 1996 (Ikonomou et 

al. 2000).  

The concentrations of PBDEs have been determined in harbor porpoises (Phocaena phocaena) from 

British Columbia, Canada (Ikonomou et al. 2000) and from the coasts of England and Wales (Law et al. 

2000).  In British Colombia (Canada) samples, the total PBDE concentrations (sum of tri- to hepta­

congeners) were 350–2,300 ng/g lipid weight; BDE 47 was found at the highest concentrations in these 

samples (range, 50–1,200 ng/g lipid weight) (Ikononmou et al. 2000).  Concentrations of total PBDEs 

(sum of 13 congeners) along the coast of England and Wales, ranged from 450 to 7,670 ng/g lipid weight, 

with BDE 47 concentrations ranging from 227 to 6,790 ng/g lipid weight (Law et al. 2000). 

During a mass mortality event on the south Atlantic coast in 1987–1988, blubber samples were collected 

from three bottlenose dolphins (Tursiops truncatus); these samples contained 180–220 ng PBDEs/g lipid 

(Kuehl et al. 1991).  Blubber samples, taken from stranded bottlenose dolphins from several locations 

around the Gulf of Mexico in 1990, contained 3,110 ng PBDEs/g lipid (Kuehl and Haebler 1995).  On the 

Dutch coast in early 1998, de Boer et al. (1998b) found PBDEs in blubber of one whitebeaked dolphin 

(Lagenorhynchus albirostris); the concentrations of BDE 47, BDE 99, and BDE 100 were 5,500, 1,000, 

and 1,200 ng/g lipid weight, respectively. 

The concentration of 19 PBDEs was determined in long-finned pilot whale (Globicephala melas) from 

the Faeroe Islands in the north Atlantic (Lindström et al. 1999).  Young males and females had the highest 

concentrations, ranging from 3,000 to 3,160 ng/g lipid; lower concentrations were observed for both adult 

females (840–1,050 ng/g lipid) and males (1,610 ng/g lipid). The predominant isomers in all samples 

were BDE 47 and BDE 99, accounting for 70% of the sum of 19 congeners.  van Bavel et al. (1999) also 

studied the concentrations of PBDEs in long-finned pilot whales.  They observed a similar trend with 

young animals having higher PBDE concentrations (740 ng/g lipid weight) and adult animals having 

lower concentrations (females, 230 ng/g lipid; males, 540 ng/g lipid).  In Beluga whales sampled in 1997 

from southeast Baffin (Cumberland Sound), the concentrations of total PBDEs and BDE 47 were 15 and 

10 ng/g lipid weight, respectively (Stern and Ikonomou 2000).  Between 1982 and 1997, total PBDE 

concentrations in archived blubber samples of beluga whales from southeast Baffin Canada increased 

significantly.  For this time period, BDE 47, BDE 99, BDE 100, and BDE 154, and total PBDEs 

increased by factors of 6.5, 10.3, 7.9, 30.6, and 6.8, respectively (Stern and Ikonomou 2000).  Three 

sperm whales (Physeter macrocephalus) and one minke whale (Balaenoptera acutorostrata) found 

stranded on the Dutch coast in early 1998 were analyzed for PBDEs (de Boer et al. 1998a, 1998b). 

Exposure to PBDEs for these animals occurred in the deep Atlantic through the food web.  The 
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6.  POTENTIAL FOR HUMAN EXPOSURE
concentrations of PBDEs in these marine mammals were as follows: sperm whale (BDE 47, 130– 
250 ng/g lipid weight; BDE 99, 32–64 ng/g lipid weight; and BDE 100, 21–35 ng/g lipid weight) and 
minke whale (BDE 47, 630 ng/g lipid weight; BDE 99, 160 ng/g lipid weight; BDE 100, 79 ng/g lipid
weight); BDE 209 (decaBDE) was below detection limits in all samples.
PBDEs, methoxylated (MeO-) PBDEs, and hydroxylated (OH-) PBDEs were evaluated in whole blood
samples collected from northern fur seal (Callorhinus ursinus), spotted seal (Phoca largha), Steller sea
lion (Eumetopias jubatus) and ribbon seal (Phoca fasciata) (Nomiyama et al. 2014), and harbor porpoise
and Dall’s porpoise (Ochiai et al. 2013) from northern Japanese coastal waters. The samples contained
3.9–280 pg/g median values of 6OH-BDE 47; <1.0–51 pg/g median values of 2’MeO-BDE 68; 2.9– 
1,020 pg/g median values of 6MeO-BDE 47; <1–18 pg/g median values of 6MeO-BDE 99; and <100– 
230 pg/g median values of total PBDEs.
Marine Birds. Increasing concentrations of PBDEs have been found in marine birds and eggs, with 
BDE 47 found at the highest concentrations.  Di- and triBDE have been detected, but not quantified, in 
black skimmer (Rynchops nigra) tissues and eggs in the United States (Stafford 1983).  In 2000, herring
gull eggs collected from 15 locations around the Great Lakes (United States and Canada) were pooled and 
analyzed for PBDEs (Norstrom et al. 2002).  A total of 25 di- to hepta-BDE congeners were identified in 
herring gull through the Great Lakes system.  No mono-, octa-, nona-, or decaBDEs were found at the 
detection limit of the analysis (0.01–0.05 ng/g wet weight).  Seven congeners, BDE 28, BDE 47, BDE 99, 
BDE 100, BDE 153, BDE 154, and BDE 184, constituted 97.5% of total PBDEs (192–1,400 ng/g wet
weight).  BDE 47 was the dominant congener (70–602 ng/g wet weight) followed by BDE 99 (52– 
459 ng/g wet weight). The highest concentrations (1,003–1,400 ng/g wet weight) were found in two Lake
Michigan colonies and in Toronto Harbor, Lake Ontario (Norstrom et al. 2002).  Muscle tissues from
ospreys (Pandion haliaetus), found dead at various locations around Sweden, were pooled and analyzed 
for PBDEs (Jansson et al. 1993; Sellström et al. 1993).  The ospreys’ diet was freshwater fish.  The
combined concentration of BDE 47, BDE 99, and BDE 100 was 2,100 ng/g lipid in samples collected
between 1982 and 1986; BDE 47 was the primary congener (86%) in these samples (n=35).  High
concentrations of PBDEs may reflect biomagnification and/or fish consumption along their migratory
routes.  The concentrations of PBDEs in common guillemots (Uria aalge) collected in 1979–1981 from
the Baltic and North Seas were 370 and 80 ng/g lipid, respectively (Jansson and Asplund 1987).  As part
of the Swedish National Environmental Monitoring Program, guillemot eggs (St. Karlsö, Baltic Sea) are
collected yearly and placed in the Swedish Natural History Museum’s Environmental Specimens Bank.
The concentrations of BDE 47, BDE 99, and BDE 100 in pooled egg samples from the specimen bank










    
     
 
      
  
   
 
    
 
      




   
 
    
  
    









6.  POTENTIAL FOR HUMAN EXPOSURE
showed a significant increase from 1969 to the beginning of the 1990s, with highs of 1,100 ng/g for
BDE 47 in 1984 and 190 ng/g for BDE 99 in 1990 (Sellström et al. 1993, 1999).  Between 1992 and 
1997, PBDE concentrations started to decrease statistically.  In 1997, the PBDE concentration (sum of
BDE 47, BDE 99, and BDE 100) was 190 ng/g lipid, with BDE 47 as the predominant congener.  
Cormorant eggs obtained from the San Francisco Bay regions had total PBDE concentrations ranging 
from 3,425 to 5,550 ng/g (median, 5,500 ng/g) and was dominated by the penta (BDE 47, BDE 99, BDE
100) congeners (Klosterhaus et al. 2012).  Sutton et al. (20015) noted decreasing levels of PBDEs in 
cormorant eggs obtained from three locations in northern California.  Eggs collected from Suisun, 
Central, and South Bays in 2012 had total PBDE levels 93, 88, and 74% lower, respectively, when 
compared to the levels in eggs collected in 2002 (see Table 6-9).
Human Body Tissues and Fluids. The quantitative determination of the concentrations of PBDEs in 
body tissues and fluids is important in determining the human body burden of these chemicals.  
Increasing concentrations of lower-brominated PBDEs have been measured in blood and breast milk in 
temporal trend studies.  Individuals who consumed fish had a somewhat higher concentration of total
PBDEs in body fluids compared to individuals who ate less fish. 
Lipid adjusted serum levels of 11 BDE congeners collected from the U.S. general population were
reported in the Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables
(CDC 2015).  Serum levels for BDE 17, BDE 28, BDE 47, BDE 66, BDE 85, BDE 99, BDE 100, 
BDE 153, BDE 154, and BDE 183 were evaluated in samples collected between 2003 and 2008; BDE
209 was evaluated in samples collected from 2005 to 2008.  In the NHANES 2003–2004 survey years, 
congener BDE 47 was detected at a concentration of 20.5 ng/g lipid (geometric mean), the highest
concentration for all samples.  BDE 28, BDE 99, BDE 47, BDE 100, and BDE 153 were in >60% of
participants (Sjödin et al. 2008).  BDE 17 was not detected above the limit of detection of 1.0 and 0.6 
ng/g lipid in survey years 2003–2004 and 2005–2008, respectively.  BDE 209 was not detected above the
limit of detection, 6.0 and 5.8 ng/g lipid, in survey years 2005–2006 and 2007–2008, respectively.  
BDE 47, BDE 99, BDE 100, BDE 153, and BDE 154 were detected in 98, 100, 100, 96, and 48%, 
respectively, of serum samples collected from 48 mothers participating in the California Childhood 
Leukemia Study from 2006 to 2007 (Whitehead et al. 2015a).  Median serum levels ranged from below
the detection limit for BDE 154 to 35 ng/g lipid for BDE 47.  BDE 47 and BDE 153 were detected in 
whole blood of 61 and 85%, respectively, of 191 children participating in the California Childhood 
Leukemia Study from 1999 to 2007 (Whitehead et al. 2015b).  The median, 75th percentile, 90th 














   
    
     
   
       
   
       
   
   




     
 
    
   
   
  





      




6.  POTENTIAL FOR HUMAN EXPOSURE
percentile, and maximum levels were 410, 820, 1,500, and 17,000 pg/mL, respectively, for BDE 47 and 
130, 270, 460, and 6,500 pg/mL, respectively, for BDE 153.  
Tables 6-10, 6-11, and 6-12 summarize representative concentrations of PBDEs found in blood (serum), 
adipose tissue, breast milk, and other body tissues or fluids, respectively.  These studies indicate that 
concentrations of lower-brominated BDEs in body fluids are a factor of 10–100-fold higher for
individuals living in the United States compared to individuals living in other regions of the world
(e.g., Europe).  Serum samples collected from 12 U.S. blood donors in 1988 were analyzed for PBDEs, 
and BDE 47, BDE 153, BDE 183, and BDE 209 were detected (Patterson et al. 2000; Sjödin et al.
2001b).  Concentrations of these congeners were similar to those found in the Sjödin et al. (1999b) study
for the control group.  The median concentrations and ranges of BDE 47, BDE 153, BDE 183, BDE 209, 
and total PBDEs (sum of four congeners) were 0.63 (<0.4–24); 0.35 (0.08–2.0); 0.17 (0.09–1.3); <1 (<1– 
34); and 2.2 ng/g lipid weight, respectively (Sjödin et al. 2001b).  DecaBDE was found at concentrations
above the limit of quantification (1 pmol/g lipid) in 5 of 12 serum samples (Patterson et al. 2000).  
Schecter et al. (2005) provided a summary of PBDE (BDE 17, BDE 28, BDE 47, BDE 66, BDE 77, BDE
85, BDE 99, BDE 100, BDE 138, BDE 153, BDE 154, BDE 183, and BDE 209) concentrations in blood 
from 29 adults residing in Mississippi and 10 adults in New York City.  These blood samples were
obtained in 2003.  These data were then compared to archived blood samples from 100 individuals
obtained in 1973 from the Dallas, Texas area and stored at the University of Texas Southwestern Medical
Center.  The 13 PBDE congeners were not detected in the blood samples from the 100 individual
collected in 1973, but all congeners were detected in at least one of the blood samples obtained from the
29 residents of Mississippi collected in 2003.  BDE 28, BDE 47, BDE 77, BDE 99, BDE 100, BDE 138, 
BDE 153, BDE 154, and BDE 183 were all detected in at least one of the blood samples obtained in 2003 
from New York City residents.  BDE 47 followed by BDE 99 were the predominant congeners detected 
in both the Mississippi and New York residents blood samples collected in 2003.
Rawn et al. (2014) analyzed data from nearly 5,000 serum samples collected from the Canadian Health
Measures Survey (CHMS) from 2007 to 2009. PBDE congeners were detected in all samples tested, with 
a range of values of 27–130 ng/g lipid (total PBDEs) and a GM of 46 ng/g lipid. BDE 47 was the
predominant congener with a GM of 22 ng/g lipid followed by BDE 153 (GM=9.4 ng/g lipid), BDE 99 
(GM=4.6 ng/g lipid), BDE 100 (GM=4.1 ng/g lipid), and BDE 209 (GM 1.1 ng/g lipid) (Rawn et al. 
2014).














        
  













    




    
   
 
 




























   
 









   
 
 
       
 
 




       
 
 







6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-10.  Concentrations (ng/g Lipid Weight) of Several Polybrominated
Diphenyl Ethers (PBDEs) in Human Blood Samplesa
Sample 
type Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference




Human Mississippi and 25 11.1 4.7 (mean) 52.6 2.7 Schecter et al. 

blood New York City (mean) (mean) (mean) (mean) 2010 

(in 2003)
Maternal Indiana 28 (9.2– 5.7 (2.4– 4.2 (1.9– 37 (15– No data Mazdai et al. 2003
serum 310) 68) 110) 580)
Fetal Indiana 25 (8.4– 7.1 (2.2– 4.1 (1.8– 39 (14– No data Mazdai et al. 2003
serum 	 210) 54) 91) 460)
Maternal Texas 14.9 3.0 2.8 27.8* Schecter et al.
serum 2010
Human United States (in 20.5 No data 3.93 (geo- No data No data CDC 2015
serum 2003–2004) 	 (geo­ metric
metric mean)
mean)
Human United States (in 21.2–74.9 4.16–23.3 4.06–14.2 	 No data No data CDC 2015
serum 2005–2006) 	 (weighted (weighted (weighted 
arithmetic arithmetic arithmetic
mean) mean) mean)
Human United States (in 20.5–53.1 4.30–10.7 4.12–11.0 	 No data No data CDC 2015
serum 2007–2008) 	 (weighted (weighted (weighted 
arithmetic arithmetic arithmetic
mean) mean) mean)










9.4 (>31 ye 
ars) (mean)
Maternal France 2.831 1.939 0.365 No data 5.783 Antignac et al.
serum 2009
Cord France 	 No data 7.434 1.467 No data 27.110 Antignac et al.
serum 2009
Maternal Spain 2.3 0.35 No data 9.6 <0.7 Vizcaino et al.
serum 2011
Cord Spain 2.3 1.5 No data 9.6 <1.2 Vizcaino et al.
serum 2011
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Table 6-10.  Concentrations (ng/g Lipid Weight) of Several Polybrominated
Diphenyl Ethers (PBDEs) in Human Blood Samplesa
Sample 







4.4 (mean) 48 (mean) 1.9 
(mean)
Rawn et al. 2014
Maternal China 0.75 No data No data 29.26 2.12 Li et al. 2013a
serum (mean) (mean) (mean)
Cord China 0.62 No data No data 41.12 1.33 Li et al. 2013a
serum (mean) (mean) (mean)

























2.1 No data No data No data No data Bergman et al.




Sweden, no fish 
intake
0.40 No data No data No data No data Bergman et al.



























Germany 3.9 No data No data 5.6* No data Schröter-Kermani
et al. 2000
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  All values are median values unless stated otherwise.
BDE = brominated diphenyl ether; LOQ = limit of quantitation














       
  
  
     
 
  
      
        
       
 
       




     
        
        
 










6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-11.  Concentrations (ng/g Lipid Weight) of Several Polybrominated
Diphenyl Ethers (PBDEs) in Human Adipose Tissue Samples
Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Northern California 7.0–28 (18, 3.1–7.3 No data No data No data She et al. 2000
mean) (4.9 mean)
San Francisco, 16.5 (5.2– No data No data No data No data Petreas et al. 2003
California 196)
Sweden 8.8 1.1 1.8 11.7 No data Haglund et al. 1997
Sweden 2.2 (mean) 1.6 (mean) 0.1 (mean) 5* (mean) No data Meironyté Guvenius
and Norén 1999
Finland 7.3 (mean) 2.3 (mean) No data 6.2–22* No data Strandman et al. 1999
Finland 0.55 0.74 No data No data No data Smeds and Saukko 
2003
Spain 1.36 0.42 No data No data Meneses et al. 1999
(mean) (mean)
Japan 0.459 0.118 0.250 1.288* No data Choi et al. 2003
France 0.651 0.166 0.168 0.752 Antignac et al. 2009
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  All values are median values unless otherwise stated.
BDE = brominated diphenyl ether; ND = not detected 













       
      
 
  
        
        
       
       
 
        
 
 
       
        
       
 
 
      
 
        
        
       






















6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-12.  Concentrations (ng/g Lipid Weight) of Several Polybrominated 
Diphenyl Ethers (PBDEs) in Human Breast Milk Samples
Location BDE 47 BDE 99 BDE 100 ΣPBDEsa BDE 209 Reference
Texas 18.4 5.7 2.9 34.0 8.24 
(maximum)
Schecter et al. 2003
Texas 24.0 4.3 3.5 39.7* No data Schecter et al. 2010
California 29.7 6.40 5.65 54.5 1.41 Park et al. 2011
Pennsylvania 26 No data 4 No data No data LaKind et al. 2009
Philippines (mean) 0.9 0.22 0.19 1.8* <0.05 Malarvannan et al.
2013
France 1.152 0.527 0.226 1.615 Antignac et al. 2009
Uppsala County,
Sweden
1.78 0.43 0.27 3.15 No data Lind et al. 2003
Sweden 1.8 0.442 0.340 3.373* No data Darnerud et al. 1998




2.80 0.69 0.45 5.00* 0.25 Abdallah and Harrad
2014
Japan 0.18–0.57 0.09–0.13 0.07–0.18 0.65–1.48* Ohta et al. 2000
Japan No data No data No data 0.66–2.8* No data Ohta et al. 2002
Japan 0.57 0.33 No data No data No data Fujii et al. 2014
















No data Norén and Meironyté 
2000
aΣPBDEs is the sum of BDE 47, BDE 99, and BDE 100, but if more congeners are included, this is marked with an 
asterisk (*).  Concentrations are median concentrations unless stated otherwise
BDE = brominated diphenyl ether
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6.  POTENTIAL FOR HUMAN EXPOSURE
Serum samples were collected from a group of 50 Laotian immigrants (aged 19–40) participating in a
reproductive outcome study in the San Francisco Bay area (Petreas et al. 2002).  Participants were 
recruited and sampled in the late 1990s.  The mean concentration of BDE 47 in serum was approximately
95 ng/g lipid. The contemporary samples were compared to serum samples taken from a group of over
400 women from the San Francisco Bay in the 1960s.  Concentrations of BDE 47 in all archived samples 
were below the limit of detection.  Petreas et al. (2003) expanded their investigation to include a diverse
group of local women from the San Francisco Bay area sampled in the late 1990s. Their results
confirmed earlier findings reported in Petreas et al. (2002).  Mean concentrations of BDE 47 in serum
samples taken from California women ranged from 5 to 510 ng/g lipid, with a median (16.5 ng/g lipid) 3– 
10 times higher than those reported from Europe (Petreas et al. 2003).  In 2001, Mazdai et al. (2003)
determined the concentration of six PBDE congeners (BDE 47, BDE 99, BDE 100, BDE 153, BDE 154, 
and BDE 183) and total PBDEs in maternal and fetal blood samples taken from subjects in Indianapolis,
Indiana.  Median concentrations of total PBDE (sum of six congeners) were 39 and 37 ng/g lipid for fetal 
and maternal serum, respectively.  BDE 47 was the predominant congener reported at median 
concentrations of 25 and 28 ng/g lipid for fetal and maternal serum samples, respectively.  When
compared with serum PBDE concentrations for a similar population of Swedish mothers and newborns, 
the concentrations for the Indiana population were 20–69-fold higher for maternal blood and 30–106-fold 
higher for fetal blood.  In fact, the median blood concentrations for this study were comparable to 
Swedish workers considered to have direct work-related exposures.  These observations indicated that 
women in some areas of North America are exposed to much higher concentrations of lower-brominated 
BDEs (i.e., BDE 47) than European women.  In general, the PBDE congener profile found in human 
serum was similar to that detected in environmental samples, except that there was an apparent decrease 
in the proportion of BDE 99.  BDE 183 was detected in <17% of the samples even though it is the
primary congener in octaBDE commercial mixtures (Mazdai et al. 2003).  The conclusion that PBDE
concentrations are higher in North America than in Europe is further supported by a study conducted in 
the Netherlands that analyzed maternal serum from 90 female volunteers collected at the 35th week of
pregnancy, and in cord serum of a number of their infants (Meijer et al. 2008).  Median concentrations of
BDE 47, BDE 99, BDE 100, BDE 153, and BDE 154 in maternal serum were reported as 0.8, 0.2, 0.2, 
1.6, and 0.5 ng/g lipid weight, respectively.  Median concentrations of BDE 47, BDE 99, BDE 100, 
BDE 153, and BDE 154 in cord serum were 0.5, 0.1, 0.1, 0.9, and 0.3 ng/g lipid weight, respectively
(Meijer et al. 2008).  These concentrations are on the same order of magnitude as reported in other areas
of Europe and much lower than concentrations typically detected in the United States (Vizcaino et al.
2011).
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6.  POTENTIAL FOR HUMAN EXPOSURE
Six PBDE congeners (BDE 28, BDE 47, BDE 66, BDE 99, BDE 100, and BDE 153) were quantified in 
40 human blood-plasma samples from Sweden. The highest concentrations in plasma were for
BDE 47 and BDE 99; these congeners made up 70% of the total PBDE concentration.  The mean 
concentration of total PBDE was 2.1±1.4 ng/g lipid weight (Klasson Wehler et al. 1997).  Whole-blood 
samples from a German environmental specimen bank, collected in 1985, 1990, 1995, and 1999, 
contained measurable quantities of BDE 28, BDE 47, BDE 66, BDE 85, BDE 99, BDE 100, BDE 153, 
and BDE 154.  An increasing temporal trend was also observed; the mean total PBDE concentration (sum
of eight congeners) increased from 3.9 ng/g lipid weight in 1985 to 5.6 ng/g lipid weight in 1999.  For the
1999 sample, BDE 47 was the major congener found, with a mean concentration of 3.9 ng/g lipid weight.  
The total PBDE concentrations were significantly lower in female blood samples (Schröter-Kermani et al.
2000).  In a study of the influence of diet on concentrations of PBDEs, BDE 47 was measured in blood 
serum from persons with high fish intake and no fish intake (Bergman et al. 1999; Sjödin et al. 2000).  
High-fish-intake groups of Swedish and Latvian men had median BDE 47 concentrations of 2.2 and 
2.4 ng/g lipid weight, respectively, whereas the no-fish-intake groups had median concentrations of
0.4 and 0.26 ng/g lipid weight, respectively (Sjödin et al. 2000). 
Serum samples collected in 2006–2007 and analyzed for different age groups in Australia suggest that
PBDE concentrations increase from infant to toddler and then gradually decrease over time (Toms et al. 
2009).  Mean total PBDE (sum of BDE 47, BDE 99, BDE 100, and BDE 153) concentrations in cord 
blood of 0–2 year olds, 2–6 year olds, 7–12 year olds, 13–30 year olds, and >31 year olds were 24, 31, 41, 
26, 20, and 9.4 ng/g lipid, respectively.  The peak mean concentration was observed in toddlers 2.6– 
3 years of age (51 ng/g lipid), which is later than when breastfeeding usually ceases, suggesting a lower
capacity to eliminate PBDEs or greater exposure through unique exposure pathways more common for
this age group (e.g., ingestion or dermal exposure of contaminated dust particles in carpeting).
BDE 47, BDE 153, BDE 154, BDE 183, and BDE 209 were measurable in blood plasma from three 
groups of workers (i.e., workers at a computer-disassembly plant, workers in a computerized office, and a
control group) (Sjödin et al. 1999a).  The median concentrations (sum of five congeners) were highest for
the computer-disassembly plant workers (26 ng/g lipid weight); the office workers had a median 
concentration of 4.1 ng/g lipid weight and the control group had a median concentration of 3.3 ng/g lipid
weight.  The congener patterns for the control group and office workers were similar, with 
BDE 47 having the highest concentrations.  For the computer disassembly plant workers, the median 
concentrations of BDE 183, BDE 153, BDE 154, BDE 47, and BDE 209 were 7.8, 4.5, 1.2, 2.9, and 
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6.  POTENTIAL FOR HUMAN EXPOSURE
4.8 ng/g lipid weight, respectively.  Blood serum samples from 19 full-time computer technicians were 
analyzed (Hagmar et al. 2000a). The serum concentrations of BDE 153, BDE 183, and BDE 209 in these
samples were found to be approximately 5 times higher than the control and office workers in the Sjödin 
et al. (1999a) study.  The median concentration for total PBDEs (for the sum of five congeners) was
10.6 pmol/g (7.0 ng/g) lipid weight.  The highest concentrations were of BDE 153.  Two octaBDE
congeners and one nonaBDE congener were also detected.  Connections were observed between fish 
consumption and serum concentrations for congeners BDE 47, BDE 153, and BDE 183, and between 
worktime at the computer and congeners BDE 153 and BDE 183.
DecaBDE, as well as hexa- through nonaBDE, has been found in composite samples from the 1987 
National Human Adipose Tissue Survey repository (Cramer at al 1990; Stanley et al. 1991). The 
concentrations ranged from not detected to 1 ng/g fat for hexaBDE, 0.001–2 ng/g fat for heptaBDE and
not detected to 8 ng/g fat for octaBDE.  NonaBDE concentrations were estimated to be >1 ng/g fat;
decaBDE was estimated to range between not detected and 0.7 ng/g fat.  In the late 1990s, breast adipose
samples collected in northern California contained quantifiable amounts of BDE 47, BDE 99, and 
BDE 153 (She et al. 2000). Mean concentrations were 18 ng/g lipid weight for BDE 47, 4.9 ng/g lipid
weight for BDE 99, and 2.2 ng/g lipid weight for BDE 153.  Average total PBDEs concentrations
(86 ng/g lipid) were the highest human concentrations reported to date.  Petreas et al. (2003) expanded
their investigation to include a diverse group of local women from the San Francisco Bay area sampled in 
the late 1990s. Their results confirmed earlier findings reported in She et al. (2000).  Mean 
concentrations of BDE 47 in adipose tissues samples taken from California women were 28.9 ng/g lipid.
In the adipose tissue of a 74-year-old Swedish male, the BDE 47 concentration was 8.8 ng/g lipid weight 
(Haglund et al. 1997).  
Adipose and liver tissue from two Swedish males were examined for several PBDEs (BDE 28, BDE 47, 
BDE 85, BDE 99, BDE 100, BDE 153, and BDE 154) (Meironyté Guvenius and Norén 1999).  The
distribution of congener concentrations in the adipose and liver tissues for each individual were similar.
BDE 47, BDE 99, and BDE 153 were the predominant congeners with adipose BDE 47 concentrations
ranging from 2 to 2.4 ng/g lipid weight, BDE 99 concentrations of 1.6 ng/g lipid weight, BDE 100 
concentrations of 0.1 ng/g lipid weight, and BDE 153 concentrations ranging from 1 to 1.3 ng/g lipid
weight.  The total PBDE concentration (i.e., the sum of the seven congeners) in adipose tissue was 5 ng/g 
lipid weight.  Human liver and adipose tissues from one woman and four men autopsied in Sweden in 
1994 were analyzed for PBDEs containing 3–6 bromine atoms (Meironyté Guvenius and Norén 2001).
PBDEs were found in all of the tissue samples. The sums of nine congeners (BDE 17, BDE 28, BDE 47, 
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6.  POTENTIAL FOR HUMAN EXPOSURE
BDE 66, BDE 100, BDE 99, BDE 85, BDE 154, and BDE 153) were 5–18 and 4–8 ng/g lipids in liver
and adipose tissue, respectively.  The PBDE congeners BDE 47, BDE 99, and BDE 153 occurred at the
highest concentrations and constituted 87–96 and 84–94% of the total sum in liver and adipose tissue, 
respectively.  Strandman et al. (1999) measured the concentration of BDE 47, BDE 99, and BDE 153 in 
adipose tissue samples from 10 randomly selected individuals in Finland.  Mean concentrations were 
7.3 ng/g fat for BDE 47, 2.2 ng/g fat for BDE 99, and 2.3 ng/g fat for BDE 153. Concentrations of
PBDEs were measured in adipose tissue samples from 13 individuals (3 women, 10 men) from
Tarragona, Spain; the mean concentrations of BDE 47, BDE 99, and BDE 153 were 1.36, 0.42, and
1.83 ng/g lipid weight, respectively.  The mean concentrations of pentaBDE and hexaBDE were 0.93 and 
1.83 ng/g lipid weight, respectively (Meneses et al. 1999).
Human Milk. Schecter et al. (2003) reported the first findings on concentrations of PBDEs congeners in 
human milk from individuals in the United States.  Forty-seven individual milk samples were analyzed
from nursing mothers, 20–41 years age, from a milk bank in Austin, Texas, and a community health clinic 
in Dallas, Texas, both in the year 2001. The median concentration of the sum of PBDE congeners was
34.0 ng/g lipid.  The predominant congener was BDE 47 (18.4 ng/g lipid); other congeners detected were 
BDE 17, BDE 28, BDE 66, 2, BDE 85, BDE 99, BDE 100, BDE 138, BDE 153, BDE 154, and BDE 183 
at median concentrations of 0.01, 1.2, 0.14, 0.41, 5.7, 2.9, 0.09, 2.0, 0.22, and 0.07 ng/g lipid, 
respectively.  DecaBDE was detected in 7 out of 47 samples with a maximum concentration of 8.24 ng/g 
lipid.  PBDE concentrations in breast milk from this study were similar to concentrations found in U.S. 
blood and adipose tissue lipid from California and Indiana and are 10–100 times greater than human 
tissue concentrations in Europe (Schecter et al. 2003).  These data have been updated to include 2001– 
2004 samples and are provided in Table 6-13 (Schecter et al. 2005).  
Median concentrations of BDE 47, BDE 100, and BDE 153 were 26, 4, and 3.5 ng/g lipid, respectively, in 
breast milk samples collected from 10 mothers in Pennsylvania (LaKind et al. 2009).  The detection 
frequency was 100% for each congener in all 35 samples collected.
Norén and Meironyté (1998, 2000) examined the temporal trends of PBDE concentrations in pooled 
breast milk samples from mothers in Stockholm, Sweden.  Between 1972 and 1997, the concentration of
PBDEs in human breast milk increased, with a doubling rate of 5 years.  In the 1997 sample, the
concentration of PBDEs (sum of eight congeners) was 4 ng/g lipid, whereas the 1972 sample contained 
0.07 ng/g lipids (Meironyté et al. 1999).  The authors suggest that the current exposure of humans to
PBDEs may not be only diet; other exposure routes may result from the presence of PBDE in both work











     
   
 





                
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  






6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-13. Concentrations of PBDE Congeners in Human Milk from Nursing 








(weeks) 17 28 47 66 77 85 99 100 138 153 154 183 209 Sum
1a 4.8 31 3 ND 0.2 2.9 0.02 ND 0.08 0.7 0.7 ND 1.5 0.06 ND ND 6.2
2a 1.3 29 3 ND 0.3 3.5 ND ND 0.08 0.7 0.5 ND 0.9 0.06 0.06 ND 6.2
3a 2.1 23 74 ND 0.2 3.9 0.06 ND 0.11 1.5 0.6 ND 0.4 0.08 ND ND 6.9
4b 4.8 32 21 — 0.3 3.5 0.14 — 0.08 1.6 0.7 0.09 1.4 0.09 0.04 — 8
5a 2.6 22 40 0.01 0.3 6.3 0.05 ND 0.23 2.8 1.2 ND 0.7 0.2 0.05 ND 11.8
6a 3.6 36 109 ND 0.4 7.8 0.09 ND 0.23 2.4 1.1 0.01 0.4 0.11 ND ND 12.5
7a 1.9 32 20 ND 0.7 8.2 0.04 ND 0.22 1.3 1.7 ND 0.9 0.12 0.08 ND 13.3
8a 6.3 25 2 ND 0.4 7.9 0.02 ND 0.38 2.3 2.7 ND 0.8 0.15 0.06 ND 14.7
9b 2.1 35 29 — 0.7 8.8 0.19 — 0.17 1.5 1.7 0.16 2 0.06 0.03 — 15.2
10a 5.5 32 30 ND 0.4 8 0.01 ND 0.44 2.9 2 ND 0.9 0.14 0.24 0.48 15.6
11b 5 20 2 0.01 1.1 10.9 0.05 ND 0.18 2 2.4 ND 1.3 0.17 0.04 ND 18.1
12a 3.4 23 3 0.01 0.4 8 0.03 ND 0.35 3.1 2.7 ND 2 0.21 0.61 0.93 18.3
13b 1.3 32 16 — 0.8 10.5 ND — 0.35 2.5 2.2 0.19 2 0.12 0.03 — 18.6
14a 3.4 25 NA 0.02 1.1 12 0.13 ND 0.23 2.5 1.8 ND 1.3 0.15 0.08 1.85 21.1
15a 2.9 21 29 0.03 0.5 10.7 0.09 ND 0.27 5.5 2.1 ND 0.9 0.35 0.07 2.74 22.4
16b 3.5 30 30 — 0.7 6.9 ND — 0.12 1.3 4.6 0.41 8.5 0.19 0.06 — 22.8
17a 1 23 2 ND 0.9 14.2 0.11 ND 0.37 3.7 2.6 ND 1.3 0.24 0.09 ND 23.5
18b 3.7 23 19 — 0.7 13.2 0.57 — 0.29 3.7 2.5 0.29 1.9 0.17 0.06 — 23.5
19a 3.2 26 2 ND 1.3 17.4 0.19 ND 0.35 4 2.1 ND 0.7 0.18 ND ND 26.2
20b 3.5 34 22 — 1 14.3 0.29 — 0.46 5.7 3.6 0.25 1.4 0.2 0.1 — 27.3
21b 3.1 33 60 — 1.4 18.4 ND — 0.25 4.1 1.8 0.09 2.1 0.16 0.06 — 28.3
22b 4.9 38 26 — 1.2 17.4 ND — 0.34 7.1 2.3 0.14 0.6 0.3 0.12 — 29.6
23a 3.4 30 2 0.01 0.7 15.2 0.06 ND 0.42 4.2 2.3 ND 3 0.22 0.03 3.97 30.1
24a 5.1 28 53 0.01 1.1 20 0.18 ND 0.53 5.1 3.9 0.01 2.7 0.32 0.11 ND 34
25b 4.7 35 NA — 1.3 20.9 0.56 — 0.31 6.3 2.9 0.14 1.2 0.22 0.17 — 34.1
26a 1.1 41 38 0.02 1.5 19.5 0.11 ND 0.41 3.4 3.3 ND 7.7 0.18 ND ND 36.1
27b 6.1 37 25 — 7.6 17.2 1.19 — 0.35 6.1 2.3 0.18 1.7 0.27 0.05 — 36.8
28b 3 27 51 — 1.4 28.2 ND — 0.51 7.5 2.9 0.25 0.7 0.2 0.75 — 42.4
29b 4.8 25 NA — 1.8 21.6 0.94 — 0.5 9.4 4.4 0.47 5.8 0.6 0.06 — 45.5
30b 2.2 39 11 — 1.1 26.8 ND — 0.75 8.9 5.3 0.58 2 0.45 0.1 — 46
31b 5.6 34 NA — 2.7 31.8 ND — 0.42 7.8 3.1 0.09 0.8 0.22 0.1 — 47
32b 3.4 27 10 — 2.6 30.1 0.75 — 0.57 5.9 6.5 0.32 2.5 0.34 0.09 — 49.6
33a 2.8 20 13 0.02 1.1 31.3 0.17 ND 0.13 10.2 5.9 0.02 1.5 0.48 0.11 2.96 53.9
34b 4 20 13 — 3.4 33.5 2.32 — 0.49 5.8 5.8 0.27 2.6 0.32 0.06 — 54.6
35b 3.3 26 17 — 1.4 32.3 0.7 — 0.66 9.6 5.7 0.46 12.4 0.51 0.05 — 63.8
36b 2.2 20 16 — 1.4 25.5 0.75 — 0.76 8 18.3 1.75 18.3 0.94 0.08 — 75.8
37a 1.1 22 51 0.04 2.2 44.3 0.55 0.03 0.64 10.8 8.1 0.02 14.7 0.56 ND ND 81.9
38b 4.3 29 38 — 5.2 34.8 0.61 — 1.94 9.8 29.2 1.2 14.5 0.96 0.1 — 98.2










     
   
 





                
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
 
    
   
 
















6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-13. Concentrations of PBDE Congeners in Human Milk from Nursing 








(weeks) 17 28 47 66 77 85 99 100 138 153 154 183 209 Sum
39a 1 26 22 0.02 1.7 54.7 0.54 ND 1.63 23.6 10 ND 4.8 1.15 0.07 ND 98.2
40b 4.9 32 38 — 3.4 49.7 1.21 — 1.2 7.7 21.1 1.4 16.3 0.93 0.15 — 103.1
41b 3.4 30 9 — 3.9 63.1 3.13 — 2.81 30.1 16.2 3.29 17.2 1.94 0.08 — 141.6
42b 1.2 21 2 0.1 10.1 120.9 1.68 0.06 2.64 30.3 20.1 0.13 16.4 2.07 ND ND 204.3
43b 1.2 33 15 — 8 139.6 ND — 4.12 44.6 23 4.47 21.8 2.76 0.18 — 248.5
44a 1 23 2 0.06 3.6 172.4 1.14 ND 6.28 69.8 31.9 0.08 8.4 3.07 0.16 ND 296.9
45b 2.1 34 13 — 7.5 199.6 6.67 — 7.73 108.5 31.7 4.12 6.9 3.62 0.36 — 376.7
46a 1.7 33 47 0.18 6.1 196.2 2.07 0.16 6.46 111 31 0.27 15.5 7.21 1.32 8.24 385.5
47b 5.1 29 28 — 16.1 271.5 3.16 — 6.29 50.4 47.4 6.86 14.1 2.87 0.12 — 418.8
48 3.18 NA 0.011 0.6 9.9 0.058 NA NA 2.7 1.3 0.022 0.62 0.13 0.072 2.4 17.81
49 3.28 NA 0.016 1.2 25 0.12 NA NA 11 4.5 0.092 3.1 0.57 0.092 0 45.69
50 3.9 NA 0.016 4.4 41 0.098 NA 1.3 11 11 0.15 6.1 0.71 0.14 0 75.91
51 3.12 NA 0.015 2.3 37 0.11 NA 0.49 6.7 6.9 0.086 11 0.39 0.11 0 65.10
52 6.31 NA 0.01 1.8 14 0.084 NA NA 2.9 2.9 0.033 2.1 0.17 0.1 0 24.1
53 7.04 37 0.02 0.71 16 0.13 NA 0.46 5.8 2.5 0.03 2.2 0.28 0.057 0.02 28.21
54 3.29 33 0.014 0.76 9 0.056 NA 0.14 1.5 2.1 0.01 2.6 0.094 0.051 0.05 16.37
55 2.44 38 0.02 1.2 19 0.18 NA 0.35 5 2.7 0.02 2.4 0.27 0.051 2.5 33.69
56 6.5 NA 0.005 0.9 6.1 0.088 NA 0.082 1 1.2 0.01 6.7 0.077 0.029 0.03 16.22
57 5.55 NA 0.005 0.9 6.1 0.088 NA 0.082 1 1.2 0.01 3.4 0.077 0.029 0.03 12.92
58 6.75 NA 0.046 1.5 24 0.18 NA 0.38 4.8 2.7 0.02 2.1 0.22 0.57 0.05 36.57
59 3.08 NA 0.016 1.2 10 0.086 NA 0.18 2 1.3 0.01 4 0.15 0.096 0.1 19.14
aAustin milk bank sample.
bDallas milk bank sample.
NA = not available; ND = not detected
Source:  Schecter et al. 2005
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and home environments.  PBDE concentrations were studied in breast milk obtained from mothers
pregnant for the first time (n=39, ages 22–36 years old) from Uppsala County, Sweden (Darnerud et al. 
1998).  The mean value of total PBDEs (sum of eight congeners) was 4.4 ng/g fat; the major congener
was BDE 47, contains ca. 55% of the total PBDEs.  Lind et al. (2003) reported concentrations of PBDEs
in human breast milk sampled from Uppsala County, Sweden.  Total PBDEs, BDE 47, BDE 99, and
BDE 100 concentrations were 4.01, 2.35, 0.62, and 0.38 ng/g lipid, respectively.  In human breast milk
from 25 German mothers, the concentrations of PBDEs ranged from 0.6 to 11 ng/g lipid (de Wit 2002).  
In 1992, the mean concentration of total PBDEs (sum of BDE 28, BDE 47, BDE 99, BDE 100, BDE 153, 
and BDE 183) was 5.8 ng/g lipid weight for samples (n=6) from mothers from Ontario and Quebec, 
Canada (Ryan and Patry 2000).  Combined samples from 1992 representing four regions of Canada and 
one representing all Canadian provinces had total PBDE concentrations ranging from 2.6 to 19 ng/g lipid 
weight; the highest concentrations were observed in the New Brunswick, Nova Scotia, and Prince Edward 
Island.  Breast milk samples from Finland, collected between 1994 and 1998, had concentrations of total
PBDEs (sum of BDE 28, BDE 47, BDE 99, and BDE 153) ranging from 0.88 to 5.9 ng/g lipid weight 
(Strandman et al. 2000).  In Japan, breast milk samples had total PBDE concentrations (sum of BDE 28, 
BDE 47, BDE 99, BDE 100, BDE 153, and BDE 154) ranging from 0.66 to 2.8 ng/g lipid weight (Ohta et 
al. 2002).  Women who consumed fish had a somewhat higher concentration of total PBDEs (range, 1.4– 
2.8 ng/g lipid weight) compared to women who ate less fish (range, 0.67–0.87 ng/g lipid weight).
BDE 47 was the major congener in most of the samples; BDE 153 concentrations were analogous to 
BDE 47 concentrations in some samples (Ohta et al. 2002). 
Hydroxy- and Methoxy- Derivatives in Biota.  Hydroxy- and methoxy- derivatives of PBDEs have been
identified in biota.  However, their origin in the environment has not yet been explained.  Anthropogenic
sources of these compounds have not been found.  Tetra- and pentabrominated methoxy (MeO) BDEs
were found in herring, salmon, grey seal, ringed seal, and white-tailed sea eagle from the Baltic region
(Asplund et al. 1999a; Haglund et al. 1997) as well as beluga whale from Svalbard and pilot whale from
the Faroe Islands (van Bavel et al. 2001).  The concentrations of hydroxy- and methoxy- derivatives were 
of the same order of magnitude as PBDEs present in the samples.  Biogenic production via metabolism of
PBDEs or natural production via biobromination has been suggested as the origin for these compounds.  
Naturally produced methoxy-tetrabrominated diphenyl ethers have been reported in tropical marine 
sponges (sp. Dysidea) as well as in green algae (sp. Cladophora) collected in Japan (Kierkegaard et al.
2004).  Kierkegaard et al. (2004) found that the concentrations of 6-methoxy-2,2’,4,4’-tetraBDE in
herring from five locations along the Swedish coast increased from south to north in the Baltic Sea.  No 
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correlation between the concentrations of BDE congeners and methoxy-brominated diphenyl ethers was
observed, indicating sources other than PBDEs for these compounds. 
Biomonitoring Historical Trends and Future Projections. Concentrations of PBDE in human and 
animal tissues have increased since their development and widespread use as flame retardants in
commercial products.  Blood samples collected from U.S. residents in 1973 did not contain measurable 
concentrations of PBDE congeners; however, many congeners have been identified at varying
concentrations in U.S. blood samples since the widespread use of PBDEs as flame retardants (Schecter et
al. 2005).  For example, the CDC reported BDE congener concentration in serum collected in 2003–2004
from the general U.S. population (CDC 2015).  The total geometric mean concentrations ranged from
below the limit of detection for BDE 17 to 20.5 ng/g lipid for BDE 47.  In general, body burden 
concentrations of PBDEs in North America are higher than in Europe due to higher historical demand and 
usage.  Since all production and use of penta-, octa-, and now decaBDE have ceased in the United States, 
future biomonitoring results will likely show a gradual decline in body burden concentrations of these
substances in U.S. residents as products containing PBDEs ultimately become rare.  Age-dependent data
on PBDE levels indicate several sources of human exposure.  Serum samples collected in Australia
suggest that PBDE levels increase from infant to toddler and then gradually decrease over time (Toms et
al. 2009).  Peak average concentrations were observed in toddlers 2.6–3 years of age (51 ng/g lipid),
which is later than when breastfeeding usually ceases, suggesting a lower capacity to eliminate PBDEs or
greater exposure through unique exposure pathways more common for this age group (e.g., ingestion or
dermal exposure of contaminated dust particles in carpeting).  The EPA Exposure Assessment of
Polybrominated Diphenyl Ethers published in May of 2010, summarizes many other biomonitoring
studies not discussed here and the reader is encouraged to consult this assessment for additional analysis 
of the environmental fate and biomonitoring of PBDEs (EPA 2010).
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Humans are exposed to PBDEs by a wide variety of routes including ingestion of contaminated foods
inhalation of air, ingestion of contaminated dusts/soils, and dermal exposure routes.  The EPA published 
an exposure assessment of the U.S. population to PBDEs and determined that the overall weight-of­
evidence suggested that bulk of U.S. exposures occur in indoor environments through ingestion and 
contact with house dust.  It concluded that house dust accounts for between 80 and 90% of total exposures
of the general population, with the remainder due primarily to food ingestion.  Watkins et al. (2011)
















   
  
  
   
 
 
   
  
   
    
     
   
      
   
 
  
     
   
    
     
  
     
 




6.  POTENTIAL FOR HUMAN EXPOSURE
determined that regular hand washing decreases the mass of PBDEs on hands from dust samples and is 
thus expected to reduce intake from hand-to-mouth activities.
Intake doses of BDE 47, BDE 99, BDE 100, and BDE 153 from all exposure pathways for the North 
American population were modeled by Wong et al. (2013).  The model assumed intake of PBDEs
increased exponentially to a peak in 2004, and has since exponentially declined. The intakes of BDE 47, 
BDE 99, BDE 100, and BDE 153 were estimated as 3.88–54, 1.59–2.39, 1.17–2.98, and 1.37–2.44 ng/kg
body weight/day depending upon how the intakes were fit to measured body burden data using different
elimination half-lives.  Trudel et al. (2011) used eight different exposure pathways (oral uptake of food, 
dust, soil, and organic films; inhalation of air; and dermal uptake of dust, soil, and organic films) to model
intakes of PBDEs for different age/gender groups in North American and European populations.  The
mean intakes for total PBDEs in the North American population were 210.0, 80.0, 79.0, 69.0, 43.0, 28.0, 
and 22.0 ng/kg body weight/day for infants, toddlers, children, female teenagers, male teenagers, female 
adults, and male adults, respectively.  These concentrations are about 3–8 times greater than the estimated
intakes for European populations.  Lorber (2008) also estimated PBDE intake of the U.S. population
through similar exposure routes. The adult intake of total PBDEs was estimated as 7.7 ng/kg body
weight/day, while the intake of children aged 1–5 years was 49.3 ng/kg body weight/day.  The intakes for
6–11 year olds and 12–19 year olds were estimated as 14.4 and 9.1 ng/kg body weight/day, respectively
(Lorber 2008).  Exposure from indoor house dust accounted for about 82% of the intake (66% from
soil/dust ingestion, 16% from soil/dust dermal contact) of total PBDEs, while inhalation and ingestion of
food and water accounted for <20% of the total intake.  BDE 47, BDE 99, BDE 100, and BDE 209 were
the predominant congeners, accounting for 26, 28, 11, and 27%, respectively, of the total intake (Lorber
2008).  The EPA 2010 Exposure Assessment of Polybrominated Diphenyl Ethers calculated the adult
intake dose of total PBDEs to be 7.1 ng/kg body weight/day (EPA 2010). The largest source contributing
to PBDE exposure in the United States was reported to be house dust (ingestion and dermal exposure),
contributing about 90% of the overall estimated intakes.  The EPA exposure assessment estimated
children intakes as 47.2 ng/kg body weight/day for 1–5 year olds, 13.0 ng/kg body weight/day for 6– 
11 year olds, and 8.3 ng/kg body weight/day for 12–19 year olds. Intake modeling using a breastfeeding
pathway, which used measured milk concentrations and infant ingestion rates of human milk, led to 
estimated infant intakes of 141 ng/kg body weight/day (EPA 2010).  While exposure to dust appears to be
the predominant exposure pathway for the general population of North American residents, PBDE
exposure through dietary routes appears to be more important for European communities (Abdallah and 
Harrad 2014; Law et al. 2008).  










   
      
       
    






       
     
   
    
      
     
 





   
  
     
    
   
  
   






6.  POTENTIAL FOR HUMAN EXPOSURE
Breast adipose samples collected in northern California in the late 1990s contained quantifiable amounts
of BDE 47, BDE 99, and BDE 153 (She et al. 2000).  Mean concentrations were 18 ng/g lipid weight for
BDE 47, 4.9 ng/g lipid weight for BDE 99, and 2.2 ng/g lipid weight for BDE 153.  In studies of the
general populations of other countries, it has also been shown that exposure to lower-brominated PBDE
congeners by the general population is widespread (see Section 6.4.4; Haglund et al. 1997; Meneses et al.
1999).  In general, concentrations of decaBDE in human tissues and body fluids are lower than for the
lower-brominated congeners, presumably due to a more rapid elimination half-life (Trudel et al. 2011).  
Consumption of fish has been associated with elevated concentrations of PBDEs in tissues from the
Swedish population (Bergman et al. 1999).  In Sweden, fish consumption is about 30 g/day; this translates 
to an estimated 0.1 μg of pentaBDE and 0.3 μg of total PBDEs from fish that is ingested by humans daily
(WHO 1994a).  The fish of greatest concern to humans are bottom feeders like carp and catfish.  Harrad
et al. (2004) estimated the daily dietary intakes of PBDEs in omnivorous and vegan diet samples from the
United Kingdom.  In this study, the median lower bound estimates of dietary exposure (i.e., where a
congener is below the detection limit, the concentration is assumed to be zero) for BDE 47, BDE 99, 
BDE 100, BDE 153, BDE 154, and total PBDEs were 46.4, 42.6, 0, 0, 0, and 90.5 ng/day, respectively
(Harrad et al. 2004).  The International Polar Year Inuit Health Survey in 2007–2008 evaluated PBDE
blood concentration for 2,172 Inuit adults in Canada (Laird et al. 2013).  The sum concentration of
BDE 47, BDE 99, and BDE 100 in the general population ranged from 0.04 to 10.6 μg/L in blood plasma.  
Like PCBs, there may be a higher risk of exposure to PBDEs in Native Americans who reside in the 
Arctic region and consume whale and seal blubber (Jaret 2000).
Workers involved in the production and manufacture of PBDE-containing plastics and plastic products
are exposed to PBDEs.  Body burden data indicate higher concentrations for workers exposed to PBDEs
than for the general population.  Occupational exposure to PBDEs also occurs in workers at plants that
dismantle electronic equipment, computer monitor repair technicians, and automobile drivers, as well as
other professions (Lindström 1999).  Occupational exposure occurs primarily by inhalation.  Inhalation of
vapor-phase PBDEs is expected to be low due to the low vapor pressures of PBDEs (see Table 4-4);
however, the inhalation of particulate phase PBDEs is possible during plastic reprocessing where grinding
or shredding of polymers with PBDEs occurs.  Occupational exposure may also likely involve oral
exposure to particulate PBDEs as a result of hand-to-mouth activity.
Air samples were taken from an electronics dismantling plant, an office with computers, and outdoors and 
then analyzed for PBDEs (Sjödin et al. 1999a, 2001a).  The electronics dismantling plant had the highest
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concentrations of PBDEs, with mean concentrations of 2.5 pmol/m3 (1.25 ng/m3) for BDE 47, 
4.6 pmol/m3 (2.6 ng/m3) for BDE 99, 6.1 pmol/m3 (3.93 ng/m3) for BDE 153, 26 pmol/m3 (18.8 ng/m3) 
for BDE 183, and 38 pmol/m3 (36.5 ng/m3) for decaBDE (BDE 209) (Sjödin et al. 1999a, 2001a).  Air
samples were found to be 4–10 times higher in PBDE concentrations near a plastic shredder when
compared to other locations in the plant (range, 0.42–200 ng/m3).  Concentrations of PBDEs in the office
(range, <0.002–0.09 ng/m3) were 400–4,000 times lower than in the plant, and PBDEs were not detected
in outside air (Sjödin et al. 1999a, 2001a). 
Lipid adjusted serum levels of 11 BDE congeners collected from the US general population were reported 
in the Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables (CDC
2015; also see http://www.cdc.gov/biomonitoring/ ). Serum levels for BDE 17, BDE 28, BDE 47, 
BDE 66, BDE 85, BDE 99, BDE 100, BDE 153, BDE 154, and BDE 183 were evaluated in samples
collected between 2003 and 2008; BDE 209 was evaluated in samples collected from 2005 to 2008.  In 
the NHANES 2003–2004 survey years, congener BDE 47 was detected at a concentration of 20.5 ng/g
lipid (geometric mean), the highest concentration for all samples. BDE-153 had the second highest
geometric mean concentration of 5.7 ng/g lipid.  BDE 28, BDE 99, BDE 47, BDE 100, and BDE 153 
were in ≥60% of participants (Sjödin et al. 2008).  The serum levels of BDE 47, BDE 99, and BDE 153 
were highest in the youngest age group (12–19 years old) and decreased for the older age groups (from
20–39 to 40–59 years old) and then increased in the ≥60 years old age group. 
BDE 47, BDE 153, BDE 154, BDE 183, and decaBDE (BDE 209) were measurable in blood plasma from
three groups of workers (i.e., workers at a computer disassembly plant, workers in a computerized office, 
and a control group) (Sjödin et al. 1999b).  The median concentrations (sum of five congeners) were 
highest for the computer disassembly plant workers (26 ng/g lipid weight); the office workers had a
median concentration of 4.1 ng/g lipid weight and the control group had a median concentration of
3.3 ng/g lipid weight.  The congener patterns for the control group and office workers were similar, with 
BDE 47 having the highest concentrations.  For the computer disassembly plant workers, the median 
concentrations of BDE 183, BDE 153, BDE 154, BDE 47, and BDE 209 were 7.8, 4.5, 1.2, 2.9, and 
4.8 ng/g lipid weight, respectively.  Blood serum samples from 19 full-time computer technicians were 
analyzed (Hagmar et al. 2000a). The serum concentrations of BDE 153, BDE 183, and BDE 209 in these
samples were found to be approximately 5 times higher than the control and office workers in the Sjödin 
et al. (1999b) study.  The median concentration for total PBDEs (for the sum of five congeners) was
10.6 pmol/g (7.0 ng/g) lipid weight.  The highest concentrations were for BDE 153.  Two octaBDE
congeners and one nonaBDE congener were also detected. 
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6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Body burden data, as well as intake modeling, suggest that infants and toddlers have higher exposures to
PBDEs as compared to older children or adults.  PBDE concentrations increase from infant to toddler and 
then gradually decrease over time.  PBDE intake values for children have been estimated using several
models (EPA 2010; Lorber 2008; Trudel et al. 2011; Wong et al. 2013).  Using the model developed by
the EPA, total PBDE intakes for children residing in the United States were estimated as 47.2 ng/kg body
weight/day for 1–5 year olds, 13.0 ng/kg body weight/day for 6–11 year olds, and 8.3 ng/kg body
weight/day for 12–19 year olds. Data from fetal tissue and several studies, including measurements of
PBDE congeners from umbilical cord blood, indicate that the fetus is exposed to PBDEs through the
mother.  
Schecter et al. (2003, 2005) reported the first findings on concentrations of PBDEs congeners in human 
milk from individuals in the United States.  The median concentration of the sum of PBDE congeners was
34.0 ng/g lipid with BDE 47 (18.4 ng/g lipid) as the predominant congener.  DecaBDE was detected in 
7 out of 47 samples with a maximum concentration of 8.24 ng/g lipid.  The concentrations of PBDEs in 
breast milk from this study were 10–100 times greater than human tissue concentrations in Europe 
(Schecter et al. 2003).  Guo et al. (2016) found that PBDE levels in breast milk samples declined in 
females from California over two sampling periods (2003–2005 and 2009–2012).  The geometric mean of
total PBDE congeners (sum of BDE 28, 47, 99, 100, 153, and 154) in breast milk was 67.8 ng/g lipid in 
the 2003–2005 sampling period (n=82) and 45.7 ng/g lipid in the 2009–2012 sampling period (n=66). 











    
   
 
 
   
     
    
 
 
   
   
    
    
   
 
  









      





6.  POTENTIAL FOR HUMAN EXPOSURE
PBDE levels were shown to increase in human milk samples collected from different regions of Canada 
from 1992 to 2002, but declined slightly from 2002 to 2005  (Ryan and Rawn 2014).  The median and 
geometric mean levels of total PBDEs (sum of BDE 28, 47, 99, 100, 153, 154, and 183) in collected milk
samples were 2.992 and 3.536 ng/g lipids in 1992, respectively, and 22.104 and 25.162 ng/g lipid, 
respectively, in 2002.  The median and geometric mean of total PBDEs in milk samples collected in
March and April 2005 were 19.948 and 21.082 ng/g lipid, respectively.  
PBDEs were detected in human placental tissues (n=102) collected between 2010 and 2011 in Durham
County, North Carolina (Leonetti et al. 2016). The geometric mean concentration of total PBDE (sum of
BDE 47, 99, 100, 153, 154, and 209) was 17.6 ng/g lipid.  The detection frequencies of the individual
congeners were:  BDE 47, 91.2%; BDE 99, 68.6%; BDE 100, 88.2%, BDE 153, 93.1%; BDE 154, 
83.3%; and BDE 209, 52.9%.  
PBDEs were detected at a median concentration of 53,000 ng/g in a variety of toys such as hard plastic
toys (racing cars, vehicles, toy weapons, etc.), foam toys, rubber/soft plastic toys (dolls and teethers), and
stuffed toys that were purchased in China from 2007 to 2008 (Chen et al. 2009).  These findings suggest
additional possible exposure routes to children and toddlers through mouthing activities and dermal
contact with toys.
PBDE congeners (predominantly BDE 47, 99, and 209) were detected in 100% of dust samples collected 
from 40 California daycare and preschool centers (Bradman et al. 2014).  The mean and median total
PBDE (BDE 47, 99, 100, 118, 153, 154, 183, 190, 197, 203, 205, 206, 207, and 209) levels in dust
samples were 7,956.6 and 4,225 ng/g, respectively.  Individual congeners (BDE 47, 99, 100 153, 154, and 
209) were detected in indoor air samples at the facilities at mean levels ranging from 0.001 to 1.63 ng/m3. 
Hoffman et al. (2016) analyzed serum levels and handwipe samples from 83 children aged 12–36 months
residing in the state of North Carolina.  Correlations between serum and handwipe levels of PBDE
congeners and behavioral patterns were observed.  For example, increased age and increased activity was 
positively correlated to levels of PBDEs in serum and handwipe samples, while time spent sleeping (a 
measure of inactivity) was negatively correlated with PBDE levels in serum. It was reported that for each
additional hour of sleep, BDE 47, BDE 99, BDE 100, and BDE 153 serum levels decreased by 12, 15, 9, 
and 10%, respectively, in the children.  BDE 47, BDE 99, BDE 100, and BDE 153 levels in handwipes
decreased 30, 31, 30, and 23% for each additional hour of sleep.  
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6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Workers who were involved in the production and manufacture of PBDE-containing plastics and plastic
products were exposed to higher concentrations of PBDEs than the general population.  Body burden data
indicate higher concentrations for workers exposed to PBDEs than for the general population.  
Occupational exposure to PBDEs also occurs in workers at plants that dismantle electronic equipment, 
computer monitor repair technicians, and automobile drivers, as well as other professions (Lindström
1999).  Occupational exposure occurs primarily by inhalation and ingestion of dust containing PBDEs.  
Stapleton et al. (2008) examined PBDE serum concentrations in workers involved with foam recycling
and carpet installation in the United States.  Serum PBDE concentrations in foam recyclers (median,
160 ng/g lipid) and carpet installers (median, 178 ng/g lipid) were significantly greater than a non-
occupationally exposed control group (median, 19.3 ng/g lipid).  
Firefighters appear to have higher exposure potential to PBDEs and other types of flame retardants
because they are exposed to the combustion products of the flame retardants as well as the original forms 
of the chemicals.  In a study conducted to examine exposure to PBDEs in 101 firefighters from Southern 
California, the median and geometric mean for total PBDEs (sum of BDE 28, 47, 99, 100, and 153) in the
serum of the firefighters were 59.1 and 66.2 ng/g lipid, respectively (Park et al. 2015).  These levels are 
approximately 40% greater when compared to the general population. The median and geometric mean 
for the same total PBDE congeners obtained from a subset of the NHANES survey with similar age and
gender as the firefighters were 36 and 40.8 ng/g lipid, respectively. 
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of PBDEs is available.  Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of PBDEs.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 











   
 
    
 
      
  
      
    
    
 
         
 
      
   
   
 
   





    
 
  
   
 
 
   
    
PBDEs 440
6.  POTENTIAL FOR HUMAN EXPOSURE
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. Many of the relevant physical and chemical properties of the 
PBDEs are available (see Tables 4-3 and 4-4).  Very limited data are available on the physical and
chemical properties for the individual congeners (Braekevelt et al. 2003; Tittlemier et al. 2002).
Important data, such as Kow, Koc, vapor pressure, and Henry’s Law constant, are necessary for the
prediction of the environmental fate and transport of PBDEs.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this
information for 2014, became available in March 2016.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions.
There are no current manufacturers of technical PBDEs in the United States.  PentaBDE and octaBDE
mixtures were voluntarily withdrawn from the U.S. marketplace by their manufacturers at the end of
2004, leaving only decaBDE being marketed for use in commercial products in the United States (EPA
2010).  In December of 2009, the two remaining U.S. producers of decaBDE, Albemarle Corporation and 
Chemtura Corporation (formerly known as the Great Lakes Chemical Corporation), and the largest U.S. 
importer, ICL Industrial Products, Inc., announced commitments to phase out manufacture and 
importation of decaBDE for most uses in the United States by December 31, 2012, and to end 
manufacture and import for all uses by the end of 2013 (EPA 2013j).  Many consumer goods enter the
United States from other countries such as China.  OctaBDE was never produced in China, and 
manufacture of the commercial pentaBDE mixture stopped in 2004; however, there are currently no 
restrictions on the use of decaBDE, which had a production volume of 20,500 metric tons in 2011 (Ni et
al. 2013).  It is unclear if items being treated with decaBDE are still entering U.S. markets from other
parts of the world.
Given the importance assigned to dust ingestion as an exposure pathway to Americans, more data are 
needed on human bioavailability of PBDEs from external matrices, such as dust, as well as food for
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exposure characterization.  Characterization of the quantity of dust containing PBDEs, ingested by
humans, and in particular young children, would improve exposure estimates.
Environmental Fate. Based on limited data, photolysis appears to be the dominant transformation 
process for some PBDEs (e.g., decaBDE) (Hua et al. 2003).  PBDEs absorb light in the environmental
spectrum.  Hua et al. (2003) found that decaBDE and the commercial octaBDE absorbed light up to 
325 nm, which indicates that these compounds may be susceptible to photodegradation at environmental
wavelengths.  However, the importance of photochemical transformation reactions in the environment
cannot be determined due to lack of quantitative rate information (EU 2002, 2003a).  Better data on 
degradation via hydroxyl radical reaction and photolysis are needed.  Based on a very limited number of
studies, biodegradation does not appear to be significant for commercial mixtures of PBDEs (EU 2002, 
2003a).  Limited studies have been done on biodegradation of PBDEs in the environment under both
aerobic and anaerobic conditions, especially studies investigating dehalogenation mechanisms (EU 2002, 
2003a).  More studies are needed to determine conclusively if commercial PBDE mixtures, such as 
decaBDE, are degraded to lower-brominated congeners (e.g., BDE 47), which appear to bioaccumulate in 
fish, animals, and humans (see Section 6.4).  Additional data on degradation via hydroxyl radical reaction 
and photolysis are needed.  Since the toxicity and the environmental fate of PBDEs depend on specific
PBDEs congeners, development of more data regarding congener-specific fate and transport of PBDEs in
the environment are needed.
Bioavailability from Environmental Media. The absorption and distribution of PBDEs as a result
of inhalation, ingestion, and dermal exposure are discussed in Sections 3.4.1 and 3.4.2. PBDEs will exist
in both the vapor and particulate phase in both indoor and outdoor air, and more data are needed 
regarding the bioavailability of these substances in these two phases (Harrad et al. 2004) and the 
bioavailability of PBDEs from PBDE-contaminated toys (Chen et al. 2009).
Food Chain Bioaccumulation. An abundance of monitoring data illustrates the uptake of lower­
brominated diphenyl ethers by aquatic organisms, which results in bioconcentration (see Section 6.4.4;
Hardy 2002b).  Congener components of the pentaBDE commercial product tend to bioconcentrate to 
different extents.  DecaBDE and octaBDE commercial products do not bioconcentrate to the extent of the
penta mixtures; however, monitoring data clearly show that even the higher-brominated congeners are 
taken up.  More information on bioaccumulation and biomagnification of PBDE and its congeners is
needed in assessing human health risks.
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Exposure Levels in Environmental Media. Reliable monitoring data for the levels of PBDEs in
contaminated media at hazardous waste sites are needed so that the information obtained on levels of
PBDEs in the environment can be used in combination with the known body burden of PBDEs to assess
the potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.
More monitoring data on the concentrations of total PBDEs and PBDE congeners in air in remote, rural, 
and urban areas, as well as areas near hazardous waste sites and incinerators, are needed.  Although
concentrations are predicted to be low, monitoring data on PBDE concentrations in finished drinking
water nationwide would be helpful.  Sediment concentrations of PBDEs tend to be dominated by higher­
brominated congeners (e.g., decaBDE or BDE 209) (deWit 2002; Dodder et al. 2002; Hale et al. 2001b, 
2002). Monitoring data indicated that the concentrations of PBDEs are increasing in aquatic organisms 
with higher concentrations near point sources (Alaee et al. 1999; Dodder et al. 2000; Johnson and Olson 
2001; Loganathan et al. 1995; Luross et al. 2000).  Additional monitoring data on environmental
concentrations of PBDEs would to useful to determine the extent of contamination in environmental
media, and also the mechanisms of human exposure to this class of chemicals.
Exposure Levels in Humans. Body-burden data indicate that there are low-level exposures to 
lower-brominated PBDEs for the general population.  Information about the average daily intake of
PBDEs is available (Bergman et al. 1999; EPA 2010; Lindström 1999; Lorber 2008; WHO 1994a).  
PBDE concentrations are reported in the current literature for serum, blood, breast milk, and adipose
tissue of the general population and occupationally exposed individuals (CDC 2015; EPA 2010; WHO
1994a).  Additional data regarding the concentrations of PBDEs in body fluids or tissues of people who 
reside near hazardous waste sites are needed. This information is necessary for assessing the need to
conduct health studies on these populations.
Exposures of Children. The most important exposure pathway for infants to PBDEs likely occurs
through ingestion of breast milk (EPA 2010).  PBDE intakes for infants and young children are typically
greater than older children and adults (EPA 2010; Lorber 2008; Trudel et al. 2011; Wong et al. 2013).  
Since children tend to spend more time playing in carpeting, this leads to the potential to greater exposure
to PBDEs through indoor dust.  PBDEs have been detected in a variety of toys such as hard plastic toys
(racing cars, vehicles, toy weapons, etc.), foam toys, rubber/soft plastic toys (dolls and teethers), and 
stuffed toys that were purchased in China from 2007 to 2008 (Chen et al. 2009).  These findings indicate
additional possible exposure routes to children and toddlers through mouthing activities and dermal
contact with toys.  Although there has been a gradual phase-out of pentaBDE, octaBDE, and now










   
   
 
    
 
 
       
   
    




    
 





   
 
  
    
   
 
 
      
   
   




6.  POTENTIAL FOR HUMAN EXPOSURE
decaBDE, products are still in households that contain these substances.  Therefore, continued 
biomonitoring data of infants and children is needed.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for PBDEs were located.  This substance is not
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry. The substance will be considered in the future when chemical selection is made for sub-
registries to be established.  The information that is amassed in the National Exposure Registry facilitates
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to
this substance.
6.8.2 Ongoing Studies 
A prospective study of 316 mothers enrolled during pregnancy being conducted at the Icahn School of
Medicine at Mount Sinai, New York will examine prenatal exposure to complex mixtures of endocrine-
disrupting compounds including PBDEs (RePORTER 2016).
A study being conducted at the University of California, Berkeley is designed to examine exposures and 
health effects in vulnerable populations, such as pregnant women and children living in California, where
stricter flammability standards have resulted in very high flame retardant exposures (RePORTER 2016).
The Center for Children's Environmental Health Research at the University of California, Berkeley will
examine novel methods of examining prenatal exposure to PBDEs and other compounds using shed
deciduous teeth and geographic information system (GIS) methods with remote sensing (RePORTER
2016).  
A study at the University of Cincinnati is investigating two groups of persistent organic chemicals for
their associations with adverse effects in child neurobehavior: PBDEs and perfluoroalkyl chemicals 
(including perfluorooctane sulfonic acid [PFOS] and perfluorooctanoic acid [PFOA]).  The research 
project will provide novel information to the public about the developmental neurotoxicity of these
chemicals.  It will also generate new data regarding PBDE exposure routes to aid in future prevention 
initiatives (RePORTER 2016).
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6.  POTENTIAL FOR HUMAN EXPOSURE
A study is being conducted at the University of California, San Diego that is collecting and analyzing
sediment and biota sample in the in the Southern California Bight for PBDEs (RePORTER 2016). 
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring PBDEs, their metabolites, and other biomarkers of exposure and effect to 
PBDEs.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the
analytical methods used for environmental samples are the methods approved by federal agencies and
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other
methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
PBDEs are analyzed in environmental and biological samples by methods quite similar to those used for
PCBs (de Kok et al. 1977; Fries 1985b; Pomerantz et al. 1978).  The analytical methods for PBDEs were 
developed relatively recently.  There have been many advances in the technology and costs of analytical
instruments used in the efforts directed at PBDE analysis.  GC/MS with capillary columns (i.e., congener
specific) is the primary analytical technique now used for PBDEs.  
Covaci et al. (2003) and Stapleton (2006) reviewed the determination of brominated flame retardants, 
with emphasis on PBDEs in environmental and human samples.  The analysis methodology for PBDEs
includes several steps: sample collection and storage, sample pretreatment, extraction, cleanup and 
fractionation, and analytical determination.  Care must be taken to assure that the sample collection 
follows quality-assurance protocols and that equipment and containers are free from contamination.  It is
important that laboratories utilize blanks when reporting trace concentrations of PBDEs.  This practice 
will minimize the influence of trace contamination samples that can originate from a variety of sources.
Most sample collections are by grab sampling; however, PBDEs may be concentrated from water onto
sorbents.  Desiccation of solid samples (e.g., soil, sediment, and sewage sludge) is largely done for
convenience.  Dry samples are more efficiently homogenized, allowing for parallel determination of other
analytes (e.g., lipid content) (Covaci et al. 2003).
PBDEs are typically separated from the biological and environmental media by extraction with organic 
solvents.  Liquid-solid extraction (e.g., Soxhlet apparatus) remains a widely used technique for solid
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7. ANALYTICAL METHODS
samples despite recent advances in other extraction techniques. Typical solvents are hexane, toluene,
hexane/acetone mixtures, or dichloromethane.  New extractions techniques, such as accelerated solvent
extraction (ASE) or microwave-assisted extraction (MAE), are also currently used by a number of
laboratories. The advantage of these techniques is lower solvent consumption and reduced extraction 
time.  Supercritical fluid extraction with solid-phase trapping has been used for the extraction of
brominated flame retardants from sediment with CO2 as the supercritical fluid.  Extraction with 
pressurized hot water (PHWE) has been used for the analysis of brominated analytes from sediment.
Liquid-liquid extraction has been applied for river and seawater samples, using hexane/acetone mixtures.
Solid-phase extraction has been used for the analysis of acidic and neutral brominated flame retardants 
from human plasma (Covaci et al. 2003). 
Cleanup steps are necessary to remove compounds that may interfere with the determination (e.g., humic
acids, lipids) of PBDEs.  Lipids (e.g., oils and fats) may be destroyed with concentrated sulfuric acid 
treatment either directly to the extract or using impregnated silica columns.  Chromatography (e.g., gel
permeation, silica gel, Florisil) is used to remove other matrix interferences and to fractionate samples 
(Covaci et al. 2003).
The identification and quantitation of PBDEs are most often accomplished by GC techniques.  Capillary
or high-resolution gas chromatography (HRGC) columns capable of separating a substantial proportion of
the congeners are indispensable, and GC detectors possessing high selectivity and sensitivity for the 
PBDEs are required.  Historically, flame-ionization detectors (FID) or electron-capture detectors (ECD)
were used.  However, the MS detectors have become the main detection tool for PBDEs.  MS detectors
have selectivity for PBDEs and can distinguish and individually measure homologs that may co-elute on a 
particular HRGC column.  The use of MS is indispensable in the definitive identification of PBDE
congeners.  One method of detection is ECNI as an ionization technique in combination with GC/MS
analysis (de Boer et al. 2000a). This method is advantageous because it offers a high sensitivity for
compounds with four or more bromine atoms.  However, ECNI, although generally more sensitive and 
less costly than other ionization methods for PBDE analysis, does not provide information on the
molecular ion cluster (as required for qualitative identification).  It is also more subject to brominated 
interferences and does not allow the use of 13C-labeled standards for quantification (Ikonomou and Rayne
2002).  Conversely, electron ionization (EI) methods suffer from fragmentation of the molecular ions, 
creating difficulties in both identification and quantitation of congeners in full-scan and single ion 
monitoring (SIM) modes, respectively.  For example, loss of bromine atoms from PBDE congeners
during EI may lead to incorrect identification of the parent ion as a lower-brominated congener.  In 
   
 








    
   
  
   
   
 
 
       
     
     
  
   
   
   
  
    
   
   
 
  
    
   
 
   
 
     
     






addition, the relatively unpredictable fragmentation during EI restricts the utility of applying relative
response factors (RRFs) of one congener for which an analytical standard is available (e.g., 
2,2,4,4’-tetraBDE or BDE 47) for other members of its homolog group (e.g., tetraBDEs).  This can result
in either under- or overestimating concentrations of congeners for which analytical standards are not
available (Ikonomou and Rayne 2002).  In general, hepta- through decaBDE congeners are difficult to
determine accurately by GC analysis, especially in biological samples (Ikonomou and Rayne 2002).  
The analysis of BDE 209 and BDE 154 has some analytical difficulties.  For example, BDE 209 (1) is not
stable at high temperatures in the GC injector and GC column; (2) is sensitive to degradation by UV light 
(i.e., both sunlight and fluorescent light); (3) behaves differently in the MS source from those of
chlorinated and lower-brominated compounds (de Boer and Cofino 2002); and (4) may easily adsorb to 
small dust particles in the laboratory, which may result in sample contamination (Covaci et al. 2003).  
Thermal decomposition of BDE 209 can be avoided using a short GC column and a thermally inert GC
injection port (Beser et al. 2014).  In contrast, BDE 154 usually co-elutes from most gas chromatographic 
columns with 2,2’,4,4’,5,5’-hexabromobiphenyl (PBB-153).  In order to ensure the separation of
BDE 154 and PBB 153, analysts need to use a sufficiently long GC column.  Thus, in order to accurately
determine the concentrations of BDE 209 and BDE 154 in analytical samples, analysts are required
perform two separate GC measurements under different operating conditions. The difficulties in the 
determination of BDE 209 have been addressed through the use of liquid chromatography (LC)/MS/MS
(Abdallah et al. 2009).  The analytes, BDE 47, BDE 85, BDE 99, BDE 100, BDE 153, BDE 154, 
BDE 183, BDE 196, BDE 197, BDE 203, BDE 206, BDE 207, BDE 208, and BDE 209, were separated
and ionized in a single run using an isotope dilution method for indoor dust samples.
7.1  BIOLOGICAL MATERIALS
Methods for the determination of organobromine compounds such as PBDEs generally consist of the
following steps:  extraction of the analyte from the sample matrix; cleanup to remove interfering
compounds; and analysis (separation and quantitation).  The primary method of analysis is GC coupled 
with MS.  Analytical methods have been developed for the determination of PBDEs in blood or serum, 
urine, feces, adipose tissue, liver, breast milk, and hair.  The methods for determining PBDE residues in
biological samples are provided in Table 7-1. 
   
 









   
 
 



















































   
 
























Table 7-1. Analytical Methods for Determining Polybrominated Diphenyl Ethers 





















Extraction with CH2Cl2 in
hexane; H2SO4 to remove 
lipids; washed with NaOH
followed by distilled water,











Soxhlet extraction; clean up 












Extraction with methylene 
chloride; evaporate; clean
up on silica gel followed by
clean up on alumina and on 
a carbon/silica gel column
HRGC/ 
HRMS





Extract with 2-propanol/ 
hexane; clean up with 










Human milk Extract with potassium
oxalate/ethanol/diethyl
ether/pentane; GPC; clean 




<0.6 ng/g fat No data WHO 1994a
Human milk Extract by column 
chromatography using 
hexane/dichloromethane/ 




5 pg/g lipids 86–102 Meironyté et
al. 1999
Human milk Extract with n-hexane; HRGC- No data >80 Ohta et al.









Extract with formic acid,
2-propanol, and water on a 










Extraction with hexane/ 












   
 








   
 
 



































    
     
    
      




Table 7-1. Analytical Methods for Determining Polybrominated Diphenyl Ethers 






















acid followed by SPE
GC/MS 140–1,300 pg/g 
(lipid weight)
40–106 Butt et al. 
2016
Human hair Physical extraction followed 
by washing with 0.3%
polyoxyethylene lauryl
ether and rinse with tap 
and distilled water;
GC/MS 0.02 ng/g No data Malarvannan 
et al. 2013
extraction using hexane/ 
dichloromethane
Human hair Extraction with 4 N HCl and
hexane (4:1); clean up on 
NaSO4/Florisil SPE









70–90 Aleksa et al.
2012a
BDE = brominated diphenyl ether; DMSO = dimethyl sulfoxide; ECD = electron capture detection; EI = electron 
impact; EILR = electron impact low-resolution; ELISA = enzyme-linked immunosorbent assay; GC = gas
chromatography; GPC = gel permeation chromatography; HRGC = high resolution gas chromatography;
HRMS = high resolution mass spectrometry; LRGC = low resolution gas chromatography; LRMS = low resolution 
mass spectrometry; MS = mass spectrometry; MTBE = methyl-tert-butyl either; NCI = negative chemical ionization;
SIM = selected ion monitoring; SPE = solid phase extraction
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7. ANALYTICAL METHODS
Determination of hydroxylated PBDEs metabolites were reported by Malmberg et al. (2005).  The
methylated derivatives of PBDE-OH metabolites were identified by GC-MS ECNI and EI analysis after
extraction from the sample matrix, cleanup to remove interfering compounds, and methylation of the
hydroxyl group.  In plasma samples, the internal standard, BDE 138, had 71 and 98% recovery (relative
standard deviation, 8 and 2%) on days 1 and 5 after dosing, respectively. 
Residues in biological samples can be extracted using sulfuric acid, 2-propanol/hexane, methylene
chloride, n-hexane, formic acid/2-propanol/water, or hexane/methyl t-butyl ether (Cramer et al. 1990;
Meironyté Guvenius et al. 2001; Ohta et al. 2002; Sellström et al. 1993; Sjödin et al. 1999a; Thomsen et
al. 2001).  Samples are cleaned up to remove interferences using Florisil, silica gel, alumina or activated-
charcoal column chromatography, gel permeation chromatography (GPC), and/or LC (Cramer et al. 1990;
Meironyté Guvenius et al. 2001; Sellström et al. 1993; Sjödin et al. 1999a).  Most techniques are based on 
analysis by GC coupled with MS (WHO 1994a).  Capillary columns and temperature programming allow
the separation of the different PBDE congeners.  High recoveries (69–104%) of PBDE residues are 
obtained by the available analytical methods.  Typically, the limit of quantitation for PBDE residues is
about 0.7 ng/g lipid in blood serum, 5 pg/g lipid in human milk, 0.3 ng/g lipid in adipose tissue, and 
0.025 pg/mg in hair (Aleksa et al. 2012a; Covaci et al. 2002; Meironyté Guvenius et al. 1999; Sjödin et al. 
1999a).  Additionally, a selective competitive enzyme-linked immunosorbent assay (ELISA) has been 
developed to detect BDE 47 (Ahn et al. 2009).  This method also reports high recoveries (83–90%) and a
limit of quantitation for BDE 47 in blood of 0.2 µg/L.
7.2  ENVIRONMENTAL SAMPLES 
Most environmental analyses have been performed using multi-residue methods involving solvent
extraction of the analytes from the sample matrix, cleanup to remove interfering compounds, 
determination by GC with confirmation using MS.  New methods and technologies are evolving, and this
has resulted in lower detection limits.  Analytical methods for the determination of PBDEs in 
environmental samples are given in Table 7-2. 
Like PCBs, air samples containing PBDEs are usually collected by pumping air through a sampler
containing a glass-fiber filter and adsorbent trap to separate the particle-bound and vapor-phase fractions,
respectively (Dodder et al. 2000; Hillery et al. 1997).  The filters and adsorbents are then Soxhlet
extracted with acetone/hexane, and the extracts are cleaned up and analyzed by high-resolution GC
techniques.  Beser et al. (2014) discussed a GC/MS method to quantify PBDEs that used microwave­
   
 









   
 
 



































































Table 7-2. Analytical Methods for Determining Polybrominated Diphenyl Ethers
(PBDEs) in Environmental Samples
Sample Analytical Sample Percent
Matrix Preparation method method detection limit recovery Reference
Air Air pumped through glass
fiber filter and adsorbent
trap; filters and adsorbents
are Soxhlet extracted with 
acetone/hexane; cleaned-up 
by column chromatography
Air Samples collected using a 
large-volume active sampler
at 30 m3/hour for 24 hours




Air Passive samplers set out
with PUF disks; PUF disks 
were collected at 10-day
intervals over 50 days; active 
samplers had low volume 
pump with PUF plugs
housed in a glass holder;
solvent extraction (collected 
hexane layer); washed with
H2SO4 back extraction using 
dimethyl sulfoxide followed 
by column elution containing 
Florisil, hexane, and 
anhydrous Na2SO4
Dust Samples collected from
vacuum cleaner bags;
extracted using hexane by
an accelerated solvent
extraction system,
concentrated, treated with 
H2SO4, liquid/liquid back
extraction using dimethyl
sulfoxide, column elution 





washed with H2SO4, then 
deionized water, and dried 
with anhydrous Na2SO4
GC/MS No data No data Dodder et al.
2000
GC/MS 0.063– 80–120% Beser et al.
0.210 pg/m3 2014






GC/MS 0.03 ng/g No data Harrad et al.
2006
ELISA 0.2 µg/L 105±22.7 Ahn et al. 2009
(specific for
BDE 47)
   
 








   
 
 
    
 
  
   
 
 

















    
 
   
 
































































Table 7-2. Analytical Methods for Determining Polybrominated Diphenyl Ethers
(PBDEs) in Environmental Samples
Sample Analytical Sample Percent
Matrix Preparation method method detection limit recovery Reference
Water Clean up by GFF followed by
PUF plugs; extraction with 
dichloromethane






sulfuric acid, GPC and silica 
gel column, and a basic
alumina column
Sewage Extract with chloroform;
evaporate and dissolve 
residue in ethanol
Sediment Extract with hexane and
dichloromethane (1:1 v/v),
treat with copper, sulfonate
with sulfuric acid, clean and
fraction using neutral, acid,
and alkaline silica gel
chromatography
Sediment Clean up by cartridge-type
Florosil extraction
Sediment Pressurized hot water
extraction coupled with clean 
up by LC
Sediment Extract with acetone; clean 
up on Florisil
Fish Extract with 
dichloromethane:n-hexane 
(1:1, v/v) column 
chromatography on silica
and Al2O3
Fish Extract with acetone-hexane 
+ hexane-ethyl ether;
treatment with sulfuric acid
or clean up on alumina;
















0.2–1.4 pg/L No data Yang et al. 2014




No data No data Zennegg et al.
2013
0.06 μg/g No data WHO 1994a 
1.93–227 pg/g 88.8−138 Tang et al. 2014
9.7 ng/g 91±6.3 Yamamoto et al.
1997
0.71 ng/g No data Kuosmanen et
al. 2002
<5 ng/g; <5 ng/g No data Watanabe et al.
1987
No data 58–106 Yang et al. 2008
0.1 μg/g fat No data Andersson and 
Blomkvist 1981
   
 








   
 
 
    
 
  


































    
 
   













     
     
       
   





Table 7-2. Analytical Methods for Determining Polybrominated Diphenyl Ethers



















added silica gel, column 
filtered; concentrated; silica
gel column followed by a 
basic alumina column eluted 
with n-hexane/ 
dichloromethane (1:1, v/v)
Fish Extract with dichloromethane GC-HRMS
on chromatography column; (NCI)
clean-up using GPC;
fractionation using silica gel
column
5–93 pg/g No data Alaee et al.
2001











Homogenize; extract with GC/MS 
n-hexane-acetone; treatment (NCI)
with sulfuric acid; GPC;
chromatography or silica gel
chromatography or activated 
charcoal
10 pg/g No data Jansson et al.
1991
Vegetables Homogenize; MAE; extract GC/MS




1-3 ng/g 99–106 Bizkarguenaga 
et al. 2014
Vegetables Extract with acetone/ 
n-hexane (1:1 v/v)
GC/MS (ion 1 ng/kg dry
trap) weight
82–98 (mean) Parolini et al.
2012
ASE = accelerated solvent extraction; BDE = brominated diphenyl ether; EC = electron capture; ECD = electron
capture detection; ELISA = enzyme-linked immunosorbent assay; GC = gas chromatography; GFF = glass fibre
filter; GPC = gel permeation chromatography; HRGC = high resolution gas chromatography; HRMS = high resolution 
mass spectrometry; LC = liquid chromatography; MAE = microwave-assisted extraction; MS = mass spectrometry;
NAA = neutron activation analysis; NCI = negative chemical ionization; PUF = polyurethane foam; SE = soxhlet
extraction
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7. ANALYTICAL METHODS
assisted extraction (MAE) rather than the traditional Soxhlet extraction technique in order to shorten the
extraction time and quantity of solvents used.  For a sampling rate of 30 m3 per hour over a sampling
duration of 24 hours, they achieved low limits of quantification (0.063 pg/m3for BDE 28, BDE 49, 
BDE 47, BDE 66, and BDE 100; 0.105 pg/m3 for BDE 119 and BDE 99; and 0.210 pg/m3 for BDE 155, 
BDE 154, BDE 153, BDE 139, and BDE 183).  Sampling of PBDEs is also performed using passive or
diffusive samplers (Covaci et al. 2003).  Hazrati and Harrad (2007) describe passive sampling with 
polyurethane foam disks (PUF) of BDE 28, BDE 47, BDE 99, and BDE 100 with mean recoveries of
57 and 62% for passive and active samplers, respectively. Harrad and Hunter (2006) performed passive
air sampling with PUF disks in the United Kingdom.  BDE 28, BDE 47, BDE 99, BDE 100, BDE 153, 
and BDE 154 were detected using GC/MS. The detection limit for individual BDEs were approximately
0.05 pg/m3.
Passive air sampling techniques have been developed to monitor both vapor- and particulate-phase 
PBDEs in indoor air through the use of a PUF disk and glass fiber filter (GFF) sampling media (Abdallah 
2010).  The PUF disks and GFFs were evaluated independently by initial soxhlet extraction with 
dichloromethane, concentration of extracts, and purification with SPE cartridge.  Elution with 
hexane:dichloromethane (1:1, v/v), evaporation, reconstitution in methanol, and analysis using
LC/MS/MS followed.  BDE 47, BDE  85, BDE 99, BDE 100, BDE 153, BDE 154, BDE 183, BDE 196, 
BDE 197, BDE 203, BDE 206, BDE 207, BDE 208, and BDE 209 were evaluated using this technique.  
The octaBDE to decaBDE analytes were detected on the GFF media only, indicating that these congeners 
are expected to primarily be found in the particulate phase.
Residues in environmental samples can be extracted using chloroform, acetone, acetone-hexane, hexane­
acetone, and hexane-ether (Andersson and Blomkvist 1981; Jansson et al. 1991; Watanabe et al. 1987;
WHO 1994a).  Samples are cleaned up to remove interferences using Florisil, silica gel, alumina or
activated charcoal column chromatography, GPC, and/or LC (Akutsu et al. 2001; Alaee et al. 2001b;
Andersson and Blomkvist 1981; Jansson et al. 1991; Watanabe et al. 1987; Yamamoto et al. 1997).  
Vegetable and soil samples have been prepared for analysis using, focused ultrasound solid-liquid
extraction (Bizkarguenaga et al. 2014).
As for biological samples, quantitation of environmental samples is also usually done by GC.  Capillary
columns are required for the separation of the individual congeners in a mixture (WHO 1994a).  High 
recoveries (88–128%) of PBDE residues in environmental samples are obtained by the available
analytical methods (Akutsu et al. 2001).  Typically, the limit of quantitation for PBDE residues is about 
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7. ANALYTICAL METHODS
0.12 ng/mL in water, 9.7 μg/kg in sediment, and 0.2 μg/kg lipid in fish (Akutsu et al. 2001; Yamamoto et
al. 1997).  The first inter-laboratory study on PBDEs in environmental samples showed that there is good 
agreement for quantification of BDE 47 and BDE 100 congeners.  Additionally, a selective competitive
ELISA has been developed to detect BDE 47 in dust (Ahn et al. 2009).  This method also reports high 
recoveries (105%) and a limit of quantitation for BDE 47 in blood of 0.2 µg/L.
7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of PBDEs is available.  Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of PBDEs.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.
Exposure.  Methods used as biomarkers for exposure to PBDEs are available (Ahn et al. 2009; Aleksa et
al. 2012a; Brilliant et al. 1978; Covaci et al. 2002; Eyster et al. 1983; Landrigan et al. 1979; Meironyté
Guvenius et al. 1999; Sjödin et al. 1999a; Wolff et al. 1982).  Analytical methods of sufficient precision 
and accuracy are presently available for the determination of PBDEs in adipose tissue, serum, breast milk,
and hair (Ahn et al. 2009; Aleksa et al. 2012a; Burse et al. 1980; Covaci et al. 2002; Domino et al. 1980;
Fawkes et al. 1982; Fehringer 1975a; Meironyté Guvenius et al. 1999; Sjödin et al. 1999a; Willet et al.
1978; Wolff et al. 1979a, 1979b).  Additional congener standards are needed for PBDEs analysis.  Only
30–40 congener standards are currently available for identification and quantification of PBDEs (Eljarrat
et al. 2002; Sjödin et al. 1998).  Metabolites are also important biomarkers for exposure to PBDEs.  
Ryden et al. (2012) discussed a GC/MS method for the analysis of hydroxylated PBDE metabolites in 
   
 








    
     
 




        
   
 
 
      
     
  











human blood.  GC/MS has been used to identify hydroxylated-BDE metabolites from recombinant
cytochrome P450 by Simpson et al. (2015), and Gross et al. (2015) used GC/MS and GC/MS/MS.
Effect. No studies have been conducted to determine if known effects of PBDEs exposure can be
quantitatively correlated with PBDE exposure. 
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. Analytical methods of sufficient sensitivity are presently available for the determination of
PBDEs in environmental samples (Akutsu et al. 2001; Andersson and Blomkvist 1981; Covaci et al. 
2003; Stapleton 2006; Yamamoto et al. 1997).  
Methods for determining degradation products and metabolites of PBDE are needed. There is no
information in the literature of detectable biodegradation of PBDEs in the environment under aerobic or
anaerobic conditions.  The analysis of PBDE pyrolysis degradation products, such as PBDD/PBDF, is
often disturbed by the presence of PBDEs.  Ebert et al. (1999) demonstrated that by using a Florisil
column in a sample clean-up process, almost complete separation of PBDEs and PBDDs/PBDFs is
achieved before analysis by GC/MS.
7.3.2 Ongoing Studies 
Analysis of PBDEs and other anthropogenic pollutants in marine mammals by a novel application of
comprehensive two-dimensional gas chromatography with time- of-flight mass spectrometry
(GCxGC/TOF-MS) is being studied at the University of California, San Diego (RePORTER 2016). 












   
  
   
 
     
   
 
 
    
   
    
  
 
   




   
  
  




      
 
   





8. REGULATIONS, ADVISORIES, AND GUIDELINES
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
ATSDR has derived an intermediate-duration inhalation MRL of 0.006 mg/m3 for lower-brominated
PBDEs based on a NOAEL for changes in thyroid hormones in rats (Great Lakes Chemical Corporation 
2000).
ATSDR has derived an acute-duration oral MRL of 0.00006 mg/kg/day for lower-brominated PBDEs
based on a LOAEL for endocrine effects in rat dams and reproductive and neurobehavioral effects in F1 
offspring from a series of reports (Kuriyama et al. 2005, 2007; Talsness et al. 2005).  ATSDR has derived 
an intermediate-duration oral MRL of 0.000003 mg/kg/day for lower-brominated PBDEs based on a 
minimal LOAEL for decreased testosterone in male rats (Zhang et al. 2013b).
ATSDR has derived an acute-duration oral MRL of 0.01 mg/kg/day for decaBDE based on a NOAEL for
neurobehavioral effects in mice (Johansson et al. 2008). ATSDR has derived an intermediate-duration 
oral MRL of 0.0002 mg/kg/day for decaBDE based on a minimal LOAEL for increased serum glucose in 
rats (Zhang et al. 2013a).
IARC has classified PBDE as a Group 3 carcinogen (not classifiable as to its carcinogenicity to humans) 
based on inadequate evidence of carcinogenicity in humans and inadequate or limited evidence in
experimental animals (IARC 2014).  The EPA assigns the cancer category Group D (not classifiable as to 
human carcinogenicity) to mono-, di-, tri-, tetra-, penta-, hexa-, octa-, and nonaBDEs (IRIS 2003a, 2003b, 
2003c, 2003d, 2003e, 2004, 2005, 2006) and reports “inadequate information” to classify the specific 
congeners 2,2’,4,4’-tetraBDE, 2,2’,4,4’,5-pentaBDE, and 2,2’,4,4’,5,5’-hexaBDE (IRIS 2008b, 2008c,
2008d). However, EPA assigns a classification of “suggestive evidence of carcinogenic potential” for 
decaBDE (IRIS 2008a).  The Department of Health and Human Services has not classified PBDEs as 
carcinogens (NTP 2011). ACGIH has no data regarding cancer classifications for PBDEs (ACGIH 2014).
The EPA’s reference doses (RfDs) for penta-, octa-, and decaBDEs are 2x10-3, 3x10-3, and 
7x10-3 mg/kg/day, respectively (IRIS 2003c, 2004, 2008a).  For the specific congeners
2,2’,4,4’-tetraBDE, 2,2’,4,4’, 5-pentaBDE, and 2,2’,4,4’,5,5’-hexaBDE, the RfDs are 1x10-4, 1x10-4, and 
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2x10-4 mg/kg/day, respectively (IRIS 2008b, 2008c, 2008d).  No reference concentrations (RfCs) were 
derived for PBDEs.
OSHA has not set PELs to protect workers against adverse health effects resulting from exposure to
PBDEs (OSHA 2013a, 2013b).  No guidelines for worker exposure limits have been recommended by
ACGIH (2014) or NIOSH (2014).
WHO has not established any air quality guidelines for PBDEs (WHO 2010). PBDEs are not designated
as hazardous air pollutants, and no acute exposure guidelines (AEGLs) have been derived (EPA 2013a, 
2014a).  The Department of Energy (DOE) has established values for responding to potential releases of
airborne monoBDE for use in community emergency planning.  The values established by the DOE
(2012) are the Protective Active Criteria (PAC-1, -2, and -3).  The PAC-1, -2, and -3 values are 0.29, 3.2, 
and 19 mg/m3, respectively, and represent increasing severity of effects (mild, irreversible, and life 
threatening, respectively) for a 1-hour exposure (DOE 2012). The American Industrial Hygiene
Association (AIHA) has no Emergency Response Planning Guidelines (ERPGs-1, -2, -3) for PBDEs
(AIHA 2014).
WHO has not established any drinking water guidelines for PBDEs (WHO 2011) and the EPA has not set
drinking water standards for PBDEs (EPA 2009a, 2009b, 2012, 2013c, 2013d, 2014c).  The FDA has not
set allowable levels for PBDEs in bottled water (FDA 2013).
Under the Toxic Substances Control Act (TSCA), mono-, penta-, octa-, and decaBDEs are on the list of
chemicals that manufacturers and importers must report for each plant site at which they manufactured or
imported PBDEs during the reporting period specified (EPA 1998a).  MonoBDE (represented by CAS
Registry Number 101-55-3) has been designated as a hazardous substance pursuant to CERCLA of 1980 
(EPA 2013g).  The owner and operator of any facility that produces, uses, or stores a CERCLA hazardous
substance is required to immediately report releases to any environmental media, if the amount released is 
equal to or exceeds the specified “reportable quantity” assigned to the substance. The reportable quantity
for monoBDE is 100 pounds (45 kg) (EPA 2013g).  However, PBDEs are no longer manufactured or
imported in the United States as of January 2014 (EPA 2013j)
The Emergency Planning and Community Right-to-Know Act (EPCRA) has identified decaBDE as a
toxic chemical and monoBDE as hazardous waste, and the Master Testing list includes penta-, octa-, and 
decaBDEs (EPA 2006, 2013e, 2014d).  MonoBDE is on the Resource Conservation and Recovery Act
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(RCRA) waste minimization persistent, bioaccumulative, and toxic (PBT) priority chemical list and the 
groundwater monitoring list (EPA 1998b, 2013f).  
The international and national regulations, advisories, and guidelines regarding PBDEs in air, water, and 
other media are summarized in Table 8-1.  











      
 
    
    
    





     
     
    
 
   
    
     
     
























     
     
     









      
  
  
    























8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to PBDEs
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification IARC 2014
DecaBDE Group 3a 
WHO Air quality guidelines No data WHO 2010





ACGIH TLV-TWA No data ACGIH 2014
AIHA ERPGs No data AIHA 2014




PAC-3 19 mg/m3 
EPA AEGLs No data EPA 2013a
Regulated toxic and flammable No data EPA 2013b
substances under Section 112(r) of the 40 CFR 68.130
Clean Air Act
Hazardous Air Pollutants No data EPA 2014a
NAAQS No data EPA 2014b
NIOSH REL No data NIOSH 2014
IDLH No data
OSHA PEL (8-hour TWA) for general industry No data OSHA 2013a
29 CFR 1910.1000,
Table Z-1




EPA Designated as hazardous substances No data EPA 2013c
in accordance with Section 311(b)(2)(A) 40 CFR 116.4
of the Clean Water Act
Drinking water contaminant candidate No data EPA 2009a
list 74 FR 51850
Drinking water standards and health No data EPA 2012
advisories
National primary drinking water No data EPA 2009b
regulations










      
 
    
    
   
 
  
   
  
  











     
    
     












































     








































8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to PBDEs
Agency Description Information Reference
NATIONAL (cont.)
National recommended water quality
criteria
No data EPA 2014c
Reportable quantities of hazardous
substances designated pursuant to 
Section 311 of the Clean Water Act
No data EPA 2013d
40 CFR 117.3
c. Food
FDA Allowable levels for contaminants in No data FDA 2013
bottled water 21 CFR 165.110
EAFUSb No data FDA 2014
d. Other




























































Chemical substances subject to 






OctaBDEs TSCA Section 4
DecaBDE TSCA Section 4
EPCRA Section 313 Toxic Chemicals EPA 2006
DecaBDE Yes
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Table 8-1. Regulations, Advisories, and Guidelines Applicable to PBDEs
Agency Description Information Reference
NATIONAL (cont.)
















Standards for owners and operators of






Superfund, emergency planning, and 
community right-to-know
Designated CERCLA hazardous













and its threshold planning quantity
No data EPA 2013i
40 CFR 355,
Appendix A
DHHS Carcinogenicity classification No data NTP 2011
aGroup 3: Not classifiable as to its carcinogenicity to humans
bThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS.
cGroup D: Not classifiable as to human carcinogenicity
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
AIHA = American Industrial Hygiene Association; BDE = brominated diphenyl ether; CERCLA = Comprehensive 
Environmental Response, Compensation, and Liability Act; CFR = Code of Federal Regulations;
DHHS = Department of Health and Human Services; DOE = Department of Energy; EAFUS = Everything Added to 
Food in the United States; EPA = Environmental Protection Agency; EPCRA = Emergency Planning and Community
Right-To-Know Act; ERPG = emergency response planning guidelines; FDA = Food and Drug Administration;
FR = Federal Register; GRAS = generally recognized as safe; IARC = International Agency for Research on Cancer;
IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; NAAQS = National
Ambient Air Quality Standards; NIOSH = National Institute for Occupational Safety and Health; NTP = National
Toxicology Program; OSHA = Occupational Safety and Health Administration; PAC = protective action criteria;
PBDE = polybrominated diphenyl ether; PBT = persistent, bioaccumulative, and toxic; PEL = permissible exposure 
limit; RCRA = Resource Conservation and Recovery Act; REL = recommended exposure limit; RfC = inhalation 
reference concentration; RfD = oral reference dose; RQ = reportable quantity; TLV = threshold limit values;
TSCA = Toxic Substances Control Act; TSD = treatment, storage, and disposal; TWA = time-weighted average;
WHO = World Health Organization
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PBDEs 527
10.  GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.













   
 
 
      




   
    
 
   
 
 
   












   
     





    
    
   
 
   
  
 










Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.













   
 
 
   
 
 




      
 
 
    
    
 
    
  
 
       
 
 












   
  
 
   
   
   
 
   
 
 





Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total
number of individuals in that population who could have developed that condition in a specified time
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study,
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.












   
 
   
  
 
   
 
 
   
  








     








   
  
 
    







   
 
 
     
    








Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based
and physiologically-based. A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a










      
    
    
 
 
    
 
 
     
 
   
  
       
  
 




   
   
    




    
 
   
    
    
 
 
   
  




   
     
 




   
   
    
 




variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.




















   







   
 
    
 








     
 
   
 
   
  
    
   
 
   
    
     
 
 




Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or
inherited characteristic that is associated with an increased occurrence of disease or other health-related
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.












   
 
    
  
 
      
   
 
  
    
    
     
    
    
  
   




   
   
   
   
 





     
  
PBDEs A-1
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration
of exposure.  MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach.  They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that










    
  
    
   
   
    
  
    
  
 
   
   
    
   
       





are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public.  They
are subject to change as new information becomes available concomitant with updating the toxicological
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop 
F-57, Atlanta, Georgia 30329-4027.













     
    
     
   
     
    
   
   
 






   
  









    
    
   
  
  
   
 
     
 
   
  
   
  





       
    
PBDEs A-3
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Polybrominated Diphenyl Ethers (PBDEs)
[lower-brominated diphenyl ethers]
CAS Numbers: 32536-52-0 (octaBDE)
Date: March 2017
Profile Status: Final
Route: [X] Inhalation [ ] Oral
Duration: [ ] Acute [X] Intermediate [ ] Chronic
Graph Key: 2
Species: Rat
Minimal Risk Level: 0.006 [ ] mg/kg/day [ ] ppm [X] mg/m3 
Reference: Great Lakes Chemical Corporation.  2000.  A 90-day inhalation toxicity study of
octabromodiphenyl oxide in albino rats, dated 04/04/02.  Submitted to the U.S. Environmental Protection
Agency under TSCA Section 8E.  OTS0574171-1.
Experimental design:  This is an unpublished study in which a commercial octaBDE product (Lot No. 
9525DA23B, bromine content 78.7%, composition and purity not otherwise specified) was administered 
to groups of 10 male and 10 female Crl:CD(SD)IGS BR rats, via nose-only inhalation as a dust aerosol, in 
measured concentrations of 0 (filtered air-only), 1.1, 16, or 202 mg/m3 for 6 hours/day, 5 days/week, for
13 weeks.  The mean MMADs in the low to high level groups were 2.0, 2.7, and 2.8 microns; the
corresponding mean GSDs were 3.37, 3.72, and 3.01.  Clinical and physical signs, body weight, food
consumption, and survival were evaluated throughout the study.  Ophthalmic, hematology (11 indices), 
serum chemistry (18 indices), and serum thyroid hormone (TSH, total T3, and total T4) evaluations were 
performed near the end of the exposure period.  Urinalyses were not conducted. Comprehensive
necropies, organ weight measurements, and histological examinations (including respiratory tract and 
thyroids) were performed following exposure termination.  
Effects noted in study and corresponding doses:  Hepatic, nasal, lung, thyroid, and ovarian effects were
observed. The liver was affected in both sexes as shown by dose-related increases in centrilobular
hepatocellular hypertrophy at ≥16 mg/m3 and liver weight (absolute and relative) at 202 mg/m3. Total
incidences of centrilobular hepatocellular hypertrophy in the 0, 1.1, 16, and 202 mg/m3 groups were
1/10 (minimal), 0/10, 3/10 (all minimal), and 10/10 (6 minimal, 2 mild, 2 moderate) in males, and 0/10, 
0/10, 3/10 (all minimal), and 6/10 (3 minimal, 3 mild) in females.  Changes in nasal goblet cells were
increased at 202 mg/m3, but showed no clear dose-related increasing trends for incidence or severity.
Total incidences of goblet cell hypertrophy (minimal or mild) were slightly increased in nasal level II of
both sexes at ≥1.1 mg/m3; incidences in 0, 1.1, 16, and 202 mg/m3 exposure groups were 4/10 (all
minimal), 9/10 (7 minimal, 2 mild), 6/10 (all minimal), and 10/10 (9 minimal, 1 mild) in males, and
2/10 (all minimal), 6/10 (all minimal), 4/10 (all minimal), and 8/10 (all minimal) in females.  Goblet cell 
hypertrophy was also slightly increased in nasal level IV in males at 202 mg/m3 (4/10, 0/10, 1/10, and 
8/10, all minimal severity, not increased in females). Histological changes in the lungs included alveolar
histiocytosis and chronic active inflammation that were only clearly induced at 202 mg/m3. Total
incidences of alveolar histiocytosis at 0, 1.1, 16, and 202 mg/m3 were 3/10 (2 mild, 1 minimal), 5/10 (all
minimal), 5/10 (all minimal), and 10/10 (5 minimal, 3 mild, 2 moderate) in males, and 0/10, 5/10 (all
minimal), 2/10 (all minimal), and 10/10 (1 minimal, 7 mild, 2 moderate) in females.  Corresponding total
incidences of chronic active lung inflammation were 0/10, 0/10, 2/10 (both minimal), and 
10/10 (5 minimal, 4 mild, 1 moderate) in males, and 0/10, 1/10 (minimal), 1/10 (minimal), and 
10/10 (2 minimal, 5 mild, 3 moderate) in females.  Gross lung changes also occurred in both sexes at
202 mg/m3; these included lung firmness and white discoloration and/or enlargement in the bronchial










   
   
  
     
     
   
  
 
    
      
 
 
   
  
   
  
     
 





    
 
   
   
  
    
   
 
   
 
    
   
     
 
      
 
       





       
 
      




and/or mediastinal lymph nodes.  The lymph node effects correlated with the histological finding of
granulomatous inflammation.  There were no exposure-related gross or histopathological changes in the
spleen, bone marrow, thymus, or other tissues, including thyroid.  Thyroid hormone assessments, 
however, showed exposure-related decreases in mean thyroxine (total T4) at ≥16 mg/m3 in both sexes and 
increases in TSH at ≥16 mg/m3 in males and 202 mg/m3 in females.  The changes were usually
statistically significant (p<0.05 or p<0.01) compared to controls and were considered to be consistent
with chemical-induced hypothyroidism.  There were no serum T3 changes.  Qualitative histological 
evaluations of step sections of ovaries showed an absence of corpora lutea in 3/10 females at 202 mg/m3, 
compared to 0/10 in the control and lower exposure groups.  This 30% incidence was interpreted to be a
treatment-related effect because an absence of corpora lutea was considered unusual in rats at 20 weeks of
age.
Other findings included some hematological alterations in 202 mg/m3 females that were not considered to
be exposure-related (slightly increased mean activated partial thromboplastin time, and decreased mean 
corpuscular hemoglobin and mean corpuscular hemoglobin concentration without effects on red blood
cell counts, hematocrit, or hemoglobin levels).  Serum chemistry evaluations showed that cholesterol was
significantly increased (66.2% more than controls, p<0.01) in 202 mg/m3 females, but the magnitude of
the elevation was not considered toxicologically significant.  Some other statistically significant serum
chemistry alterations (increased mean globulin and total protein, decreased albumin/globulin ratio) also 
occurred in the 202 mg/m3 females, but were not considered exposure-related due to small magnitudes of
changes and lack of similar findings in the males.
Dose and end point used for MRL derivation:  1.1 mg/m3
[X] NOAEL  [ ] LOAEL
Considering the unclear adversity of minimal severity goblet cell hypertrophy, lack of clear dose-related
increasing trends for incidence and severity of this nasal effect, identification of both a NOAEL
(1.1 mg/m3) and LOAEL (16 mg/m3) for changes in thyroid hormones, and abundant evidence for thyroid 
effects of PBDEs in oral studies, the NOAEL for effects on thyroid hormones is the most appropriate
basis for derivation of the MRL.
Uncertainty factors used in MRL derivation:
[X] 3 for extrapolation from animals to humans with dosimetric adjustments
[X] 10 for human variability
[X] 3 modifying factor for incomplete database
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
Was a conversion used from intermittent to continuous exposure? The NOAEL was adjusted to
continuous exposure as follows:  1.1 mg/m3 x 6 hours/24 hours x 5 days/7 days = 0.196 mg/m3 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  The
human equivalent NOAEL (NOAELHEC) was calculated from the duration-adjusted NOAEL (NOAELADJ) 
using EPA RfC methodology as follows:
NOAELHEC = NOAELADJ x RDDR = 0.196 mg/m3 x 2.7 = 0.53 mg/m3
The RDDR for the extrathoracic region was used to extrapolate deposited doses in rats to deposited doses
in humans.  The following parameters were used to calculate the RDDR of 2.7:  MMAD of 2.0 μm with a










   
 
 
     
 
       
 
      
 
 
    
    
     
     
    
     
    
  
   
    
  
      
  
  
     
    
     
  
 
     
 
  
    






mean GSD (sigma g) of 3.37; default human body weight of 70 kg, and a default female F344 rat body 
weight of 180 g.
Based on these values, the MRL for lower brominated diphenyl ethers is derived as follows:
MRL = NOAELHEC ÷ (UF x MF) = 0.53 ÷ (30 x 3) = 0.006 mg/m3 
Other additional studies or pertinent information that lend support to this MRL:  This is the only
intermediate-duration inhalation study of PBDEs.
The thyroid is a sensitive target of lower-brominated BDEs in orally exposed animals.  A LOAEL for
reduced serum T4 hormone levels in rat dams that were exposed to 2,2’,4,4’,5-pentaBDE (BDE 99)
(Kuriyama et al. 2007) was used as a co-critical end point for the basis for the acute oral MRL for lower­
brominated BDEs.  This study is supported by numerous studies that report reduced serum T4 levels in
adult, nonpregnant mice and rats following acute exposure to commercial pentaBDE mixtures 
(Bromkal 70, Bromkal 70-5 DE, DE-71), and the commercial octaBDE mixture DE-79, or
2,2’,4,4’-tetraBDE (BDE 47), indicating significant reductions of 19–92% following gavage exposure at
doses ≥10 and ≥0.8 mg/kg/day in rats and mice, respectively, for 1–14 days (Darnerud and Sinjari 1996;
Fowles et al. 1994; Hallgren and Darnerud 1998, 2002; Hallgren et al. 2001;Hoppe and Carey 2007;
Richardson et al. 2008; Stoker et al. 2004, 2005; Zhou et al. 2001).  In developing animals, numerous
studies have reported decreased serum T4 and/or T3 levels in pups after gestational and lactational
exposure to commercial pentaBDE mixtures (DE-71, Bromkal 70-5 DE), BDE 99, or BDE 47 at doses as 
low as 0.3 mg/kg/day in rats and 452 mg/kg/day in mice (Blanco et al. 2013; Bondy et al. 2011, 2013;
Ellis-Hutchings et al. 2006; Kodavanti et al. 2010; Kuriyama et al. 2007; Miller et al. 2012; Poon et al. 
2011; Shah et al. 2011; Skarman et al. 2005; Szabo et al. 2009; Wang et al. 2011a; Zhou et al. 2002).
Hepatic effects observed in critical study also support the selected point of departure (POD), as a dose-
related increased centrilobular hepatocellular hypertrophy was observed in males and females exposed to
octaBDE at concentrations ≥16 mg/m3; however, this end point was not selected as a co-critical effect, as 
the increase in incidence was only significant at 202 mg/m3 (Great Lakes Chemical Corporation 2000).
Hydroxylated metabolites (OH-PBDEs) may be responsible for the toxic action of PBDEs.  There is some 
evidence that the CYPs involved in metabolism of PBDEs, as well as the OH-PBDEs formed, are 
different in rats and humans (Erratico et al. 2011, 2012, 2013)—see Section 3.4.3 for more information.  
However, there is no available evidence indicating that the complement of OH-PBDEs formed in humans
is any more or less potent than the complement of OH-PBDEs formed in rats. Therefore, the current use 
of an animal-to-human uncertainty factor is appropriate for calculating an MRL based on effects observed
in rats.
Agency Contact (Chemical Manager):  Hana Pohl













     
    
     
   
    
   
   
   
 
      
 
    








   
 
   
   




     
 
   
      
  
   
   














MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Polybrominated Diphenyl Ethers (PBDEs)
[lower-brominated diphenyl ethers]
CAS Numbers: 60348-60-9 (2,2’,4,4’,5-pentaBDE)
Date: March 2017
Profile Status: Final
Route: [ ] Inhalation [X] Oral
Duration: [X] Acute [ ] Intermediate [ ] Chronic
Graph Key: 24, 60, 63
Species: Rat
Minimal Risk Level: 0.00006 (6x10-5) [X] mg/kg/day [ ] ppm [ ] mg/m3 
References:  Kuriyama SN, Talsness CE, Grote K, et al.  2005. Developmental exposure to low dose
PBDE 99: effects on male fertility and neurobehavior in rat offspring.  Environ Health Perspect
113(2):149-154.  
Talsness CE, Shakibaei M, Kuriyama SN, et al.  2005. Ultrastructural changes observed in rat ovaries 
following in utero and lactational exposure to low doses of a polybrominated flame retardant.  Toxicol
Lett 157(3):189-202.
Kuriyama SN, Wanner A, Fidalgo-Neto AA, et al. 2007.  Developmental exposure to low-dose PBDE­
99: Tissue distribution and thyroid hormone levels.  Toxicology 242(1-3):80-90.
Experimental design:  In the first study (Kuriyama et al. 2005), pregnant rats (16–20/group) were given a
single dose of 2,2’,4,4’,5-pentaBDE (BDE 99, 98% purity) at 0, 0.06, or 0.3 mg/kg via gavage in peanut
oil vehicle on GD 6.  Dams were allowed to deliver, and litter size was not artificially altered.  Emergence 
of postnatal reflexes and developmental landmarks (eruption of incisors, fur development, eye opening, 
and testes descent) was evaluated in all pups (163–200/group).  Locomotor activity was evaluated over
24-hour periods on PNDs 36 and 71 in one male and female per litter (16–20 litters/group).  F1 male
offspring were sacrificed as adults (~PND 140, 12 males/group) and the thymus, spleen, liver, testis,
epididymis, seminal vesicle, and ventral prostate were weighed. The right testis and caudal epididymis 
were retained for spermatid and sperm counts and morphology, respectively.  Additionally, blood was
collected for analysis of testosterone and LH levels.  In 15–19 F1 males/group, reproductive function was
assessed at ~PND 150.  F1 males were mated with untreated females in a 1:1 ratio for 14 days.  The
ability of males to impregnate unexposed females was assessed, and pregnant dams were sacrificed on
GD 21 for assessment of the number of implantations, resorptions, and fetuses in the F2 generation.  
Uterine and fetal weight was recorded, and fetuses were sexed and examined for external anomalies.  In a 
separate group of F1 males, male sexual behavior was assessed in 20 males/group at ~PND 160.  F1
males were mated with untreated females in estrus (1:1) and the sexual behavior of each mating was 
recorded for 20 minutes.
In the second study (Talsness et al. 2005), pregnant rats (14–17/group) were exposed to BDE 99 
according to the exposure protocol for Study 1.  The F1 offspring were weaned on PND 22.  The female
offspring were necropsied in estrus (based on vaginal cytology) on approximately PND 90.  Histological 
evaluation of the ovary (10/group), uterus (5–7/group), and vagina (5–9/group) was performed.  Ovarian 
follicles were counted in 10 ovaries from each group.  One ovary from one female offspring in each group 
was analyzed by transmission electron microscopy.  Twenty virgin F1 females per group were mated with 
non-exposed males to evaluate fertility. The F1 dams were sacrificed on GD 21 and the uterus was 
excised.  The uterine and F2 fetal weights and the number of implantations, resorptions, and fetuses were 












   
 








   
   
    
   







    
  
   
   
     
      
 
 
     
  
  
      
   
   
 
   
   
   
   
 
   
  




determined.  The F2 fetuses were examined for external anomalies and when present, they were stained 
and examined for skeletal anomalies.
In the third study (Kuriyama et al. 2007), pregnant rats (15–20/group) were exposed to BDE 99 according 
to the exposure protocol for Study 1.  On PND 1, approximately half of the dams (8–10/group) and their
offspring were sacrificed. Liver samples were collected for enzyme activity (EROD, UDPGT) and blood
was collected for determination of thyroid hormones (T3, free-T3, T4, free-T4).  In pups, blood and liver
tissue were pooled by gender on a litter basis.  On PND 14, 2 pups/sex/litter (7–11 litters/group) were
sacrificed, and liver samples and blood were collected for analysis.  On PND 22, remaining dams (7– 
11/group) and 2 pups/sex/litter were sacrificed, and liver samples and blood were collected for analysis.
Effects noted in study and corresponding doses: 
Study 1 (Kuriyama et al. 2005): No exposure-related effects were observed for the age at fur development
or eye opening, testes descent, or the ability to master the rotating rod test.  However, significant delays in
the eruption of incisors in F1 pups and the development of the cliff-drop aversion reflex were observed in 
F1 males in the 0.3 mg/kg group, compared with controls.  Total activity, time spent active, the duration 
of activity per active phase, and the total activity per active phase were all significantly increased in F1
offspring on PND 36 in the 0.3 mg/kg group, compared with controls.  On PND 71, the increased total
activity and time spent active persisted in the 0.3 mg/kg group, and was also significantly increased in the
0.06 mg/kg group.  In the group sacrificed on PND 140, no exposure-related changes were observed in
body weight, liver weight, or thymus weight; however, absolute spleen weight was significantly increased 
by 9% in the 0.06 and 0.3 mg/kg groups, and relative spleen weight was significantly increased by 12% in 
the 0.06 mg/kg group.  Compared with controls, significantly altered male reproductive organ weights at
PND 140 included a 10 and 11% decrease in relative testes and epididymis weight, respectively, in the
0.3 mg/kg group and a 5% decrease in relative epididymis weight in the 0.06 mg/kg group; no significant
changes were observed in absolute organ weights.  In both dose groups, the number of spermatids and 
sperm and daily sperm production were significantly decreased, compared with controls.  No exposure-
related effects were observed for sperm morphology.  No changes were observed in serum testosterone or
LH levels.  Despite sperm alterations, no significant exposure-related effects were observed in male 
reproductive function or the majority of male sexual behaviors. The only significantly altered male 
sexual behavior was a 32% decrease in the percent of males with two or more ejaculations.
Study 2 (Talsness et al. 2005): No statistically significant, exposure-related histological changes were 
observed at the light microscopic level in the ovary, uterus, or vagina of female offspring, and no 
exposure-related effects were observed in the number of ovarian follicles.  However, multiple
ultrastructural changes were noted in the ovaries of PND 90 female offspring from dams exposed to
0.06 or 0.3 mg/kg, including destruction of the surface of the serosal epithelial cells, necrosis, and
numerous vesicular structures with dense granular material within the cytoplasm.  Additional changes 
observed in the 0.3 mg/kg group included degenerative changes and aggregates of small and large
vesicles filled with homogeneously dense granular material in the cytoplasm and clumped chromatin
within the condensed nucleus.  No exposure-related changes were found for F1 female pregnancy rate,
total implantation sites, implantation sites/dam, F2 fetuses/gravid dam, or total number of live F2 fetuses.  
However, the resorption rates were 12 and 15% in the 0.06 and 0.3 mg/kg groups, respectively, compared 
with the control rate of 9%.  Statistics were not reported; however, the resorption rates in the exposed rats 
were also reportedly increased compared with historical controls (average control resorption rate=5.4%,
with rates up to 10% considered to be within normal limits).  In addition, the percentage of litters with 
resorptions was higher in the exposed females, being 47% in the control group and 69 and 72% in the
0.06 and 0.3 mg/kg groups, respectively.  In F2 pups, mean fetal weight was significantly increased by
5% in the 0.06 mg/kg group, but not in the 0.3 mg/kg group, compared with controls.  Three fetuses from
different litters in the 0.3 mg/kg/day group showed skeletal anomalies (tail, skull, vertebrae); however, 














   
  
   
  
  








   
  
      
  
 
   
 




      
 
 





    
 
      
  
   
  
     
   
  
 





this incidence of anomalies in 3/18 litters is not significantly elevated compared with the control 
incidence of 0/19 (Fisher’s exact test, performed for this review).
Study 3 (Kuriyama et al. 2007): Serum T4 levels were significantly decreased by 23–33% in the 0.06 and 
0.3 mg/kg dams, sacrificed on PND 1.  No changes were observed in T3, free-T3, or free-T4 at PND 1 or
any thyroid hormone levels at PND 22 in dams.  In pups, no dose-related changes were observed at
PND 1 or 14.  At PND 22, serum T4 was significantly decreased by in F1 males and females and serum
free-T4 was significantly decreased in F1 females from the 0.3 mg/kg group (19–23% reductions).  
Hepatic EROD activity was significantly decreased in PND 22 dams from the 0.3 mg/kg group; no other
changes in hepatic enzyme activity were observed in dams. In F1 offspring, hepatic UDPGT activity was 
significantly increased in females at PND 1 and EROD activity was significantly elevated in males at
PND 22; no other changes in hepatic enzyme activity were observed in F1 offspring.
Dose and end point used for MRL derivation: 0.06 mg/kg
[   ] NOAEL  [X] LOAEL
Collectively, these studies indicate a LOAEL of 0.06 mg/kg for endocrine effects in F0 dams (reduced 
serum T4) and reproductive and neurobehavioral effects in F1 adult offspring (impaired spermatogenesis, 
ultrastructural changes in ovaries, increased resorptions in F1 females mated to unexposed males, and
increased spontaneous motor activity).  A NOAEL was not identified.
Uncertainty factors used in MRL derivation:
[X] 10 for extrapolation from a LOAEL to a NOAEL
[X] 10 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable
(gavage studies).
Was a conversion used from intermittent to continuous exposure? Not applicable (single exposure 
studies).
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Other additional studies or pertinent information that lend support to this MRL: 
Support for reproductive effects in F1 animals as a co-critical end point: In a companion study to the
critical studies described above, pregnant rats (8/group) were administered 2,2´,4,4´-tetrabromodiphenyl
ether (BDE 47, 98% purity) at 0, 0.14, or 0.7 mg/kg via gavage in peanut oil vehicle on GD 6 (Talsness et
al. 2008).  As observed in pentaBDE-exposed F1 females, ultrastructural changes (accumulation of
vesicular structures with homogeneously dense granular material in the cytoplasm of the stromal cells,
large vacuoles) were observed in the ovaries of F1 females from both dose groups on PND 100.  No 
exposure-related changes were observed in F1 female fertility or F2 litter parameters.  F1 males were not
evaluated for developmental reproductive effects following tetraBDE exposure.
Support for altered open-field activity in F1 animals as a co-critical end point: Alterations in open-field
activity have been consistently reported in mice exposed to BDE 99 at doses ≥0.8 mg/kg on PND 3 or 10 
and evaluated at 2–8 months of age, characterized by decreased activity during the first 20-minute period 










   
     
   
    
    
  
    
      
      
    
  
      
 
     
 
 
     
    
      
      
 
     
      
     
   




   
  
  
   
  






followed by increased activity during the third 20-minute period (Eriksson et al. 2002b, 2006; Fischer et
al. 2008; Sand et al. 2004; Viberg et al. 2002, 2004a, 2004b). These findings indicate an initial decrease 
in activity, but also a lack of habituation to new surroundings.  The study authors noted that this
nonhabituating behavior profile (i.e., decreased activity early in the test period and increased activity late
in the test period) has also been reported in adult mice neonatally exposed to certain PCB congeners.  
Several other 1-day exposure studies have reported similar findings in rats and mice following exposure
to various lower-brominated PBDEs.  Decreased spontaneous activity and/or impaired habituation was
observed in rats exposed to BDE 99 at 8 mg/kg on PND 10, mice exposed to 2,2’,4,4’,5,5’-hexaBDE
(BDE 153) at ≥0.45 mg/kg on PND 10, mice exposed to BDE 47 at 10.5 mg/kg on PND 10, mice exposed 
to the 2,2’,3,4,4’,5’,6-heptaBDE (BDE 183) at 15.2 mg/kg on PND 3, and mice exposed to the
2,2’,3,4,4’,5,5’,6-octaBDE (BDE 203) at 16.8 mg/kg on PND 3 or 10 (Eriksson et al. 2001; Viberg et al. 
2003a, 2005, 2006).  Increased vertical activity was significantly increased at 4 months, but not at
2 months, in mice exposed to BDE 47 at ≥1 mg/kg on PND 10; no changes were observed in horizontal
activity or habituation (Gee and Moser 2008).  No changes in open-field behavior were observed in mice 
exposed to BDE 183 at 15.2 mg/kg or 2,2’,3,3’,4,4’,5,5’,6-nonaBDE (BDE 206) at 18.5 on PND 10 
(Viberg et al. 2006).
Additional neurobehavioral changes observed in the studies described above included learning and 
memory impairments in the Morris water maze or radial arm maze in mice exposed to BDE 99 at
0.8 mg/kg on PND 10, mice exposed to BDE 153 at ≥0.9 mg/kg on PND 10, and mice exposed to 
BDE 203 at 16.8 mg/kg on PND 10, and in rats exposed to BDE 47 at ≥1 mg/kg on PND 10 (Fischer et al.
2008; He et al. 2009, 2011; Viberg et al. 2003a, 2006).
Support for decreased serum T4 in F0 dams as a co-critical end point: Numerous studies report reduced 
serum T4 levels in adult, nonpregnant mice and rats following acute exposure to commercial pentaBDE
mixtures (Bromkal 70, Bromkal 70-5 DE, DE-71), the commercial octaBDE mixture DE-79, or BDE 47.  
Significant reductions of 19–92% have been reported following gavage exposure at doses ≥10 and 
≥0.8 mg/kg/day in rats and mice, respectively, for 1–14 days (Darnerud and Sinjari 1996; Fowles et al.
1994; Hallgren and Darnerud 1998, 2002; Hallgren et al. 2001;Hoppe and Carey 2007; Richardson et al. 
2008; Stoker et al. 2004, 2005; Zhou et al. 2001).  
Toxicokinetic considerations: Hydroxylated metabolites (OH-PBDEs) may be responsible for the toxic 
action of PBDEs. There is some evidence that the CYPs involved in metabolism of PBDEs, as well as the 
OH-PBDEs formed, are different in rats and humans (Erratico et al. 2011, 2012, 2013)—see Section 3.4.3 
for more information.  However, there is no available evidence indicating that the complement of
OH-PBDEs formed in humans is any more or less potent than the complement of OH-PBDEs formed in 
rats. Therefore, the current use of an animal-to-human uncertainty factor is appropriate for calculating an 
MRL based on effects observed in rats.
Agency Contact (Chemical Manager):  Hana Pohl













     
    
     
   
    
    
   
   
 
     
 
      




   
    
    
    






     
  
   
   
   
 





























MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Polybrominated Diphenyl Ethers (PBDEs)
[lower-brominated diphenyl ethers]
CAS Numbers: 5436-43-1 (2,2’,4,4’-tetraBDE)
Date: March 2017
Profile Status: Final
Route: [ ] Inhalation [X] Oral
Duration: [ ] Acute [X] Intermediate [ ] Chronic
Graph Key: 164
Species: Rat
Minimal Risk Level: 0.000003 (3x10-6) [X] mg/kg/day [ ] ppm [ ] mg/m3 
Reference:  Zhang Z, Zhang X, Sun Z, et al. 2013b. Cytochrome P450 3A1 mediates 

2,2',4,4'-tetrabromodiphenyl ether-induced reduction of spermatogenesis in adult rats. PLoS ONE 

8(6):e66301.  http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0066301. 

August 14, 2014. 

Experimental design:  Male rats (20/group) were administered 2,2’,4,4’-tetrabromodiphenyl ether
(BDE 47; ≥98.7%) at 0, 0.001, 0.03, or 1 mg/kg/day via gavage in corn oil 6 days/week for 8 weeks.  
Twenty-four hours after the final BDE 47 treatment, rats were sacrificed.  Testes were fixed for
histological analysis and labeling of apoptotic cells or prepared for analysis of sperm production.  Daily
sperm production was estimated by dividing the total number of mature spermatids per testis by 6.1 (i.e., 
the days of the seminiferous cycle that the spermatids are present in the seminiferous epithelium).
Testicular samples were examined for ROS and mRNA expression of apoptosis related proteins (ser15,
ser473, p53, PTEN, AKT, BAD, caspase 3, FAS, FASL).  Serum levels of E2, FSH, LH, and testosterone
were measured.
Effects noted in study and corresponding doses:  Histological examination of the testes showed a 

significant increase in the number of multinucleated giant cells (arising from spermatocytes that aborted 

meiosis) at ≥0.03 mg/kg/day and abundant vacuolar spaces in the seminiferous epithelium at 1 mg/kg/day
(quantitative data not reported).  Additionally, the number of apoptotic cells was significantly increased 
by 1.9- and 3-fold in the testes of rats from the 0.03 and 1 mg/kg/day groups, respectively, and the mRNA
levels of several apoptosis genes were elevated in a dose-related manner.  Daily sperm production was
significantly decreased by 23% in the 1 mg/kg/day group, compared with controls.  Serum testosterone 
was significantly decreased by ~34, 53, and 62% in the 0.001, 0.03, and 1 mg/kg/day groups, 
respectively, compared with controls.  No exposure-related changes were observed in serum E2, FSH, or
LH levels. Testicular ROS levels were significantly elevated at 1 mg/kg/day, compared with controls. 
Dose and end point used for MRL derivation:  0.001 mg/kg/day
[ ] NOAEL  [X ] LOAEL  [ ] BMDL1SD
BMD modeling was performed on the serum testosterone data to assess suitability of this approach for
determining the POD.  Since testosterone data were presented graphically, GrabIt! software was used to
extract the means and standard deviations. The data are shown in Table A-1.  











   
 
   
   
   
   
   
 


























         
 
 
         
 
 
         
 
 
         
          
          
 
 
         
 
 
         








   



















Table A-1.  Digitally Extracted Serum Testosterone Levels Following Exposure to
BDE 47 (Zhang et al. 2013b)





Modeling was performed using the reference benchmark response (BMR) of 1 standard deviation change
from the mean (1SD).  Results are shown in Table A-2 and Figure A-1.
Table A-2.  Modeling Results for Decreased Serum Testosterone Levels 
Following Exposure to BDE 47 (Zhang et al. 2013b)

























<0.0001 0.14 <0.0001 -3.34 0.20 3.96 108.73 0.54 0.32
Exponential
(model 3)d 
<0.0001 0.14 <0.0001 -3.34 0.20 3.96 108.73 0.54 0.32
Exponential
(model 4)d 
<0.0001 0.14 0.11 0.00 0.00 1.13 66.79 0.0003 0.0002
Exponential
(model 5)d 
<0.0001 0.14 N/A 0.00 0.00 1.13 68.79 0.0003 0.0002
Hilld <0.0001 0.14 0.18 0.02 -0.10 1.00 66.09 0.0002 0.0001
Lineare <0.0001 0.14 <0.0001 -3.34 0.10 3.99 109.09 0.65 0.45
Polynomial
(2-degree)e 
<0.0001 0.14 <0.0001 -3.34 0.10 3.99 109.09 0.65 0.45
Polynomial
(3-degree)e 
<0.0001 0.14 <0.0001 -3.34 0.10 3.99 109.09 0.65 0.45
Powerd,e <0.0001 0.14 <0.0001 -3.34 0.10 3.99 109.09 0.65 0.45
aValues >0.05 fail to meet conventional goodness-of-fit criteria.
bValues <0.10 fail to meet conventional goodness-of-fit criteria.
cScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose.
dPower restricted to ≥1.
eCoefficients restricted to be negative.
AIC = Akaike Information Criterion; BDE = brominated diphenyl ether; BMD = maximum likelihood estimate of the 
exposure concentration associated with the selected benchmark response; BMDL = 95% lower confidence limit on 
the BMD (subscripts denote benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk);
NA = not applicable (BMDL computation failed or the BMD was higher than the highest dose tested); SD = standard 
deviation














   
 
  
   
   
     
  
   
  
      
 
   
     
  
   
 
















10:58 09/18 2014 
Figure A-1.  Fit of Hill Model to Data for Decreased Serum Testosterone Levels 
Following Exposure to BDE 47 (Zhang et al. 2013b)
Goodness-of-fit statistics indicate inadequate fit to the data for all models except the Exponential 4 and
Hill models, which were considered unsuitable for use in MRL derivation because they did not provide
reliable information about the shape of the dose-response curve.  For example, using the BMR of 1SD, 
the BMD, which should be within the range of the data points for best model performance, is a full order
of magnitude lower than the lowest dose used in the study.  When an alternate BMR of 50% change from
the mean (50RD) was used in order to get the BMD within the range of observation, the BMDL
calculation failed (data not shown).  The observed instability in the BMD and BMDL calculations
indicates that the model is not suitable for use in MRL derivation.
In the absence of a suitable model, the minimal LOAEL of 0.001 mg/kg/day for decreased serum
testosterone was chosen as the POD for MRL derivation; no NOAEL was identified. The change in
testosterone is considered a minimal LOAEL because it is unclear if the magnitude of change represents a 
biologically adverse effect; however, this statistically significant reduction in serum testosterone is 
considered an early indication of damage to the male reproductive system, considering the additional
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Uncertainty factors used in MRL derivation:
[X] 3 for use of a minimal LOAEL
[X] 10 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable
(gavage study).
Was a conversion used from intermittent to continuous exposure? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Other additional studies or pertinent information that lend support to this MRL: One additional rat study
and a mouse study reported histopathological changes in the testes following intermediate-duration 
exposure to tetraBDE at ≥0.03 mg/kg/day; neither study evaluated serum testosterone levels (Huang et al. 
2015; Wang et al. 2013).  In the rat study, a NOAEL of 0.001 mg/kg/day and a LOAEL of
0.03 mg/kg/day were identified for increased epithelial thickness and spermatocyte apoptosis in the testes 
of males exposed to BDE 47 for 8 weeks via gavage (Huang et al. 2015).  In the mouse study, a NOAEL
of 0.0015 mg/kg/day and a LOAEL of 0.045 mg/kg/day were identified for germ cell loss and increased
apoptosis in the testes of males exposed to BDE 47 for 30 days via gavage (Wang et al. 2013). Testis 
sections in control and 0.0015 mg/kg/day groups were normal.  In the 0.045, 0.15, and 30 mg/kg/day 
groups, “some” seminiferous tubules exhibited complete germ cell loss and had a Sertoli cell-only
phenotype (no incidence data reported).  No exposure-related changes were observed in Leydig cells.
The TUNEL assay showed a significant, dose-related increase in the number of apoptotic cells.
Quantitative data were not reported; however, from the qualitative figures, it appears that apoptotic cells
were observed at doses ≥0.045 mg/kg/day.  
No other study evaluated testicular histopathology or serum testosterone levels in male laboratory animals 
following exposure to tetraBDE (BDE47).  Following intermediate exposure to other congeners, no 
changes in testicular histology were observed in rats exposed to commercial pentaBDE mixtures
(Bromkal 70-5 DE; DE-71) at gavage doses up to 250 mg/kg/day for 15–28 days (Becker et al. 2012;
Oberg et al. 2010), commercial penta- or octaBDE mixtures (DE-71, unspecified octa mixture) at dietary
doses up to 750 mg/kg/day for 28–90 days (IRDC 1976, 1977; WIL Research Laboratories 1984), or a
dietary PBDE mixture containing 52.1% pentaBDE (DE-71), 44.2% decaBDE (BDE 209), and 0.4%
octaBDE (DE-79) at doses up to 20 mg/kg/day for 70 days (Ernest et al. 2012).  However, testicular
apoptosis was not evaluated in any of these studies.  Serum testosterone was significantly decreased by
40–45% in rats exposed once to BDE 99 at 0.06 or 1.2 mg/kg (Alonso et al. 2010).  Other studies
evaluating serum testosterone levels after intermediate-duration exposure to lower-brominated PBDEs
mixtures (DE-71, dietary PBDE mixture described above) did not report exposure-related decreases 
(Becker et al. 2012; Ernest et al. 2012; Stoker et al. 2005).  These data suggest that individual congeners 
(BDE 47, BDE 99) may have a greater capacity to alter serum testosterone levels than PBDE mixtures.
One-generation studies of the BDE 47 congener reported developmental effects at ≥0.03 mg/kg/day, 
including:
• Impaired spatial learning in the Barnes maze in PNW 8 offspring of mouse dams fed cornflakes 
dosed with BDE 47 from pre-mating day 28 through PND 21 (Koenig et al. 2012).















   
  
 
    
 
  
   









• Decreased center-field activity in an open field (indicating increased anxiety) in PND 60 female
offspring from mouse dams fed cornflakes dosed with BDE 47 from pre-mating day 28 through 
PND 21 (Ta et al. 2011).
• Decreased pre-weaning weight, decreased pup vocalizations on PNDs 8–10, and decreased 
sociability on PND 72 in female offspring of mouse dams exposed to BDE 47 via gavage from
pre-mating day 28 through PND 21 (Woods et al. 2012)
Hydroxylated metabolites (OH-PBDEs) may be responsible for the toxic action of PBDEs.  There is some 
evidence that the CYPs involved in metabolism of PBDEs, as well as the OH-PBDEs formed, are 
different in rats and humans (Erratico et al. 2011, 2012, 2013)—see Section 3.4.3 for more information.  
However, there is no available evidence indicating that the complement of OH-PBDEs formed in humans
is any more or less potent than the complement of OH-PBDEs formed in rats. Therefore, the current use 
of an animal-to-human uncertainty factor is appropriate for calculating an MRL based on effects observed
in rats.
Agency Contact (Chemical Manager):  Hana Pohl













     
   
     
   
    
   
   
   
 
    
 
   









   
  
  





   
    
    




     
  
 
    






MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Polybrominated Diphenyl Ethers (PBDEs)
[decabromodiphenyl ether (decaBDE)]
CAS Numbers: 1163-19-5 
Date: February 2017
Profile Status: Final
Route: [ ] Inhalation [X] Oral
Duration: [X] Acute [ ] Intermediate [ ] Chronic
Graph Key: 12
Species: Mouse
Minimal Risk Level:  0.01 [X] mg/kg/day [ ] ppm [ ] mg/m3 
References: Johansson N, Viberg H, Fredriksson A, et al.  2008.  Neonatal exposure to deca-brominated 
diphenyl either (PBDE 209) causes dose-response changes in spontaneous behavior and cholinergic 
susceptibility in adult mice.  Neurotoxicology 29:911-919.
Buratovic S, Viberg H, Fredriksson A, et al. 2014. Developmental exposure to the polybrominated 
diphenyl ether PBDE 209: Neurobehavioural and neuroprotein analysis in adult male and female mice. 
Environ Toxicol Pharmacol 38(2):570-585.
Experimental design: In the first study (Johansson et al. 2008), neonatal male mice (3–4 litters/group)
were given single doses of 2,2’,3,3’,4,4’,5,5’,6,6’-decaBDE (BDE 209, 98% purity) at 0, 1.34, 2.22, 13.4, 
or 20.1 mg/kg via gavage in a 20% fat emulsion vehicle (1:10 mixture egg lecithin and peanut oil) on 
PND 3.  Mice were observed for clinical signs of toxicity and body weight was measured at PND 3 and 
PNW 4.  Spontaneous motor behavior (locomotion, rearing, total activity) was evaluated in an open field 
at 2 months (10 mice/group) and 4 months (16 mice/group).  Motor activity was measured during a 60­
minute period, divided into three 20-minute intervals.  Nicotine-induced behavior was evaluated at 4
months following single subcutaneous injections of 80 µg nicotine/kg (8/group) or 10 mL 0.9% NaCl/kg
(8/group).  Anxiety was assessed at 4 months using the elevated plus maze.
In the second study (Buratovic et al. 2014), neonatal male mice (6 litters/group; 31–40 males and 23– 
34 females per group) were administered 2,2’,3,3’,4,4’,5,5’,6,6’-decaBDE (BDE 209, >95% purity) at 
doses of 0, 1.34, 5.76, or 13.4 mg/kg via gavage in a 20% fat emulsion vehicle (1:10 mixture egg lecithin
and peanut oil) on PND 3.  Mice were observed for clinical signs of toxicity and body weight changes
throughout the study (no further details were provided).  Spontaneous motor behavior (locomotion, 
rearing, total activity) was evaluated in an open field at 2 months (18/sex/group).  Motor activity was
measured during a 60-minute period, divided into three 20-minute intervals.  Directly after spontaneous
motor evaluation, 9/sex/group were injected with a cholinergic agent (0.25 mg/kg paraoxon in males, 
80 µg/kg nicotine in females), while the other 9/sex/group were injected with 0.9% saline, for evaluation 
of cholinergic-induced locomotion.  At 4 months, spontaneous behavior was assessed again in the saline-
injected animals only (9 males/group at all doses and 9 females/group in the control and high-dose group 
only).  Learning and memory was assessed using the Morris water maze at 5 and 7 months in 13– 
15 males from the 0, 5.76, and 13.4 mg/kg groups only (the same mice were evaluated at each time point).  
Male and female mice were sacrificed at 7 months. The cerebral cortex and hippocampus from control
and high-dose males and females were removed and processed for neuroprotein analysis using Western
blot.











   




     
     
 
    
   
     
   
   
   
  
 
   
 
     
 
   
   
     
  
    
       
    
  
      




   
      
      
   
   





    
 





Effects noted in study and corresponding doses:
Study 1 (Johansson et al. (2008): No clinical signs of toxicity or body weight effects were observed.  At
2 months, significantly decreased locomotion, rearing, and total activity were observed during the first
20-minute interval of the open field assessment in mice exposed to ≥2.22 mg/kg, compared with controls.  
However, during the third 20-minute interval, when activity should decrease due to habituation, 
locomotion, rearing, and total activity were significantly increased in mice exposed to ≥13.4 mg/kg.  
None of the end points measured were significantly altered at 1.34 mg/kg.  At 4 months, significantly
decreased locomotion, rearing, and total activity were observed during the first interval of the open field
assessment in mice exposed to ≥2.22 mg/kg, compared with controls.  During the third interval, 
significantly increased locomotion, rearing, and total activity were observed in mice exposed to 
≥2.22 mg/kg.  Additionally, total activity, but not rearing or locomotion, was significantly decreased 
during the first 20-mintue interval in the 1.34 mg/kg group; no significant changes were observed during
the third interval in the 1.34 mg/kg group.  Statistical analysis shows that habituation ability declined in 
mice exposed to ≥2.22 mg/kg from 2 to 4 months of age.  At 4 months, nicotine exposure caused
significantly decreased activity during the first interval in mice exposed to ≥13.4 mg/kg, compared with 
saline-injected mice from the same decaBDE exposure group.  This finding is the opposite of the
expected increase in activity due to nicotine exposure, which was observed in controls and lower dose
decaBDE groups.  During third interval, mice exposed to ≥13.4 mg/kg and nicotine showed impaired 
habituation.  No exposure-related effects were observed in the elevated plus maze assessment.
Study 2 (Buratovic et al. 2014): No clinical signs of toxicity or body weight effects were observed.  In 
spontaneous activity assessment, a dose-related decrease in locomotion, rearing, and total activity was
observed during the first 20 minutes of open field testing in a novel environment at 2 months.  Decreases
were significant at all doses tested in both sexes; however, findings were only dose-related for total 
activity.  However, during the third 20-minute interval, when activity should decrease due to habituation, 
locomotion, rearing, and total activity were significantly increased in males and females at ≥5.76 mg/kg.
At 2 months, cholinergic agents caused decreased activity during the first interval in mice exposed to 
≥5.76 mg/kg, compared with saline-injected mice from the same decaBDE exposure group. This finding
is the opposite of the expected increase in activity due to paraoxon or nicotine exposure, which was
observed in controls and low-dose decaBDE groups.  During the third interval, mice exposed to
≥5.76 mg/kg and cholinergic agent showed impaired habituation.  At 4 months, total activity during the
first 20 minutes was still significantly decreased at all doses in males, and locomotion and rearing were 
significantly decreased in males in the mid- and high-dose groups only; all three parameters were 
significantly decreased in high-dose females (other doses not evaluated).  All three parameters were 
significantly increased in high-dose males and females during the third 20-minute period, indicating
decreased habituation; locomotion and rearing were also slightly, but significantly, increased in mid-dose 
males.  In the Morris water maze, initial learning was comparable between exposed and control mice at
5 and 7 months.  However, latencies to find the escape platform during the reversal learning phase
(learning to find the escape platform in a new location after initial training) were significantly longer in
mid- and high-dose males at 5 and 7 months (other exposure groups not assessed).  After sacrifice,
significant increases in protein levels of CaMKII, Gap-43, and Tau were observed in the cortex and 
hippocampus in male mice and increased levels of Tau were observed in the cortex and hippocampus of
female mice.  No changes in synaptophysin were observed.
Dose and end point used for MRL derivation:  1.34 mg/kg
[X] NOAEL  [ ] LOAEL
In the first study (Johansson et al. 2008), a NOAEL of 1.34 mg/kg and a LOAEL of 2.22 mg/kg were
determined for the nonhabituating profile (i.e., decreased activity early in the test period and increased 










     
     
  
  
       
  
   
  
   
 
   
   
    
     
   
   









      
 
 




     
   
    
  
    
    
 
    
   
     
 
 
    
   
     




activity late in the test period). The singular finding of decreased total activity during the first 20-minute
interval at 4 months in the 1.34 mg/kg group was not considered sufficient to establish a LOAEL of
1.34 mg/kg.  The nonhabituating profile, which is a common effect observed with developmental PBDE
exposure (Eriksson et al. 2002b, 2006; Fischer et al. 2008; Sand et al. 2004; Viberg et al. 2002, 2003a, 
2004a, 2004b), was considered to be a stronger basis for a NOAEL/LOAEL determination. BMD
modeling was performed on the habituation ratio (activity during the last 20-minute interval/activity
during the first 20-minute interval) at 2 and 4 months reported by Johansson et al. (2008) to assess 
suitability of this approach for determining the POD.  However, none of the models provided an adequate
fit with constant or nonconstant variance.
In the second study (Buratovic et al. 2014), a NOAEL of 1.34 mg/kg and a LOAEL of 5.76 mg/kg were
determined for the nonhabituating profile (i.e., decreased activity early in the test period and increased
activity late in the test period).  Similar to the Johansson et al. (2008) study, the finding of decreased total
activity during the first 20-minute interval at 2 and 4 months in the 1.34 mg/kg group was not considered 
sufficient to establish a LOAEL of 1.34 mg/kg.  The nonhabituating profile was considered to be a
stronger basis for a NOAEL/LOAEL determination, and additional neurological effects (impaired
learning, altered response to cholinergic agents) support a LOAEL of 5.76 mg/kg. The quantitative
habituation ratio was not reported by Buratovic et al. (2014); therefore, BMD modeling was not
performed for this study.
Uncertainty factors used in MRL derivation:
[X] 10 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable
(gavage study).
Was a conversion used from intermittent to continuous exposure? Not applicable (single exposure study).
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Other additional studies or pertinent information that lend support to this MRL:  In a similar study, 
decreased spontaneous activity and impaired habituation were also observed in 2- and 6-month-old mice
exposed to BDE 209 at doses ≥2.22 mg/kg on PND 3 (lowest dose tested) (Viberg et al. 2003b). These
effects were not observed if exposure was on PND 10 or 19 at doses up to 20.1 mg/kg (Viberg et al. 
2003b).  Additionally, decreased spontaneous activity was observed in 2-month-old rats following
exposure to BDE 209 doses ≥6.7 mg/kg on PND 3 (lowest dose tested) (Viberg et al. 2007).  At
20.1 mg/kg, impaired habituation and decreased nicotine-induced behavior were also observed.  This 
nonhabituating behavior profile (i.e., decreased activity early in the test period and increased activity late
in the test period) is consistent with neurobehavioral alterations observed following early postnatal
exposure to lower-brominated PBDEs and has been reported in adult mice neonatally exposed to certain 
PCB congeners (see Acute MRL Worksheet for lower-brominated PBDEs for more details).
Additional neurodevelopmental effects observed in mice following acute exposure to BDE 209 from 
PND 2 to 15 at 20 mg/kg/day via micropipette include delayed ontogeny of reflexes, increased 
locomotion in males at PND 70, and learning impairment and impulsivity at 16 months, but not at
3 months (Rice et al. 2007, 2009). In rats, impaired learning was observed in Morris water maze in
PND 25 rat offspring of dams exposed to BDE 209 from GD 1 to 14 at doses ≥30 mg/kg/day via gavage
(Chen et al. 2014).











    
 
  
   







Hydroxylated metabolites (OH-PBDEs) may be responsible for the toxic action of PBDEs.  There is some 
evidence that the CYPs involved in metabolism of PBDEs, as well as the OH-PBDEs formed, are 
different in rats and humans (Erratico et al. 2011, 2012, 2013)—see Section 3.4.3 for more information.  
However, there is no available evidence indicating that the complement of OH-PBDEs formed in humans
is any more or less potent than the complement of OH-PBDEs formed in rats. Therefore, the current use 
of an animal-to-human uncertainty factor is appropriate for calculating an MRL based on effects observed
in rats.
Agency Contact (Chemical Manager):  Hana Pohl













     
   
     
   
    
    
   
   
 
      
 
     
      
 
 
   








   
 
  
   
    
  
    













    
PBDEs A-19
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Polybrominated Diphenyl Ethers (PBDEs)
[decabromodiphenyl ether (decaBDE)]
CAS Numbers: 1163-19-5 
Date: March 2017
Profile Status: Final
Route: [ ] Inhalation [X] Oral
Duration: [ ] Acute [X] Intermediate [ ] Chronic
Graph Key: 29
Species: Rat
Minimal Risk Level: 0.0002 (2x10-4) [X] mg/kg/day [ ] ppm [ ] mg/m3 
Reference:  Zhang Z, Sun ZZ, Xiao X, et al. 2013a. Mechanism of BDE 209-induced impaired glucose
homeostasis based on gene microarray analysis of adult rat liver. Arch Toxicol 87(8):1557-1567.
Experimental design: Adult male rats were administered 2,2′,3,3′,4,4′,5,5′,6,6′-decabromodiphenyl ether
(BDE 209) at 0, 0.05, 1, or 20 mg/kg/day daily via gavage in corn oil for 8 weeks.  Rats were observed 
for clinical signs of toxicity and body weights were measured every 3 days.  Rats were fasted for 24 hours
after the final gavage treatment, and then sacrificed.  Body weights and heart, spleen, lung, kidney, and 
liver weights were recorded.  Blood was collected for clinical chemistry analysis (serum total cholesterol,
triglycerides, glucose, insulin, and TNF-α) and determination of plasma markers of oxidative stress
(MDE, GSH, and SOD).  Liver samples from three rats in the control and low-dose (0.05 mg/kg/day)
groups were collected for microarray analysis (Affymetrix GeneChip), and gene ontogeny category,
pathway, gene-act-network and gene co-expression analyses were conducted.  Quantitative real-time-PCR 
was performed to quantitate gene expression to validate the gene expression data obtained from
microarray analysis.
Effects noted in study and corresponding doses:  No clinical signs of toxicity or body weight effects were 
observed. The relative liver weight was significantly decreased at 1 and 20 mg/kg/day by 9% (absolute 
liver weights were not reported).  No changes were observed in relative weights of heart, spleen, lung, or
kidney.  No exposure-related changes were reported in serum cholesterol or triglyceride levels.  Serum
glucose levels were significantly increased by 12, 18, and 21% in 0.05, 1, and 20 mg/kg/day groups, 
compared with controls.  Serum insulin was significantly decreased by 50–60% at 1 and 20 mg/kg/day.  
Subsequent to this finding, the pancreas was evaluated histologically.  Consistent with the insulin 
findings, morphological changes at 1 and 20 mg/kg/day included blurred boundaries among pancreatic 
islet cells (quantitative data not reported).  Plasma SOD activity was significantly decreased in all
exposed groups and plasma GSH was significantly decreased at 1 and 20 mg/kg/day.  Serum TNF-α was 
significantly increased at 1 and 20 mg/kg/day.
BDE 209 induced 1,257 liver gene transcript changes, and 18 canonical pathways were significantly
enriched.  Four of them were involved in immune diseases, including autoimmune thyroid disease, graft­
versus-host disease, allograft rejection, and T1DM.  Subsequently, gene act network and gene
coexpression network found that some major histocompatibility complex molecules and TNF-α were 
involved in the T1DM pathway.
Dose and end point used for MRL derivation:  0.05 mg/kg/day
[ ] NOAEL  [X] LOAEL  [ ] BMDL1SD 












    
    
  


























         
 
 
         
 
 
         
 
 
         
          
          
 
 
         
 
 
         
          
 








     
  
   
  
































BMD modeling was performed on the serum glucose data to assess suitability of this approach for
determining the POD. Modeling was performed using the reference BMR of one standard deviation
change from the mean (1SD), as well as an alternate BMR of 20% change from the mean (RD20).  The
alternate BMR of RD20 was identified by the reference value range for rat glucose levels, which varies
~20% around the mean (reference mean [range] = 118.1 mg/dL [77–141 mg/dL]; Charles River
Laboratories 1998).  Results are shown in Table A-3 and Figure A-2.
Table A-3.  Modeling Results for Increased Serum Glucose Levels Following 
Exposure to BDE 209 (Zhang et al. 2013a)
























0.0006 0.71 0.0009 2.09 -0.10 -2.66 46.79 18.09 11.79
Exponential
(model 3)d 
0.0006 0.71 0.0009 2.09 -0.10 -2.66 46.79 18.09 11.79
Exponential
(model 4)d 
0.0006 0.71 0.33 0.00 0.00 0.68 35.65 0.04 0.01
Exponential
(model 5)d 
0.0006 0.71 N/A 0.00 0.00 0.68 37.65 0.04 0.01
Hilld,e 0.0006 0.71 0.41 -0.01 0.08 -0.61 35.37 0.03 0.006
Linearf 0.0006 0.71 0.0009 2.09 -0.11 -2.65 46.75 17.89 11.35
Polynomial
(2-degree)f 
0.0006 0.71 0.0009 2.09 -0.11 -2.65 46.75 17.89 11.35
Polynomial
(3-degree)f 
0.0006 0.71 0.0009 2.09 -0.11 -2.65 46.75 17.89 11.35





Hilld,f 0.0006 0.71 0.41 0.54 NA -0.61 35.37 21.84 0.05
aValues >0.05 fail to meet conventional goodness-of-fit criteria.
bValues <0.10 fail to meet conventional goodness-of-fit criteria.
cScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose.
dPower restricted to ≥1.
eSelected model. With constant variance model applied, the only models that provided adequate fit to the means
were the Exponential (model 4) and the Hill models.  BMDLs for models providing adequate fit were sufficiently close
(differed by <2–3-fold), so the model with the lowest AIC was selected (Hill model).
fCoefficients restricted to be positive.
AIC = Akaike Information Criterion; BDE = brominated diphenyl ether; BMD = maximum likelihood estimate of the 
exposure concentration associated with the selected benchmark response; BMDL = 95% lower confidence limit on 
the BMD (subscripts denote benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk);
NA = not applicable (BMDL computation failed or the BMD was higher than the highest dose tested); RD = relative 
deviation; SD = standard deviation
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Figure A-2.  Fit of Hill Model to Data for Increased Serum Glucose Levels 
Following Exposure to DecaBDE (Zhang et al. 2013a)
Goodness-of-fit statistics indicate inadequate fit to the data for all models except the Exponential 4 and 
Hill models, which were considered unsuitable for use in MRL derivation because they did not provide
reliable information about the shape of the dose-response curve.  For example, using the reference BMR
of 1SD change from the mean, the ratio of BMD:BMDL is 5 for the Hill model (0.03/0.006) and 4 for the
Exponential Model 4 (0.04/0.01). These values are quite high and suggest that the data do not permit
accurate estimation of the BMDL. Using the BMR of RD20 for the Hill model, the ratio was much 
higher still (21.84/0.05=437). The fact that this ratio changes so much with BMR underscores the 
instability in the BMDL estimates using this model.
In the absence of a suitable model, the minimal LOAEL of 0.05 mg/kg/day based on a 12% increase in 
serum glucose was chosen as the POD for MRL derivation. The change in glucose is considered a
minimal LOAEL because it is unclear if the magnitude of change represents a biologically adverse effect;
however, the increase in serum glucose is considered to be part of a spectrum of effects indicative of
altered insulin homeostasis and toxicity to the pancreas, including decreased serum insulin and 
morphological changes in pancreatic islet cells observed at ≥1 mg/kg/day, following BDE 209 exposure.










   
 




       
 
 





     
   
    
   





   
   
 
    
   




    
  
     
    
  
 
        
  
   
 
  








Uncertainty factors used in MRL derivation:
[X] 3 for use of a minimal LOAEL
[X] 10 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable
(gavage study).
Was a conversion used from intermittent to continuous exposure? Not applicable (doses administered
daily).
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Other additional studies or pertinent information that lend support to this MRL: The association between 
PBDE-exposure and diabetes has been evaluated in a few human studies.  An analysis of cross-sectional
NHANES data showed a significant increase in risk of diabetes associated with serum levels of BDE 153
(but not BDE 28, BDE 47, BDE 99, or BDE 100; BDE 209 was not assessed), although the risk was
higher with exposure to 50–75th percentile BDE 153 levels than >75th percentile BDE 153 levels (Lim et
al. 2008).  Serum BDE 153 concentrations (but not BDE 28, BDE 47, BDE 85, BDE 99, BDE 100, or
BDE 154) were also shown to be significantly associated with increased odds of developing gestational
diabetes in a cohort of 258 pregnant women; again, BDE 209 was not assessed (Smarr et al. 2016).  
However, other cross-sectional and prospective studies found no relationship between serum PBDE
concentrations and diabetes in an adult cohort from Wisconsin (Turyk et al. 2015), an elderly cohort in 
Finland (Airaksinen et al. 2011), or an elderly cohort in Sweden (Lee et al. 2011).
Only one other animal study evaluated the pancreas following decaBDE exposure.  In rats exposed to 
BDE 209 via gavage for 28 days at doses of 0, 0.27, 0.82, 2.47, 7.4, 22.2, 66.7, or 200 mg/kg/day, slight
or moderate insulitis was observed in the Langerhan’s islets of the “majority of samples,” but findings 
were not exposure-related (Van der ven et al. 2008a).  Similarly, no exposure-related effects were 
observed for serum glucose levels (Van der ven et al. 2008a). The only other study evaluating serum
glucose levels after decaBDE exposure instead reported reduced serum glucose levels in male rats 
exposed to 20 mg/kg/day of a dietary PBDE mixture containing 52.1% pentaBDE (DE-71), 44.2%
decaBDE (BDE 209), and 0.4% octaBDE (DE-79) for 70 days (Ernest et al. 2012).  The observed 
decreased glucose levels could be due to the pentaBDE component, as male rats exposed to the
commercial pentaBDE mixture DE-71 at doses of 0.27–200 mg/kg/day for 28 days also showed 
decreased glucose levels; study authors did not report the lowest dose at which glucose levels were 
significantly lower in male rats, but they reported a BMD10RD of 179.55 mg/kg/day and a BMDL10RD of
66.7 mg/kg/day (Van der ven et al. 2008b).  Other effects occurred at doses 4–40-fold higher than the
observed pancreatic and related effects:
• A LOAEL of 2 mg/kg/day was identified for transient histopathological effects in the liver of
male offspring and kidney of female offspring of rat dams exposed to BDE 209 from GD 10 to 
PND 21 (no NOAEL identified) (Fujimoto et al. 2011).
• A LOAEL of 10 mg/kg/day was identified for hepatocytic swelling in the liver, vacuolization in 
the interstitial cells of testes, and sperm damage in PND 71 male offspring of mouse dams
exposed to BDE 209 from GD 0 to 17 (no NOAEL identified) (Tseng et al. 2008, 2013).

















   
 
  
   










• A LOAEL of 20 mg/kg/day was identified for decreased anxiety in mice treated with BDE 209 by 
daily gavage for 15 days (no NOAEL identified) (Heredia et al. 2012).
• A LOAEL of 20.1 mg/kg/day was identified for altered hippocampal electrophysiology in rats
exposed to BDE 209 from GD 1 to PND 41, PNDs 1–21, or PNDs 22–41 (no NOAEL identified)
(Xing et al. 2009).
Hydroxylated metabolites (OH-PBDEs) may be responsible for the toxic action of PBDEs.  There is some 
evidence that the CYPs involved in metabolism of PBDEs, as well as the OH-PBDEs formed, are 
different in rats and humans (Erratico et al. 2011, 2012, 2013)—see Section 3.4.3 for more information.  
However, there is no available evidence indicating that the complement of OH-PBDEs formed in humans
is any more or less potent than the complement of OH-PBDEs formed in rats. Therefore, the current use 
of an animal-to-human uncertainty factor is appropriate for calculating an MRL based on effects observed
in rats.
Agency Contact (Chemical Manager):  Hana Pohl
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APPENDIX B.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions:
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.










    
    
   
 
 
    
     




    
     
 
   
    
  
  
    
   
    
    
  
 
   
    









   
     
  
   
  
      




   





MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement,
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in
conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.


















   
 
  
      




   
      
   
 
 
   
  
  
   
 






    
    
   
 
    
 
 
    
 




    















See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable
exposure period within the LSE table and figure.
(3) Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen,
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7) System.  This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8) NOAEL.  A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").












       
  
    
   
    
 
 
    
 
       
    
   
 
 









   
 
 
      
  
 
   
      
 
   
   




      
      
     
 
     















(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 of the profile.
(11) CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in
experimental or epidemiologic studies.  CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases.
(12) Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15) Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.










   
    
   
 
 








(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).






         
 













    
      




















































































































































1 →  Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)Exposure 
Less serious Serious (ppm)Key to frequency/ NOAEL



































10	 (CEL, lung tumors,
nasal tumors)




Nitschke et al. 1981
Wong et al. 1982
NTP 1982
NTP 1982
12 → a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 






        























Chronic (≥ 365 days) Intermediate (15-364 days)
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APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor










   
   
           





   
  
  



























   
  
   












DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization




Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie










   
   
  











   
   
  







   
  














   





   
  
  
   
   
PBDEs C-3
APPENDIX C
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances












   












   
  




















   
  
  













OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell





RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization










   
   
  
  

















≥ greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
 
 
 
